{"text": "risk reduction of cognitive decline and dementia who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "i risk reduction of cognitive decline and dementia who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 3, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "ii risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "isbn 978 - 92 - 4 - 155054 - 3", "metadata": {"doc_name": "9789241550543-eng", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "© world health organization 2019", "metadata": {"doc_name": "9789241550543-eng", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "some rights reserved. this work is available under the creative commons attribution - noncommercial - sharealike 3. 0", "metadata": {"doc_name": "9789241550543-eng", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "igo licence ( cc by - nc - sa 3. 0 igo ; https : / / creativecommons. org / licenses / by - nc - sa / 3. 0 / igo ). under the terms of this licence, you may copy, redistribute and adapt the work for non - commercial purposes, provided the work is appropriately cited, as indicated below. in any use of this work, there should be no suggestion that who endorses any specific organization, products or services.", "metadata": {"doc_name": "9789241550543-eng", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the use of the who logo is not permitted. if you adapt the work, then you must license your work under the same", "metadata": {"doc_name": "9789241550543-eng", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "or equivalent creative commons licence. if you create a translation of this work, you should add the following disclaimer along with the suggested citation : “ this translation was not created by the world health organization ( who ). who is not responsible for", "metadata": {"doc_name": "9789241550543-eng", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the content or accuracy of this translation. the original english edition shall be the binding", "metadata": {"doc_name": "9789241550543-eng", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and authentic edition ”. any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the world intellectual property organization. suggested citation. risk reduction of cognitive decline and dementia : who guidelines. geneva : world health organization ; 2019. licence : cc by - nc - sa 3. 0 igo. cataloguing - in - publication ( cip ) data. cip data are available at http : / / apps. who. int / iris.", "metadata": {"doc_name": "9789241550543-eng", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "sales, rights and licensing. to purchase who publications, see http : / / apps. who. int / bookorders. to submit requests for", "metadata": {"doc_name": "9789241550543-eng", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "commercial use and queries on rights and licensing, see http : / / www. who. int / about / licensing.", "metadata": {"doc_name": "9789241550543-eng", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "third - party materials. if you wish to reuse material from this work that is attributed to a third party, such as tables, figures or", "metadata": {"doc_name": "9789241550543-eng", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. the risk of claims resulting from infringement of any third - party - owned component in the work rests solely with the user. general disclaimers. the designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of who concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. the mention of specific companies or of certain manufacturers ’ products does not imply that they are endorsed or recommended by who in preference to others of a similar nature that are not mentioned. errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. all reasonable precautions have been taken by who to verify the information contained in this publication. however, the published material is being distributed without warranty of any kind, either expressed or implied. the responsibility for the interpretation and use of the material lies with the reader. in no event shall who be liable for damages arising from its use. design and layout : erica lefstad printed in france", "metadata": {"doc_name": "9789241550543-eng", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. 1 background and rationale for these guidelines..... 1", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "1.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. 2 related who guidelines and tools......................... 3", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "1.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. 3 target audience.................................................... 4", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "1.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. 4 goals and objectives............................................ 4", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "1.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. 5 guiding principles................................................ 5 2. guideline development process........................................................ 6", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "1.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. 1 guideline development group............................... 7", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "2.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. 2 declarations of interest by the gdg members and external reviewers......................................... 7", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "2.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. 3 collaboration with external partners..................... 8", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "2.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. 4 identifying, appraising and synthesizing available evidence................................................ 8", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "2.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. 5 decision - making during the gdg meeting.............. 10", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "2.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. 6 document preparation and peer review................ 11 3. evidence and recommendations............................. 12", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "2.6", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 1 physical activity interventions............................. 13", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "3.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 2 tobacco cessation interventions.......................... 16", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "3.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 3 nutritional interventions..................................... 18", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "3.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 4 interventions for alcohol use disorders................. 22", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "3.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 5 cognitive interventions....................................... 25", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "3.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 6 social activity...................................................... 27", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "3.6", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 7 weight management........................................... 29", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "3.7", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 8 management of hypertension.............................. 32", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "3.8", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 9 management of diabetes...................................... 35", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "3.9", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 10 management of dyslipidaemia............................. 38", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "3.10", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 11 management of depression................................. 40", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "3.11", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 12 management of hearing loss................................ 43 4. implementation considerations................................... 46 5. publication, dissemination and evaluation................................... 48", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "3.12", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "5. 1 publication and dissemination............................... 49", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "5.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "5. 2 monitoring and evaluation..................................... 50", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "5.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "5. 3 implications for further research............................ 50", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "5.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "5. 4 future review and update...................................... 51 references...................................................... 52", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "5.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "annex 1 : guideline development", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "5.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "group members........................................... 60 annex 2 : assessment of conflict of interest....................................................... 62 annex 3 : scoping questions............... 67", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "5.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "annex 4 : evidence review", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "5.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "methodology................................................ 72 web annex : evidence profiles ( who / msd / mer / 19. 1 ) ;", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "5.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "https : / / www. who. int / mental _ health / neurology / dementia / guidelines _ risk _ reduction / en / index. html", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "5.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "glossary............................................................ 77", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "5.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "iii contents", "metadata": {"doc_name": "9789241550543-eng", "page": 5, "section": "5.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "iv risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "v foreword", "metadata": {"doc_name": "9789241550543-eng", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "dementia is a rapidly growing public health problem affecting around 50 million people around", "metadata": {"doc_name": "9789241550543-eng", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the world. there are nearly 10 million new cases every year and this figure is set to triple by 2050. dementia is a major cause of disability and dependency among older people and can devastate the lives of affected individuals, their carers and families. additionally, the disease inflicts a heavy economic burden on societies as a whole, with the costs of caring for people with dementia estimated to rise to us $ 2 trillion annually by 2030. while there is no curative treatment for dementia, the proactive management of modifiable risk factors can delay or slow onset or progression of the disease. in may 2017, the seventieth world", "metadata": {"doc_name": "9789241550543-eng", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "health assembly endorsed a global action plan on the public health response to dementia 2017 – 2025,", "metadata": {"doc_name": "9789241550543-eng", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "urging member states to develop, as soon as feasible, ambitious national responses to address this challenge. dementia risk reduction is one of the seven action areas in the global action plan. these new who guidelines provide the knowledge base for health care providers, governments,", "metadata": {"doc_name": "9789241550543-eng", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "policy - makers and other stakeholders to reduce the risks of cognitive decline and dementia through", "metadata": {"doc_name": "9789241550543-eng", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "a public health approach. as many of the risk factors for dementia are shared with those of non -", "metadata": {"doc_name": "9789241550543-eng", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "communicable diseases, the key recommendations can be effectively integrated into programmes", "metadata": {"doc_name": "9789241550543-eng", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "for tobacco cessation, cardiovascular disease risk reduction and nutrition.", "metadata": {"doc_name": "9789241550543-eng", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "i urge all stakeholders to make the best use of these recommendations to improve the lives of", "metadata": {"doc_name": "9789241550543-eng", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "people with dementia, their carers and their families. dr ren minghui", "metadata": {"doc_name": "9789241550543-eng", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "assistant director - general for universal health coverage / communicable", "metadata": {"doc_name": "9789241550543-eng", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and noncommunicable diseases, world health organization", "metadata": {"doc_name": "9789241550543-eng", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "vi risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "guideline development group chair : martin prince, king ’ s college, london, united kingdom. members : charles alessi, public health england, london, united kingdom ; kaarin j anstey, university of new south wales, sydney, australia ; kimberly ashby - mitchell, caribbean public health agency, port of spain, trinidad and tobago ; adelina comas - herrera, london school of economics, london, united kingdom ; amit dias, department of preventive and social medicine, goa medical college bambolim, goa, india ; cleusa p ferri, federal university of sao paulo, sao paulo, brazil ; riadh gouider, razi hospital, faculty of medicine, tunis, tunisia ; shinya ishii, ministry of health, labour and welfare, tokyo, japan ; yves joanette, canadian institutes of health research, government of canada ; joseph kibachio, ministry of health, nairobi, kenya ; miia kivipelto, karolinska institutet, stockholm, sweden ; shanthi mendis, colombo, sri lanka ; ayesha motala, university of kwazulu - natal, durban, south africa ; ronald c petersen, mayo clinic, rochester, united states of america ; dorairaj prabhakaran, public health foundation of india, new delhi, india ; suzana shahar,", "metadata": {"doc_name": "9789241550543-eng", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "kwazulu - natal, durban, south africa ; ronald c petersen, mayo clinic, rochester, united states of america ; dorairaj prabhakaran, public health foundation of india, new delhi, india ; suzana shahar, universiti kebangsaan malaysia, selangor, malaysia ; ameenah bibi mia sorefan, ministry of health and quality of life, quatre - bornes, mauritius ; kusumadewi suharya ( dy ), alzheimer ’ s disease international, jakarta, indonesia ; huali wang, dementia care & research center, peking university institute of mental health, beijing, china.", "metadata": {"doc_name": "9789241550543-eng", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "grade methodologist : corrado barbui, university", "metadata": {"doc_name": "9789241550543-eng", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "of verona, italy. external review group abdullah al khatami, ministry of health, saudi arabia ; emiliano albanese, universita della svizzera italiana, switzerland ; alistair burns, university of manchester, united kingdom ; linda clare, university of exeter, united kingdom ; jacqueline dominguez, institute for dementia care asia, quezon city, philippines ; hillary doxford, 3 nations dementia working group, united kingdom ; maelenn guerchet, global observatory for ageing and dementia care, king ’ s college london, united kingdom ; mariella guerra, institute of memory, depression and related disorders, lima, peru ; luis miguel f gutierrez robledo, instituto nacional de geriatria, institutos nacionales de salud de mexico, mexico city, mexico ; vladimir hachinski, university of western ontario in london, ontario, canada ; qurat - ul ain khan, aga khan university hospital, karachi, pakistan ; sebastian koehler, maastricht university, the netherlands ; jae - hong lee, university of ulsan college of medicine, seoul, republic of korea ; gill livingstone, university college london, united kingdom ; jean claude mbanya, doctoral school of life sciences, health and environment, university of yaounde i, cameroon ; james mckillop, service user group representative, united kingdom ; elaine rashbrook, public", "metadata": {"doc_name": "9789241550543-eng", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": ", university college london, united kingdom ; jean claude mbanya, doctoral school of life sciences, health and environment, university of yaounde i, cameroon ; james mckillop, service user group representative, united kingdom ; elaine rashbrook, public health england, united kingdom ; rajat ray, national drug dependence treatment centre, all india institute of medical sciences, new delhi, india ; helen rochford brennan, european working group of people with dementia, ireland ; andrew sommerlad, university college london, united kingdom ; kate swaffer, dementia alliance international, australia ; weili xu, karolinska", "metadata": {"doc_name": "9789241550543-eng", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "institutet, finland.", "metadata": {"doc_name": "9789241550543-eng", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "who guideline steering group", "metadata": {"doc_name": "9789241550543-eng", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "overall coordination : tarun dua, programme", "metadata": {"doc_name": "9789241550543-eng", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "manager, department of mental health and substance abuse ; neerja chowdhary, technical officer, department of mental health and substance abuse. who headquarters members : katthyana aparicio reyes, department of service delivery and safety ; islene araujo de carvalho, department of ageing and life course ; lubna bhatti, department of prevention of noncommunicable diseases ; fiona bull, department of prevention of noncommunicable diseases ; shelly chadha, department of management of noncommunicable diseases, disability, violence and injury prevention ; alarcos cieza, department of management of noncommunicable diseases, disability, violence and injury prevention ; stefanie freel, department of mental health and substance abuse ; maria garcia casal, department of nutrition for health and development ; angela luzia herscheid, acknowledgements", "metadata": {"doc_name": "9789241550543-eng", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "viiacknowledgements department of mental health and substance abuse ; michal herz, department of mental health and", "metadata": {"doc_name": "9789241550543-eng", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "substance abuse ; dzmitry krupchanka, department", "metadata": {"doc_name": "9789241550543-eng", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "of mental health and substance abuse ; artin mahdanian, department of mental health and substance abuse ; shanthi pal, department of essential medicines and health products ; anne margriet pot, department of ageing and life course ; gojka roglic, department of management of noncommunicable diseases, disability, violence and injury prevention ; katrin seeher, department of mental health and substance abuse. who regional office advisors : nazneen anwar, who regional office for south - east asia ; dan chisholm, who regional office for europe ; devora kestel, who regional office for the americas ; sebastiana da gama nkomo, who regional office for africa ; khalid saeed, who regional office for the eastern mediterranean ; martin vandendyck, who regional office for the western pacific. who evidence review and synthesis teams : mariagnese barbera, university of eastern finland, kuopio, finland ; nicole a ee, university of new south wales, sydney, australia ; jenni kumlala, karolinska institutet, stockholm, sweden ; ruth peters, university of new south wales, sydney, australia ; lidan zheng, university of new south wales, sydney, australia. funding source funds received from public health england, united kingdom ; centers for disease control and prevention, united states of america ; and the who core", "metadata": {"doc_name": "9789241550543-eng", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "new south wales, sydney, australia ; lidan zheng, university of new south wales, sydney, australia. funding source funds received from public health england, united kingdom ; centers for disease control and prevention, united states of america ; and the who core voluntary contributions account were used for the development of these guidelines.", "metadata": {"doc_name": "9789241550543-eng", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "viii risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "ace angiotensin converting enzyme", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "ad alzheimer disease adas - cog alzheimer disease assessment scale - cog adl activities of daily living", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "ahrq agency for healthcare research and quality ( united states of america ) arb angiotensin receptor blocker", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "bmi body mass index ccb calcium channel blocker ci confidence interval cvrf cardiovascular risk factors cvd cardiovascular disease", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "dalys disability - adjusted life years dash dietary approaches to stop hypertension doi declaration of interest", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "embase excerpta medica database", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "erg external review group", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "gdg guideline development group ( who )", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "gdp gross domestic product", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "grade grading of recommendations assessment, development and evaluation", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "hiv human immunodeficiency virus", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "iadl instrumental activities of daily living", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "icope integrated care for older people ( who )", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "lmic low - and middle - income countries mci mild cognitive impairment mdrs mattis dementia rating scale mesh medical subject headings mhgap mental health gap action programme ( who ) mmse mini mental state examination", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "ncds noncommunicable diseases nia national institute on aging ( united states of america )", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "nice national institute of health and care excellence ( united kingdom ) or odds ratio", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "acronyms", "metadata": {"doc_name": "9789241550543-eng", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "ixacronyms pen package of essential noncommunicable disease interventions ( who )", "metadata": {"doc_name": "9789241550543-eng", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pico population, intervention, comparison, outcome", "metadata": {"doc_name": "9789241550543-eng", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pufa polyunsaturated fatty acids", "metadata": {"doc_name": "9789241550543-eng", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "rct randomized controlled trial rr relative risk smd standardized mean difference", "metadata": {"doc_name": "9789241550543-eng", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "x risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 12, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "executive summary introduction dementia is a rapidly growing global public health problem. worldwide, around 50 million people have dementia, with approximately 60 % living in low - and middle - income countries ( lmic ). every year, there are nearly 10 million new cases. the total number of people with dementia is projected to reach 82 million in 2030 and 152 million in 2050. dementia leads to increased costs for governments, communities, families and individuals, and to loss in productivity for economies. in 2015, the total global societal cost of dementia was estimated to be us $ 818 billion, equiv - alent to 1. 1 % of global gross domestic product ( gdp ). crucially, while age is the strongest known risk factor for cognitive decline, dementia is not a natural or inevi - table consequence of ageing. several recent studies have shown a relationship between the development of cognitive impairment and dementia with lifestyle - related risk factors, such as physical inactivity, tobacco use, unhealthy diets and harmful use of alcohol. certain medical conditions are associated with an increased risk of developing dementia, including hypertension, diabetes, hypercholesterolemia, obesity and depression. other potentially modifiable risk factors include social isolation and cognitive inactivity. the existence of potentially modifiable risk factors means that prevention of dementia is possible through a public health approach, including the", "metadata": {"doc_name": "9789241550543-eng", "page": 12, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "hypercholesterolemia, obesity and depression. other potentially modifiable risk factors include social isolation and cognitive inactivity. the existence of potentially modifiable risk factors means that prevention of dementia is possible through a public health approach, including the implementation of key interventions that delay or slow cognitive decline or dementia. in may 2017, the seventieth world health assembly endorsed the global action plan on the public health response to dementia 2017 – 2025 ( who, 2017a ). the action plan includes seven strategic action areas and", "metadata": {"doc_name": "9789241550543-eng", "page": 12, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "xiexecutive summary dementia risk reduction is one of them. the action plan calls upon the who secretariat to strengthen, share and disseminate an evidence base to support policy interventions for reducing potentially modifiable risk factors for dementia. this involves providing a database of available evidence on the prevalence of those risk factors and the impact of reducing them ; and supporting the formulation and implementation of evidence - based, multisectoral interventions for reducing the risk of dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the risk reduction guidelines for cognitive decline", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and dementia are aligned with who ’ s mandate to provide evidence - based guidance for a public health response to dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "guideline development", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "methods the process of development of these guidelines followed the who handbook for guideline development and involved :", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. recruitment of the guideline development", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "group ( gdg ) ;", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. declaration of interest by gdg members and peer", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "reviewers ;", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. scoping review to formulate questions and select", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "outcomes ;", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "4. identification, appraisal and synthesis of available", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "evidence ;", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "5. formulation of recommendations with inputs from", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "a wide range of stakeholders ; and", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "6. preparation of documents and plans for", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "dissemination. the gdg, an international group of experts, provided input into the scope of the guidelines and assisted the steering group in developing the key questions. a total of 12 pico ( population, intervention, comparison and outcome ) questions were developed. to address the pico questions, a series of searches for systematic reviews was conducted and grading of recommendations assessment, development and evaluation ( grade ) evidence profiles prepared. during a meeting at who headquarters in geneva, 2 – 3 july 2018, the gdg discussed the evidence, sought clarifications and interpreted the findings in order to develop recommendations. the gdg considered the balance of benefit and harm of each intervention ; values and preferences ; costs and resource use ; and other relevant practical issues for providers in lmic.", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "when making a strong recommendation, the gdg", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "was confident that the desirable effects of the inter - vention outweigh any undesirable effects. when the gdg was uncertain about the balance between the desirable and undesirable effects, the gdg issued a", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "conditional recommendation. strong recommenda -", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "tions imply that most individuals would want the intervention and should receive it, while conditional", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "recommendations imply that different choices may", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "be appropriate for individual patients and they may require assistance at arriving at management decisions. the gdg members reached a unanimous agreement on all the recommendations and ratings.", "metadata": {"doc_name": "9789241550543-eng", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "xii risk reduction of cognitive decline and dementia : who guidelines summary of", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "recommendations physical activity interventions physical activity should be recommended to adults with normal cognition to reduce the", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "risk of cognitive decline. quality of evidence : moderate", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : strong physical activity may be recommended to adults with mild cognitive impairment to", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "reduce the risk of cognitive decline. quality of evidence : low", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : conditional tobacco cessation interventions interventions for tobacco cessation should be offered to adults who use tobacco since they", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "may reduce the risk of cognitive decline and dementia in addition to other health benefits. quality of evidence : low", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : strong nutritional interventions", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the mediterranean - like diet may be recommended to adults with normal cognition and mild cognitive impairment to reduce the risk of cognitive decline and / or dementia. quality of evidence : moderate", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : conditional a healthy, balanced diet should be recommended to all adults based on who", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "recommendations on healthy diet.", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "quality of evidence : low to high ( for different dietary components ) strength of the recommendation : strong vitamins b and e, polyunsaturated fatty acids and multi - complex supplementation", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "should not be recommended to reduce the risk of cognitive decline and / or dementia. quality of evidence : moderate", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : strong", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "interventions", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "for alcohol use disorders", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "interventions aimed at reducing or ceasing hazardous and harmful drinking should be offered to adults with normal cognition and mild cognitive impairment to reduce the risk of cognitive decline and / or dementia in addition to other health benefits. quality of evidence : moderate ( for observational evidence )", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : conditional cognitive interventions cognitive training may be offered to older adults with normal cognition and with mild", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "cognitive impairment to reduce the risk of cognitive decline and / or dementia. quality of evidence : very low to low", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : conditional", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "social activity there is insufficient evidence for social activity and reduction of risk of cognitive", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "decline / dementia. social participation and social support are strongly connected to good health and well - being throughout life and social inclusion should be supported over the life - course.", "metadata": {"doc_name": "9789241550543-eng", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "xiiiexecutive summary", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "weight", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "management interventions for mid - life overweight and / or obesity may be offered to reduce the risk", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "of cognitive decline and / or dementia. quality of evidence : low to moderate", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : conditional management of hypertension", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "management of hypertension should be offered to adults with hypertension according to existing who guidelines. quality of evidence : low to high ( for different interventions )", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : strong management of hypertension may be offered to adults with hypertension to reduce the", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "risk of cognitive decline and / or dementia. quality of evidence : very low ( in relation to dementia outcomes )", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : conditional management of diabetes mellitus the management of diabetes in the form of medications and / or lifestyle interventions", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "should be offered to adults with diabetes according to existing who guidelines. quality of evidence : very low to moderate ( for different interventions )", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : strong the management of diabetes may be offered to adults with diabetes to reduce the risk of", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "cognitive decline and / or dementia. quality of evidence : very low", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : conditional management of dyslipidaemia management of dyslipidaemia at mid - life may be offered to reduce the risk of cognitive", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "decline and dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "quality of evidence : low strength of the recommendation : conditional management of depression there is currently insufficient evidence to recommend the use of antidepressant medicines for reducing the risk of cognitive decline and / or dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the management of depression in the form of antidepressants and / or psychological", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "interventions should be provided to adults with depression according to existing who mhgap guidelines. management of hearing loss", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "there is insufficient evidence to recommend use of hearing aids to reduce the risk of", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "cognitive decline and / or dementia. screening followed by provision of hearing aids should be offered to older people for timely identification and management of hearing loss as recommended in the who icope guidelines.", "metadata": {"doc_name": "9789241550543-eng", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "xiv risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 16, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1 introduction", "metadata": {"doc_name": "9789241550543-eng", "page": 16, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. 1 background and rationale", "metadata": {"doc_name": "9789241550543-eng", "page": 17, "section": "1.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "for these guidelines dementia, a group of disorders characterized by a decline from a previously attained cognitive level that affects activities of daily living ( adl ) and social functioning, poses one of the greatest global challenges for health and social care in the 21st century. in 2015, dementia affected 50 million people worldwide ( or roughly 5 % of the world ’ s elderly population, i. e. those above the age of 60 years ). the number of people with dementia is expected to increase to 82 million in 2030 and 152 million by 2050 with the estimated proportion of the population aged 60 and over with dementia at a", "metadata": {"doc_name": "9789241550543-eng", "page": 17, "section": "1.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "given time between 5 to 8 % 1 because dementia", "metadata": {"doc_name": "9789241550543-eng", "page": 17, "section": "1.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "rises exponentially during old age and the world ’ s population is ageing. these projections assume constant age - and sex - specific prevalence of dementia over time, and, accordingly, the steepest rises are expected especially in low - and middle - income countries ( lmic ), where the demographic changes will be more marked. dementia is a major cause of disability and dependency among older people worldwide, and it has a significant impact not only on individuals but also on carers, families, communities and societies. dementia accounts for 11. 9 % of the years lived with disability due to a noncommunicable disease ( ncd ) worldwide. dementia leads to increased costs for governments, communities, families and individuals, and to loss in productivity for economies. the annual global cost of dementia is estimated to be us $ 818 billion ( oecd, 2015 ; who, 2017b ). nearly 85 % of costs are related to family and social, rather than medical, care ( gbd 2015 neurological disorders collaborator group, 2017 ). most health systems are ill - equipped and under - resourced to respond to the current needs associated with dementia. thus, societal ageing and the associated increases in dementia prevalence will likely have major health - service implications for the care of people with dementia and support for affected families. there are many different causes and types of demen - tia. primary dementias include", "metadata": {"doc_name": "9789241550543-eng", "page": 17, "section": "1.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "thus, societal ageing and the associated increases in dementia prevalence will likely have major health - service implications for the care of people with dementia and support for affected families. there are many different causes and types of demen - tia. primary dementias include : dementia due to alzheimer disease ( ad ), vascular dementia, dementia with lewy bodies and frontotemporal dementia ( in which the decline in cognitive abilities itself is mostly due to an underlying neurodegenera - tive process and not directly caused by other etiologies ). alzheimer disease is the most common, followed by vascular dementia and dementia with lewy bodies. mixed", "metadata": {"doc_name": "9789241550543-eng", "page": 17, "section": "1.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "dementia with features of more than one type is", "metadata": {"doc_name": "9789241550543-eng", "page": 17, "section": "1.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "also common, especially in older adults, while frontotemporal dementia is a less common form but relatively more frequent before old age.", "metadata": {"doc_name": "9789241550543-eng", "page": 17, "section": "1.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "secondary dementias are those caused by, or", "metadata": {"doc_name": "9789241550543-eng", "page": 17, "section": "1.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "closely related to, some other recognizable disease, such as hiv, head injury, multiple sclerosis, thyroid disorders or vitamin b12 deficiency. in these secondary dementias, cognitive impairment is typically accompanied by symptoms and signs in other organ systems and the treatment focuses on management of the underlying disease. for the scope of these guidelines we refer to primary dementias. though early treatment of some diseases may have the potential to prevent the onset of secondary dementias, we are not including these", "metadata": {"doc_name": "9789241550543-eng", "page": 17, "section": "1.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1 who & king ’ s college london ( 2017 ). global prevalence of dementia – updated figures 2017. available at :", "metadata": {"doc_name": "9789241550543-eng", "page": 17, "section": "1.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "https : / / www. who. int / news - room / fact - sheets / detail / dementia", "metadata": {"doc_name": "9789241550543-eng", "page": 17, "section": "1.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "secondary dementias in the scope of these guidelines since there are prevention or appropriate management and treatment strategies for most of these specific diseases and conditions, which effectively reduce", "metadata": {"doc_name": "9789241550543-eng", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "dementia - related signs and symptoms. however,", "metadata": {"doc_name": "9789241550543-eng", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "late - onset dementia is a heterogeneous and multifactorial condition and some factors ( i. e. head trauma, b12 deficiency earlier in life ) may also contribute to the development of dementia later in", "metadata": {"doc_name": "9789241550543-eng", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "life ( not only secondary dementia ).", "metadata": {"doc_name": "9789241550543-eng", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "risk factors for dementia non - modifiable risk factors for dementia include gene polymorphisms, age, gender, race / ethnicity and family history. crucially, while age is the strongest known risk factor for cognitive decline, dementia is not a natural or inevitable consequence of ageing. during the last two decades, several studies have shown a relationship between the development of cognitive impairment and dementia with educational attainment, and lifestyle - related risk factors, such as physical inactivity, tobacco use, unhealthy diets and harmful use of alcohol. further, certain medical conditions are associated with an increased risk of developing dementia, including hypertension, diabetes, hypercholesterolemia, obesity and depression. other potentially modifiable risk factors may include social isolation and cognitive inactivity. the risk factors included in the scope of these guidelines were chosen based on recent systematic reviews and guidelines, i. e. national institute of health and care excellence ( united kingdom ) ( nice, 2015 ) ; the united states of america agency for healthcare research and quality ( ahrq ) systematic review ( kane et al., 2017 ) ; the world alzheimer report 2014 ( prince, et al., 2014 ) and the report by the lancet commission on dementia prevention, intervention, and care ( livingston et al., 2017 ). the current focus on modifiable risk factors is justified by their potential", "metadata": {"doc_name": "9789241550543-eng", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "report 2014 ( prince, et al., 2014 ) and the report by the lancet commission on dementia prevention, intervention, and care ( livingston et al., 2017 ). the current focus on modifiable risk factors is justified by their potential to be targeted for prevention of dementia, and / or the delay of the progression of", "metadata": {"doc_name": "9789241550543-eng", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "cognitive decline.", "metadata": {"doc_name": "9789241550543-eng", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "need for these guidelines the existence of potentially modifiable risk factors means that prevention of dementia is possible through a public health approach, including the implementation of key interventions that delay or slow cognitive decline or dementia. in may 2017, the seventieth world health assembly endorsed the global action plan on the public health response to dementia 2017 – 2025 ( who, 2017a ). the vision of the action plan is a world in which dementia is prevented and people with dementia and their carers live well and receive the care and support they need to fulfil their potential with dignity, respect, autonomy and equality. the goal of the action plan is to improve the lives of people with dementia, their carers and families, while decreasing the impact of dementia on them as well as on communities and countries. the action plan includes seven strategic action areas, and dementia risk reduction is one of them. the action plan calls upon the who secretariat to strengthen, share and disseminate an evidence base to support policy interventions for reducing potentially modifiable risk factors for dementia. this involves providing a database of available evidence on the prevalence of those risk factors and the impact of reducing them ; and supporting the formulation and implementation of evidence - based, multi - sectoral interventions for reducing the risk of dementia. these current guidelines represent the first steps to support countries as they develop approaches to delay or prevent the onset of dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. 2 related who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 19, "section": "1.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and tools several existing who guidelines and tools designed for the general population are relevant for addressing health conditions that may increase the risk of cognitive decline or dementia in individuals with normal cognition or mild cognitive impairment ( mci ). the following who guidelines and tools were consulted when developing the current guidelines :", "metadata": {"doc_name": "9789241550543-eng", "page": 19, "section": "1.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• mhgap intervention guide – version 2. 0 for mental,", "metadata": {"doc_name": "9789241550543-eng", "page": 19, "section": "1.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "neurological and substance use disorders in non - specialized health settings. geneva : who, 2016. http : / / www. who. int / mental _ health / mhgap / mhgap _ intervention _ guide _ 02 / en /", "metadata": {"doc_name": "9789241550543-eng", "page": 19, "section": "1.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• prevention and control of noncommunicable", "metadata": {"doc_name": "9789241550543-eng", "page": 19, "section": "1.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "diseases : guidelines for primary health care in low - resource settings. geneva : who, 2012. http : / / apps. who. int / iris / bitstream / 10665 / 76173 / 1 / 9789241548397 _ eng. pdf", "metadata": {"doc_name": "9789241550543-eng", "page": 19, "section": "1.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• package of essential noncommunicable ( pen )", "metadata": {"doc_name": "9789241550543-eng", "page": 19, "section": "1.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "disease interventions for primary health care in low - resource settings. geneva : who, 2010. http : / / www. who. int / cardiovascular _ diseases / publications / pen2010 / en /", "metadata": {"doc_name": "9789241550543-eng", "page": 19, "section": "1.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• global recommendations on physical activity for", "metadata": {"doc_name": "9789241550543-eng", "page": 19, "section": "1.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "health. geneva : who, 2010. http : / / www. who. int / dietphysicalactivity / publications / 9789241599979 / en /", "metadata": {"doc_name": "9789241550543-eng", "page": 19, "section": "1.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• integrated care for older people ( icope ) :", "metadata": {"doc_name": "9789241550543-eng", "page": 19, "section": "1.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "recommendations on interventions to improve physical and mental capacities of older people at community level. geneva : who, 2016. 2 available at http : / / www. who. int / mental _ health / action _ plan _ 2013 / en / 3 available at http : / / www. who. int / nmh / publications / ncd - action - plan / en / 4 available at http : / / who. int / ageing / global - strategy / en / 5 available at http : / / www. who. int / substance _ abuse / activities / gsrhua / en / 6 available at http : / / www. who. int / dietphysicalactivity / indicators % 20english. pdf", "metadata": {"doc_name": "9789241550543-eng", "page": 19, "section": "1.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. 3", "metadata": {"doc_name": "9789241550543-eng", "page": 20, "section": "1.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "target audience the guidelines are primarily targeted at health care providers working at a first or second level facility or at district level, including basic outpatient and inpatient services. the health care providers could be doctors, nurses or other cadres of health workers. quality improvement teams at all levels of the system will benefit from the work. in addition, the guidelines and their derivative products have implications for policy - makers, health care planners and programme managers at national and international level, as well as the general population.", "metadata": {"doc_name": "9789241550543-eng", "page": 20, "section": "1.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. 4", "metadata": {"doc_name": "9789241550543-eng", "page": 20, "section": "1.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "goals and objectives", "metadata": {"doc_name": "9789241550543-eng", "page": 20, "section": "1.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• to provide evidence - based recommendations on", "metadata": {"doc_name": "9789241550543-eng", "page": 20, "section": "1.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "lifestyle behaviours and interventions to delay or prevent cognitive decline and dementia in the general population.", "metadata": {"doc_name": "9789241550543-eng", "page": 20, "section": "1.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• to provide evidence - based recommendations on", "metadata": {"doc_name": "9789241550543-eng", "page": 20, "section": "1.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "management of specific physical and mental health conditions to delay or prevent cognitive decline and dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 20, "section": "1.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. 5", "metadata": {"doc_name": "9789241550543-eng", "page": 21, "section": "1.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "guiding principles the following principles have informed the development of these guidelines and should guide their implementation :", "metadata": {"doc_name": "9789241550543-eng", "page": 21, "section": "1.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• the guidelines should expedite the achievement of", "metadata": {"doc_name": "9789241550543-eng", "page": 21, "section": "1.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the goals outlined in the global action plan on the public health response to dementia 2017 – 2025, as well as target 3. 4 of the sustainable development goals, which focuses on reducing the premature mortality from ncds and the promotion of mental health and well - being ( un, 2019 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 21, "section": "1.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• the process of developing these guidelines, and", "metadata": {"doc_name": "9789241550543-eng", "page": 21, "section": "1.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "their subsequent implementation, should concretely foster the right to equal levels of health for people at risk of cognitive decline and dementia and promote their active involvement.", "metadata": {"doc_name": "9789241550543-eng", "page": 21, "section": "1.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• the recommendations should be implemented", "metadata": {"doc_name": "9789241550543-eng", "page": 21, "section": "1.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "with accompanying efforts to safeguard the human rights of persons living with cognitive decline and dementia, including reduction of stigma and discrimination, reducing barriers to seek health and social care services, and ensuring informed decision - making in treatment choices. implementation of the recommendations should be tailored to the local context, including the availability of financial and human resources. however, the inequities addressed in these guidelines are common across all countries, and should be made a priority in health services. 7 available at http : / / www. who. int / mental _ health / action _ plan _ 2013 / en / 8 available at http : / / www. who. int / nmh / publications / ncd - action - plan / en / 9 available at http : / / who. int / ageing / global - strategy / en / 10 available at http : / / www. who. int / substance _ abuse / activities / gsrhua / en / 11 available at http : / / www. who. int / dietphysicalactivity / indicators % 20english. pdf", "metadata": {"doc_name": "9789241550543-eng", "page": 21, "section": "1.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "6 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "guideline development process 2", "metadata": {"doc_name": "9789241550543-eng", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. 1", "metadata": {"doc_name": "9789241550543-eng", "page": 23, "section": "2.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "guideline development group a who guideline steering group, led by the department of mental health and substance abuse, was established with representatives from who regional offices and relevant who departments and programmes. the guideline steering group provided overall support to the guideline development process. two additional groups were established : a guideline development group ( gdg ) and an external review group ( erg ). the gdg included a panel of academicians and clinicians with multidisciplinary expertise on the conditions covered by the guidelines. consideration was given to geographic diversity and gender balance ( see annex 1 ). as a respected researcher in the field, the chairperson was selected for their extensive experience of guideline development methodology, and their participation in other guideline development groups. each potential gdg member was asked to complete the who declaration of interest ( doi ) form. these were reviewed by the steering group.", "metadata": {"doc_name": "9789241550543-eng", "page": 23, "section": "2.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. 2 declarations of interest by", "metadata": {"doc_name": "9789241550543-eng", "page": 23, "section": "2.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the gdg members and external reviewers all gdg members, peer reviewers and systematic review team members were requested to complete the doi prior to the evidence review process for guideline development. invitations to participate in the gdg meeting were sent only after the doi had been reviewed and approved. the gdg members were also required to complete a confidentiality undertaking. once received, the who secretariat reviewed the dois, as well as additional information ( internet and bibliographic database search ), and evaluated if there were any conflicts of interest and if so, whether these required a management plan. the group composition was finalized after this process. the names and brief biographies of the members being considered for participation in the gdg were disclosed for public notice and comment prior to the meeting. at the beginning of the gdg meeting, the doi of each gdg member were presented and gdg members, as well as external partners, were asked to update their doi with relevant changes by notifying the who secretariat. declarations of interest were reassessed for potential conflict before the face - to - face meeting in geneva. none of the members had major conflicts of interest. all decisions were documented ( see annex 2 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 23, "section": "2.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. 3 collaboration with", "metadata": {"doc_name": "9789241550543-eng", "page": 24, "section": "2.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "external partners the center for alzheimer research at the karolinska institutet, stockholm, sweden, and the school of psychology at the university of new south wales and neuroscience research, australia, supported the development of the guidelines by conducting the evidence review and synthesis.", "metadata": {"doc_name": "9789241550543-eng", "page": 24, "section": "2.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. 4 identifying, appraising", "metadata": {"doc_name": "9789241550543-eng", "page": 24, "section": "2.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and synthesizing available evidence", "metadata": {"doc_name": "9789241550543-eng", "page": 24, "section": "2.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the procedure of the scoping review to identify", "metadata": {"doc_name": "9789241550543-eng", "page": 24, "section": "2.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the draft population, intervention, comparison, outcome ( pico ) questions consisted of the identification of potentially modifiable risk factors and interventions for cognitive decline or dementia. these interventions are summarized in existing who guidelines listed earlier, such as the prevention and control of noncommunicable diseases ; package of essential noncommunicable ( pen ) disease interventions for primary health care in low - resource settings ; and integrated care for older people ( icope ) guidelines. these guidelines, however, do not include cognitive decline or dementia as outcomes. among recent summary reports, the lancet commission on dementia prevention, intervention, and care report summarizes the emerging knowledge on dementia risk factors and interventions ( livingston et al., 2017 ). the risk factors and interventions reported in this set of systematic reviews included education, exercise, maintaining social engagement, reducing smoking, and management of hearing loss, depression, hypertension, diabetes and obesity. another systematic review requested and supported by the national institute on aging ( nia ) at the national institutes of health, united states of america, also identified risk factors and evidence for interventions, specifically cognitive training, blood pressure management and exercise ( kane et al., 2017 ). the interventions reported in these reviews have formed the basis of the interventions included in the pico questions. the population in these guidelines considered adults with normal cognition as well as those with mci. we", "metadata": {"doc_name": "9789241550543-eng", "page": 24, "section": "2.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and exercise ( kane et al., 2017 ). the interventions reported in these reviews have formed the basis of the interventions included in the pico questions. the population in these guidelines considered adults with normal cognition as well as those with mci. we use the term mci to refer to a disorder characterized by impairment of memory, learning difficulties and reduced ability to concentrate on a task for more than brief periods, beyond what is expected in normal ageing. there is often a marked feeling of mental fatigue when mental tasks are attempted, and new learning is found to be subjectively difficult even when objectively successful. none of these symptoms is so severe that a diagnosis of dementia can be made. individuals diagnosed with mci, however, are at greater risk of developing dementia ; the inclusion of adults with mci in these guidelines will enable the use of interventions to slow the progression of cognitive decline, i. e. the transition from mci to dementia itself.", "metadata": {"doc_name": "9789241550543-eng", "page": 24, "section": "2.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "9 the scope of these guidelines is prevention / risk reduction of cognitive decline or dementia ( main outcomes of interest ). cognitive decline is defined as a noticeable and measurable loss or abnormality in", "metadata": {"doc_name": "9789241550543-eng", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "attention functions, memory functions or higher", "metadata": {"doc_name": "9789241550543-eng", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "level cognitive functions ( including attention, language and reasoning ). dementia is a syndrome that includes cognitive decline and other symptoms and can be diagnosed based on icd - 10 criteria. it involves a decline in memory with impairment of at least one other cognitive function, such as skilled movements ( limb apraxia ), language ( aphasia ) or executive function ( e. g. planning, attention and abstract reasoning ). this decline should represent a change from previous behaviour, and impair social and / or occupational functioning. as stated in the background section, when we use the word dementia in this document, we are referring to the primary or neurodegenerative dementias. the gdg provided input into the scope of the guidelines and assisted the steering group in developing the key questions. twelve pico - structured questions were developed ( annex 3 ). outcomes were rated by gdg members according to their importance, as “ critical ”, “ important ” or “ unimportant ”. those outcomes rated as critical and important were selected for inclusion into the pico. regular communication and discussions with the gdg were held by email and teleconferences, respectively.", "metadata": {"doc_name": "9789241550543-eng", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the systematic review team developed protocols", "metadata": {"doc_name": "9789241550543-eng", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "to review the evidence that existed for the inter - ventions to reduce the risk of cognitive decline and / or dementia ( as outlined in the pico questions ) for adults with normal cognition or mci ( annex 4 ). existing relevant systematic reviews were identified for each of the pico questions. the steering group assessed the quality of existing reviews using the assessment of multiple systematic reviews ( amstar ) checklist. systematic reviews found to be of high quality were also assessed for timeliness to ensure that the most current evidence was used. the grading of recommendations assessment, development and evaluation ( grade ) methodology", "metadata": {"doc_name": "9789241550543-eng", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "( guyatt et al., 2011 ), as well as the who handbook", "metadata": {"doc_name": "9789241550543-eng", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "for guideline development, were used to develop the evidence profiles. the quality assessment of the evidence was performed according to grade considering study design – randomized controlled trials ( rct ) or observational studies, risk of bias, inconsistency, indirectness, imprecision and risk of reporting bias. evidence was characterized as either", "metadata": {"doc_name": "9789241550543-eng", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "high, moderate, low or very low.", "metadata": {"doc_name": "9789241550543-eng", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "guideline development process", "metadata": {"doc_name": "9789241550543-eng", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. 5 decision - making during", "metadata": {"doc_name": "9789241550543-eng", "page": 26, "section": "2.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the gdg meeting the gdg met at the who headquarters in geneva, 2 – 3 july 2018. the evidence review was sent out in advance and it was summarized in a presentation during the meeting. the gdg members discussed the evidence, clarified points and interpreted the findings in order to develop recommendations based on the draft prepared by the who secretariat. the gdg considered the relevance of the recommendations for adults with normal cognition or mci based on the grade evidence - to - decision ( etd ) framework ( alonso - coello et al., 2016 ), considering the balance of benefit and harm of each intervention ; values and preferences of the individuals involved ; costs and resource use ; acceptability of the intervention to health care providers in lmic ; feasibility of implementation ; and impact on equity and human rights. no surveys or formal cost - effectiveness studies to determine resource constraints were conducted but discussions of these domains were informed by the combined expertise and experience of the gdg members. equity and human rights were considered by specifically searching databases that include studies from lmic, examining data for disaggregation for specific subgroups. potential differential effects of the interventions on different subgroups of people related to economic status, employment or occupation, education, place of residence, gender or ethnicity were considered by the gdg. taking into account these considerations, when making a strong recommendation, the", "metadata": {"doc_name": "9789241550543-eng", "page": 26, "section": "2.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "differential effects of the interventions on different subgroups of people related to economic status, employment or occupation, education, place of residence, gender or ethnicity were considered by the gdg. taking into account these considerations, when making a strong recommendation, the gdg was confident that the desirable effects of the intervention outweigh any undesirable effects. when the gdg was uncertain about the balance between the desirable and undesirable effects, the gdg issued a conditional recommendation. strong recommendations imply that most individuals would want the intervention and should receive it, while conditional recommendations imply that different choices may be appropriate for individual patients and they may require assistance at arriving at management decisions. in some instances, even when the quality of evidence was low or very low, it was agreed that if the recommendation would be of general benefit, and this was seen to outweigh the harms, it may still be rated as strong. in the event of a disagreement, the chair and the methodologist would ascertain whether the dispute was related to the interpretation of the data or to the way that the recommendation was formulated. if a consensus agreement was not reached, the gdg members agreed to a majority vote of 70 %, to determine a decision. who staff members present at the meeting, as well as other external technical experts involved in the collection and review of the evidence, were", "metadata": {"doc_name": "9789241550543-eng", "page": 26, "section": "2.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "agreement was not reached, the gdg members agreed to a majority vote of 70 %, to determine a decision. who staff members present at the meeting, as well as other external technical experts involved in the collection and review of the evidence, were excluded from voting. the gdg members reached a consensus agreement on all recommendations and ratings and voting was not needed.", "metadata": {"doc_name": "9789241550543-eng", "page": 26, "section": "2.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. 6", "metadata": {"doc_name": "9789241550543-eng", "page": 27, "section": "2.6", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "document preparation and peer review the draft guideline and evidence profiles prepared by who staff and the gdg were circulated to the erg and the steering group. the role of the erg was to identify any errors or missing data and to comment on clarity, setting - specific issues and implications for", "metadata": {"doc_name": "9789241550543-eng", "page": 27, "section": "2.6", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "implementation rather than changing the recommen -", "metadata": {"doc_name": "9789241550543-eng", "page": 27, "section": "2.6", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "dations. all inputs and remarks were discussed and agreed with the gdg by email.", "metadata": {"doc_name": "9789241550543-eng", "page": 27, "section": "2.6", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "12 risk reduction of cognitive decline and dementia : who guidelines this section provides an overview of each pico question described", "metadata": {"doc_name": "9789241550543-eng", "page": 28, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "under the following headings : background ; recommendations and additional considerations ; supporting evidence for the recommendations and the rationale for the recommendations based on the evidence synthesized as well as criteria listed in the etd tables. complete evidence profiles for each", "metadata": {"doc_name": "9789241550543-eng", "page": 28, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pico question including the grade tables and the etd tables are included", "metadata": {"doc_name": "9789241550543-eng", "page": 28, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "in the web annex. evidence and recommendations 3", "metadata": {"doc_name": "9789241550543-eng", "page": 28, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 1", "metadata": {"doc_name": "9789241550543-eng", "page": 29, "section": "3.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "physical activity interventions background a physically active lifestyle is linked to brain health. in large observational studies with follow - up periods extending decades, physically active people seem less likely to develop cognitive decline, all - cause dementia, vascular dementia and alzheimer disease when compared with inactive people ( gallaway et al., 2017 ; hamer & chida, 2009 ; sofi et al., 2011 ; stephen et al., 2017 ). especially, the highest levels of physical exercise seem to be most protective ( hamer & chida, 2009 ; sofi et al., 2011 ). physical activity seems to have beneficial effects on brain structures, which may underlie this association ( rovio et al., 2010 ). other potential mechanisms underlying the association are most likely indirect, such as the positive effects of physical exercise on other modifiable cardiovascular risk factors ( cvrfs ), including hypertension, insulin resistance and high cholesterol levels as well as other biological mechanisms, including but not limited to enhancing the immune system function, anti - inflammatory properties, and increasing neurotrophic factors. physical activity interventions are described in", "metadata": {"doc_name": "9789241550543-eng", "page": 29, "section": "3.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "who ’ s global recommendations on physical activity", "metadata": {"doc_name": "9789241550543-eng", "page": 29, "section": "3.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "for health ( 2010 ). recommendations and considerations recommendation 1 :", "metadata": {"doc_name": "9789241550543-eng", "page": 29, "section": "3.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "physical activity should be recommended to adults with normal cognition to reduce the risk", "metadata": {"doc_name": "9789241550543-eng", "page": 29, "section": "3.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "of cognitive decline. quality of evidence : moderate strength of the recommendation : strong", "metadata": {"doc_name": "9789241550543-eng", "page": 29, "section": "3.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "14 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "recommendation 2 : physical activity may be recommended to adults with mci to reduce the risk of cognitive decline. quality of evidence : low strength of the recommendation : conditional", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "who ’ s global recommendations on physical activity for health ( 2010 )", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "( http : / / www. who. int / dietphysicalactivity / publications / 9789241599979 / en / ) below is an extract from these recommendations for adults 65 years and above : for adults 65 years and above, physical activity includes recreational or leisure - time physical activity, transportation ( e. g. walking or cycling ), occupational ( if the person is still engaged in work ), household chores, play, games, sports or planned exercise, in the context of daily, family, and community activities. in order to improve cardiorespiratory and muscular fitness, bone and functional health, and reduce the risk of ncds, depression and cognitive decline, the following are recommended :", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. adults aged 65 years and above should do at least 150 minutes of moderate - intensity", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "aerobic physical activity throughout the week, or do at least 75 minutes of vigorous - intensity", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "aerobic physical activity throughout the week, or an equivalent combination of moderate -", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and vigorous - intensity activity.", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. aerobic activity should be performed in bouts of at least 10 minutes ’ duration. 3. for additional health benefits, adults aged 65 years and above should increase their moderate -", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "intensity aerobic physical activity to 300 minutes per week, or engage in 150 minutes of vigorous - intensity aerobic physical activity per week, or an equivalent combination of moderate - and vigorous - intensity activity.", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "4. adults of this age group with poor mobility should perform physical activity to enhance balance", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and prevent falls on 3 or more days per week.", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "5. muscle - strengthening activities should be done involving major muscle groups, on 2 or more", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "days per week.", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "6. when adults of this age group cannot do the recommended amounts of physical activity due to", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "health conditions, they should be as physically active as their abilities and conditions allow. overall, across all the age groups, the benefits of implementing the above recommendations, and of being physically active, outweigh the harms. at the recommended level of 150 minutes per week of moderate - intensity activity, musculoskeletal injury rates appear to be uncommon. in a population - based approach, in order to decrease the risks of musculoskeletal injuries, it would be appropriate to encourage a moderate start with gradual progress to higher levels of physical activity.", "metadata": {"doc_name": "9789241550543-eng", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "15 evidence and recommendations additional considerations include :", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• physical activity is easily available for everybody", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and has a large range of beneficial effects.", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• aerobic activity plays a key role in the beneficial", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "effect of physical activity.", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "supporting evidence and", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "rationale for physical activity interventions ( e. g. aerobic, resistance training or multicomponent physical activity ) compared with usual care or no intervention, four systematic reviews were identified for six different physical activity interventions ( barha et al., 2017 ; barreto et al., 2017 ; northey et al., 2018 ; song et al., 2018 ). these were :", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. aerobic exercise intervention versus usual care or", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "no intervention in adults with normal cognition.", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. training exercise intervention versus usual care or", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "no intervention in adults with normal cognition.", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. multimodal exercise intervention versus usual", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "care or no intervention in adults with normal cognition.", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "4. aerobic exercise intervention versus usual care or", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "no intervention in adults with mci.", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "5. training exercise intervention versus usual care or", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "no intervention in adults with mci.", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "6. multimodal exercise intervention versus usual", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "care or no intervention in adults with mci. for cognitive outcomes in healthy adults, there is moderate quality evidence which indicates that physical activity interventions have a positive effect on cognition. there is low to moderate quality evidence that suggests that physical activity does not affect risk of mci and dementia. for cognitive outcomes in adults with mci, there is low quality evidence that indicates that physical activity interventions have a positive effect on cognition. however, these benefits are not consistent across all", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "cognitive domains.", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the evidence shows that the effect size is larger for aerobic training versus resistance training and there is stronger evidence for adults with normal cognition ( especially aerobic training ) than in adults with mci. the gdg concluded that the desirable effects of physical activity outweighed the undesirable effects. overall, low to moderate quality evidence has shown that physical activity has a small but beneficial effect on cognition. even in mci populations, low quality evidence suggests cognitive benefits of physical exercise. the effect of these interventions seems to be mostly due to aerobic exercise. based on the quality of evidence, a strong recommendation was made for healthy adults and a conditional one for adults with mci.", "metadata": {"doc_name": "9789241550543-eng", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 2", "metadata": {"doc_name": "9789241550543-eng", "page": 32, "section": "3.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "tobacco cessation interventions background tobacco dependence is the leading cause of preventable death globally, causing an estimated 5 million deaths per year ( who, 2011 ) and worldwide medical costs ranging in billions of us dollars ( lightwood et al., 2000 ). tobacco is the major risk factor for a number of conditions, including many types of cancers, cardiovascular diseases ( cvds ) and risk factors, and respiratory disorders ( us department of health human services, 2004 ), and tobacco cessation has been demonstrated to significantly reduce these health risks ( pirie et al., 2013 ). tobacco cessation has also been associated with reduced depression, anxiety and stress, and improved mood and quality of life compared with continuing to smoke ( taylor et al., 2014 ). tobacco dependence is also associated with other disorders and age - related conditions, such as frailty and work ability in older people ( amorim et al., 2014 ; kojima et al., 2015 ), as well as dementia and cognitive decline ( durazzo et al., 2014 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 32, "section": "3.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "interventions to treat tobacco dependence can be", "metadata": {"doc_name": "9789241550543-eng", "page": 32, "section": "3.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "very diverse, based on either or both behavioural / psychological strategies and various pharmacological treatments. non - pharmacological interventions can have mixed results ( niaura, 2008 ). counselling is the most frequently used approach, but others have also been explored, such as mindfulness - based approaches, cognitive behavioural therapy, behavioural activation therapy, motivational interviewing, contingency manage - ment, and exposure and / or aversion to smoking. among the pharmacological therapies for tobacco cessation, nicotine replacement therapy, bupropion and varenicline are the most common, but low overall treatment efficacy and adverse effects are key limitations ( gomez - coronado", "metadata": {"doc_name": "9789241550543-eng", "page": 32, "section": "3.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "et al., 2018 ). combinations of non - pharmacological", "metadata": {"doc_name": "9789241550543-eng", "page": 32, "section": "3.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and pharmacological approaches seem to be the most effective in supporting tobacco cessation ( gomez - coronado et al., 2018 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 32, "section": "3.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "17 evidence and recommendations additional considerations include :", "metadata": {"doc_name": "9789241550543-eng", "page": 33, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• in keeping with interventions described in the", "metadata": {"doc_name": "9789241550543-eng", "page": 33, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "who training package for tobacco dependence, people who make use of tobacco should be advised to quit and the appropriate programmes aimed at preventing tobacco use uptake, promoting tobacco cessation, as well as diagnosing and treating tobacco dependence, should be established ( http : / / www. who. int / tobacco / publications / building _ capacity / training _ package / treatingtobaccodependence / en / ). the interventions include behavioural interventions, as well as pharmacological ones ( i. e. nicotine replacement therapy, bupropion, varenicline ).", "metadata": {"doc_name": "9789241550543-eng", "page": 33, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• individual level interventions should be provided", "metadata": {"doc_name": "9789241550543-eng", "page": 33, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "in the context of population level tobacco cessation programmes.", "metadata": {"doc_name": "9789241550543-eng", "page": 33, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "supporting evidence and", "metadata": {"doc_name": "9789241550543-eng", "page": 33, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "rationale no systematic reviews comparing tobacco cessation interventions with no intervention were identified. a large body of observational evidence is available on tobacco smoking as a risk factor for cognitive impairment and dementia. these studies show an association between tobacco smoking ( including in mid - life ) and dementia, or cognitive decline, in later life ( beydoun et al., 2014 ; di marco et al., 2014 ; lafortune et al., 2016 ; north et al., 2015 ; xu et al., 2015 ; zhong et al., 2015 ). only limited adverse events have been reported and only for pharmacological interventions ( motooka et al., 2018 ). therefore, any type of intervention aimed at tobacco cessation is likely to be more beneficial than detrimental. the gdg made a strong recommendation although", "metadata": {"doc_name": "9789241550543-eng", "page": 33, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "evidence from experimental intervention trials is", "metadata": {"doc_name": "9789241550543-eng", "page": 33, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "not available, since tobacco use has substantial established harm and the epidemiological / observational evidence on tobacco use and increased risk of dementia fulfils most of the bradford - hill ’ s criteria for causation ( lafortune et al., 2016 ). the evidence is strong, the population attributable risk is high, reproducible in different settings and with different study designs, specific, and indicates a dose - response effect. in addition, criteria such as temporality ( mid - life smoking is correlated to a higher risk of late life dementia ) ( lafortune et al., 2016 ), coherence ( experimental laboratory results are in keeping with the observational evidence ) ( durazzo et al., 2014 ) and mecha - nistic evidence suggest that smoking causes brain damage, underpinning subsequent cognitive decline. recommendations and considerations recommendation :", "metadata": {"doc_name": "9789241550543-eng", "page": 33, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "interventions for tobacco cessation should be offered to adults who use tobacco since they may reduce the risk of cognitive decline and dementia in addition to other health benefits. quality of evidence : low", "metadata": {"doc_name": "9789241550543-eng", "page": 33, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of recommendation : strong", "metadata": {"doc_name": "9789241550543-eng", "page": 33, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 3", "metadata": {"doc_name": "9789241550543-eng", "page": 34, "section": "3.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "nutritional interventions population : adults with normal cognition or mci", "metadata": {"doc_name": "9789241550543-eng", "page": 34, "section": "3.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "intervention :", "metadata": {"doc_name": "9789241550543-eng", "page": 34, "section": "3.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "dietary supplements ( e. g. b vitamins, antioxidants, omega - 3 and ginkgo ) comparison :", "metadata": {"doc_name": "9789241550543-eng", "page": 34, "section": "3.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "care as usual / placebo or one treatment", "metadata": {"doc_name": "9789241550543-eng", "page": 34, "section": "3.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "versus another outcomes :", "metadata": {"doc_name": "9789241550543-eng", "page": 34, "section": "3.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• critical – cognitive function – incident mci – dementia • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates", "metadata": {"doc_name": "9789241550543-eng", "page": 34, "section": "3.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 3a for adults with normal cognition or mci, are nutritional interventions including dietary supplements more effective than usual care or no intervention in reducing the risk / progression of cognitive decline and / or dementia? 3. 3b for adults with normal cognition or mci, are nutritional interventions such as healthy dietary patterns ( e. g. the mediterranean diet ) more effective than usual care or no intervention in reducing the risk / progression of cognitive decline and / or dementia? population : adults with normal cognition or mci", "metadata": {"doc_name": "9789241550543-eng", "page": 34, "section": "3.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "intervention :", "metadata": {"doc_name": "9789241550543-eng", "page": 34, "section": "3.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "healthy dietary pattern ( e. g. the mediterranean diet ) comparison : care as usual or no intervention outcomes :", "metadata": {"doc_name": "9789241550543-eng", "page": 34, "section": "3.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• critical – cognitive function – incident mci – dementia • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates", "metadata": {"doc_name": "9789241550543-eng", "page": 34, "section": "3.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "background a healthy diet throughout the life course plays a crucial role in optimal development, and in maintaining health and preventing ncds. previous dietary intervention studies have shown that dietary changes are involved in prevention of many conditions that increase the risk of dementia, such as diabetes ( diabetes prevention program research group, 2002 ; tuomilehto et al., 2001 ) and cvd ( rees et al., 2013 ). mechanistic and animal models have", "metadata": {"doc_name": "9789241550543-eng", "page": 34, "section": "3.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "19 evidence and recommendations suggested a variety of pathways that link dietary factors to neuropathological changes in the development of dementia ( swaminathan & jicha, 2014 ). therefore, dietary factors may be involved in the development of dementia, both directly and through their role on other risk factors, and a healthy diet may have a great preventive potential for cognitive impairment. the mediterranean diet is the most extensively studied dietary approach, in general as well as in relation to cognitive function. several systematic reviews of observational studies have concluded that high adherence to the mediterranean diet is associated with decreased risk of mci and ad, but modest adherence is not ( singh et al., 2014 ; wu & sun, 2017 ). moreover, among participants with normal cognition, higher adherence is associated with better episodic memory and global cognition ( loughrey et al., 2017 ). other promising dietary approaches associated with better cognitive function include : dietary approaches to stop hypertension ( dash ) ( berendsen et al., 2017 ; morris et al., 2015a ; 2015b ; wengreen et al., 2013 ) ; and the brain health - specific mediterranean - dash intervention for neurodegenerative delay ( mind ) diet. concerning individual foods and nutrients, consumption of fruit and vegetables ( jiang et al., 2017 ; wu et al., 2017 ) and fish ( bakre", "metadata": {"doc_name": "9789241550543-eng", "page": 35, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "- specific mediterranean - dash intervention for neurodegenerative delay ( mind ) diet. concerning individual foods and nutrients, consumption of fruit and vegetables ( jiang et al., 2017 ; wu et al., 2017 ) and fish ( bakre et al., 2018 ; zhang et al., 2016 ) are most consistently associated with decreased risk of dementia. higher fish consumption has been linked to lower memory decline among healthy participants in many studies ( samieri et al., 2018 ), as well as intake of polyunsaturated fatty acids ( pufa ) ( fish - derived ) ( zhang et al., 2016 ). other foods and nutrients that have been associated with reduced risk of dementia or cognitive impairment are nuts, olive oil and coffee ( solfrizzi et al., 2017 ). evidence has also been reported concerning folate, vitamin e, carotenes, vitamin c and vitamin d ( balion et al., 2012 ; dangour et al., 2010 ; rafnsson et al., 2013 ; travica et al., 2017 ), but findings are inconsistent. recommendations and considerations recommendation 1 :", "metadata": {"doc_name": "9789241550543-eng", "page": 35, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the mediterranean - like diet may be recommended to adults with normal cognition and mci", "metadata": {"doc_name": "9789241550543-eng", "page": 35, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "to reduce the risk of cognitive decline and / or dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 35, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "quality of evidence : moderate", "metadata": {"doc_name": "9789241550543-eng", "page": 35, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : conditional recommendation 2 :", "metadata": {"doc_name": "9789241550543-eng", "page": 35, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "healthy, balanced diet should be recommended to all adults based on who recommendations", "metadata": {"doc_name": "9789241550543-eng", "page": 35, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "on healthy diet.", "metadata": {"doc_name": "9789241550543-eng", "page": 35, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "quality of evidence : low to high ( for different dietary components )", "metadata": {"doc_name": "9789241550543-eng", "page": 35, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : strong recommendation 3 :", "metadata": {"doc_name": "9789241550543-eng", "page": 35, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "vitamins b and e, pufa and multi - complex supplementation should not be recommended to reduce the risk of cognitive decline and / or dementia. quality of evidence : moderate", "metadata": {"doc_name": "9789241550543-eng", "page": 35, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : strong", "metadata": {"doc_name": "9789241550543-eng", "page": 35, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "20 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "additional considerations include :", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• the evidence and recommendations provided", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "assume that the nutritional status and potential micronutrients deficiencies in both mid - life and old age have been assessed and treated.", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• a balanced and varied diet represents a natural", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "source of polyphenols and protein.", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• the recommendation about vitamins b and e,", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pufa and multi - complex supplementation applies to people without nutrient deficiency.", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "supporting evidence and", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "rationale observational studies have consistently reported that a healthy diet is associated with better cognitive performance ( berendsen et al., 2017 ; frith et al., 2018 ; loughrey et al., 2017 ; morris et al., 2015 ; wengreen et al., 2013 ), but the evidence from clinical trials is more inconsistent ( d ’ cunha et al., 2018 ; fitzpatrick - lewis et al., 2015a ; 2015b ; forbes et al., 2015 ; radd - vagenas et al., 2018 ; solfrizzi et al., 2018 ). it is important to acknowledge that interventions with dietary modifications that improve several aspects of dietary intake at once are more likely to promote better cognition compared with supplementation with only some nutrients. dietary factors may have synergistic effects that are only evident in combinations of foods ( jacobs jr et al., 2009 ). who recommendations on a healthy diet ( http : / / www. who. int / en / news - room / fact - sheets / detail / healthy - diet )", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "for adults, the who guidelines recommend the following.", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "a healthy diet contains :", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• fruits, vegetables, legumes ( e. g. lentils, beans ), nuts and whole grains ( e. g. unprocessed maize,", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "millet, oats, wheat, brown rice ).", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• at least 400 g ( five portions ) of fruits and vegetables a day. potatoes, sweet potatoes, cassava", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and other starchy roots are not classified as fruits or vegetables.", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• less than 10 % of total energy intake from free sugars which is equivalent to 50 g ( or around 12", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "level teaspoons ) for a person of healthy body weight consuming approximately 2000 calories per day, but ideally less than 5 % of total energy intake for additional health benefits. most free sugars are added to foods or drinks by the manufacturer, cook or consumer, and can also be found in sugars naturally present in honey, syrups, fruit juices and fruit juice concentrates.", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• less than 30 % of total energy intake from fats. unsaturated fats ( found in fish, avocado, nuts,", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "sunflower, canola and olive oils ) are preferable to saturated fats ( found in fatty meat, butter, palm and coconut oil, cream, cheese, ghee and lard ) and trans - fats of all kinds, including both industrially produced trans - fats ( found in processed food, fast food, snack food, fried food, frozen pizza, pies, cookies, biscuits, wafers, margarines and spreads ) and ruminant trans - fats ( found in meat and dairy foods from ruminant animals, such as cows, sheep, goats, camels and others ). it is suggested to reduce the intake of saturated fats to less than 10 % of total energy intake and trans - fats to less than 1 % of total energy intake. in particular, industrially produced trans - fats are not part of a healthy diet and should be avoided.", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• less than 5 g of salt ( equivalent to approximately 1 teaspoon ) per day and use iodized salt.", "metadata": {"doc_name": "9789241550543-eng", "page": 36, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "21 evidence and recommendations regarding nutritional interventions, such as dietary supplements or healthy dietary patterns ( e. g. the mediterranean diet ) compared with usual care or no intervention, six systematic reviews were identified for nine different nutritional interventions. these interventions were :", "metadata": {"doc_name": "9789241550543-eng", "page": 37, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. multi - supplement complexes versus placebo in", "metadata": {"doc_name": "9789241550543-eng", "page": 37, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "adults with normal cognition ( d ’ cunha et al., 2018 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 37, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. multi - supplement complexes versus placebo in", "metadata": {"doc_name": "9789241550543-eng", "page": 37, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "adults with mci ( fitzpatrick - lewis et al., 2015 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 37, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. pufa versus placebo ( forbes et al., 2015 ). 4. vitamin b versus placebo ( forbes et al., 2015 ). 5. vitamin e versus placebo ( forbes et al., 2015 ). 6. polyphenols versus placebo ( solfrizzi et al., 2018 ). 7. protein supplementation versus placebo", "metadata": {"doc_name": "9789241550543-eng", "page": 37, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "( solfrizzi et al., 2018 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 37, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "8. chicken essence versus placebo ( teoh et al.,", "metadata": {"doc_name": "9789241550543-eng", "page": 37, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2016 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 37, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "9. mediterranean diet versus alternate or usual diet", "metadata": {"doc_name": "9789241550543-eng", "page": 37, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "( radd - vagenas et al., 2018 ). the outcomes of incident mci and dementia were only reported for interventions involving multi - supplement complexes in adults with normal cognition and the mediterranean diet ( d ’ cunha et al., 2018 ; radd - vagenas et al., 2018 ). however, neither of these interventions showed a direct effect in reducing the incidence of dementia and / or mci. all of the interventions / comparisons reported cognitive outcomes. there was moderate quality evidence that the mediterranean diet can improve verbal and visual memory ( radd - vagenas et al., 2018 ). a meta - analysis showed results that approached significance for global cognition and consistently positive, but non - significant, results were reported for all other cognitive outcomes ( attention, working memory, processing speed, language and executive function ) ( radd - vagenas et al., 2018 ). a consistent positive effect of polyphenols on cognitive performance was also found, however, the quality of the evidence was low ( solfrizzi et al., 2018 ). similarly, protein supplementations were found to have a beneficial effect on cognition in older adults, but the results were inconsistent and the quality of the evidence was low ( solfrizzi et al., 2018 ). overall, no effects were found for multi - complex ( d ’ cunha", "metadata": {"doc_name": "9789241550543-eng", "page": 37, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "a beneficial effect on cognition in older adults, but the results were inconsistent and the quality of the evidence was low ( solfrizzi et al., 2018 ). overall, no effects were found for multi - complex ( d ’ cunha et al., 2018 ; fitzpatrick - lewis et al., 2015 ), vitamins b and e ( forbes et al., 2015 ), and pufa supplementation ( forbes et al., 2015 ). low - quality evidence was reported for protein and polyphenols supplementation ( solfrizzi et al., 2018 ), and moderate evidence of a beneficial effect of the mediterranean diet was found ( radd - vagenas et al., 2018 ). three multi - supplement complex interventions : docosahexaenoic acid ( dha ) + eicosapentaenoic acid ( epa ) + vitamin e + soy phospholipids + tryptophan + melatonin ; vitamin e + multivitamin ; lyophilized royal jelly + gingko biloba + panax ginseng ; were examined and none showed an increased risk of any serious adverse event during the follow - up period ( moderate quality evidence, fitzpatrick - lewis et al., 2015 ). the gdg concluded that the benefits of a mediterranean diet and a balanced diet outweighed the", "metadata": {"doc_name": "9789241550543-eng", "page": 37, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "showed an increased risk of any serious adverse event during the follow - up period ( moderate quality evidence, fitzpatrick - lewis et al., 2015 ). the gdg concluded that the benefits of a mediterranean diet and a balanced diet outweighed the harms and provided conditional and strong recommendations respectively. the gdg noted that vitamin e and protein supplementation at high doses have been associated with undesirable non - anticipated effects that outweigh the benefits and recommended against their use.", "metadata": {"doc_name": "9789241550543-eng", "page": 37, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 4", "metadata": {"doc_name": "9789241550543-eng", "page": 38, "section": "3.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "interventions for alcohol use disorders background excessive alcohol consumption is common in many countries ( gell et al., 2015 ). in 2012, 5. 9 % of all deaths worldwide ( about 3. 3 million ) were directly attributable to harmful use of alcohol ( who, 2014 ). furthermore, excessive consumption of alcohol is one of the leading causes of general disability globally ( who, 2014 ), being a direct cause in more than 200 diseases including risk factors for dementia and injury conditions ( who, 1992 ; who 2019a ). there is extensive evidence on excessive alcohol as a risk factor for dementia and cognitive decline ( langballe et al., 2015 ; sachdeva et al., 2016 ; zhou et al., 2014 ). several approaches have been applied in interventions aimed at hazardous and harmful use of alcohol. pharmacological therapies with different types of drugs ( e. g. opioid antagonists, aldh2 inhibitors ) have shown various degrees of efficacy for adults with alcohol use disorders, although none of them showed to be superior in comparison trials. behaviour and psychological interventions have shown to be effective in alcohol use disorders, and especially among those with hazardous and harmful drinking. screening and brief intervention in primary care is one of the most cost - effective means of reducing alcohol - attributable morbidity and deaths ( kaner, 2018 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 38, "section": "3.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "alcohol use disorders, and especially among those with hazardous and harmful drinking. screening and brief intervention in primary care is one of the most cost - effective means of reducing alcohol - attributable morbidity and deaths ( kaner, 2018 ). interventions for alcohol use disorders have been described in the mhgap intervention guide - version 2. 0 for mental, neurological and substance use", "metadata": {"doc_name": "9789241550543-eng", "page": 38, "section": "3.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "disorders in non - specialized health settings", "metadata": {"doc_name": "9789241550543-eng", "page": 38, "section": "3.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "( http : / / www. who. int / mental _ health / mhgap / mhgap _ intervention _ guide _ 02 / en / ).", "metadata": {"doc_name": "9789241550543-eng", "page": 38, "section": "3.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "23 evidence and recommendations recommendations and considerations recommendation", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "interventions aimed at reducing or ceasing hazardous and harmful drinking should be offered", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "to adults with normal cognition and mci to reduce the risk of cognitive decline and / or dementia in addition to other health benefits.", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "quality of evidence : moderate ( for observational evidence )", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : conditional", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "who mhgap intervention guide - version 2 for mental, neurological and substance use disorders in non - specialized health settings", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "( http : / / www. who. int / mental _ health / mhgap / mhgap _ intervention _ guide _ 02 / en / ) the who mhgap intervention guide recommends the following : harmful use of alcohol", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• provide psychoeducation and emphasize that the level / pattern of alcohol use is causing", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "harm to health.", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• explore the person ’ s motivations for alcohol use. conduct motivational interviewing. • advise stopping alcohol completely or consuming at a non - harmful level ( if a non - harmful", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "level exists ) and indicate your intention in supporting the person in doing so. ask the person", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "if they are ready to try to make this change.", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• explore strategies for reducing or stopping use and strategies for reducing harm. • address food, housing and employment needs. • offer regular follow - up.", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "alcohol dependence", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• thiamine during alcohol use. • diazepam during alcohol detoxification to treat withdrawal symptoms. • naltrexone, acamprosate or disulfiram to prevent relapse after detoxification. • psychosocial interventions if available, e. g. cognitive behaviour therapy, motivational", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "enhancement therapy, contingency management therapy, family counselling or therapy, problem - solving counselling or therapy ; self - help groups.", "metadata": {"doc_name": "9789241550543-eng", "page": 39, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "24 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 40, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "additional considerations include :", "metadata": {"doc_name": "9789241550543-eng", "page": 40, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• interventions can be based on lifestyle /", "metadata": {"doc_name": "9789241550543-eng", "page": 40, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "behavioural changes or pharmacological treatments in accordance with the who mhgap guidelines. lifestyle behavioural interventions are likely to be more acceptable and have fewer adverse events.", "metadata": {"doc_name": "9789241550543-eng", "page": 40, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• a u - shaped relationship between alcohol", "metadata": {"doc_name": "9789241550543-eng", "page": 40, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "consumption and cognitive function has been reported. however, due to methodological limitations in most studies that describe this effect, it is not possible to assume that a light to moderate consumption of alcohol is, in fact, protective toward dementia and / or cognitive", "metadata": {"doc_name": "9789241550543-eng", "page": 40, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "decline. this, in addition to other health risks", "metadata": {"doc_name": "9789241550543-eng", "page": 40, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and the social and economic burden associated with alcohol, do not favour a general recommendation of its use.", "metadata": {"doc_name": "9789241550543-eng", "page": 40, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• individual level interventions should be provided", "metadata": {"doc_name": "9789241550543-eng", "page": 40, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "in the context of who global strategy to reduce harmful use of alcohol ( who 2010 ) and population level interventions, through strengthening restrictions on alcohol availability, enforcing drink driving countermeasures, facilitating access to screening, brief interventions, and treatment, enforcing bans or comprehensive restrictions on alcohol advertising, sponsorship, and promotion,", "metadata": {"doc_name": "9789241550543-eng", "page": 40, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "raising prices on alcohol through excise taxes", "metadata": {"doc_name": "9789241550543-eng", "page": 40, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and pricing policies.", "metadata": {"doc_name": "9789241550543-eng", "page": 40, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "supporting evidence and", "metadata": {"doc_name": "9789241550543-eng", "page": 40, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "rationale no systematic reviews were identified for interventions for hazardous and harmful alcohol consumption ( behavioural, psychological and pharmacological interventions ) and reduced the risk of cognitive decline and / or dementia. however, a large body of observational evidence is available on alcohol as a risk factor for cognitive decline and dementia ( beydoun et al., 2014 ; hersi et al., 2017 ; ilomaki et al., 2015 ; lafortune et al., 2016 ; piazza - gardner et al., 2013 ; xu et al., 2017 ). generally, single studies did not always show similar results ( mostly due to differences in study design ) but the most consistent pattern is that of a u - shaped relationship between alcohol consumption and dementia and / or cognitive impairment, which clearly links excessive alcohol consumption to a significantly increased risk ( xu et al., 2017 ). a range of adverse events has also been reported for pharmacological interventions aimed at reducing excessive alcohol consumption while lifestyle interventions are mostly based on behavioural interventions and no evidence of adverse events ( apart from those related to withdrawal syndrome ) have been identified ( nice, 2011 ). overall, the gdg concluded that the benefits outweighed the harms and, based on the strong observational evidence, made a conditional recommendation for interventions to reduce or cease hazardous and harmful alcohol use.", "metadata": {"doc_name": "9789241550543-eng", "page": 40, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 5", "metadata": {"doc_name": "9789241550543-eng", "page": 41, "section": "3.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "cognitive interventions background dementia is preceded by cognitive decline. however, not everyone who is exposed to dementia risk factors will go on to develop cognitive impairment. the concept of cognitive reserve has been proposed as a protective factor that may reduce the risk of clinical onset of dementia and cognitive decline ( stern, 2012 ). cognitive reserve refers to the brain ’ s ability to cope with or compensate for neuropathology or damage ( stern, 2012 ). studies have shown that increased cognitive activity may stimulate ( or increase ) cognitive reserve and have a buffering effect against rapid cognitive decline ( stern & munn, 2010 ) as well as a significant reduction in the risk of mci or ad diagnosis in those who reported high compared with low levels of cognitive activities ( combined or = 0. 38, 95 % ci : 0. 15 – 0. 99 ) ( sattler, 2012 ). increased cognitive activity can be achieved through cognitive stimulation therapy and / or cognitive training. cognitive stimulation therapy refers to “ participation in a range of activities aimed at improving cognitive and social functioning ” ( clare & woods, 2004 ), while cognitive training refers to “ guided practice of specific standardized tasks designed to enhance particular cognitive functions ” ( clare & woods, 2004 ). the nia ( united states of america ) identified cognitive training as an intervention aimed at preventing or delaying the onset of age - related cognitive decline, mci, or clinical alzheimer", "metadata": {"doc_name": "9789241550543-eng", "page": 41, "section": "3.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "designed to enhance particular cognitive functions ” ( clare & woods, 2004 ). the nia ( united states of america ) identified cognitive training as an intervention aimed at preventing or delaying the onset of age - related cognitive decline, mci, or clinical alzheimer ’ s - type dementia ( kane et al., 2017 ). additionally, the who icope guidelines ( http : / / www. who. int / ageing / publications / guidelines - icope / en / ) recommend cognitive stimulation for older adults with cognitive impairment. these interventions were assessed against outcomes that were judged as critical and important for this population.", "metadata": {"doc_name": "9789241550543-eng", "page": 41, "section": "3.5", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "26 risk reduction of cognitive decline and dementia : who guidelines supporting evidence and", "metadata": {"doc_name": "9789241550543-eng", "page": 42, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "rationale for cognitive stimulation versus usual care or no intervention in healthy older adults, evidence was extracted from one systematic review ( strout et al., 2016 ). no evidence for adults with mci was available. the review reported that half of the interventions evaluated proved to be effective in improving cognitive outcomes in at least one cognitive domain – executive function, attention, memory, language and / or processing speed ( strout et al., 2016 ). the quality of the evidence was low. the results were reported in narrative form and no meta - analysis was conducted. no evidence for incident mci or dementia was available. for cognitive training versus usual care or no intervention in healthy older adults, evidence was extracted from one systematic review ( chiu et al., 2017 ). the review conducted a meta - analysis which showed that cognitive training in healthy older adults has a moderate positive effect on overall cognitive functioning. the quality of evidence was low. no evidence for incident mci or dementia was available. for cognitive training versus usual care or no intervention in adults with mci, evidence was extracted from two systematic reviews ( chandler et al., 2016 ; sherman et al., 2017 ). with regards to cognitive function outcome, the quality of evidence is low showing that cognitive training in adults with mci has a small positive effect on cognition. with regards to incident dementia outcome, the quality of evidence", "metadata": {"doc_name": "9789241550543-eng", "page": 42, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "; sherman et al., 2017 ). with regards to cognitive function outcome, the quality of evidence is low showing that cognitive training in adults with mci has a small positive effect on cognition. with regards to incident dementia outcome, the quality of evidence is very low as the results were narratively reported. it was reported that one study found that half of the control group, but none of the intervention group, developed dementia at the 8 - month follow - up, while another found that more of the intervention group reported incident dementia at the 2 - year follow - up ( chandler et al., 2016 ). with regards to quality of life and functional level, the quality of evidence is low showing that cognitive training in adults with mci has a small positive effect on adl but not quality of life. the evidence for cognitive interventions is mainly in studies with older adults. the gdg concluded that in this population the desirable effects of the intervention outweighed the undesirable effects and provided a conditional recommendation for cognitive training. the evidence for cognitive stimulation in reducing the risk of dementia was insufficient and no recommendation was made by the gdg. recommendations and considerations recommendation : cognitive training may be offered to older adults with normal cognition and with mci to reduce the risk of cognitive decline and / or dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 42, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "quality of evidence : very low to low", "metadata": {"doc_name": "9789241550543-eng", "page": 42, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : conditional", "metadata": {"doc_name": "9789241550543-eng", "page": 42, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 6", "metadata": {"doc_name": "9789241550543-eng", "page": 43, "section": "3.6", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "social activity background social engagement is an important predictor of well - being throughout life ( cherry et al., 2011 ). social disengagement conversely, has been shown to place older individuals at increased risk of cognitive impairment and dementia ( fratiglioni et al., 2004 ). a systematic review and meta - analysis of longitudinal cohort studies showed that lower social participation, less frequent social contact and loneliness were associated with higher rates of incident dementia ( kuiper et al., 2015 ). the lancet commission on dementia prevention, intervention, and care identified social engagement as an intervention that could be used to prevent dementia ( livingston et al., 2017 ). recommendations and considerations", "metadata": {"doc_name": "9789241550543-eng", "page": 43, "section": "3.6", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "there is insufficient evidence for social activity and reduction of risk of cognitive", "metadata": {"doc_name": "9789241550543-eng", "page": 43, "section": "3.6", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "decline / dementia. social participation and social support are strongly connected to good health and well - being", "metadata": {"doc_name": "9789241550543-eng", "page": 43, "section": "3.6", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "throughout life and social inclusion should be supported over the life - course.", "metadata": {"doc_name": "9789241550543-eng", "page": 43, "section": "3.6", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "( global age - friendly cities : a guide, http : / / www. who. int / ageing / publications / global _ age _ friendly _ cities _ guide _ english. pdf )", "metadata": {"doc_name": "9789241550543-eng", "page": 43, "section": "3.6", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "28 risk reduction of cognitive decline and dementia : who guidelines supporting evidence and", "metadata": {"doc_name": "9789241550543-eng", "page": 44, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "rationale for preservation and promotion of social activity including community and family engagement versus care as usual or no intervention, evidence was extracted from one systematic review examining adults with normal cognition ( kelly et al., 2017 ). no evidence for adults with mci was available. for cognitive function outcomes, the quality of the evidence is very low. three rcts, which assessed the association between cognitive function and social activity, were deemed eligible. the review findings were reported narratively ( kelly et al., 2017 ). overall cognition was measured by varied composite measures of global cognition, including the adas - cog, mmse and mdrs. one of the three rcts found social activity intervention to be significantly associated with improvements in cognitive function ( pitkala et al., 2011 ). no data were available for incident mci or dementia, quality of life, functional level ( adl, iadl ), adverse events or drop - outs. the gdg concluded that the evidence is limited and inconclusive, so no recommendation was made for social activity and risk of cognitive decline / dementia. furthermore, there is a risk of bias arising from reverse causality whereby low social engagement prior to diagnosis of cognitive decline or dementia may be at least in part due to the disease process. the gdg did not make a recommendation against social activity as they concluded that social activity has a wide range of", "metadata": {"doc_name": "9789241550543-eng", "page": 44, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "reverse causality whereby low social engagement prior to diagnosis of cognitive decline or dementia may be at least in part due to the disease process. the gdg did not make a recommendation against social activity as they concluded that social activity has a wide range of other benefits to health and well - being.", "metadata": {"doc_name": "9789241550543-eng", "page": 44, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 7", "metadata": {"doc_name": "9789241550543-eng", "page": 45, "section": "3.7", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "weight management background overweight and obesity are some of the best characterized and established risks for a variety of ncds, responsible for at least 2. 8 million deaths each year worldwide, and of an estimated 35. 8 million ( 2. 3 % ) of global disability - adjusted life years ( dalys ) ( who, 2019b ). in 2008, 35 % of adults aged 20 + were overweight ( bmi ≥ 25 kg / m 2 ) ( 34 % men and 35 % of women ), with significantly variable prevalence among world areas, with the united states of america, europe and the eastern mediterranean regions with the highest concentration of people with overweight / obesity ( who, 2019b ). overweight and obesity, in particular, have been linked to a number of medical complications such as type 2 diabetes ( chan et al., 1994 ), cancer ( renehan et al., 2015 ), premature mortality ( fontana & hu, 2014 ), and cvd ( eckel, 1997 ), both as direct risk factors as well as risks for other cardiovascular risk factors, such as high cholesterol and hypertension. obesity has been steadily rising, particularly among older adults in the last few decades ( nguyen & el - serag, 2010 ) and although an increasing body of evidence suggests that overweight ( 25 < bmi < 30 ) in older adults could be more protective than", "metadata": {"doc_name": "9789241550543-eng", "page": 45, "section": "3.7", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "been steadily rising, particularly among older adults in the last few decades ( nguyen & el - serag, 2010 ) and although an increasing body of evidence suggests that overweight ( 25 < bmi < 30 ) in older adults could be more protective than normal weight in terms of overall mortality ( flicker et al., 2010 ), a link has also been established between excess of fat body mass and cognitive impairment ( xu et al., 2011 ). a recent systematic review and meta - analysis of observational studies conducted on a total of about 600 000 individuals showed that obesity ( but not overweight ) at mid - life increases the risk of dementia ( rr = 1. 33 ; 95 % ci : 1. 08 – 1. 63 ) ( albanese et al., 2017 ). it has been suggested that weight loss could indirectly reduce the risk of dementia by improving a variety of metabolic factors linked with the pathogenesis of cognitive impairment and dementia ( i. e. glucose", "metadata": {"doc_name": "9789241550543-eng", "page": 45, "section": "3.7", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "30 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "tolerance, insulin sensitivity, blood pressure, oxidative stress, and inflammation ) ( bennett et al., 2009 ). however, a direct beneficial effect of weight reduction intervention is also plausible. although, so far, evidence of potential cognitive benefits of weight loss seem to be strongly associated with increased physical activity ( colcombe et al., 2006 ; erickson et al., 2010 ), in 2011 a systematic review concluded that intentional weight loss can improve performance in some cognitive domains, at least in people with obesity ( siervo et al., 2011 ). additional considerations include :", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• lifestyle interventions that included both diet and", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "physical activity components seemed to show the best results.", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• in addition to interventions at individual level,", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "lifestyle interventions at the population level, such as activity parks, green spaces and infrastructure to support active commuting, need to be considered.", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• being underweight in both late - mid - life and old age", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "might be associated with a higher risk of dementia. however, it is likely that this association is explained, at least in part, by reverse causality, whereby brain pathology may cause weight loss before the clinical onset of dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• unintentional weight loss and malnutrition are", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "associated with poor health outcomes and should be investigated and treated at all ages. however, it is unlikely that interventions that favour weight gain in people who are underweight in either mid - or late life can reduce the risk of dementia or cognitive impairment. recommendation : interventions for mid - life overweight and / or obesity may be offered to reduce the risk of cognitive decline and / or dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "quality of evidence : low to moderate", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : conditional", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "who guidance on overweight and obesity outlined in prevention and control of noncommunicable diseases : guidelines for primary health care in low - resource settings ( 2012 ) ( http : / / www. who. int / nmh / publications / phc2012 / en / )", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "who guidance on overweight and obesity should be followed.", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• advise overweight patients to reduce weight by following a balanced diet. • advise patients to give preference to low glycaemic - index foods ( beans, lentils, oats and", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "unsweetened fruit ) as the source of carbohydrates in their diet.", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• advise patients to reduce sedentary behaviour and practise regular daily physical activity", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "appropriate for their physical capabilities ( e. g. walking ). recommendations and considerations", "metadata": {"doc_name": "9789241550543-eng", "page": 46, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "31 evidence and recommendations", "metadata": {"doc_name": "9789241550543-eng", "page": 47, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "supporting evidence and", "metadata": {"doc_name": "9789241550543-eng", "page": 47, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "rationale for weight reduction with behavioural and / or lifestyle interventions ( or control of obesity ) compared with usual care or no intervention, evidence was extracted from one systematic review examining adults with normal cognition who are overweight or obese ( veronese et al., 2017 ). no evidence for adults with mci was available. there was low to moderate evidence that lifestyle interventions aimed at weight reduction could improve cognitive function in the attention, memory and language domains. interventions were very short ( ranging from 8 to 48 weeks ). no data were found in relation to incident mci and dementia outcomes. no evidence of adverse events was identified. for pharmacological interventions for weight reduction ( or control of obesity ) compared with usual care or no intervention, no systematic reviews were found. the gdg concluded that the benefits of the interventions outweighed the harms and provided a conditional recommendation. since the observational evidence of a correlation between overweight / obesity and increased risk of dementia is stronger and more consistent in mid - life than in late life ( hersi et al., 2017 ; lafortune et al., 2016 ; pedditzi et al., 2016 ; prickett et al., 2015 ; xu et al., 2015 ), the gdg made a conditional recommendation for this population.", "metadata": {"doc_name": "9789241550543-eng", "page": 47, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 8 management of hypertension background", "metadata": {"doc_name": "9789241550543-eng", "page": 48, "section": "3.8", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "hypertension in mid - life has been associated with", "metadata": {"doc_name": "9789241550543-eng", "page": 48, "section": "3.8", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "an increased risk of late life dementia ( kivipelto et al., 2001 ). in particular, a pattern of increased blood", "metadata": {"doc_name": "9789241550543-eng", "page": 48, "section": "3.8", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pressure during mid - life followed by a rapid decrease", "metadata": {"doc_name": "9789241550543-eng", "page": 48, "section": "3.8", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "in blood pressure later in life has been found in", "metadata": {"doc_name": "9789241550543-eng", "page": 48, "section": "3.8", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "individuals who go on to develop dementia ( kivipelto", "metadata": {"doc_name": "9789241550543-eng", "page": 48, "section": "3.8", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "et al., 2001 ; launer et al., 2000 ; stewart et al., 2009 ). there is mixed evidence relating to the reduction of blood pressure in late mid - or late life and subsequent cognitive decline or dementia, however, there is evidence to show that the reduction of hypertension can have substantial benefits in reducing cardiovascular morbidity and mortality and thus improving overall health of the ageing population ( musini et al., 2009 ). hypertension can be prevented through a range of lifestyle factors, including eating a healthy diet, maintaining a healthy weight and participating in an adequate amount of physical activity. it can also be controlled through antihypertensive medication. however, the evidence for the effectiveness of blood pressure lowering treatments in reducing the risk of cognitive decline and dementia risk is mixed. recommendation 1 :", "metadata": {"doc_name": "9789241550543-eng", "page": 48, "section": "3.8", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "management of hypertension should be offered to adults with hypertension according to", "metadata": {"doc_name": "9789241550543-eng", "page": 48, "section": "3.8", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "existing who guidelines.", "metadata": {"doc_name": "9789241550543-eng", "page": 48, "section": "3.8", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "quality of evidence : low to high ( for different interventions )", "metadata": {"doc_name": "9789241550543-eng", "page": 48, "section": "3.8", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : strong recommendations and considerations", "metadata": {"doc_name": "9789241550543-eng", "page": 48, "section": "3.8", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "33 evidence and recommendations hearts technical package for cardiovascular disease management in", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "primary health care : evidence - based treatment protocols", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "( http : / / apps. who. int / iris / bitstream / handle / 10665 / 260421 / who - nmh - nvi - 18. 2 - eng. pdf? sequence = 1 ) medications used to treat hypertension", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• there are four main classes of antihypertensive medications : angiotensin converting enzyme ( ace )", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "inhibitors ; angiotensin receptor blockers ( arb ) ; calcium channel blockers ( ccb ) ; and thiazide and thiazide - like diuretics. any of these four classes of antihypertensive medication may be used unless there are specific contraindications. proper treatment of hypertension usually requires a combination of hypertension medications. notes on specific hypertension medications", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• pregnant women and women of childbearing age not on effective contraception should not be given", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "ace inhibitors, arbs or thiazide / thiazide - like diuretics ; ccbs should be used. if not controlled with intensification dose of medication, refer to specialist.", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• beta blockers are not recommended as first - line therapy. if a heart attack has been diagnosed", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "within the previous three years, or there is atrial fibrillation or heart failure, then a beta blocker should be added to the starting dose of antihypertensive medication. patients with angina may also benefit from treatment with a beta blocker. other treatment considerations", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• if there is a prior heart attack or stroke, or the person is otherwise at high risk of cvd, start a statin", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "at the same time as starting antihypertensive medication. ( statins should not be used in women who are or who may become pregnant. )", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• if there is a prior heart attack or ischemic stroke, start low - dose aspirin. • the hypertension protocols included in this module serve well for initiation and maintenance of", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "successful treatment. if there are serious adverse events, lack of control of blood pressure, or if a major medical event intervenes, then referral to a specialist will be needed.", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• if the patient is already on another medication regimen, blood pressure is controlled to the target", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "level, and the medications the patient is taking are accessible and affordable, there is no reason to change the regimen.", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• if the patient feels faint on standing, check blood pressure while standing. if the systolic blood", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pressure is consistently less than 110 mm hg in a patient on medical treatment, consider reducing the dosage or number of medications used. recommendation 2 :", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "management of hypertension may be offered to adults with hypertension to reduce the risk", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "of cognitive decline and / or dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "quality of evidence : very low ( in relation to dementia outcomes )", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : conditional", "metadata": {"doc_name": "9789241550543-eng", "page": 49, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "34 risk reduction of cognitive decline and dementia : who guidelines supporting evidence and", "metadata": {"doc_name": "9789241550543-eng", "page": 50, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "rationale for treatment of hypertension in the form of antihypertensive medication versus placebo or no intervention, evidence was extracted from two systematic reviews examining adults with normal cognition and hypertension ( parsons et al., 2016 ; weiss et al., 2016 ). no evidence for adults with mci was available. with regard to cognitive function and incident dementia outcomes, the quality of the evidence was low, which showed that antihypertensive therapy has no effect on cognitive decline or incidence of dementia. with regard to quality of life and functional level outcomes, the quality of evidence is very low, showing that antihypertensive therapy does not decrease quality of life or functional level. with regard to adverse events, the quality of evidence was very low, showing mixed findings with regard to antihypertensive use. there were no data on incident mci and overall drop - out rates. initial results from the sprint - mind trial, a substudy of the systolic blood pressure intervention trial ( sprint ) that aims to evaluate the effect of intensive blood pressure control on risk of dementia, support the possibility of a dose - response relationship between blood pressure and risk of cognitive decline or dementia ( sprint - mind 2019 ). observational evidence suggests a strong association between hypertension and incident cognitive decline / dementia. for treatment of hypertension in the form of lifestyle interventions versus placebo", "metadata": {"doc_name": "9789241550543-eng", "page": 50, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "response relationship between blood pressure and risk of cognitive decline or dementia ( sprint - mind 2019 ). observational evidence suggests a strong association between hypertension and incident cognitive decline / dementia. for treatment of hypertension in the form of lifestyle interventions versus placebo or no intervention, no systematic reviews were found. the gdg made a strong recommendation for management of hypertension for its established health benefits and a conditional recommendation for hypertension management for reducing the risk of cognitive decline / dementia. the gdg concluded that though there is limited clinical trial evidence that treatment of hypertension reduces the risk of cognitive decline or dementia, the benefits outweighed the harms since the evidence suggests that intervention does not lower quality of life or functional level and there are mixed results regarding adverse effects which may depend on the drug used. additionally, robust evidence for a causal relationship is available.", "metadata": {"doc_name": "9789241550543-eng", "page": 50, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 9", "metadata": {"doc_name": "9789241550543-eng", "page": 51, "section": "3.9", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "management of diabetes background the presence of late life diabetes has been linked to an increased risk of dementia ( luchsinger, 2010 ; prince et al., 2014 ; profenno et al., 2010 ). however, the mechanism by which this occurs is unclear. poor glucose control has been associated with lower cognitive functioning and greater cognitive decline ( yaffe et al., 2012 ). in addition, the complications associated with diabetes, such as nephropathy ( kidney damage ), retinopathy ( eye damage ), hearing impair - ment and cvd, have all been found to increase the risk of dementia ( bruce et al., 2014 ; exalto et al., 2013 ). the literature examining interventions that aim to improve glycaemic control shows mixed findings with regard to cognitive outcomes ( launer et al., 2011 ; luchsinger et al., 2011 ). in addition, the evidence on the effectiveness of medication for diabetes in reducing dementia risk is inconsistent ( cheng et al., 2014 ; moore et al., 2013 ; parikh et al., 2011 ). there is some evidence to suggest that treating the cardiovascular comor - bidities associated with diabetes, such as high choles - terol and hypertension, may mediate the risk for dementia ( johnson et al., 2012 ; parikh et al., 2011", "metadata": {"doc_name": "9789241550543-eng", "page": 51, "section": "3.9", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "evidence to suggest that treating the cardiovascular comor - bidities associated with diabetes, such as high choles - terol and hypertension, may mediate the risk for dementia ( johnson et al., 2012 ; parikh et al., 2011 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 51, "section": "3.9", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "36 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 52, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "recommendation 1 : management of diabetes in the form of medications and / or lifestyle interventions should be offered to adults with diabetes according to existing who guidelines.", "metadata": {"doc_name": "9789241550543-eng", "page": 52, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "quality of evidence : very low to moderate ( for different interventions )", "metadata": {"doc_name": "9789241550543-eng", "page": 52, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : strong recommendation 2 : management of diabetes may be offered to adults with diabetes to reduce the risk of cognitive decline and / or dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 52, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "quality of evidence : very low", "metadata": {"doc_name": "9789241550543-eng", "page": 52, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : conditional package of essential noncommunicable ( pen ) disease interventions for primary health care in low - resource settings ( https : / / www. who. int / cardiovascular _ diseases / publications / pen2010 / en / ). for individuals with diabetes, the who guidelines recommend the following treatments : type 1 diabetes", "metadata": {"doc_name": "9789241550543-eng", "page": 52, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• daily insulin injections ( level 1 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 52, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "type 2 diabetes", "metadata": {"doc_name": "9789241550543-eng", "page": 52, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• oral hypoglycaemic agents for type 2 diabetes, if glycaemic targets are not achieved with", "metadata": {"doc_name": "9789241550543-eng", "page": 52, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "modification of diet, maintenance of a healthy body weight and regular physical activity ( level 1 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 52, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• metformin as initial drug in overweight patients ( level 1 ) and non - overweight ( level 4 ). • other classes of antihyperglycaemic agents, added to metformin if glycaemic targets are not", "metadata": {"doc_name": "9789241550543-eng", "page": 52, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "met ( level 3 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 52, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• reduction of cardiovascular risk for those with diabetes and 10 - year cardiovascular risk > 20 %", "metadata": {"doc_name": "9789241550543-eng", "page": 52, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "with aspirin, angiotensin converting enzyme inhibitor and statins ( level 1 ). recommendations and considerations", "metadata": {"doc_name": "9789241550543-eng", "page": 52, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "37 evidence and recommendations", "metadata": {"doc_name": "9789241550543-eng", "page": 53, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "supporting evidence and", "metadata": {"doc_name": "9789241550543-eng", "page": 53, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "rationale for treatment of diabetes in the form of medications for glycaemic control versus placebo or no intervention, evidence was extracted from one systematic review examining adults with normal cognition and type 2 diabetes ( areosa sastre et al., 2017 ). no evidence for adults with mci was available. the quality of the evidence was moderate for cognitive function outcomes and very low for incident dementia outcomes, which showed intensive as opposed to standard glycaemic control has an unclear effect on cognitive function and no effect on incident dementia. the evidence reviewed included data from a large study set across 215 collaborating centres in 20 countries in asia, australasia, europe and north america. the quality of evidence for adverse events was very low, showing intensive glycaemic control increases the risk of hypoglycaemic events. no data on incident mci, quality of life, functional outcomes", "metadata": {"doc_name": "9789241550543-eng", "page": 53, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "or drop - out rates were available. overall, in adults", "metadata": {"doc_name": "9789241550543-eng", "page": 53, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "with normal cognition, the evidence may favour standard glycaemic control because intense glycaemic control has no effect on cognitive function but may result in increased episodes of hypoglycaemia. for treatment of diabetes in the form of diet and life - style interventions versus placebo or no intervention, evidence was extracted from one systematic review examining adults with normal cognition and type 2 diabetes ( podolski et al., 2017 ). no evidence for adults with mci was available. the quality of evidence was very low and the findings were mixed. no meta - analysis was conducted and there were no robust data on clinical significance. the gdg made a strong recommendation for management of diabetes for its established health benefits and a conditional recommendation for diabetes management for reducing the risk of cognitive decline / dementia. the gdg concluded that though there is limited clinical trial evidence on the management of diabetes to reduce the risk of cognitive decline or dementia, the benefits outweighed the harms and there is robust observational evidence to suggest diabetes increases the risk of cognitive decline and dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 53, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 10", "metadata": {"doc_name": "9789241550543-eng", "page": 54, "section": "3.10", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "management of dyslipidaemia background elevated serum cholesterol is one of the key modifiable cardiovascular risk factors. a third of ischaemic heart disease worldwide is attributable to dyslipidaemia and it is estimated to be the cause of 2. 6 million deaths ( 4. 5 % of total ) per year, as well as a considerable proportion of disability ( who, 2019b ). the prevalence of raised total cholesterol among countries seems to correlate with wealth : in high - income countries, more than 50 % of adults have elevated total cholesterol level, more than double the rate in low - income countries ( who, 2019c ). the idea that raised level of blood cholesterol could be related to an increased risk of dementia was already introduced in the mid - 1970s ( richardson et al., 2000 ). since then, a number of epidemiological studies have demonstrated a close relationship between high serum cholesterol levels and the onset of ad / dementia ( kivipelto et al., 2002 ; solomon et al., 2007 ; whitmer et al., 2005 ), but results have been inconsistent, with other studies showing no or negative correlation ( mainous et al., 2005 ; mielke et al., 2005 ). based on the severity of the dyslipidaemia and", "metadata": {"doc_name": "9789241550543-eng", "page": 54, "section": "3.10", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "., 2005 ), but results have been inconsistent, with other studies showing no or negative correlation ( mainous et al., 2005 ; mielke et al., 2005 ). based on the severity of the dyslipidaemia and cvd overall risk, lifestyle or pharmacological approaches can be undertaken to reduce blood cholesterol. weight reduction and decreasing saturated fats in the diet ( decreasing the consumption of food of animal origin ) are the most common and effective lifestyle recommen - dations ( perk et al., 2012 ). however, dyslipidaemia is often controlled and managed pharmacologically, with statins being the drugs of first choice. several observational studies have investigated the possible beneficial effect of statins therapy in preventing dementia, but bias and heterogeneity hampered the overall quality of the evidence ( song et al., 2013 ; swiger et al., 2013 ; wong et al., 2013 ). recently, a re - analysis of statin use in ad patients from failed clinical trials suggested that the use of simvastatin may slow the progression of cognitive decline in some people ( geifman et al., 2017 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 54, "section": "3.10", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "39 evidence and recommendations recommendations and considerations recommendation :", "metadata": {"doc_name": "9789241550543-eng", "page": 55, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "management of dyslipidaemia at mid - life may be offered to reduce the risk of cognitive decline and dementia. quality of evidence : low", "metadata": {"doc_name": "9789241550543-eng", "page": 55, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "strength of the recommendation : conditional additional considerations include :", "metadata": {"doc_name": "9789241550543-eng", "page": 55, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• statin treatment in older adults should not be", "metadata": {"doc_name": "9789241550543-eng", "page": 55, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "specifically initiated for preventing cognitive decline and / or dementia but may be used for other health benefits according to who ’ s prevention and control of noncommunicable diseases : guidelines for primary", "metadata": {"doc_name": "9789241550543-eng", "page": 55, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "health care in low - resource settings", "metadata": {"doc_name": "9789241550543-eng", "page": 55, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "( http : / / www. who. int / nmh / publications / phc2012 / en / ).", "metadata": {"doc_name": "9789241550543-eng", "page": 55, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "supporting evidence and", "metadata": {"doc_name": "9789241550543-eng", "page": 55, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "rationale for control of dyslipidaemia through treatment with statins compared with placebo, evidence was extracted from one systematic review examining adults with normal cognition and dyslipidaemia ( mcguinness et al., 2016 ). no evidence for adults with mci was available. the quality of the evidence was moderate for cognitive function outcomes and low for incident dementia outcomes, showing that treatment with statins has no effect on either incident dementia and / or cognitive decline. there is moderate quality evidence that the treatment with statins does not increase the incidence of serious adverse events. a large body of observational evidence has linked dyslipidaemia to an increased risk of dementia and / or cognitive decline and found an association between control of dyslipidaemia and reduction of dementia and / or cognitive decline risk ( geifman et al., 2017 ; hersi et al., 2017 ; reitz, 2013 ; song et al., 2013 ). overall, indirect evidence suggests that managing dyslipidaemia in mid - life can help reduce the risk of cognitive decline and / or dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 55, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "no studies were identified that specifically aimed", "metadata": {"doc_name": "9789241550543-eng", "page": 55, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "at controlling dyslipidaemia through lifestyle interventions and included outcomes related to dementia and / or cognitive impairment. the gdg concluded that the desirable effects of dyslipidaemia treatment outweigh the undesirable effects and made a conditional recommendation. the observational evidence reported a stronger correlation between high cholesterol and dementia in mid - life rather than late life ( hersi et al., 2017 ; reitz, 2013 ). the systematic review evidence that focused on clinical trials in older adults ( 65 + ) showed that statin treatment has no effect on cognition or dementia outcomes ( mcguinness et al., 2016 ). therefore, the gdg concluded that there were no grounds to recommend the use of statin and the control of cholesterol in late life but only in mid - life.", "metadata": {"doc_name": "9789241550543-eng", "page": 55, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 11", "metadata": {"doc_name": "9789241550543-eng", "page": 56, "section": "3.11", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "management of depression background there is a substantial body of evidence linking depression to cognitive decline and dementia. a review carried out as part of the world alzheimer report in 2014 combined 32 studies into a meta - analysis which looked at the effect of depression on the risk of incident dementia. this involved 62, 568 participants", "metadata": {"doc_name": "9789241550543-eng", "page": 56, "section": "3.11", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "with a median follow - up of 5 years ( range 2 to 17 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 56, "section": "3.11", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the review reported that the presence of depression nearly doubled the risk of dementia ( pooled effect size = 1. 97, 95 % ci : 1. 67 – 2. 32 ) ( prince et al., 2014 ). the authors also carried out a meta - regression looking at follow - up time. they reported a trend toward smaller effect sizes in studies with longer follow - up suggesting that depression may have a prodromal role in dementia. it is noteworthy to mention that cognitive impairment may be the main symptom of depression in the elderly ; a phenomenon that used to be called pseudodementia. there are several potential explanations for the link between depression and cognitive impairment or dementia. some of these include associations between depression, noradrenergic changes and white matter lesions, depression which stems from insight into impairment at early stages of decline, depression highlighting underlying deficits, i. e. by reducing motivation and bringing its own cognitive deficits ( camus et al., 2004 ; jorm, 2001 ; kales et al., 2005 ; schweitzer et al., 2002 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 56, "section": "3.11", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "41 evidence and recommendations recommendations and considerations there is currently insufficient evidence to recommend the use of antidepressant medicines for reducing the risk of cognitive decline and / or dementia. the management of depression, in the form of antidepressants and / or psychological interventions, should be provided to adults with depression according to existing who mhgap guidelines.", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "who mhgap intervention guide - version 2 for mental, neurological and substance use disorders in non - specialized health settings", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "( https : / / www. who. int / mental _ health / mhgap / mhgap _ intervention _ guide _ 02 / en / )", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "for adults with moderate to severe depressive disorder, the who guidelines recommend the", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "following treatments : psychosocial / non - pharmacological treatment and advice", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• psychoeducation ( for the person and his or her family, as appropriate ). • addressing current psychosocial stressors. • reactivate social networks. • brief psychological treatments, if available. • offer regular follow - up.", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "antidepressant medication", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• select an antidepressant from the national or who formulary. selective serotonin reuptake", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "inhibitors ( fluoxetine ) and tricyclic antidepressants ( amitriptyline ) are antidepressants mentioned in the who formulary and are on the who model list of essential medicines.", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• in selecting an antidepressant, consider the symptom pattern of the person, the side - effect", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "profile of the medication, and the efficacy of previous antidepressant treatments, if any.", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• for co - morbid medical conditions, before prescribing antidepressants, consider potential for", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "drug - disease or drug - drug interaction. consult the national or the who formulary.", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• combining antidepressants with other psychotropic medication requires supervision by, or", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "consultation with a specialist.", "metadata": {"doc_name": "9789241550543-eng", "page": 57, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "42 risk reduction of cognitive decline and dementia : who guidelines supporting evidence and", "metadata": {"doc_name": "9789241550543-eng", "page": 58, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "rationale for pharmacological interventions to treat depression ( antidepressant medication ) compared with usual care or placebo, evidence was extracted from one systematic review examining adults with normal cognition and major depressive disorder ( baune et al., 2018 ). no evidence for adults with mci was available. the review conducted a network meta - analysis and reported standardized mean differences in the digit symbol substitution test as a measure of cognition function. the review reported that vortioxetine ( versus placebo ) improved cognitive functioning while duloxetine, sertraline, citalopram, escitalopram, phenelzine and nortriptyline showed no effect ( baune et al., 2018 ). the quality of the evidence was very low and no data were reported for incident mci or dementia outcomes, quality of life, adverse events, functional level or drop - out rates. overall, the true balance of effects is difficult to ascertain. the evidence favours the use of vortioxetine ( but not other pharmacological interventions ) to treat depression for reducing the risk of cognitive decline or dementia. however, no data on adverse effects were available, e. g. drug - related side - effects or interactions. for psychological interventions to treat depression compared with placebo or no intervention, no relevant systematic reviews were found.", "metadata": {"doc_name": "9789241550543-eng", "page": 58, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the gdg therefore concluded that there was", "metadata": {"doc_name": "9789241550543-eng", "page": 58, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "insufficient evidence currently for depression manage - ment and reduction of risk of cognitive decline / dementia. they also concluded that the management of depression is important for its other benefits and did not make a negative recommendation against this intervention.", "metadata": {"doc_name": "9789241550543-eng", "page": 58, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. 12", "metadata": {"doc_name": "9789241550543-eng", "page": 59, "section": "3.12", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "management of hearing loss background hearing loss is a prevalent age - related disorder. as the fourth leading cause of years lived with disability in the global population ( who, 2012 ), it is estimated to affect one in three adults aged 65 and older, with this statistic growing annually ( wilson et al., 2017 ). the implications of hearing loss, however, are often underestimated both at the individual and population level ( blustein et al., 2018 ). hearing impairment has debilitating consequences on functional ability and social and emotional well - being. deteriorations in hearing impact on individuals ’ ability to communicate with others, which in turn can result in feelings of frustration, isolation, loneliness ( ciorba et al., 2012 ). older adult populations who already experience the isolating effects of age - related factors, such as diminished mobility, driving cessation, death of partners or living alone, are particularly vulnerable to these psychosocial impacts. hearing loss is also associated with increased risk of cognitive decline or dementia ( lin et al., 2013 ). a recent meta - analysis of prospective cohort studies showed that the relative risk of hearing impairment on incident alzheimer ’ s and mci was 2. 82 ( 95 % ci : 1. 47 – 5. 42 ). ( zheng et al., 2017 ). additionally, a meta - analysis published by the lancet commission", "metadata": {"doc_name": "9789241550543-eng", "page": 59, "section": "3.12", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "of hearing impairment on incident alzheimer ’ s and mci was 2. 82 ( 95 % ci : 1. 47 – 5. 42 ). ( zheng et al., 2017 ). additionally, a meta - analysis published by the lancet commission showed that hearing loss can almost double the risk of incident dementia ( rr = 1. 94, 95 % ci : 1. 38 – 2. 73 ) ( livingston et al., 2017 ). hearing loss and cognitive impairment or dementia, individually, and in combination, predict functional ability and burden of care. hearing loss interventions, therefore, have the potential to substantially improve outcomes for older people on multiple domains.", "metadata": {"doc_name": "9789241550543-eng", "page": 59, "section": "3.12", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "44 risk reduction of cognitive decline and dementia : who guidelines who guidelines on integrated care for older people ( icope )", "metadata": {"doc_name": "9789241550543-eng", "page": 60, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "( http : / / www. who. int / ageing / publications / guidelines - icope / en / ) for older adults, who recommends the following : screening followed by provision of hearing aids should be offered to older people for timely identification and management of hearing loss. considerations for recommendation :", "metadata": {"doc_name": "9789241550543-eng", "page": 60, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• community awareness about hearing loss and the positive benefits of audiological rehabilitation", "metadata": {"doc_name": "9789241550543-eng", "page": 60, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "in older people, through community case finding and outreach activities, should be promoted.", "metadata": {"doc_name": "9789241550543-eng", "page": 60, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• health care professionals should be encouraged to screen older adults for hearing loss by", "metadata": {"doc_name": "9789241550543-eng", "page": 60, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "periodically questioning them about their hearing. audiological examination, otoscopic examination and the whispered voice test are also recommended.", "metadata": {"doc_name": "9789241550543-eng", "page": 60, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• hearing aids are the treatment of choice for older people with hearing loss, because they minimize", "metadata": {"doc_name": "9789241550543-eng", "page": 60, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "reduction in hearing and improve daily functioning.", "metadata": {"doc_name": "9789241550543-eng", "page": 60, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• medications should be reviewed for potential ototoxicity. • people with chronic otitis media or sudden hearing loss, or who fail any screening tests, should", "metadata": {"doc_name": "9789241550543-eng", "page": 60, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "be referred to an otolaryngologist. there is insufficient evidence to recommend use of hearing aids to reduce the risk of cognitive decline and / or dementia. screening followed by provision of hearing aids should be offered to older people for timely identification and management of hearing loss as recommended in the who icope guidelines. recommendations and considerations", "metadata": {"doc_name": "9789241550543-eng", "page": 60, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "45 evidence and recommendations", "metadata": {"doc_name": "9789241550543-eng", "page": 61, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "supporting evidence and", "metadata": {"doc_name": "9789241550543-eng", "page": 61, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "rationale for interventions to treat hearing loss ( e. g. hearing aids ) versus care as usual or no intervention, evidence was extracted from one systematic review examining adults with normal cognition and hearing loss ( cherko et al., 2016 ). no evidence for adults with mci was available. for cognitive function and quality of life, the quality of evidence is very low. no meta - analyses were performed and results were reported narratively with no numerical data to support conclusions ( cherko et al., 2016 ). based on two studies including measures of cognitive function, the review concluded that while hearing aids use was found to be associated with improvements in cognitive function, these benefits may be limited in that cognitive improvements have been shown to revert to baseline at 1 year follow - up. they also concluded that use of hearing aids in older people was associated with improvements in quality of life outcomes based on two studies. overall, the evidence does not favour either the intervention or the comparison. hearing aids may improve quality of life but the amount of evidence available is limited. no data are available for incident mci or dementia, functional level ( adl, iadl ), adverse events or drop - outs. the gdg concluded that there is currently insufficient evidence to recommend the use of hearing aids to reduce the risk of cognitive decline / dementia. the gdg also concluded that the use of hearing aids", "metadata": {"doc_name": "9789241550543-eng", "page": 61, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "##dl ), adverse events or drop - outs. the gdg concluded that there is currently insufficient evidence to recommend the use of hearing aids to reduce the risk of cognitive decline / dementia. the gdg also concluded that the use of hearing aids is important to correct hearing loss in older adults for their other benefits and recommend following the icope guidelines in this regard.", "metadata": {"doc_name": "9789241550543-eng", "page": 61, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "46 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 62, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "implementation considerations 4", "metadata": {"doc_name": "9789241550543-eng", "page": 62, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "47 implementation considerations countries will be supported to implement the guidelines through training of health care personnel and using centres of excellence on improved quality of care. the implementation will also be supported locally through the adoption of the global action plan on the public health response to dementia 2017 – 2025 ; the comprehensive mental health action plan 2013 – 2020 ; and the global action plan for the prevention and control of noncommunicable diseases 2013 – 2020 at country level. the national capacity building process will also be supported through who collaboration with international organizations and associations. given that many of the interventions included in these guidelines are strongly related to the management of risk factors for cvd and diabetes, the implementation of these recommendations should be combined, whenever possible and in the relevant target population, with the ongoing prevention programmes to reduce the risk of these conditions. the optimal preventive effect may be obtained by addressing several risk factors at the same time. collaboration among different stake - holders and multidisciplinary approaches will also be needed. the recommendations contained in these guidelines should be adapted into a locally appropriate document that can meet the needs of each country and its health services. who headquarters will work closely with the regional and country offices, as well as implementing partners and public health agencies at the national level, to ensure communication and country - specific adaptations of the guidelines, through regional and national meetings. as countries consider how to implement these guidelines, the", "metadata": {"doc_name": "9789241550543-eng", "page": 63, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "closely with the regional and country offices, as well as implementing partners and public health agencies at the national level, to ensure communication and country - specific adaptations of the guidelines, through regional and national meetings. as countries consider how to implement these guidelines, the budgetary and human resource requirements, and other health systems implications should be analysed to identify which inputs and systems are currently available, and which areas require additional investment. these may include training of health workers, supply of medicines and adaptations of health information systems to collect data on service utilization. to support country implementation, who will produce a series of subsidiary tools that will address clinical and service delivery aspects of the imple - mentation of the recommendations included in these guidelines.", "metadata": {"doc_name": "9789241550543-eng", "page": 63, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "48 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 64, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "publication, dissemination and evaluation 5", "metadata": {"doc_name": "9789241550543-eng", "page": 64, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "5. 1", "metadata": {"doc_name": "9789241550543-eng", "page": 65, "section": "5.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "publication and dissemination the guidelines will be disseminated as a print publication and electronically on a dedicated internet space on the who website. the guidelines will be disseminated through both the mental health and ncd dissemination activities of the global action plan on the public health response to dementia 2017 – 2025 ( such as the global dementia observatory knowledge exchange platform ), the comprehensive mental health action plan 2013 – 2020 and the global action plan for the prevention and control of noncommunicable diseases 2013 – 2020. these guidelines will be appended to the mhgap guidelines and disseminated through the mhgap evidence resource centre and other mhgap derivative products, including the mhgap intervention guide. since these guidelines are linked to other who guidelines such as ncd and icope guidelines and other resources on ageing,", "metadata": {"doc_name": "9789241550543-eng", "page": 65, "section": "5.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "dissemination will occur along with these guidelines.", "metadata": {"doc_name": "9789241550543-eng", "page": 65, "section": "5.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the guidelines and products are developed in english, and will be translated into other who official languages for wider dissemination and in collaboration with who regional offices. local adaptation is necessary to ensure that the guidelines are appropriate for the local conditions that affect the care of people with cognitive decline and dementia in health facilities and the community. adaptation will include language translation and ensuring that the interventions are acceptable in the specific socio - cultural context and suitable for the local health system. the adapte manual for guideline adaptation outlines the approach to be used. 12 the acceptability and applicability of the recommendations will be examined in the specific cultural context, including the availability of health services, expertise and resources, and the organization of health services, as well as population characteristics, cultural beliefs and value judgments. relevant departments in ministries of health will be notified of the guidelines through who regional and country offices. a briefing package will be prepared for technical officers outside of who headquarters that will include an executive summary and q & a related to policy and programme implications. dissemination will also be encouraged through who collaboration with international organizations and associations. in coordination with who communications, the media will be notified of the new guidelines. countries will be supported to implement the guidelines through the training of health care personnel on improved quality of care and using centres of excellence. capacity - building activities will be undertaken through web - based platforms and regional workshops. dissemination will be supported by", "metadata": {"doc_name": "9789241550543-eng", "page": 65, "section": "5.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "new guidelines. countries will be supported to implement the guidelines through the training of health care personnel on improved quality of care and using centres of excellence. capacity - building activities will be undertaken through web - based platforms and regional workshops. dissemination will be supported by the publication of selected systematic reviews and evidence in peer review journals, and presentations and workshops at key conferences and events.", "metadata": {"doc_name": "9789241550543-eng", "page": 65, "section": "5.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "12 http : / / www. g - i - n. net / document - store / working - groups - documents / adaptation / adapte - resource - toolkit - guideline - adaptation - 2 - 0. pdf", "metadata": {"doc_name": "9789241550543-eng", "page": 65, "section": "5.1", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "5. 2", "metadata": {"doc_name": "9789241550543-eng", "page": 66, "section": "5.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "monitoring and evaluation following publication of these guidelines, who will continue to collect regular feedback from implemen - tation activities in order to evaluate their usefulness and impact. information will be used to evaluate the quality of the guidelines and to identify areas where improvement is required. who ’ s global dementia observatory, an online data and knowledge exchange platform for dementia, provides the framework for monitoring implementation of these guidelines 13.", "metadata": {"doc_name": "9789241550543-eng", "page": 66, "section": "5.2", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "5. 3", "metadata": {"doc_name": "9789241550543-eng", "page": 66, "section": "5.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "implications for further research the majority of the recommendations align with current guidelines for the treatment of pre - existing health conditions and dependencies. however, more evidence is needed to determine what the impact of these interventions are on the outcomes of incident", "metadata": {"doc_name": "9789241550543-eng", "page": 66, "section": "5.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "mci or dementia.", "metadata": {"doc_name": "9789241550543-eng", "page": 66, "section": "5.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "no recommendations could be made for social activity and hearing loss due to insufficient evidence. some trials are currently being conducted for hearing loss interventions. these guidelines may need to be updated once these results are released. however, currently there is little research being conducted that examines the impact of social activity on cognitive decline and dementia. part of the difficulty in conducting this type of research is that social activity is difficult to define and quantify, and it is also difficult to differentiate it from the physical or mental activities which are often a component of this type of intervention. the development of standardized protocols for social activity interventions may therefore", "metadata": {"doc_name": "9789241550543-eng", "page": 66, "section": "5.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "need to precede the running of clinical trials.", "metadata": {"doc_name": "9789241550543-eng", "page": 66, "section": "5.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "some of the evidence presented here is based on rcts with relatively short follow - up periods ( e. g. interventions for cognitive training, depression, social activity ). this limits our ability to judge the potential impact of the interventions on the development of cognitive decline and dementia as they have long prodromal periods. more evidence needs to be gathered with longer term follow - up periods in order to more accurately estimate the impact of these interventions in reducing the risk of cognitive decline / dementia in the long run. in addition, more research needs to be conducted to understand how timing affects the impact of these interventions on cognitive decline and dementia ( e. g. mid - life versus late life", "metadata": {"doc_name": "9789241550543-eng", "page": 66, "section": "5.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "physical activity ).", "metadata": {"doc_name": "9789241550543-eng", "page": 66, "section": "5.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the prevalence of dementia is increasing in lmic. however, the majority of clinical trials have been conducted in high - income countries, so there is very little evidence on the effectiveness of these interventions for lmic. more attention needs to be", "metadata": {"doc_name": "9789241550543-eng", "page": 66, "section": "5.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "given to understanding how best to reduce the risk", "metadata": {"doc_name": "9789241550543-eng", "page": 66, "section": "5.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "of cognitive decline and dementia in lmic. 13 available at : https : / / www. who. int / mental _ health / neurology / dementia / global _ observatory / en /", "metadata": {"doc_name": "9789241550543-eng", "page": 66, "section": "5.3", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "5. 4", "metadata": {"doc_name": "9789241550543-eng", "page": 67, "section": "5.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "future review and update it is expected that the guidelines will be reviewed again in five years. new evidence in these areas is", "metadata": {"doc_name": "9789241550543-eng", "page": 67, "section": "5.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "regularly monitored by the who secretariat,", "metadata": {"doc_name": "9789241550543-eng", "page": 67, "section": "5.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "in consultation with gdg members and technical experts identified for the evidence review process, who collaborating centres and academic institutions. with the increasing evidence from multidomain intervention trials expected to be reported in the coming years, the addition of a pico question addressing such interventions should be considered in future revisions. publication, dissemination and evaluation", "metadata": {"doc_name": "9789241550543-eng", "page": 67, "section": "5.4", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "52 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 68, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "albanese e, launer lj, egger m, prince mj, giannakopoulos p, wolters, fj et al. ( 2017 ). body mass index in midlife and dementia : systematic review and meta - regression analysis of 589, 649 men and women followed in longitudinal studies. alzheimer ' s & dementia. 8 : 165 – 178. doi : 10. 1016 / j. dadm. 2017. 05. 007. alonso - coello p, schunemann hj, moberg j, brignardello - petersen r, aki ea, davoli m et al. ( 2016 ). grade evidence to decision ( etd ) frameworks : a systematic and transparent approach to making well informed healthcare choices. 1 : introduction. british medical journal. 353. doi : 10. 1136 / bmj. i2016. amorim js, salla s, trelha cs ( 2014 ). factors associated with work ability in the elderly : systematic review. revista brasileira de epidemiologia. 17 ( 4 ) : 830 – 841. andrieu s, guyonnet s, coley n, cantet c, bonnefoy m, bordes s et al. ( 2017 ). effect of long - term omega - 3 polyunsatura", "metadata": {"doc_name": "9789241550543-eng", "page": 68, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "##0 – 841. andrieu s, guyonnet s, coley n, cantet c, bonnefoy m, bordes s et al. ( 2017 ). effect of long - term omega - 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints ( mapt ) : a randomised, placebo - controlled trial. lancet neurology. 16 ( 5 ) : 377 – 389. areosa sastre a, vernooij rw, gonzalez - colaco harmand m, martinez g ( 2017 ). effect of the treatment of type 2 diabetes mellitus on the development of cognitive impairment and dementia. cochrane database of systematic reviews. ( 6 ) : cd003804. bakre at, chen r, khutan r, wei l, smith t, qin g et al. ( 2018 ). association between fish consumption and risk of dementia : a new study from china and a systematic literature review and meta - analysis. public health nutrition. 21 ( 10 ) : 1921 – 1932. doi : 10. 1017 / s136898001800037x. balion c, griffith le, strifler l, henderson m, patterson c, heckman g et al. ( 2012 ). vitamin", "metadata": {"doc_name": "9789241550543-eng", "page": 68, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": ". doi : 10. 1017 / s136898001800037x. balion c, griffith le, strifler l, henderson m, patterson c, heckman g et al. ( 2012 ). vitamin d, cognition, and dementia : a systematic review and meta - analysis. neurology. 79 ( 13 ) : 1397 –", "metadata": {"doc_name": "9789241550543-eng", "page": 68, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1405. doi : 10. 1212 / wnl. 0b013e31826c197f.", "metadata": {"doc_name": "9789241550543-eng", "page": 68, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "barbera m, mangialasche f, jongstra s, guillemont j, ngandu t, beishuizen c et al. ( 2018 ). designing an internet - based multidomain intervention for the prevention of cardiovascular disease and cognitive impairment in older adults : the hatice trial. journal of alzheimer ' s disease. 62 ( 2 ) : 649 – 663 ( http : / / wwfingers. com / myb - trial /, accessed 5 february 2019 ). barreto ps, demougeot l, vellas b, rolland y ( 2017 ). exercise training for preventing dementia, mild cognitive impairment, and clinically meaningful cognitive decline : a systematic review and meta - analysis. journals of gerontology series a : biological sciences & medical sciences. dec 5 2017 [ epub ahead of print ]. barha ck, davis jc, falck rs, nagamatsu ls, liu - ambrose t ( 2017 ). sex differences in exercise efficacy to improve cognition : a systematic review and meta - analysis of randomized controlled trials in older humans. frontiers in neuroendocrinology. 46 : 71 – 85. baune bt, brignone m, larsen kg ( 2018 ). a network meta - analysis comparing effects of various antidepressant classes on the digit symbol substitution test ( dsst ) as a", "metadata": {"doc_name": "9789241550543-eng", "page": 68, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "##rinology. 46 : 71 – 85. baune bt, brignone m, larsen kg ( 2018 ). a network meta - analysis comparing effects of various antidepressant classes on the digit symbol substitution test ( dsst ) as a measure of cognitive dysfunction in patients with major depressive disorder. international journal of neuropsychopharmacology. 21 ( 2 ) : 97 – 107. doi : 10. 1093 / ijnp / pyx070. bennett s, grant mm, aldred s ( 2009 ). oxidative stress in vascular dementia and alzheimer ' s disease : a common pathology. journal of alzheimer ' s disease. 17 ( 2 ) : 245 – 257. doi : 10. 3233 / jad - 2009 - 1041. berendsen am, kang jh, van de rest o, feskens ejm, de groot l, grodstein f ( 2017 ). the dietary approaches to stop hypertension diet, cognitive function, and cognitive decline in american older women. journal of the american medical directors association. 18 ( 5 ) : 427 – 432. doi : 10. 1016 / j. jamda. 2016. 11. 026. beydoun ma, beydoun ha, gamaldo aa, teel a, zonderman ab, wang y ( 2014 )", "metadata": {"doc_name": "9789241550543-eng", "page": 68, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "432. doi : 10. 1016 / j. jamda. 2016. 11. 026. beydoun ma, beydoun ha, gamaldo aa, teel a, zonderman ab, wang y ( 2014 ). epidemiologic studies of modifiable factors associated with cognition and dementia : systematic review and meta - analysis. bmc public health. 14 ( 1 ) : 643. blustein j, weinstein be, chodosh j ( 2018 ). tackling hearing loss to improve the care of older adults. british medical journal.", "metadata": {"doc_name": "9789241550543-eng", "page": 68, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "360. doi : 10. 1136 / bmj. k21.", "metadata": {"doc_name": "9789241550543-eng", "page": 68, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "bruce dg, davis wa, starkstein se, davis tm ( 2014 ). mid - life predictors of cognitive impairment and dementia in type 2 diabetes mellitus : the fremantle diabetes study. journal of alzheimer ' s disease. 42 ( 3 ) : s63 – 70. doi : 10. 3233 / jad - 132654. camus v, kraehenbuhl h, preisig m, bula cj, waeber g ( 2004 ). geriatric depression and vascular diseases : what are the links? journal of affective disorders. 81 ( 1 ) : 1 – 16. doi : https : / / doi. org / 10. 1016 / j. jad. 2003. 08. 003. chan jm, rimm eb, colditz ga, stampfer mj, willett wc ( 1994 ). obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. diabetes care. 17 ( 9 ) : 961 – 969. chandler mj, parks ac, marsiske m, rotblatt lj, smith ge ( 2016 ). everyday impact of cognitive interventions in mild cognitive impairment : a systematic review and meta - analysis. neuropsychology review. 26 ( 3 ) : 225 – 251. doi : 10. 1007 / s11065", "metadata": {"doc_name": "9789241550543-eng", "page": 68, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "ge ( 2016 ). everyday impact of cognitive interventions in mild cognitive impairment : a systematic review and meta - analysis. neuropsychology review. 26 ( 3 ) : 225 – 251. doi : 10. 1007 / s11065 - 016 - 9330 - 4. references", "metadata": {"doc_name": "9789241550543-eng", "page": 68, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "53references", "metadata": {"doc_name": "9789241550543-eng", "page": 69, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "cheng c, lin ch, tsai yw, tsai cj, chou ph, lan th ( 2014 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 69, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "type 2 diabetes and antidiabetic medications in relation to dementia diagnosis. journals of gerontology series a : biological sciences & medical sciences. 69 ( 10 ) : 1299 – 1305. doi : 10. 1093 / gerona / glu073. cherko m, hickson l, bhutta m ( 2016 ). auditory deprivation and health in the elderly. maturitas. 88 : 52 – 57. doi : 10. 1016 / j. maturitas. 2016. 03. 008. cherry ke, walker ej, brown js, volaufova j, lamotte lr, welsh da et al. ( 2011 ). social engagement and health in younger, older, and oldest - old adults in the louisiana healthy aging study. journal of applied gerontology. 32 ( 1 ) : 51 – 75. doi : 10. 1177 / 0733464811409034. chiu h - l, chu h, tsai j - c, liu d, chen y - r, yang h - l et al. ( 2017 ). the effect of cognitive - based training for the healthy older people : a meta - analysis of randomized controlled trials. plos one. 12 ( 5 ) : e0176742. ciorba a, bianchini c, pelucchi", "metadata": {"doc_name": "9789241550543-eng", "page": 69, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "cognitive - based training for the healthy older people : a meta - analysis of randomized controlled trials. plos one. 12 ( 5 ) : e0176742. ciorba a, bianchini c, pelucchi s, pastore a ( 2012 ). the impact of hearing loss on the quality of life of elderly adults. clinical interventions in aging. 7 : 159 – 163. doi : 10. 2147 / cia. s26059. clare l & woods rt ( 2004 ). cognitive training and cognitive rehabilitation for people with early - stage alzheimer ' s disease : a review. neuropsychological rehabilitation. 14 ( 4 ) : 385 – 401. doi : 10. 1080 / 09602010443000074. colcombe sj, erickson ki, scalf pe, kim js, prakash r, mcauley e et al. ( 2006 ). aerobic exercise training increases brain volume in aging humans. journals of gerontology series a : biological sciences & medical sciences. 61 ( 11 ) : 1166 – 1170. d ’ cunha nm, georgousopoulou en, dadigamuwage l, kellett j, panagiotakos db, thomas j et al. ( 2018 ). effect of long - term nutraceutical and dietary", "metadata": {"doc_name": "9789241550543-eng", "page": 69, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "cunha nm, georgousopoulou en, dadigamuwage l, kellett j, panagiotakos db, thomas j et al. ( 2018 ). effect of long - term nutraceutical and dietary supplement use on cognition in the elderly : a 10 - year systematic review of randomised controlled trials. british journal of nutrition. 119 ( 3 ) : 280 – 298. dangour ad, whitehouse pj, rafferty k, mitchell sa, smith l, hawkesworth s et al. ( 2010 ). b - vitamins and fatty acids in the prevention and treatment of alzheimer ' s disease and dementia : a systematic review. journal of alzheimer ' s disease. 22 ( 1 ) : 205 – 224. doi : 10. 3233 / jad - 2010 - 090940. di marco ly, marzo a, munoz - ruiz m, ikram ma, kivipelto m, ruefenacht d et al. ( 2014 ). modifiable lifestyle factors in dementia : a systematic review of longitudinal observational cohort studies. journal of alzheimer ' s disease. 42 ( 1 ) : 119 – 135. doi : 10. 3233 / jad - 132225. diabetes prevention program research group ( 2002 ). reduction in the incidence of type 2 diabetes with lifestyle intervention or metform", "metadata": {"doc_name": "9789241550543-eng", "page": 69, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "' s disease. 42 ( 1 ) : 119 – 135. doi : 10. 3233 / jad - 132225. diabetes prevention program research group ( 2002 ). reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. new england journal of medicine. 346 ( 6 ) : 393 – 403. doi : 10. 1056 / nejmoa012512. durazzo tc, mattsson n, weiner mw, alzheimer ' s disease neuroimaging initiative ( 2014 ). smoking and increased alzheimer ' s disease risk : a review of potential mechanisms. alzheimer ' s & dementia, 10 ( 3 ) : s122 – s145. eckel rh ( 1997 ). obesity and heart disease : a statement for healthcare professionals from the nutrition committee, american heart association. circulation. 96 ( 9 ) : 3248 – 3250. erickson ki, raji ca, lopez ol, becker jt, rosano c, newman ab et al. ( 2010 ). physical activity predicts gray matter volume in late adulthood : the cardiovascular health study. neurology. 75 ( 16 ) : 1415 – 1422. doi : 10. 1212 / wnl. 0b013e3181f88359. exalto lg, biessels gj, karter", "metadata": {"doc_name": "9789241550543-eng", "page": 69, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": ". 75 ( 16 ) : 1415 – 1422. doi : 10. 1212 / wnl. 0b013e3181f88359. exalto lg, biessels gj, karter aj, huang es, katon wj, minkoff jr et al. ( 2013 ). risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes : a cohort study. lancet diabetes & endocrinology. 1 ( 3 ) : 183 – 190. doi : 10. 1016 / s2213 - 8587 ( 13 ) 70048 - 2. fitzpatrick - lewis d, warren r, ali mu, sherifali d, raina p ( 2015 ). treatment for mild cognitive impairment : a systematic review and meta - analysis. cmaj open. 3 ( 4 ) : e419 – 27. flicker l, mccaul ka, hankey gj, jamrozik k, brown wj, byles je et al. ( 2010 ). body mass index and survival in men and women aged 70 to 75. journal of american geriatrics society. 58 ( 2 ) : 234 – 241. doi : 10. 1111 / j. 1532 - 5415. 2009. 02677. x. fontana l & hu fb ( 2014 )", "metadata": {"doc_name": "9789241550543-eng", "page": 69, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "journal of american geriatrics society. 58 ( 2 ) : 234 – 241. doi : 10. 1111 / j. 1532 - 5415. 2009. 02677. x. fontana l & hu fb ( 2014 ). optimal body weight for health and longevity : bridging basic, clinical, and population research. aging cell. 13 ( 3 ) : 391 – 400. doi : 10. 1111 / acel. 12207. forbes sc, holroyd - leduc jm, poulin mj, hogan db ( 2015 ). effect of nutrients, dietary supplements and vitamins on cognition : a systematic review and meta - analysis of randomized controlled trials. canadian geriatrics journal. 18 ( 4 ) : 231. fratiglioni l, paillard - borg s, winblad b ( 2004 ). an active and socially integrated lifestyle in late life might protect against dementia. lancet neurology. 3 ( 6 ) : 343 – 353. doi : https : / / doi. org / 10. 1016 / s1474 - 4422 ( 04 ) 00767 - 7. frith e, shivappa n, mann j r, hebert jr, wirth md, loprinzi pd ( 2018 ). dietary inflammatory index and memory function : population - based", "metadata": {"doc_name": "9789241550543-eng", "page": 69, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "##22 ( 04 ) 00767 - 7. frith e, shivappa n, mann j r, hebert jr, wirth md, loprinzi pd ( 2018 ). dietary inflammatory index and memory function : population - based national sample of elderly americans. british journal of nutrition. 119 ( 5 ) : 552 – 558. doi : 10. 1017 / s0007114517003804.", "metadata": {"doc_name": "9789241550543-eng", "page": 69, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "54 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 70, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "gallaway pj, miyake h, buchowski ms, shimada m, yoshitake y, kim as et al. ( 2017 ). physical activity : a viable way to reduce the risks of mild cognitive impairment, alzheimer ’ s disease, and vascular dementia in older adults. brain sciences. 7 ( 2 ) : 22. gbd 2015 neurological disorders collaborator group ( 2017 ). global, regional, and national burden of neurological disorders during 1990 – 2015 : a systematic analysis for the global burden of disease study 2015. lancet neurology. 16 ( 11 ) : 877 – 897. geifman n, brinton rd, kennedy re, schneider ls, butte aj ( 2017 ). evidence for benefit of statins to modify cognitive decline and risk in alzheimer ’ s disease. alzheimer ' s research & therapy. 9 ( 10 ) : 1. doi : 10. 1186 / s13195 - 017 - 0237 - y. gell l, meier ps, goyder e ( 2015 ). alcohol consumption among the over 50s : international comparisons. alcohol & alcoholism. 50 ( 1 ) : 1 – 10. doi : 10. 1093 / alcalc / agu082. gomez - coronado n, walker aj, berk m, dodd s ( 2018 ). current and emerging pharm", "metadata": {"doc_name": "9789241550543-eng", "page": 70, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "50 ( 1 ) : 1 – 10. doi : 10. 1093 / alcalc / agu082. gomez - coronado n, walker aj, berk m, dodd s ( 2018 ). current and emerging pharmacotherapies for cessation of tobacco smoking. pharmacotherapy : journal of human pharmacology & drug therapy. 38 ( 2 ) : 235 – 258. guyatt g, oxman ad, aki ae, kunz r, vist g, brozek j et al. ( 2011 ). grade guidelines : 1. introduction - grade evidence profiles and summary of findings tables. journal of clinical epidemiology. 64 ( 4 ) : 383 – 394. doi : 10. 1016 / j. jclinepi. 2010. 04. 026. hamer m & chida y ( 2009 ). physical activity and risk of neurodegenerative disease : a systematic review of prospective evidence. psychological medicine. 39 ( 1 ) : 3 – 11. hersi m, irvine b, gupta p, gomes j, birkett n, krewski d ( 2017 ). risk factors associated with the onset and progression of alzheimer ' s disease : a systematic review of the evidence. neurotoxicology. 61 : 143 – 187. doi : 10. 1016 / j", "metadata": {"doc_name": "9789241550543-eng", "page": 70, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "n, krewski d ( 2017 ). risk factors associated with the onset and progression of alzheimer ' s disease : a systematic review of the evidence. neurotoxicology. 61 : 143 – 187. doi : 10. 1016 / j. neuro. 2017. 03. 006. ilomaki j, jokanovic n, ck tan e, lonnroos e ( 2015 ). alcohol consumption, dementia and cognitive decline : an overview of systematic reviews. current clinical pharmacology. 10 ( 3 ) : 204 – 212. jacobs jr, dr, gross md, tapsell lc ( 2009 ). food synergy : an operational concept for understanding nutrition. american journal of clinical nutrition. 89 ( 5 ) : 1543s – 1548s. jiang x, huang j, song d, deng r, wei j, zhang z ( 2017 ). increased consumption of fruit and vegetables is related to a reduced risk of cognitive impairment and dementia : meta - analysis. frontiers in aging neuroscience. 9 ( 18 ). doi : 10. 3389 / fnagi. 2017. 00018. johnson ml, parikh n, kunik me, schulz pe, patel jg, chen h et al. ( 2012 ). antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. alzheimer ' s", "metadata": {"doc_name": "9789241550543-eng", "page": 70, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": ", parikh n, kunik me, schulz pe, patel jg, chen h et al. ( 2012 ). antihypertensive drug use and the risk of dementia in patients with diabetes mellitus. alzheimer ' s & dementia. 8 ( 5 ) : 437 – 444. doi : 10. 1016 / j. jalz. 2011. 05. 2414. jorm af ( 2001 ). history of depression as a risk factor for dementia : an updated review. australian and new zealand journal of psychiatry. 35 ( 6 ) : 776 – 781. doi : 10. 1046 / j. 1440 - 1614. 2001. 00967. x. kales hc, maixner df, mellow am ( 2005 ). cerebrovascular disease and late - life depression. american journal of geriatric psychiatry. 13 ( 2 ) : 88 – 98. doi : 10. 1176 / appi. ajgp. 13. 2. 88. kane rl, butler m, fink ha, brasure m, davila h, desai p et al. ( 2017 ). interventions to prevent age - related cognitive decline, mild cognitive impairment, and clinical alzheimer ’ s - type dementia. rockville ( md ) : agency for healthcare research and quality. kaner efs", "metadata": {"doc_name": "9789241550543-eng", "page": 70, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": ", desai p et al. ( 2017 ). interventions to prevent age - related cognitive decline, mild cognitive impairment, and clinical alzheimer ’ s - type dementia. rockville ( md ) : agency for healthcare research and quality. kaner efs, beyer fr, muirhead c, campbell f, pienaar ed, bertholet n et al. ( 2018 ). effectiveness of brief alcohol interventions in primary care populations. cochrane database of systematic reviews. ( 2 ) : cd004148. doi : 10. 1002 / 14651858. cd004148. pub4. kelly me, duff h, kelly s, mchugh power je, brennan s, lawlor ba et al. ( 2017 ). the impact of social activities, social networks, social support and social relationships on the cognitive functioning of healthy older adults : a systematic review. systematic reviews. 6 ( 1 ) : 259. doi : 10. 1186 / s13643 - 017 - 0632 - 2. kivipelto m, helkala el, laakso mp, hanninen t, hallikainen m, alhainen k et al. ( 2002 ). apolipoprotein e epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late", "metadata": {"doc_name": "9789241550543-eng", "page": 70, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "##ikainen m, alhainen k et al. ( 2002 ). apolipoprotein e epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late - life alzheimer disease. annals of internal medicine. 137 ( 3 ) : 149 – 155. kivipelto m, helkala el, laakso mp, hanninen t, hallikainen m, alhainen k et al. ( 2001 ). midlife vascular risk factors and alzheimer ' s disease in later life : longitudinal, population based study. bmj. 322 ( 7300 ) : 1447 – 1451. kivipelto m, mangialasche f, ngandu t, world wide fingers network ( 2017 ). world wide fingers will advance dementia prevention. lancet neurology. 17 ( 1 ) : 27. kojima g, iliffe s, walters k ( 2015 ). smoking as a predictor of frailty : a systematic review. bmc geriatrics. 15 ( 1 ) : 131.", "metadata": {"doc_name": "9789241550543-eng", "page": 70, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "55references kuiper js, zuidersma m, voshaar rco, zuidema su, van den heuvel er, stolk rp et al. ( 2015 ). social relationships and risk of dementia : a systematic review and meta - analysis of longitudinal cohort studies. ageing research reviews. 22 : 39 – 57. lafortune l, martin s, kelly s, kuhn i, remes o, cowan a, brayne c ( 2016 ). behavioural risk factors in mid - life associated with successful ageing, disability, dementia and frailty in later life : a rapid systematic review. plos one. 11 ( 2 ) : e0144405. langballe em, ask h, holmen j, stordal e, saltvedt i, selbaek g et al. ( 2015 ). alcohol consumption and risk of dementia up to 27 years later in a large, population - based sample : the hunt study, norway. european journal of epidemiology. 30 ( 9 ) : 1049 –", "metadata": {"doc_name": "9789241550543-eng", "page": 71, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1056. doi : 10. 1007 / s10654 - 015 - 0029 - 2.", "metadata": {"doc_name": "9789241550543-eng", "page": 71, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "launer lj, miller me, williamson jd, lazar rm, gerstein hc, murray am et al. ( 2011 ). effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes ( accord mind ) : a randomised open - label substudy. lancet neurology. 10 ( 11 ) : 969 – 977. doi : 10. 1016 / s1474 - 4422 ( 11 ) 70188 - 0. launer lj, ross gw, petrovitch h, masaki k, foley d, white lr et al. ( 2000 ). midlife blood pressure and dementia : the honolulu - asia aging study. neurobiology of aging. 21 ( 1 ) : 49 – 55. lightwood j, collins d, lapsley h, novotny te ( 2000 ). estimating the cost of tobacco use. in : jha p & chaloupka f, editors. tobacco control in developing countries. oxford : oxford university press. lin fr, yaffe k, xia j, xue ql, harris tb, purchase - helzner e et al. ( 2013 ). hearing loss and cognitive decline in older adults. jama internal medicine. 173 ( 4 ) : 293 – 299. doi : 10. 1001 / jamainternmed. 2013", "metadata": {"doc_name": "9789241550543-eng", "page": 71, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": ", purchase - helzner e et al. ( 2013 ). hearing loss and cognitive decline in older adults. jama internal medicine. 173 ( 4 ) : 293 – 299. doi : 10. 1001 / jamainternmed. 2013. 1868. livingston g, sommerlad a, orgeta v, costafreda sg, huntley j, ames d et al. ( 2017 ). dementia prevention, intervention, and care. lancet. 390 ( 10113 ) : 2673 – 2734. loughrey dg, lavecchia s, brennan s, lawlor ba, kelly me ( 2017 ). the impact of the mediterranean diet on the cognitive functioning of healthy older adults : a systematic review and meta - analysis. advances in nutrition. 8 ( 4 ) : 571 – 586. doi : 10. 3945 / an. 117. 015495. luchsinger ja ( 2010 ). diabetes, related conditions, and dementia. journal of neurological sciences. 299 ( 1 – 2 ) : 35 – 38. doi : 10. 1016 / j. jns. 2010. 08. 063. luchsinger ja, palmas w, teresi ja, silver s, kong j, eimicke jp et al. ( 2011 ). improved diabetes control in the elderly delays global cognitive decline. journal of nutrition,", "metadata": {"doc_name": "9789241550543-eng", "page": 71, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": ". 063. luchsinger ja, palmas w, teresi ja, silver s, kong j, eimicke jp et al. ( 2011 ). improved diabetes control in the elderly delays global cognitive decline. journal of nutrition, health & aging. 15 ( 6 ) : 445 – 449. mainous ag 3rd, eschenbach sl, wells bj, everett cj, gill jm ( 2005 ). cholesterol, transferrin saturation, and the development of dementia and alzheimer ' s disease : results from an 18 - year population - based cohort. family medicine. 37 ( 1 ) : 36 – 42. mcguinness b, craig d, bullock r, passmore p ( 2016 ). statins for the prevention of dementia. cochrane database of systematic reviews. ( 1 ) : cd003160. doi : 10. 1002 / 14651858. cd003160. pub3. mielke mm, zandi pp, sjogren m, gustafson d, ostling s, steen b et al. ( 2005 ). high total cholesterol levels in late life associated with a reduced risk of dementia. neurology. 64 ( 10 ) : 1689 – 1695. doi : 10. 1212 / 01. wnl. 0000161870. 78572", "metadata": {"doc_name": "9789241550543-eng", "page": 71, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "total cholesterol levels in late life associated with a reduced risk of dementia. neurology. 64 ( 10 ) : 1689 – 1695. doi : 10. 1212 / 01. wnl. 0000161870. 78572. a5. moll van charante ep, richard e, eurelings ls, van dalen jw, ligthart sa, van bussel ef et al. ( 2016 ). effectiveness of a 6 - year multidomain vascular care intervention to prevent dementia ( prediva ) : a cluster - randomised controlled trial. lancet. 388 ( 10046 ) : 797 – 805. moore em, mander ag, ames d, kotowicz ma, carne rp, brodaty h et al. ( 2013 ). increased risk of cognitive impairment in patients with diabetes is associated with metformin. diabetes care. 36 ( 10 ) : 2981 – 2987. doi : 10. 2337 / dc13 - 0229. morris mc, tangney cc, wang y, sacks fm, barnes ll, bennett da et al. ( 2015a ). mind diet slows cognitive decline with aging. alzheimer ' s & dementia. 11 ( 9 ) : 1015 – 1022. doi : 10. 1016 / j. jalz. 2015. 04. 01", "metadata": {"doc_name": "9789241550543-eng", "page": 71, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "et al. ( 2015a ). mind diet slows cognitive decline with aging. alzheimer ' s & dementia. 11 ( 9 ) : 1015 – 1022. doi : 10. 1016 / j. jalz. 2015. 04. 011. morris mc, tangney cc, wang y, sacks fm, bennett da, aggarwal nt ( 2015b ). mind diet associated with reduced incidence of alzheimer ' s disease. alzheimer ' s & dementia. 11 ( 9 ) : 1007 – 1014. doi : 10. 1016 / j. jalz. 2014. 11. 009. motooka y, matsui t, slaton rm, umetsu r, fukuda a, naganuma m et al. ( 2018 ). adverse events of smoking cessation treatments ( nicotine replacement therapy and non - nicotine prescription medication ) and electronic cigarettes in the food and drug administration adverse event reporting system, 2004− 2016. sage open medicine. 6 : 2050312118777953. musini vm, tejani am, bassett k, wright jm ( 2009 ). pharmacotherapy for hypertension in the elderly. cochrane database of systematic reviews. ( 4 ) : cd000028. doi : 10. 1002 / 14651858. cd000028. pub2", "metadata": {"doc_name": "9789241550543-eng", "page": 71, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "##m ( 2009 ). pharmacotherapy for hypertension in the elderly. cochrane database of systematic reviews. ( 4 ) : cd000028. doi : 10. 1002 / 14651858. cd000028. pub2.", "metadata": {"doc_name": "9789241550543-eng", "page": 71, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "56 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 72, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "ngandu t, lehtisalo j, solomon a, levalahti e, ahtiluoto s, antikainen r et al. ( 2015 ). a 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at - risk elderly people ( finger ) : a randomised controlled trial. lancet. 385 ( 9984 ) : 2255 – 2263. nguyen dm & el - serag hb ( 2010 ). the epidemiology of obesity. gastroenterology clinics of north america. 39 ( 1 ) : 1 – 7. doi : 10. 1016 / j. gtc. 2009. 12. 014. niaura r ( 2008 ). nonpharmacologic therapy for smoking cessation : characteristics and efficacy of current approaches. american journal of medicine. 121 ( 4 ) : s11 – s19. nice ( 2011 ). alcohol - use disorders : diagnosis, assessment and management of harmful drinking and alcohol dependence. clinical guideline 115. london : national institute for health and care excellence ( https : / / www. nice. org. uk / guidance / cg115, accessed 8 april 2019 ). nice ( 2015 ). dementia, disability and frailty in later life – mid - life approaches to delay or", "metadata": {"doc_name": "9789241550543-eng", "page": 72, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "care excellence ( https : / / www. nice. org. uk / guidance / cg115, accessed 8 april 2019 ). nice ( 2015 ). dementia, disability and frailty in later life – mid - life approaches to delay or prevent onset. nice guideline 16. london : national institute for health and care excellence ( https : / / www. nice. org. uk / guidance / ng16, accessed 3 february 2019 ). north t - l, palmer tm, lewis sj, cooper r, power c, pattie a et al. ( 2015 ). effect of smoking on physical and cognitive capability in later life : a multicohort study using observational and genetic approaches. bmj open. 5 ( 12 ) : e008393. northey jm, cherbuin n, pumpa kl, smee dj, rattray b ( 2018 ). exercise interventions for cognitive function in adults older than 50 : a systematic review with meta - analysis. british journal of sports medicine. 52 ( 3 ) : 154 – 160. oecd ( 2015 ). addressing dementia : the oecd response. paris : organization for economic co - operation and development ( http : / / www. oecd. org / health / addressing - dementia - 9789264231726 - en. htm, accessed 3", "metadata": {"doc_name": "9789241550543-eng", "page": 72, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the oecd response. paris : organization for economic co - operation and development ( http : / / www. oecd. org / health / addressing - dementia - 9789264231726 - en. htm, accessed 3 february 2019 ). parikh nm, morgan ro, kunik me, chen h, aparasu rr, yadav rk et al. ( 2011 ). risk factors for dementia in patients over 65 with diabetes. international journal of geriatric psychiatry. 26 ( 7 ) : 749 – 757. doi : 10. 1002 / gps. 2604. parsons c, murad mh, andersen s, mookadam f, labonte h ( 2016 ). the effect of antihypertensive treatment on the incidence of stroke and cognitive decline in the elderly : a meta - analysis. future cardiology. 12 ( 2 ) : 237 – 248. doi : 10. 2217 / fca. 15. 90. pedditzi e, peters r, beckett n ( 2016 ). the risk of overweight / obesity in mid - life and late life for the development of dementia : a systematic review and meta - analysis of longitudinal studies. age & ageing. 45 ( 1 ) : 14 – 21. doi : 10. 1093 / ageing / afv151. perk j", "metadata": {"doc_name": "9789241550543-eng", "page": 72, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "life for the development of dementia : a systematic review and meta - analysis of longitudinal studies. age & ageing. 45 ( 1 ) : 14 – 21. doi : 10. 1093 / ageing / afv151. perk j, de backer g, gohlke h, graham i, reiner z, verschuren m et al. ( 2012 ). european guidelines on cardiovascular disease prevention in clinical practice ( version 2012 ). the fifth joint task force of the european society of cardiology and other societies on cardiovascular disease prevention in clinical practice ( constituted by representatives of nine societies and by invited experts ). european heart journal. 33 ( 13 ) : 1635 – 1701. doi : 10. 1093 / eurheartj / ehs092. piazza - gardner ak, gaffud tj, barry ae ( 2013 ). the impact of alcohol on alzheimer ' s disease : a systematic review. aging & mental health. 17 ( 2 ) : 133 – 146. pirie k, peto r, reeves gk, green j, beral v, million women study collaborators ( 2013 ). the 21st century hazards of smoking and benefits of stopping : a prospective study of one million women in the uk. lancet. 381 ( 9861 ) : 133 – 141. pitkala kh, routasalo p,", "metadata": {"doc_name": "9789241550543-eng", "page": 72, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2013 ). the 21st century hazards of smoking and benefits of stopping : a prospective study of one million women in the uk. lancet. 381 ( 9861 ) : 133 – 141. pitkala kh, routasalo p, kautiainen h, sintonen h, tilvis rs ( 2011 ). effects of socially stimulating group intervention on lonely, older people ' s cognition : a randomized, controlled trial. american journal of geriatric psychiatry. 19 ( 7 ) : 654 – 663. doi : 10. 1097 / jgp. 0b013e3181f7d8b0. podolski n, brixius k, predel hg, brinkmann c ( 2017 ). effects of regular physical activity on the cognitive performance of type 2 diabetic patients : a systematic review. metabolic syndrome & related disorders. 15 ( 10 ) : 481 – 493. prickett c, brennan l, stolwyk r ( 2015 ). examining the relationship between obesity and cognitive function : a systematic literature review. obesity research & clinical practice. 9 ( 2 ) : 93 – 113. doi : https : / / doi. org / 10. 1016 / j. orcp. 2014. 05. 001. prince m, albanese e, guerchet m, prina m (", "metadata": {"doc_name": "9789241550543-eng", "page": 72, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "9 ( 2 ) : 93 – 113. doi : https : / / doi. org / 10. 1016 / j. orcp. 2014. 05. 001. prince m, albanese e, guerchet m, prina m ( 2014 ). world alzheimer report 2014. dementia and risk reduction : an analysis of protective and modifiable risk factors. london : alzheimer ' s disease international. profenno la, porsteinsson ap, faraone sv ( 2010 ). meta - analysis of alzheimer ' s disease risk with obesity, diabetes, and related disorders. biological psychiatry. 67 ( 6 ) : 505 – 512. doi : 10. 1016 / j. biopsych. 2009. 02. 013.", "metadata": {"doc_name": "9789241550543-eng", "page": 72, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "57references radd - vagenas s, duffy sl, naismith sl, brew bj, flood vm, fiatarone singh ma ( 2018 ). effect of the mediterranean diet on cognition and brain morphology and function : a systematic review of randomized controlled trials. american journal of clinical nutrition. 107 ( 3 ) : 389 – 404. rafnsson sb, dilis v, trichopoulou a ( 2013 ). antioxidant nutrients and age - related cognitive decline : a systematic review of population - based cohort studies. european journal of nutrition. 52 ( 6 ) : 1553 – 1567. doi : 10. 1007 / s00394 - 013 - 0541 - 7. rees k, hartley l, flowers n, clarke a, hooper l, thorogood m et al. ( 2013 ). ' mediterranean ' dietary pattern for the primary prevention of cardiovascular disease. cochrane database of systematic reviews. ( 8 ) : cd009825. doi : 10. 1002 / 14651858. cd009825. pub2. reitz c ( 2013 ). dyslipidemia and the risk of alzheimer ' s disease. current atherosclerosis reports. 15 ( 3 ) : 307. doi : 10. 1007 / s1 1883 - 012 - 03", "metadata": {"doc_name": "9789241550543-eng", "page": 73, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "##tz c ( 2013 ). dyslipidemia and the risk of alzheimer ' s disease. current atherosclerosis reports. 15 ( 3 ) : 307. doi : 10. 1007 / s1 1883 - 012 - 0307 - 3. renehan ag, zwahlen m, egger m ( 2015 ). adiposity and cancer risk : new mechanistic insights from epidemiology. nature reviews. cancer. 15 ( 8 ) : 484 – 498. doi : 10. 1038 / nrc3967. richardson ws, glasziou p, polashenski wa, wilson mc ( 2000 ). a new arrival : evidence about differential diagnosis. evidence based medicine. 5 ( 6 ) : 164. rovio s, spulber g, nieminen lj, niskanen e, winblad b, tuomilehto j et al. ( 2010 ). the effect of midlife physical activity on structural brain changes in the elderly. neurobiology of aging. 31 ( 11 ) : 927 – 1936. sachdeva a, chandra m, choudhary m, dayal p, anand ks ( 2016 ). alcohol - related dementia and neurocognitive impairment : a review study. international journal of high risk behaviors & addiction. 5", "metadata": {"doc_name": "9789241550543-eng", "page": 73, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "sachdeva a, chandra m, choudhary m, dayal p, anand ks ( 2016 ). alcohol - related dementia and neurocognitive impairment : a review study. international journal of high risk behaviors & addiction. 5 ( 3 ) : e27976. doi : 10. 5812 / ijhrba. 27976. samieri c, morris mc, bennett da, berr c, amouyel p, dartigues jf et al. ( 2018 ). fish intake, genetic predisposition to alzheimer disease, and decline in global cognition and memory in 5 cohorts of older persons. american journal of epidemiology. 187 ( 5 ) : 933 – 940. doi : 10. 1093 / aje / kwx330. sattler c, toro p, schonknecht p, schroder j ( 2012 ). cognitive activity, education and socioeconomic status as preventive factors for mild cognitive impairment and alzheimer ’ s disease. psychiatry research. 196 ( 1 ) : 90 – 5. schweitzer i, tuckwell v, o ' brien j, ames d ( 2002 ). is late onset depression a prodrome to dementia? international journal of geriatric psychiatry. 17 ( 11 ) : 997 – 1005. doi : 10. 100", "metadata": {"doc_name": "9789241550543-eng", "page": 73, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": ", tuckwell v, o ' brien j, ames d ( 2002 ). is late onset depression a prodrome to dementia? international journal of geriatric psychiatry. 17 ( 11 ) : 997 – 1005. doi : 10. 1002 / gps. 525. sherman ds, mauser j, nuno m, sherzai d ( 2017 ). the efficacy of cognitive intervention in mild cognitive impairment ( mci ) : a meta - analysis of outcomes on neuropsychological measures. neuropsychology review. 27 ( 4 ) : 440 – 484. doi : 10. 1007 / s11065 - 017 - 9363 - 3. siervo m, arnold r, wells jc, tagliabue a, colantuoni a, albanese e et al. ( 2011 ). intentional weight loss in overweight and obese individuals and cognitive function : a systematic review and meta - analysis. obesity reviews. 12 ( 11 ) : 968 – 983. doi : 10. 1111 / j. 1467 - 789x. 2011. 00903. x. singh b, parsaik ak, mielke mm, erwin pj, knopman ds, petersen rc et al. ( 2014 ). association of mediterranean diet with mild cognitive impairment and alzheimer ' s disease : a", "metadata": {"doc_name": "9789241550543-eng", "page": 73, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "##3. x. singh b, parsaik ak, mielke mm, erwin pj, knopman ds, petersen rc et al. ( 2014 ). association of mediterranean diet with mild cognitive impairment and alzheimer ' s disease : a systematic review and meta - analysis. journal of alzheimer ' s disease. 39 ( 2 ) : 271 – 282. doi : 10. 3233 / jad - 130830. sofi f, valecchi d, bacci d, abbate r, gensini gf, casini a et al. ( 2011 ). physical activity and risk of cognitive decline : a meta - analysis of prospective studies. journal internal medicine. 269 ( 1 ) : 107 – 117. solfrizzi v, custodero c, lozupone m, imbimbo bp, valiani v, agosti p et al. ( 2017 ). relationships of dietary patterns, foods, and micro - and macronutrients with alzheimer ' s disease and late - life cognitive disorders : a systematic review. journal of alzheimer ' s disease. 59 ( 3 ) : 815 – 849. doi : 10. 3233 / jad - 170248. solfrizzi v, agosti p, lozupone m, custodero c, schilardi a, valiani v et al. ( 2018", "metadata": {"doc_name": "9789241550543-eng", "page": 73, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "849. doi : 10. 3233 / jad - 170248. solfrizzi v, agosti p, lozupone m, custodero c, schilardi a, valiani v et al. ( 2018 ). nutritional intervention as a preventive approach for cognitive - related outcomes in cognitively healthy older adults : a systematic review. journal of alzheimer ' s disease. ( preprint ) 1 – 26. solomon a, kareholt i, ngandu t, winblad b, nissinen a, tuomilehto j et al. ( 2007 ). serum cholesterol changes after midlife and late - life cognition : twenty - one - year follow - up study. neurology. 68 ( 10 ) : 751 – 756. doi : 10. 1212 / 01. wnl. 0000256368. 57375. b7. song y, nie h, xu y, zhang l, wu y ( 2013 ). association of statin use with risk of dementia : a meta - analysis of prospective cohort studies. geriatrics & gerontology international. 13 ( 4 ) : 817 – 824. doi : 10. 1111 / ggi. 1204 4. song d, yu dsf, li pwc, lei y (", "metadata": {"doc_name": "9789241550543-eng", "page": 73, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "studies. geriatrics & gerontology international. 13 ( 4 ) : 817 – 824. doi : 10. 1111 / ggi. 1204 4. song d, yu dsf, li pwc, lei y ( 2018 ). the effectiveness of physical exercise on cognitive and psychological outcomes in individuals with mild cognitive impairment : a systematic review and meta - analysis. international journal of nursing studies. 79 : 155 – 164.", "metadata": {"doc_name": "9789241550543-eng", "page": 73, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "58 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 74, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "sprint mind investigators for the sprint research group ( 2019 ). effect of intensive vs standard blood pressure control on probable dementia : a randomized clinical trial. jama. 321 ( 6 ) : 553 – 561. doi : 10. 1001 / jama. 2018. 21442. stephen r, hongisto k, solomon a, lonnroos e ( 2017 ). physical activity and alzheimer ’ s disease : a systematic review. journals of gerontology series a : biological sciences & medical sciences. 72 ( 6 ) : 733 – 739. stern c & munn z ( 2010 ). cognitive leisure activities and their role in preventing dementia : a systematic review. international journal of evidence - based healthcare. 8 ( 1 ) : 2 – 17. doi : 10. 1111 / j. 1744 - 1609. 2010. 00150. x. stern y ( 2012 ). cognitive reserve in ageing and alzheimer ' s disease. lancet neurology. 11 ( 11 ) : 1006 – 1012. doi : 10. 1016 / s1474 - 4422 ( 12 ) 70191 - 6. stewart r, xue ql, masaki k, petrovitch h, ross gw, white lr et al. ( 2009 ). change in blood pressure and incident dementia : a 32 - year prospective study. hypertension", "metadata": {"doc_name": "9789241550543-eng", "page": 74, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "6. stewart r, xue ql, masaki k, petrovitch h, ross gw, white lr et al. ( 2009 ). change in blood pressure and incident dementia : a 32 - year prospective study. hypertension. 54 ( 2 ) : 233 – 240. doi : 10. 1161 / hypertensionaha. 109. 128744. strout ka, david dj, dyer ej, gray rc, robnett rh, howard, ep ( 2016 ). behavioral interventions in six dimensions of wellness that protect the cognitive health of community - dwelling older adults : a systematic review. journal of the american geriatrics society. 64 ( 5 ) : 944 – 958. swaminathan a & jicha ga ( 2014 ). nutrition and prevention of alzheimer ' s dementia. frontiers in aging neuroscience. 6 : 282. doi : 10. 3389 / fnagi. 2014. 00282. swiger kj, manalac rj, blumenthal rs, blaha mj, martin ss ( 2013 ). statins and cognition : a systematic review and meta - analysis of short - and long - term cognitive effects. mayo clinic proceedings. 88 ( 11 ) : 1213 – 1221. doi : 10. 1016 / j. mayocp. 2013. 07. 013. taylor g, mc", "metadata": {"doc_name": "9789241550543-eng", "page": 74, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "meta - analysis of short - and long - term cognitive effects. mayo clinic proceedings. 88 ( 11 ) : 1213 – 1221. doi : 10. 1016 / j. mayocp. 2013. 07. 013. taylor g, mcneill a, girling a, farley a, lindson - hawley n, aveyard p ( 2014 ). change in mental health after smoking cessation : systematic review and meta - analysis. british medical journal. 348 : g1151. travica n, ried k, sali a, scholey a, hudson i, pipingas a ( 2017 ). vitamin c status and cognitive function : a systematic review. nutrients. 9 ( 9 ). doi : 10. 3390 / nu9090960. tuomilehto j, lindstrom j, eriksson jg, valle tt, hamalainen h, ilanne - parikka p et al. ( 2001 ). prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. new england journal of medicine. 344 ( 18 ) : 1343 – 1350. doi : 10. 1056 / nejm200105033441801. un ( 2019 ). sustainable development goals. united nations ( https : / / www. un. org / sustainabledev", "metadata": {"doc_name": "9789241550543-eng", "page": 74, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "18 ) : 1343 – 1350. doi : 10. 1056 / nejm200105033441801. un ( 2019 ). sustainable development goals. united nations ( https : / / www. un. org / sustainabledevelopment / sustainable - development - goals /, accessed 4 february 2019 ). us department of health human services ( 2004 ). the health consequences of smoking : a report of the surgeon general. veronese n, facchini s, stubbs b, luchini c, solmi m, manzato e et al ( 2017 ). weight loss is associated with improvements in cognitive function among overweight and obese people : a systematic review and meta - analysis. neuroscience & biobehavioral reviews. 72 : 87 – 94. weiss j, kerfoot a, freeman m, motu ' apuaka m, fu r, low a et al. ( 2016 ). benefits and harms of treating blood pressure in older adults : a systematic review and meta - analysis. va evidence - based synthesis program reports. washington ( dc ) : department of veterans affairs ( us ). wengreen h, munger rg, cutler a, quach a, bowles a, corcoran c et al. ( 2013 ). prospective study of dietary approaches to stop hypertension - and mediterranean - style dietary", "metadata": {"doc_name": "9789241550543-eng", "page": 74, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "us ). wengreen h, munger rg, cutler a, quach a, bowles a, corcoran c et al. ( 2013 ). prospective study of dietary approaches to stop hypertension - and mediterranean - style dietary patterns and age - related cognitive change : the cache county study on memory, health and aging. american journal of clinical nutrition. 98 ( 5 ) : 1263 – 1271. doi : 10. 3945 / ajcn. 112. 051276. whitmer ra, sidney s, selby j, johnston sc, yaffe k ( 2005 ). midlife cardiovascular risk factors and risk of dementia in late life. neurology. 64 ( 2 ) : 277 – 281. doi : 10. 1212 / 01. wnl. 0000149519. 47454. f2 who ( 1992 ). the icd - 10 classification of mental and behavioural disorders : clinical descriptions and diagnostic guidelines. geneva : world health organization. who ( 2011 ). who report on the global tobacco epidemic, 2011 : warning about the dangers of tobacco. geneva : world health organization. who ( 2012 ). hearing loss in persons 65 and older based on who global estimates on prevalence of hearing loss. geneva : world health organization ( https : / / www. who. int / pbd / deafness /", "metadata": {"doc_name": "9789241550543-eng", "page": 74, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "world health organization. who ( 2012 ). hearing loss in persons 65 and older based on who global estimates on prevalence of hearing loss. geneva : world health organization ( https : / / www. who. int / pbd / deafness / news / ge _ 65years. pdf, accessed 4 february 2019 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 74, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "59references who ( 2014 ). global status report on alcohol and health. geneva : world health organzation ( https : / / www. who. int / substance _ abuse / publications / alcohol _ 2014 / en /, accessed 4 february 2019 ). who ( 2017a ). global action plan on the public health response to dementia 2017 – 2025. geneva : world health organization ( https : / / www. who. int / mental _ health / neurology / dementia / action _ plan _ 2017 _ 2025 / en /, accessed 4 february 2019 ). who ( 2017b ). 10 facts on dementia. world health organization ( http : / / www. who. int / features / factfiles / dementia / en /, accessed 4 february 2019 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 75, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "who ( 2019a ). management of substance abuse : alcohol.", "metadata": {"doc_name": "9789241550543-eng", "page": 75, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "world health organization ( www. who. int / substance _ abuse / facts / alcohol / en, accessed 4 february 2019 ).", "metadata": {"doc_name": "9789241550543-eng", "page": 75, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "who ( 2019b ). global health observatory data : obesity.", "metadata": {"doc_name": "9789241550543-eng", "page": 75, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "world health organization ( http : / / www. who. int / gho / ncd / risk _ factors / obesity _ text / en /, accessed 4 february 2019 ). who ( 2019c ). global health observatory data : raised cholesterol. world health organization ( https : / / www. who. int / gho / ncd / risk _ factors / cholesterol _ text / en /, accessed 4 february 2019 ). who ( 2010 ). global strategy to reduce the harmful use of", "metadata": {"doc_name": "9789241550543-eng", "page": 75, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "alcohol. world health organization ( https : / / apps. who. int / iris /", "metadata": {"doc_name": "9789241550543-eng", "page": 75, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "bitstream / handle / 10665 / 44395 / 9789241599931 _ eng. pdf? sequence = 1 ) wilson bs, tucci dl, merson mh, o ' donoghue gm ( 2017 ). global hearing health care : new findings and perspectives. lancet. 390 ( 10111 ) : 2503 – 2515. doi : https : / / doi. org / 10. 1016 / s0140 - 6736 ( 17 ) 31073 - 5. wong wb, lin vw, boudreau d, devine eb ( 2013 ). statins in the prevention of dementia and alzheimer ' s disease : a meta - analysis of observational studies and an assessment of confounding. pharmacoepidemiology & drug safety. 22 ( 4 ) : 345 –", "metadata": {"doc_name": "9789241550543-eng", "page": 75, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "358. doi : 10. 1002 / pds. 3381.", "metadata": {"doc_name": "9789241550543-eng", "page": 75, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "wu l & sun d ( 2017 ). adherence to mediterranean diet and risk of developing cognitive disorders : an updated systematic review and meta - analysis of prospective cohort studies. scientific reports. 7 : 41317. doi : 10. 1038 / srep41317. wu l, sun d, tan y ( 2017 ). intake of fruit and vegetables and the incident risk of cognitive disorders : a systematic review and meta - analysis of cohort studies. journal of nutrition, health & aging. 21 ( 10 ) : 1284 – 1290. doi : 10. 1007 / s12603 - 017 - 0875 - 6. xu wl, atti ar, gatz m, pedersen nl, johansson b, fratiglioni l ( 2011 ). midlife overweight and obesity increase late - life dementia risk : a population - based twin study. neurology. 76 ( 18 ) : 1568 – 1574. doi : 10. 1212 / wnl. 0b013e3182190d09. xu w, tan l, wang h - f, jiang t, tan m - s, tan l et al. ( 2015 ). meta - analysis of modifiable risk factors for alzheimer ' s disease. journal of neurology, neurosurgery & psychiatry. 86 ( 12 ). doi", "metadata": {"doc_name": "9789241550543-eng", "page": 75, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": ", tan m - s, tan l et al. ( 2015 ). meta - analysis of modifiable risk factors for alzheimer ' s disease. journal of neurology, neurosurgery & psychiatry. 86 ( 12 ). doi : 10. 1136 / jnnp - 2015 - 310548. xu w, wang h, wan y, tan c, li j, tan l, yu jt ( 2017 ). alcohol consumption and dementia risk : a dose - response meta - analysis of prospective studies. european journal of epidemiology. 32 ( 1 ) : 31 – 42. doi : 10. 1007 / s10654 - 017 - 0225 - 3. yaffe k, falvey c, hamilton n, schwartz av, simonsick em, satterfield s et al ( 2012 ). diabetes, glucose control, and 9 - year cognitive decline among older adults without dementia. archives of neurology. 69 ( 9 ) : 1170 – 1175. doi : 10. 1001 / archneurol. 2012. 1117. zhang y, chen j, qiu j, li y, wang j, jiao j ( 2016 ). intakes of fish and polyunsaturated fatty acids and mild - to - severe cognitive impairment risks : a dose - response meta - analysis of 21", "metadata": {"doc_name": "9789241550543-eng", "page": 75, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "j, qiu j, li y, wang j, jiao j ( 2016 ). intakes of fish and polyunsaturated fatty acids and mild - to - severe cognitive impairment risks : a dose - response meta - analysis of 21 cohort studies. american journal of clinical nutrition. 103 ( 2 ) : 330 – 340. doi : 10. 3945 / ajcn. 115. 124081. zheng y, fan s, liao w, fang w, xiao s, liu j ( 2017 ). hearing impairment and risk of alzheimer ’ s disease : a meta - analysis of prospective cohort studies. neurological sciences. 38 ( 2 ) : 233 – 239 zhong g, wang y, zhang y, guo jj, zhao y ( 2015 ). smoking is associated with an increased risk of dementia : a meta - analysis of prospective cohort studies with investigation of potential effect modifiers. plos one. 10 ( 3 ) : e0118333. zhou s, zhou r, zhong t, li r, tan j, zhou h ( 2014 ). association of smoking and alcohol drinking with dementia risk among elderly men in china. current alzheimer research. 11 ( 9 ) : 899 – 907.", "metadata": {"doc_name": "9789241550543-eng", "page": 75, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "60 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "annex 1 : guideline development group members name gender who region affiliation area of expertise", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. charles alessi m european public health england, united", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "kingdom health reform, preventable dementia", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. kaarin anstey f western", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pacific university of new south wales and neuroscience research, australia research in dementia epidemiology and risk reduction and cognitive ageing", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. kimberly", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "ashby - mitchell f americas caribbean public health agency, trinidad and tobago research on effects of diet and physical activity on cognitive status", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "4. corrado barbui m european university of verona, italy mental health research and training,", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "public health, health systems strengthening", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "5. adelina", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "comas - herrera f european london school of economics, united kingdom health economist, dementia research", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "6. amit dias m south - east", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "asia department of preventive and social medicine, goa medical college, india dementia, public health in lmic", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "7. cleusa p ferri f americas federal university of sao paulo,", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "brazil research in dementia and 10 / 66 group, dementia risk factors in lmic", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "8. riadh gouider m eastern alzheimer ’ s centre, razi", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "hospital, tunis ; tunisian society of neurology, tunisia dementia research in areas of epidemiology, neuropsychological assessment and risk factors", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "9. shinya ishii m western", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pacific health and welfare bureau for the elderly ; ministry of health, labour and welfare, tokyo, japan health policy, neurology of alzheimer ’ s disease and dementia", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "10. yves joanette m americas canadian institutes of health", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "research, government of canada dementia research", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "11. joseph kibachio m african ministry of health, nairobi,", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "kenya public health, health policy, ncds", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "12. miia kivipelto f european karolinska institutet, stockholm", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "university, stockholm, sweden dementia research in the field of early diagnosis and prevention", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "13. shanthi mendis f south - east", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "asia independent consultant in global health, sri lanka ncds and cardiology, health policy development, capacity strengthening, implementation research particularly in lmic", "metadata": {"doc_name": "9789241550543-eng", "page": 76, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "61annex 1 : guideline development group members name gender who region affiliation area of expertise", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "14. ayesha motala f african university of kwazulu - natal,", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "south africa epidemiology and genetics of diabetes mellitus", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "15. ronald petersen m americas mayo clinic, united states of", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "america memory disorders, aging and alzheimer ' s disease", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "16. dorairaj", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "prabhakaran m south - east asia", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "centre for chronic conditions", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and injuries & public health foundation of india cardiovascular disease prevention, epidemiology, developmental origin, and biomarkers of cardiovascular diseases and diabetes", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "17. martin prince m european health foundation of india public health aspects of ageing and", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "chronic disease in lmic, dementia, guideline development", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "18. suzana shahar f western", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pacific universiti kebangsaan, malaysia nutrition, micronutrients, dietary interventions", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "19. ameenah bibi mia", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "sorefan f african alzheimer ’ s association of mauritius ; ministry of health & quality of life, mauritius ageing, dementia and alzheimer ’ s disease", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "20. kusumadewi", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "suharya ( dy ) f western pacific alzheimer ’ s disease international, indonesia dementia and public health", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "21. huali wang f western", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pacific dementia care & research center, peking university institute of mental health, china dementia research and education", "metadata": {"doc_name": "9789241550543-eng", "page": 77, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "62 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "annex 2 : assessment of conflict of interest individuals involved in assessment of conflict of interest :", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "tarun dua, programme manager, department", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "of mental health and substance abuse, who headquarters.", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "neerja chowdhary, technical officer, department", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "of mental health and substance abuse, who headquarters.", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "to comply with who ’ s conflict of interest policy,", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the secretariat followed the revised guidelines for declaration of interests ( who experts ). 14 declarations of interest ( doi ) were requested from : ( a ) all gdg members ; ( b ) all external partners involved in the evidence review process ; ( c ) all experts invited to review the evidence profiles. a letter requesting completion of a doi form and", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "submission of a curriculum vitae as well as was sent to all gdg members, the external review group and", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "external partners. they were asked to agree to the publication of a summary of declarations in the guide - line. the gdg members were also required to complete a confidentiality undertaking. once received, the who secretariat reviewed the dois as well as additional information ( internet and bibliographic database search ) and evaluated if there are any conflicts of interest and if so, whether these require a management plan. in order to enhance its management of conflicts of interest as well as strengthen public trust and transparency in connection with who meetings and activities involving the provision of technical / normative advice, the names and brief biographies members being considered for participation in the gdg were disclosed for public notice and comment prior to the meeting. at the beginning of the gdg meeting, the doi of each gdg member were presented and gdg members and external partners were asked to update their doi with relevant changes by notifying the responsible technical officer.", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the follow up and suggested actions agreed upon", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "to manage the conflicts of interest declared are summarized below :", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• if members declare interests that are relevant to", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the meeting, the who secretariat will note any potential conflict of interest and summarize these and then decide whether and to what extent they can participate in the guideline development.", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• if the conflict is deemed to be significant, the", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "who secretariat will decide if the conflict necessitates exclusion of that person from participating in the guideline process or if their participation should be limited.", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• these decisions are made on a case - by - case basis.", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "below is a summary of the declared conflicts of interest and how these were managed. a. gdg members gdg members with no relevant interests declared on the doi form and no relevant interests found in the cv", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. kaarin j anstey, university of new south wales,", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "sydney, australia ;", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. kimberly ashby - mitchell, caribbean public", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "health agency, port of spain, trinidad and tobago ;", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. corrado barbui, university of verona, verona, italy. 4. amit dias, department of preventive and", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "social medicine, goa medical college bambolim,", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "goa, india ; 5. suharya dy ( kusumadewi ), alzheimer ’ s disease", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "international, jakarta, indonesia ;", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "6. cleusa p. ferri, federal university of sao paulo,", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "sao paulo, brazil.", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "7. riadh gouider, razi hospital, faculty of", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "medicine, tunis, tunisia ;", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "8. shinya ishii, ministry of health, labour and", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "welfare, tokyo, japan ;", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "14 who office of compliance, risk management and ethics ( cre ) http : / / intranet. who. int / homes / cre / ethics / doiexperts /", "metadata": {"doc_name": "9789241550543-eng", "page": 78, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "63", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "9. yves joanette, canadian institute of health", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "research, government of canada.", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "10. joseph kibachio, ministry of health, nairobi,", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "kenya ;", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "11. shanthi mendis, colombo, sri lanka ; 12. dorairaj prabhakaran, public health foundation", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "of india, new delhi, india ;", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "13. ameenah bibi mia sorefan, ministry of health", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and quality of life, quatre - bornes, mauritius gdg members who have declared an interest on the doi form or where a potentially relevant interest has been noted from the cv charles alessi, public health england, london, united - kingdom dr alessi declared that the travel costs for the gdg meeting were covered by his organization. action : this interest was deemed insignificant or minimal and unlikely to affect, or be reasonably perceived to affect, dr alessi ’ s judgement in the development of the present guidelines. he is deemed to be participating in the guideline development process in an individual capacity and not representing", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "any organization. no further action was necessary", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "adelina comas - herrera, london school of economics, london, united - kingdom dr comas - herrera declared in her doi from that she had received research support routed via her university on various research projects on dementia in 2015 and 2016. these amounts were used to pay her salary by the university. she also declared receiving a payment of us $ 1000 in 2017 to advise a", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pharmaceutical company, axovant sciences gmbh.", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the topic was on the availability of data on dementia costs for a medicine that has since been withdrawn due to lack of effectiveness. action : it was felt that this interest is insignificant or minimal and unlikely to affect, or be reasonably perceived to affect, dr comas - herera ’ s judgement in the development of the present guidelines. no further action", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "was necessary.", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "miia kivipelto, karolinska institutet, stockholm, sweden dr kivipelto declared in her doi form that she currently serves on the advisory board of a finnish", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "company that focuses on early diagnosis and e - health solutions for which she received €2500.", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "she is also on the governance committee of aarp, a non - profit organization for healthy ageing for which she received €800. she also declared that she has received research grants related to risk factors for dementia and is a founding member of world - wide fingers, an interdisciplinary network to share experiences, harmonize data and plan joint international initiatives for the risk reduction of cognitive decline and dementia. action : this interest was deemed insignificant or minimal and unlikely to affect, or be reasonably perceived to affect, dr kivipelto ’ s judgement in the development of the present guidelines. she is deemed to be participating in the guideline development process in an individual capacity and not representing any", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "organization. no further action was necessary", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "ayesha motala, university of kwazulu - natal, durban, south africa. dr motala declared that as a public servant working in a government institute, she seeks sponsorships to meetings from various organizations, especially when her scientific abstracts are accepted for presentations. the sponsorships are merely for attending the meetings, with no obligation to the sponsoring companies. annex 2 : assessment of conflict of interest", "metadata": {"doc_name": "9789241550543-eng", "page": 79, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "64 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 80, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "details of such sponsorship for which she received a total amount of us $ 26 000 : 4 – 8 december 2017 : international diabetes federation ( idf ) congress, abu dhabi : sanofi aventis sponsorship for travel and accommodation ; 11 – 15 september 2017 : european association for the study of diabetes ( easd ) congress, lisbon : pfizer sponsorship for travel and accommodation ; 8 – 13 june 2018 : american diabetes association ( ada ), san diego : boehringer ingelheim sponsorship for travel and accommodation : a member of her collaborating scientific team presented a paper. action : it was felt that this interest is insignificant or minimal and unlikely to affect, or be reasonably perceived to affect, dr motala ’ s contribution as an external reviewer for these guidelines. no further action", "metadata": {"doc_name": "9789241550543-eng", "page": 80, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "was necessary. ronald c. petersen, mayo clinic, rochester, usa", "metadata": {"doc_name": "9789241550543-eng", "page": 80, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "dr petersen declared that he is a clinical trials consultant for five pharmaceutical companies : from four of these ( roche inc, merck inc, genetech inc and ge healthcare ) he receives less than us $ 10 000 and from one ( biogen inc ) he receives less that us $ 15 000 as consultancy fees. action : it was felt that this interest is unlikely to affect, or be reasonably perceived to affect, dr petersen ’ s contribution as an external reviewer for these guidelines since these grants are not related to the topic of interest.", "metadata": {"doc_name": "9789241550543-eng", "page": 80, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "no further action was necessary.", "metadata": {"doc_name": "9789241550543-eng", "page": 80, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "martin prince, king ’ s college london, london, united kingdom professor prince declared in his doi form that he currently receives research support through a grant from the national institute of health research ( nihr, uk ) amounting to £7 million over four years. professor prince is the pi and 20 % of his salary costs are charged to the grant. the work focuses on health systems strengthening in sub saharan africa and one theme relates to the topic of these guidelines i. e. integrated primary healthcare for multimorbid conditions. action : it was felt that this interest is insignificant or minimal and unlikely to affect, or be reasonably perceived to affect, professor prince ’ s judgement in the development of the present guidelines. no further action", "metadata": {"doc_name": "9789241550543-eng", "page": 80, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "was necessary", "metadata": {"doc_name": "9789241550543-eng", "page": 80, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "suzana shahar, universiti kebangsaan malaysia, selangor, malaysia dr sahar has declared in her doi form that she has a clinical trial agreement through her university with biotropics, a company that develops bio - resources into superior natural health product. the research involves evaluating the efficacy of asian traditional herbs in improving cognition and mood. the funding amount is us $ 100 000 between 2014 and 2018. action : it was felt that this interest is insignificant or minimal and unlikely to affect, or be reasonably perceived to affect, dr sahar ’ s contribution as an external reviewer for these guidelines. no further action", "metadata": {"doc_name": "9789241550543-eng", "page": 80, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "was necessary", "metadata": {"doc_name": "9789241550543-eng", "page": 80, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "huali wang, dementia care & research center, peking university institute of mental health, beijing,", "metadata": {"doc_name": "9789241550543-eng", "page": 80, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "china.", "metadata": {"doc_name": "9789241550543-eng", "page": 80, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "dr wang declared in her doi form that prior to 2016, she had worked as a consultant with neowave inc. to develop a tablet - based cognitive training program. she also declared that she had received support for travelling to meetings form eisai china amounting to", "metadata": {"doc_name": "9789241550543-eng", "page": 80, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "us $ 7000 prior to 2017. the meeting were all", "metadata": {"doc_name": "9789241550543-eng", "page": 80, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "alzheimer ’ s disease international ( adi ) conferences.", "metadata": {"doc_name": "9789241550543-eng", "page": 80, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "65 action : it was felt that this interest is insignificant or minimal and unlikely to affect, or be reasonably perceived to affect, dr wang ’ s contribution as an external reviewer for these guidelines. no further action was necessary b. external review group members of the external review group with no relevant interests declared on the doi form and no relevant interests found in the cv", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. abdullah al khatami, ministry of health,", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "saudi arabia", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. alistair burns, university of manchester, uk 3. linda clare, university of exeter, uk 4. jacqueline dominguez, institute for dementia", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "care asia, quezon city, philippines 5. maelenn guerchet, the global observatory for", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "ageing and dementia care, king ' s college london, uk", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "6. mariella guerra, institute of memory,", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "depression and related disorders – imeder, lima, peru", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "7. luis miguel f. gutierrez robledo, instituto", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "nacional de geriatria, institutos nacionales de salud de mexico, mexico city, mexico", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "8. vladimir hachinski, university of western", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "ontario in london, ontario, canada", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "9. qurat ul ain khan, aga khan university hospital,", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "karachi, pakistan.", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "10. sebastian koehler, maastricht university,", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the netherlands", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "11. jae - hong lee, university of ulsan college of", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "medicine, seoul, korea", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "12. gill livingstone, university college london, uk 13. jean claude mbanya, doctoral school of life", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "sciences, health and environment, university of yaounde i, cameroon.", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "14. james mckillop, service user group", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "representative, uk", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "15. rajat ray, national drug dependence treatment", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "centre, all india institute of medical sciences, new delhi, india", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "16. helen rochford brennan, european working", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "group of people with dementia, ireland", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "17. kate swaffer, dementia alliance international,", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "australia", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "18. weili xu, karolinska institute, finland", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "members of the external review group who have declared an interest on the doi form or where a potentially relevant interest has been noted from the cv", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "emiliano albanese, universita della svizzera italiana,", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "switzerland dr albanese declared in his doi form that he receives research support from the economic and research council uk as part of the stride ( strengthening responses to dementia in developing countries ) research consortium which focuses on dementia research in low and middle income countries. the amount of us $ 50 000 is provided to the institution to which he is affiliated. action : it was felt that this interest is insignificant or minimal and unlikely to affect, or be reasonably perceived to affect, dr albanese ’ s contribution as an external reviewer for these guidelines. no further action", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "was necessary. hillary doxford, 3 nations dementia working", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "group, uk ms doxford declared in her doi form that she has served on a grant review panel assessing and prioritizing grant applications for funding dementia research projects for the national institute for health research, uk. the income she received for this was £450. she is also a voluntary member of the dementia", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "programme board in the uk department of health", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "and social care as a person with lived experience.", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "action : it was felt that this interest is insignificant or", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "minimal and unlikely to affect, or be reasonably perceived to affect, ms doxford ’ s contribution as an external reviewer for these guidelines. no further action was necessary. annex 2 : assessment of conflict of interest", "metadata": {"doc_name": "9789241550543-eng", "page": 81, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "66 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "elaine rashbrook, public health england, uk dr rashbrook declared in her doi form that she is employed by public health england ( phe ), a government agency, as consultant specialist life course since 2015. phe supports work on dementia risk reduction in line with the government strategy. there is no identified financial value for the work. action : it was felt that this interest is insignificant or minimal and unlikely to affect, or be reasonably perceived to affect, dr rashbrook ’ s contribution as an external reviewer for these guidelines. she is deemed to be providing her review in an individual capacity and not representing any organization. no further action", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "was necessary.", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "andrew sommerlad, university college london, uk dr sommerlad declared in his doi form that he receives research support from the wellcome trust in the form of a personal research fellowship to examiner whether social isolation is a risk factor for dementia the amount of funding is £201 311 from 2016 to 2019. action : it was felt that this interest is insignificant or minimal and unlikely to affect, or be reasonably perceived to affect, dr sommerlad ’ s contribution as an external reviewer for these guidelines. no further action was necessary", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "b. external partners", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "external partners with no relevant interests declared on the doi form and no relevant interests found in the cv", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. mariagnese barbera, university of eastern", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "finland, kuopio, finland ;", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. nicole a. ee, university of new south wales,", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "sydney, australia ;", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. jenni kumlala, karolinska institutet, stockholm,", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "sweden ;", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "4. ruth peters, university of new south wales,", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "sydney, australia ;", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "5. lidan zheng, university of new south wales,", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "sydney, australia. none of the external partners declared relevant interests on the doi forms nor were relevant interests found in the cv.", "metadata": {"doc_name": "9789241550543-eng", "page": 82, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "67 annex 3 : scoping questions interventions addressing lifestyle and behaviour risk factors", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. physical activity interventions for adults with normal cognition or mild cognitive impairment, are physical activity interventions more", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "effective than usual care or no intervention in reducing the risk of cognitive decline and / or dementia? p : adults ( age above 18 years ) with normal cognition or mci", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "i : physical activity interventions ( aerobic, resistance training or multicomponent physical activity ) c : care as usual or no intervention o : • critical – cognitive function – incident mci – dementia", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. tobacco cessation interventions for adults with normal cognition or mild cognitive impairment who use tobacco, are interventions for", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "tobacco cessation more effective than usual care or no intervention in reducing the risk of cognitive decline and / or dementia? p : adults with normal cognition or mci who use tobacco", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "i : interventions for tobacco cessation ( behavioural interventions and pharmacological interventions including", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "nicotine replacement therapy, bupropion, varenicline )", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "c : care as usual or no intervention o : • critical – cognitive function – incident mci – dementia", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. nutritional interventions 3a. for adults with normal cognition or mild cognitive impairment, are nutritional interventions such", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "as dietary supplements more effective than usual care or no intervention in reducing the risk of cognitive decline and / or dementia? p : adults with normal cognition or mci", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "i : dietary supplements ( e. g. b vitamins, antioxidants, omega - 3 and ginkgo ) ;", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "c : care as usual or no intervention", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "o : • critical – cognitive function – incident mci – dementia • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "annex 3 : scoping questions", "metadata": {"doc_name": "9789241550543-eng", "page": 83, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "68 risk reduction of cognitive decline and dementia : who guidelines 3b. for adults with normal cognition or mild cognitive impairment, are nutritional interventions such", "metadata": {"doc_name": "9789241550543-eng", "page": 84, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "as healthy dietary patterns ( e. g. mediterranean diet ) more effective than usual care or no intervention in reducing the risk of cognitive decline and / or dementia? p : adults with normal cognition or mci", "metadata": {"doc_name": "9789241550543-eng", "page": 84, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "i : healthy dietary pattern ( e. g. mediterranean diet )", "metadata": {"doc_name": "9789241550543-eng", "page": 84, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "c : care as usual or no intervention", "metadata": {"doc_name": "9789241550543-eng", "page": 84, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "o : • critical – cognitive function – incident mci – dementia", "metadata": {"doc_name": "9789241550543-eng", "page": 84, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "4. interventions for alcohol use disorders for adults with normal cognition or mild cognitive impairment and alcohol use disorders, are", "metadata": {"doc_name": "9789241550543-eng", "page": 84, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "behavioural and psychological interventions to treat alcohol use disorders more effective than usual care or no intervention in reducing the risk of cognitive decline and / or dementia? p : adults with normal cognition or mci and excessive use of alcohol", "metadata": {"doc_name": "9789241550543-eng", "page": 84, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "i : • behavioural and psychological interventions to treat alcohol use disorders ( e. g. motivational interviewing ) • pharmacological interventions to treat alcohol use disorders c : care as usual or no intervention o : • critical – cognitive function – incident mci – dementia • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates", "metadata": {"doc_name": "9789241550543-eng", "page": 84, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "69 specific interventions", "metadata": {"doc_name": "9789241550543-eng", "page": 85, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "5. cognitive interventions for adults with normal cognition or mild cognitive impairment is cognitive stimulation or cognitive", "metadata": {"doc_name": "9789241550543-eng", "page": 85, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "training more effective than usual care or no intervention in reducing the risk of cognitive decline and / or dementia? p : adults with normal cognition or mci", "metadata": {"doc_name": "9789241550543-eng", "page": 85, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "i : • cognitive stimulation • cognitive training", "metadata": {"doc_name": "9789241550543-eng", "page": 85, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "c : care as usual or no intervention", "metadata": {"doc_name": "9789241550543-eng", "page": 85, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "o : • critical – cognitive function – incident mci – dementia", "metadata": {"doc_name": "9789241550543-eng", "page": 85, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "6. social activity for adults with normal cognition or mild cognitive impairment is preserving and promoting a high", "metadata": {"doc_name": "9789241550543-eng", "page": 85, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "level of social activity more effective than usual care or no intervention in reducing the risk of cognitive decline and / or dementia?", "metadata": {"doc_name": "9789241550543-eng", "page": 85, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "p : adults with normal cognition or mci", "metadata": {"doc_name": "9789241550543-eng", "page": 85, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "i : preservation and promotion of social activity including community and family engagement", "metadata": {"doc_name": "9789241550543-eng", "page": 85, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "c : care as usual or no intervention", "metadata": {"doc_name": "9789241550543-eng", "page": 85, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "o : • critical – cognitive function – incident mci – dementia • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates", "metadata": {"doc_name": "9789241550543-eng", "page": 85, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "annex 3 : scoping questions", "metadata": {"doc_name": "9789241550543-eng", "page": 85, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "70 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "interventions for health conditions", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "7. weight management for adults with normal cognition or mild cognitive impairment who are overweight or obese, are", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "interventions for weight reduction ( or control of obesity ) more effective than usual care or no intervention in reducing the risk of cognitive decline and / or dementia? p : adults with normal cognition or mci who are overweight or obese", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "i : weight management • non - pharmacological interventions, e. g. cognitive - behavioural intervention strategies, lifestyle interventions • pharmacological interventions, e. g. weight - loss medication ( e. g. orlistat )", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "c : care as usual or no intervention", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "o : • critical – cognitive function – incident mci – dementia", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "8. management of hypertension for adults with normal cognition or mild cognitive impairment and hypertension,", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "is treatment of hypertension more effective than placebo / no intervention in reducing the risk", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "of cognitive decline / dementia? p : adults with normal cognition or mci with hypertension", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "i : antihypertensive medication, lifestyle interventions", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "c : placebo / no intervention", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "o : • critical – cognitive function – incident mci – dementia", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "9. management of diabetes mellitus for adults with normal cognition or mild cognitive impairment and diabetes mellitus,", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "is treatment of diabetes more effective than placebo / no intervention in reducing the risk", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "of cognitive decline and / or dementia?", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "p : adults with normal cognition or mci with diabetes mellitus i : • medications for glycaemic control • diet and lifestyle interventions", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "c : placebo / no intervention", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "o : • critical – cognitive function – incident mci – dementia • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates", "metadata": {"doc_name": "9789241550543-eng", "page": 86, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "71annex 3 : scoping questions", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "10. management of dyslipidaemia for adults with normal cognition or mild cognitive impairment and dyslipidaemia,", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "is treatment of dyslipidaemia more effective than placebo or no intervention in reducing", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the risk of cognitive decline and / or dementia? p : adults with normal cognition or mci with dyslipidaemia", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "i : • statins ( e. g. simvastatin and pravastatin ) • lifestyle interventions", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "c : placebo or no intervention", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "o : • critical – cognitive function – incident mci – dementia", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "11. management of depression for adults with normal cognition or mild cognitive impairment and depressive disorder,", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "is treatment of depression more effective than usual care, placebo or no intervention in reducing", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the risk of cognitive decline and / or dementia?", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "p : adults with normal cognition or mci with moderate to severe depressive disorder i : • pharmacological interventions to treat depression ( antidepressant medication ) • psychological interventions to treat depression ( e. g. cognitive behavioural therapy, problem - solving", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "therapy, interpersonal therapy, behavioural activation ) c : care as usual or placebo or no intervention", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "o : • critical – cognitive function – incident mci – dementia", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "12. management of hearing loss for adults with normal cognition or mild cognitive impairment and hearing loss,", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "is treatment of hearing loss more effective than usual care, or no intervention in reducing", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the risk of cognitive decline and / or dementia?", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "p : adults with normal cognition or mci with hearing loss i : interventions to treat hearing loss ( e. g. hearing aids )", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "c : care as usual or no intervention", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "o : • critical – cognitive function – incident mci – dementia • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates • important – quality of life – functional level ( adl, iadl ) – adverse events – drop - out rates", "metadata": {"doc_name": "9789241550543-eng", "page": 87, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "72 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "annex 4 : evidence review methodology comprehensive searches of major bibliographic databases were conducted to identify one systematic review that matched each of the outcomes for each of the pico questions. the aim was to identify systematic reviews that were timely, of high quality and relevant to each of the pico questions. the search strategies differed slightly between the two teams ( based in the karolinska institutet, sweden and university of new south wales, australia. however, in general, the following process was employed :", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "1. search for systematic reviews ( including meta -", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "analyses ) that were published in the last 2 years for each of the pico questions. the searches were run from april to june 2018.", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "2. if no relevant high - quality systematic reviews were", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "identified from the 2 years for any of the pico questions, the search was expanded to include systematic reviews from the last 5 years for that pico question. for the relevant pico questions, the 2016 ahrq systematic review was also consulted. the aim of the ahrq review was to examine interventions to prevent cognitive decline and dementia. the review systematically searched records between january 2009 and september 2016.", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "3. for the hearing loss question, there was very", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "limited evidence available, therefore searches were expanded to include all systematic reviews ever published.", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "4. based on the gdg ’ s feedback during the gdg", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "meeting in july 2018, the searches were expanded to further include systematic reviews of obser - vational studies. the searches were re - run july to august 2018.", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the following bibliographic databases", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "were searched :", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• bibliographic • medline • cochrane • psycinfo • embase • nice.", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "relevant to lmic", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• global index medicus / global health library • who regional database • wholis • database of impact evaluations • ajol • koreamed • indmed • hrcak • arabpsycnet • herdin neon • eurasiahealth.", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "after the searches were run using the search strategies listed below, titles and abstracts of all results were screened in endnote ; subsequently the full texts of those papers were reviewed that could not be excluded based on the title / abstract review.", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "grade evidence tables for each outcome of each pico question, one or more systematic reviews were then selected to be used within the grade evidence tables. the following criteria were used when selecting which systematic review to use within the grade evidence tables :", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• published in the last 5 years, ideally 2 years", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "( timeliness ).", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• high quality ( i. e. measured using amstar 2 15", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "criteria ).", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "15 shea bj, grimshaw jm, wells ga, boers m, andersson n, hamel c et al", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "( 2007 ). development of amstar : a measurement tool to assess the methodological quality of systematic reviews. bmc medical research methodology. 7 : 10.", "metadata": {"doc_name": "9789241550543-eng", "page": 88, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "73annex 3 : scoping questions", "metadata": {"doc_name": "9789241550543-eng", "page": 89, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• closely relevant to the pico question. • comprehensive systematic reviews given", "metadata": {"doc_name": "9789241550543-eng", "page": 89, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "preference, where possible.", "metadata": {"doc_name": "9789241550543-eng", "page": 89, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "• cochrane reviews or other meta - analyses given", "metadata": {"doc_name": "9789241550543-eng", "page": 89, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "preference, where possible / appropriate. the grade methodology involves rating the quality of the studies included in the systematic review according to study design, risk of bias, inconsistency, indirectness, imprecision, and publication bias. together with the effect sizes of studies, an overall “ certainty of evidence ” is provided of either very low, low, moderate or high. grade evidence tables were completed using the gradepro online tool. 16 the same criteria were used", "metadata": {"doc_name": "9789241550543-eng", "page": 89, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "as for the mhgap intervention guide when completing", "metadata": {"doc_name": "9789241550543-eng", "page": 89, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "the grade evidence tables in terms of the assessment of the quality of studies ( for risk of bias, inconsistency, indirectness, imprecision, and publication bias ). 17 search strategies separate searches were performed for each of the 12 pico questions. where pico questions included both pharmacological and non - pharmacological interventions, searches were run separately for these. filters were used in the bibliographic databases where possible to restrict the searches to systematic reviews and meta - analyses, as well as to humans. no further restrictions were employed, for example in terms of language ( apart from the publication date, as mentioned above ). the “ advanced search ” option was selected in bibliographic databases, where possible.", "metadata": {"doc_name": "9789241550543-eng", "page": 89, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pico 1 for adults with normal cognition or mild cognitive impairment, are physical activity interventions more effective than usual care or no intervention in reducing the risk of cognitive decline and / or dementia? search strategy ( dementia or cognit * or “ mild cognitive impairment ” or “ alzheimer disease ” or “ dementia vascular ” or “ dementia multi - infarct ” or mci or “ cognitive dysfunction ” or neuropsychologi * or “ health - related quality ” of life or “ life quality ” or “ activities daily living ” or “ chronic limitation of activity ” or “ limitation of activity, chronic ” or adl or “ activities of daily living ” or “ drug - related side effects and adverse reactions ” or “ adverse drug event ” or “ adverse drug reaction ” or “ long term adverse effects ” or “ adverse effects, long term disease - free survival ” or “ event - free survival ” or “ adverse effects ” ) and ( exercise or “ exercise therapy ” or “ acute exercise ” or “ aerobic exercise ” or “ exercise training ” or “ exercise, aerobic ” or “ exercise, isometric ” or “ exercise, physical ” or “ isometric exercise or physical activity ” or “ resistance training ” ) pico 2 for adults with normal cognition or mild cognitive impairment who use tobacco, are interventions for tobacco cessation more effective than usual care or no intervention in reducing the", "metadata": {"doc_name": "9789241550543-eng", "page": 89, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "” or “ isometric exercise or physical activity ” or “ resistance training ” ) pico 2 for adults with normal cognition or mild cognitive impairment who use tobacco, are interventions for tobacco cessation more effective than usual care or no intervention in reducing the risk of cognitive decline and / or dementia? search strategy ( dementia or cognit * or mild cognitive impairment or alzheimer disease or dementia vascular or dementia multi - infarct or mci or cognitive dysfunction or neuropsychologi * or health - related quality of life or life quality or activities, daily living or chronic limitation of activity or limitation 16 https : / / gradepro. org /", "metadata": {"doc_name": "9789241550543-eng", "page": 89, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "17 see http : / / www. who. int / mental _ health / mhgap / evidence / mhgap _", "metadata": {"doc_name": "9789241550543-eng", "page": 89, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "guideline _ process _ 2009. pdf", "metadata": {"doc_name": "9789241550543-eng", "page": 89, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "74 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 90, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "of activity, chronic or adl or activities of daily living or drug - related side effects and adverse reactions or adverse drug event or adverse drug reaction or long term adverse effects or adverse effects, long term disease - free survival or event - free survival or adverse effects ) and ( tobacco or smoking or tobacco use cessation or giving up smoking or quitting smoking or stopping smoking or smoking cessation or smoking reduction or tobacco use cessation products or varenicline or nicotinic agonists or nicotine inhalant or nicotine lozenge or nicotine lozenges or nicotine nasal spray or nicotine patch or nicotine polacrilex or nicotine replacement products or nicotine transdermal patch or smoking cessation products ) and ( behavior or behaviour or drug therapy or pharmacologic therapy or pharmacotherapy or cognitive behavioural therapy or cognitive behavioural therapy or drug therapy or cognitive", "metadata": {"doc_name": "9789241550543-eng", "page": 90, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "therapy or online therapy or treatment )", "metadata": {"doc_name": "9789241550543-eng", "page": 90, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pico 3 3a. for adults with normal cognition or mild cognitive impairment, are nutritional interventions such as dietary supplements more effective than usual care or no intervention in reducing the risk / progression of cognitive decline and / or dementia? 3b. for adults with normal cognition or mild cognitive impairment, are nutritional interventions such as healthy dietary patterns ( e. g. mediterranean diet ) more effective than usual care or no intervention in reducing the risk / progression of cognitive decline and / or dementia? search strategy ( dementia or cognit * or “ mild cognitive impairment ” or “ alzheimer disease ” or alzheimer * or “ dementia vascular ” or “ dementia multi - infarct ” or mci or “ cognitive dysfunction ” or neuropsychologi * or “ health - related quality of life ” or “ life quality ” or “ quality of life ” or “ activities of daily living ” or “ chronic limitation of activity ” or “ limitation of activity, chronic ” or adl or “ activities of daily living ” or “ drug - related side effects and adverse reactions ” or “ adverse drug event ” or “ adverse drug reaction ” or “ long term adverse effects ” or “ adverse effects, long term ” or “ disease - free survival ” or “ event - free survival ” or “ adverse effects ” ) and ( “ dietary supple - ments ” or “ dietary supplementations ” or “ food supplementations", "metadata": {"doc_name": "9789241550543-eng", "page": 90, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "or “ adverse effects, long term ” or “ disease - free survival ” or “ event - free survival ” or “ adverse effects ” ) and ( “ dietary supple - ments ” or “ dietary supplementations ” or “ food supplementations ” or “ food supplements ” or “ herbal supplements ” or neutraceuticals or nutraceuticals or nutriceuticals or diet or vitamin or food ) pico 4 for adults with normal cognition or mild cognitive impairment and alcohol use disorders, are behavioural and psychological interventions to treat alcohol use disorders more effective than usual care or no intervention in reducing the risk of cognitive decline and / or dementia? search strategy ( dementia or cognit * or mild cognitive impairment or alzheimer disease or dementia vascular or dementia multi - infarct or mci or cognitive dysfunction or neuropsychologi * or health - related quality of life or life quality or activities, daily living or chronic limitation of activity or limitation of activity, chronic or adl or activities of daily living or drug - related side effects and adverse reactions or adverse drug event or adverse drug reaction or long term adverse effects or adverse effects, long term disease - free survival or event - free survival or adverse effects ) and ( alcohol drinking or binge drinking or drunkenness or alcohol intoxication or alcoholism or alcohol withdrawal ) and ( add in behavior or behaviour or", "metadata": {"doc_name": "9789241550543-eng", "page": 90, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "effects or adverse effects, long term disease - free survival or event - free survival or adverse effects ) and ( alcohol drinking or binge drinking or drunkenness or alcohol intoxication or alcoholism or alcohol withdrawal ) and ( add in behavior or behaviour or drug therapy or pharmacologic therapy or pharmacotherapy or cognitive behavioural therapy or cognitive behavioural therapy or drug therapy or cognitive therapy or online therapy or treatment )", "metadata": {"doc_name": "9789241550543-eng", "page": 90, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "75annex 3 : scoping questions pico 5 for adults with normal cognition or mild cognitive impairment is cognitive stimulation or cognitive training more effective than usual care or no intervention in reducing the risk of cognitive decline and / or dementia? search strategy ( systemati * or meta analys * ) and ( dementia or cognit * or mci or neuropsycholog * or alzheimer * ) and ( \" brain training \" or \" cognitive training \" or \" brain fitness \" or games or \" memory training \" or", "metadata": {"doc_name": "9789241550543-eng", "page": 91, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "( stimulation and cognit * )", "metadata": {"doc_name": "9789241550543-eng", "page": 91, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pico 6 for adults with normal cognition or mild cognitive impairment is preserving and promoting a high level of social activity more effective than usual care or no intervention in reducing the risk of cognitive decline and / or dementia? search strategy ( \" social interaction \" or \" social networks \" or \" social processes \" or \" social behaviour \" or \" social behavior \" or \" community networks \" or \" social media \" or family ) and ( dementia or cognit * or \" mild cognitive impairment \" or mci or \" cognitive dysfunction \" or neuropsycholog * or alzheime * ) and ( systemati * or", "metadata": {"doc_name": "9789241550543-eng", "page": 91, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "meta - analys * )", "metadata": {"doc_name": "9789241550543-eng", "page": 91, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pico 7 for adults with normal cognition or mild cognitive impairment who are overweight or obese, are interventions for weight reduction ( or control of obesity ) more effective than usual care or no intervention in reducing the risk of cognitive decline and / or dementia? search strategy ( dementia or cognit * or mild cognitive impairment or alzheimer disease or dementia vascular or dementia multi - infarct or mci or cognitive dysfunction or neuropsychologi * or health - related quality of life or life quality or activities, daily living or chronic limitation of activity or limitation of activity, chronic or adl or activities of daily living or drug - related side effects and adverse reactions or adverse drug event or adverse drug reaction or long term adverse effects or adverse effects, long term disease - free survival or event - free survival or adverse effects ) and ( overweight or body weight or body mass index or weight loss or body weight changes ) and ( behavior or behaviour or drug therapy or pharmacologic therapy or pharmacotherapy or cognitive behavioural therapy or cognitive behavioural therapy or drug therapy or cognitive therapy or online therapy or", "metadata": {"doc_name": "9789241550543-eng", "page": 91, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "treatment or appetite depressants )", "metadata": {"doc_name": "9789241550543-eng", "page": 91, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pico 8 for adults with normal cognition or mild cognitive impairment and hypertension, is treatment of hypertension more effective than placebo / no intervention in reducing reduce the risk of cognitive decline / dementia? search strategy ( systemati * or meta - analys * ) and ( dementia or cognit * or \" mild cognitive impairment \" or mci or \" cognitive dysfunction \" or neuropsycholog * or alzheimer ' s or alzheimer ) and ( behaviour or behavior or \" drug therapy \" or \" pharmacologic therapy \" or pharmacotherapy or \" cognitive behavioural therapy \" or \" cognitive behavioral therapy \" or \" cognitive therapy \" or \" online therapy \" or \" anti - hypertensive \" or antihypertensive or treatment ) and ( hypertension or \" blood pressure \" or systolic or diastolic or prehypertension )", "metadata": {"doc_name": "9789241550543-eng", "page": 91, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "76 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 92, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pico 9 for adults with normal cognition or mild cognitive impairment and diabetes mellitus, is treatment of diabetes more effective than placebo / no intervention in reducing the risk of cognitive decline and / or dementia? search strategy ( systemati * or meta - analys * ) and ( dementia or cognit * or \" mild cognitive impairment \" or mci or \" cognitive dysfunction \" or neuropsycholog * or alzheime * ). ab. and diabetes. af. and ( \" hypoglycemic agents \" or treatment or therapy or pharmacotherapy", "metadata": {"doc_name": "9789241550543-eng", "page": 92, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "or behaviour or behavior )", "metadata": {"doc_name": "9789241550543-eng", "page": 92, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pico 10 for adults with normal cognition or mild cognitive impairment and dyslipidaemia, is treatment of dyslipidaemia more effective than placebo or no intervention in reducing reduce the risk of cognitive decline and / or dementia? search strategy ( dementia or cognit * or mild cognitive impairment or alzheimer disease or dementia vascular or dementia multi - infarct or mci or cognitive dysfunction or neuropsychologi * or health - related quality of life or life quality or activities, daily living or chronic limitation of activity or limitation of activity, chronic or adl or activities of daily living or drug - related side effects and adverse reactions or adverse drug event or adverse drug reaction or long term adverse effects or adverse effects, long term disease - free survival or event - free survival or adverse effects ) and ( cholesterol or hypercholes - terolemia or lipo - proteins or hdl cholesterol or ldl cholesterol or triglycerides ) and ( behavior or behaviour or drug therapy or pharmalogic therapy or pharmacotherapy or cognitive behavioural therapy or cognitive behavioural therapy or drug therapy or cognitive therapy or online therapy or treatment or statins or hydroxymethylglutaryl - coa reductase inhibitors or anticholesteremic agents ) pico 11 for adults with normal cognition or mild cognitive impairment and depressive", "metadata": {"doc_name": "9789241550543-eng", "page": 92, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "therapy or cognitive therapy or online therapy or treatment or statins or hydroxymethylglutaryl - coa reductase inhibitors or anticholesteremic agents ) pico 11 for adults with normal cognition or mild cognitive impairment and depressive disorder, is treatment of depression more effective than usual care, placebo or no intervention in reducing the risk of cognitive decline and / or dementia? search strategy ( depression or depressive ) and ( systemati * or meta - analys * ) and ( dementia or cognit * or \" mild cognitive impairment \" or mci or \" cognitive dysfunction \" or neuropsycholog * or alzheimer ' s or alzheimer * ) and ( treatment or therapy or pharmacotherapy or", "metadata": {"doc_name": "9789241550543-eng", "page": 92, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "antidepressan * or antidepressiv * )", "metadata": {"doc_name": "9789241550543-eng", "page": 92, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "pico 12 for adults with normal cognition or mild cognitive impairment and hearing loss, is treatment of hearing loss more effective than usual care, or no intervention in reducing the risk of cognitive decline and / or dementia? search strategy ( hearing aids or cochlear implants or hearing implants ) and ( hearing loss or deafness or hearing impairment or hypoacusis or intervention or treatment ) and ( dementia or cognit * or mild cognitive impairment or alzheimer ' s disease or dementia vascular or dementia multi - infarct or mci or cognitive dysfunction or neuropsycholog * )", "metadata": {"doc_name": "9789241550543-eng", "page": 92, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "77glossary adverse event any untoward medical occurrence in a patient or clinical investigation subject caused by health care management. aerobic exercise a type of physical exercise that requires free oxygen to adequately meet energy demands via the aerobic metabolism. during aerobic exercise, oxygen is used to “ burn ” fats and glucose in order to produce adenosine triphosphate, the basic energy carrier for all cells. this type of exercise improves physical fitness by promoting the circulation of oxygen through the blood, is associated with an increased rate of breathing, and includes any type of exercise that, when performed at levels of intensity sufficiently supported by the aerobic metabolism, can be performed for extended periods of time. behavioural activation a behavioural treatment for depression in which the person with depression is guided to increase the number of rewarding activities in his or her life. body mass index an objective measurement calculated as body mass ( or weight in kg ) divided by the square of the body height ( in metres ), universally expressed in units of kg / m2. bmi is used as approximate indicator of the amount of tissue mass ( muscle, bone, and fat ) in an individual. based on the correlation between bmi and the degree of risk for certain disease, such as diabetes or atherosclerosis, bmi values are categorized as underweight, normal weight, overweight, or obese ; obesity can", "metadata": {"doc_name": "9789241550543-eng", "page": 93, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "an individual. based on the correlation between bmi and the degree of risk for certain disease, such as diabetes or atherosclerosis, bmi values are categorized as underweight, normal weight, overweight, or obese ; obesity can also be subcategorized in moderate severe and morbid. cognitive behavioural intervention / therapy a type of psychological therapy that involves identifying and correcting distorted maladaptive beliefs, while using thought exercises and real experiences to facilitate symptom reduction and improved functioning. cognitive decline the physiological decay of brain functions such as memory, attention or learning ability, for example, which is associated with the normal ageing process. it differs from cognitive impairment in that anyone who ages develops some kind of cognitive decline, although at different degrees. cognitive impairment, instead, is normally the result of a pathological event : injury, disease, or increased levels of cognitive decline. cognitive function cerebral activities, i. e. reasoning, memory, attention, and language that lead to the attainment of information and knowledge. cognitive stimulation participation in a range of activities designed to improve cognitive and social functioning. cognitive training guided practice of specific standardized tasks designed to enhance particular cognitive functions. dementia dementia, a group of disorders characterized by a decline from a previously attained cognitive level that affects activities of daily living or social functioning. dietary supplements dietary supplements include vitamins, minerals, fibre, fatty", "metadata": {"doc_name": "9789241550543-eng", "page": 93, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "specific standardized tasks designed to enhance particular cognitive functions. dementia dementia, a group of disorders characterized by a decline from a previously attained cognitive level that affects activities of daily living or social functioning. dietary supplements dietary supplements include vitamins, minerals, fibre, fatty acids, or amino acids, among other substances. they are either intended to provide nutrients in order to increase their consumption, or to provide non - nutrient chemicals which are claimed to have a biologically beneficial effect. health - related quality of life an individual ’ s or a group ’ s perceived physical and mental health over time. as a multidimensional concept, it includes domains related to physical, mental, emotional and social functioning, and it is a way to assess the impact of health status on quality of life. mediterranean diet a diet which consists of a high intake of cereals, fruits, fish, legumes, and vegetables and low intake of meat and dairy. glossary", "metadata": {"doc_name": "9789241550543-eng", "page": 93, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "78 risk reduction of cognitive decline and dementia : who guidelines", "metadata": {"doc_name": "9789241550543-eng", "page": 94, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "mild cognitive impairment a disorder characterized by impairment of memory, learning difficulties and reduced ability to concentrate on a task for more than brief periods. there is often a marked feeling of mental fatigue when mental tasks are attempted, and new learning is found to be subjectively difficult even when objectively successful. none of these symptoms are so severe that a diagnosis of either dementia or delirium can be made. motivational interviewing an established evidence - based practice in the treatment of individuals with substance use disorders that focuses on exploring and resolving ambivalence and centres on motivational processes within the individual that facilitate change.", "metadata": {"doc_name": "9789241550543-eng", "page": 94, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "multidomain intervention", "metadata": {"doc_name": "9789241550543-eng", "page": 94, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "intervention normally aimed to prevent / address a certain disease or condition by acting simultaneously on a range of risk factors, which may be either correlated or independent from each other.", "metadata": {"doc_name": "9789241550543-eng", "page": 94, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "nicotine replacement therapy", "metadata": {"doc_name": "9789241550543-eng", "page": 94, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "a type of treatment that makes use of special products which provide small, steady doses of nicotine to help stop cravings and relieve withdrawal symptoms when an individual is trying to stop using tobacco. these products include nicotine gum, nicotine inhaler, nicotine nasal spray, nicotine lozenges, and nicotine patch. they do not contain any of the other chemicals found in tobacco products. physical activity any bodily movement produced by skeletal muscles that requires energy expenditure – including activities undertaken while working, playing, carrying out household chores, travelling, and engaging in recreational pursuits", "metadata": {"doc_name": "9789241550543-eng", "page": 94, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "physical exercise : subcategory of physical activity", "metadata": {"doc_name": "9789241550543-eng", "page": 94, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "that is planned, structured, repetitive, and aims to improve or maintain one or more components of physical fitness. problem - solving therapy a type of psychological therapy where the patient systematically identifies his or her problems ; generates alternative solutions for each problem ; selects the best solution ; develops and conducts a plan ; and evaluates whether this has solved the problem.", "metadata": {"doc_name": "9789241550543-eng", "page": 94, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "quality of life", "metadata": {"doc_name": "9789241550543-eng", "page": 94, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "an individual ’ s perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.", "metadata": {"doc_name": "9789241550543-eng", "page": 94, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "resistance training", "metadata": {"doc_name": "9789241550543-eng", "page": 94, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "a form of physical exercise that, by the moving of the limbs against high loads or fixed resistances, causes skeletal muscles contraction, building their strength, anaerobic endurance, and size. the external resistance can be represented by dumbbells, rubber exercise tubing, the own body weight, bricks, bottles of water, machine specifically designed to this purpose, or any other object that causes the muscles to contract. the forces involved must be such that relatively few repetitions are possible without a substantial rest period. resistance or strength training is primarily an anaerobic activity, although some proponents have adapted it to provide the benefits of aerobic exercise through circuit training. social activity social activities are varied and difficult to define, however they may include meeting friends, attending events or functions, volunteering or participating in occupational duties or group recreational activities.", "metadata": {"doc_name": "9789241550543-eng", "page": 94, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "for further information, please contact :", "metadata": {"doc_name": "9789241550543-eng", "page": 96, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "department of mental health and", "metadata": {"doc_name": "9789241550543-eng", "page": 96, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "substance abuse,", "metadata": {"doc_name": "9789241550543-eng", "page": 96, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "world health organization avenue appia 20", "metadata": {"doc_name": "9789241550543-eng", "page": 96, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "ch - 1211 geneva 27", "metadata": {"doc_name": "9789241550543-eng", "page": 96, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "switzerland", "metadata": {"doc_name": "9789241550543-eng", "page": 96, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "email : whodementia @ who. int", "metadata": {"doc_name": "9789241550543-eng", "page": 96, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "website : www. who. int / mental _ health /", "metadata": {"doc_name": "9789241550543-eng", "page": 96, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "neurology / dementia / en isbn 978 - 92 - 4 - 155054 - 3", "metadata": {"doc_name": "9789241550543-eng", "page": 96, "section": "NO_SECTION", "domain": "other", "doc_id": "9789241550543-eng"}}
{"text": "attention - deficit / hyperactivity disorder : what you need to know", "metadata": {"doc_name": "adhd-2024", "page": 1, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "what is adhd? attention - deficit / hyperactivity disorder ( adhd ) is a developmental disorder marked by persistent symptoms of inattention, hyperactivity, and impulsivity. some people mostly have symptoms of inattention. others mostly have symptoms of hyperactivity and impulsivity. some people have both types of symptoms. symptoms begin in childhood and can interfere with daily life, including social relationships and school or work performance. adhd is well - known among children and teens, but many adults also have the disorder. effective treatments are available to manage symptoms. what are the symptoms of adhd? people with adhd may experience an ongoing pattern of : [UNK] inattention : difficulty paying attention [UNK] hyperactivity : showing too much energy or moving and talking too much [UNK] impulsivity : acting without thinking or having difficulty with self - control signs of inattention can include frequent difficulty with : [UNK] paying attention to details, leading to careless mistakes at school, work, or during other activities [UNK] concentrating on tasks or activities, for instance, while having conversations, taking tests, completing assignments, or reading papers [UNK] listening when spoken to directly [UNK] following instructions or finishing tasks at school, work, or home [UNK] organizing tasks and activities, managing time, and meeting deadlines [UNK] completing tasks that require sustained attention, such as homework, large projects, and complicated forms [UNK] losing things", "metadata": {"doc_name": "adhd-2024", "page": 2, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "spoken to directly [UNK] following instructions or finishing tasks at school, work, or home [UNK] organizing tasks and activities, managing time, and meeting deadlines [UNK] completing tasks that require sustained attention, such as homework, large projects, and complicated forms [UNK] losing things, such as backpacks, books, keys, wallets, and phones [UNK] getting easily distracted by unrelated thoughts or stimuli [UNK] forgetting about daily activities, such as chores, errands, and events, or other important things, like assignments, appointments, and phone calls signs of hyperactivity and impulsivity can include often : [UNK] fidgeting, tapping hands or feet, or squirming while seated [UNK] moving around when expected to remain seated, such as in the classroom or office, or feeling restless in these situations [UNK] running, climbing, or moving around at times when it is not appropriate [UNK] being constantly “ on the go ” and acting as if driven by a motor [UNK] being unable to quietly play or take part in hobbies and activities [UNK] talking excessively [UNK] answering questions before they are fully asked or finishing other people ’ s sentences [UNK] struggling to wait or be patient, such as when playing a game or waiting in line [UNK] interrupting or intruding on others, for example, in conversations, games, or meetings", "metadata": {"doc_name": "adhd-2024", "page": 2, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "what causes adhd? researchers are not sure what causes adhd, although many studies suggest that genes play a large role. like many other disorders, adhd probably results from a combination of factors. in addition to genetics, researchers are looking at differences in brain development and neurobiology among people with adhd compared to those without the disorder. they are also studying environmental factors that might increase the risk of developing adhd, including brain injuries, nutrition, and social environments. how is adhd diagnosed? based on their specific symptoms, a person can be diagnosed with one of three types of adhd : [UNK] inattentive : mostly symptoms of inattention but not hyperactivity or impulsivity [UNK] hyperactive - impulsive : mostly symptoms of hyperactivity and impulsivity but not inattention [UNK] combined : symptoms of both inattention and hyperactivity and impulsivity adhd symptoms must begin in childhood ( before age 12 ). symptoms often continue into the teen", "metadata": {"doc_name": "adhd-2024", "page": 3, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "years and adulthood. the criterion for a diagnosis differs slightly based on age.", "metadata": {"doc_name": "adhd-2024", "page": 3, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "[UNK] children up to 16 years must show at least six symptoms of inattention, hyperactivity and impulsivity, or both. [UNK] adults and youth over 16 years must show at least five symptoms of inattention, hyperactivity and impulsivity, or both. to be diagnosed with adhd, a person ’ s symptoms must also : [UNK] occur for at least 6 months [UNK] be present in two or more settings ( for example, at home, at work, in school, or with friends ) [UNK] interfere with or impair social, school, or work functioning stress, sleep disorders, anxiety, depression, and other physical conditions or illnesses can cause similar symptoms to those of adhd. a health care provider needs to do a thorough evaluation to determine the cause of symptoms, make a diagnosis, and identify effective treatments. primary care providers sometimes diagnose and treat adhd, or they may refer the person to a mental health professional. during an evaluation, a provider usually : [UNK] examines the person ’ s mental health and medical history, including their mood and past or current health conditions. [UNK] looks at the person ’ s current or, if an adult, childhood behavior and school experiences. to obtain this information, the provider may ask for permission to talk with family, friends, partners, teachers, and others who know the person well and have seen them in different settings to learn", "metadata": {"doc_name": "adhd-2024", "page": 3, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "or, if an adult, childhood behavior and school experiences. to obtain this information, the provider may ask for permission to talk with family, friends, partners, teachers, and others who know the person well and have seen them in different settings to learn about behaviors and experiences at home, school, or elsewhere. [UNK] uses standardized behavior rating scales or adhd symptom checklists to determine whether the person meets the criteria for a diagnosis of adhd. [UNK] administers psychological tests that look at cognitive skills, such as working memory, executive functioning ( abilities such as planning and decision - making ), visual and spatial abilities, or reasoning. such tests can help identify psychological or cognitive ( thinking - related ) strengths and challenges and identify or rule out possible learning disabilities.", "metadata": {"doc_name": "adhd-2024", "page": 3, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "does adhd look the same in everyone? anyone can have adhd. however, boys and men tend to display more hyperactive and impulsive symptoms, while girls and women are more likely to be diagnosed with inattentive adhd. adhd can also be diagnosed at any age, although symptoms must have begun in childhood ( before age 12 ). adults with adhd often have a history of problems with school, work, and relationships. adhd symptoms may change as a person gets older. [UNK] children show hyperactivity and impulsivity as the most common symptoms. as academic and social demands increase, symptoms of inattention often become more prominent and begin to interfere with academic performance and peer relationships. [UNK] adolescents usually show less hyperactivity and may appear as restless or fidgeting. symptoms of inattention and impulsivity typically continue and may cause academic, organizational, or relationship challenges. teens with adhd are more likely to engage in impulsive, risky behaviors, such as substance use and unsafe sexual activity.", "metadata": {"doc_name": "adhd-2024", "page": 4, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "[UNK] adults, including older adults, can show inattention, restlessness, and impulsivity, although, in", "metadata": {"doc_name": "adhd-2024", "page": 4, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "some people, those symptoms become less severe and less impairing. they may also be irritable, have a low tolerance for frustration and stress, or experience frequent or intense mood changes. some adults may not have been diagnosed with adhd when younger because their teachers or family did not recognize the disorder, they had a mild form of the disorder, or they managed well until experiencing the demands of adulthood. but it is never too late to seek a diagnosis and treatment for adhd and other mental health conditions that may co - occur with it. effective treatment can make day - to - day life easier for people with adhd and their families. how is adhd treated? although there is no cure for adhd, current treatments may help reduce symptoms and improve functioning. common treatments for adhd are medication, psychotherapy, and other behavioral interventions. for children, treatment often includes parent education and school - based programs. researchers are studying new treatments for people with adhd, such as cognitive training and neurofeedback. these options are usually explored only after medication and psychotherapy have already been tried. for many people, treatment involves a combination of elements. medication stimulants are the most common type of medication used to treat adhd, and research shows them to be highly effective. they work by increasing levels of brain chemicals involved in thinking and attention. like all medications, st", "metadata": {"doc_name": "adhd-2024", "page": 4, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "combination of elements. medication stimulants are the most common type of medication used to treat adhd, and research shows them to be highly effective. they work by increasing levels of brain chemicals involved in thinking and attention. like all medications, stimulants can have side effects and must be prescribed and monitored by a health care provider. tell the provider about other medications you or your child are taking. medications for common health problems, such as diabetes, anxiety, and depression, can interact with stimulants, in which case, a provider can suggest other medication options. health care providers sometimes prescribe nonstimulant medications like antidepressants to treat adhd. however, the u. s. food and drug administration ( fda ) has not approved these medications specifically for adhd. sometimes, a person must try several different medications or dosages before finding the one that works for them. nimh has information on stimulants and other mental health medications at www. nimh. nih. gov / medications. you can learn more about specific medications, including the latest approvals, side effects, warnings, and patient information, on the fda website at www. fda. gov / drugsatfda.", "metadata": {"doc_name": "adhd-2024", "page": 4, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "psychotherapy and behavioral interventions psychological interventions for adhd can take many forms and be combined with medication and other elements for parents, families, and teachers. adding therapy to an adhd treatment plan can help some people better cope with daily challenges, gain confidence, or manage impulsive and risky behaviors. therapy is especially helpful if adhd co - occurs with other mental disorders, such as anxiety, depression, conduct problems, or substance use disorders. you can learn about other mental disorders at www. nimh. nih. gov / health. several psychosocial interventions have been shown to help manage symptoms and improve functioning. [UNK] behavioral therapy helps a person change their behavior. it might involve practical assistance, such as organizing tasks or completing schoolwork, learning social skills, or monitoring one ’ s behavior. [UNK] cognitive behavioral therapy helps a person become aware of attention and concentration challenges and work on skills to improve focus and organization and complete daily tasks ( for instance, by breaking large tasks into smaller, more manageable steps ). [UNK] family and marital therapy helps family members learn to handle disruptive behaviors, encourage behavior changes, and improve interactions with children and partners. some people find it helpful to get support from a professional life coach or adhd coach who can teach them skills to improve daily functioning. for more information on psychotherapy, including what to look for in a therapist and how to find one,", "metadata": {"doc_name": "adhd-2024", "page": 5, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "partners. some people find it helpful to get support from a professional life coach or adhd coach who can teach them skills to improve daily functioning. for more information on psychotherapy, including what to look for in a therapist and how to find one, visit www. nimh. nih. gov / psychotherapies. parent education and support therapy for children and teens requires parents to play an active role. treatment sessions with the child alone are more likely to be effective for treating symptoms of anxiety or depression that may co - occur with adhd than for managing core symptoms of the disorder. mental health professionals can educate parents about the disorder and how it affects a family. they also can help parents develop new skills, attitudes, and ways of relating to their child. examples include parenting skills training, stress management techniques for parents, and support groups that help parents and families connect with others who have similar concerns. school - based programs many children and teens with adhd benefit from school - based behavioral interventions and academic accommodations. interventions include behavior management plans or classroom - taught organizational and study skills. accommodations include preferential seating in the classroom, reduced classwork, and extended time on tests and exams. schools may provide accommodations through what is called a 504 plan or, for children who qualify for special education services, an", "metadata": {"doc_name": "adhd-2024", "page": 5, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "individualized education plan ( iep ).", "metadata": {"doc_name": "adhd-2024", "page": 5, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "to learn more about special education services and the individuals with disabilities education act, visit https : / / idea. ed. gov.", "metadata": {"doc_name": "adhd-2024", "page": 5, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "cognitive training", "metadata": {"doc_name": "adhd-2024", "page": 6, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "cognitive training approaches involve repeatedly using a program or activity over several", "metadata": {"doc_name": "adhd-2024", "page": 6, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "weeks to improve specific functions, such as memory or attention. exercises are tailored to the person ’ s ongoing performance. cognitive training is shown to modestly improve the tasks being practiced. for instance, research shows the training can help memory, attention, inhibition, planning, and cognitive flexibility in people with adhd. however, these improvements don ’ t usually translate to changes in core adhd symptoms of impulsivity and hyperactivity. neurofeedback neurofeedback is a noninvasive technique in which an electronic device monitors and records a person ’ s brain activity, providing them with immediate feedback to support self - regulation. the device measures brain activity through such means as eeg or fmri scans and feeds the information back to the person, usually in the form of a computer screen or visual cue. through this feedback, people learn to self - regulate their brain activity to directly alter the associated behavior. the assumption is that, with repeated, real - time information, people can change their internal brain activity, with observable effects on behavior and cognition. for people with adhd, neurofeedback is used to train and improve specific cognitive functions. although it is shown to help reduce some adhd symptoms, the effects of neurofeedback remain lower than those seen from medication and psychotherapy. additional research is needed to refine the treatment and determine", "metadata": {"doc_name": "adhd-2024", "page": 6, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "to train and improve specific cognitive functions. although it is shown to help reduce some adhd symptoms, the effects of neurofeedback remain lower than those seen from medication and psychotherapy. additional research is needed to refine the treatment and determine for whom it works and under what conditions. complementary health approaches some people may explore complementary health approaches to manage symptoms of adhd. these", "metadata": {"doc_name": "adhd-2024", "page": 6, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "can include natural products, vitamins and supplements, diet changes, and acupuncture. others find", "metadata": {"doc_name": "adhd-2024", "page": 6, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "it helpful to make lifestyle changes, like adding more physical exercise to their daily schedule. unlike psychotherapy and medication that are scientifically shown to improve adhd symptoms, complementary health approaches generally have not been found to treat adhd effectively and do not qualify as evidence - supported interventions.", "metadata": {"doc_name": "adhd-2024", "page": 6, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "for more information, visit the national center for complementary and integrative health at", "metadata": {"doc_name": "adhd-2024", "page": 6, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "www. nccih. nih. gov / health / attention - deficit - hyperactivity - disorder - at - a - glance. how can i find help? if you ’ re unsure of where to get help, a health care provider is a good place to start. they can refer you to a qualified mental health professional, such as a psychologist, psychiatrist, or clinical social worker, who can help figure out the next steps. find tips for talking with a health care provider about your or your child ’ s mental health at www. nimh. nih. gov / talkingtips. the centers for disease control and prevention ( cdc ) has information about adhd symptoms, diagnosis, and treatment, as well as additional resources for families and providers, at www. cdc. gov / adhd.", "metadata": {"doc_name": "adhd-2024", "page": 6, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "the substance abuse and mental health services administration ( samhsa ) also has resources for finding support at https : / / findsupport. gov and locating mental health services in your area at", "metadata": {"doc_name": "adhd-2024", "page": 6, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "https : / / findtreatment. gov. for additional resources, visit www. nimh. nih. gov / findhelp.", "metadata": {"doc_name": "adhd-2024", "page": 6, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "how can i help myself? medication and therapy are the most effective treatments for adhd. other strategies may also help manage symptoms. [UNK] get regular exercise, especially when feeling hyperactive or restless. [UNK] eat regular, healthy meals. [UNK] get plenty of sleep. try to turn off screens at least 1 hour before bedtime and get between 7 – 9 hours of sleep every night. [UNK] stick to a consistent routine. [UNK] work on time management and organization. prioritize time - sensitive tasks and write down assignments, messages, appointments, reminders, and important thoughts. [UNK] take short breaks during tasks that require sustained attention to help maintain focus and prevent burnout. break large tasks into smaller, more manageable steps. [UNK] connect with people and maintain relationships. schedule activities with friends, particularly supportive people who understand your challenges with adhd. [UNK] take medications as directed. avoid alcohol, tobacco, and drugs not prescribed for you. how can i help my child? [UNK] be patient, flexible, and understanding. adhd can be frustrating both for people who have it and the people in their lives. adhd may make it hard for your child to perform certain tasks or", "metadata": {"doc_name": "adhd-2024", "page": 7, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "behaviors. some children may need to use different strategies to help them succeed.", "metadata": {"doc_name": "adhd-2024", "page": 7, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "[UNK] use clear, simple, direct language to explain rules and expectations. reward behaviors that meet these expectations with positive reinforcement. provide consistent praise or rewards for acting in a desired way. [UNK] offer practical help, such as on tasks like cleaning and organizing, or simply be present and engaged while your child works, which can give them a sense of accountability and motivation and help them stay focused and on track. [UNK] provide opportunities to explore different activities and interests. help your child discover their unique talents and build confidence in their abilities.", "metadata": {"doc_name": "adhd-2024", "page": 7, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "if you or someone you know is struggling or having thoughts of suicide, call or text the 988 suicide and crisis lifeline at 988 or chat at 988lifeline. org. in life - threatening situations,", "metadata": {"doc_name": "adhd-2024", "page": 7, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "call 911.", "metadata": {"doc_name": "adhd-2024", "page": 7, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "clinical trials clinical trials are research studies that look at ways to prevent, detect, or treat diseases and conditions. these studies help show whether a treatment is safe and effective in people. some people join clinical trials to help doctors and researchers learn more about a disease and improve health care. other people, such as those with health conditions, join to try treatments that aren ’ t widely available. nimh supports clinical trials across the united states. talk to a health care provider about clinical trials and whether one is right for you. for more information, visit www. nimh. nih. gov / clinicaltrials. for more information learn more at www. nimh. nih. gov / health. for information about various health topics, visit the national library of medicine ’ s medlineplus resource at https : / / medlineplus. gov. contact us", "metadata": {"doc_name": "adhd-2024", "page": 8, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "national institute of mental health", "metadata": {"doc_name": "adhd-2024", "page": 8, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "office of science policy, planning, and communications 60", "metadata": {"doc_name": "adhd-2024", "page": 8, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "01 executive boulevard, msc 9663 bethesda, md 20892 - 9663 phone : 1 - 866 - 615 - 6464 email : nimhinfo @ nih. gov website : www. nimh. nih. gov", "metadata": {"doc_name": "adhd-2024", "page": 8, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "en espanol : www. nimh. nih. gov / espanol reprints the information in this publication is in the public domain and may be reused or copied without permission. however, you may not reuse or copy images. please cite the national institute of mental health as the source. read our copyright policy to learn more about our guidelines for reusing nimh content at www. nimh. nih. gov / copyright. u. s. department of health and human services national institutes of health nih publication no. 24 - mh - 8300 2 024", "metadata": {"doc_name": "adhd-2024", "page": 8, "section": "NO_SECTION", "domain": "adhd", "doc_id": "adhd-2024"}}
{"text": "attention deficit hyperactivity disorder : diagnosis and management nice guideline published : 14 march 2018 last updated : 13 september 2019 www. nice. org. uk / guidance / ng87 © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ).", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 1, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "your responsibility the recommendations in this guideline represent the view of nice, arrived at after careful consideration of the evidence available. when exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. it is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian. all problems ( adverse events ) related to a medicine or medical device used for treatment or in a procedure should be reported to the medicines and healthcare products regulatory agency using the yellow card scheme. local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. they should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing nice recommendations wherever possible. attention deficit hyperactivity disorder : diagnosis", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 2, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "way that would be inconsistent with complying with those duties. commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing nice recommendations wherever possible. attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 2 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 2, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 1 service organisation and training................................................................................................... 6", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 2 recognition, identification and referral......................................................................................... 8", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 3 diagnosis.......................................................................................................................................... 12", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4 information and support................................................................................................................. 13", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5 managing adhd.............................................................................................................................. 17", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 6 dietary advice.................................................................................................................................. 23", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7 medication........................................................................................................................................ 24", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.7", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8 maintenance and monitoring.......................................................................................................... 32", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.8", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 9 adherence to treatment.................................................................................................................. 36", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.9", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 10 review of medication and discontinuation.................................................................................. 37 terms used in this guideline................................................................................................................. 39 recommendations for research...............................................................", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": ".................................................................................... 40 1 children and young people aged 5 to 18 years – brief, group - based, adhd - focused, parent - training intervention.............................................................................................................................. 40 2 medication choice in people with coexisting conditions...............................", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "....... 40 2 medication choice in people with coexisting conditions............................................................... 40 3 medication choice in people with no previous medication for adhd........................................... 41 4 prescribing beyond monotherapy.................................................................................................... 41 rationale and impact............................", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "................. 41 rationale and impact................................................................................................................... 42 recognition............................................................................................................................................ 42", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "................................................. 42 information and support....................................................................................................................... 42 managing adhd – planning treatment................................................................................................ 43 managing adhd –", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "............................................. 43 managing adhd – children under 5 years.......................................................................................... 45 managing adhd – children aged 5 years and over and young people............................................ 45 managing adhd – adults........................................................................", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "................................................................................................ 48 attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 3 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 3, "section": "1.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "medication – care arrangements......................................................................................................... 49 medication – baseline assessment...................................................................................................... 49 medication – choice............................................................", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 4, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": ".................................................................................................................... 50 medication – considerations when prescribing and dose titration.................................................. 51 medication – monitoring effectiveness and adverse effects............................................................ 52 adherence to treatment............................", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 4, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": ".................. 52 adherence to treatment....................................................................................................................... 53 review of medication and discontinuation......................................................................................... 54 putting this guideline into practice..................................", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 4, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "......... 54 putting this guideline into practice............................................................................................ 55 context......................................................................................................................................... 57 finding more information and committee details..........................", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 4, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "................. 57 finding more information and committee details..................................................................... 59 update information..................................................................................................................... 60 attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 4 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 4, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "this guideline replaces cg72, ta98, esnm19, esuom8 and esnm70. this guideline is the basis of qs39. overview this guideline covers recognising, diagnosing and managing attention deficit hyperactivity disorder ( adhd ) in children, young people and adults. it aims to improve recognition and diagnosis, as well as the quality of care and support for people with adhd. who is it for?", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 5, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• healthcare professionals • commissioners and providers • people with adhd, and their families and carers", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 5, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 5 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 5, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 1 service organisation and training service organisation", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 6, "section": "1.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 1. 1 people with attention deficit hyperactivity disorder ( adhd ) would benefit from improved organisation of care and better integration of child health services, child and adolescent mental health services ( camhs ) and adult mental health services. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 6, "section": "1.1.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 1. 2 mental health services for children, young people and adults, and child health services, should form multidisciplinary specialist adhd teams and / or clinics for children and young people, and separate teams and / or clinics for adults. these teams and clinics should have expertise in the diagnosis and management of adhd, and should :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 6, "section": "1.1.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• provide diagnostic, treatment and consultation services for people with", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 6, "section": "1.1.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "adhd who have complex needs, or where general psychiatric services are in doubt about the diagnosis and / or management of adhd", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 6, "section": "1.1.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• put in place systems of communication and protocols for information sharing", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 6, "section": "1.1.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "among paediatric, child and adolescent, forensic, and adult mental health services for people with adhd, including arrangements for transition between child and adult services attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 6 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 6, "section": "1.1.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 1. 3 every locality should develop a multi - agency group, with representatives from multidisciplinary specialist adhd teams, paediatrics, mental health and learning disability trusts, forensic services, camhs, the directorate for children and young people ( dcyp ; including services for education and social services ), parent support groups and others with a significant local involvement in adhd services. the group should :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 7, "section": "1.1.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• oversee the implementation of this guideline • start and coordinate local training initiatives, including the provision of", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 7, "section": "1.1.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "training and information for teachers about the characteristics of adhd and its basic behavioural management", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 7, "section": "1.1.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• oversee the development and coordination of parent - training / education", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 7, "section": "1.1.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "programmes", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 7, "section": "1.1.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• consider compiling a comprehensive directory of information and services for", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 7, "section": "1.1.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "adhd including advice on how to contact relevant services and assist in the development of specialist teams. [ 2008, amended 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 7, "section": "1.1.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 1. 4 a young person with adhd receiving treatment and care from camhs or paediatric services should be reassessed at school - leaving age to establish the need for continuing treatment into adulthood. if treatment is necessary, arrangements should be made for a smooth transition to adult services with details of the anticipated treatment and services that the young person will require. precise timing of arrangements may vary locally but should usually be completed by the time the young person is 18 years. see nice ' s guideline on transition from children ' s to adults ' services for young people using health or attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 7 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 7, "section": "1.1.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 1. 5 during the transition to adult services, a formal meeting involving camhs and / or paediatrics and adult psychiatric services should be considered, and full information provided to the young person about adult services. for young people aged 16 years and older, the care programme approach ( cpa ) should be used as an aid to transfer between services. the young person, and when appropriate the parent or carer, should be involved in the planning. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 8, "section": "1.1.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 1. 6 after transition to adult services, adult healthcare professionals should carry out a comprehensive assessment of the person with adhd that includes personal, educational, occupational and social functioning, and assessment of any coexisting conditions, especially drug misuse, personality disorders, emotional problems and learning difficulties. [ 2008 ] training", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 8, "section": "1.1.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 1. 7 trusts should ensure that specialist adhd teams for children, young people and adults jointly develop age - appropriate training programmes for the diagnosis and management of adhd for mental health, paediatric, social care, education, forensic and primary care providers and other professionals who have contact with people with adhd. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 8, "section": "1.1.7", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 1. 8 child and adult psychiatrists, paediatricians, and other child and adult mental health professionals ( including those working in forensic services ) should undertake training so that they are able to diagnose adhd and provide treatment and management in accordance with this guideline. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 8, "section": "1.1.8", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 2 recognition, identification and referral recognition", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 8, "section": "1.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 2. 1 be aware that people in the following groups may have increased prevalence of adhd compared with the general population : attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 8 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 8, "section": "1.2.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 2. 2 be aware that adhd is thought to be under - recognised in girls and women and that :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 9, "section": "1.2.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• they are less likely to be referred for assessment for adhd • they may be more likely to have undiagnosed adhd • they may be more likely to receive an incorrect diagnosis of another mental", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 9, "section": "1.2.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "health or neurodevelopmental condition. [ 2018 ] attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 9 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 9, "section": "1.2.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 2. 3 universal screening for adhd should not be undertaken in nursery, primary and secondary schools. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 10, "section": "1.2.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 2. 4 when a child or young person with disordered conduct and suspected adhd is referred to a school ' s special educational needs coordinator ( senco ), the senco, in addition to helping the child with their behaviour, should inform the parents about local parent - training / education programmes. see nice ' s guideline on antisocial behaviour and conduct disorders in children and young people. [ 2008, amended 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 10, "section": "1.2.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 2. 5 referral from the community to secondary care may involve health, education and social care professionals ( for example, gps, paediatricians, educational psychologists, sencos, social workers ) and care pathways can vary locally. the person making the referral to secondary care should inform the child or young person ' s gp. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 10, "section": "1.2.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 2. 6 when a child or young person presents in primary care with behavioural and / or attention problems suggestive of adhd, primary care practitioners should determine the severity of the problems, how these affect the child or young person and the parents or carers, and the extent to which they pervade different domains and settings. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 10, "section": "1.2.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 2. 7 if the child or young person ' s behavioural and / or attention problems suggestive of adhd are having an adverse impact on their development or family life, consider :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 10, "section": "1.2.7", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• a period of watchful waiting of up to 10 weeks", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 10, "section": "1.2.7", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 10 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 10, "section": "1.2.7", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 2. 8 if the child or young person ' s behavioural and / or attention problems are associated with severe impairment, referral should be made directly to secondary care ( that is, a child psychiatrist, paediatrician, or specialist adhd camhs ) for assessment. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 11, "section": "1.2.8", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 2. 9 primary care practitioners should not make the initial diagnosis or start medication in children or young people with suspected adhd. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 11, "section": "1.2.9", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 2. 10 adults presenting with symptoms of adhd in primary care or general adult psychiatric services, who do not have a childhood diagnosis of adhd, should be referred for assessment by a mental health specialist trained in the diagnosis and treatment of adhd, where there is evidence of typical manifestations of adhd ( hyperactivity / impulsivity and / or inattention ) that :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 11, "section": "1.2.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• began during childhood and have persisted throughout life • are not explained by other psychiatric diagnoses ( although there may be", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 11, "section": "1.2.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "other coexisting psychiatric conditions )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 11, "section": "1.2.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• have resulted in or are associated with moderate or severe psychological,", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 11, "section": "1.2.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "social and / or educational or occupational impairment. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 11, "section": "1.2.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 2. 11 adults who have previously been treated for adhd as children or young people and present with symptoms suggestive of continuing adhd should be referred to general adult psychiatric services for assessment. the symptoms should be associated with at least moderate or severe psychological and / or social or educational or occupational impairment. [ 2008 ] attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 11 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 11, "section": "1.2.11", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 3 diagnosis", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 3. 1 adhd should only be diagnosed by a specialist psychiatrist, paediatrician or other appropriately qualified healthcare professional with training and expertise in diagnosing adhd, on the basis of :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• a full clinical and psychosocial assessment of the person ; this should include", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "discussion about behaviour and symptoms in the different domains and settings of the person ' s everyday life and", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• a full developmental and psychiatric history and • observer reports and assessment of the person ' s mental state. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "as an option, use qbtest to help diagnose adhd in people aged 6 to 17 years as recommended in nice ' s diagnostics guidance on digital technologies for assessing adhd. [ 2024 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 3. 2 a diagnosis of adhd should not be made solely on the basis of rating scale or observational data. however, rating scales such as the conners ' rating scales and the strengths and difficulties questionnaire are helpful added tools, and observations ( for example, at school ) are useful when there is doubt about symptoms. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 3. 3 for an adhd diagnosis, symptoms of hyperactivity, impulsivity or inattention should :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• meet the diagnostic criteria for hyperkinetic disorder in dsm - 5 or icd - 11 ( but", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "exclusion based on a pervasive developmental disorder or an uncertain time of onset is not recommended ) and", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• cause at least moderate psychological, social, or educational or occupational", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "impairment based on interview or direct observation in multiple settings and", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• be happening often, occurring in 2 or more important settings including", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "social, familial, educational or occupational settings. [ 2008, amended 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 3. 4 as part of the diagnostic process, include an assessment of the person ' s needs, coexisting conditions, social, familial and educational or occupational attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 12 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 12, "section": "1.3.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 3. 5 consider adhd in all age groups, with symptom criteria adjusted for age - appropriate changes in behaviour. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 13, "section": "1.3.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 3. 6 take children and young people ' s views into account wherever possible when determining the clinical significance of impairment resulting from adhd symptoms. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 13, "section": "1.3.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4 information and support", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 13, "section": "1.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4. 1 use this guideline with nice ' s guidelines on service user experience in adult mental health and patient experience in adult nhs services to improve the experience of care for adults with adhd. the principles also apply to children and young people, and their parents or carers. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 13, "section": "1.4.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4. 2 healthcare professionals working with children and young people with adhd should follow the recommendations on general principles of care in nice ' s guideline on antisocial behaviour and conduct disorder in children and young people. this does not mean that all children and young people with adhd have coexisting antisocial behaviour and conduct disorder but that the same general principles of care apply when working with children and young people with adhd. [ 2018 ] supporting people with adhd", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 13, "section": "1.4.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4. 3 following a diagnosis of adhd, have a structured discussion with people ( and their families or carers as appropriate ) about how adhd could affect their life. this could include :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 13, "section": "1.4.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• the positive impacts of receiving a diagnosis, such as :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 13, "section": "1.4.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "－ improving their understanding of symptoms － identifying and building on individual strengths attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 13 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 13, "section": "1.4.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4. 4 inform people receiving a diagnosis of adhd ( and their families or carers as appropriate ) about sources of information, including :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 14, "section": "1.4.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• local and national support groups and voluntary organisations • websites • support for education and employment.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 14, "section": "1.4.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "people who have had an assessment but whose symptoms and impairment fall short of a diagnosis of adhd may benefit from similar information. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 14, "section": "1.4.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4. 5 provide information to people with adhd ( and their families and carers as attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 14 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 14, "section": "1.4.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4. 6 ask families or carers of people with adhd how the adhd affects themselves and other family members, and discuss any concerns they have. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 15, "section": "1.4.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4. 7 encourage family members or carers of people with adhd to seek an assessment of their personal, social and mental health needs, and to join self - help and support groups if appropriate. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 15, "section": "1.4.7", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4. 8 think about the needs of a parent with adhd who also has a child with adhd, including whether they need extra support with organisational strategies ( for example, with adherence to treatment, daily school routines ). [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 15, "section": "1.4.8", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4. 9 offer advice to parents and carers of children and young people with adhd about the importance of :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 15, "section": "1.4.9", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• positive parent – and carer – child contact • clear and appropriate rules about behaviour and consistent management • structure in the child or young person ' s day. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 15, "section": "1.4.9", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4. 10 offer advice to families and carers of adults with adhd about :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 15, "section": "1.4.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• how adhd may affect relationships", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 15, "section": "1.4.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 15 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 15, "section": "1.4.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4. 11 explain to parents and carers that any recommendation of parent - training / education does not imply bad parenting, and that the aim is to optimise parenting skills to meet the above - average parenting needs of children and young people with adhd. [ 2018 ] involving schools, colleges and universities", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 16, "section": "1.4.11", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4. 12 when adhd is diagnosed, when symptoms change, and when there is transition between schools or from school to college or college to university, obtain consent and then contact the school, college or university to explain :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 16, "section": "1.4.12", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• the validity of a diagnosis of adhd and how symptoms are likely to affect", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 16, "section": "1.4.12", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "school, college or university life", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 16, "section": "1.4.12", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• other coexisting conditions ( for example, learning disabilities ) are distinct", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 16, "section": "1.4.12", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "from adhd and may need different adjustments", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 16, "section": "1.4.12", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• the treatment plan and identified special educational needs, including advice", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 16, "section": "1.4.12", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "for reasonable adjustments and environmental modifications within the educational placement", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 16, "section": "1.4.12", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• the value of feedback from schools, colleges and universities to people with", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 16, "section": "1.4.12", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "adhd and their healthcare professionals. [ 2018 ] involving other healthcare professionals", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 16, "section": "1.4.12", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4. 13 when a person with adhd has a coexisting condition, contact the relevant healthcare professional, with consent, to explain :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 16, "section": "1.4.13", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• the validity, scope and implications of a diagnosis of adhd • how adhd symptoms are likely to affect the person ' s behaviour ( for example,", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 16, "section": "1.4.13", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "organisation, time management, motivation ) and adherence to specific attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 16 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 16, "section": "1.4.13", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5 managing adhd planning treatment", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 17, "section": "1.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 1 healthcare providers should ensure continuity of care for people with adhd. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 17, "section": "1.5.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 2 ensure that people with adhd have a comprehensive, holistic shared treatment plan that addresses psychological, behavioural and occupational or educational needs. take into account :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 17, "section": "1.5.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• the severity of adhd symptoms and impairment, and how these affect or", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 17, "section": "1.5.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "may affect everyday life ( including sleep )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 17, "section": "1.5.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• their goals • their resilience and protective factors • the relative impact of other neurodevelopmental or mental health conditions.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 17, "section": "1.5.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "[ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 17, "section": "1.5.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 3 regularly discuss with people with adhd, and their family members or carers, how they want to be involved in treatment planning and decisions ; such discussions should take place at intervals to take account of changes in attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 17 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 17, "section": "1.5.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 4 before starting any treatment for adhd, discuss the following with the person, and their family or carers as appropriate, encouraging children and young people to give their own account of how they feel :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 18, "section": "1.5.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• the benefits and harms of non - pharmacological and pharmacological", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 18, "section": "1.5.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "treatments ( for example, the efficacy of medication compared with no treatment or non - pharmacological treatments, potential adverse effects and non - response rates )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 18, "section": "1.5.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• the benefits of a healthy lifestyle, including exercise • their preferences and concerns ( it is important to understand that a person ' s", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 18, "section": "1.5.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "decision to start, change or stop treatment may be influenced by media coverage, teachers, family members, friends and differing opinion on the validity of a diagnosis of adhd )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 18, "section": "1.5.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• how other mental health or neurodevelopmental conditions might affect", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 18, "section": "1.5.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "treatment choices", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 18, "section": "1.5.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• the importance of adherence to treatment and any factors that may affect", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 18, "section": "1.5.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "this ( for example, it may be difficult to take medication at school or work, or to remember appointments ). record the person ' s preferences and concerns in their treatment plan. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 18, "section": "1.5.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 5 ask young people and adults with adhd if they wish a parent, partner, close friend or carer to join discussions on treatment and adherence. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 18, "section": "1.5.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 6 reassure people with adhd, and their families or carers as appropriate, that they can revisit decisions about treatments. [ 2018 ] attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 18 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 18, "section": "1.5.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 7 offer an adhd - focused group parent - training programme to parents or carers of children under 5 years with adhd as first - line treatment. see recommendations 1. 5. 1 to 1. 5. 10 in nice ' s guideline on antisocial behaviour and conduct disorders in children and young people. this does not imply that all children under 5 years with adhd have antisocial behaviour or conduct disorder, but that the same general principles of care apply. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 19, "section": "1.5.7", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 8 if after an adhd - focused group parent - training programme, adhd symptoms across settings are still causing a significant impairment in a child under 5 years after environmental modifications have been implemented and reviewed, obtain advice from a specialist adhd service with expertise in managing adhd in young children ( ideally a tertiary service ). [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 19, "section": "1.5.8", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 9 do not offer medication for adhd for any child under 5 years without a second specialist opinion from an adhd service with expertise in managing adhd in young children ( ideally a tertiary service ). [ 2018 ] attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 19 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 19, "section": "1.5.9", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 10 give information about adhd ( see recommendation 1. 4. 3 ) and offer additional support to parents and carers of all children aged 5 years and over and young people with adhd. the support should be adhd focused, can be group based and as few as 1 or 2 sessions. it should include :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 20, "section": "1.5.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• education and information on the causes and impact of adhd • advice on parenting strategies • with consent, liaison with school, college or university ( see recommendation", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 20, "section": "1.5.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 4. 12 )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 20, "section": "1.5.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• both parents and carers if feasible. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 20, "section": "1.5.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 11 if a child aged 5 years or over or young person has adhd and symptoms of oppositional defiant disorder or conduct disorder, offer parents and carers a parent - training programme in line with recommendations 1. 5. 1 to 1. 5. 10 in nice ' s guideline on antisocial behaviour and conduct disorders in children and young people, as well as group - based adhd - focused support. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 20, "section": "1.5.11", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 12 consider individual parent - training programmes for parents and carers of children attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 20 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 20, "section": "1.5.12", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 13 offer medication for children aged 5 years and over and young people only if :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 21, "section": "1.5.13", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• their adhd symptoms are still causing a persistent significant impairment in", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 21, "section": "1.5.13", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "at least one domain after environmental modifications have been implemented and reviewed", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 21, "section": "1.5.13", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• they and their parents and carers have discussed information about adhd", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 21, "section": "1.5.13", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "( see recommendation 1. 5. 4 )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 21, "section": "1.5.13", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• a baseline assessment has been carried out ( see recommendation 1. 7. 4 ).", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 21, "section": "1.5.13", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "see the recommendations on medication. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 21, "section": "1.5.13", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 14 consider a course of cognitive behavioural therapy ( cbt ) for young people with adhd who have benefited from medication but whose symptoms are still causing a significant impairment in at least one domain, addressing the following areas :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 21, "section": "1.5.14", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• social skills with peers • problem - solving • self - control • active listening skills • dealing with and expressing feelings. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 21, "section": "1.5.14", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 21 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 21, "section": "1.5.14", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 15 offer medication to adults with adhd if their adhd symptoms are still causing a significant impairment in at least one domain after environmental modifications have been implemented and reviewed. see the recommendations on medication choice. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 22, "section": "1.5.15", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 16 consider non - pharmacological treatment for adults with adhd who have :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 22, "section": "1.5.16", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• made an informed choice not to have medication • difficulty adhering to medication • found medication to be ineffective or cannot tolerate it. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 22, "section": "1.5.16", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 17 consider non - pharmacological treatment in combination with medication for adults with adhd who have benefited from medication but whose symptoms are still causing a significant impairment in at least one domain. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 22, "section": "1.5.17", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 5. 18 when non - pharmacological treatment is indicated for adults with adhd, offer the following as a minimum :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 22, "section": "1.5.18", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• a structured supportive psychological intervention focused on adhd", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 22, "section": "1.5.18", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 22 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 22, "section": "1.5.18", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 6 dietary advice", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 23, "section": "1.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 6. 1 healthcare professionals should stress the value of a balanced diet, good nutrition and regular exercise for children, young people and adults with adhd. [ 2008 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 23, "section": "1.6.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 6. 2 do not advise elimination of artificial colouring and additives from the diet as a generally applicable treatment for children and young people with adhd. [ 2016 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 23, "section": "1.6.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 6. 3 ask about foods or drinks that appear to influence hyperactive behaviour as part of the clinical assessment of adhd in children and young people, and :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 23, "section": "1.6.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• if there is a clear link, advise parents or carers to keep a diary of food and", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 23, "section": "1.6.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "drinks taken and adhd behaviour", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 23, "section": "1.6.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• if the diary supports a relationship between specific foods and drinks and", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 23, "section": "1.6.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "behaviour, offer referral to a dietitian", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 23, "section": "1.6.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• ensure that further management ( for example, specific dietary elimination ) is", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 23, "section": "1.6.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "jointly undertaken by the dietitian, mental health specialist or paediatrician, and the parent or carer and child or young person. [ 2016 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 23, "section": "1.6.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 6. 4 do not advise or offer dietary fatty acid supplementation for treating adhd in children and young people. [ 2016 ] attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 23 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 23, "section": "1.6.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 6. 5 advise the family members or carers of children with adhd that there is no evidence about the long - term effectiveness or potential harms of a ' few food ' diet for children with adhd, and only limited evidence of short - term benefits. [ 2016 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.6.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7 medication these recommendations, with the exception of recommendation 1. 7. 29, are for healthcare professionals with training and expertise in diagnosing and managing adhd.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 1 use this guideline with nice ' s guideline on medicines optimisation : the safe and effective use of medicines to enable the best possible outcomes. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 2 all medication for adhd should only be initiated by a healthcare professional with training and expertise in diagnosing and managing adhd. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 3 healthcare professionals initiating medication for adhd should :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• be familiar with the pharmacokinetic profiles of all the short - and long - acting", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "preparations available for adhd", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• ensure that treatment is tailored effectively to the individual needs of the", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "child, young person or adult", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• take account of variations in bioavailability or pharmacokinetic profiles of", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "different preparations to avoid reduced effect or excessive adverse effects. [ 2018 ] baseline assessment", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 4 before starting medication for adhd, people with adhd should have a full assessment, which should include :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• a review to confirm they continue to meet the criteria for adhd and need", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "treatment", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• a review of mental health and social circumstances, including :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 24 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 24, "section": "1.7.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 5 refer for a cardiology opinion before starting medication for adhd if any of the following apply :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 25, "section": "1.7.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• history of congenital heart disease or previous cardiac surgery • history of sudden death in a first - degree relative under 40 years suggesting a", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 25, "section": "1.7.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "cardiac disease", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 25, "section": "1.7.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• shortness of breath on exertion compared with peers • fainting on exertion or in response to fright or noise • palpitations that are rapid, regular and start and stop suddenly ( fleeting", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 25, "section": "1.7.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 25 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 25, "section": "1.7.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 6 refer to a paediatric hypertension specialist before starting medication for adhd if blood pressure is consistently above the 95th centile for age and height for children and young people. [ 2018 ] to find out why the committee made the 2018 recommendations on medication – baseline assessment, and how they might affect practice, see the rationale and impact section on medication – baseline assessment. full details of the evidence and the committee ' s discussion are in evidence review d : pharmacological safety. medication choice – children aged 5 years and over and young people recommendations 1. 7. 7 to 1. 7. 10 update nice ' s technology appraisal guidance on methylphenidate, atomoxetine and dexamfetamine for adhd in children and adolescents ( ta98 ).", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 26, "section": "1.7.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 7 offer methylphenidate ( either short or long acting ) as the first line pharmacological treatment for children aged 5 years and over and young people with adhd. march 2018 – this is an off - label use for children aged 5 years. see nice ' s information on prescribing medicines. [ 2018 ] attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 26 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 26, "section": "1.7.7", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 8 consider switching to lisdexamfetamine for children aged 5 years and over and young people who have had a 6 - week trial of methylphenidate at an adequate dose and not derived enough benefit in terms of reduced adhd symptoms and associated impairment. march 2018 – this is an off - label use for children aged 5 years. see nice ' s information on prescribing medicines. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 27, "section": "1.7.8", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 9 consider dexamfetamine for children aged 5 years and over and young people whose adhd symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile. march 2018 – dexamfetamine is only licensed to treat adhd in children and young people aged 6 to 17 years when response to methylphenidate is clinically inadequate. it is not licensed for children and young people aged 5 to 17 years who have responded to but are intolerant of lisdexamfetamine. see nice ' s information on prescribing medicines. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 27, "section": "1.7.9", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 10 offer atomoxetine or guanfacine to children aged 5 years and over and young people if :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 27, "section": "1.7.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• they cannot tolerate methylphenidate or lisdexamfetamine or • their symptoms have not responded to separate 6 - week trials of", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 27, "section": "1.7.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "lisdexamfetamine and methylphenidate, having considered alternative preparations and adequate doses. march 2018 – this is an off - label use of atomoxetine and guanfacine for children aged 5 years. see nice ' s information on prescribing medicines. [ 2018 ] medication choice – adults", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 27, "section": "1.7.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 11 offer lisdexamfetamine or methylphenidate as first - line pharmacological treatment for adults with adhd. march 2018 – this is an off - label use of lisdexamfetamine for adults with no adhd attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 27 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 27, "section": "1.7.11", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 12 consider switching to lisdexamfetamine for adults who have had a 6 - week trial of methylphenidate at an adequate dose but have not derived enough benefit in terms of reduced adhd symptoms and associated impairment. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 28, "section": "1.7.12", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 13 consider switching to methylphenidate for adults who have had a 6 - week trial of lisdexamfetamine at an adequate dose but have not derived enough benefit in terms of reduced adhd symptoms and associated impairment. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 28, "section": "1.7.13", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 14 consider dexamfetamine for adults whose adhd symptoms are responding to lisdexamfetamine but who cannot tolerate the longer effect profile. march 2018 – this is an off - label use of dexamfetamine. see nice ' s information on prescribing medicines. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 28, "section": "1.7.14", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 15 offer atomoxetine to adults if :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 28, "section": "1.7.15", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• they cannot tolerate lisdexamfetamine or methylphenidate or • their symptoms have not responded to separate 6 - week trials of", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 28, "section": "1.7.15", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "lisdexamfetamine and methylphenidate, having considered alternative preparations and adequate doses. march 2018 – this is an off - label use of atomoxetine for adults with no adhd symptoms in childhood. see nice ' s information on prescribing medicines. [ 2018 ] further medication choices", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 28, "section": "1.7.15", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 16 obtain a second opinion or refer to a tertiary service if adhd symptoms in a child aged 5 years or over, a young person or adult are unresponsive to one or more stimulants and one non - stimulant. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 28, "section": "1.7.16", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 17 do not offer any of the following medication for adhd without advice from a attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 28 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 28, "section": "1.7.17", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 18 offer the same medication choices to people with adhd and anxiety disorder, tic disorder or autism spectrum disorder as other people with adhd. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 29, "section": "1.7.18", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 19 for children aged 5 years and over, young people and adults with adhd experiencing an acute psychotic or manic episode :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 29, "section": "1.7.19", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• stop any medication for adhd • consider restarting or starting new adhd medication after the episode has", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 29, "section": "1.7.19", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "resolved, taking into account the individual circumstances, risks and benefits of the adhd medication. [ 2018 ] to find out why the committee made the 2018 recommendations on medication choice, and how they might affect practice, see the rationale and impact section on medication – choice. full details of the evidence and the committee ' s discussion are in evidence review c : pharmacological efficacy and sequencing. attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 29 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 29, "section": "1.7.19", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 20 when prescribing stimulants for adhd, think about modified - release once - daily preparations for the following reasons :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 30, "section": "1.7.20", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• convenience • improving adherence • reducing stigma ( because there is no need to take medication at school or in", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 30, "section": "1.7.20", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "the workplace )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 30, "section": "1.7.20", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• reducing problems of storing and administering controlled drugs at school • the risk of stimulant misuse and diversion with immediate - release", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 30, "section": "1.7.20", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "preparations", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 30, "section": "1.7.20", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• their pharmacokinetic profiles.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 30, "section": "1.7.20", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "immediate - release preparations may be suitable if more flexible dosing regimens are needed, or during initial titration to determine correct dosing levels. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 30, "section": "1.7.20", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 21 when prescribing stimulants for adhd, be aware that effect size, duration of effect and adverse effects vary from person to person. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 30, "section": "1.7.21", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 22 think about using a modified - release preparation of methylphenidate in the morning and an immediate - release preparation of methylphenidate at another time of the day to extend the duration of effect. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 30, "section": "1.7.22", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 23 be cautious about prescribing stimulants for adhd if there is a risk of diversion for cognitive enhancement or appetite suppression. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 30, "section": "1.7.23", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 24 do not offer immediate - release stimulants or modified - release stimulants that can be easily injected or insufflated if there is a risk of stimulant misuse or diversion. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 30, "section": "1.7.24", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 25 prescribers should be familiar with the requirements of controlled drug legislation governing the prescription and supply of stimulants. see nice ' s guideline on attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 30 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 30, "section": "1.7.25", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 26 during the titration phase, adhd symptoms, impairment and adverse effects should be recorded at baseline and at each dose change on standard scales by parents and teachers, and progress reviewed regularly ( for example, by weekly telephone contact ) with a specialist. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 31, "section": "1.7.26", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 27 titrate the dose against symptoms and adverse effects in line with the bnf or bnf for children until dose optimisation is achieved, that is, reduced symptoms, positive behaviour change, improvements in education, employment and relationships, with tolerable adverse effects. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 31, "section": "1.7.27", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 28 ensure that dose titration is slower and monitoring more frequent if any of the following are present in people with adhd :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 31, "section": "1.7.28", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• neurodevelopmental disorders ( for example, autism spectrum disorder, tic", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 31, "section": "1.7.28", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "disorders, learning disability [ intellectual disability ] )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 31, "section": "1.7.28", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• mental health conditions ( for example, anxiety disorders [ including", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 31, "section": "1.7.28", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "obsessive – compulsive disorder ], schizophrenia or bipolar disorder, depression, personality disorder, eating disorder, post - traumatic stress disorder, substance misuse )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 31, "section": "1.7.28", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• physical health conditions ( for example, cardiac disease, epilepsy or acquired", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 31, "section": "1.7.28", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "brain injury ). [ 2018 ] to find out why the committee made the 2018 recommendations on medication – considerations when prescribing and dose titration, and how they might affect practice, see the rationale and impact section on medication – considerations when prescribing and dose titration. full details of the evidence and the committee ' s discussion are in evidence review d : pharmacological safety. attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 31 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 31, "section": "1.7.28", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 7. 29 after titration and dose stabilisation, prescribing and monitoring of adhd medication should be carried out under shared care protocol arrangements with primary care. [ 2018 ] to find out why the committee made the 2018 recommendations on medication – care arrangements, and how they might affect practice, see the rationale and impact section on medication – care arrangements. full details of the evidence and the committee ' s discussion are in evidence review d : pharmacological safety.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 32, "section": "1.7.29", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8 maintenance and monitoring", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 32, "section": "1.8", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 1 monitor effectiveness of medication for adhd and adverse effects, and document in the person ' s notes. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 32, "section": "1.8.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 2 encourage people taking medication for adhd to monitor and record their adverse effects, for example, by using an adverse effect checklist. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 32, "section": "1.8.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 3 consider using standard symptom and adverse effect rating scales for clinical assessment and throughout the course of treatment for people with adhd. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 32, "section": "1.8.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 4 ensure that children, young people and adults receiving treatment for adhd have review and follow - up according to the severity of their condition, regardless of whether or not they are taking medication. [ 2018 ] height and weight", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 32, "section": "1.8.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 5 for people taking medication for adhd :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 32, "section": "1.8.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• measure height every 6 months in children and young people", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 32, "section": "1.8.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 32 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 32, "section": "1.8.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 6 if weight loss is a clinical concern, consider the following strategies :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 33, "section": "1.8.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• taking medication either with or after food, rather than before meals • taking additional meals or snacks early in the morning or late in the evening", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 33, "section": "1.8.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "when stimulant effects have worn off", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 33, "section": "1.8.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• obtaining dietary advice • consuming high - calorie foods of good nutritional value • taking a planned break from treatment • changing medication. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 33, "section": "1.8.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 7 if a child or young person ' s height over time is significantly affected by medication ( that is, they have not met the height expected for their age ), consider a planned break in treatment over school holidays to allow ' catch - up ' growth. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 33, "section": "1.8.7", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 8 consider monitoring bmi of adults with adhd if there has been weight change as a result of their treatment, and changing the medication if weight change persists. [ 2018 ] cardiovascular", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 33, "section": "1.8.8", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 9 monitor heart rate and blood pressure and compare with the normal range for attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 33 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 33, "section": "1.8.9", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 10 do not offer routine blood tests ( including liver function tests ) or ecgs to people taking medication for adhd unless there is a clinical indication. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 34, "section": "1.8.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 11 if a person taking adhd medication has sustained resting tachycardia ( more than 120 beats per minute ), arrhythmia or systolic blood pressure greater than the 95th percentile ( or a clinically significant increase ) measured on 2 occasions, reduce their dose and refer them to a paediatric hypertension specialist or adult physician. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 34, "section": "1.8.11", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 12 if a person taking guanfacine has sustained orthostatic hypotension or fainting episodes, reduce their dose or switch to another adhd medication. [ 2018 ] tics", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 34, "section": "1.8.12", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 13 if a person taking stimulants develops tics, think about whether :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 34, "section": "1.8.13", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• the tics are related to the stimulant ( tics naturally wax and wane ) and • the impairment associated with the tics outweighs the benefits of adhd", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 34, "section": "1.8.13", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "treatment. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 34, "section": "1.8.13", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 14 if tics are stimulant related, reduce the stimulant dose, or consider changing to guanfacine ( in children aged 5 years and over and young people only ), atomoxetine ( off - label use for adults with no adhd symptoms in childhood ), clonidine ( off - label use for children ), or stopping medication. clonidine should only be considered for people under 18 years after advice from a tertiary adhd service. [ 2018 ] sexual dysfunction", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 34, "section": "1.8.14", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 15 monitor young people and adults with adhd for sexual dysfunction ( that is, erectile and ejaculatory dysfunction ) as potential adverse effects of atomoxetine. [ 2018 ] attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 34 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 34, "section": "1.8.15", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 16 if a person with adhd develops new seizures or a worsening of existing seizures, review their adhd medication and stop any medication that might be contributing to the seizures. after investigation, cautiously reintroduce adhd medication if it is unlikely to be the cause of the seizures. [ 2018 ] sleep", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 35, "section": "1.8.16", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 17 monitor changes in sleep pattern ( for example, with a sleep diary ) and adjust medication accordingly. [ 2018 ] worsening behaviour", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 35, "section": "1.8.17", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 18 monitor the behavioural response to medication, and if behaviour worsens adjust medication and review the diagnosis. [ 2018 ] stimulant diversion", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 35, "section": "1.8.18", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 8. 19 healthcare professionals and parents or carers should monitor changes in the potential for stimulant misuse and diversion, which may come with changes in circumstances and age. [ 2018 ] to find out why the committee made the 2018 recommendations on medication – monitoring adverse effects, and how they might affect practice, see the rationale and impact section on medication – monitoring effectiveness and adverse effects. full details of the evidence and the committee ' s discussion are in evidence review d : pharmacological safety. attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 35 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 35, "section": "1.8.19", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 9 adherence to treatment", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 9. 1 use this guideline with nice ' s guideline on medicines adherence to improve the care for adults with adhd. the principles also apply to children and young people. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 9. 2 be aware that the symptoms of adhd may lead to people having difficulty adhering to treatment plans ( for example, remembering to order and collect medication ). [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 9. 3 ensure that people are fully informed of the balance of risks and benefits of any treatment for adhd and check that problems with adherence are not due to misconceptions ( for example, tell people that medication does not change personality ). [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 9. 4 encourage the person with adhd to use the following strategies to support adherence to treatment :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• being responsible for their own health, including taking their medication as", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "needed", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• following clear instructions about how to take the medication in picture or", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "written format, which may include information on dose, duration, adverse effects, dosage schedule ( the instructions should stay with the medication, for example, a sticker on the side of the packet )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• using visual reminders to take medication regularly ( for example, apps,", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "alarms, clocks, pill dispensers, or notes on calendars or fridges )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• taking medication as part of their daily routine ( for example, before meals or", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "after brushing teeth )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• attending peer support groups ( for both the person with adhd and for the", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "families and carers ). [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.4", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 9. 5 encourage parents and carers to oversee adhd medication for children and young people. [ 2018 ] attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 36 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 36, "section": "1.9.5", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 9. 6 support adherence to non - pharmacological treatments ( for example, cbt ) by discussing the following :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 37, "section": "1.9.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• the balance of risks and benefits ( for example, how the treatment can have a", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 37, "section": "1.9.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "positive effect on adhd symptoms )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 37, "section": "1.9.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• the potential barriers to continuing treatment, including :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 37, "section": "1.9.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "－ not being sure if it is making any difference － the time and organisational skills needed to commit to the treatment － the time that might be needed outside of the sessions ( for example, to complete homework )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 37, "section": "1.9.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• strategies to deal with any identified barriers ( for example, scheduling", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 37, "section": "1.9.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "sessions to minimise inconvenience or seeking courses with child care provision )", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 37, "section": "1.9.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• a possible effect of treatment being increased self - awareness, and the", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 37, "section": "1.9.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "challenging impact this may have on the person and the people around them", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 37, "section": "1.9.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• the importance of long - term adherence beyond the duration of any initial", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 37, "section": "1.9.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "programme ( for example, by attending follow - up / refresher support to sustain learned strategies ). [ 2018 ] to find out why the committee made the 2018 recommendations on adherence to treatment and how they might affect practice, see the rationale and impact section on adherence to treatment. full details of the evidence and the committee ' s discussion are in evidence review g : adherence.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 37, "section": "1.9.6", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 10 review of medication and discontinuation", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 37, "section": "1.10", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 10. 1 a healthcare professional with training and expertise in managing adhd should attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 37 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 37, "section": "1.10.1", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 10. 2 encourage people with adhd to discuss any preferences to stop or change medication and to be involved in any decisions about stopping treatments. [ 2018 ]", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 38, "section": "1.10.2", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. 10. 3 consider trial periods of stopping medication or reducing the dose when assessment of the overall balance of benefits and harms suggests this may be appropriate. if the decision is made to continue medication, the reasons for this should be documented. [ 2018 ] to find out why the committee made the 2018 recommendations on review of medication and discontinuation, and how they might affect practice, see the rationale and impact section on review of medication and discontinuation. full details of the evidence and the committee ' s discussion are in evidence review i : withdrawal and drug holidays. attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 38 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 38, "section": "1.10.3", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "terms used in this guideline domains domains refer to areas of function, for example, interpersonal relationships, education and occupational attainment, and risk awareness. environmental modifications environmental modifications are changes that are made to the physical environment in order to minimise the impact of a person ' s adhd on their day - to - day life. appropriate environmental modifications will be specific to the circumstances of each person with adhd and should be determined from an assessment of their needs. examples may include changes to seating arrangements, changes to lighting and noise, reducing distractions ( for example, using headphones ), optimising work or education to have shorter periods of focus with movement breaks ( including the use of ' i need a break ' cards ), reinforcing verbal requests with written instructions and, for children, the appropriate use of teaching assistants at school. reasonable adjustments reasonable adjustments is a term that refers to the legal obligations of employers and higher education providers to make sure that workers or students with disabilities, or physical or mental health conditions are not substantially disadvantaged when doing their jobs or during their education. settings settings refer to the physical location, for example, home, nursery, friends or family homes. shared treatment plan a written treatment plan shared between healthcare professional and the person with adhd ; for children, this may be shared more widely ( for example, with families, schools or social care, if relevant and", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 39, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": ", nursery, friends or family homes. shared treatment plan a written treatment plan shared between healthcare professional and the person with adhd ; for children, this may be shared more widely ( for example, with families, schools or social care, if relevant and agreed ). attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 39 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 39, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "recommendations for research the guideline committee has made the following recommendations for research. 1 children and young people aged 5 to 18 years – brief, group - based, adhd - focused, parent - training intervention what is the clinical and cost effectiveness, and optimum length, of a brief parent - training intervention for parents and carers of children and young people with attention deficit hyperactivity disorder ( adhd ) aged 5 to 18 years? why this is important there was no clear evidence identified about the benefit of formal parent - training programmes for adhd symptoms in children and young people aged 5 to 18 years. the cost effectiveness of these programmes was unclear, partly because of uncertainty over the number of sessions and the length of programme needed to achieve clinical benefit. this research recommendation would help address these uncertainties. 2 medication choice in people with coexisting conditions what is the clinical and cost effectiveness of adhd medications in people with adhd and tic disorders, a history of psychosis or mania, or personality disorder? why is this important no evidence was identified to justify different medication choices in people with adhd and tic disorders, a history of psychosis or mania, or emotional dysregulation. these groups are often excluded from trials. there are reasons ( for example, mechanism of action of medication options, previous reports of adverse effects ) to suspect that these groups may respond differently", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 40, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "of psychosis or mania, or emotional dysregulation. these groups are often excluded from trials. there are reasons ( for example, mechanism of action of medication options, previous reports of adverse effects ) to suspect that these groups may respond differently to different drugs, but a lack of trials to confirm this. primarily there are some concerns that stimulant medication may worsen the symptoms of attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 40 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 40, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "any of these coexisting conditions and therefore non - stimulant medication should be preferred. 3 medication choice in people with no previous medication for adhd what is the clinical and cost effectiveness of adhd medications in people with adhd with no previous medication for the condition? why is this important most of the evidence to support the recommendations for medication choices for people with adhd comes from studies in people who have previously received medication. therefore, these studies often include a population not representative of the people with newly diagnosed adhd. there may be differing levels of efficacy of the various treatment options in people who have received no previous medication for adhd. 4 prescribing beyond monotherapy what is the clinical and cost effectiveness of various adhd prescribing strategies when monotherapy has failed? why is this important this guideline makes recommendations for the medication choices for people with adhd up to the point at which common monotherapies are exhausted. there is very little evidence to guide healthcare professionals beyond this point, particularly with regard to whether there is a benefit of prescribing stimulant and non - stimulant medication together. attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and -", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 41, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "##nt medication together. attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 41 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 41, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "rationale and impact recognition recommendations 1. 2. 1 and 1. 2. 2 why the committee made the recommendations evidence showed that the prevalence of attention deficit hyperactivity disorder ( adhd ) is higher in some groups than in the general population. the committee agreed that a recommendation was needed to raise awareness of these groups among non - specialists to help them avoid missing a diagnosis of adhd. although no evidence was identified for a higher prevalence in people known to the youth justice system or adult criminal justice system and people with acquired brain injury, the committee agreed that in their experience, these groups often receive a late diagnosis of adhd or a misdiagnosis. no evidence was found on the increased risk of missing a diagnosis of adhd in girls. but the committee discussed the different symptoms often found in this group, and agreed to make a recommendation to raise awareness. how the recommendations might affect practice the recommendations are to raise awareness among non - specialists of a possible diagnosis of adhd in groups of people that they are already seeing. the recommendations may increase the rates of diagnosis and referral for adhd, but these should be accurate and therefore appropriate. return to recommendations information and support recommendations 1. 4. 1 to 1. 4. 13 why the committee made the recommendations good information and support tailored to needs and circumstances are important for all attention deficit hyperactivity disorder : diagnosis and management ( ng", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 42, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": ". return to recommendations information and support recommendations 1. 4. 1 to 1. 4. 13 why the committee made the recommendations good information and support tailored to needs and circumstances are important for all attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 42 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 42, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "people using nhs services, but some aspects are particularly important for people with adhd. evidence identified the need for information tailored to family circumstances, particularly when a child has adhd, and to highlight the importance of daily structure for adults with adhd. evidence showed the importance of discussing key areas following a diagnosis of adhd, particularly the positive impacts of receiving a diagnosis, such as improving understanding of symptoms. the committee used the evidence and their experience to agree other areas for discussion, including driving and possible issues with education and employment. they noted that schools, colleges and universities may sometimes question a diagnosis of adhd and not understand how symptoms can affect daily functioning. in addition, healthcare professionals treating a coexisting condition may not be aware of how adhd symptoms may affect behaviour ( organisation and time management ) and adherence to treatment. there was evidence that parents of children with adhd often feel a sense of isolation when attending parent - training programmes. the committee agreed that healthcare professionals should explain to parents that an invitation to attend a parent - training programme does not imply bad parenting. the committee discussed the difficulties in families where parents may also have adhd and made a recommendation to remind healthcare professionals that these families may need extra support. in the committee ' s experience, people who are assessed for adhd but not given a formal diagnosis are a neglected group who would benefit from advice on where to get support", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 43, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "and made a recommendation to remind healthcare professionals that these families may need extra support. in the committee ' s experience, people who are assessed for adhd but not given a formal diagnosis are a neglected group who would benefit from advice on where to get support for troublesome symptoms. how the recommendations might affect practice the recommendations should reflect good current practice. healthcare professionals may spend more time discussing the potential impacts of a diagnosis, but this is likely to mean improved quality of life for the person with adhd and better management of their symptoms. return to recommendations managing adhd – planning treatment recommendations 1. 5. 1 to 1. 5. 6 attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 43 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 43, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "why the committee made the recommendations evidence showed the importance of joint decision - making when planning treatment ; particularly important was the discussion before starting treatment. this was also the committee ' s experience and they recommended that these discussions should be repeated throughout care. the committee recommended key areas highlighted in the evidence that should be discussed with the person and their family before starting treatment. this included the benefits and harms of medications and consideration of these alongside other treatment choices. in the committee ' s experience, other mental health and neurodevelopmental conditions may affect treatment choices and how successful these are. the committee emphasised the importance of a holistic approach to managing adhd. evidence indicated that parents and carers of children with adhd found it hard to make decisions about treatment and wanted time to think about the effect of any environmental modifications. the committee recognised that systematic use of environmental modifications is important for limiting the impact of adhd symptoms. the committee agreed that the effect of environmental modifications should be reviewed and taken into account when considering other treatment options. the committee also recognised the importance of having the opportunity to regularly revisit and discuss earlier decisions and so recommended that healthcare professionals remind people that they can do this if they wish. the committee acknowledged that it is important to include children and young people in any treatment discussions and recommended they should be encouraged to say how they feel. this should include their views on the", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 44, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "that healthcare professionals remind people that they can do this if they wish. the committee acknowledged that it is important to include children and young people in any treatment discussions and recommended they should be encouraged to say how they feel. this should include their views on the aims and effect of any treatments. healthcare professionals should be aware that these will change as the child matures and will need revisiting. the committee also recognised that it was important that young people and adults should have as much support as they need and should be asked if they would like someone to join discussions about treatment. decisions around treatment can have many influences, including teachers, peers and the media. how the recommendations might affect practice the recommendations should reflect good current practice. where practice might change, attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 44 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 44, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "it is predominantly the approach to care that will be affected. return to recommendations managing adhd – children under 5 years recommendations 1. 5. 7 to 1. 5. 9 why the committee made the recommendations in a very young child, the impact of adhd symptoms on behaviour is assessed across different settings. evidence showed a clinically important benefit on some measures of symptoms of an adhd - focused group parent - training programme for children under 5 years. there was limited evidence on the efficacy of medication, and because of concerns and lack of evidence about the long - term effects of medication in very young children, particularly in terms of growth and development, the committee agreed to recommend a group - based parent - training programme as first - line treatment. however, the committee agreed that untreated adhd can have far - reaching, long - lasting negative impacts on a child ' s life and some children may still have a significant impairment after the programme and environmental modifications. for these exceptional circumstances, the committee drew on their experience to recommend that healthcare professionals should seek further specialist advice, ideally from a tertiary service. how the recommendations might affect practice the recommendations reflect good current practice and do not indicate a change in practice from the 2008 recommendations. return to recommendations managing adhd – children aged 5 years and over and young people recommendations 1. 5. 10 to 1. 5. 14 attention deficit hyperactivity disorder :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 45, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "current practice and do not indicate a change in practice from the 2008 recommendations. return to recommendations managing adhd – children aged 5 years and over and young people recommendations 1. 5. 10 to 1. 5. 14 attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 45 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 45, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "why the committee made the recommendations the committee discussed evidence on non - pharmacological interventions and evidence on medication for managing adhd in children and young people. evidence indicated that some parents and carers of children aged 5 years and over and young people can benefit from group support. after discussion of current good practice and consideration of the balance of benefits and costs, the committee decided to recommend offering additional support that could be group - based adhd - focused support and as few as 1 or 2 sessions for parents and carers of all children and young people with adhd. evidence showed the benefit of medication in this age group in improving adhd symptoms and this was in line with the committee ' s experience. the committee acknowledged there are concerns about recommending medication for adhd and particularly the uncertainty over the long - term adverse effects of medication in growing children. however, the committee agreed that untreated adhd can have far - reaching, long - lasting negative impacts on a child or young person ' s life ( for example, affecting academic performance, interpersonal relationships, work, personal issues, substance use and driving ). medication offers a better balance of benefits and costs than non - pharmacological interventions, so the committee agreed to recommend it when adhd symptoms are persistent and still causing a significant impairment in at least one domain of everyday life despite the implementation and review of environmental modifications. the", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 46, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "of benefits and costs than non - pharmacological interventions, so the committee agreed to recommend it when adhd symptoms are persistent and still causing a significant impairment in at least one domain of everyday life despite the implementation and review of environmental modifications. the committee was aware of the implications of medication in this young population and made several recommendations to ensure its responsible use. these include recommendations on :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 46, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• checking that environmental modifications have been done before starting medication • carrying out a thorough baseline assessment • ensuring that medication is initiated only by healthcare professionals with training and", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 46, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "expertise in diagnosing and managing adhd", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 46, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• early review of medication to optimise its use ( including checking for adverse effects ) • regular review to ensure that medication is continued only for as long as it is needed • offering adhd - focused support for all children and young people with adhd.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 46, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 46 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 46, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "these recommendations are in the sections on planning treatment, baseline assessment, care arrangements and review. combining a full parent - training programme with medication did not offer a good balance of benefits and costs for all children and young people in this age group, so the committee decided not to make a recommendation on this. some evidence showed a benefit of cognitive behavioural therapy ( cbt ) in young people with adhd. the committee agreed that this should be considered when a young person has benefited from medication but still has symptoms that are causing a significant impairment. they used their experience to recommend areas that a programme should address. how the recommendations might affect practice the 2018 recommendations ensure that parents and carers of all children and young people with adhd receive adhd - focused information and support. children and young people aged 5 years and over are offered medication by a healthcare professional with training and expertise in diagnosing and managing adhd only if adhd symptoms are still causing a significant impairment in at least one domain of their everyday life despite implementation of environmental modifications. this choice follows discussion with the child or young person and their parents or carers and a full baseline assessment. the recommendations make it clear that where a child has symptoms of oppositional defiant disorder or conduct disorder, parents and carers should be offered a parent - training programme in line with the recommendations in nice ' s guideline on antisocial behaviour and conduct", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 47, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "the recommendations make it clear that where a child has symptoms of oppositional defiant disorder or conduct disorder, parents and carers should be offered a parent - training programme in line with the recommendations in nice ' s guideline on antisocial behaviour and conduct disorders. the current categorisation of adhd focuses on the presence of significant impairment in the different domains of everyday life and across settings, rather than using the previously used terms of mild, moderate and severe adhd. there is considerable overlap with the guideline population described in the 2008 recommendation. the 2018 recommendations reflect current practice and are unlikely to result in a substantial increase in prescribing and resource use. return to recommendations attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 47 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 47, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "managing adhd – adults recommendations 1. 5. 15 to 1. 5. 18 why the committee made the recommendations evidence directly comparing medication with non - pharmacological treatment supported the use of medication for first - line treatment of adhd in adults. the committee acknowledged there are concerns about recommending medication for adhd and in particular the uncertainty over the long - term benefits and the adverse effects of medication. however, the committee agreed that untreated adhd can have a negative impact on a person ' s life, with lower educational attainment, and higher criminality. so they agreed to recommend medication when adhd symptoms are still causing a significant impairment in at least one domain of everyday life despite environmental modifications. evidence indicated a benefit of non - pharmacological treatment, although this was less than for medication. there was also evidence of the importance of offering a choice of treatments, so the committee agreed that non - pharmacological treatment should be considered for adults who have made an informed choice not to have medication, have difficulty adhering to medication or have found they cannot tolerate medication or it is ineffective. based on their experience, the committee recommended that the treatment may include elements of or a full programme of cbt and should include a structured supportive psychological intervention focused on adhd, with regular follow - up and information. combining medication with non - pharmacological treatment did not", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 48, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "the committee recommended that the treatment may include elements of or a full programme of cbt and should include a structured supportive psychological intervention focused on adhd, with regular follow - up and information. combining medication with non - pharmacological treatment did not offer the best balance of benefits and costs, so the committee decided that combination treatment should only be considered when medication has offered some benefit but symptoms continue to cause a significant impairment. how the recommendations might affect practice the recommendations reflect good current practice. return to recommendations attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 48 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 48, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "medication – care arrangements recommendations 1. 7. 2 and 1. 7. 29 why the committee made the recommendations the committee discussed the roles of different healthcare professionals in initiating, monitoring and reviewing medication. they agreed, based on their experience, that medication should only be initiated and titrated by a healthcare professional with training and expertise in diagnosing and managing adhd. but after dose stabilisation, prescribing and monitoring should be carried out under shared care protocol arrangements with primary care. the exact balance between primary and secondary care will vary depending on the circumstances of the person with adhd and the available primary and secondary care services. how the recommendations might affect practice the recommendations reflect good current practice. return to recommendations 1. 7. 2 and 1. 7. 29 medication – baseline assessment recommendations 1. 7. 4 to 1. 7. 6 why the committee made the recommendations the committee noted that it is important to carry out a baseline assessment before starting adhd medication. evidence was limited on what should be assessed clinically, but the committee used their experience and expert advice to recommend a general review of health and social circumstances, and a review of physical health. the committee used their experience to outline criteria for referral for a cardiologist opinion. how the recommendations might affect practice the recommendations reflect good current practice. attention deficit hyperactivity disorder : diagnosis and management ( ng87", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 49, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "review of physical health. the committee used their experience to outline criteria for referral for a cardiologist opinion. how the recommendations might affect practice the recommendations reflect good current practice. attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 49 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 49, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "return to recommendations medication – choice recommendations 1. 7. 7 to 1. 7. 19 why the committee made the recommendations evidence showed a clinically important benefit for monotherapy with the stimulants methylphenidate and lisdexamfetamine compared with placebo or other drugs. this was supported by the committee ' s experience that stimulants work more quickly than non - stimulant drugs ( for example, atomoxetine and guanfacine ), which can take longer to have an effect. the committee used the evidence, their experience and the drug licensing to recommend methylphenidate as a treatment for children aged 5 years and over and young people, and lisdexamfetamine or methylphenidate as a treatment for adults. the committee acknowledged the rising cost of dexamfetamine since 2008 and agreed that it should only be considered when lisdexamfetamine is effective but the longer effect profile is not well tolerated. the committee agreed that if methylphenidate has not been effective for children aged over 5 years and young people, then lisdexamfetamine could be considered. atomoxetine and guanfacine were the non - stimulant drugs with the most convincing evidence. the committee noted that atomoxetine is more widely used and that there was stronger evidence for", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 50, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "##fetamine could be considered. atomoxetine and guanfacine were the non - stimulant drugs with the most convincing evidence. the committee noted that atomoxetine is more widely used and that there was stronger evidence for a benefit of atomoxetine compared with placebo than guanfacine compared with placebo. one trial directly comparing atomoxetine with guanfacine generally showed a clinically important benefit of guanfacine. taking into account the licensing status of these drugs and the familiarity of most healthcare professionals with them, the committee recommended that in children aged 5 years and over and young people, either drug could be offered after intolerance or a lack of response to stimulants ( methylphenidate and lisdexamfetamine ). because guanfacine is not licensed for use in adults and there was no evidence specifically supporting its use in this population, the committee recommended atomoxetine for adults with intolerance or a lack of response to stimulants. attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 50 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 50, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "further medication choices there was not enough evidence to justify specific recommendations for other drugs so the committee recommended that after at least one stimulant and non - stimulant had been tried, healthcare professionals should obtain a second opinion or refer to a tertiary service. medication choice for people with coexisting conditions there was very little evidence on medication choice for people with adhd and coexisting conditions and so the committee made research recommendations to address this gap. the committee agreed that neither the available evidence nor their experience justified a different choice of adhd medication for people with adhd and coexisting conditions, but there should be careful consideration of drug interactions and baseline assessments, slower titration, more careful monitoring and recording of adverse effects, and regular weekly telephone contact. however, the committee recommended that adhd medication should be stopped in people experiencing a psychotic episode because they agreed that adhd medication could worsen psychotic symptoms. how the recommendations might affect practice the recommendations reflect good current practice. return to recommendations medication – considerations when prescribing and dose titration recommendations 1. 7. 20 to 1. 7. 28 why the committee made the recommendations the committee discussed that the careful initiation of adhd medication is key to a successful treatment plan. this includes starting and titrating medication according to the bnf or the bnf for children and the person ' s tolerance", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 51, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "why the committee made the recommendations the committee discussed that the careful initiation of adhd medication is key to a successful treatment plan. this includes starting and titrating medication according to the bnf or the bnf for children and the person ' s tolerance until the dose is optimised ( reduced symptoms, positive behaviour change, improvements in education, employment and relationships, and tolerable adverse effects ). the committee agreed that healthcare professionals should be aware of the pharmacokinetic profiles of adhd medication attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 51 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 51, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "because preparations can vary in their profiles. this is important when considering which medication or formulation to prescribe. how the recommendations might affect practice the recommendations reflect good current practice. return to recommendations medication – monitoring effectiveness and adverse effects recommendations 1. 8. 1 to 1. 8. 19 why the committee made the recommendations evidence showed clinically important differences in sleep disturbance, decreased appetite and weight changes in people taking adhd medication. in the committee ' s experience, these are some of the most troublesome adverse effects. because of concerns about decreased appetite and weight change, the committee advised that weight should be checked every 3 months in children aged 10 years and under, and at least every 6 months in older children and young people ; bmi should be monitored in adults. the committee recommended that changes in sleep pattern should be recorded and medication adjusted accordingly. there was some evidence that people on atomoxetine may experience sexual dysfunction, in particular erectile dysfunction, and the committee agreed that this should be monitored. how the recommendations might affect practice the committee noted that the recommendations will reinforce current best practice. return to recommendations attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 52 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 52, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "adherence to treatment recommendations 1. 9. 1 to 1. 9. 6 why the committee made the recommendations the evidence identified several factors that affect adherence to treatment and these were supported by the committee ' s own experience. the evidence highlighted time management and forgetfulness as particular issues, so the committee made a recommendation that healthcare professionals should be aware that people with adhd may have problems remembering to order and collect medication. the committee provided examples of how healthcare professionals might encourage people to follow strategies that support adherence ( for example, following clear instructions and using visual reminders ). a common worry about treatment is that it might change personality and the committee agreed that this could affect adherence to both medication and non - pharmacological treatments. misconceptions about the effects of treatment and worries about adverse effects were common themes identified, and the committee agreed that it was important that healthcare professionals address these. evidence identified that the attitudes of people close to a person with adhd can influence adherence. the committee agreed that it was important that although children and young people should take responsibility for their own health ( including taking medication ), parents and carers should oversee them. the committee discussed that adherence to non - pharmacological treatment was an important issue that was rarely addressed. they used their own experience to recommend that healthcare professionals discuss the commitment, time and organisational skills needed for successful adherence to non - pharm", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 53, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "the committee discussed that adherence to non - pharmacological treatment was an important issue that was rarely addressed. they used their own experience to recommend that healthcare professionals discuss the commitment, time and organisational skills needed for successful adherence to non - pharmacological treatment. how the recommendations might affect practice the committee noted that the recommendations will reinforce current best practice. return to recommendations attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 53 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 53, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "review of medication and discontinuation recommendations 1. 10. 1 to 1. 10. 3 why the committee made the recommendations evidence identified concerns around lack of follow - up and the opportunity to review medication choices and this was supported by the committee ' s experience. they agreed that a yearly review with an adhd specialist should be a comprehensive assessment that revisits the areas discussed when starting treatment but also the effect of current treatment. this would ensure that decisions around continuing or stopping treatment are fully informed. limited evidence showed possible worsening of adhd symptoms on stopping medication but supported a reduction in adverse effects after withdrawal. the committee used their experience to make a recommendation on emphasising the importance of assessing the overall benefits and harms of medication as part of a review. the committee agreed that it was important to highlight the elements of a medication review that are important for someone with adhd ; they based the elements on evidence on adverse effects of medication, management of treatment, adherence and information and support. how the recommendations might affect practice the committee noted that the recommendations will reinforce current best practice. return to recommendations attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 54 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 54, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "putting this guideline into practice nice has produced tools and resources to help you put this guideline into practice. putting recommendations into practice can take time. how long may vary from guideline to guideline, and depends on how much change in practice or services is needed. implementing change is most effective when aligned with local priorities. changes recommended for clinical practice that can be done quickly – like changes in prescribing practice – should be shared quickly. this is because healthcare professionals should use guidelines to guide their work – as is required by professional regulating bodies such as the general medical and nursing and midwifery councils. changes should be implemented as soon as possible, unless there is a good reason for not doing so ( for example, if it would be better value for money if a package of recommendations were all implemented at once ). different organisations may need different approaches to implementation, depending on their size and function. sometimes individual practitioners may be able to respond to recommendations to improve their practice more quickly than large organisations. here are some pointers to help organisations put nice guidelines into practice :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 55, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "1. raise awareness through routine communication channels, such as email or", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 55, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "newsletters, regular meetings, internal staff briefings and other communications with all relevant partner organisations. identify things staff can include in their own practice straight away.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 55, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "2. identify a lead with an interest in the topic to champion the guideline and motivate", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 55, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "others to support its use and make service changes, and to find out any significant issues locally.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 55, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "3. carry out a baseline assessment against the recommendations to find out whether", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 55, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "there are gaps in current service provision.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 55, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "4. think about what data you need to measure improvement and plan how you will collect", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 55, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "it. you may want to work with other health and social care organisations and specialist attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 55 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 55, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "groups to compare current practice with the recommendations. this may also help identify local issues that will slow or prevent implementation.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 56, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "5. develop an action plan, with the steps needed to put the guideline into practice, and", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 56, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "make sure it is ready as soon as possible. big, complex changes may take longer to implement, but some may be quick and easy to do. an action plan will help in both cases.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 56, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "6. for very big changes include milestones and a business case, which will set out", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 56, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "additional costs, savings and possible areas for disinvestment. a small project group could develop the action plan. the group might include the guideline champion, a senior organisational sponsor, staff involved in the associated services, finance and information professionals.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 56, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "7. implement the action plan with oversight from the lead and the project group. big", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 56, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "projects may also need project management support.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 56, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "8. review and monitor how well the guideline is being implemented through the project", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 56, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "group. share progress with those involved in making improvements, as well as relevant boards and local partners. nice provides a comprehensive programme of support and resources to maximise uptake and use of evidence and guidance. see our into practice pages for more information. also see leng g, moore v, abraham s, editors ( 2014 ) achieving high quality care – practical experience from nice. chichester : wiley. attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 56 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 56, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "context attention deficit hyperactivity disorder ( adhd ) is a heterogeneous disorder characterised by the core symptoms of hyperactivity, impulsivity and inattention, which are judged excessive for the person ' s age or level of overall development. the diagnosis is made on the basis of observed and reported behavioural symptoms. two main diagnostic systems are in current use, the international classification of mental and behavioural disorders 10th revision ( icd - 10 ) and the diagnostic and statistical manual of mental disorders 5th edition ( dsm - 5 ). both systems require that symptoms are present in several settings such as school / work, home life and leisure activities. symptoms should be evident in early life, if only in retrospect ; for icd - 10, by age 7 years and for dsm - 5, by age 12 years. adhd may persist into adult life. prevalence rates for icd - 10 ( identifying hyperkinetic disorder ) are 1 to 2 % in childhood. under the previous, less stringent dsm - iv criteria, childhood prevalence rates were 3 to 9 % and these may increase under the new dsm - 5 criteria. the causes of adhd are not fully understood but a number of risk factors are associated with the condition. genetic factors can have an influence, with family members frequently affected. the diagnosis of adhd in older family members such as parents", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 57, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "- 5 criteria. the causes of adhd are not fully understood but a number of risk factors are associated with the condition. genetic factors can have an influence, with family members frequently affected. the diagnosis of adhd in older family members such as parents may have previously been missed and should be considered. both the icd - 10 and dsm - 5 require the presence of functional impairment due to symptoms of adhd, with the symptoms adversely affecting psychological, social and / or educational / occupational functioning. the impact of adhd may vary considerably in its severity, which is best judged by considering the level of impairment, pervasiveness, and familial and social context. for some people, symptoms may be limited to certain settings and cause minimal impairment in a limited number of domains ( for example, ability to complete schoolwork, work tasks, avoiding common hazards and forming positive interpersonal relationships ). in other people, multiple symptom areas ( hyperactivity, inattention and impulsivity ) are present in multiple settings, and this causes significant impairment across multiple domains. symptoms and impact can also change over time. for some people, symptoms and impairment may be reduced through environmental modifications, such as a modified school curriculum or choice of employment. symptoms of adhd can overlap with those of other related disorders. therefore, care in differential diagnosis is needed. adhd may also", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 57, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "some people, symptoms and impairment may be reduced through environmental modifications, such as a modified school curriculum or choice of employment. symptoms of adhd can overlap with those of other related disorders. therefore, care in differential diagnosis is needed. adhd may also coexist with other disorders. common attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 57 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 57, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "coexisting conditions in children include disorders of mood, conduct, learning, motor control, language and communication, and anxiety disorders ; in adults, they include personality disorders, bipolar disorder, obsessive - compulsive disorder and substance misuse. where there are coexisting conditions, it is important to try to differentiate the level of impairment due to adhd, because this will guide the treatment plan. in addition, adhd is under - recognised in some populations, which can mean that a lack of appropriate diagnosis and treatment adversely affects people ' s quality of life. the aim of this guideline is to raise awareness of populations at risk and to provide clear advice on managing adhd. the guideline covers children under 5 years, children and young people aged 5 to 17 years, and adults aged 18 years or over who are at risk of adhd or have a diagnosis of adhd. the guideline covers all primary, secondary and community care settings in which nhs - funded care is provided for people with adhd. attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 58 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 58, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "finding more information and committee details to find nice guidance on related topics, including guidance in development, see the nice topic page on mental health and behavioural conditions. for full details of the evidence and the guideline committee ' s discussions, see the evidence reviews. you can also find information about how the guideline was developed, including details of the committee. nice has produced tools and resources to help you put this guideline into practice. for general help and advice on putting nice guidelines into practice, see resources to help you put guidance into practice. attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 59 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 59, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "update information september 2019 : recommendation 1. 7. 4 was amended to indicate that an electrocardiogram is not needed before starting stimulants, atomoxetine or guanfacine if cardiovascular history and examination are normal and the person is not on medicine that poses an increased cardiovascular risk. the corresponding rationale section was also updated to reflect this change. this recommendation is marked [ 2018, amended 2019 ]. april 2018 : following publication, some amendments were made to recommendations 1. 5. 10, 1. 5. 12, 1. 5. 13, 1. 7. 4, 1. 7. 7 and 1. 8. 14 and the related rationale and impact sections to clarify their meaning. information about the marketing authorisation for methylphenidate was also added to recommendation 1. 7. 11. march 2018 : this guideline updates and replaces nice guideline cg72 ( published september 2008 ). new recommendations have been added on recognition, information and support, managing attention deficit hyperactivity disorder ( adhd ; including non - pharmacological treatment ), medication, follow - up and monitoring, adherence, and review of medication and discontinuation. these are marked as [ 2018 ]. we also made some changes without an evidence review :", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 60, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• we have clarified the names of services. • we have added cross - references to nice guidelines on transition from children ' s to", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 60, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "adults ' services and antisocial behaviour and conduct disorders in children and young people.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 60, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• we have clarified that any support for parents and carers before a formal diagnosis", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 60, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "should be group - based and adhd focused.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 60, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "• we have made changes to reflect the most recent version of dsm.", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 60, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "these are marked [ 2008, amended 2018 ]. attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 60 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 60, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "minor changes since publication may 2025 : we added a link to relevant diagnostics guidance in the section on diagnosis. january 2023 : we have updated recommendation 1. 2. 1 because adhd is now recognised as a neurodevelopmental disorder and recommendation 1. 3. 3 to update icd - 10 to icd - 11. march 2022 : we clarified that recommendation 1. 7. 22 only covers preparations of methylphenidate. isbn : 978 - 1 - 4731 - 2830 - 9 attention deficit hyperactivity disorder : diagnosis and management ( ng87 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 61 of 61", "metadata": {"doc_name": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933", "page": 61, "section": "NO_SECTION", "domain": "adhd", "doc_id": "attention-deficit-hyperactivity-disorder-diagnosis-and-management-pdf-1837699732933"}}
{"text": "autism spectrum disorder in adults : diagnosis and management clinical guideline published : 27 june 2012 last updated : 14 june 2021 www. nice. org. uk / guidance / cg142 © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ).", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 1, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "your responsibility the recommendations in this guideline represent the view of nice, arrived at after careful consideration of the evidence available. when exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. it is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian. all problems ( adverse events ) related to a medicine or medical device used for treatment or in a procedure should be reported to the medicines and healthcare products regulatory agency using the yellow card scheme. local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. they should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing nice recommendations wherever possible. autism spectrum disorder in adults : diagnosis and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 2, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "way that would be inconsistent with complying with those duties. commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing nice recommendations wherever possible. autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 2 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 2, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1 general principles of care.............................................................................................................. 10", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 3, "section": "1.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2 identification and assessment..................................................................................................... 16", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 3, "section": "1.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 3 identifying the correct interventions and monitoring their use................................................ 23", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 3, "section": "1.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4 interventions for autism................................................................................................................ 24", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 3, "section": "1.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 5 interventions for behaviour that challenges............................................................................... 28", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 3, "section": "1.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 6 interventions for coexisting mental disorders............................................................................ 31", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 3, "section": "1.6", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 7 assessment and interventions for families, partners and carers............................................. 32", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 3, "section": "1.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8 organisation and delivery of care................................................................................................ 33 terms used in this guideline............................................................................................................... 37 recommendations for research......................................................", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 3, "section": "1.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "........................................................................................... 40 1 facilitated self - help for anxiety and depression in autistic adults.............................................. 40 2 the structure and organisation of specialist teams..................................................................... 41 3 augmentative communication devices for autistic adults......................................", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 3, "section": "1.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "41 3 augmentative communication devices for autistic adults........................................................... 41 finding more information and committee details................................................................... 43 update information................................................................................................................... 44 autism spectrum disorder in adults : diagnosis and management ( cg142 ) ©", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 3, "section": "1.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "................................. 44 autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 3 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 3, "section": "1.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "this guideline is the basis of qs51. overview this guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder ( autism, asperger ' s syndrome and atypical autism ) in people aged 18 and over. it aims to improve access and engagement with interventions and services, and the experience of care, for people with autism. who is it for?", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 4, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• health and social care professionals ( including those in the independent sector ) • commissioners and providers • adults with autism and their families, partners and carers", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 4, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 4 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 4, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "introduction autism is a lifelong neurodevelopmental condition, the core features of which are persistent difficulties in social interaction and communication and the presence of stereotypic ( rigid and repetitive ) behaviours, resistance to change or restricted interests. the way that autism is expressed in individual people differs at different stages of life, in response to interventions, and with the presence of coexisting conditions such as learning disabilities ( also called ' intellectual disabilities ' ). autistic people also commonly experience difficulty with cognitive and behavioural flexibility, altered sensory sensitivity, sensory processing difficulties and emotional regulation difficulties. the features of autism may range from mild to severe and may fluctuate over time or in response to changes in circumstances. a significant proportion of autistic adults across the whole autistic spectrum experience social and economic exclusion. their condition is often overlooked by healthcare, education and social care professionals, which creates barriers to accessing the support and services they need to live independently. in addition, autistic people are more likely to have coexisting mental and physical disorders, and other developmental disorders. some may have contact with the criminal justice system, as either victims of crime or offenders, and it is important that their needs are recognised. there is wide variation in rates of identification and referral for diagnostic assessment, waiting times for diagnosis, models of multi - professional working, assessment criteria and diagnostic practice", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 5, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "as either victims of crime or offenders, and it is important that their needs are recognised. there is wide variation in rates of identification and referral for diagnostic assessment, waiting times for diagnosis, models of multi - professional working, assessment criteria and diagnostic practice for adults with features of autism. these factors contribute to delays in reaching a diagnosis and subsequent access to appropriate services. when the diagnostic assessment process works well, professionals, the autistic person and their family, partner or carer ( s ) communicate right from the start and the autistic person is involved in the decisions relating to their care. this lays the foundation for a long - term understanding between the autistic person, their family, partner or carer ( s ) and the professionals supporting their needs. however, many adults have difficulties accessing a diagnostic assessment. even if they manage to obtain a diagnosis they may receive no follow - up support because of the absence of appropriate services or an agreed care pathway. in this guideline ' autism ' refers to ' autism spectrum disorders ' encompassing autism, asperger ' s syndrome and atypical autism ( or pervasive developmental disorder not autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 5, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "not autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 5 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 5, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "otherwise specified ). the guideline development group recognises, however, that different individuals and groups prefer a variety of terms for autism including autistic spectrum condition, autistic spectrum difference and neurodiversity ( in recent department of health, national audit office and public accounts committee documents, ' autism ' is used to cover all of these terms ). this guideline covers the care provided by primary, community, secondary, tertiary and other health and social care professionals who have direct contact with, and make decisions concerning the care of, autistic adults. a number of recommendations in this guideline have been adapted from recommendations in other nice clinical guidelines. where this occurred, the guideline development group was careful to preserve the meaning and intent of the original recommendations. changes to wording or structure were made in order to fit the recommendations into this guideline. the guideline will assume that prescribers will use a drug ' s summary of product characteristics ( spc ) to inform decisions made with individual patients. in this guideline, recommendations are marked with a note if drugs do not have a uk marketing authorisation for the indication in question at the time of publication. prescribers should check each drug ' s spc for current licensed indications. autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 6, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "question at the time of publication. prescribers should check each drug ' s spc for current licensed indications. autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 6 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 6, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "key priorities for implementation the following recommendations have been identified as priorities for implementation. general principles of care", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 7, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• all staff working with autistic adults should :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 7, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "－ work in partnership with autistic adults and, where appropriate, with their families, partners or carers － offer support and care respectfully － take time to build a trusting, supportive, empathic and non - judgemental relationship as an essential part of care.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 7, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• in order to effectively provide care and support for autistic adults, the local autism", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 7, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "multi - agency strategy group should include representation from managers, commissioners and clinicians from adult services, including mental health, learning disability, primary healthcare, social care, housing, educational and employment services, the criminal justice system and the third sector. there should be meaningful representation from autistic people and their families, partners and carers. identification and assessment", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 7, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• consider assessment for possible autism when a person has :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 7, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "－ one or more of the following : [UNK] persistent difficulties in social interaction [UNK] persistent difficulties in social communication [UNK] stereotypic ( rigid and repetitive ) behaviours, resistance to change or restricted interests, and － one or more of the following : [UNK] problems in obtaining or sustaining employment or education autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 7 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 7, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "[UNK] difficulties in initiating or sustaining social relationships [UNK] previous or current contact with mental health or learning disability services [UNK] a history of a neurodevelopmental condition ( including learning disabilities and attention deficit hyperactivity disorder ) or mental disorder.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 8, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• for adults with possible autism who do not have a moderate or severe learning", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 8, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "disability, consider using the autism - spectrum quotient – 10 items ( aq - 10 ). ( if a person has reading difficulties, read out the aq - 10. ) if a person scores 6 or above on the aq - 10, or autism is suspected based on clinical judgement ( taking into account any past history provided by an informant ), offer a comprehensive assessment for autism.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 8, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• when assessing behaviour that challenges carry out a functional analysis ( see", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 8, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "recommendation 1. 5. 3 ) including identifying and evaluating any factors that may trigger or maintain the behaviour, such as : － physical disorders － the social environment ( including relationships with the family, partner, carer ( s ) and friends ) － the physical environment, including sensory factors － coexisting mental disorders ( including depression, anxiety disorders and psychosis ) － communication problems － changes to routine or personal circumstances. interventions for autism", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 8, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• for autistic adults without a learning disability or with a mild learning disability, who", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 8, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "are having difficulty obtaining or maintaining employment, consider an individual supported employment programme. organisation and delivery of care", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 8, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• autism strategy groups should be responsible for developing, managing and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 8, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 8 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 8, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "evaluating local care pathways. the group should appoint a lead professional responsible for the local autism care pathway. the aims of the strategy group should include : － developing clear policy and protocols for the operation of the pathway － ensuring the provision of multi - agency training about signs and features suggesting possible autism, and training and support on the operation of the pathway － making sure the relevant professionals ( health, social care, housing, educational and employment services and the third sector ) are aware of the local autism pathway and how to access services － supporting the integrated delivery of services across all care settings － supporting the smooth transition to adult services for young people going through the pathway － auditing and reviewing the performance of the pathway. autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 9 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 9, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1 general principles of care principles for working with autistic adults and their families, partners and carers", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 10, "section": "1.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 1 all staff working with autistic adults should :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 10, "section": "1.1.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• work in partnership with autistic adults and, where appropriate, with their", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 10, "section": "1.1.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "families, partners and carers", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 10, "section": "1.1.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• offer support and care respectfully • take time to build a trusting, supportive, empathic and non - judgemental", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 10, "section": "1.1.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "relationship as an essential part of care.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 10, "section": "1.1.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 2 all staff working with autistic adults should have an understanding of the :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 10, "section": "1.1.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• nature, development and course of autism • impact on personal, social, educational and occupational functioning", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 10, "section": "1.1.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 10 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 10, "section": "1.1.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 3 all health and social care professionals providing care and support for autistic adults should have a broad understanding of the :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• nature, development and course of autism • impact on personal, social, educational and occupational functioning • impact of and interaction with the social and physical environment • impact on and interaction with other coexisting mental and physical disorders", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "and their management", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• potential discrepancy between intellectual functioning as measured by iq and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "adaptive functioning as reflected, for example, by difficulties in planning and performing activities of daily living including education or employment.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 4 all health and social care professionals providing care and support for autistic adults should :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• aim to foster the person ' s autonomy, promote active participation in", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "decisions about care and support self - management", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• maintain continuity of individual relationships wherever possible • ensure that comprehensive information about the nature of, and interventions", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "and services for, their difficulties is available in an appropriate language or format ( including various visual, verbal and aural, easy read, and different colour and font formats )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• consider whether the person may benefit from access to a trained advocate.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 5 all health and social care professionals providing care and support for autistic adults and their families, partners and carers should :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• ensure that they are easily identifiable ( for example, by producing or wearing", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "appropriate identification ) and approachable", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• clearly communicate their role and function", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 11 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 11, "section": "1.1.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 6 all health and social care professionals providing care and support for autistic adults and their families, partners and carers should ensure that they are :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.6", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• familiar with recognised local and national sources ( organisations and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.6", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "websites ) of information and / or support for autistic people", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.6", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• able to discuss and advise on how to access and engage with these", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.6", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "resources.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.6", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 7 encourage autistic adults to participate in self - help or support groups or access one - to - one support, and provide support so that they can attend meetings and engage in the activities.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 8 in all settings, take into account the physical environment in which autistic adults are assessed, supported and cared for, including any factors that may trigger behaviour that challenges. if necessary make adjustments or adaptations to the :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• amount of personal space given ( at least an arm ' s length ) • setting using visual supports ( for example, use labels with words or symbols", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "to provide visual cues about expected behaviour )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• colour of walls and furnishings ( avoid patterns and use low - arousal colours", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "such as cream )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• lighting ( reduce fluorescent lighting, use blackout curtains or advise use of", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "dark glasses or increase natural light )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• noise levels ( reduce external sounds or advise use of earplugs or ear", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "defenders ). autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 12 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 12, "section": "1.1.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 9 all health and social care professionals providing care and support for autistic adults should :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 13, "section": "1.1.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• be aware of under - reporting and under - recognition of physical disorders in", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 13, "section": "1.1.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "autistic people", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 13, "section": "1.1.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• be vigilant for unusual likes and dislikes about food and / or lack of physical", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 13, "section": "1.1.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "activity", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 13, "section": "1.1.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• offer advice about the beneficial effects of a healthy diet and exercise, taking", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 13, "section": "1.1.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "into account any hyper - and / or hypo - sensory sensitivities ; if necessary, support referral to a gp or dietician.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 13, "section": "1.1.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 10 all staff working with autistic adults should be sensitive to issues of sexuality, including asexuality and the need to develop personal and sexual relationships. in particular, be aware that problems in social interaction and communication may lead to the autistic person misunderstanding another person ' s behaviour or to their possible exploitation by others.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 13, "section": "1.1.10", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 11 ensure that autistic adults who have caring responsibilities receive support to access the full range of mental and physical health and social care services, including :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 13, "section": "1.1.11", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• specific information, advice and support to parents about their parenting role,", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 13, "section": "1.1.11", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "including parent training if needed, by professionals experienced in the care of autistic adults and children", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 13, "section": "1.1.11", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• social support, such as childcare, to enable them to attend appointments,", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 13, "section": "1.1.11", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "groups and therapy sessions, and to access education and employment. autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 13 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 13, "section": "1.1.11", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 12 in order to effectively provide care and support for autistic adults, the local autism multi - agency strategy group should include representation from managers, commissioners and clinicians from adult services, including mental health, learning disability, primary healthcare, social care, housing, educational and employment services, the criminal justice system and the third sector. there should be meaningful representation from autistic people and their families, partners and carers.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 14, "section": "1.1.12", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 13 in each area a specialist community - based multidisciplinary team for autistic adults ( the specialist autism team ) should be established. the membership should include :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 14, "section": "1.1.13", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• psychologists with training and experience in working with autistic adults • nurses • occupational therapists • psychiatrists • social workers • speech and language therapists • support staff ( for example, staff supporting access to housing, educational", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 14, "section": "1.1.13", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "and employment services, financial advice, and personal and community safety skills ).", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 14, "section": "1.1.13", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 14 the specialist autism team should have a key role in the delivery and coordination of :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 14, "section": "1.1.14", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• specialist diagnostic and assessment services • specialist care and interventions • advice and training to other health and social care professionals on the", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 14, "section": "1.1.14", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "diagnosis, assessment, care and interventions for autistic adults ( as not all may be in the care of a specialist team ) autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 14 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 14, "section": "1.1.14", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 15 discuss with autistic adults if and how they want their families, partners or carers to be involved in their care. during discussions, take into account any implications of the mental capacity act ( 2005 ) and any communication needs the person may have ( see recommendation 1. 1. 5 ).", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 15, "section": "1.1.15", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 16 if the autistic person wants their family, partner or carer ( s ) to be involved, encourage this involvement and :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 15, "section": "1.1.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• negotiate between the autistic person and their family, partner or carer ( s )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 15, "section": "1.1.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "about confidentiality and sharing of information on an ongoing basis", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 15, "section": "1.1.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• explain how families, partners and carers can help support the autistic person", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 15, "section": "1.1.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "and help with care plans", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 15, "section": "1.1.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• make sure that no services are withdrawn because of involvement of the", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 15, "section": "1.1.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "family, partner or carer ( s ), unless this has been clearly agreed with both the autistic person and their family, partner or carer ( s ).", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 15, "section": "1.1.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 17 give all families, partners and carer ( s ) ( whether or not the person wants them to be involved in their care ) verbal and written information about :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 15, "section": "1.1.17", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• autism and its management • local support groups and services specifically for families, partners and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 15, "section": "1.1.17", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "carers autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 15 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 15, "section": "1.1.17", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 1. 18 if an autistic person does not want their family, partners or carer ( s ) to be involved in their care :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 16, "section": "1.1.18", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• give the family, partner or carer ( s ) verbal and written information about who", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 16, "section": "1.1.18", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "they can contact if they are concerned about the person ' s care", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 16, "section": "1.1.18", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• bear in mind that autistic people may be ambivalent or negative towards their", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 16, "section": "1.1.18", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "family or partner. this may be for many different reasons, including a coexisting mental disorder or prior experience of violence or abuse.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 16, "section": "1.1.18", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2 identification and assessment principles for the effective assessment of autism", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 16, "section": "1.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 1 staff who have responsibility for the identification or assessment of autistic adults should adapt these procedures, if necessary, to ensure their effective delivery, including modifications to the setting in which assessment is delivered ( see recommendation 1. 1. 8 ) and the duration and pacing of the assessment. identification and initial assessment of possible autism", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 16, "section": "1.2.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 2 consider assessment for possible autism when a person has :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 16, "section": "1.2.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• one or more of the following :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 16, "section": "1.2.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "－ persistent difficulties in social interaction － persistent difficulties in social communication － stereotypic ( rigid and repetitive ) behaviours, resistance to change or restricted interests, and autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 16 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 16, "section": "1.2.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 3 for adults with possible autism who do not have a moderate or severe learning disability, consider using the autism - spectrum quotient – 10 items ( aq - 10 ). ( if a person has reading difficulties, read out the aq - 10. ) if a person scores 6 or above on the aq - 10, or autism is suspected based on clinical judgement ( taking into account any past history provided by an informant ), offer a comprehensive assessment for autism. [ amended 2021 ]", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 17, "section": "1.2.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 4 for adults with possible autism who have a moderate or severe learning disability, consider a brief assessment to ascertain whether the following behaviours are present ( if necessary using information from a family member, partner or carer ) :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 17, "section": "1.2.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• difficulties in reciprocal social interaction including :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 17, "section": "1.2.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "－ limited interaction with others ( for example, being aloof, indifferent or unusual ) － interaction to fulfil needs only － interaction that is naive or one - sided", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 17, "section": "1.2.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• lack of responsiveness to others • little or no change in behaviour in response to different social situations • limited social demonstration of empathy • rigid routines and resistance to change", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 17, "section": "1.2.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 17 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 17, "section": "1.2.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 5 a comprehensive assessment should :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 18, "section": "1.2.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• be undertaken by professionals who are trained and competent • be team - based and draw on a range of professions and skills • where possible involve a family member, partner, carer or other informant or", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 18, "section": "1.2.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "use documentary evidence ( such as school reports ) of current and past behaviour and early development.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 18, "section": "1.2.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 6 at the beginning of a comprehensive assessment, discuss with the person the purpose of the assessment and how the outcome of the assessment will be fed back to them. feedback should be individualised, and consider involving a family member, partner, carer or advocate, where appropriate, to support the person and help explain the feedback.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 18, "section": "1.2.6", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 7 during a comprehensive assessment, enquire about and assess the following :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 18, "section": "1.2.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• core autism features ( difficulties in social interaction and communication and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 18, "section": "1.2.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "the presence of stereotypic behaviour, resistance to change or restricted interests ) that have been present in childhood and continuing into adulthood", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 18, "section": "1.2.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• early developmental history, where possible • behavioural problems • functioning at home, in education or in employment • past and current physical and mental disorders", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 18, "section": "1.2.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 18 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 18, "section": "1.2.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 8 to aid more complex diagnosis and assessment for adults, consider using a formal assessment tool, such as :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 19, "section": "1.2.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• the following tools for people who do not have a learning disability :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 19, "section": "1.2.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "－ the adult asperger assessment ( aaa ; includes the autism - spectrum quotient [ aq ] and the empathy quotient [ eq ] ) － the autism diagnostic interview – revised ( adi - r ) － the autism diagnostic observation schedule – generic ( ados - g ) － the asperger syndrome ( and high - functioning autism ) diagnostic interview ( asdi ) － the ritvo autism asperger diagnostic scale – revised ( raads - r )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 19, "section": "1.2.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• the following tools in particular for people with a learning disability :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 19, "section": "1.2.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "－ the ados - g － the adi - r.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 19, "section": "1.2.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 9 to organise and structure the process of a more complex assessment, consider using a formal assessment tool, such as the diagnostic interview for social and communication disorders ( disco ), the ados - g or the adi - r.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 19, "section": "1.2.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 10 during a comprehensive assessment, take into account and assess for possible differential diagnoses and coexisting disorders or conditions, such as :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 19, "section": "1.2.10", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• other neurodevelopmental conditions ( use formal assessment tools for", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 19, "section": "1.2.10", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "learning disabilities )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 19, "section": "1.2.10", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• mental disorders ( for example, schizophrenia, depression or other mood", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 19, "section": "1.2.10", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 19 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 19, "section": "1.2.10", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 11 do not use biological tests, genetic tests or neuroimaging for diagnostic purposes routinely as part of a comprehensive assessment.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 20, "section": "1.2.11", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 12 during a comprehensive assessment, assess the following risks :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 20, "section": "1.2.12", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• self - harm ( in particular in people with depression or a moderate or severe", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 20, "section": "1.2.12", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "learning disability )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 20, "section": "1.2.12", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• rapid escalation of problems • harm to others • self - neglect • breakdown of family or residential support • exploitation or abuse by others.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 20, "section": "1.2.12", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "develop a risk management plan if needed.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 20, "section": "1.2.12", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 13 develop a care plan based on the comprehensive assessment, incorporating the risk management plan and including any particular needs ( such as adaptations to the social or physical environment ), and also taking into account the needs of the family, partner or carer ( s ).", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 20, "section": "1.2.13", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 14 provide a ' health passport ' ( for example, a laminated card ) for autistic adults, which includes information for all staff about the person ' s care and support needs. advise the person to carry the health passport at all times. autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 20 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 20, "section": "1.2.14", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 15 as part of a comprehensive assessment consider developing a 24 - hour crisis management plan, where necessary in conjunction with specialist mental health services, which should detail :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.15", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• the likely trigger ( s ) for a crisis • the nature and speed of the reaction to any trigger ( s ), including details about", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.15", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "the way in which autism may impact on a person ' s behaviour leading up to and during a crisis", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.15", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• the role of the specialist team and other services ( including outreach and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.15", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "out - of - hours services ) in responding to a crisis", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.15", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• advice to primary care professionals and other services on their", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.15", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "responsibilities and appropriate management in a crisis", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.15", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• advice for families, partners and carers about their role in a crisis • the nature of any changes or adaptations to the social or physical", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.15", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "environment ( see recommendation 1. 1. 8 ) needed to manage a crisis.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.15", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 16 consider obtaining a second opinion ( including referral to another specialist autism team if necessary ), if there is uncertainty about the diagnosis or if any of the following apply after diagnostic assessment :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• disagreement about the diagnosis within the autism team • disagreement with the person, their family, partner, carer ( s ) or advocate", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "about the diagnosis", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• a lack of local expertise in the skills and competencies needed to reach", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "diagnosis in autistic adults", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• the person has a complex coexisting condition, such as a severe learning", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "disability, a severe behavioural, visual, hearing or motor problem, or a severe mental disorder.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 17 on an individual basis, and using information from the comprehensive assessment and physical examination, and clinical judgement, consider further investigations, including : autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 21 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 21, "section": "1.2.17", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 18 offer all adults who have received a diagnosis of autism ( irrespective of whether they need or have refused further care and support ) a follow - up appointment to discuss the implications of the diagnosis, any concerns they have about the diagnosis, and any future care and support they may require. assessment of behaviour that challenges", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 22, "section": "1.2.18", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 19 assessment of behaviour that challenges should be integrated into a comprehensive assessment for autistic adults.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 22, "section": "1.2.19", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 2. 20 when assessing behaviour that challenges carry out a functional analysis ( see recommendation 1. 5. 3 ) including identifying and evaluating any factors that may trigger or maintain the behaviour, such as :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 22, "section": "1.2.20", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• physical disorders • the social environment ( including relationships with family members,", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 22, "section": "1.2.20", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "partners, carers and friends )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 22, "section": "1.2.20", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• the physical environment, including sensory factors • coexisting mental disorders ( including depression, anxiety disorders and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 22, "section": "1.2.20", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "psychosis )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 22, "section": "1.2.20", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• communication problems", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 22, "section": "1.2.20", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 22 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 22, "section": "1.2.20", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 3 identifying the correct interventions and monitoring their use", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 3. 1 when discussing and deciding on interventions with autistic adults, consider :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• their experience of, and response to, previous interventions • the nature and severity of their autism • the extent of any associated functional impairment arising from the autism, a", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "learning disability or a mental or physical disorder", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• the presence of any social or personal factors that may have a role in the", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "development or maintenance of any identified problem ( s )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• the presence, nature, severity and duration of any coexisting disorders • the identification of predisposing and possible precipitating factors that could", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "lead to crises if not addressed.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 3. 2 when discussing and deciding on care and interventions with autistic adults, take into account the :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• increased propensity for elevated anxiety about decision - making in autistic", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "people", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• greater risk of altered sensitivity and unpredictable responses to medication • environment, for example whether it is suitably adapted for autistic people, in", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "particular those with hyper - and / or hypo - sensory sensitivities ( see recommendation 1. 1. 8 )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• presence and nature of hyper - and / or hypo - sensory sensitivities and how", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "these might impact on the delivery of the intervention", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• importance of predictability, clarity, structure and routine for autistic people", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 23 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 23, "section": "1.3.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 3. 3 when discussing and deciding on interventions with autistic adults, provide information about :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 24, "section": "1.3.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• the nature, content and duration of any proposed intervention • the acceptability and tolerability of any proposed intervention • possible interactions with any current interventions and possible side effects • the implications for the continuing provision of any current interventions.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 24, "section": "1.3.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 3. 4 when deciding on options for pharmacological interventions for behaviour that challenges or coexisting mental disorders in autistic adults :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 24, "section": "1.3.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• be aware of the potential for greater sensitivity to side effects and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 24, "section": "1.3.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "idiosyncratic responses in autistic people and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 24, "section": "1.3.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• consider starting with a low dose.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 24, "section": "1.3.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 3. 5 for any intervention used in autistic adults, there should be a regular review of :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 24, "section": "1.3.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• the benefits of the intervention, where feasible using a formal rating of the", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 24, "section": "1.3.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "target behaviour ( s )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 24, "section": "1.3.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• any adverse events • specific monitoring requirements of pharmacological interventions as", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 24, "section": "1.3.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "highlighted by the summary of product characteristics", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 24, "section": "1.3.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• adherence to the intervention.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 24, "section": "1.3.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4 interventions for autism psychosocial interventions for the core features of autism", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 24, "section": "1.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 1 for autistic adults without a learning disability or with a mild to moderate learning autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 24 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 24, "section": "1.4.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 2 social learning programmes to improve social interaction should typically include :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 25, "section": "1.4.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• modelling • peer feedback ( for group - based programmes ) or individual feedback ( for", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 25, "section": "1.4.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "individually delivered programmes )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 25, "section": "1.4.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• discussion and decision - making • explicit rules • suggested strategies for dealing with socially difficult situations.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 25, "section": "1.4.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 3 do not provide facilitated communication for autistic adults. psychosocial interventions focused on life skills", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 25, "section": "1.4.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 4 for autistic adults of all ranges of intellectual ability, who need help with activities of daily living, consider a structured and predictable training programme based on behavioural principles.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 25, "section": "1.4.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 5 for autistic adults without a learning disability or with a mild to moderate learning disability, who are socially isolated or have restricted social contact, consider :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 25, "section": "1.4.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• a group - based structured leisure activity programme • an individually delivered structured leisure activity programme for people who", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 25, "section": "1.4.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "find group - based activities difficult.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 25, "section": "1.4.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 6 a structured leisure activity programme should typically include : autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 25 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 25, "section": "1.4.6", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 7 for autistic adults without a learning disability or with a mild to moderate learning disability, who have problems with anger and aggression, offer an anger management intervention, adjusted to the needs of autistic adults.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 26, "section": "1.4.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 8 anger management interventions should typically include :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 26, "section": "1.4.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• functional analysis of anger and anger - provoking situations • coping - skills training and behaviour rehearsal • relaxation training • development of problem - solving skills.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 26, "section": "1.4.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 9 for autistic adults without a learning disability or with a mild learning disability, who are at risk of victimisation, consider anti - victimisation interventions based on teaching decision - making and problem - solving skills.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 26, "section": "1.4.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 10 anti - victimisation interventions should typically include :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 26, "section": "1.4.10", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• identifying and, where possible, modifying and developing decision - making", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 26, "section": "1.4.10", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "skills in situations associated with abuse", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 26, "section": "1.4.10", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• developing personal safety skills.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 26, "section": "1.4.10", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 11 for autistic adults without a learning disability or with a mild learning disability, who are having difficulty obtaining or maintaining employment, consider an individual supported employment programme.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 26, "section": "1.4.11", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 12 an individual supported employment programme should typically include : autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 26 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 26, "section": "1.4.12", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 13 do not use anticonvulsants for the management of core features of autism in adults.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 27, "section": "1.4.13", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 14 do not use chelation for the management of core features of autism in adults.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 27, "section": "1.4.14", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 15 do not use the following interventions for the management of core features of autism in adults :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 27, "section": "1.4.15", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• exclusion diets ( such as gluten - or casein - free and ketogenic diets ) • vitamins, minerals and dietary supplements ( such as vitamin b6 or iron", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 27, "section": "1.4.15", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "supplementation ).", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 27, "section": "1.4.15", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 16 do not use drugs specifically designed to improve cognitive functioning ( for example, cholinesterase inhibitors ) for the management of core features of autism or routinely for associated cognitive or behavioural problems in adults.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 27, "section": "1.4.16", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 17 do not use oxytocin for the management of core features of autism in adults.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 27, "section": "1.4.17", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 18 do not use secretin for the management of core features of autism in adults.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 27, "section": "1.4.18", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 19 do not use testosterone regulation for the management of core features of autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 27 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 27, "section": "1.4.19", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 20 do not use hyperbaric oxygen therapy for the management of core features of autism in adults.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 28, "section": "1.4.20", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 21 do not use antipsychotic medication for the management of core features of autism in adults.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 28, "section": "1.4.21", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 4. 22 do not use antidepressant medication for the routine management of core features of autism in adults.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 28, "section": "1.4.22", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 5 interventions for behaviour that challenges", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 28, "section": "1.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 5. 1 before initiating other interventions for behaviour that challenges, address any identified factors that may trigger or maintain the behaviour ( see recommendation 1. 2. 20 ) by offering :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 28, "section": "1.5.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• the appropriate care for physical disorders ( for example, gastrointestinal", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 28, "section": "1.5.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "problems or chronic pain )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 28, "section": "1.5.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• treatment for any coexisting mental disorders, including psychological and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 28, "section": "1.5.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "pharmacological interventions ( for example, anxiolytic, antidepressant or antipsychotic medication ), informed by existing nice guidance", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 28, "section": "1.5.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• interventions aimed at changing the physical or social environment ( for", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 28, "section": "1.5.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "example, who the person lives with ) when problems are identified, such as : － advice to the family, partner or carer ( s ) － changes or accommodations to the physical environment ( see recommendation 1. 1. 8 ).", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 28, "section": "1.5.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 5. 2 first offer a psychosocial intervention for the behaviour that challenges if no coexisting mental or physical disorder, or problem related to the physical or social environment, has been identified as triggering or maintaining behaviour that challenges. autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 28 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 28, "section": "1.5.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 5. 3 when deciding on the nature and content of a psychosocial intervention to address behaviour that challenges, use a functional analysis. the functional analysis should facilitate the targeting of interventions that address the function ( s ) of problem behaviour ( s ) by :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 29, "section": "1.5.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• providing information, from a range of environments, on :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 29, "section": "1.5.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "－ factors that appear to trigger the behaviour － the consequences of the behaviour ( that is, the reinforcement received as a result of their behaviour )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 29, "section": "1.5.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• identifying trends in behaviour occurrence, factors that may be evoking that", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 29, "section": "1.5.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "behaviour, and the needs that the person is attempting to meet by performing the behaviour.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 29, "section": "1.5.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 5. 4 in addition to the functional analysis, base the choice of intervention ( s ) on :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 29, "section": "1.5.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• the nature and severity of the behaviour • the person ' s physical needs and capabilities • the physical and social environment • the capacity of staff and families, partners or carers to provide support • the preferences of the autistic person and, where appropriate, their family,", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 29, "section": "1.5.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "partner or carer ( s )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 29, "section": "1.5.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• past history of care and support.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 29, "section": "1.5.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "psychosocial interventions for behaviour that challenges", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 29, "section": "1.5.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 5. 5 psychosocial interventions for behaviour that challenges should be based on behavioural principles and informed by a functional analysis of behaviour ( see recommendation 1. 5. 3 ).", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 29, "section": "1.5.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 5. 6 psychosocial interventions for behaviour that challenges should include :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 29, "section": "1.5.6", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• clearly identified target behaviour ( s )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 29, "section": "1.5.6", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 29 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 29, "section": "1.5.6", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 5. 7 consider antipsychotic medication in conjunction with a psychosocial intervention for behaviour that challenges when there has been no or limited response to psychosocial or other interventions ( such as environmental adaptations ). antipsychotic medication should be prescribed by a specialist and quality of life outcomes monitored carefully. review the effects of the medication after 3 – 4 weeks and discontinue it if there is no indication of a clinically important response at 6 weeks. in june 2012 this was an off - label use of antipsychotic medication. see nice ' s information on prescribing medicines. pharmacological interventions for behaviour that challenges", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 30, "section": "1.5.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 5. 8 consider antipsychotic medication alone for behaviour that challenges when psychosocial or other interventions could not be delivered because of the severity of the behaviour that challenges. antipsychotic medication should be prescribed by a specialist and quality of life outcomes monitored carefully. review the effects of the medication after 3 – 4 weeks and discontinue it if there is autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 30 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 30, "section": "1.5.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 5. 9 do not routinely use anticonvulsants for the management of behaviour that challenges in autistic adults.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.5.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 6 interventions for coexisting mental disorders", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.6", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 6. 1 staff delivering interventions for coexisting mental disorders to autistic adults should :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.6.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• have an understanding of the core features of autism and their possible", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.6.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "impact on the treatment of coexisting mental disorders", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.6.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• consider seeking advice from a specialist autism team regarding delivering", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.6.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "and adapting these interventions for autistic people. psychosocial interventions for coexisting mental disorders", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.6.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 6. 2 for autistic adults and coexisting mental disorders, offer psychosocial interventions informed by existing nice guidance for the specific disorder.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.6.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 6. 3 adaptations to the method of delivery of cognitive and behavioural interventions for autistic adults and coexisting common mental disorders should include :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.6.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• a more concrete and structured approach with a greater use of written and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.6.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "visual information ( which may include worksheets, thought bubbles, images and ' tool boxes ' )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.6.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• placing greater emphasis on changing behaviour, rather than cognitions, and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.6.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "using the behaviour as the starting point for intervention", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.6.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• making rules explicit and explaining their context • using plain english and avoiding excessive use of metaphor, ambiguity and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.6.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 31 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 31, "section": "1.6.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 6. 4 for autistic adults and coexisting mental disorders, offer pharmacological interventions informed by existing nice guidance for the specific disorder.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 32, "section": "1.6.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 7 assessment and interventions for families, partners and carers", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 32, "section": "1.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 7. 1 offer families, partners and carers of autistic adults an assessment of their own needs ( see the nice guideline on supporting adult carers for recommendations on identifying, assessing and meeting the caring, physical and mental health needs of families, partners and carers ).", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 32, "section": "1.7.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 7. 2 when the needs of families, partners and carers have been identified, provide information about, and facilitate contact with, a range of support groups including those specifically designed to address the needs of families, partners and carers of autistic people. see the nice guideline on supporting adult carers.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 32, "section": "1.7.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 7. 3 offer information, advice, training and support to families, partners and carers if they :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 32, "section": "1.7.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• need help with the personal, social or emotional care of the family member,", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 32, "section": "1.7.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "partner or friend or", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 32, "section": "1.7.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• are involved in supporting the delivery of an intervention for their family", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 32, "section": "1.7.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "member, partner or friend ( in collaboration with professionals ). autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 32 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 32, "section": "1.7.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8 organisation and delivery of care developing local care pathways", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8. 1 local care pathways should be developed to promote implementation of key principles of good care. pathways should be :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• negotiable, workable and understandable for autistic adults, their families,", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "partners and carers, and professionals", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• accessible and acceptable to all people in need of the services served by the", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "pathway", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• responsive to the needs of autistic adults and their families, partners and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "carers", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• integrated so that there are no barriers to movement between different levels", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "of the pathway", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• outcome focused ( including measures of quality, service user experience and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "harm ).", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.1", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8. 2 autism strategy groups should be responsible for developing, managing and evaluating local care pathways. the group should appoint a lead professional responsible for the local autism care pathway. the aims of the strategy group should include :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• developing clear policy and protocols for the operation of the pathway • ensuring the provision of multi - agency training about features of autism, and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "training and support on the operation of the pathway", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• making sure the relevant professionals ( health, social care, housing,", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "educational and employment services and the third sector ) are aware of the local autism pathway and how to access services", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• supporting the integrated delivery of services across all care settings • supporting the smooth transition to adult services for young people going", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "through the pathway autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 33 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 33, "section": "1.8.2", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8. 3 the autism strategy group should develop local care pathways that promote access to services for all autistic adults, including :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 34, "section": "1.8.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• people with coexisting physical and mental disorders ( including substance", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 34, "section": "1.8.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "misuse )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 34, "section": "1.8.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• women • people with learning disabilities • older people • people from black and minority ethnic groups • transgender people • homeless people • people from the traveller community • people in the criminal justice system • autistic parents.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 34, "section": "1.8.3", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8. 4 when providing information about local care pathways to autistic adults and their families, partners and carers, all professionals should :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 34, "section": "1.8.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• take into account the person ' s knowledge and understanding of autism and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 34, "section": "1.8.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "its care and management", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 34, "section": "1.8.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• ensure that such information is appropriate to the communities using the", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 34, "section": "1.8.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "pathway.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 34, "section": "1.8.4", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8. 5 the autism strategy group should design local care pathways that promote a range of evidence - based interventions at each step in the pathway and support autistic adults in their choice of interventions.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 34, "section": "1.8.5", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8. 6 the autism strategy group should design local care pathways that respond promptly and effectively to the changing needs of all populations served by the autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 34 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 34, "section": "1.8.6", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8. 7 the autism strategy group should design local care pathways that provide an integrated programme of care across all care settings. pathways should :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 35, "section": "1.8.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• minimise the need for transition between different services or providers • allow services to be built around the pathway and not the pathway around", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 35, "section": "1.8.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "the services", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 35, "section": "1.8.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• establish clear links ( including access and entry points ) to other care", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 35, "section": "1.8.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "pathways ( including those for physical healthcare needs )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 35, "section": "1.8.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• have designated staff who are responsible for the coordination of people ' s", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 35, "section": "1.8.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "engagement with the pathway. improving access to care", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 35, "section": "1.8.7", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8. 8 there should be a single point of referral ( including self - referral ) to specialist services for autistic adults.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 35, "section": "1.8.8", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8. 9 support access to services and increase the uptake of interventions by :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 35, "section": "1.8.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• delivering assessment and interventions in a physical environment that is", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 35, "section": "1.8.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "appropriate for people with hyper - and / or hypo - sensory sensitivities ( see recommendation 1. 1. 8 )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 35, "section": "1.8.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• changing the professional responsible for the person ' s care if a supportive", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 35, "section": "1.8.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "and caring relationship cannot be established.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 35, "section": "1.8.9", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8. 10 support access to services and increase the uptake of interventions by : autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 35 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 35, "section": "1.8.10", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8. 11 if residential care is needed for autistic adults it should usually be provided in small, local community - based units ( of no more than six people and with well - supported single person accommodation ). the environment should be structured to support and maintain a collaborative approach between the autistic person and their family, partner or carer ( s ) for the development and maintenance of interpersonal and community living skills.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 36, "section": "1.8.11", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8. 12 residential care environments should include activities that are :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 36, "section": "1.8.12", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• structured and purposeful • designed to promote integration with the local community and use of local", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 36, "section": "1.8.12", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "amenities", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 36, "section": "1.8.12", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• clearly timetabled with daily, weekly and sequential programmes that", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 36, "section": "1.8.12", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "promote choice and autonomy.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 36, "section": "1.8.12", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8. 13 residential care environments should have :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 36, "section": "1.8.13", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• designated areas for different activities that provide visual cues about", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 36, "section": "1.8.13", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "expected behaviour", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 36, "section": "1.8.13", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• adaptations to the physical environment for people with hyper - and / or hypo -", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 36, "section": "1.8.13", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "sensory sensitivities ( see recommendation 1. 1. 8 )", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 36, "section": "1.8.13", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• inside and outside spaces where the autistic person can be alone ( for", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 36, "section": "1.8.13", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "example, if they are over - stimulated ). autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 36 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 36, "section": "1.8.13", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "1. 8. 14 residential care staff should :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 37, "section": "1.8.14", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• understand the principles and attitudes underpinning the effective delivery of", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 37, "section": "1.8.14", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "residential care for autistic adults", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 37, "section": "1.8.14", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• work in collaboration with health and community care staff from a range of", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 37, "section": "1.8.14", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "specialist services to support the delivery of a comprehensive care plan", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 37, "section": "1.8.14", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• be trained in assessing and supporting the needs of autistic adults • be consistent and predictable, but with some flexibility to allow change and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 37, "section": "1.8.14", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "choice", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 37, "section": "1.8.14", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• be committed to involving families, partners and carers.", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 37, "section": "1.8.14", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "terms used in this guideline this section defines terms that have been used in a particular way for this guideline. augmentative communication an alternative way of helping people with communication difficulties by using assistive technology such as computers or other devices, such as a speech output device. behavioural principles ideas, such as reinforcement and function of behaviour, that underlie behavioural therapies and underpin many interventions teaching adaptive skills for community living for autistic people, including those with behaviour that challenges. behaviour that challenges a term used to describe behaviour that is a result of the interaction between individual and environmental factors, and includes stereotypic behaviour ( such as rocking or hand flapping ), anger, aggression, self - injury, and disruptive or destructive behaviour. such behaviour is seen as challenging when it affects the person ' s or other people ' s quality of life and or jeopardises their safety. autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 37 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 37, "section": "1.8.14", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "care pathway a system designed to improve the overall quality of healthcare by standardising the care process and promoting organised efficient service user care based on best evidence to optimise service user outcomes. chelation a procedure that involves using one or more substances ( chelating agents ) to remove materials that are toxic, including heavy metals such as mercury, from the body. easy read an accessible format for written communication designed for people with a learning disability. it uses simple jargon - free language, short sentences and illustrations. facilitated communication a therapeutic intervention whereby a facilitator supports the hand or arm of an autistic person while using a keyboard or other devices with the aim of helping the person to develop pointing skills and to communicate. functional analysis a method for understanding the causes and consequences of behaviour and its relationship to particular stimuli, and the function of the behaviour. the function of a particular behaviour can be analysed by typically identifying ( 1 ) the precursor or trigger of the behaviour, ( 2 ) the behaviour itself, and ( 3 ) the consequence of the behaviour. hyper - and hypo - sensory sensitivities being over - sensitive ( hyper - sensitive ) or under - sensitive ( hypo - sensitive ) to sound, light, colour, smell or taste, which can cause anxiety or even pain in an autistic person. informant a family member, partner, carer or", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 38, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "hyper - sensitive ) or under - sensitive ( hypo - sensitive ) to sound, light, colour, smell or taste, which can cause anxiety or even pain in an autistic person. informant a family member, partner, carer or other third party known to the autistic person who is autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 38 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 38, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "able to provide information about the person ' s features and behaviour so that professionals can have a fuller picture of the person ' s developmental history. some assessment tools for autism require information from informants. learning disability lower intellectual ability ( usually defined as an iq of less than 70 ) that leads to problems in learning, developing new skills, communication and carrying out daily activities. learning disability severities are defined by the following iq scores : mild = 50 – 69, moderate = 35 – 49 and severe = 20 – 34. a person with a mild to moderate learning disability may only need support in certain areas. however, a person with a moderate to severe learning disability may have no speech or limited communication, a significantly reduced ability to learn new skills and require support with daily activities such as dressing and eating. learning disabilities are different from ' learning difficulties ', like dyslexia, which do not affect intellect. learning disability is sometimes also called ' intellectual disability '. modelling a technique used in behavioural therapy that utilises video and other media. the service user observes target behaviour on the video or computer screen, and repeats it. reinforcement a technique used in behavioural therapy to teach ' rules ' of social engagement through providing prompts for behaviour. reinforcement may be by the autistic person or those working with or caring for them. autism spectrum disorder in adults : diagnosis and management ( cg", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 39, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "used in behavioural therapy to teach ' rules ' of social engagement through providing prompts for behaviour. reinforcement may be by the autistic person or those working with or caring for them. autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 39 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 39, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "recommendations for research the guideline development group has made the following recommendations for research, based on its review of evidence, to improve nice guidance and patient care in the future. the guideline development group ' s full set of recommendations for research is detailed in the full guideline. 1 facilitated self - help for anxiety and depression in autistic adults what is the clinical and cost effectiveness of facilitated self - help for the treatment of mild anxiety and depressive disorders in autistic adults? why this is important anxiety and depressive disorders commonly coexist in autistic people and are associated with poorer health outcomes and quality of life. this may occur because of the direct impact of the anxiety or depression but also because of a negative interaction with the core features of autism. there is limited access and poor uptake of facilitated self - help by autistic people, largely due to limited availability but also because current systems for the delivery of such interventions are not adapted for use by autistic people. in adults without autism, facilitated self - help is an effective intervention for mild to moderate depression and anxiety. the development of novel methods for the delivery of facilitated self - help could make effective interventions available to a wider group of people. the suggested programme of research would need to : ( a ) develop current methods for the delivery of self - help measures to take into account the impact of autism and possibly include", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 40, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "facilitated self - help could make effective interventions available to a wider group of people. the suggested programme of research would need to : ( a ) develop current methods for the delivery of self - help measures to take into account the impact of autism and possibly include developments in the nature of the materials, the methods for their delivery and the nature, duration and extent of their facilitation ; ( b ) test the feasibility of the novel methods in a series of pilot studies ; and ( c ) formally evaluate the outcomes ( including symptoms, satisfaction and quality of life ) in a large - scale randomised trial. autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 40 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 40, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "2 the structure and organisation of specialist teams what structure and organisation of specialist autism teams are associated with improvements in care for autistic people? why this is important the department of health ' s autism strategy ( 2010 ) proposes the introduction of a range of specialist services for autistic people ; these will usually be built around specialist autism teams. however, there is little evidence to guide the establishment and development of these teams. there is uncertainty about the precise nature of the population to be served ( all autistic people or only those who have an iq of 70 or above ), the composition of the team, the extent of the team ' s role ( for example, diagnosis and assessment only, a primarily advisory role or a substantial care coordination role ), the interventions provided by the team, and the team ' s role and relationship with regard to non - statutory care providers. therefore it is likely that in the near future a number of different models will be developed, which are likely to have varying degrees of success in meeting the needs of autistic people. given the significant expansion of services, this presents an opportunity for a large - scale observational study, which should provide important information on the characteristics of teams associated with positive outcomes for autistic people in terms of access to services and effective coordination of care. 3 augmentative communication devices for autistic adults what is the clinical and cost", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 41, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "study, which should provide important information on the characteristics of teams associated with positive outcomes for autistic people in terms of access to services and effective coordination of care. 3 augmentative communication devices for autistic adults what is the clinical and cost effectiveness of augmentative communication devices for autistic adults? why this is important many autistic people experience significant communication problems ( for example, the absence of any spoken language or significant deficits in interpersonal skills ), which have a profound effect on their ability to lead a full and rewarding life. it is probable that these problems are related to the core features of autism and are likely to persist for most people given the life - long course of autism and the lack of effective interventions for these autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 41 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 41, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "core features. a number of communication devices have been developed for autism but few, if any, have been subjected to a proper evaluation in adults. despite this lack of formal evaluation, individual services have made considerable investments in augmentative communication devices. research that provides high - quality evidence on the acceptability and the clinical and cost effectiveness of augmentative communication devices could bring about significant improvements in the lives of autistic adults. the suggested programme of research would need to identify current devices for which there is : ( a ) some evidence of benefit ( for example, case series and small - scale pilot studies ) ; ( b ) some evidence that it meets a key communication need for autistic people ( based on reviews of people ' s need in this area ) ; and ( c ) indication that the device is feasible for routine use. the identified device ( s ) should then be formally evaluated in a large - scale randomised trial. autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 42 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 42, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "finding more information and committee details to find nice guidance on related topics, including guidance in development, see the nice topic page on autism. for full details of the evidence and the guideline committee ' s discussions, see the full guideline. you can also find information about how the guideline was developed, including details of the committee. nice has produced tools and resources to help you put this guideline into practice. for general help and advice on putting nice guidelines into practice, see resources to help you put guidance into practice. autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 43 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 43, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "update information june 2021 : we amended recommendation 1. 2. 3 to clarify that when the autism - spectrum quotient – 10 items ( aq - 10 ) is used to assess for possible autism, the score at which the person should be offered a comprehensive assessment is 6 or above. throughout the guideline we changed ' people with autism ' to ' autistic people ', ' challenging behaviour ' to ' behaviour that challenges ', and ' symptoms ' to ' features ' to align with current terminology. august 2016 : the following recommendations for research have been removed :", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 44, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• what is the clinical and cost effectiveness of cbt for the treatment of moderate and", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 44, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "severe anxiety disorders in autistic adults?", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 44, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "• what is the clinical and cost effectiveness of selective serotonin reuptake inhibitors", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 44, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "( ssris ) for the treatment of moderate and severe depression in autistic adults? minor changes since publication january 2023 : we have updated the link to the autism - spectrum quotient – 10 items ( aq - 10 ) tool. march 2022 : we have changed the description of psychologists in recommendation 1. 1. 13, in line with current practice and the british psychological society ' s best practice in psychology recruitment. july 2020 : we linked to the nice guideline on supporting adult carers in recommendations 1. 1. 17, 1. 7. 1 and 1. 7. 2. october 2015 : title changed from ' autism : recognition, referral, diagnosis and management of adults on the autism spectrum ' to ' autism spectrum disorder in adults : diagnosis and management ', for clarity and consistency with other guidance on this topic. isbn : 978 - 1 - 4731 - 2039 - 6 autism spectrum disorder in adults : diagnosis and management ( cg142 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 44 of 44", "metadata": {"doc_name": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909", "page": 44, "section": "NO_SECTION", "domain": "autism", "doc_id": "autism-spectrum-disorder-in-adults-diagnosis-and-management-pdf-35109567475909"}}
{"text": "implementing the early intervention in psychosis access and waiting time standard", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 1, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "version 3, 16 february 2023", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 1, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "all significant changes – excluding the foreword – from the previous edition of this guidance ( version 2, published december 2020 ) have been highlighted in yellow. classification : official publication reference : pr1954", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 1, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "1. 1 document purpose....................................................................................... 8", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "1.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "1. 2 the early intervention in psychosis access and waiting time standard........ 9", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "1.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "1. 3 expectations of commissioners and providers............................................. 9", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "1.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. what is first episode psychosis and why is rapid access to effective", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "1.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "treatment so important?................................................................................ 11", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "1.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 1 experiences of first episode psychosis : a service user and carer perspective...................................................................................................... 11", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 2 expectations of commissioners and providers........................................... 12", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 3 how common is first episode psychosis?.................................................. 13", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 4 what is the impact of not having timely access to effective treatment?..... 14", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 5 what are the benefits / impact of having timely access to effective treatment?........................................................................................................ 15", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.5", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 6 what is an eip service?............................................................................. 16", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.6", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 7 relevant nice guidelines and quality standards....................................... 17", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.7", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 8 other key functions of eip services........................................................... 20", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.8", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 8. 1 supporting identification of psychosis and rapid referral.................................. 20", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.8.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 8. 2 recognising and addressing co - existing health problems............................... 22", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.8.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 8. 3 support with social issues............................................................................... 23", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.8.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 8. 4 families and carers......................................................................................... 23", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.8.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 9 the eip workforce..................................................................................... 25", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.9", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 9. 1 other staffing.................................................................................................. 29", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.9.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 10 a service user perspective....................................................................... 29", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.10", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 11 eip service models.................................................................................. 30", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.11", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 12 at - risk mental state.................................................................................. 33", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.12", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. the access and waiting time standard...................................................... 37", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "2.12", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 1 requirements of the standard.................................................................... 37", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "3.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 2 measuring and reporting performance against the referral to treatment ( rtt ) waiting time requirement........................................................................ 38", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "3.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 2. 1 measuring the clock start : referral, recognition and initial assessment............ 38", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "3.2.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 2. 2 measuring the clock stop : start of treatment.................................................... 42", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 2, "section": "3.2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 2. 3 reporting performance against the referral to treatment ( rtt ) waiting time requirement............................................................................................................. 44", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 3, "section": "3.2.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 3 measuring and reporting performance against the requirement that the treatment accessed is in line with nice recommendations............................. 45", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 3, "section": "3.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 3. 1 what is nice - recommended treatment?......................................................... 45", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 3, "section": "3.3.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 3. 2 reporting nice - recommended interventions using snomed - ct codes........ 46", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 3, "section": "3.3.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 3. 3 national clinical audit of psychosis................................................................ 46", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 3, "section": "3.3.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 4 routine collection of outcomes data.......................................................... 47", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 3, "section": "3.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "4. key commissioning and service development considerations.................. 50", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 3, "section": "3.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "appendix 1 : expert reference group membership...................................... 56 special acknowledgments....................................................................................... 58 appendix 2 : expert reference group 2020 refresh membership................. 60 appendix 3 : essential components of a nice - approved care package........ 62 appendix 4 : the full referral to treatment pathway....................................... 69 references.......................................", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 3, "section": "3.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "......... 69 references.................................................................................................... 70", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 3, "section": "3.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 4, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "foreword in 2016 i wrote the foreword for the original version of this guidance document. the 2016 version of implementing the early intervention in psychosis access and waiting time standard : guidance acknowledged the success of early intervention in psychosis ( eip ) services at improving service users ’ outcomes and experience and ushered in one of the first waiting time standards for mental health in the nhs ’ s history. importantly, as well as timely access, this standard also carried an expectation that service users should have access to the full range of nice recommended treatments once they were in the service. in that foreword i talked about parity of esteem and the clear need for more investment into mental health services. with the publication of the nhs long term plan we are further along in that mission to have parity for mental health services with a commitment of a ringfenced local investment fund worth at least £2. 3 billion a year in real terms by 2023 / 24 to ensure that the nhs provides high quality, evidence - based mental health services. the nhs long term plan reconfirmed the nhs ’ s commitment to the eip access and waiting time standard that 60 % of people with a first episode of psychosis should start treatment within two weeks of referral and receive a high quality nice recommended care package. the nhs long term plan also highlighted that eip teams should provide care to people aged 14 - 65 years and support those at high", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 4, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "first episode of psychosis should start treatment within two weeks of referral and receive a high quality nice recommended care package. the nhs long term plan also highlighted that eip teams should provide care to people aged 14 - 65 years and support those at high risk of developing psychosis. these commitments sit within wider transformation work to improve england ’ s community mental health services and crisis services. eip services now form a key part of a rapidly transforming mental health offer. this updated guidance document is the work of a group of service users, carers, clinicians and commissioners, and provides further clarity on our nhs long term plan. it is updated with more recent evidence and research and also provides more detail on the type of care that children and young people and those most at risk of developing psychosis should receive from eip services. this guidance remains focused on supporting commissioners to invest in and deliver world class eip services. since 2016, eip services have made huge improvements in the quality and timeliness of care. from may 2021 to may 2022, eip services nationally saw nearly 34, 000 new referrals and have continued to meet and exceed the national waiting", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 4, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "4 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 5, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "time standard. there have been continued improvements in the percentage of people receiving psychological interventions – such as cbt for psychosis and family intervention – and 2021 / 22 data shows marked improvements in the percentage of people receiving physical health interventions and employment support, and an increase in service user outcomes being measured. while we have seen significant improvement, we continue on the journey to improve mental health services and support the establishment of world class early intervention services. so much progress has been made at a time when the pandemic has made the provision of high - quality care particularly challenging but all the more critical. i want to thank eip services for all their incredible work and dedication to date and icbs for their support for these critical services going forward. professor tim kendall national clinical director for mental health", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 5, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "5 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 6, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "key messages", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 6, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "1. psychosis is characterised by hallucinations, delusions and affects the", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 6, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "perception of reality, with the potential to cause considerable distress and disability for the person and their family or carers. a diagnosis of schizophrenia, bipolar disorder, psychotic depression or other less common psychotic disorder will usually be made, although it can take months or even years for a final diagnosis.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 6, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. treatment can begin as soon as a first episode of psychosis has been", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 6, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "identified – it does not have to wait for a final diagnosis and services are encouraged to embrace diagnostic uncertainty. treatment should be provided by a service capable of providing a full and effective early intervention in psychosis ( eip ) package of national institute for health and care excellence ( nice ) - recommended care, normally a specialist eip team. these services are evidence - based, cost - saving and preferred by service users and carers over generic services. services should ensure there is a competent skill mix to provide necessary care and support to people experiencing first episode psychosis of all - ages, including children and young people.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 6, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. people who experience psychosis can and do recover. the time from onset of", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 6, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "psychosis to the provision of evidence - based treatment has a significant influence on long - term outcomes. the sooner treatment is started the better the outcome and the lower the overall cost of care.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 6, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "4. the short and longer - term economic benefits of eip services are significant,", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 6, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "with estimated net cost savings of £7, 972 per person after the first four years, and £6, 780 per person in the next four to 10 years if full eip provisions are provided. over a 10 - year period this would result in £15 of costs saved for every £1 invested in eip services. the majority of these cost savings can be attributed to the reduction in use of crisis and inpatient services, improved employment outcomes and the reduction in risk of future hospitalisation as a result of improved management and reduced risk of relapse.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 6, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "6 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "5. the access and waiting time standard is targeted at all people aged 14 - 65", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "experiencing first episode psychosis ( including that associated with trauma or substance misuse ). the standard is also relevant for people at high risk of psychosis ( ‘ at - risk mental state ’ ). by 2023 / 24, 60 % of people experiencing first episode psychosis should commence a nice - recommended package of care within two weeks of referral. treatment will be deemed to have commenced when the person : a. has had an initial assessment, and b. has been accepted on to the caseload of an eip service capable of providing a full package of nice - recommended care, and c. has been allocated to and engaged with an eip care co - ordinator.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "6. all services providing eip will be expected routinely to record data regarding", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "eip waiting times, nice - recommended interventions and outcome measures via the mental health services dataset.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "7. all eip services should provide the full range of psychological, psychosocial,", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "pharmacological and other interventions shown to be effective in nice guidelines and quality standards, including support for families and carers. effective and integrated approaches are needed to address the social and wider needs of people with psychosis to help them live full, hopeful and productive lives and achieve the best recovery possible. eip services also need the capacity to triage, assess and treat people with an at - risk mental state, as well as to help those not accepted to access appropriate treatment and support.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "8. commissioning eip services should be underpinned by an estimated local", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "incidence of psychosis, derived to incorporate a range of demographic features such as ethnicity, age, population density and deprivation to ensure services are designed to serve fully the needs of a particular locality and the specific cohorts of people that it comprises.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "9. commissioners and providers should ensure that everyone aged 14 - 65 years", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "old, including children and young people ( aged under 18 ) benefit fully from the standard and that there are robust local arrangements in place to ensure that specialist expertise in working with children and young people with psychosis", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "7 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 8, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "is available. this is in the context of the nhs long term plan commitment to provide a comprehensive offer of care for 0 - 25 year olds.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 8, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "10. it is likely that services will require investment and significant development in", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 8, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "order to meet the two key conditions of the access and waiting time standard and that this can be met equally for children and young people and the relevant data flowed. commissioning and service development plans should be co - produced with a range of stakeholders, including service users, carers, partner organisations and relevant voluntary sector organisations.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 8, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "1. 1 document purpose this guide is intended to support local implementation of the eip access and waiting time standard by commissioners and mental health providers. this document was originally published in 2016, and was subsequently updated in 2020 ( and again in 2022 ) to reflect the new ambitions in the nhs long term plan and nhs mental health implementation plan 2020 / 21 - 23 / 34, as well as experience gained in the first five years of implementation.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 9, "section": "1.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "1. 2 the early intervention in psychosis access and waiting time standard the five - year forward view for mental health ( fyfvfmh ) set the ambition that by 2021, at least 60 % of people with a first episode psychosis would start treatment with a nice - recommended package of care with a specialist early intervention in psychosis service within two weeks of referral. the nhs long term plan specifies that all areas should commission services in line with this guidance, providing a service that covers an age range of 14 - 65 and has a provision with an ‘ at - risk mental state ’ ( arms ). the eip access and waiting time standard is ‘ two - pronged ’ and both conditions must be met for the standard to be deemed to have been achieved :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 10, "section": "1.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "1. a maximum wait of two weeks from referral to start of treatment 2. treatment delivered in accordance with nice guidelines and quality", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 10, "section": "1.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "standards for psychosis and schizophrenia – either in children and young people cg155 ( 2013 ) and qs102, or in adults cg178 ( 2014 ) and qs180. the approach to measurement of performance against the standard has been designed to ensure that both elements can be assessed and that outcomes ( clinician and service user reported ) are routinely collected and reviewed.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 10, "section": "1.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "1. 3 expectations of commissioners and providers the nhs long term plan and associated nhs mental health implementation plan re - affirm the nhs ’ s commitment to ensure that all people experiencing first episode psychosis are able to access nice - concordant care, this includes children and young people ( aged 14 and above ), as part of the commitment to develop a comprehensive 0 - 25 offer. commissioners are responsible for ensuring that local plans are developed and implemented in collaboration with service users and their families or carers, as well", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 10, "section": "1.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "10 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 11, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "as the local mental health provider and partner organisations, including voluntary and third sector organisations, drug and alcohol commissioners and providers and local authorities ( social care, housing, debt, benefit advice, employment and education ) to provide a framework for collaborative action. the reduction of inequalities in access and outcomes should be central to the development of eip services. local commissioners must make explicit in their plans how they have taken into account the duties placed on them under the equality act 2010 and their duties with regard to reducing health inequalities as set out in the health and social care act 2012. service design and communications should be appropriate and accessible to meet the needs of diverse communities ( see guidance for commissioners on the equality and health inequalities duties ).", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 11, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 1 experiences of first episode psychosis : a service user and carer perspective “ my first experience of psychosis occurred when i left home to go to university. this was a sudden change and there was a heavy party culture there involving late nights and increased alcohol consumption. this on top of the stress of a heavy workload all contributed to triggering my first episode of mania which led to psychosis. “ although i had previously suffered from depression since my early teenage years this episode led to my current diagnosis of bipolar affective disorder. in this manic state i started behaving erratically, spending large amounts of money and having endless energy, racing thoughts and elated mood. this led to me staying up all night, feeling no need for sleep. i had new found confidence and would talk excessively at a face pace about unusual and irrelevant things. “ this obvious change in behaviour concerned my friends who tried to talk to me but at that point i was in denial anything was wrong. however soon this developed into psychosis where i had paranoid and delusional thoughts that someone was out to harm me. i became increasingly scared and whenever i heard sirens outside, i thought they were relating to me. the whole experience was incredibly scary and distressing as even though the thoughts and feelings had no basis, they felt very real to me at the time. ” source : taken from the early youth", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 12, "section": "2.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "heard sirens outside, i thought they were relating to me. the whole experience was incredibly scary and distressing as even though the thoughts and feelings had no basis, they felt very real to me at the time. ” source : taken from the early youth engagement ( eye ) in first episode psychosis project. 1 2", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 12, "section": "2.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 2 expectations of commissioners and providers table 1 provides an overview of the clinical definitions for first episode psychosis and arms : table 1 : clinical definitions for first episode psychosis and arms first episode psychosis", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 13, "section": "2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• term used to describe the first time a person experiences a", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 13, "section": "2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "combination of symptoms known as psychosis.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 13, "section": "2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• during an episode of psychosis, a person ’ s perception,", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 13, "section": "2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "thoughts, moods and behaviour are significantly altered : each individual ’ s experiences are unique and will include a combination of symptoms.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 13, "section": "2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• core clinical symptoms ‘ positive ’, ie they are added", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 13, "section": "2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "experiences, including hallucinations and delusions.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 13, "section": "2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 3 how common is first episode psychosis? incidence rates refer to the number of new cases during a given period. the predicted incidence for the whole of england ( for ages 16 - 64 ) in 2020 is 25. 2 per 100, 000. 3 however, it is important to note that incidence levels can vary significantly from one area to another according to age, sex, ethnicity, population density and social deprivation. for this reason, studies conducted to date in england have tended to be conducted in more urban settings and have reported a higher incidence rate of 31. 7 per 100, 000. 4 the psymaptic prediction tool takes these issues into account to provide estimates of future incidence of psychotic disorders for local systems of care in england up to 2025. 5 first episode psychosis occurs most commonly between late teens and late twenties, with more than three quarters of men and two thirds of women experiencing their first episode before the age of 35. 6 this means that areas serving younger populations ( eg areas with higher education colleges and universities ) may have higher rates of psychosis.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 14, "section": "2.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 4 what is the impact of not having timely access to effective treatment? psychosis and psychotic disorders can be extremely debilitating. a long duration of untreated psychosis is associated with poorer personal recovery, increased service use and poorer economic outcomes in both the short and long term. 9 people who do not access effective treatment quickly are far more likely to experience poor physical health, lower levels of social functioning, poorer occupational and educational outcomes and increased contact with the criminal justice system.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 15, "section": "2.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• in the uk, only 8 % of people with schizophrenia are in work, despite many", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 15, "section": "2.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "more being willing and able to work. 10", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 15, "section": "2.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• if untreated or poorly treated, psychosis can become a long - term condition", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 15, "section": "2.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "with high levels of relapse, high rates of inpatient admission, increased detentions under the mental health act and high rates of comorbid physical health conditions.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 15, "section": "2.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• for society, the current cost of psychosis is estimated to be £11. 8 billion", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 15, "section": "2.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "per year. this results from direct healthcare costs, lost productivity due to unemployment or death and informal costs to families and carers. there are significant gains to be made by ensuring that people experiencing psychosis for the first time have rapid access to effective, evidence - based treatment. people with severe and prolonged mental illness ( diagnoses that usually involve psychosis, such as schizophrenia and bipolar disorder ) are at - risk of dying on average 15 to 20 years earlier than the general population, 11 this is largely because of preventable physical health conditions, including cardiovascular disease and smoking. this is further exacerbated by the effects of antipsychotic medications", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 15, "section": "2.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 5 what are the benefits / impact of having timely access to effective treatment? recovery from a first episode of psychosis is possible ; if people of all ages, in particular children and young people receive the right treatment at the right time from an eip service they can go on to lead full, hopeful and productive lives.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 16, "section": "2.5", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• people experience improved outcomes when receiving care from an eip", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 16, "section": "2.5", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "service compared with standard care. improved outcomes can be facilitated by the positive, therapeutic relationship with a care co - ordinator. 14", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 16, "section": "2.5", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• evidence shows that early treatment with cbt can prevent at - risk mental", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 16, "section": "2.5", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "states from developing into first episode psychosis. 15 16", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 16, "section": "2.5", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• family intervention has been shown to improve outcomes significantly,", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 16, "section": "2.5", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "predominantly through supporting the family to understand the experience of psychosis and to respond appropriately, 17 resulting in relapse rates reducing by 40 %.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 16, "section": "2.5", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• there is evidence that cbtp reduces rehospitalisation rates and length of", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 16, "section": "2.5", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "stay, reduces symptom severity and can improve social functioning. there is also a strong indication that it reduces symptomatology and has a positive effect on social functioning. 18", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 16, "section": "2.5", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• in the long term, a 10 - year follow - up study reported higher rates of", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 16, "section": "2.5", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "symptomatic recovery ( 50 % ) and a 90 % reduction in risk of unnatural - cause mortality when full family involvement was present at the first contact. 19", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 16, "section": "2.5", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 6 what is an eip service? an eip service is a multidisciplinary community mental health service that provides treatment and support to people experiencing or at high risk of developing psychosis. this support typically continues for three years. the defining characteristic of an eip service is its strong ethos of hope and whole - team commitment to enabling recovery through the provision of effective, individually tailored, evidence - based interventions and support to service users and their families / carers.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 17, "section": "2.6", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 7 relevant nice guidelines and quality standards the following nice guidelines and their accompanying quality standards are directly relevant to the provision of eip services :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 18, "section": "2.7", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• psychosis and schizophrenia in children and young people nice", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 18, "section": "2.7", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "guideline", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 18, "section": "2.7", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• bipolar disorder, psychosis and schizophrenia in children and young", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 18, "section": "2.7", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "people nice quality standard", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 18, "section": "2.7", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• psychosis and schizophrenia in adults nice guideline • psychosis and schizophrenia in adults nice quality standard", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 18, "section": "2.7", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "the key requirements of the quality standards ( the individual statements ) are summarised in the table below. tables providing further detail regarding the interventions recommended by nice can be found in appendix 3.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 18, "section": "2.7", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "18 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 19, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "children and young people quality statements adults quality statements maximum waiting time from referral to treatment children and young people who are referred to a specialist mental health service with a first episode of psychosis start assessmenti within two weeks. adults with a first episode of psychosis start treatment in early intervention in psychosis services within two weeks of referral. psychological therapy children and young people newly diagnosed with a first episode of psychosis and their family members are offered family intervention. children and young people newly diagnosed with bipolar depression or a first episode of psychosis are offered a psychological intervention. family members of adults with psychosis or schizophrenia are offered family intervention. adults with psychosis or schizophrenia are offered cognitive behavioural therapy for psychosis ( cbtp ). support for carers and families parents and carers of children and young people newly diagnosed with bipolar disorder, psychosis or schizophrenia are given information about carer - focused education and support. carers of adults with psychosis or schizophrenia are offered carer - focused education and support programmes.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 19, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "i the qs102 committee reasoned that it was not appropriate to say ‘ start treatment ’ within two weeks of being referred because many children and young people will need to undergo a period of assessment before a diagnosis can be made and treatment can be started. please note, however, that the ‘ early intervention in psychosis access and waiting time standard ’ is for people aged 14 - 65 and treatment will be deemed to have commenced when the person :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 19, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• has had an initial assessment, and • has been accepted on to the caseload of an eip service capable of providing a full package of nice - recommended care, and • has been allocated to and engaged with an eip care co - ordinator.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 19, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "19 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 20, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "children and young people quality statements adults quality statements physical health and healthy lifestyles children and young people with bipolar disorder, psychosis or schizophrenia are given healthy lifestyle advice at diagnosis and at annual review. adults with psychosis or schizophrenia are offered combined healthy eating and physical activity programmes and help to stop smoking. adults with psychosis or schizophrenia have specific comprehensive physical health assessments. medicines management children and young people with bipolar disorder, psychosis or schizophrenia prescribed antipsychotic medication have their treatment monitored for side effects. adults with schizophrenia who have not responded adequately to treatment with at least two antipsychotic drugs are offered clozapine. education, employment and training children and young people with bipolar disorder, psychosis or schizophrenia have arrangements for accessing education or employment - related training included in their care plan. adults with psychosis or schizophrenia who wish to find or return to work are offered supported employment programmes. crisis care children and young people with bipolar disorder, psychosis or schizophrenia who are in crisis are offered home treatment if it is suitable.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 20, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 8 other key functions of eip services", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 21, "section": "2.8", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 8. 1 supporting identification of psychosis and rapid referral failure to identify first episode psychosis and refer appropriately to eip services can have a significant detrimental impact on service user experience and outcomes. there are still too many instances of people with first episode psychosis accessing mental health services for the first time only when they reach crisis point. another common scenario is that the person is initially referred to generic community mental health services ( adult or children and young people ’ s ), resulting in an increase in delay and the duration of untreated psychosis as the person will not commence the right expert treatment and is more likely to disengage with mental health services. 20", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 21, "section": "2.8.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "21 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 22, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "due to these complexities for some people it is important to offer an extended assessment. this can be up to three months so that the team can make use of the time to fully understand the key difficulties a person is experiencing and decide upon the most appropriate care pathway. it is important to note that the extended assessment pathway and the at - risk mental state pathway have similarities but are in fact quite different. there are several reasons why identification of psychosis in people of all - ages may be impaired or delayed :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 22, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• the clinical signs, which may not be easily identifiable, are often missed ; a", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 22, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "guide is available to aid referrers if they suspect psychosis to enable prompt access to services. 21", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 22, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• there may be other comorbid health problems that disguise or compound", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 22, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "symptoms, for example when a child or young person has a learning disability or autism or where psychotic experiences are attributed to trauma or substance use.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 22, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• people may not seek help from mental health services, or fully disclose their", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 22, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "experiences, because of stigma, lack of insight or distrust of services that are not attuned to youth culture or the cultural characteristics of the communities they serve.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 22, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• due to transitions ( such as moving to university ) there may be difficulties in", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 22, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "communication between services and concerned families and friends. people who are experiencing psychotic symptoms related solely to substance use may be best supported in another part of the core community - mental health offer. clinicians should work alongside the individual to agree the most appropriate place for the individual to receive care and support. supporting referrers and colleagues to identify first episode psychosis and refer appropriately and rapidly is an important function of any eip service", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 22, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• in addition to clinical protocols between eip teams and generic community", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 22, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "mental health services, it is especially important that there are regular liaison and training arrangements with community children and young people ’ s mental health services. this will help to ensure that they are well equipped to identify first episode psychosis and arms in young people and can confidently refer rapidly and appropriately to an eip team.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 22, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 8. 2 recognising and addressing co - existing health problems a person may experience first episode psychosis with several comorbidities, including other mental health problems. this can impact directly on health outcomes and indirectly by introducing potential barriers to care. it is vital, therefore, that any coexisting problem is recognised and addressed. mental health problems co - existing mental health problems are extremely common for people of all ages with psychosis ; for example, anxiety disorders and / or depression are present in over 50 % of first episode psychosis patients and can have significant impact on recovery. 22 23 around 40 % of people with first episode psychosis misuse substances at some point in their lifetime. as a result, people may present under the influence of a range of substances, including alcohol, cannabis, cocaine or amphetamines. 24 people of all ages with psychosis may also present with history of trauma. this may include emotional, physical and / or sexual trauma and a range of other adverse life experiences. 25 26 neurodevelopmental disorders are common in children and young people presenting with psychosis. it has been estimated that in childhood - onset psychosis, premorbid autism is present in 28 - 55 % of children27 28 and extremely low premorbid iq ( lower than 70 ) has been found in 30 %. 29 an eip service should", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 23, "section": "2.8.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "been estimated that in childhood - onset psychosis, premorbid autism is present in 28 - 55 % of children27 28 and extremely low premorbid iq ( lower than 70 ) has been found in 30 %. 29 an eip service should comprise of staff who have experience and skills in working with people who have co - occurring problems with substance misuse, a history of trauma and neurodevelopmental disorders. this should include clinicians with expertise in working with children and young people. physical health problems people with psychosis often have poor physical health. 30 this is the primary cause of premature mortality and higher rates of death in this population. being exposed to antipsychotic medication for the first time can make people particularly vulnerable to side effects, such as rapid weight gain31 32 and adverse cardio - metabolic disturbance. 33 a combination of weight gain, poor diet and nutrition and lack of physical activity can also lead to high rates of illnesses such as diabetes and cardiovascular diseases. 34", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 23, "section": "2.8.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 8. 3 support with social issues after an acute episode of psychosis, there is an increased likelihood of social adversity, poverty, loneliness and social isolation, unemployment and homelessness, which can impair and slow recovery. social issues such as housing, debt, benefit advice, employment or education as well as the strength of cultural and community support are often central to the lives of people experiencing psychosis. eip services should be equipped to address these important care needs and work closely with local government, social care workers and other agencies to address any key social care needs to ensure people with psychosis, their families and carers can access additional support, as outlined in the care act 2014.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 24, "section": "2.8.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 8. 4 families and carers families and carers play an invaluable role in helping people to recover from psychosis. it is vital that this is acknowledged, valued and supported, both in terms", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 24, "section": "2.8.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "24 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 25, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "of recognising families and carers as expert partners in care and in ensuring that they can access support both as individuals and in their caring role. “ faced with the turmoil of a loved one ’ s emerging psychosis, their very first experience of specialist mental health services is pivotal for carers. repeated failed attempts to get help from a service which seems indifferent to the needs of their family member or close friend will never be forgotten … but get that initial encounter right and the way is paved for a positive collaborative relationship with the carer ( s ) which may prove crucial to the ongoing care and recovery of an individual. ” source : a carer, 2015. nice guidelines ( cg 178 ) recommend that carers of people with first episode psychosis should be offered a carer - focused education and support programme as soon as possible ( qs 80 ref ). programmes should provide information about psychosis and its treatment and provide support ( including access to mutual support through group forums ) to help people manage their caring role and to provide a positive message about recovery. while family intervention, referral for a carer ’ s assessment and carers ’ involvement in the planning and delivery of care are all important, a carer - focused education and support programme would be regarded as distinct from these. the principle aim is to support carer resilience and to equip carers with the", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 25, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "’ involvement in the planning and delivery of care are all important, a carer - focused education and support programme would be regarded as distinct from these. the principle aim is to support carer resilience and to equip carers with the knowledge, information and resources to fulfil this vital role. there should be an explicit resource actively promoted to all carers. a programme can be delivered in groups or individually and will typically ( but not exclusively ) include :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 25, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• orientation to the eip service • understanding psychosis and its causes • treatments available, including psychological therapies • medication and side - effects • recovery approaches • managing different symptoms / unusual experiences • dealing with difficult behaviours", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 25, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 9 the eip workforce having the right eip workforce with the right skills is essential to ensuring that care can be delivered in line with nice recommendations. eip services are multidisciplinary and the key staff roles, functions and necessary competencies are described below. eip services should be provided by a team of staff, with specialist knowledge and appropriate training in working with people with psychosis. teams should work in a truly holistic way to support the individual. a workforce tool developed by health education england is available to support planners with designing their workforce and skill mix. all staff should have specialist knowledge and should have appropriate training to work with people with psychosis. ii table 2 provides an overview of the key roles within eip teams :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 26, "section": "2.9", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "ii https : / / www. nice. org. uk / guidance / cg178 / ifp / chapter / your - care - team", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 26, "section": "2.9", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "26 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "table 2 : key roles within eip teams role functions and necessary competencies care co - ordinator", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• skilled in engagement and working with a biopsychosocial formulation ( ie supporting people across the spectrum of their", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "biological, psychological and social needs ), and function as part of a multidisciplinary team and utilise recovery - based approaches to care planning.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• work flexibly and creatively with people in order to achieve their individual goals, supporting them across a range of", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "health and social care needs, including housing, benefits and debt advice.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• a mix of care co - ordinators is recommended which come from a range of professions but typically will be nurses,", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "occupational therapists, social workers. care co - ordinators may also deliver family intervention if they are trained and supervised in their delivery. care co - ordinators working with cyp should have specific cyp knowledge and experience, including the wider services supporting them, including education and local authority children ’ s services & social care.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• evidence shows that lower caseloads for care co - ordinators support greater client involvement and can improve service", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "user outcomes. the eip workforce calculator can be used to support areas to assess local workforce requirements. psychiatrist • dedicated consultant psychiatrist input is essential, 39 to provide both direct service user contact and to support to the multidisciplinary team ( mdt ). consultant should be involved whenever there are doubts or conflicting opinions about diagnosis, safety or prescribing.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• medical team members should proactively be involved in clinical assessment, particularly if other members of the", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "workforce complete the face - to - face assessment.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• all eip services providing to under 18 ’ s should include a consultant psychiatrist with training in child and adolescent", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "mental health", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• should also be involved in decisions about acceptance on to caseload and discharge especially where this is unplanned.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 27, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "27 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "psychological therapist / clinical psychologist", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• psychological therapists and clinical psychologists should have had formal training in cbt for psychosis and / or family", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "intervention and be assessed as having the competencies to deliver these interventions, in line with the available competency framework.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• psychological therapists and clinical psychologists in cypmh services offering an eip response should also have had", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "formal training in cbt for psychosis and / or family intervention for psychosis.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• all staff delivering psychological therapies must have regular clinical supervision from a suitably qualified supervisor.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "education and employment specialists", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• education and employment specialists are skilled in supporting people in work, training or education, with an emphasis", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "on employment or education as a primary goal. these workers should be an integral part of the clinical team, not an external resource. competencies and attitudes should include high levels of initiative, empathy and persistence with specific knowledge of the local job market. there is some evidence that workers should be trained in motivational interviewing to help people achieve better long - term outcomes. 40", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• those working with young people should have training in working with those who have additional learning needs as a", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "result of atypical neurodevelopment.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• as part of a comprehensive package of nice care, individuals should be able to access individual placement and", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "support ( ips ), either via the secondary mental health service or via other locally commissioned services. peer - support workers", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• lived experience of mental distress and work alongside others with mental health difficulties to support one another, peer", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "support is based on shared understanding, respect and mutual empowerment between people in similar situations.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• peer support workers add to the skill mix of a team by offering a type of relational work that complements the learned", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "expertise of their clinical colleagues. people with lived experience of accessing early intervention in psychosis services or of caring for someone who uses these services ( experts by experience ) can be well suited to the role of peer support worker.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 28, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "28 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 29, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "social workers • as care co - ordinators, social workers focus on personalisation and recovery to support people to make positive, self - directed change.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 29, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• trained to work in partnership with people using services, their families and carers, to optimise involvement and find", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 29, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "collaborative solutions clinicians with expertise for working with children", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 29, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• teams should include as an integral part of the service, clinicians ( particularly clinical psychologists and child and", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 29, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "adolescent psychiatrists ) who should also have specialist neurodevelopment assessment and management skills and an understanding of the role of trauma, including that experienced by looked - after children.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 29, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 9. 1 other staffing teams will require sufficient management and administrative support. support workers and peer support workers should also form part of the workforce and eip service users should have access to specialist mental health pharmacists and occupational therapists. teams working with children and young people will also need to include clinicians ( particularly clinical psychologists and child and adolescent psychiatrists ) who will also offer specialist neurodevelopmental assessment and management skills and an understanding of the role of trauma including that experienced by looked after children.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 30, "section": "2.9.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 10 a service user perspective “ i encountered early intervention services in 2011 while i was taking a year out of university. i had travelled to thailand and after the third week there i started getting symptoms of paranoia that led to a psychotic episode where i saw, heard and smelled things that weren ’ t real. i was travelling alone so i was scared by these experiences which seemed very real at the time. i was very anxious and did not understand how i could carry on in the world if these things were real. “ when back in england, i thought that my family were imposters with thai people in their bodies. i did not trust them and didn ’ t eat or drink anything they gave me or want to leave the house. it was a stressful time for all of us and my family contacted the gp. the gp and crisis team assessed me and i was taken to hospital on a section of the mental health act. “ after 4 weeks of being in hospital i was introduced to the early intervention service. they looked after me through my hardest times and empowered me to understand my experiences, look after myself and pursue my goals. i took medication and had some side effects, but i was given choice and control over what medication i took to limit side effects and maintain my health. “ cbt therapy helped me to challenge my thoughts and understand my condition through identifying early warning signs and triggers.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 30, "section": "2.10", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "medication and had some side effects, but i was given choice and control over what medication i took to limit side effects and maintain my health. “ cbt therapy helped me to challenge my thoughts and understand my condition through identifying early warning signs and triggers. under their guidance i recovered from psychosis.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 30, "section": "2.10", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 11 eip service models there are two models for eip service delivery : stand - alone and hub and spoke. in a stand - alone service, the team works independently from the generic community mental health teams ( cmhts ) and care co - ordinators assertively outreach to people when they are experiencing first episode psychosis. there is a clear evidence base for the delivery of eip in a stand - alone model. research shows these teams are more clinically and cost - effective, and better able to implement nice - recommended interventions. the hub and spoke model is one where some eip staff members ( ‘ spokes ’ ) are based within generic cmhts and link to an eip ‘ hub ’ for access to specialist skills, support and supervision. the evidence for these teams is limited as there are significant risks associated with this model, including :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 31, "section": "2.11", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• isolation of eip workers • limitations in clinical supervision • lack of availability for trained therapists • issues with travel time", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 31, "section": "2.11", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "31 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 32, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• abrupt or gradual increases in caseloads.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 32, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "hub - and - spoke models may however be appropriate for very sparse, rural areas where there may be issues with providing a stand - alone eip function. regardless of the locally agreed model, systems should consider how the eip service is a key function of the new and integrated models of primary and community mental health care, as articulated in the nhs long term plan. considerations for children and young people all children and young people, aged 14 and above, experiencing first episode psychosis should receive a comprehensive package of nice concordant care within two weeks of referral to a specialist service. for the purpose of calculating waiting times, a specialist service includes any team that is identified as delivering a component of the locality ’ s specialist eip response which must be comprehensive across the full 14 to 65 years age range. as set out in the nhs long term plan and the ltp mental health implementation plan 2019 / 20 - 2023 / 24, children and young people accessing eip services should have a seamless experience of nice concordant care ; all services supporting children and young people, between the ages of 14 to 18, with first episode psychosis, should be able to support them for at least the duration of the full three years, avoiding premature transitioning to alternative services. as services have extended their upper age range to 65 years, commissioners and providers may wish to also consider the refinement or development", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 32, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "be able to support them for at least the duration of the full three years, avoiding premature transitioning to alternative services. as services have extended their upper age range to 65 years, commissioners and providers may wish to also consider the refinement or development of eip services. this would facilitate a focus on cyp and young adults aged 14 to 25 years, reflecting the nhs long term plan ambition for a new approach to young adult mental health services for people aged 18 to 25 which will support the transition to adulthood and improve outcomes across the life course. table 3 below sets out key considerations for providing care to children and young people aged 14 and above. while the evidence base is limited for children and young people under the age of 14 experiencing first episode psychosis, due to the low incidence, many of the principles of care and support set out below would be relevant to their care and support within children and young people ’ s mental health services :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 32, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "32 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 33, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "table 3 : key considerations for providing care to children and young people aged 14 and above area detail nice concordant care", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 33, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• evidence based interventions should be offered routinely :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 33, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "assessments and interventions should be delivered in line with nice guidelines.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 33, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• staff should be competent in delivering interventions and", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 33, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "working with families and carers, as well as providing support with social needs. workforce • practitioners working with children and young people should have necessary training, expertise and support in children and young people ’ s mental health, as well as the required competencies in delivering eip interventions.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 33, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• eip services should include practitioners with expertise in", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 33, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "identifying neurodevelopmental disorders in children and young people in the presence of psychosis41 and make reasonable adjustments to their service, including communication preferences, to facilitate vocational and educational recovery and social functioning.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 33, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• staff should also be fully competent in safeguarding procedures", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 33, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "and working with colleagues from social care. collaboration • there should be a strong interface and relationship between children and young people ’ s mental health services and eip teams.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 33, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• expertise in working with children and young people and their", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 33, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "families or carers is integral.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 33, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• joint working protocols are essential to support close working.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 33, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. 12 at - risk mental state the nhs long term plan and the long term plan mental health implementation plan 2019 / 20 – 2023 / 24 make it clear that a comprehensive eip service should ensure that people, including children and young people, with an at - risk mental state have to access to evidence - based care and support. the waiting time element of the eip standard requires that anyone with a suspected first episode of psychosis should be referred for assessment. if the person is not experiencing first episode psychosis but may have an at - risk mental state, the clock will stop when :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 34, "section": "2.12", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• the person is accepted on to the caseload of an appropriate secondary", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 34, "section": "2.12", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "mental health service", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 34, "section": "2.12", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• the person is allocated to and engaged with a care co - ordinator, to stop", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 34, "section": "2.12", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "clock through mhsds", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 34, "section": "2.12", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• an at - risk mental state assessment has commenced by an appropriately", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 34, "section": "2.12", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "trained and qualified clinician.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 34, "section": "2.12", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "34 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 35, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "early detection which focuses on early identification and provision of preventative strategies should be a core activity for mental health services, with the aim of providing a comprehensive and timely assessment, with subsequent care and support where this need is identified. evidence suggests that for many people experiencing at - risk mental state, many protective social factors are still intact. for example, people are still engaged in education or work and usually have a range of social contacts and a supportive family group. for the person who develops distressing psychotic symptoms and does not have prompt access to effective treatment, deterioration in family and social life can occur very quickly. 42 arms provision can also support a reduction in the duration of untreated psychosis ( dup ), which is the length of time between the onset of psychotic symptoms and the subsequent detection, diagnosis and commencement of treatment. 43 this can be achieved by early case finding but also being able to quickly transfer people into first episode psychosis care if they do transition to a first episode psychosis. minimising dup is critical for service users, their families and the team providing care and support. arms provision : key aims and nice guidance the overall aim of arms provision is to delay or prevent the onset of severe mental health problems, including psychosis, as well as provide a stepped care approach for people experiencing emerging psychotic symptoms. arms provision should identify people who are experiencing an arms. this is", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 35, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "overall aim of arms provision is to delay or prevent the onset of severe mental health problems, including psychosis, as well as provide a stepped care approach for people experiencing emerging psychotic symptoms. arms provision should identify people who are experiencing an arms. this is particularly important in children and young people. following a comprehensive assessment, evidence - based care, support and interventions should be provided to individuals experiencing an arms. practitioners should be competent in completing a thorough assessment and formulation which also considers the effects on presenting symptoms of adverse childhood experiences, including trauma and neglect, as well as potential learning difficulties and neurodevelopmental conditions. table 4 below provides an overview of the nice guidance for individuals who are identified as experiencing an arms :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 35, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "35 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 36, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "table 4 : nice guidance for individuals experiencing arms component children and young people adults maximum waiting time from referral to treatment children and young people who are referred to a specialist mental health service with a suspected first episode of psychosis start assessment within two weeks. adults with a suspected first episode of psychosis start assessment within two weeks of referral. specialist assessment, iii ie consultant psychiatrist or trained specialist with experience in arms children and young people ’ s mental health services or an eip service provide assessment if a child or young person experiences :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 36, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• transient or attenuated", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 36, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "psychotic symptoms ; or", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 36, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• other experiences or", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 36, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "behaviours suggestive of possible psychosis. suitably trained clinician to provide an assessment if a person is distressed, has a decline in social functioning and has :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 36, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• transient or attenuated psychotic", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 36, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "symptoms ; or", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 36, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• other experiences or behaviours", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 36, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "suggestive of possible psychosis ; or first degree relative with psychosis or schizophrenia. individual cbt with or without family intervention individual cbt with or without family intervention delivered by a trained therapist individual cbt with or without family intervention delivered by a trained therapist interventions for co - existing mental health problems to be offered for depression, any of the anxiety disorders, emerging personality disorder or substance misuse, along with individual cbt ( with or without family intervention ). to be offered for depression, any of the anxiety disorders, emerging personality disorder or substance misuse, along with individual cbt ( with or without family intervention ).", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 36, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "iii an example of a comprehensive assessment tool is the comprehensive assessment of at - risk mental states ( caarms ) that identifies people at risk of developing psychosis and outlines a care plan and package of care.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 36, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "36 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "individuals experiencing an arms will require a period of active treatment lasting up to two years. they should be monitored regularly for at least another year after treatment. this means that those with arms will be seen for a minimum of two years and a maximum of three years in total. monitoring should include the use of a structured and validated assessment tool, for example the comprehensive assessment of at - risk mental states ( caarms ). arms provision may also include support for people to live well and maintain their social and family links : including, education and employment support and support to maintain good physical health. provision may also be made to provide support for carers and families. the current evidence base for providing care and support for people with arms is 14 to 35 years. nice guidance also recommends that individuals with an arms should not be prescribed anti - psychotic medication. models of care there are two options for the delivery of arms provision : the stand - alone or integrated arms model. commissioners and service leads should work jointly to identify the most appropriate model for their local population. figure 1 below provides an overview of the key features of different models of arms provision, including some of the benefits for each model. mechanisms should be in place to monitor access rates for all people entering the service, as well the quality the quality of the care and support provided. figure 1 : different models of arms provision", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 1 requirements of the standard by 2024, 95 % of people experiencing first episode psychosis will be treated with a nice - approved care packageiv within two weeks of referral. the standard is targeted at people aged 14 to 65 in line with nice recommendations. v as indicated in the nhs mental health implementation plan, all areas should ensure there is provision for people with an arms. the standard is ‘ two - pronged ’ and both conditions must be met for the standard to be deemed to have been achieved :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 38, "section": "3.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "1. a maximum wait of two weeks from referral to start of treatment, and 2. treatment delivered in accordance with nice guidelines and quality", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 38, "section": "3.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "standards for psychosis and schizophrenia – either in children and young people cg155 ( 2013 ) and qs102, or in adults cg178 ( 2014 ) and qs180. the approach to measurement of performance against the standard has been designed to ensure that both elements can be assessed and outcomes ( clinician and service user reported ) routinely reviewed.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 38, "section": "3.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "iv throughout the rest of this tool the term ‘ nice - recommended ’ package of care / intervention has been used at the request of nice. v eip services may also be clinically appropriate for people outside the 14 - 65 age group. professionals should use their clinical judgement when considering whether people outside the 14 - 65 age group should be referred to / accepted by eip services with commissioners and providers ensuring that people are not inappropriately restricted from accessing care", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 38, "section": "3.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 2 measuring and reporting performance against the referral to treatment ( rtt ) waiting time requirement", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 39, "section": "3.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 2. 1 measuring the clock start : referral, recognition and initial assessment referral and recognition figure 2 : referral to clock start", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 39, "section": "3.2.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "the clock for the two - week pathway starts when a referral has been identified or flagged as ‘ suspected first episode psychosis ’ or is recognised as such upon receipt. referrals would usually be made either to a central triage point ( ‘ single point of access ’ ) or direct to an eip service. referrals may come from any source and may be internal ( for example from a children and young people ’ s mental health service, a cmht, an inpatient ward, prison or forensic mental health services ) or external ( for example from a gp, carer, school or self - referral ). the key ‘ rules ’ for this part of the pathway are as follows :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 39, "section": "3.2.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• if a single point of access or triage service receives a referral flagged as", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 39, "section": "3.2.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‘ suspected first episode psychosis ’ this will start the clock", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 39, "section": "3.2.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "39 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 40, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• if a single point of access or triage service receives a referral not flagged as", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 40, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‘ suspected first episode psychosis ’, but the person is assessed or triaged as such, this should be flagged and moved on to the first episode psychosis pathway, and the clock will start on the date that the single point of access or triage service received the referral", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 40, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• if a single point of access or triage service receives a referral flagged as", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 40, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‘ suspected first episode psychosis ’, but following consultation with the eip service it is triaged as clearly not psychosis, the referral should not enter the pathway or be counted against the access and waiting time standard", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 40, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• if an eip service accepts direct referrals, the clock will start from the date", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 40, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "the referral is received by the eip service.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 40, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• if a service user within a generic cypmh service or adult cmht is", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 40, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "identified as suspected psychosis, the clock will start from identification or flagging as ‘ suspected first episode psychosis ’. the clock starts regardless of referral source, the age of the person being referred or comorbidities such as learning disabilities, substance misuse, personality disorder or autism. the only exemptions from these arrangements will be referrals of people who are experiencing psychotic symptoms with a confirmed organic cause, for example, brain diseases such as huntington ’ s and parkinson ’ s disease, hiv or syphilis, dementia, or brain tumours or cysts. initial assessment figure 3 : initial assessment", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 40, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "40 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 41, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "assessment for first episode psychosis should be completed by a competent and qualified professional ( see section 3. 5. 1 ). assessments should be completed with the support of the full multidisciplinary team, enabling a team - based formulation of the individual ’ s needs. it is vital for services to work proactively to engage people experiencing first episode psychosis because it is often those who do not engage with services immediately who are most in need of support. services must ensure that they engage equally effectively with people from all cultural backgrounds. non - attendance or cancellations will not stop or pause the clock for the access and waiting time standard. the first assessment is a critical step in an engagement process upon which therapeutic alliances and interventions are built. however, feelings of ambivalence towards the process are common and natural on the part of service users ( and sometimes families and carers too ). where people referred do not attend or agree to an initial assessment, appropriate contact should be made with the referrer and with families or carers to gather further information and to provide support and advice to them where they have already become involved. where families or carers have not been involved, a decision to contact them can be made if a safety assessment of the available information warrants it. guidelines on capacity and information sharing should always be followed. if someone aged 16 or over is assessed as lacking mental capacity", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 41, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "carers have not been involved, a decision to contact them can be made if a safety assessment of the available information warrants it. guidelines on capacity and information sharing should always be followed. if someone aged 16 or over is assessed as lacking mental capacity, steps may be taken in their best interests in accordance with the mental capacity act 2005 and its code of practice. attempts must continue to be made to engage the person and make an assessment, including visiting them at home or a mutually agreed location. depending on the urgency of the situation, this should occur at least twice within the two - week period after referral and more frequently if there are safety issues, if necessary, in collaboration with the crisis resolution home treatment team. if contact has not been possible, a care co - ordinator should be allocated within the two - week period to continue attempts to complete an assessment and liaise with carers and the referrer. this will not stop the clock but represents good practice.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 41, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "41 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 42, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "in these circumstances, if there is enough suspicion about the presence of psychosis that the eip service continues to work with the family and carers, this may include the allocated care co - ordinator undertaking therapeutic work with the family. it is important in cases of poor engagement that services continue to make all efforts to engage the service user. this will help to prevent people from ‘ falling through gaps ’ and receiving inadequate care, and it can reduce the risk of long - term poorer outcomes and increased use of healthcare resources ( and associated costs ). commissioners should review cases with providers on a six - monthly basis where the service has been unable to assess someone who was referred with a possible first episode psychosis. vi where contact is not made, discharge from the pathway should only occur with prior agreement of the carer and referrer, and the clock will then stop. in such cases, details should be recorded, and information provided to enable rapid reassessment by the eip service if necessary. in scenarios where the individual moves areas ( for example, to another county or to university ), transfer of care to a local eip service ( or its equivalent ) should occur unless it is more appropriate to maintain contact ( for example, if the service user returns to the area periodically ). in all circumstances, there should be effective communication with primary care.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 42, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "vi commissioners and providers will need to work together to ensure that any review uses service user data appropriately and lawfully", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 42, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 2. 2 measuring the clock stop : start of treatment figure 4 : clock stop", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 43, "section": "3.2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "notes :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 43, "section": "3.2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "1. the early intervention in psychosis scoring matrix contains a scoring matrix,", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 43, "section": "3.2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "comprising three domains and a sub - matrix of three domains. an overall score will be calculated from domains in the scoring matrix only and will not include items in the sub - matrix. each item, each domain and an overall rating will be scored at one of four levels : level 4 : top performing level 3 : performing well level 2 : needs improvement level 1 : greatest need for improvement", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 43, "section": "3.2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2. ‘ engaged with an eip care co - ordinator ’ means that the care co - ordinator actively", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 43, "section": "3.2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "engages to form a therapeutic professional relationship with the person and offers treatment to them.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 43, "section": "3.2.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "43 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "assessment by the eip service will ascertain whether the person :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• is experiencing first episode psychosis ( see section 2. 2. 1 ) • is not currently experiencing first episode psychosis but may have an at - risk", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "mental state ( see section 2. 2. 2 )", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• does not have evidence of first episode psychosis or of an at - risk mental", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "state. if there is any doubt about the presence of psychosis or an at - risk mental state, the person should remain in the eip service until the diagnosis is clear. following completion of the eip assessment, if the person is experiencing first episode psychosis the clock will stop when :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• the person is accepted on to the caseload of an eip service assessed as", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "capable of providing a full package of nice - recommended care, vii and", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• the person is allocated to and engaged with an eip care co - ordinatorviii", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "( engagement with the care co - ordinator should begin immediately upon allocation ). if the person is not experiencing first episode psychosis but may have an at - risk mental state, the clock will stop when :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• the person is accepted on to the caseload of an eip service, and • the person is allocated to and engaged with an eip care co - ordinator, ix and • an at - risk mental state assessment has commenced by an appropriately", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "trained and qualified clinician. if the person is assessed as not experiencing first episode psychosis or an at - risk mental state the clock will stop, but the service should still ensure that the person is supported to access any further help they need. this could involve :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• discharging the person back to primary care, with advice about next steps,", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "for example, treatment of depression, anxiety or any other common mental health problem", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• referring the person to an appropriate mental health service.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "vii see figure 3, note 1. viii see figure 3, note 2. ix see figure 3, note 2.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 44, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 2. 3 reporting performance against the referral to treatment ( rtt ) waiting time requirement submission of data via the mental health services dataset ( mhsds ) all mental health teams contributing to the eip, nice concordant service pathway, including those for children and young people under 18 years of age, should flow data to the mhsds for the eip standard and to support the national audit of eip services. the mhsds is a patient - level, output - based, secondary uses data set, which delivers robust, comprehensive, nationally consistent and comparable person - based information for children, young people and adults who are in contact with mental health and learning disability services. as a ‘ secondary uses ’ data set it re - uses clinical and operational data for purposes other than direct patient care. the mhsds will enable collection, measurement and reporting of the eip referral to treatment waiting time. technical guidance to support data submission to the mhsds for the eip standard has been developed and is available alongside this document via the nhs england website.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 45, "section": "3.2.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 3 measuring and reporting performance against the requirement that the treatment accessed is in line with nice recommendations", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 46, "section": "3.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 3. 1 what is nice - recommended treatment? the second ‘ prong ’ of the eip access and waiting time standard requires that the treatment provided is in accordance with nice recommendations. section 3. 4 sets out the key components of the two nice guidelines and accompanying quality standards that are directly relevant to the provision of eip services :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 46, "section": "3.3.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• psychosis and schizophrenia in children and young people nice", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 46, "section": "3.3.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "guideline", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 46, "section": "3.3.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• bipolar disorder, psychosis and schizophrenia in children and young", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 46, "section": "3.3.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "people nice quality standard", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 46, "section": "3.3.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• psychosis and schizophrenia in adults nice guideline • psychosis and schizophrenia in adults nice quality standard", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 46, "section": "3.3.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "nice recommends that specific therapeutic interventions should be delivered in the context of a holistic and recovery - focused service model as described in section 3. 3 and section 3. 5. this will require an appropriate workforce with the requisite skills and competencies ( see section 3. 6 ) and an effective service model ( see section 3. 7 ). this must be fully inclusive of all people, including children and young people, between 14 to 65 years of age. measurement of performance will focus upon delivery of the requirements of the above guidelines and quality standards. however, section 3. 4 also makes clear the expectation that eip services should continue to offer care and treatment to people who go on to receive a diagnosis of bipolar disorder or unipolar psychotic depression. therefore, depending on the emerging diagnosis, other nice guidelines and quality standards ( listed in section 3. 4 ) might also be relevant to the continuing treatment of people accessing eip services.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 46, "section": "3.3.1", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 3. 2 reporting nice - recommended interventions using snomed - ct codes the mhsds includes a mechanism through which nice - recommended interventions can be reported as part of routine dataset submissions : use of systematized nomenclature of medicine - clinical terms ( snomed - ct ) codes. to submit interventions data in this way, providers firstly need to ensure that their electronic care record systems are developed to allow eip clinicians to record the therapeutic interventions recommended by nice that take place during a clinical contact – eg ‘ cbt for psychosis ’ ( see section 3. 4 and appendix 3 ). providers will need to develop their electronic care record so that clinicians can record interventions using a set list of activity types ( eg making these available via a drop - down menu ). the relevant interventions can be found in appendix 3 and further information can be found in the mhsds user guidance and recording and reporting on nice - recommended interventions using snomed - ct codes.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 47, "section": "3.3.2", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 3. 3 national clinical audit of psychosis the national clinical audit of psychosis ( ncap ) has been commissioned by the healthcare quality improvement partnership ( on behalf of nhs england ) to conduct an annual audit of eip services ’ ability to provide timely access to nice - approved packages of care. an assessment framework for the ‘ second prong ’ of the eip standard ( ie care in accordance with nice recommendations ) and an accompanying four - point performance assessment scale has been developed. the early intervention in psychosis scoring matrix contains a scoring matrix, comprising three domains and a sub - matrix of three domains. an overall score will be calculated from domains in the scoring matrix only and will not include items in the sub - matrix. each item, each domain and an overall rating will be scored at one of four levels :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 47, "section": "3.3.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• level 4 : top performing • level 3 : performing well • level 2 : needs improvement • level 1 : greatest need for improvement", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 47, "section": "3.3.3", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3. 4 routine collection of outcomes data clarity on expected service user outcomes is key to measuring and monitoring the effectiveness of services. the eip expert reference group has recommended that three outcome tools should be used in eip services. as a minimum, these should be used :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 48, "section": "3.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• during initial assessment • at six and 12 months • annually, and • upon discharge.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 48, "section": "3.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "however, services should be working towards routine and regular use of these or other suitable measures this will support care planning and ongoing monitoring of service users to determine whether shared treatment goals are being achieved, to reinforce the therapeutic alliance and to ensure full pre - and post - treatment outcome data for 100 % of all cases. the three recommended tools together provide ratings of the clinician ’ s assessment alongside service users ’ views of their needs, experience and stage of recovery. these have been chosen because they have been well researched and cover a wide range of relevant outcomes while being brief and practical to use in routine clinical settings :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 48, "section": "3.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• health of the nation outcome scales ( honos )", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 48, "section": "3.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‒ this clinician - rated outcome measure covers safety, substance use, physical health, symptoms and social issues. 44 it has been used regularly in services as it forms part of the clustering tool and therefore is familiar to clinicians. the child and adolescent version ( honosca ) should be used for under 18s.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 48, "section": "3.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• dialog", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 48, "section": "3.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‒ a service user - rated outcome and experience measure, which focuses on quality of life, care needs and treatment satisfaction. 45", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 48, "section": "3.4", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "48 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• the process of recovery questionnaire ( qpr )", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‒ developed in collaboration with service users, 46 the qpr asks about key aspects of personal recovery including connectedness, hope, identity, meaning to life and empowerment. both dialog and the qpr were developed for people aged over 18, although they may be suitable for some young people. the decision about which measure to use should be taken on a case by case basis in collaboration with the young person. if dialog and / or qpr are deemed inappropriate a general functioning tool should be used as a measure of outcome including the suite of outcome measures in routine use in children and young people ’ s mental health services. the goal based outcome measure ( gbo ) is a clinically relevant tool which is readily integrated within clinical practice while the strengths and difficulties questionnaire ( sdq ) and experience of service questionnaire ( esq ) are generic outcomes and experience measures respectively – all of which are available within mhsds. within the community mental health transformation, services outside of eip are recommended to use and flow data from three patient reported outcome measures ( proms ) by the end of 23 / 24. these three measures are :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• dialog", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‒ as above.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• goal based outcomes ( gbo )", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‒ a measure that focuses on an individual ’ s personal goals.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• reqol - 10", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‒ a 10 item prom that measures the factors associated with personal recovery, plus there is an additional question that asks about physical health. reqol has been developed for people aged 16 and up. to allow for outcomes to be measured consistently throughout a person ’ s care journey, it would be beneficial for eip to use the same outcome measures as other community services. to ensure existing service users are not impacted by the introduction of new proms during their time in eip services, changes will be implemented incrementally.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "49 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 50, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "in 2023 / 24 the national standard for service users to have paired scores from at least two outcome measures will remain ; however, the choice of outcome measure will increase to include gbo and reqol in addition to honos, qpr and dialog.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 50, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "50 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "4. key commissioning and service", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "development considerations all areas will have an existing eip service, but it is likely that services will require investment and significant development in order to meet the two key conditions of the access and waiting time standard and that this can be met equally for children and young people and the relevant data flowed. this section provides a step - by - step process that local commissioners and providers can follow. commissioning and service development plans should be co - produced with a range of stakeholders, including service users and their families or carers, partner organisations and relevant voluntary sector organisations. step 1 : understand local demand commissioners should develop a good understanding of local demand, drawing upon local provider intelligence. to achieve this, they should :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• use the national mental health intelligence network ’ s fingertips tool to", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "establish the estimated psychosis incidence rate per 100, 000. ‒ while the access and waiting time standard is applicable to people aged 14 - 65 it should be noted that the incidence rate defined by the fingertips tool is for people aged 16 to 65 years. the incidence rate can be multiplied by the population of 16 to 65 - year olds in the local system catchment area to understand the expected number of new cases of first episode psychosis expected per year. eip is typically a 3 - year service. ‒ further estimations should be put in place for young people aged 14 and 15 years old. fingertips uses the predictions tool, psymaptic, which provides predicted incidence rates for local authority areas. ‒ commissioners should familiarise themselves with the methodology used to produce these predictions, including the confidence levels and caveats that apply.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• work with providers to understand the current referral rate :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‒ this will be higher than the incidence rate because a number of people are referred who do not go on to develop first episode psychosis – this may mean additional referrals totalling up to double the incidence rate.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "51 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‒ systems will need a clear understanding of referrals for eip and arms for the full age - range, ie 14 to 65 - year olds. ‒ this should also include ensuring the referral demand of children and young people in the 14 to 18 and under 14 age group is captured, especially if these referrals have previously been directed to children and young people ’ s mental health services.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• arrive at a local referral estimate. combine the two factors above with any", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "specific local factors that may impact on the referral rate.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• understand the demographic profile. beneath an overall incidence rate for", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "an area, incidence rates vary across age, gender and ethnicity. step 2 : develop an outline service model commissioners and providers should work together, using the staffing models, service examples and pathways provided in this tool to :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• apply the understanding of local need to identify the staffing complement", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "and competencies required. the workforce planning tool can be used to help with this.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• consider any reasons why the use of a standalone team would not be the", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "appropriate model, such as geography. if using a hub and spoke model, consider how the service will overcome the inherent risks of this approach and deliver the same benefits as the evidence - based stand - alone model.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• consider the age - appropriateness of the service offered. this should be", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "informed by the age profile of the icb area and the impact it has on incidence, and arrangements for those under 18.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• outline the service model, including consideration of the number of teams,", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "management, clinical leadership, and any specific characteristics the team will need to address demographic considerations identified in step 1.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• identify and understand current referral pathways, including external and", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "internal referral sources ( for example, self - referrals, gps, inpatient wards, assessment teams, crisis resolution and home treatment teams, drug and alcohol services, schools, colleges and universities, and the police ), partners in service delivery or identification of referrals ( for example,", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 52, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "52 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 53, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "voluntary and community organisations and social services ) and discharge pathways ( for example, into cmhts, primary care ).", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 53, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• commission arms pathway, this includes working to identify estimated", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 53, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "demand for arms provision in the local population to develop provision for people experiencing an arms. step 3 : obtain baseline current service provision and identify gaps once an outline service model has been developed, a plan should be produced that sets out how to progress from current service provision to the new model. commissioners should work with their providers to :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 53, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• compare staffing numbers, skill - mix and competencies in the new model", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 53, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "with current provision. ‒ as well as current staffing of eip services, this should consider the resources currently being used for those aged over 35 and under 18 ( if not currently supported by an eip service ). ‒ consideration also needs to be given to the qualifications, competencies and supervision arrangements of those providing cbt for psychosis and family intervention, prescribing, and those providing employment support and physical health interventions.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 53, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• the pathway should include staff who have specific training, experience", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 53, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "and skills in both eip and cyp mh. ‒ this should also include competencies in relation to atypical neuro - development, safeguarding and education settings, for further information see the university college london competence framework for child and adolescent mental health services.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 53, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• identify gaps in provision. this should enable development of recruitment", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 53, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "and training plans. this work should be informed by the findings of the eip national clinical audit ( see section 4. 3. 3 ). step 4 : agree service redesign, recruitment and training plans once assessment of workforce requirements has been made, the implications for service reconfiguration, recruitment and workforce development will need to be", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 53, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "53 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 54, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "considered jointly with providers. a task and finish design and implementation group will need to be established to ensure the necessary changes are made. commissioners should :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 54, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• agree service redesign plans with providers. this may involve major or", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 54, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "minor redesign, but should include arrangements to ensure : ‒ the eip service can routinely provide nice - recommended interventions to people with or at high risk of developing first episode psychosis aged 14 - 65 ‒ interventions are provided by suitably qualified staff who are properly supervised ‒ clinician and service - user reported outcomes are routinely collected and used effectively to improve care.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 54, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• agree recruitment plans with providers, including how they will address any", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 54, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "specific demographic issues. all areas should ensure that the workforce is reflective of the population it serves, with due regard for all protected characteristics.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 54, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• agree training plans with providers, engaging local education and training", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 54, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "boards as necessary, and ensuring that : ‒ there are sufficient numbers of people trained in cbt for psychosis ‒ staff delivering family intervention are suitably trained ‒ staff delivering educational and employment support are suitably trained ‒ all staff have a good knowledge of the importance of physical health interventions for people with psychosis, and how they will deliver these. step 5 : design local referral to treatment pathways and accompanying protocols and guidance having identified referral pathways in step 2, local services and commissioners will need to develop protocols and guidance consistent with their current referral practices, for example single point of access or referral directly to eip services, and electronic care record systems. they should :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 54, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• compile a list of external and internal referral sources", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 54, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‒ consulting with stakeholders to ensure the list is comprehensive.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 54, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "54 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• ensure that protocols and guidance are in place for the pathway", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‒ these should make it clear who should be referred and when in order to ensure that the access and waiting time standard can be met. there should also be protocols to ensure children and young people ’ s mental health services and adult services work together as described in section 3. 7. 4.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• provide education and training programme for referrers", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‒ to ensure that people with suspected first episode psychosis or an at - risk mental state are picked up in primary care, or in other non - specialist settings, including education, youth justice and third sector services counselling, and promptly referred.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• consider a public awareness campaign", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "‒ working with local authorities and other partners to raise the overall levels of awareness in the population about psychosis, in order to increase early help seeking and improve the likelihood of signs or symptoms of psychosis being recognised and reducing the stigma associated with it. step 6 : ensure the necessary changes have been made to provider electronic care records and information systems to enable monitoring of performance against the standard the electronic care record system should enable collection and submission of data in three key areas :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• referral to treatment waiting time performance • performance against the requirement that the treatment accessed is in line", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "with nice recommendations", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• routine measurement of outcomes", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "step 7 : agree data quality improvement and performance monitoring plans commissioners should :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• agree a data quality improvement plan with their provider to ensure full", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "reporting against the standards ( as per step 7 above ), including timescales and milestones.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• agree a schedule for performance reporting - this may be worked into", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "existing performance reporting and management arrangements.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 55, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "55 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 56, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "step 8 : agree benefits realisation plan this should identify key benefits and set out how they will be delivered, measured and reported, in the context of a multi - year development trajectory. key benefits of providing an eip service should include :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 56, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• reduced waiting times for people accessing services through meeting the", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 56, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "two - week maximum rtt waiting time standard", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 56, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• improved care for individuals, families and carers through routine access to", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 56, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "the full range of nice - recommended interventions delivered by suitably qualified and supervised staff", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 56, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• improved mental health, physical health and social outcomes for service", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 56, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "users", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 56, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• improved experience of services for people in need of mental health care", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 56, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "and their families", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 56, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• potential for reduced costs, through reduced use of crisis and acute", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 56, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "services, including use of the mental health act 1983", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 56, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• improved awareness and satisfaction among referrers.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 56, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "56 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 57, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "appendix 1 : expert reference group membership matthew patrick ( chair ) chief executive, south london and maudsley nhs foundation trust tim kendall ( facilitator ) director, national collaborating centre for mental health, medical director and consultant psychiatrist sheffield health and social care nhs foundation trust, visiting professor, university college london tom ayers service director, community services, sheffield health and social care nhs foundation trust ; national service advisor, national collaborating centre for mental health alison brabban national clinical advisor for smi ( iapt ), nhs england ceri dare expert by experience rhiannon england gp clinical lead for mental health city and hackney paul french associate director, greater manchester west nhs mental health trust ; clinical lead for mental health, greater manchester, lancashire and south cumbria strategic clinical network ; honorary professor, institute of psychology health and society, university of liverpool philippa garety professor of clinical psychology, department of psychology, institute of psychiatry, psychology and neuroscience, king ’ s college london ; honorary consultant clinical psychologist, clinical director and joint leader, psychosis clinical academic group, king ’ s health partners and south london and maudsley nhs foundation trust rebecca gate research assistant, national collaborating centre for mental health becki hemming mental health access and waiting times programme manager, mental health clinical policy and strategy team, medical directorate, nhs england", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 57, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "57 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 58, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "sonia johnson professor of social and community psychiatry, division of psychiatry, university college london peter jones professor of psychiatry, university of cambridge sarah khan deputy head of mental health, mental health clinical policy and strategy team medical directorate, nhs england david kingdon smi expert reference group chair, wessex academic health science network ; national clinical advisor, national collaborating centre for mental health james kirkbride sir henry dale fellow, division of psychiatry, university college london warren larkin consultant clinical psychologist, early intervention in psychosis service ; clinical director children and families network, lancashire care nhs foundation trust suzanne law research assistant, national collaborating centre for mental health belinda lennox clinical senior lecturer, department of psychiatry, university of oxford max marshall medical director, lancashire care nhs foundation trust stephen mcgowan national lead. iris early intervention in psychosis network jonathan mitchell consultant psychiatrist, sheffield health and social care nhs foundation trust maryla moulin senior project manager, national collaborating centre for mental health carol paton chief pharmacist, oxleas nhs foundation trust paula reid senior policy officer, rethink mental illness david shiers retired gp, leek, north staffordshire ; carer representative jo smith professor of early intervention and psychosis, university of worcester", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 58, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "58 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 59, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "geraldine strathdee national clinical director mental health, nhs england clare taylor senior editor, national collaborating centre for mental health alison yung clinical professor of psychiatry, university of manchester and honorary consultant psychiatrist, greater manchester west nhs mental health foundation trust", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 59, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "special acknowledgments susie acknew clinical psychologist, worcestershire early intervention in psychosis service, worcestershire health and care nhs trust sarah amani senior program manager, oxford academic health science network rachel ball service manager, leeds eip service, ‘ aspire ’ max birchwood professor of youth mental health, division of health and wellbeing, warwick medical school, university of warwick anita brewin consultant clinical psychologist and clinical lead, bradford and airedale eip service frank burbach consultant clinical psychologist, lead for triangle of care and early intervention in psychosis and head of psychology and psychological therapies somerset partnership nhs foundation trust ; operational manager for step, aspergers services and carers services roger davies clinical psychologist, adolescent mental health team, city and hackney specialist camhs, east london foundation trusts jane dunning deputy director of clinical strategy, nhs england north mental health team guy dodgson consultant clinical psychologist in eip, northumberland, tyne and wear nhs foundation trust", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 59, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "59 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 60, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "tony gillam clinical manager, worcestershire eip service, worcestershire health and care nhs trust lynne howey consultant clinical psychologist, tees, esk and wear valleys nhs foundation trust chris jackson clinical lead, birmingham and solihull eip service louise johns consultant clinical psychologist and project lead, iapt - smi psychosis demonstration site, south london and maudsley nhs foundation trust paul jones team manager, southampton eip service steve jones national service advisor, children & young people ’ s mental health programme, nhs england claude jousselin clinical service lead slam early intervention and oasis, lambeth early onset service clare lamb consultant child and adolescent psychiatrist, north wales adolescent service and facts iain macmillan consultant psychiatrist, northumberland, tyne and wear nhs foundation trust david monk partner and co - founder, symmetric margaret oates outcomes and informatics project manager, medical directorate, mental health unit, nhs england mary parfaitt regional quality assurance manager, midlands and east sacha schofield headteacher, becton school, kenwood centre and hospital and home education service, sheffield judd skelton interim head of integrated commissioning – adults and older people, salford tom tasker clinical lead for mental health, salford matthew taylor associate clinical director, early intervention pathway, south london and maudsley nhs foundation trust and clinical senior lecturer, king ' s college london", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 60, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "60 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 61, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "kim thompson regional medical manager, nhs england north mental health team miranda wolpert cyp iapt national informatics advisor ann york child and adolescent psychiatrist, clinical lead, cyp iapt south west collaborative", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 61, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "appendix 2 : expert reference group 2020 refresh membership alison brabban ( chair ) national clinical advisor for smi ( iapt ), nhs england consultant clinical psychologist, tees, esk and wear valleys paul french clinical lead for national clinical audit of psychosis, national clinical audit of psychosis jay nairn senior programme manager, adult mental health, nhs england shael ahmed business support, adult mental health, nhs england beth mcgeever programme manager, adult mental health, nhs england stephen mcgowan regional clinical lead for early intervention in psychosis, nhs england ; national lead for the iris early intervention in psychosis network sarah amani senior programme manager at south eip programme, hosted by university of oxford professor rachel upthgrove professor of psychiatry and youth mental health consultant psychiatrists early intervention in psychosis guy dodgson trust wide lead for early intervention in psychosis, cumbria, northumberland, tyne and wear nhs foundation trust", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 61, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "61 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 62, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "margaret oates outcomes and informatics senior programme manager, nhs england madhuri pankhania network quality improvement manager, east of england clinical network david mccluskey clinical network manager, north west coast clinical network, nhs england veenu gupta service user advisor, national clinical audit of psychosis carl money senior analyst, nhs england prathiba chitsabesan national speciality advisor children & young people ’ s mental health programme, nhs england ; consultant child and adolescent psychiatrist, pennine care nhs foundation trust. dawn hyde south east eip families and carers participation lead, south east and south west clinical network vidyah adamson strategic clinical and transformation lead eip, nottinghamshire healthcare nhs foundation trust ; regional clinical lead for early intervention in psychosis, east midlands clinical network steve jones national service advisor, children & young people ’ s mental health programme, nhs england", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 62, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "62 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 63, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "appendix 3 : essential components of a nice - approved care package this appendix provides a summary of nice - recommended interventions from :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 63, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• psychosis and schizophrenia in children and young people nice guideline • psychosis and schizophrenia in adults nice guideline • psychosis and schizophrenia in adults nice quality standard.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 63, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "table 5 : nice - recommended interventions for children and young people with psychosis intervention delivery of the interventions provider outcome assessment to address psychiatric, medical, physical health and wellbeing, psychological and psychosocial, developmental, social, occupational, and economic domains, and to routinely monitor coexisting conditions, for all children and young people with first episode psychosis. specialist eip service, whether situated in a children and young people ’ s mental health service or an adult eip service with input from consultants from children and young people ’ s mental health services. comprehensive co - produced biopsychosocial formulation inclusive of trauma and adversity", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 63, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "63 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 64, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "intervention delivery of the interventions provider outcome family intervention to be offered in conjunction with cbt for psychosis and antipsychotic medication. advice that they are more effective in combination should be provided. if the child or young person has a psychological intervention without antipsychotics, a time limit of 1 month for reviewing treatment options should be agreed. to be delivered between three months and one year over at least 10 planned sessions ; the child or young person with psychosis should be included if practical ; and the family ' s preference for single - or multi - family group intervention and the relationship between the main carer and the child or young person with psychosis should be taken into account. a therapist or care co - ordinator, who is trained in family intervention reduced hospitalisation and relapse, and improved social functioning antipsychotic medication to be offered in conjunction with cbt for psychosis and family intervention. advice that they are more effective in combination should be provided. a baseline investigation and regular and systematic monitoring of symptoms and side effects should be conducted. psychiatrist reduced symptom severity and associated distress, improved rates of recovery, decreased relapse rates monitoring of physical health to be monitored at least once a year. children and young people who smoke or who have high blood pressure, raised lipid levels or increased waist measurement should be identified and cardiovascular disease and diabetes monitored for. mental", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 64, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "relapse rates monitoring of physical health to be monitored at least once a year. children and young people who smoke or who have high blood pressure, raised lipid levels or increased waist measurement should be identified and cardiovascular disease and diabetes monitored for. mental healthcare provider maintains responsibility for monitoring physical health and the effects of antipsychotic medication for at least the first 12 months or until the child or young person ’ s condition has stabilised ; thereafter, the responsibility for this monitoring may be transferred to primary care ( the gp or practice nurse ) under shared care arrangements to reduce the trajectory towards weight gain, minimise adverse change in glucose and lipid metabolism, improved quality of life and improved rate of smoking cessation", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 64, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "64 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 65, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "table 6 : nice - recommended interventions for children and young people with an at - risk mental state intervention delivery of the interventions provider outcome assessment to be carried out if a child or young person experiences either :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 65, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• transient or attenuated psychotic symptoms • other experiences or behaviours suggestive of possible", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 65, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "psychosis. if no clear diagnosis can be made, monitor for changes in symptoms and functioning for up to 3 years children and young people ’ s mental health services or an eip service ; assessments in children and young people ’ s mental health services should include a consultant psychiatrist ; assessments in eip services should be multidisciplinary to identify whether a child or young person may be at risk of developing psychosis individual cbt with or without family intervention to be offered along with interventions recommended in nice guidelines for coexisting mental health problems ( see row below ). cbt : deliver on a one - to - one basis over at least 16 planned sessions. for the number of sessions of family intervention see table 4. clinical psychologists or cbt therapists, who have undertaken training on a course meeting competency standards for nice - recommended therapy. a therapist or care coordinator, who is trained in family intervention. to prevent transition to psychosis interventions for co - existing mental health problems to be offered for depression, any of the anxiety disorders, emerging personality disorder or substance misuse, along with individual cbt ( with or without family intervention ). primary care, children and young people ’ s mental health services, substance misuse services to treat coexisting mental health problems antipsychotic medication not to be offered to children and young people for psychotic symptoms or mental state changes not sufficient", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 65, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": ". primary care, children and young people ’ s mental health services, substance misuse services to treat coexisting mental health problems antipsychotic medication not to be offered to children and young people for psychotic symptoms or mental state changes not sufficient for a diagnosis of psychosis or schizophrenia or with the aim of decreasing the risk or preventing psychosis. n / a n / a", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 65, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "65 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 66, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "table 7 : nice - recommended interventions for adults with psychosis intervention delivery of the interventions provider outcome comprehensive multidisciplinary assessment to address psychiatric, medical, physical health and wellbeing, psychological and psychosocial, developmental, social, occupational, and economic domains, and to routinely monitor coexisting conditions, for all people with first episode psychosis. psychiatrist, a psychologist or a professional with expertise in the psychological treatment of people with psychosis or schizophrenia comprehensive co - produced biopsychosocial formulation inclusive of trauma and adversity antipsychotic medication to be offered in combination with family intervention and individual cbt for psychosis for first episode psychosis and subsequent episodes. the choice of drug should be made by the service user and healthcare professional together, after provision of information and discussion about the likely benefits and possible side effects of each drug. adults with schizophrenia whose symptoms have not responded adequately to treatment with at least two antipsychotic drugs used sequentially should be offered clozapine. antipsychotic medication should not be offered to people considered to be at increased risk of developing psychosis or with the aim of decreasing the risk of or preventing psychosis. psychiatrist reduced symptom severity, and associated distress, improved rates of recovery. cbt for psychosis to be offered in combination with family intervention and antipsychotic medication for first episode psychosis and", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 66, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "decreasing the risk of or preventing psychosis. psychiatrist reduced symptom severity, and associated distress, improved rates of recovery. cbt for psychosis to be offered in combination with family intervention and antipsychotic medication for first episode psychosis and subsequent episodes. cbt for psychosis should be delivered on a one - to - one basis over at least 16 planned sessions. clinical psychologists or cbt therapists who have undertaken specific training in cbt for psychosis on a course meeting competency standards for nice - recommended therapy. reduced distress and severity of symptoms, improved social functioning and reduced hospital rates", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 66, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "66 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 67, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "intervention delivery of the interventions provider outcome family intervention to be offered in combination with individual cbt for psychosis and antipsychotic medication for first episode psychosis and subsequent episodes. family intervention should be delivered for between three months and one year over at least 10 planned sessions ; the person with psychosis should be included if practical ; and the family ' s preference for single - or multi - family group intervention and the relationship between the main carer and the person with psychosis should be taken into account. a therapist or care co - ordinator who is trained in family intervention reduced hospitalisation and relapse, increased medication adherence and improvement in social functioning supported employment programmes and vocational rehabilitation to be offered to people with psychosis who wish to return to work. other occupational or educational activities, including pre - vocational training, can be considered for people who are unable to work or are unsuccessful in finding employment. trained vocational workers or employment specialists, who are aware of the specific needs of people with psychosis. higher rates of competitive employment, longer duration of employment and number of hours worked. carer - focused education and support programmes to be offered as early as possible to all carers. these programmes, which may be part of a family intervention, should be available as needed and provide a message about recovery. any eip team member reduced carer burden, reduced long - term distress and improved experience", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 67, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "early as possible to all carers. these programmes, which may be part of a family intervention, should be available as needed and provide a message about recovery. any eip team member reduced carer burden, reduced long - term distress and improved experience of caregiving.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 67, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "67 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 68, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "intervention delivery of the interventions provider outcome physical health interventions and monitoring a combined healthy eating and physical activity programme should be offered to people with psychosis, especially those taking antipsychotics. weight and cardiovascular and metabolic indicators of morbidity should be monitored. if a person has rapid or excessive weight gain, abnormal lipid levels or problems with blood glucose management, interventions in line with relevant nice guidance should be offered. help to stop smoking should be offered. mental healthcare provider maintains responsibility for monitoring physical health and the effects of antipsychotic medication for at least the first 12 months or until the person ’ s condition has stabilised ; thereafter, the responsibility for this monitoring may be transferred to primary care ( the gp or practice nurse ) under shared care arrangements to reduce the trajectory towards weight gain, minimise adverse change in glucose and lipid metabolism, improved quality of life and improved rate of smoking cessation", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 68, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "68 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 69, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "table 8 : nice - recommended interventions for adults with an at - risk mental state intervention delivery of the interventions provider outcome assessment to be carried out if a person is distressed, has a decline in social functioning and has any of the following :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 69, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "• transient or attenuated psychotic symptoms • other experiences or behaviours suggestive of possible psychosis • a first degree relative with psychosis or schizophrenia.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 69, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "a consultant psychiatrist or mental health practitioner in an eip service or specialist mental health service with training in identifying at - risk mental states. to identify whether or not a person may be at - risk of developing psychosis individual cbt with or without family intervention to be offered along with interventions recommended in nice guidelines for coexisting mental health problems ( see row below ). cbt : deliver on a one - to - one basis over at least 16 planned sessions. for the number of sessions of family intervention see table 7. clinical psychologists or cbt therapists, who have undertaken training on a course meeting competency standards for nice - recommended therapy. a therapist or care coordinator who is trained in family intervention. to prevent transition to psychosis interventions for coexisting mental health problems to be offered for depression, any of the anxiety disorders, emerging personality disorder or substance misuse, along with individual cbt ( with or without family intervention ). primary care, secondary care mental health services, substance misuse services to treat coexisting mental health problems antipsychotic medication not to be offered for people considered to be at increased risk of developing psychosis or with the aim of decreasing the risk or preventing psychosis. n / a n / a", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 69, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "69 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 70, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "appendix 4 : the full referral to treatment pathway", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 70, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "70 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 71, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "references", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 71, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "1 greenwood ke, berry c, labuschagne k, chandler r, peters e, de visser r, field a and garety p. ( 2011 ). http : / / www. nihr. ac. uk / research / research - for - patient - benefit _ 1. htm 2 greenwood ke, berry c, labuschagne k, chandler r, peters e, de visser r, field a and garety p. ( 2015 ). facilitating engagement and hope to protect against social disability : the early youth", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 71, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "engagement ( eye ) project and beyond. schizophrenia bulletin 41 : suppl 1 s174", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 71, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "3 mcdonald k, ding t, ker h, dliwayo tr, osborn d, wohland p, et al. forecasting population need for mental health care : a bayesian methodology applied to the epidemiology of psychotic disorders to inform early intervention in psychosis service provision in england. br j psych. under review 4 kirkbride jb, errazuriz a, croudace tj, morgan c, jackson d, boydell j, et al. incidence of schizophrenia and other psychoses in england, 1950 – 2009 : a systematic review and meta - analyses. plos one. 2012 ; 7 : e31660. 5 www. psymaptic. org 6 marshall m, lewis s, lockwood a, drake r, jones p, croudace t. association between duration of untreated psychosis and outcome in cohorts of first - episode patients : a systematic review. archives of general psychiatry. 2005 ; 62 : 975 – 83. 7 kirkbride jb, fearon p, morgan c, dazzan p, morgan k, tarrant j, et al. heterogeneity in incidence rates of schizophrenia and other psychotic syndromes : findings from the 3 - center aesop study. archives of general psychiatry. 2006 ; 63 : 250 – 58. 8 march d, hatch", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 71, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "##rant j, et al. heterogeneity in incidence rates of schizophrenia and other psychotic syndromes : findings from the 3 - center aesop study. archives of general psychiatry. 2006 ; 63 : 250 – 58. 8 march d, hatch sl, morgan c, kirkbride jb, bresnahan m, fearon p, et al. psychosis and place. epidemiologic reviews. 2008 ; 30 : 84 – 100. 9 marshall m, lewis s, lockwood a, drake r, jones p, croudace t. association between duration of untreated psychosis and outcome in cohorts of first - episode patients : a systematic review. archives of general psychiatry. 2005 ; 62 : 975 – 83. 10 bevan s, gulliford j, steadman k, taskila t, thomas r, moise a. working with schizop hrenia :", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 71, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "pathways to employment, recovery and inclusion. uk : lancaster university ; 2013.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 71, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "11 wahlbeck k, westman j, nordentoft m, gissler m, laursen tm. outcomes of nordic mental health systems : life expectancy of patients with mental disorders. the british journal of psychiatry. 2011 ; 199 : 453 – 58. 12 jacobs r, aylott l, dare c, doran t, gilbody s, goddard m, et al. the association between primary care quality and health - care use, costs and outcomes for people with serious mental illness : a retrospective observational study. health serv deliv res 2020 ; 8 ( 25 ) 13 power, p. & robinson, j. ( 2009 ). suicide prevention in first - episode psychosis. in : p. mcgorry & h. jackson ( eds ), the recognition and management of early psychosis : a preventative approach. cambridge university press. 14 bird v, premkumar p, kendall t, whittington c, mitchell j, kuipers e. early intervention services, cognitive – behavioural therapy and family intervention in early psychosis : systematic review. the british journal of psychiatry. 2010 ; 197 : 350 – 56. 15 stafford mr, jackson h, mayo - wilson e, morrison ap, kendall t. early interventions to prevent psychosis : systematic review and meta - analysis. british medical journal. 2013 ; 346 : f185", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 71, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "; 197 : 350 – 56. 15 stafford mr, jackson h, mayo - wilson e, morrison ap, kendall t. early interventions to prevent psychosis : systematic review and meta - analysis. british medical journal. 2013 ; 346 : f185. 16 van der gaag m, smit f, bechdolf a, et al. preventing a first episode of psychosis : meta - analysis of randomized controlled prevention trials of 12 month and longer - term follow - ups. schizophr res. 2013 ; 149 ( 1 - 3 ) : 56 - 62. doi : 10. 1016 / j. schres. 2013. 07. 004 17 camacho - gomez m, castellvi p. effectiveness of family intervention for preventing relapse in first - episode psychosis until 24 months of follow - up : a systematic review with meta - analysis of randomized controlled trials. schizophr bull. 2020 ; 46 ( 1 ) : 98 - 109. doi : 10. 1093 / schbul / sbz038 18 bird v, premkumar p, kendall t, whittington c, mitchell j, kuipers e. early intervention services, cognitive - behavioural therapy and family intervention in early psychosis : systematic review. br j psychiatry. 2010 ; 197 ( 5 ) : 350 - 356.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 71, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": ", whittington c, mitchell j, kuipers e. early intervention services, cognitive - behavioural therapy and family intervention in early psychosis : systematic review. br j psychiatry. 2010 ; 197 ( 5 ) : 350 - 356. doi : 10. 1192 / bjp. bp. 109. 074526", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 71, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "71 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 72, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "19 revier cj, reininghaus u, dutta r, fearon p, murray rm, doody ga, et al. ten - year outcomes of first - episode psychoses in the mrc æsop - 10 study. the journal of nervous and mental disease. 2015 ; 203 : 379.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 72, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "20 birchwood m, connor c, lester h, patterson p, freemantle n, marshall m, et al. reducing", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 72, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "duration of untreated psychosis : care pathways to early intervention in psychosis services. the british journal of psychiatry. 2013 ; 203 : 58 – 64.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 72, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "21 french p, shiers d, jones p. gp guidance : early detection of emerging psychosis - 2014 update. royal college of general practitioners & royal college of psychiatrists ; 2014.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 72, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "22 upthegrove r, birchwood m, ross k, brunett k, mccollum r, jones l. the evolution of depression and suicidality in first episode psychosis. acta psychiatr scand. 2010 sep ; 122 ( 3 ) : 211 - 8. 23 brunet, kat, birchwood, m. j., upthegrove, rachel, michail, maria and ross, kerry ( 2012 ) a prospective study of ptsd following recovery from first - episode psychosis : the threat from persecutors, voices, and patienthood. british journal of clinical psychology, 51 ( 4 ). pp. 418 - 433. 24 nice. psychosis with coexisting substance misuse : assessment and management in adults and young people. nice clinical guideline 120. london : nice ; 2011. 25 bebbington p, jonas s, kuipers e, king m, cooper c, brugha t, et al. childhood sexual abuse and psychosis : data from a cross - sectional national psychiatric survey in england. the british journal of psychiatry. 2011 ; 199 : 29 - 37. 26 varese f, smeets f, drukker m, lieverse r, lataster t, viechtbauer w, et al. childhood adversities increase the risk of psychosis", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 72, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "; 199 : 29 - 37. 26 varese f, smeets f, drukker m, lieverse r, lataster t, viechtbauer w, et al. childhood adversities increase the risk of psychosis : a meta - analysis of patient - control, prospective - and cross - sectional cohort studies. schizophrenia bulletin. 2012 ; 38 : 661 - 71. 27 nccmh. psychosis and schizophrenia in adults : the nice guideline on treatment and management. leicester and london : the british psychology society and the royal college of psychiatrists ; 2014. [ full guideline ] 28 rapoport j, chavez a, greenstein d, addington a, gogtay n. autism spectrum disorders and childhood - onset schizophrenia : clinical and biological contributions to a relation revisited. journal of the american academy of child & adolescent psychiatry. 2009 ; 48 : 10 - 18. 29 jacobsen l, rapoport j. research update : childhood - onset schizophrenia : implications for clinical and neurobiological research. journal of child psychology and psychiatry. 1998 ; 39 : 101 - 13. 30 marder sr, glynn sm, wirshing wc, wirshing da, ross d, widmark c, et al. maintenance treatment of schizophrenia with risperidone or haloperidol : 2 - year outcomes. american journal", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 72, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "##der sr, glynn sm, wirshing wc, wirshing da, ross d, widmark c, et al. maintenance treatment of schizophrenia with risperidone or haloperidol : 2 - year outcomes. american journal of psychiatry. 2014 ; 160 : 1405 – 12. 31 alvarez - jimenez m, gonzalez - blanch c, crespo - facorro b, hetrick s, rodriguez - sanchez jm, perez - iglesias r, et al. antipsychotic - induced weight gain in chronic and first - episode psychotic disorders. cns drugs. 2008 ; 22 : 547 - 62. 32 kahn rs, fleischhacker ww, boter h, davidson m, vergouwe y, keet ip, et al. effectiveness of antipsychotic drugs in first - episode schizophrenia and schizophreniform disorder : an open randomised clinical trial. the lancet. 2008 ; 371 : 1085 - 97. 33 foley dl, morley ki. systematic review of early cardiometabolic outcomes of the first treated episode of psychosis. archives of general psychiatry. 2011 ; 68 : 609 - 16. 34 leucht s, burkard t, henderson j, maj m, sartorius n. physical illness and schizophrenia : a review of the literature. act", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 72, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "##sis. archives of general psychiatry. 2011 ; 68 : 609 - 16. 34 leucht s, burkard t, henderson j, maj m, sartorius n. physical illness and schizophrenia : a review of the literature. acta psychiatrica scandinavica. 2007 ; 116 : 317 - 33. 35 duffy sa, kilbourne am, austin kl, dalack gw, woltmann em, waxmonsky j, et al. risk of smoking and receipt of cessation services among veterans with mental disorders. psychiatric services. 2012 ; 63 : 325 - 32. 36 himelhoch s, daumit g. to whom do psychiatrists offer smoking - cessation counseling? american journal of psychiatry. 2014 ; 160 : 2228 - 30. 37 iris. iris guidelines update september 2012 : revision of the original 1998 iris guidelines. london : rethink & nhs confederation ; 2012. 38 curtis l. unit costs of health and social care. canterbury : personal social services research unit ; 2014.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 72, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "72 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 73, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "39 csip / nimhe. new ways of working for everyone : a best practice implementation guide. uk : dh publications ; 2007. 40 craig t, shepherd g, rinaldi m, smith j, carr s, preston f, singh s. vocational rehabilitation in early psychosis : cluster randomised trial. the british journal of psychiatry. 2014 ; 205 : 145 - 150. 41 nice. autism diagnosis in children and young people : recognition, referral and diagnosis of children and young people on the autism spectrum. nice clinical guideline 128. london : nice ;", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 73, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "2011.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 73, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "42 french, p. 2004. early detection and cognitive therapy for people at high risk of developing psychosis : a treatment approach. 43 valmaggia, lucia r et al. “ duration of untreated psychosis and need for admission in patients who engage with mental health services in the prodromal phase. ” the british journal of psychiatry : the journal of mental science vol. 207, 2 ( 2015 ) : 130 - 134. doi : 10. 1192 / bjp. bp. 114. 150623. 44 wing j, beevor a, curtis r, park s, hadden s, burns a. health of the nation outcome scales ( honos ). research and development. the british journal of psychiatry. 1998 ; 172 : 11 – 18. 45 priebe s, mccabe r, bullenkamp j, hansson l, lauber c, martinez - leal r, et al. structured patient – clinician communication and 1 - year outcome in community mental healthcare. cluster randomised controlled trial. the british journal of psychiatry. 2007 ; 191 : 420 – 26. 46 law h, neil st, dunn g, morrison ap. psychometric properties of the questionnaire about the process of recovery ( qpr ). schizophrenia research. 2014 ; 156 : 184 – 89.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 73, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "73 | implementing the eip access and waiting time standard : guidance", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 74, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "nhs england wellington house 133 - 155 waterloo road london se1 8ug", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 74, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "this publication can be made available in a number of alternative formats on request.", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 74, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "© nhs england 2022 | pr1954", "metadata": {"doc_name": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard", "page": 74, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "B1954-implementing-the-early-intervention-in-psychosis-access-and-waiting-time-standard"}}
{"text": "dementia : assessment, management and support for people living with dementia and their carers nice guideline published : 20 june 2018 www. nice. org. uk / guidance / ng97 © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ).", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 1, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "your responsibility the recommendations in this guideline represent the view of nice, arrived at after careful consideration of the evidence available. when exercising their judgement, professionals and practitioners are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or the people using their service. it is not mandatory to apply the recommendations, and the guideline does not override the responsibility to make decisions appropriate to the circumstances of the individual, in consultation with them and their families and carers or guardian. all problems ( adverse events ) related to a medicine or medical device used for treatment or in a procedure should be reported to the medicines and healthcare products regulatory agency using the yellow card scheme. local commissioners and providers of healthcare have a responsibility to enable the guideline to be applied when individual professionals and people using services wish to use it. they should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing nice recommendations wherever possible. dementia : assessment, management and support for", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 2, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "way that would be inconsistent with complying with those duties. commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing nice recommendations wherever possible. dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 2 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 2, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1 involving people living with dementia in decisions about their care........................................... 11", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2 diagnosis.......................................................................................................................................... 14", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 3 care coordination............................................................................................................................ 20", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 4 interventions to promote cognition, independence and wellbeing............................................ 21", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5 pharmacological interventions for dementia................................................................................ 22", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 6 medicines that may cause cognitive impairment......................................................................... 26", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7 managing non - cognitive symptoms.............................................................................................. 27", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 8 assessing and managing other long - term conditions in people living with dementia............. 30", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 9 risks during hospital admission..................................................................................................... 32", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.9", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 10 palliative care................................................................................................................................. 32", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.10", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 11 supporting carers........................................................................................................................... 33", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.11", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 12 moving to different care settings................................................................................................. 35", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 13 staff training and education......................................................................................................... 35 terms used in this guideline................................................................................................................. 37 putting this guideline into practice.........................................", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.13", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": ".. 37 putting this guideline into practice........................................................................................... 40 recommendations for research................................................................................................ 42 1 case management............................................................................", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.13", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "................................................................................................... 42 2 staff training....................................................................................................................................... 42 dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.13", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "........ 42 dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 3 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 3, "section": "1.13", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "3 anticholinergic burden...................................................................................................................... 43 4 managing delirium superimposed on dementia.............................................................................. 43 5 care and support planning.............................................................", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "..................................................................................................... 43 finding more information and committee details.................................................................... 45 update information.....................................................................................................", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "................................................................. 46 dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 4 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "this guideline replaces cg42, esuom41 and esuom40. this guideline partially replaces ta217. this guideline is the basis of qs50 and qs184. overview this guideline covers diagnosing and managing dementia ( including alzheimer ' s disease ). it aims to improve care by making recommendations on training staff and helping carers to support people living with dementia. nice has also produced a guideline on mid - life approaches to delay or prevent the onset of dementia. who is it for?", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• healthcare and social care professionals caring for and supporting people living with", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "dementia", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• commissioners and providers of dementia health and social care services • housing associations, private and voluntary organisations contracted by the nhs or", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "social services to provide care for people living with dementia", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• people living with dementia, their families and carers", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 5 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "about this guideline dementia is a term used to describe a range of cognitive and behavioural symptoms that can include memory loss, problems with reasoning and communication and change in personality, and a reduction in a person ' s ability to carry out daily activities, such as shopping, washing, dressing and cooking. the most common types of dementia are : alzheimer ' s disease, vascular dementia, mixed dementia, dementia with lewy bodies and frontotemporal dementia. dementia is a progressive condition, which means that the symptoms will gradually get worse. this progression will vary from person to person and each will experience dementia in a different way – people may often have some of the same general symptoms, but the degree to which these affect each person will vary ( dementia gateway, social care institute for excellence ). a report published by the alzheimer ' s society found that in 2013 there were approximately 815, 000 people living with dementia in the uk. if current trends continue, this number is expected to increase to 1, 143, 000 by 2025. in england, the national dementia and antipsychotic prescribing audit found that approximately 31, 000 people were newly diagnosed with dementia in 2011. this is an increase of 8 % between 2006 and 2011. finally, in december 2017, there were 456, 739 people on gp registers with a formal diagnosis of dementia, up from approximately 290,", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "people were newly diagnosed with dementia in 2011. this is an increase of 8 % between 2006 and 2011. finally, in december 2017, there were 456, 739 people on gp registers with a formal diagnosis of dementia, up from approximately 290, 000 people in 2009 / 10, with the majority of this difference accounted for by an increase in diagnosis rates. the alzheimer ' s society report found that in 2013 the total cost of dementia in the uk was estimated to be £26. 3 billion. of this, approximately £4. 3 billion consists of health care, and approximately £10. 3 billion consists of social care. the remaining £11. 6 billion accounts for estimated unpaid care contributions. why is it needed? providing care and support is very complex, because of the number of people living with dementia and the variation in the symptoms each person faces. this has led to considerable variation in practice. areas that pose particular challenges for services and practitioners may include :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• coordinating care and support between different services", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 6 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• what support carers need, and how this should be provided • staff training.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "this guideline makes evidence - based recommendations aiming to support these areas of practice. dementia also has significant costs for health and social care services. because of this, it is important to ensure that people living with dementia can get the care and support they need, and that services provide this in an efficient and cost - effective way. in addition, new methods for diagnosing and assessing dementia have been developed. amyloid imaging techniques have been licensed for use in the uk, and new evidence is available for cerebrospinal fluid examination. there is also evidence on different approaches to assess and diagnose dementia subtypes. the guideline makes new recommendations on dementia diagnosis, based on a review of the latest evidence. what does it cover? this guideline addresses how dementia should be assessed and diagnosed. it covers person - centred care and support, tailored to the specific needs of each person living with dementia. as part of this, it can help professionals involve people living with dementia and their carers in decision - making, so they can get the care and support they need. it also addresses care coordination and staff training, and how dementia may impact on the care offered for other conditions. the guideline does not cover every aspect of dementia care or support, or areas where recommendations would be the same for people with or without dementia. it focuses on areas where :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• there is variation in practice, and enough evidence is available to identify what works", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "best", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• people living with dementia need different care and support to people in the same", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "situation who do not have dementia. dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 7 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "how has it been developed? this guideline has been developed by a multidisciplinary guideline committee, using an extensive review of research evidence. to ensure that the committee had the necessary social care expertise, a subgroup of social care practitioners was recruited to develop recommendations in this area. given the costs of dementia and the financial pressures facing health and social care services, the committee focused on making recommendations in areas where there is good evidence available. this will help services make the most of limited resources. for areas with a lack of evidence, the committee has made recommendations for future research ( on health and social care topics ) to address gaps in the evidence base. future updates of the guideline will look at any relevant new research that has been published. some recommendations are made with more certainty than others. we word our recommendations to reflect this. in the sections on interventions we use ' offer ' to reflect a strong recommendation, usually where there is clear evidence of benefit. we use ' consider ' to reflect a recommendation for which the evidence of benefit is less certain. for more information see making decisions using nice guidelines. how does it relate to statutory and non - statutory guidance? the guideline complements existing legislation and guidance. it describes how services and professionals can provide high - quality care and support. the prime minister ' s challenge on dementia 2020 sets out the uk government ' s strategy for transforming dementia care", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "- statutory guidance? the guideline complements existing legislation and guidance. it describes how services and professionals can provide high - quality care and support. the prime minister ' s challenge on dementia 2020 sets out the uk government ' s strategy for transforming dementia care within the uk. the aims of the strategy include :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• improving diagnosis, assessment and care for people living with dementia • ensuring that all people living with dementia have equal access to diagnosis • providing all nhs staff with training on dementia appropriate to their role • ensuring that every person diagnosed with dementia receives meaningful care.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "since the 2006 nice guideline on dementia was developed, key new legislation has been implemented. the care act 2014 created a new legislative framework for adult social care, dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 8 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "and also gives carers a legal right to assessment and support. relevant legislation and statutory guidance", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• nhs england ( 2015 ) accessible information standard • care act 2014 • health and social care act 2008 ( regulated activities ) regulations 2014 • department of health ( 2014 ) care act 2014 : statutory guidance for implementation • department of health ( 2014 ) positive and proactive care : reducing the need for", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "restrictive interventions", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• health and social care act 2012 • equality act 2010 • mental capacity act 2005 • human rights act 1998", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "relevant policies and non - statutory guidance", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• information commissioner ' s office ( 2017 ) guide to the general data protection", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "regulation", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• nhs england ( 2017 ) dementia : good care planning • nhs england ( 2015 ) implementation guide and resource pack for dementia care • skills for health, health education england and skills for care ( 2015 ) dementia core", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "skills education and training framework. this framework was commissioned and funded by the department of health and developed in collaboration by skills for health and health education england in partnership with skills for care", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• department of health ( 2014 ) nhs outcomes framework 2015 to 2016 • department of health ( 2014 ) adult social care outcomes framework 2015 to 2016", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 9 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "person - centred care this guideline offers best - practice advice on care and support for people living with dementia and their families and carers. the principles of person - centred care underpin good practice in dementia care, and they are reflected in the recommendations. these principles assert :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• the human value of people living with dementia ( regardless of age or cognitive", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "impairment ) and their families and carers", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• the individuality of people living with dementia, and how their personality and life", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "experiences influence their response to dementia", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• the importance of the person ' s perspective • the importance of relationships and interactions with others to the person living with", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "dementia, and their potential for promoting wellbeing. finally, the principles emphasise the importance of taking account of the needs of carers ( whether they are family and friends or paid care - workers ), and supporting and enhancing their input. dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 10 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1 involving people living with dementia in decisions about their care involving people in decision - making", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 11, "section": "1.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1. 1 encourage and enable people living with dementia to give their own views and opinions about their care.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 11, "section": "1.1.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1. 2 if needed, use additional or modified ways of communicating ( for example visual aids or simplified text ). dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 11 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 11, "section": "1.1.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1. 3 consider using a structured tool to assess the likes and dislikes, routines and personal history of a person living with dementia. providing information", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 12, "section": "1.1.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1. 4 provide people living with dementia and their family members or carers ( as appropriate ) with information that is relevant to their circumstances and the stage of their condition.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 12, "section": "1.1.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1. 5 be aware of the obligation to provide accessible information as detailed in the nhs accessible information standard. for more guidance on providing information and discussing people ' s preferences with them, see the nice guidelines on patient experience in adult nhs services and people ' s experience in adult social care services.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 12, "section": "1.1.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1. 6 at diagnosis, offer the person and their family members or carers ( as appropriate ) oral and written information that explains :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 12, "section": "1.1.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• what their dementia subtype is and the changes to expect as the condition", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 12, "section": "1.1.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "progresses", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 12, "section": "1.1.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• which healthcare professionals and social care teams will be involved in their", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 12, "section": "1.1.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "care and how to contact them", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 12, "section": "1.1.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• if appropriate, how dementia affects driving, and that they need to tell the", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 12, "section": "1.1.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "driver and vehicle licensing agency ( dvla ) and their car insurer about their dementia diagnosis", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 12, "section": "1.1.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• their legal rights and responsibilities • their right to reasonable adjustments ( in line with the equality act 2010 ) if", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 12, "section": "1.1.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "they are working or looking for work", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 12, "section": "1.1.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• how the following groups can help and how to contact them :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 12, "section": "1.1.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "－ local support groups, online forums and national charities － financial and legal advice services dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 12 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 12, "section": "1.1.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1. 7 if it has not been documented earlier, ask the person at diagnosis :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.1.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• for their consent for services to share information • which people they would like services to share information with ( for example", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.1.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "family members or carers )", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.1.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• what information they would like services to share.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.1.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "document these decisions in the person ' s records.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.1.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1. 8 after diagnosis, direct people and their family members or carers ( as appropriate ) to relevant services for information and support ( see recommendations 1. 3. 1 and", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.1.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 3. 2 on care coordination ).", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.3.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1. 9 for people who do not want follow - up appointments and who are not using other services, ask if they would like to be contacted again at a specified future date.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.1.9", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1. 10 ensure that people living with dementia and their carers know how to get more information and who from if their needs change.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.1.10", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1. 11 tell people living with dementia ( at all stages of the condition ) about research studies they could participate in. advance care planning", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.1.11", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1. 12 offer early and ongoing opportunities for people living with dementia and people involved in their care ( see recommendation 1. 1. 7 ) to discuss :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.1.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• the benefits of planning ahead • lasting power of attorney ( for health and welfare decisions and property and", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.1.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "financial affairs decisions )", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.1.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• an advance statement about their wishes, preferences, beliefs and values", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.1.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "regarding their future care dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 13 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 13, "section": "1.1.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 1. 13 at each care review, offer people the chance to review and change any advance statements and decisions they have made.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 14, "section": "1.1.13", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2 diagnosis initial assessment in non - specialist settings", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 14, "section": "1.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 1 at the initial assessment take a history ( including cognitive, behavioural and psychological symptoms, and the impact symptoms have on their daily life ) :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 14, "section": "1.2.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• from the person with suspected dementia and • if possible, from someone who knows the person well ( such as a family", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 14, "section": "1.2.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "member ).", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 14, "section": "1.2.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 2 if dementia is still suspected after initial assessment :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 14, "section": "1.2.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• conduct a physical examination and • undertake appropriate blood and urine tests to exclude reversible causes of", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 14, "section": "1.2.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "cognitive decline and", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 14, "section": "1.2.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• use cognitive testing.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 14, "section": "1.2.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 3 when using cognitive testing, use a validated brief structured cognitive instrument such as :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 14, "section": "1.2.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• the 10 - point cognitive screener ( 10 - cs ) • the 6 - item cognitive impairment test ( 6cit )", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 14, "section": "1.2.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 14 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 14, "section": "1.2.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 4 do not rule out dementia solely because the person has a normal score on a cognitive instrument.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 15, "section": "1.2.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 5 when taking a history from someone who knows the person with suspected dementia, consider supplementing this with a structured instrument such as the informant questionnaire on cognitive decline in the elderly ( iqcode ) or the functional activities questionnaire ( faq ).", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 15, "section": "1.2.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 6 refer the person to a specialist dementia diagnostic service ( such as a memory clinic or community old age psychiatry service ) if :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 15, "section": "1.2.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• reversible causes of cognitive decline ( including delirium, depression,", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 15, "section": "1.2.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "sensory impairment [ such as sight or hearing loss ] or cognitive impairment from medicines associated with increased anticholinergic burden ) have been investigated and", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 15, "section": "1.2.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• dementia is still suspected.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 15, "section": "1.2.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 7 if the person has suspected rapidly - progressive dementia, refer them to a neurological service with access to tests ( including cerebrospinal fluid examination ) for creutzfeldt – jakob disease and similar conditions.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 15, "section": "1.2.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 8 for more guidance on assessing for dementia in people with learning disabilities, see the nice guideline on mental health problems in people with learning disabilities. diagnosis in specialist dementia diagnostic services", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 15, "section": "1.2.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 9 diagnose a dementia subtype ( if possible ) if initial specialist assessment dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 15 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 15, "section": "1.2.9", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 10 if alzheimer ' s disease is suspected, include a test of verbal episodic memory in the assessment.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 16, "section": "1.2.10", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 11 consider neuropsychological testing if it is unclear :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 16, "section": "1.2.11", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• whether the person has cognitive impairment or • whether their cognitive impairment is caused by dementia or • what the correct subtype diagnosis is.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 16, "section": "1.2.11", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 12 use validated criteria to guide clinical judgement when diagnosing dementia subtypes, such as :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 16, "section": "1.2.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• international consensus criteria for dementia with lewy bodies • international ftd criteria for frontotemporal dementia ( progressive non - fluent", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 16, "section": "1.2.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "aphasia and semantic dementia )", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 16, "section": "1.2.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• international frontotemporal dementia consortium criteria for behavioural", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 16, "section": "1.2.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "variant frontotemporal dementia", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 16, "section": "1.2.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• ninds - airen criteria ( national institute of neurological disorders and stroke", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 16, "section": "1.2.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "and association internationale pour la recherche et l ' enseignement en neurosciences ) for vascular dementia", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 16, "section": "1.2.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• nia criteria ( national institute on aging ) for alzheimer ' s disease • movement disorders society criteria for parkinson ' s disease dementia • international criteria for creutzfeldt - jakob disease.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 16, "section": "1.2.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 13 offer structural imaging to rule out reversible causes of cognitive decline and to assist with subtype diagnosis, unless dementia is well established and the subtype is clear.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 16, "section": "1.2.13", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 14 only consider further tests ( recommendations 1. 2. 15 – 28 ) if : dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 16 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 16, "section": "1.2.14", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 15 if the diagnosis is uncertain ( see recommendation 1. 2. 14 ) and alzheimer ' s disease is suspected, consider either :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 17, "section": "1.2.15", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• fdg - pet ( fluorodeoxyglucose - positron emission tomography - ct ), or", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 17, "section": "1.2.15", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "perfusion spect ( single - photon emission ct ) if fdg - pet is unavailable or", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 17, "section": "1.2.15", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• examining cerebrospinal fluid for :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 17, "section": "1.2.15", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "－ either total tau or total tau and phosphorylated - tau 181 and － either amyloid beta 1 – 42 or amyloid beta 1 – 42 and amyloid beta 1 – 40. if a diagnosis cannot be made after one of these tests, consider using the other one.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 17, "section": "1.2.15", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 16 be aware that the older a person is, the more likely they are to get a false positive with cerebrospinal fluid examination.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 17, "section": "1.2.16", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 17 do not rule out alzheimer ' s disease based solely on the results of ct or mri scans.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 17, "section": "1.2.17", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 18 do not use apolipoprotein e genotyping or electroencephalography to diagnose alzheimer ' s disease.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 17, "section": "1.2.18", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 19 be aware that young - onset alzheimer ' s disease has a genetic cause in some people. dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 17 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 17, "section": "1.2.19", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 20 if the diagnosis is uncertain ( see recommendation 1. 2. 14 ) and dementia with lewy bodies is suspected, use 123 i - fp - cit spect.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 18, "section": "1.2.20", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 21 if 123 i - fp - cit spect is unavailable, consider 123 i - mibg cardiac scintigraphy.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 18, "section": "1.2.21", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 22 do not rule out dementia with lewy bodies based solely on normal results on 123 i - fp - cit spect or 123 i - mibg cardiac scintigraphy. further tests for frontotemporal dementia", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 18, "section": "1.2.22", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 23 if the diagnosis is uncertain ( see recommendation 1. 2. 14 ) and frontotemporal dementia is suspected, use either :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 18, "section": "1.2.23", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• fdg - pet or • perfusion spect.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 18, "section": "1.2.23", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 24 do not rule out frontotemporal dementia based solely on the results of structural, perfusion or metabolic imaging tests.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 18, "section": "1.2.24", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 25 be aware that frontotemporal dementia has a genetic cause in some people. further tests for vascular dementia", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 18, "section": "1.2.25", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 26 if the dementia subtype is uncertain and vascular dementia is suspected, use mri. if mri is unavailable or contraindicated, use ct.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 18, "section": "1.2.26", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 27 do not diagnose vascular dementia based solely on vascular lesion burden.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 18, "section": "1.2.27", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 28 be aware that young - onset vascular dementia has a genetic cause in some people. dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 18 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 18, "section": "1.2.28", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 29 only conduct case finding for suspected dementia as part of a clinical trial that also provides an intervention to people diagnosed with dementia. telling the difference between delirium and dementia in people without a diagnosis of either", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 19, "section": "1.2.29", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 30 for people who are in hospital and have cognitive impairment with an unknown cause, consider using one of the following to find out whether they have delirium or delirium superimposed on dementia, compared with dementia alone :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 19, "section": "1.2.30", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• the long confusion assessment method ( cam ) • the observational scale of level of arousal ( osla ).", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 19, "section": "1.2.30", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 31 do not use standardised instruments ( including cognitive instruments ) alone to distinguish delirium from delirium superimposed on dementia.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 19, "section": "1.2.31", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 32 if it is not possible to tell whether a person has delirium, dementia, or delirium superimposed on dementia, treat for delirium first. for guidance on treating delirium, see treating delirium in the nice guideline on delirium. review after diagnosis", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 19, "section": "1.2.32", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 33 after a person is diagnosed with dementia, ensure they and their family members or carers ( as appropriate ) have access to a memory service or equivalent hospital - or primary - care - based multidisciplinary dementia service.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 19, "section": "1.2.33", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 34 memory services and equivalent hospital - and primary - care - based multidisciplinary dementia services should offer a choice of flexible access or prescheduled monitoring appointments.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 19, "section": "1.2.34", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 2. 35 when people living with dementia or their carers have a primary care appointment, assess for any emerging dementia - related needs and ask them if they need any more support. dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 19 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 19, "section": "1.2.35", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 3 care coordination", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 20, "section": "1.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 3. 1 provide people living with dementia with a single named health or social care professional who is responsible for coordinating their care.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 20, "section": "1.3.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 3. 2 named professionals should :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 20, "section": "1.3.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• arrange an initial assessment of the person ' s needs, which should be face to", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 20, "section": "1.3.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "face if possible", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 20, "section": "1.3.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• provide information about available services and how to access them • involve the person ' s family members or carers ( as appropriate ) in support and", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 20, "section": "1.3.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "decision - making", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 20, "section": "1.3.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• give special consideration to the views of people who do not have capacity", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 20, "section": "1.3.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "to make decisions about their care, in line with the principles of the mental capacity act 2005", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 20, "section": "1.3.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• ensure that people are aware of their rights to and the availability of local", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 20, "section": "1.3.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "advocacy services, and if appropriate to the immediate situation an independent mental capacity advocate", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 20, "section": "1.3.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• develop a care and support plan, and :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 20, "section": "1.3.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "－ agree and review it with the involvement of the person, their family members or carers ( as appropriate ) and relevant professionals － specify in the plan when and how often it will be reviewed － evaluate and record progress towards the objectives at each review － ensure it covers the management of any comorbidities － provide a copy of the plan to the person and their family members or carers ( as appropriate ). transferring information between services and care settings", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 20, "section": "1.3.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 3. 3 when developing care and support plans and advance care and support plans, dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 20 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 20, "section": "1.3.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 3. 4 service providers should ensure that information ( such as care and support plans and advance care and support plans ) can be easily transferred between different care settings ( for example home, inpatient, community and residential care ).", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.3.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 3. 5 staff delivering care and support should maximise continuity and consistency of care. ensure that relevant information is shared and recorded in the person ' s care and support plan. making services accessible", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.3.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 3. 6 service providers should design services to be accessible to as many people living with dementia as possible, including :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.3.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• people who do not have a carer or whose carer cannot support them on their", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.3.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "own", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.3.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• people who do not have access to affordable transport, or find transport", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.3.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "difficult to use", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.3.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• people who have other responsibilities ( such as work, children or being a", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.3.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "carer themselves )", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.3.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• people with learning disabilities, sensory impairment ( such as sight or hearing", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.3.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "loss ) or physical disabilities", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.3.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• people who may be less likely to access health and social care services, such", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.3.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "as people from black, asian and minority ethnic groups.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.3.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 4 interventions to promote cognition, independence and wellbeing", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 4. 1 offer a range of activities to promote wellbeing that are tailored to the person ' s preferences. dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 21 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 21, "section": "1.4.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 4. 2 offer group cognitive stimulation therapy to people living with mild to moderate dementia.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 22, "section": "1.4.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 4. 3 consider group reminiscence therapy for people living with mild to moderate dementia.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 22, "section": "1.4.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 4. 4 consider cognitive rehabilitation or occupational therapy to support functional ability in people living with mild to moderate dementia.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 22, "section": "1.4.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 4. 5 do not offer acupuncture to treat dementia.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 22, "section": "1.4.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 4. 6 do not offer ginseng, vitamin e supplements, or herbal formulations to treat dementia.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 22, "section": "1.4.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 4. 7 do not offer cognitive training to treat mild to moderate alzheimer ' s disease.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 22, "section": "1.4.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 4. 8 do not offer interpersonal therapy to treat the cognitive symptoms of mild to moderate alzheimer ' s disease.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 22, "section": "1.4.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 4. 9 do not offer non - invasive brain stimulation ( including transcranial magnetic stimulation ) to treat mild to moderate alzheimer ' s disease, except as part of a randomised controlled trial.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 22, "section": "1.4.9", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5 pharmacological interventions for dementia managing medicines for all dementia subtypes", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 22, "section": "1.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 1 for guidance on managing medicines ( including covert administration ), see the nice guidelines on managing medicines for adults receiving social care in the community and managing medicines in care homes. pharmacological management of alzheimer ' s disease", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 22, "section": "1.5.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 2 the three acetylcholinesterase ( ache ) inhibitors donepezil, galantamine and dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 22 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 22, "section": "1.5.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 3 memantine monotherapy is recommended as an option for managing alzheimer ' s disease for people with :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 23, "section": "1.5.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• moderate alzheimer ' s disease who are intolerant of or have a", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 23, "section": "1.5.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "contraindication to ache inhibitors or", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 23, "section": "1.5.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• severe alzheimer ' s disease.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 23, "section": "1.5.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "treatment should be under the conditions specified in 1. 5. 5. this recommendation is from nice technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of alzheimer ' s disease.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 23, "section": "1.5.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 4 for people with an established diagnosis of alzheimer ' s disease who are already taking an ache inhibitor :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 23, "section": "1.5.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• consider memantine in addition to an ache inhibitor if they have moderate", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 23, "section": "1.5.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "disease", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 23, "section": "1.5.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• offer memantine in addition to an ache inhibitor if they have severe disease.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 23, "section": "1.5.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 5 treatment should be under the following conditions :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 23, "section": "1.5.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• for people who are not taking an ache inhibitor or memantine, prescribers", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 23, "section": "1.5.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "should only start treatment with these on the advice of a clinician who has the necessary knowledge and skills. this could include : － secondary care medical specialists such as psychiatrists, geriatricians and neurologists － other healthcare professionals ( such as gps, nurse consultants and dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 23 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 23, "section": "1.5.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 6 if prescribing an ache inhibitor ( donepezil, galantamine or rivastigmine ), treatment should normally be started with the drug with the lowest acquisition cost ( taking into account required daily dose and the price per dose once shared care has started ). however, an alternative ache inhibitor could be prescribed if it is considered appropriate when taking into account adverse event profile, expectations about adherence, medical comorbidity, possibility of drug interactions and dosing profiles. this recommendation is from nice technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of alzheimer ' s disease.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 24, "section": "1.5.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 7 when using assessment scales to determine the severity of alzheimer ' s disease, healthcare professionals should take into account any physical, sensory or learning disabilities, or communication difficulties that could affect the results and make any adjustments they consider appropriate. healthcare professionals should also be mindful of the need to secure equality of access to treatment for patients from different ethnic groups, in particular those from different cultural backgrounds. this recommendation is from nice technology appraisal guidance on donepezil, dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 24 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 24, "section": "1.5.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 8 when assessing the severity of alzheimer ' s disease and the need for treatment, healthcare professionals should not rely solely on cognition scores in circumstances in which it would be inappropriate to do so. these include :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 25, "section": "1.5.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• if the cognition score is not, or is not by itself, a clinically appropriate tool for", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 25, "section": "1.5.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "assessing the severity of that patient ' s dementia because of the patient ' s learning difficulties or other disabilities ( for example, sensory impairments ), linguistic or other communication difficulties or level of education or", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 25, "section": "1.5.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• if it is not possible to apply the tool in a language in which the patient is", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 25, "section": "1.5.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "sufficiently fluent for it to be appropriate for assessing the severity of dementia or", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 25, "section": "1.5.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• if there are other similar reasons why using a cognition score, or the score", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 25, "section": "1.5.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "alone, would be inappropriate for assessing the severity of dementia. in such cases healthcare professionals should determine the need for initiation or continuation of treatment by using another appropriate method of assessment. this recommendation is from nice technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of alzheimer ' s disease.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 25, "section": "1.5.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 9 do not offer the following specifically to slow the progress of alzheimer ' s disease, except as part of a randomised controlled trial :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 25, "section": "1.5.9", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• diabetes medicines • hypertension medicines • statins • non - steroidal anti - inflammatory drugs ( nsaids ), including aspirin.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 25, "section": "1.5.9", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 25 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 25, "section": "1.5.9", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 10 offer donepezil or rivastigmine to people with mild to moderate dementia with lewy bodies.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 26, "section": "1.5.10", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 11 only consider galantamine for people with mild to moderate dementia with lewy bodies if donepezil and rivastigmine are not tolerated.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 26, "section": "1.5.11", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 12 consider donepezil or rivastigmine for people with severe dementia with lewy bodies.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 26, "section": "1.5.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 13 consider memantine for people with dementia with lewy bodies if ache inhibitors are not tolerated or are contraindicated.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 26, "section": "1.5.13", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 14 only consider ache inhibitors or memantine for people with vascular dementia if they have suspected comorbid alzheimer ' s disease, parkinson ' s disease dementia or dementia with lewy bodies.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 26, "section": "1.5.14", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 15 do not offer ache inhibitors or memantine to people with frontotemporal dementia. note that logopenic aphasia, which has previously been included in some diagnostic guidelines for frontotemporal dementia, has now been shown to most commonly be caused by alzheimer ' s disease", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 26, "section": "1.5.15", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 16 do not offer ache inhibitors or memantine to people with cognitive impairment caused by multiple sclerosis.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 26, "section": "1.5.16", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 5. 17 for guidance on pharmacological management of parkinson ' s disease dementia, see parkinson ' s disease dementia in the nice guideline on parkinson ' s disease.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 26, "section": "1.5.17", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 6 medicines that may cause cognitive impairment", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 26, "section": "1.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 6. 1 be aware that some commonly prescribed medicines are associated with dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 26 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 26, "section": "1.6.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 6. 2 consider minimising the use of medicines associated with increased anticholinergic burden, and if possible look for alternatives :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 27, "section": "1.6.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• when assessing whether to refer a person with suspected dementia for", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 27, "section": "1.6.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "diagnosis", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 27, "section": "1.6.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• during medication reviews with people living with dementia.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 27, "section": "1.6.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 6. 3 be aware that there are validated tools for assessing anticholinergic burden ( for example, the anticholinergic cognitive burden scale ), but there is insufficient evidence to recommend one over the others.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 27, "section": "1.6.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 6. 4 for guidance on carrying out medication reviews, see medication review in the nice guideline on medicines optimisation.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 27, "section": "1.6.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7 managing non - cognitive symptoms agitation, aggression, distress and psychosis", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 27, "section": "1.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 1 before starting non - pharmacological or pharmacological treatment for distress in people living with dementia, conduct a structured assessment to :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 27, "section": "1.7.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• explore possible reasons for their distress and • check for and address clinical or environmental causes ( for example pain,", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 27, "section": "1.7.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "delirium or inappropriate care ).", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 27, "section": "1.7.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 2 as initial and ongoing management, offer psychosocial and environmental interventions to reduce distress in people living with dementia.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 27, "section": "1.7.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 3 only offer antipsychotics for people living with dementia who are either :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 27, "section": "1.7.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• at risk of harming themselves or others or • experiencing agitation, hallucinations or delusions that are causing them", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 27, "section": "1.7.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 27 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 27, "section": "1.7.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 4 be aware that for people with dementia with lewy bodies or parkinson ' s disease dementia, antipsychotics can worsen the motor features of the condition, and in some cases cause severe antipsychotic sensitivity reactions. for more guidance, see the advice on managing delusions and hallucinations in the nice guideline on parkinson ' s disease. be aware that interventions may need to be modified for people living with dementia.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 28, "section": "1.7.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 5 before starting antipsychotics, discuss the benefits and harms with the person and their family members or carers ( as appropriate ). consider using a decision aid to support this discussion. nice has produced a patient decision aid on antipsychotic medicines for treating agitation, aggression and distress in people living with dementia.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 28, "section": "1.7.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 6 when using antipsychotics :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 28, "section": "1.7.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• use the lowest effective dose and use them for the shortest possible time • reassess the person at least every 6 weeks, to check whether they still need", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 28, "section": "1.7.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "medication.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 28, "section": "1.7.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 7 stop treatment with antipsychotics :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 28, "section": "1.7.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• if the person is not getting a clear ongoing benefit from taking them and • after discussion with the person taking them and their family members or", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 28, "section": "1.7.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "carers ( as appropriate ).", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 28, "section": "1.7.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 8 ensure that people living with dementia can continue to access psychosocial and dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 28 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 28, "section": "1.7.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 9 for people living with dementia who experience agitation or aggression, offer personalised activities to promote engagement, pleasure and interest.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 29, "section": "1.7.9", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 10 do not offer valproate to manage agitation or aggression in people living with dementia, unless it is indicated for another condition. if relevant, follow the mhra safety advice on the use of valproate, valproate use in people younger than 55 years, valproate use in women and girls, valproate use in men and anti - epileptic drugs in pregnancy. depression and anxiety", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 29, "section": "1.7.10", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 11 for people living with mild to moderate dementia who have mild to moderate depression and / or anxiety, consider psychological treatments.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 29, "section": "1.7.11", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 12 do not routinely offer antidepressants to manage mild to moderate depression in people living with mild to moderate dementia, unless they are indicated for a pre - existing severe mental health problem. sleep problems", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 29, "section": "1.7.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 13 do not offer melatonin to manage insomnia in people living with alzheimer ' s disease.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 29, "section": "1.7.13", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 14 for people living with dementia who have sleep problems, consider a personalised multicomponent sleep management approach that includes sleep hygiene education, exposure to daylight, exercise and personalised activities. parkinson ' s disease", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 29, "section": "1.7.14", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 15 for guidance on managing parkinson ' s disease symptoms in people with parkinson ' s disease dementia or dementia with lewy bodies, see the nice dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 29 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 29, "section": "1.7.15", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 8 assessing and managing other long - term conditions in people living with dementia", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 30, "section": "1.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 8. 1 ensure that people living with dementia have equivalent access to diagnosis, treatment and care services for comorbidities to people who do not have dementia. for more guidance on assessing and managing multimorbidity, see the nice guidelines on multimorbidity and older people with social care needs and multiple long - term conditions.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 30, "section": "1.8.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 8. 2 for more guidance on providing support for older adults with learning disabilities, see the nice guideline on care and support of people growing older with learning disabilities. pain", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 30, "section": "1.8.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 8. 3 consider using a structured observational pain assessment tool :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 30, "section": "1.8.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• alongside self - reported pain and standard clinical assessment for people", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 30, "section": "1.8.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "living with moderate to severe dementia", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 30, "section": "1.8.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• alongside standard clinical assessment for people living with dementia who", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 30, "section": "1.8.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "are unable to self - report pain.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 30, "section": "1.8.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 8. 4 for people living with dementia who are in pain, consider using a stepwise treatment protocol that balances pain management and potential adverse events.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 30, "section": "1.8.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 8. 5 repeat pain assessments for people living with dementia :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 30, "section": "1.8.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• who seem to be in pain • who show signs of behavioural changes that may be caused by pain • after any pain management intervention.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 30, "section": "1.8.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 30 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 30, "section": "1.8.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 8. 6 for guidance on managing the risk of falling for people living with dementia ( in community and inpatient settings ), see the nice guideline on falls in older people. when using this guideline :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 31, "section": "1.8.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• take account of the additional support people living with dementia may need", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 31, "section": "1.8.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "to participate effectively", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 31, "section": "1.8.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• be aware that multifactorial falls interventions may not be suitable for a", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 31, "section": "1.8.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "person living with severe dementia. diabetes", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 31, "section": "1.8.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 8. 7 for guidance on setting hba1c targets for people living with severe dementia who have type 2 diabetes, see recommendation 1. 6. 9 in the nice guideline on type 2 diabetes in adults. incontinence", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 31, "section": "1.8.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 8. 8 for guidance on pharmacological treatment of overactive bladder, see the nice technology appraisal on mirabegron for treating symptoms of overactive bladder.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 31, "section": "1.8.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 8. 9 for guidance on treating faecal incontinence, see recommendations 1. 7. 2 and", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 31, "section": "1.8.9", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 7. 8 in the nice guideline on faecal incontinence. sensory impairment", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 31, "section": "1.7.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 8. 10 for guidance on hearing assessments for people with suspected or diagnosed dementia, see adults with suspected dementia in the nice guideline on hearing loss.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 31, "section": "1.8.10", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 8. 11 encourage people living with dementia to have an eye test soon after diagnosis if they have not had one recently, and then every 2 years. consider referring people who cannot organise appointments themselves. dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 31 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 31, "section": "1.8.11", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 9 risks during hospital admission", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 32, "section": "1.9", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 9. 1 be aware of the increased risk of delirium in people living with dementia who are admitted to hospital. see the nice guideline on delirium for interventions to prevent and treat delirium.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 32, "section": "1.9.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 9. 2 when thinking about admission to hospital for a person living with severe dementia, carry out an assessment that balances their current medical needs with the additional harms they may face in hospital, for example :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 32, "section": "1.9.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• disorientation • a longer length of stay • increased mortality • increased morbidity on discharge • delirium • the effects of being in an impersonal or institutional environment.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 32, "section": "1.9.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 9. 3 when thinking about admission to hospital for a person living with dementia, take into account :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 32, "section": "1.9.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• any advance care and support plans • the value of keeping them in a familiar environment.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 32, "section": "1.9.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 10 palliative care", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 32, "section": "1.10", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 10. 1 from diagnosis, offer people living with dementia flexible, needs - based palliative care that takes into account how unpredictable dementia progression can be.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 32, "section": "1.10.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 10. 2 for people living with dementia who are approaching the end of life, use an anticipatory healthcare planning process ( see recommendation 1. 1. 12 on advance care planning ). involve the person and their family members or carers ( as appropriate ) as far as possible, and use the principles of best - interest decision - dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 32 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 32, "section": "1.10.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 10. 3 for standards and measures on palliative care, see the nice quality standard on end of life care for adults.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 33, "section": "1.10.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 10. 4 for guidance on care for people in the last days of life, see the nice guideline on care of dying adults.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 33, "section": "1.10.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 10. 5 for guidance on best interests decision - making, see the nice guideline on decision - making and mental capacity.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 33, "section": "1.10.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 10. 6 encourage and support people living with dementia to eat and drink, taking into account their nutritional needs.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 33, "section": "1.10.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 10. 7 consider involving a speech and language therapist if there are concerns about a person ' s safety when eating and drinking.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 33, "section": "1.10.7", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 10. 8 do not routinely use enteral feeding in people living with severe dementia, unless indicated for a potentially reversible comorbidity. nice has produced a patient decision aid on enteral ( tube ) feeding for people living with severe dementia.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 33, "section": "1.10.8", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 11 supporting carers", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 33, "section": "1.11", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 11. 1 offer carers of people living with dementia a psychoeducation and skills training intervention that includes :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 33, "section": "1.11.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• education about dementia, its symptoms and the changes to expect as the", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 33, "section": "1.11.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "condition progresses", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 33, "section": "1.11.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• developing personalised strategies and building carer skills • training to help them provide care, including how to understand and respond", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 33, "section": "1.11.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "to changes in behaviour", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 33, "section": "1.11.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• training to help them adapt their communication styles to improve", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 33, "section": "1.11.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "interactions with the person living with dementia dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 33 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 33, "section": "1.11.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 11. 2 ensure that the support provided to carers is :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 34, "section": "1.11.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• tailored to their needs and preferences and to what they want it to achieve", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 34, "section": "1.11.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "( for example, providing information on carer ' s employment rights for carers who work or want to work )", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 34, "section": "1.11.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• designed to help them support people living with dementia • available at a location they can get to easily • provided in a format suitable for them ( for example individual or group", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 34, "section": "1.11.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "sessions, or online training and support )", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 34, "section": "1.11.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• available from diagnosis and as needed after this.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 34, "section": "1.11.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 11. 3 be aware that carer interventions are likely to be most effective when provided as group sessions.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 34, "section": "1.11.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 11. 4 advise carers about their right to carer assessment, and assessment for respite care and other support ( see the nice guideline on supporting adult carers for recommendations on identifying, assessing and meeting the caring, physical and mental health needs of families and carers ).", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 34, "section": "1.11.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 11. 5 be aware that carers of people living with dementia are at an increased risk of depression. for guidance on identifying and managing depression, see the nice guideline on depression in adults. dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 34 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 34, "section": "1.11.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 12 moving to different care settings", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.12", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 12. 1 for guidance on managing transition between care settings for people living with dementia, see :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.12.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• the nice guideline on transition between inpatient hospital settings and", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.12.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "community or care home settings for adults with social care needs", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.12.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• the nice guideline on transition between inpatient mental health settings and", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.12.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "community or care home settings", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.12.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• section 1. 2 of the nice guideline on medicines optimisation.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.12.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "follow the principles in these guidelines for transitions between other settings ( for example from home to a care home or respite care ).", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.12.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 12. 2 review the person ' s needs and wishes ( including any care and support plans and advance care and support plans ) after every transition.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.12.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 13 staff training and education", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.13", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 13. 1 care and support providers should provide all staff with training in person - centred and outcome - focused care for people living with dementia, which should include :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.13.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• understanding the signs and symptoms of dementia, and the changes to", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.13.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "expect as the condition progresses", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.13.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• understanding the person as an individual, and their life story • respecting the person ' s individual identity, sexuality and culture • understanding the needs of the person and their family members or carers • the principles of the mental capacity act 2005 and the care act 2014.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.13.1", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 13. 2 care providers should provide additional face - to - face training and mentoring to staff who deliver care and support to people living with dementia. this should dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 35 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 35, "section": "1.13.2", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 13. 3 consider giving carers and / or family members the opportunity to attend and take part in staff dementia training sessions.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 36, "section": "1.13.3", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 13. 4 consider training staff to provide multi - sensory stimulation for people with moderate to severe dementia and communication difficulties.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 36, "section": "1.13.4", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 13. 5 ensure that all health and social care staff are aware of :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 36, "section": "1.13.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• the extent of their responsibility to protect confidentiality under data", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 36, "section": "1.13.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "protection legislation and", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 36, "section": "1.13.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "• any rights that family members, carers and others have to information about", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 36, "section": "1.13.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "the person ' s care ( see recommendation 1. 3. 5 on information sharing between different care settings ).", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 36, "section": "1.13.5", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. 13. 6 health and social care professionals advising people living with dementia ( including professionals involved in diagnosis ) should be trained in starting and dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 36 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 36, "section": "1.13.6", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "holding difficult and emotionally challenging conversations. terms used in this guideline case finding a strategy of actively assessing people who are at risk for a particular disease, before they present with symptoms and before there is clinical suspicion of the condition. it does not refer to situations such as assessing people for dementia after an acute episode of delirium, where clinical suspicion of dementia is likely to already be raised. cognitive rehabilitation identifying functional goals that are relevant to the person living with dementia, and working with them and their family members or carers to achieve these. the emphasis is on improving or maintaining functioning in everyday life, building on the person ' s strengths and finding ways to compensate for impairments, and supporting independence. cognitive rehabilitation does not aim to improve cognition, but addresses the disability resulting from the impact of cognitive impairment on everyday functioning and activity. rehabilitation is sometimes referred to as ' reablement '. cognitive stimulation engaging in a range of activities and discussions ( usually in a group ) that are aimed at general improvement of cognitive and social functioning. cognitive training guided practice on a set of standard tasks that are designed to reflect particular cognitive functions. there may be a range of difficulty levels, to fit the tasks to each person ' s level of ability. interpersonal therapy brief structured attachment - focused therapies for people with mild to moderate depression. these therapies are based on the idea that difficulties interacting with other", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 37, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "of difficulty levels, to fit the tasks to each person ' s level of ability. interpersonal therapy brief structured attachment - focused therapies for people with mild to moderate depression. these therapies are based on the idea that difficulties interacting with other dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 37 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 37, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "people can cause psychological symptoms such as depressed mood, which then make the difficulties with interaction worse, causing a cycle. interpersonal therapies aim to help people interact more effectively with others, and through this improve the psychological symptoms. therapy typically focuses on relationship issues such as conflict, difficulty starting or maintaining relationships, grief and loss, and life changes. prescribing risperidone and haloperidol the marketing authorisation for risperidone only covers short - term treatment ( up to 6 weeks ) of persistent aggression in people with moderate to severe alzheimer ' s disease unresponsive to non - pharmacological approaches and when there is a risk of harm to self or others. the marketing authorisation for haloperidol only covers treatment of persistent aggression and psychotic symptoms in people with moderate to severe alzheimer ' s dementia and vascular dementia when non - pharmacological treatments have failed and when there is a risk of harm to self or others. refer a referral to a diagnostic service does not have to involve a clinic appointment. people can be seen in community settings ( such as their home or a care home ), or advice can be provided to the referrer without a formal appointment being made. the key issue is to ensure that dementia specialists are involved, both for advice on diagnosis and to ensure appropriate access to post - diagnostic support and treatment. specialists are those", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 38, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": ", or advice can be provided to the referrer without a formal appointment being made. the key issue is to ensure that dementia specialists are involved, both for advice on diagnosis and to ensure appropriate access to post - diagnostic support and treatment. specialists are those with the appropriate knowledge and skills and include secondary care medical specialists ( for example psychiatrists, geriatricians and neurologists ) and other healthcare professionals ( for example gps, nurse consultants and advanced nurse practitioners ) with specialist expertise in assessing and diagnosing dementia. social care terms for social care terms see the think local, act personal care and support jargon buster. specialist clinician specialist clinicians ( for the purpose of starting and monitoring treatment with cholinesterase inhibitors and memantine ) are those with the appropriate knowledge and skills and include secondary care medical specialists ( for example psychiatrists, geriatricians and neurologists ) and other healthcare professionals ( for example gps, nurse dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 38 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 38, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "consultants and advanced nurse practitioners ) with specialist expertise in diagnosing and treating alzheimer ' s disease. verbal episodic memory episodic memories include information about recent or past events and experiences ( rather than factual knowledge, or habits and skills ). they may be recent, or from the distant past ( remote or long - term episodic memory ). tests to assess episodic memory may use either verbal or visual material. examples of verbal episodic memory tests include reading the person a list of words or a short story and asking them to recall this information, both immediately and after a delay. dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 39 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 39, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "putting this guideline into practice nice has produced tools and resources to help you put this guideline into practice. putting recommendations into practice can take time. how long may vary from guideline to guideline, and depends on how much change in practice or services is needed. implementing change is most effective when aligned with local priorities. changes recommended for clinical practice that can be done quickly – like changes in prescribing practice – should be shared quickly. this is because healthcare professionals should use guidelines to guide their work – as is required by professional regulating bodies such as the general medical and nursing and midwifery councils. changes should be implemented as soon as possible, unless there is a good reason for not doing so ( for example, if it would be better value for money if a package of recommendations were all implemented at once ). different organisations may need different approaches to implementation, depending on their size and function. sometimes individual practitioners may be able to respond to recommendations to improve their practice more quickly than large organisations. here are some pointers to help organisations put nice guidelines into practice :", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 40, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "1. raise awareness through routine communication channels, such as email or", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 40, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "newsletters, regular meetings, internal staff briefings and other communications with all relevant partner organisations. identify things staff can include in their own practice straight away.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 40, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "2. identify a lead with an interest in the topic to champion the guideline and motivate", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 40, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "others to support its use and make service changes, and to find out any significant issues locally.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 40, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "3. carry out a baseline assessment against the recommendations to find out whether", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 40, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "there are gaps in current service provision.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 40, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "4. think about what data you need to measure improvement and plan how you will collect", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 40, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "it. you may want to work with other health and social care organisations and specialist dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 40 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 40, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "groups to compare current practice with the recommendations. this may also help identify local issues that will slow or prevent implementation.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 41, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "5. develop an action plan, with the steps needed to put the guideline into practice, and", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 41, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "make sure it is ready as soon as possible. big, complex changes may take longer to implement, but some may be quick and easy to do. an action plan will help in both cases.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 41, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "6. for very big changes include milestones and a business case, which will set out", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 41, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "additional costs, savings and possible areas for disinvestment. a small project group could develop the action plan. the group might include the guideline champion, a senior organisational sponsor, staff involved in the associated services, finance and information professionals.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 41, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "7. implement the action plan with oversight from the lead and the project group. big", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 41, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "projects may also need project management support.", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 41, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "8. review and monitor how well the guideline is being implemented through the project", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 41, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "group. share progress with those involved in making improvements, as well as relevant boards and local partners. nice provides a comprehensive programme of support and resources to maximise uptake and use of evidence and guidance. see our into practice pages for more information. also see leng g, moore v, abraham s, editors ( 2014 ) achieving high quality care – practical experience from nice. chichester : wiley. dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 41 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 41, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "recommendations for research the guideline committee has made the following recommendations for research. the committee ' s full set of research recommendations is detailed in the full guideline. 1 case management what is the effectiveness and cost effectiveness of high - intensity case management compared with usual care on quality of life ( for the person living with dementia and for their carers ) and the timing of entry to long - term care? why this is important there is evidence that case management is an effective intervention for people living with dementia. however, the effectiveness and cost effectiveness of high - intensity case management has not been tested in the uk. it has a high upfront cost, but there is some evidence from settings outside the uk that it may reduce the use of other services, leading to cost savings across the whole system. because of the cost, robust evidence of effectiveness and cost effectiveness from a uk setting is needed. 2 staff training what is the cost effectiveness of using a dementia - specific addition to the care certificate for community staff, including dementia - specific elements on managing anxiety, communication, nutritional status and personal care? why this is important robust evidence demonstrates the effectiveness of intensive training for staff heavily involved in providing care and support for people living with dementia. however, it is not clear if it is effective to provide basic training to all staff who come into contact with people living with dementia, or how this training should be provided. one", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 42, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "staff heavily involved in providing care and support for people living with dementia. however, it is not clear if it is effective to provide basic training to all staff who come into contact with people living with dementia, or how this training should be provided. one possibility is an expanded version of the care certificate that includes additional dementia - specific elements. because this training would need to be given to a large number of staff, there needs to be good evidence of benefits, specifically in improving quality of life for people dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 42 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 42, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "living with dementia and their carers, to justify the upfront costs. 3 anticholinergic burden does actively reducing anticholinergic burden in people living with dementia improve cognitive outcomes compared with usual care? why this is important many people living with dementia are still prescribed medicines with a high anticholinergic burden ( which can be caused by individual medicines or by combinations of medicines ). it is often unclear if this prescribing is appropriate, or whether actively reducing the number of these medicines would improve cognition. randomised controlled trials could be conducted, using structured tools to assess anticholinergic burden and actively switching medicines if possible. this would help to identify whether cognition can be improved without adversely affecting the management of the conditions these medicines are prescribed for. 4 managing delirium superimposed on dementia what are the most clinically and cost - effective non - pharmacological interventions for helping the long - term recovery of people with delirium superimposed on dementia? why this is important the acute management of delirium superimposed on dementia is likely to be similar to the management of delirium in people without dementia. however, there may be differences in the interventions needed to aid long - term recovery, particularly because people with different severities of dementia will have different baseline cognitive status. research on the most effective non - pharmacological methods of", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 43, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "without dementia. however, there may be differences in the interventions needed to aid long - term recovery, particularly because people with different severities of dementia will have different baseline cognitive status. research on the most effective non - pharmacological methods of promoting long - term recovery would help to identify whether alternative approaches are needed for people living with dementia. 5 care and support planning what are the most effective methods of care planning for people who do not have regular contact with an informal carer? dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 43 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 43, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "why this is important many randomised controlled trials of care planning or case management specifically exclude people without an informal carer. conducting similar studies on case management and care planning for people without an informal carer would fill this gap in the evidence base, and help to identify whether these people have different needs. dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 44 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 44, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "finding more information and committee details to find nice guidance on related topics, including guidance in development, see the nice topic page on dementia. for full details of the evidence and the guideline committee ' s discussions, see the full guideline. you can also find information about how the guideline was developed, including details of the committee. nice has produced tools and resources to help you put this guideline into practice. for general help and advice on putting our guidelines into practice, see resources to help you put nice guidance into practice. dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 45 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 45, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "update information june 2018 : this guideline is an update of the nice guideline on dementia ( cg42, published november 2006 ) and replaces it. it also replaces recommendation 1. 3 in the nice technology appraisal guidance on donepezil, galantamine, rivastigmine and memantine for the treatment of alzheimer ' s disease. minor changes since publication june 2025 : we amended recommendation 1. 8. 11 on eye tests to ensure problems with eyesight are identified soon after a diagnosis of dementia to help reduce risk of falls and improve quality of life. april 2025 : we updated the links to safety advice from the medicines and healthcare products regulatory agency ( mhra ) in recommendation 1. 7. 10. october 2021 : we have linked to the nice guideline on supporting adult carers in recommendation 1. 11. 4. october 2018 : links have been added to patient decision aids from some recommendations. isbn : 978 - 1 - 4731 - 2978 - 8 dementia : assessment, management and support for people living with dementia and their carers ( ng97 ) © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 46 of 46", "metadata": {"doc_name": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109", "page": 46, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-assessment-management-and-support-for-people-living-with-dementia-and-their-carers-pdf-1837760199109"}}
{"text": "dementia diagnosis and management a brief pragmatic resource for general practitioners", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 1, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "2", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 2, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia diagnosis and management", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 2, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "a brief pragmatic resource for general practitioners", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 2, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "version number : 1", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 2, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "first published : 14 / 01 / 2015", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 2, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "updated : n / a", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 2, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "prepared by :", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 2, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "alistair burns, national clinical director for dementia, nhs england paul twomey, medical director, north yorkshire and humber at nhs england, elizabeth barrett, general practitioner, derbyshire, dan harwood, consultant old age psychiatrist, london, nick cartmell, general practitioner, south devon and torbay, deborah cohen, director of service integration, cambridge and peterborough, david findlay, consultant old age psychiatrist, dundee, sunil gupta, general practitioner, essex, catherine twomey, general practitioner, gp appraiser,", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 2, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "north, yorkshire and humber", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 2, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "classification : official", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 2, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "publications gateway ref. number : 02615", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 2, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "3", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 3, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "contents", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 3, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "introduction 4", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 3, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia revealed. what primary care needs to know 5", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 3, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "ask the expert 9", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 3, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "case scenarios 14", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 3, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "what next? the link between dementia care, enhanced services and appraisal 17", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 3, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "request for feedback 18", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 3, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "appendix 1 dementia narrative 19", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 3, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "appendix 2 nhs england north dementia coding guidance 20", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 3, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "useful further reading and sources of information 24", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 3, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "4", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "introduction", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "this resource pack has been brought together with the aim of supporting gps to identify and appropriately manage dementia patients in the primary care", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "environment.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "currently, patients who do not wish to attend a memory clinic or undergo investigations and frail patients, especially in care homes, frequently fail to receive a timely diagnosis of dementia. the records then do not clearly flag up their diagnosis which can have negative consequences for the patient and the true prevalence of", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia remains unknown.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "patients should not be denied a diagnosis because they are not suitable for the memory clinic pathway. in addition, there are patients whose memory loss is simply not identified. it is therefore in the interest of the patients and the health care community for gps to play an active role in the diagnosis and management of dementia patients. this will have implications regarding training and resource allocation.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "‘ dementia revealed – what primary care needs to know ’ ( the dementia primer ) is an", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "overview of dementia management. if that document is “ what to do? ” then this", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "contribution is “ how to do it? ” the dementia primer has been summarised in this resource pack to provide a quick overview of the key points. it is anticipated that the summary of the dementia primer will raise questions and uncertainties for gps, so we have added an “ ask the expert ’ section in which practical questions are posed to professor alistair burns ( national clinical director for dementia, nhs england ). these are then supported by descriptions of some clinical case scenarios.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the process of reading this resource pack, running a data quality toolkit to", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "interrogate the practice it system to find missing dementia patients, reviewing", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "notes and cases and reflecting on the management of dementia is ideal material for gp appraisal and some further ideas about this are given later.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "after reading and reflecting on this resource pack gps should be able to : describe the key features of dementia and explain which patients particularly merit referral to the specialist service ; describe the role of cognitive testing in the diagnosis and management of dementia and produce a plan for their own practice which incorporates", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "appropriate tools ;", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "explain how and when anti - dementia treatments in primary care are safe to be", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "introduced", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "create a strategy for themselves and their practice to improve the detection and management of dementia", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 4, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "5", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia revealed. what primary care needs to know", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the following is a summarised and slightly updated version of the original document, which provides further and more detailed information and is available at : http : / / www. england. nhs. uk / wp - content / uploads / 2014 / 09 / dementia - revealed -", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "toolkit. pdf", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "increasing role for the gp", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "gps need to build up their capabilities to assess, detect ( including diagnose ) and treat dementia and its common causes. patients who you know have dementia but cannot or will not go to specialist clinics should not be deprived of diagnosis, support and medication.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "diagnosis of dementia", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia is a syndrome ( essentially brain failure ) affecting higher functions of the brain. there are a number of different causes. there is no single ‘ dementia test ’. cognitive decline, specifically memory loss alone, is not sufficient to diagnose dementia. there needs to be an impact on daily functioning related to a decline in the ability to judge, think, plan and organise. there is an associated change in", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "behaviour such as emotional lability, irritability, apathy or coarsening of social skills.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "there must be evidence of decline over time ( months or years rather than days or weeks ) to make a diagnosis of dementia – delirium and depression are the two most common conditions in the differential diagnosis.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "‘ timely ’ diagnosis is when the patient wants it or when the carers need it. sub - typing dementia is important in guiding prescribing decisions. most sub - typing can be arrived at by taking a careful history. differentiating vascular dementia and alzheimer ’ s becomes more challenging in older patients and in terms of post diagnostic support may not significantly influence management. sub - types include :", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "alzheimer ’ s disease vascular dementia mixed alzheimer ’ s / vascular dementia lewy body dementia ( lbd ) dementia in parkinson ’ s disease dementia unspecified", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "advice on the coding of the various types of dementia can be found in the appendix.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "it is helpful for someone in the practice to be familiar with a couple of cognition tools since it is unrealistic to do anything but a brief ‘ screen ’ in a normal primary care consultation. being able to draw a perfect clock, to all intents and purposes, renders", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "a diagnosis of dementia unlikely.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "brain scans ( ct or mri ) are not essential for a clinical diagnosis of dementia. if a scan is justified, detailed clinical information is crucial for the radiologist.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 5, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "6", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "blood tests rarely contribute to the diagnosis but are needed to rule out underlying pathology and are necessary for qof reporting.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "indications for referral", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the following are some examples of patients who would normally benefit from", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "referral :", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "suspected parkinson ’ s disease dementia ( pdd ) or lewy body dementia ( lbd ) ; younger people with suspected dementia, where the chances of there being a", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "rarer neurological condition are greater ;", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "an atypical presentation or course which may indicate focal dementia or a brain", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "tumour ; high risk situations, such as challenging behaviour, psychosis or other risks ; safeguarding concerns ; potentially contentious legal issues ; associated significant psychiatric morbidity or history ;", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "patients with learning disability ( ld ) ( especially patients with down ’ s syndrome,, who have a particularly high risk of developing dementia ). assessing dementia in patients with ld requires specialist psychological input ; suspected alcohol related dementia.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "drug treatment", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "( for full prescribing information please refer to the british national formulary )", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "there is little to choose between acetylcholinesterase inhibitors ( acheis ). price and tolerability are the key deciders. the main side - effects of acheis are syncope and gi upset and they are contraindicated in heart block, significant cardiac conduction", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "problems or if the pulse rate is < 60.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "memantine is an alternative, if cardiac problems preclude an achei, and also has a licence for use in severe dementia but it is more expensive. renal function needs to", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "be checked before prescribing. consideration of memantine should generally", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "involve a specialist.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "most people with mild to moderate alzheimer ’ s disease will respond to and derive valuable benefits from one of the acheis or, as an alternative in moderate to severe", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "disease, memantine. their use is recommended by nice ( www. nice. org. uk ).", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "systematic follow - up is needed, but not necessarily in a specialist hospital clinic. acheis should be continued, even when dementia enters the more severe stages, providing they are well tolerated.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 6, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "7", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "behavioural and psychological symptoms of dementia", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "behavioural and psychological symptoms of dementia ( bpsd ) are manifestations of need and may be markers of distress. the first approach is to understand the need and try to address it. underlying pain and infection must be sought and treated and", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "carers should be trained and supported.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "there is a relatively small range of drugs that can be used and drugs should not be", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the first option. anti - depressants and anti - alzheimer drugs may help bpsd.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "if anti - psychotics are considered to be justified for the management of bpsd, they should be initiated by ( or in consultation with ) a specialist and used only for short periods. low dose, regularly reviewed risperidone is an option, ideally for a", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "maximum of six weeks. anti - psychotics are potentially fatal in lewy body dementia", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "and parkinson ’ s disease dementia and should not be used without specialist psychiatric advice.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "delirium", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "patients with dementia are at increased risk of delirium which is common and may take far longer - sometimes months to recover from than people realise. delirium can damage cognition. anticholinergic drugs contribute to delirium risk and should be avoided.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "alcohol", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "alcohol related problems are much more frequent in older people than is commonly realised. alcohol misuse may be a cause, an effect, or a complication of dementia.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia and driving", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "a diagnosis of dementia must be reported to the dvla but many patients may continue to hold a licence and drive – their licence is taken away only when they are considered to be unfit to drive. mild cognitive impairment is not automatically reportable to the dvla. an independent driving assessment may be useful ; although everyone may have an opinion, the only person qualified to say whether a person is safe to drive or not is a registered driving test examiner.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "further information about driving can be found on the alzheimer ’ s society website.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 7, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "8", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "carers", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "carers are the most valuable resource in dementia care and we should have a high level of awareness of their needs. carers may be referred for a carer ’ s assessment and benefit check. carers ’ groups provide support and information.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "carers often neglect their own health because of their caring responsibilities. the alzheimer ’ s society can help with counselling, social support, benefit forms and grant applications.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "social care and legal aspects", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "social care is based on eligibility criteria and is means tested. it is helpful for the practice to know if patients have refused services that they have been assessed as needing.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the threshold for full nhs continuing care funding in dementia is high, and may be withdrawn if needs reduce. funded nursing care may be awarded to pay for a nursing care component if needed.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "adult safeguarding has an increasingly high profile. there needs to be an adult safeguarding lead in the practice who is appropriately trained. mental capacity is issue specific and must be based on a current assessment. separate lasting power of attorney ( lpoa ) forms are needed for financial affairs and for decisions about care. lpoa does not apply until the patient loses capacity and they can be rescinded at any time before that. it is good advice to recommend thinking about lpoa sooner rather than later.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "end of life", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "end of life care planning is important in dementia. patients with dementia should be encouraged to express their wishes and have them incorporated into advance care plans and advance statements.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "relatives of residents in care homes often feel guilty and distressed. bereavement reactions, following a death from dementia, can be complex and referral to bereavement support may be indicated.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 8, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "9", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "ask the expert – questions posed to alistair burns", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "which cognition tool would you recommend for use in primary care to support the diagnosis of dementia?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "there are a number of options and the most important advice is to become familiar and comfortable with a small selection. the choice may also be guided by the", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "amount of time which is available :", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "one minute", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "if memory problems ( or other symptoms suggestive of dementia ) are raised as the person is just leaving or in passing during an already demanding consultation, then simply enquiring about memory can be a helpful general prompt, for example, ‘ has the person been more forgetful in the last 12 months to the extent that it has significantly affected their daily life? ’ ( for instance, difficulty using the phone,", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "managing shopping lists, using money, managing their medication, driving, etc. ). it", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "is helpful to involve family or a close friend if possible.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "a few minutes within the consultation", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "if the issue of dementia arises during the interview and there is no time to go into it in detail, the mini - cog ( a brief cognitive screening test ) may be suitable.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the mini - cog is administered as follows :", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "1. instruct the patient to listen carefully to and remember three unrelated words ( e. g.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "ball, car, man ) and then repeat the words.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "2. ask the patient to draw the face of a clock, either on a blank sheet of paper or on", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "a sheet with the clock circle already drawn on the page. after the patient puts the numbers on the clock face, ask him or her to draw the hands of the clock to read a specific time ( ten to two or ten past ten is popular as it resembles a smiley face ).", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "3. ask the patient to repeat the three previously stated words.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "if the three words are correctly recalled, then this suggests there is no significant cognitive impairment.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "if none are recalled, this suggests there is significant impairment.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "if 1 or 2 are recalled, use the clock drawing test as an arbiter – if it is normal, then there is unlikely to be significant impairment, if it is abnormal, then further enquiry is needed.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 9, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "10", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "ten minute consultation", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "for the ten minute consultation, we would recommend gpcog ( the general", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "practitioner assessment of cognition ) which is available at http : / / www. gpcog. com. au / index. php", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "it is quick and easy to administer and has the advantage of incorporating the view of", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "a carer or relative.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "an alternative tool would be the 6 - cit which is available at http : / / www. patient. co. uk / doctor / six - item - cognitive - impairment - test - 6cit", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "cognition tools should not be used in isolation, but abnormal results alongside a careful history, examination and normal screening blood tests should enable a diagnosis to be made by gps in those with a typical presentation.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "fifteen minute planned review", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "in the primary care setting, the montreal cognitive assessment ( moca ), http : / / www. mocatest. org /, is the instrument of choice. it can take up to 15 minutes and would clearly need a special session to make a diagnosis.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "general considerations in diagnosis", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "there should be a long history reflecting the progressive and insidious course of dementia. it may not be possible to diagnose dementia in a single consultation but rather after a period of current and historic review of the patient. the diagnosis should usually include input from a carer or relative which corroborates the history and demonstrates the negative effect of the memory loss on the functional abilities or personality of the patient over a prolonged period.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "what are the main differential diagnoses / potential contributing factors?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the three ds", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "depression which may be contributing to the presentation in a patient with", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "drugs with strong anticholinergic activity such as tricyclic antidepressants ( e. g. amitriptyline ), older drugs for bladder problems ( e. g. oxybutynin ) and first generation antihistamines ( promethazine, chlorpheniramine ) should be stopped if possible or substituted for a drug with less anticholinergic activity. all opiates affect cognitive function - consider regular paracetamol or topical analgesia or use the lowest possible dose of opiate.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "delirium - the diagnosis should be clear from the time scale ( starts suddenly and stops suddenly ) and the general condition of the patient ( i. e. they look unwell ). asymptomatic bacteriuria is unlikely to be a significant cause of delirium.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 10, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "11", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 11, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "currently, which patients are most suitable for gp management?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 11, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the frail and elderly, where continuity of care and on - going management of co - morbidities can be most appropriately provided by the gp with support from other agencies. patients who are reluctant to engage with the specialist service.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 11, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "do you see an evolving role for the gp in dementia management? will uncomplicated cases be diagnosed and treated in primary care and if so how do we ensure that they receive the appropriate support that might have been offered by a memory team?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 11, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "as local care pathways evolve and the relationship with the specialist memory service matures, it is anticipated that gps will gradually take an increasing role in managing those patients with standard presentations. this must be complemented", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 11, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "by direct access to appropriate community dementia resources.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 11, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "is it necessary to follow up patients on anti - dementia drugs with repeat scores to assess the effectiveness of the treatment?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 11, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "no. it is more important to make an assessment of the global functioning of the patient and the gp and relatives / carers may be in a good position to make this assessment. small changes in scores may not be significant. for gp management it is anticipated that, providing the patient is tolerating the treatment and there are no contraindications the treatment will be maintained until such a time as it becomes inappropriate such as in extreme frailty.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 11, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "can you explain how you distinguish between mild cognitive impairment and early dementia and when to offer treatment in this situation? would you have flexibility on the score if there is significant concern from the patient and family regarding the effect on functioning?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 11, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "this reflects a significant complexity which should be managed by engagement of the specialist service. it is addressed in the dementia narrative which was included in the national enhanced service for dementia identification specification ( appendix 1 ).", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 11, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "gps may be concerned about recognising and subsequently accurately coding the subgroups of dementia. the narrative in the dementia enhanced service specification says that gps can confidently diagnose dementia, but then goes on to say that specialist advice is often needed to determine the subgroup and recommend treatment choices, including differentiating between vascular dementia and alzheimer ' s. if this is the case then this would limit the value of any gp diagnosis. do you have any practical advice about this?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 11, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the diagnosis of dementia is based on the recognition of the typical syndrome of ‘ chronic brain failure ’. atypical presentations should be referred for specialist advice regarding the more unusual sub - types. vascular dementia in isolation is rare ; the", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 11, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "12", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 12, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "majority of presentations are alzheimer ’ s or mixed dementia i. e. alzheimer ’ s and a vascular element. it is important to note that ageing changes may be identified on the ct scan in older patients particularly in the white matter. it is not usually appropriate to attribute dementia solely to vascular disease and therefore withhold medication unless there is a clear relationship to a significant stroke. ( see case 5 ).", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 12, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "can you give some practical advice about the initiation and follow up of medication for alzheimer ’ s disease?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 12, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "initiation of the most commonly used anti - alzheimer drugs ( the acetylcholinesterase", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 12, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "inhibitors ) is usually by a specialist. shared care protocols should be in place to", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 12, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "facilitate their prescription by gps in appropriate circumstances where this is locally agreed. more and more memory clinics are relying on primary care colleagues to follow up patients who have been established on medication and so gps will gradually become more familiar with the drugs.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 12, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the acetylcholinesterase inhibitors are licensed for the treatment of mild to moderate alzheimer ’ s disease. donepezil is the most commonly used. the class of agents can cause bradycardia and can exacerbate symptoms of gastric and duodenal ulcers, precipitate bronchospasm and may cause convulsions. dizziness, headache and nausea are the most common side effects with abdominal disturbance and nightmares also commonly reported. nice state that initiation of cholinesterase inhibitors should only be by specialists although we know of protocols being developed jointly by gps, pharmacists and memory clinic specialists. where there is", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 12, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "interest in developing things further, local conversations should take place.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 12, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "they should be used with great caution if the pulse rate is < 60. if the pulse rate is > 70 beats per minute and regular there is no necessity to undertake an ecg. if the pulse is < 70, or irregular, an ecg is required and if there is a conduction abnormality, or an abnormal rhythm, specialist advice should be sought. it is usually safe to prescribe when atrial fibrillation is well controlled, providing the pulse is above", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 12, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "60. similarly, if the patient is on beta - blockers it may be worthwhile considering a", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 12, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "reduction in dose to keep the pulse rate > 60.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 12, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "first line treatment is donepezil 5mg once daily. patients should be reviewed at one month to check for side effects and at three months to review its benefit, at which point the dose can be increased to 10mg if it is well tolerated with no slowing of the pulse. a dose increment would justify a further 3 month review and subsequently follow up should be annual in line with qof. the review should include input from the carers and any community dementia resources that have interacted with the patient either at their home or at an appropriate site in the community.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 12, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "memantine usually requires some specialist assessment before prescribing.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 12, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "13", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 13, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "is there any evidence that managing vascular risk reduces the progression of dementia? in practical terms are we likely to be diagnosing patients with vascular dementia who are already known to have vascular disease and therefore already had consideration of anti -", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 13, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "platelet treatment and statin?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 13, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "there is no consensus that managing vascular risk factors for a patient with vascular or mixed dementia slows the progression. empirically, there should be good control of these factors independent of a vascular dementia diagnosis. agree that most patients with an element of vascular dementia will already have been considered for secondary prevention.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 13, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "can you give advice on how to recognise lewy body dementia?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 13, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "there is an association with symptoms of parkinsonism. patients often exhibit daytime fluctuations in alertness and confusion, experience visual hallucinations and typically have disturbed sleep with increased nocturnal motor activity. there may be a history of sensitivity to neuroleptics.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 13, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "should patients be coded with dementia when this diagnosis is obvious but they have made it clear that they do not accept the diagnosis and would be upset to have this label on the records?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 13, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "it would be appropriate to include the diagnosis in the record in this situation since this is important to support the care, safety and well - being of the patient, especially in situations such as hospital admissions and social care assessments. it would be important to include a comment explaining the patient ’ s views on the matter.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 13, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "this is a difficult clinical presentation and the gp should strive to engage with the patient to help them to come to terms with the diagnosis and enable them to receive appropriate management. even when they are reticent to accept the diagnosis patients should receive appropriate support and this can sometimes be achieved through gradual involvement of the specialist service and support workers. it is also essential to regularly revisit their views and understanding to support their management. such cases, whilst relatively rare, are complex and advice from the specialist service may be appropriate, particularly if there are concerns about vulnerability and safety. the involvement of family members and carers may also be influential in progressing the understanding of the patient and their management.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 13, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "14", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "case scenarios", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "examples of cases which would justify referral", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "1. a 53 - year - old man with down ’ s syndrome who is usually well and only normally", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "attends for routine check - ups. he is well supported by the local learning disability", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "team. five years ago, he had an episode of depression which was treated for six months with antidepressants. the history now goes back about a year, characterised by some agitation and his memory appears worse according to his elderly parents. he always used to be punctilious about his arrangements in going to the day centre but now he often lies in bed and doesn ’ t seem to remember he has to go there on tuesdays and thursdays. he has put on some weight and people have noticed he has a predilection for sweet fruits. on two occasions in the last six months, he seems to have had some visual hallucinations describing seeing small people in his room at night which made him frightened. in your consultation, he appears disorientated and withdrawn and certainly not his usual self. you have concerns about his memory.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "comment : we know that about half of people with down ’ s syndrome develop", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "pathological changes of alzheimer ' s disease. the presentation of the accompanying dementia can be complex and physical and psychiatric comorbid conditions such as", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "hypothyroidism and depression or psychosis are important to exclude or treat. a", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "specialist assessment including input from the learning disability service is needed here.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "2. a 62 - year - old, successful, recently retired businessman attends complaining of", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "memory loss. he says his wife and family have noticed a problem over the last few months. in his last year at work he had missed several appointments. he has become depressed in mood over the last few months as he sees little future now he has retired. his speech has changed in that it has become ‘ sticky ’ and his childhood", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "stammer has returned. his wife has said that, curiously, he has started to make sudden muscular movements at night while he is asleep.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "comment : this is a rather unusual presentation in a relatively young person. the symptoms could well be due to alzheimer ' s disease. the myoclonic jerks are", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "unusual in the early stages and the speech disturbance may be connected with a primary progressive aphasia. the fact that he is coming complaining of the symptoms suggests a degree of insight. he is describing symptoms of depression so a trial of antidepressants ( e. g. sertraline 50mg a day, increasing after two weeks all being well to 100 mg ) might be appropriate while referring him to a memory clinic, or possibly a neurology clinic.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 14, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "3. a 78 year old man presents with a nine month history of episodes of confusion", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "with visual hallucinations and some paranoid ideas ( that his wife is stealing his", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "money ). he had a transient ischaemic attack four years ago and made a full", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "recovery. his only medication is aspirin. his family have remarked that sometimes he seems back to normal but at other times he can be very disorientated. he has become agitated when he does not recognise family members. his wife has noticed that his gait is shuffling sometimes. a few months ago, he became very agitated one night and was seen by a doctor who prescribed some risperidone – he became very stiff after two doses and his family did not give him any more. on examination, he has a blank expression, he is fully orientated to time and place and there is no", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "evidence of depression. he is guarded when talking about his wife.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "comment : the symptoms are suggestive of lewy body dementia. his symptoms", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "could easily be incorrectly attributed to cerebrovascular disease given the history of tia since this may also cause parkinsonism ( in which the absence of tremor is common ). the giveaway is the fluctuation of his mental state, the parkinsonian features and the psychiatric symptomatology along with previous sensitivity to", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "neuroleptics. this may be someone who you might refer to a physician with an", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "interest in parkinson ' s disease since they would know about lewy body dementia,", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "or a memory clinic to be seen by a consultant psychiatrist. this may vary depending", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "on local arrangements.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "cases which could be safely diagnosed by a gp", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "4. an 85 year old woman attends with her husband who reports that she has been", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "increasingly forgetful since a hip replacement last year. her speech is more repetitive so that she sometimes asks the same question four or five times within an hour. she is also more anxious and tends to get in a muddle with paperwork. she has addressed birthday cards to the wrong people and last week she burnt her ready - meal in the oven. she is relatively independent in her activities of daily living but requires some prompting. she denies there is a problem and puts her memory problems down to “ just getting old ”. she has a past medical history of a tia two years ago, has treated hypertension and is on atorvastatin and aspirin. she has", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "some osteoarthritis and mild hearing impairment but is otherwise well.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "comment : likely alzheimer ’ s disease though may have a vascular component. does not need a scan but does need cognitive assessment, an examination, full dementia blood screen, a more detailed history and brief risk assessment ( driving, fire, falls etc. ). potential candidate for acei if there are no contraindications. will need signposting to any available community support.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the son attends to speak to the gp and wants to know why his mother has not been referred to a memory clinic which he has read about in the paper. why has she not had a scan? would her care be better if she saw a specialist? he is worried that his", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "father may have difficulty coping.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the gp knows the lady well and there are no signs to suggest this is anything like a", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "stroke or brain tumour which could be revealed on a brain scan. a scan has a small", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dose of radiation and can be distressing. if the son is worried about his father coping,", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 15, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "official 16", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 16, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "that is something which can be managed straight away with a referral to a dementia advisor plus support from local agencies. of course, his mother can have a second", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 16, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "opinion and a brain scan if she and the family wish it.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 16, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "5. a 90 year old man is seen for review. he has been in a nursing home for six", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 16, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "months following a stroke which caused a dense left hemiparesis and mild motor dysphasia. on admission to the care home he was noted to be drowsy and had frequent visual hallucinations. following treatment of a uti these symptoms improved, but he remains disorientated in time and place, with repetitive muddled", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 16, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "speech and often does not remember the names of staff. he is on regular", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 16, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "co - codamol, oxybutynin, and anti - hypertensive medication as well as low dose aspirin and a statin.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 16, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "comment : - this is either vascular dementia ( post - stroke ) or mixed alzheimer ’ s disease / vascular dementia. the distinction is a little academic, but a description of his functioning before the cva and the progression or otherwise of his symptoms post - stroke may help to decide. multiple medications ( opiate and anticholinergic ) may be contributing to his impairment. delirium would be unlikely as there is a long history and no obvious acute medical problems. he does not need a scan and definitely has dementia – gp can make this diagnosis. a blood screen, physical examination and urine dipstick may be helpful if feasible and not distressing to the patient. oxybutinin and codeine should be stopped if possible. a cognitive assessment is needed. ensure care home manager and relatives know the", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 16, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "diagnosis.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 16, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the patient ’ s son and daughter ask for an appointment. they want to know why their father has not been offered medication for his memory loss. he was not perfect before the stroke, so how do we know that he would not respond to treatment?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 16, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "a fair question. be clear what the likely improvements would be – they are generally in terms of memory and general functioning and will not make a difference to his symptoms of stroke which are disabling to him. there can be side effects to medication and can be upsetting if he has swallowing difficulties. if there is a significant element of alzheimer ’ s disease before the stroke ( i. e. memory difficulties and functional disabilities which significantly affected the person ’ s life, more than just “ not perfect ” ) then a trial of an acetylcholinesterase may be appropriate - probably one for a specialist opinion at some point but a diagnosis of dementia can be recorded and acted upon.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 16, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "official 17", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "what next?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the link between dementia care enhanced services", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the additional dementia enhanced service encourages gps to diagnose dementia and also encourages practices to use a dementia data quality toolkit to find potential cases and improve dementia coding. gps are going to be looking at ways of improving their knowledge of dementia, reviewing cases and discussing with colleagues. they may wish to involve their ccg with regard to developing resources", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "to support dementia care in the community. as professionals, doctors will want to view the enhanced service as an opportunity to add quality to the lives of their", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "patients who are suffering with dementia", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "continuing professional development ( cpd ) and appraisal", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "if you have read this document and considered its implications for your practice then it counts towards your cpd. if you hold a clinical meeting to discuss the management of dementia this would be further cpd. time can be allocated for preparation for the", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "doctor who leads the meeting.. it is easy in the time - pressured environment of the", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "surgery to forget that this is what gp appraisal is all about. we often do the work but", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "do not give ourselves the credit for it in our appraisal documentation.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "quality improvement activity ( qia )", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia data quality toolkits provide practices with a list of potential dementia patients. if you write up your response to running a toolkit you will have satisfied the", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "requirement to provide a quality improvement activity for appraisal and revalidation. the potential responses will vary depending on the findings.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "if there are patients who have attended the memory service and been diagnosed with dementia, but do not have a gp code, how has this happened? this could be written up as a significant event. do you need to look at your system for coding out - patient letters for example? have you found a number of patients who have been labelled with a code which highlights memory loss but have not been followed up? lack of time or lack of confidence in making the diagnosis may be possible explanations for failing to diagnose dementia. do you need to develop a system to highlight memory issues with a due diary or recall system? are you familiar with suitable cognitive assessment tools? how do you currently manage patients in care homes who have dementia but have never had a formal diagnosis?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "evidence of quality improvement of this type which has resulted from engaging with an enhanced service and undertaking self - directed learning justifies further credits which should be commensurate with the time taken to undertake the activities.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 17, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "official 18", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 18, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "request for feedback", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 18, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "this format is a new venture and we are keen to receive your feedback. we would like to know if you have found the style useful. have we covered the topic in a way which has addressed your learning needs? have we covered the learning outcomes successfully? do you have any suggestions for improvement?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 18, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "we are keen to facilitate a dialogue between general practice, clinical leads and dementia specialists with a view to developing closer links and improved joint working. we would be happy to receive any further questions which you might like to ask our expert resources. these will be collated to look for themes and incorporated into our planned revision of this document which should be available in around three", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 18, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "months. similarly you might like to send case scenarios for comment.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 18, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "please send your feedback, questions or comments to paul. twomey @ nhs. net", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 18, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "official 19", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "appendix 1", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia narrative", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "diagnosing dementia : any appropriately skilled clinician can and brain", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "scanning not always needed", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia is a clinical syndrome and implies brain failure ( analogous to heart", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "failure or liver failure ). the diagnosis is a two stage process.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "step 1 is to make a diagnosis of dementia, differentiating it from : depression ; delirium ; the effect of drugs and ; the changes in memory expected as part of normal", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "ageing. a key feature is that for a diagnosis of dementia, it should affect daily living", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "activities and should be progressive.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "step 2 is to determine the cause of condition – the commoner causes are", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "alzheimer ’ s disease, vascular dementia and lewy body dementia.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "both stages are based on a comprehensive assessment including a history, including one from an informant, a physical and mental state examination, including a specific", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "assessment of cognitive function and selected ancillary investigations ( dementia :", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "nice clinical guideline 42, www. nice. org ).", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "any clinician who has the appropriate skills can recognise and make a", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "diagnosis of dementia.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "specialist advice may be needed in particular clinical situations where the presentation or course is atypical and in groups such as people with learning disabilities. also, specialist advice is more often needed to diagnose the exact cause", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "of the dementia. this may have clinical implications for the prescription of", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "medication such as drugs for alzheimer ’ s disease, treatment of vascular risk factors in vascular dementia or avoidance of neuroleptics in lewy body dementia.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "in terms of brain scanning, the nice dementia guideline states “ imaging may not always be needed in those presenting with moderate to severe dementia, if the diagnosis is already clear. ”", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "post diagnostic support which should be person centred goes hand in hand with the diagnosis ( which does not necessarily have to result in the prescription of medication ) and is largely independent of the cause of the dementia.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "alistair burns national clinical director for dementia", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "nhs england october 2014", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 19, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "official 20", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "appendix 2", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia coding across the north region", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "this guidance document is prepared for use across the north region to provide a consistent way of coding dementia in gp practices. it was agreed by members of the north regional mental health, dementia and neurological conditions oversight group", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "on monday 28th july 2014 to use central guidance as the regional standard. further", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "changes were included following circulation to dementia clinical leads of north strategic clinical networks and the development of a csu data quality tool to assist in", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "data cleansing. the guidance continues to be refined as comments are received from users of this guidance.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "elements of this model are adopted from nhs london guidance on dementia coding produced by dr paul russell, gp, london dementia clinical team & professor sube banerjee, london clinical director for dementia, and leeds north", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "ccg to identify codes which correlate directly to the dementia register.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "this guidance will be utilised in the coding clean - up exercise carried out across the", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "north region as part of the intervention & support team proposal in 2014 / 15.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "this guidance is provided to encourage memory services to code correspondence to primary care and to help practices decide how to code those patients who aren ’ t currently on the gp practice register but should be – whether derived from the need", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "to correct coding identified by the practice or diagnosing a patient for the first time. it is important that any code used, adds patients to the gp practice dementia register.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "there is no requirement for practices to changes codes already in use or cease using preferred codes, as long as those codes include patients on the gp practice", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia register.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "we are aware of issues with local coding on emis systems such as ‘ emisnqdv1 ’, which are used as default codes by the system supplier, and are looking into how this", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "can be corrected.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "guidance on dementia coding", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "what is the big issue for north gps in coding dementia? there is a dementia diagnosis gap of 40. 7 % in the north, which means that only 59. 3 % of those who we would expect to have dementia, based on population", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "prevalence rates, are recorded on gp practice dementia registers1. we believe one", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "of the reasons behind this apparently low diagnosis rate is a lack of accurate coding", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "due to there being confusion with the available codes. this note for gps contains", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "guidance to help address this.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "why is it so important to diagnose and accurately code dementia?", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "1. it means the patient ’ s care can be planned, managed and monitored, so that they", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "can be signposted to supportive services and prescribed appropriate medication.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "1 qof data sept 2014", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 20, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "official 21", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "2. diagnosis gives power to the patient and their families, as it brings clarity in terms", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "of what is happening to them, and provides them with the ability to make choices themselves ( national dementia strategy, 2009 ).", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "3. the coding of dementia and putting the patient on the dementia register means", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "we can develop an accurate picture of north dementia rates to inform commissioning of high quality, cost effective services in response.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "4. it means that gps can see their own practice performance rise.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "making dementia coding simple", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the north region has adopted elements of this gp dementia coding guideline from colleagues previously at nhs london ( created by a team of gps working to improve dementia care in london with support from specialist experts ) 2 and work carried out by leeds north ccg to identify codes which correlate directly to the dementia register.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "guideline", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "1. we propose the use of eight codes in primary care, which are listed below.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "using these codes will ensure that the patient is added to the gp practice dementia register.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "2. if the specific type of dementia is unknown, for whatever reason, please use the", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "read code eu02z “ unspecified dementia ” or ctv3 code xe1z6, as", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "appropriate for your gp practice system. this can always be changed later when more information is available. please do not use 1461. 00 “ h / o dementia ”,", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "28e.. 00 “ cognitive decline ” or similar codes for this purpose – these codes will not", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "add the patient to your practice dementia register.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "3. if the patient is diagnosed with mild cognitive impairment ( not dementia ), please", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "use read code eu057 or ctv3 code x00rs, as appropriate for your gp practice system.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "4. please use this guidance in conjunction with your local csu developed data", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "quality tool when conducting data cleansing.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "2 dr paul russell, gp, london dementia clinical team & professor sube banerjee, london clinical director for dementia, feb 2012", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 21, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "official 22", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the main codes which general practitioners should use to code for dementia in primary care are : icd code & description read code ( e. g. emis practices ) & description ctv3 code ( e. g. systmone practices ) & description", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "f00 or [ x ] eu00", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia in alzheimer ’ s disease eu00. dementia in alzheimer ' s disease eu00. alzheimer ' s disease", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "f01 vascular dementia eu01. vascular dementia xe1xs vascular dementia", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "f00. 2 or [ x ] eu002 dementia in alzheimer ’ s disease, atypical or mixed type ( mixed dementia ) eu002 dementia in alzheimer ' s dis, atypical or mixed type eu002 dementia in alzheimer ' s dis, atypical or mixed type", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "f02. 3 or", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "[ x ] eu023", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia in parkinson ’ s disease eu023 dementia in parkinson ' s disease eu023 dementia in parkinson ' s disease", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "f03 unspecified", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia eu02z unspecified dementia xe1z6 unspecified dementia", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "g31. 0", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "circumscribed brain atrophy including : fronto - temporal dementia, pick ’ s disease, progressive isolated aphasia", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "eu020 pick ’ s disease", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "x0034 frontotemporal dementia – includes", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "pick ’ s disease and", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "progressive isolated", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "aphasia", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "eu02y dementia in other diseases specified elsewhere", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "g31. 8", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "other specified degenerative disease of the nervous system including : grey matter degeneration, lewy body disease, lewy body dementia, subacute necrotizing encephalopathy eu025 lewy body dementia x003a lewy body dementia f10. 7 residual and late onset psychotic disorder due to alcohol including : alcoholic dementia other alcoholic dementia chronic alcoholic brain syndrome e012. residual and late onset psychotic disorder due to alcohol xa25j alcoholic dementia", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "lower level codes can also be used i. e. e. g. eu000 - z early, late, mixed and unspecified", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "lower level codes can also be used i. e. eu010 - z all the read codes and ctv3 codes included in the above table will add patients to the qof dementia register.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 22, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "official 23", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 23, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "with thanks to nhs london and dr paul russell, gp, london dementia clinical team & professor sube banerjee, london clinical director for dementia and leeds north ccg for sharing their", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 23, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "documentation and learning to inform this guidance. thanks also to those who have commented and supported the further development of this guidance. author - kim thompson, regional medical manager, nhs england north 19. 12. 14", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 23, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "in collaboration with the northern england, yorkshire & humber, cheshire & merseyside and greater", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 23, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "manchester, lancashire & south cumbria strategic clinical networks.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 23, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "official 24", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "useful further reading and sources of information", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "for assessment of cognition : a handy guide to the major scales www. alzheimers. org. uk / site / scripts / download _ info. php? downloadid = 1045", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "for management of agitation and behavioural and psychological symptoms in dementia ( bpsd ), using a stepped care approach www. alzheimers. org. uk / site / scripts / download _ info. php? downloadid = 609", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "specific alternatives to medication for agitation", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "www. bps. org. uk and search “ alternatives to antipsychotics ”", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia partnerships : a very useful source of information on all aspects of", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "dementia www. dementiapartnerships. com", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "the dementia prevalence calculator – a guide to your local dementia prevalence", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "rate. you need to register.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "www. dementiapartnerships. com / diagnosis / dementia - prevalence - calculator /", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "bishara d. and harwood d. ( 2014 ). safe prescribing of physical health medication in patients with dementia. international journal geriatric psychiatry, 29, 1230 –", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "1241.", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "corbett a, burns a and ballard c. don ’ t use antipsychotics routinely to treat agitation and aggression in people with dementia bmj 2014 ; 349 doi :", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "http : / / dx. doi. org / 10. 1136 / bmj. g6420 ( published 03 november 2014 ).", "metadata": {"doc_name": "dementia-diag-mng-ab-pt", "page": 24, "section": "NO_SECTION", "domain": "dementia", "doc_id": "dementia-diag-mng-ab-pt"}}
{"text": "psychosis and schizophrenia in adults : prevention and management information for the public published : 1 february 2014 www. nice. org. uk about this information nice guidelines provide advice on the care and support that should be offered to people who use health and care services. this information explains the advice about psychosis and schizophrenia in adults that is set out in nice ' s guideline on psychosis and schizophrenia in adults. this is an update of advice on schizophrenia that nice produced in 2009. does this information apply to me? yes, if you are an adult at risk of or with a diagnosis of psychosis or schizophrenia. © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 1 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 1, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "for children and young people, see nice ' s guideline on psychosis and schizophrenia in children and young people. psychosis and schizophrenia psychosis and schizophrenia are mental health problems that affect how a person thinks, feels and behaves. they can make it hard for the person to think clearly and tell the difference between what ' s real and what ' s not. the person may act differently or lose interest in things and other people. the main symptoms are called ' psychotic ' symptoms. these are :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• hearing voices and sometimes seeing things that are not really there ( called a", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "hallucination )", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• believing that something is real or true when it is not ( called a delusion ) ; such as,", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "believing they are being watched or having their thoughts monitored. for most people, the symptoms start when they are young adults, but they can happen at any age. the first time a person has these symptoms is called a ' first episode of psychosis '. some people only ever have one episode of psychosis, but others may have more than one. there are different types of psychosis ; schizophrenia is one type, but psychosis can also sometimes occur in people with bipolar disorder or depression. ( see the section on other nice guidance for details of our guidance on bipolar disorder and depression. ) your care team a range of care professionals who specialise in different areas of treatment and support may be involved in your care. these could include psychiatrists, psychologists, gps and other primary care professionals, specialist nurses and social workers. working with you your care team should build a supportive relationship with you and your family or carers based on hope, optimism and trust. they should talk with you about psychosis and schizophrenia and explain any tests, treatments or support you should be offered so that psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 2 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "you can decide together what is best for you. your family or carer can be involved in helping to make decisions, but only if you agree. there is a list of questions you can use to help you talk with your care team. you may like to read nice ' s information for the public on service user experience in adult mental health. this sets out what adults should be able to expect when they use the nhs. we also have more information on the nice website about making decisions about your care. some treatments or care described here may not be suitable for you. if you think that your treatment does not match this advice, talk to your care team. getting help early if you are at risk of or have a first episode of psychosis you should be assessed by a psychiatrist or a specialist in psychosis and treated quickly if you are at risk of developing psychosis or have a first episode of psychosis. if you are at risk of developing psychosis you may be at risk of developing psychosis if you are distressed and finding life difficult and have :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 3, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• hallucinations or delusions that last for a short amount of time • other experiences or behaviour that suggest you may have psychosis or • a close relative with psychosis or schizophrenia.", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 3, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "if you are at risk, you should be offered :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 3, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• an assessment straightaway • psychological therapy called cognitive behavioural therapy ( or cbt for short ) to help", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 3, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "with the symptoms. psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 3 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 3, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "you and your family may also be offered psychological therapy called family intervention. see psychological therapy for more information. if you have another mental health problem, or a problem with drugs or alcohol, you should be offered treatment for those as well. you should not be offered medication to treat the symptoms of psychosis ( called antipsychotic medication ) at this point. if, after psychological therapy, you are still having the same problems, but your healthcare professionals do not think you are experiencing psychosis, they should keep seeing you regularly for up to 3 years to make sure your symptoms are not getting worse. if you do not want to see your health professional regularly, you should be given advice about contacting services if your symptoms get worse. if you have a first episode of psychosis the first time you have an episode of psychosis you should be assessed straightaway and offered help and treatment from an early intervention service, which provides support for people with symptoms of psychosis. if you are having a crisis and need urgent help you may be seen and given treatment at home by a crisis resolution and home treatment team. assessment an assessment is a meeting with healthcare professionals to find out if you have a mental health problem and which treatments might be most suitable. these professionals should include a psychiatrist, psychologist or a professional who specialises in psychological therapy for people with psychosis or schizophrenia. if you are at risk of", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 4, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "professionals to find out if you have a mental health problem and which treatments might be most suitable. these professionals should include a psychiatrist, psychologist or a professional who specialises in psychological therapy for people with psychosis or schizophrenia. if you are at risk of developing psychosis, you should be assessed at a specialist mental health service or an early intervention service. if you have a first episode of psychosis, you should be assessed at an early intervention service. psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 4 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 4, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "the healthcare professionals should ask you about your life, your thoughts, feelings and behaviour, your general health and wellbeing, and your mental health. they should carry out a physical examination and check for any health problems. in particular, they should check for mental health problems such as post - traumatic stress disorder, depression and anxiety, and problems with drugs or alcohol. they should develop a care plan with you ( with details of your treatment and support ) as soon as possible after the assessment, and give you a copy. treatment options treatment for a first episode if you have a first episode of psychosis, you should be offered both :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 5, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• antipsychotic medication and • psychological therapies called cognitive behavioural therapy ( or cbt for short ) and", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 5, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "family intervention ( for you and your family ). see antipsychotic medication and psychological therapy for more information. treatment for another episode if you have another episode, you should be offered the same treatment ( antipsychotic medication, cbt and family intervention ) as for a first episode, or a review of your current treatment. you may continue to receive treatment and care from the early intervention service, but you may also be offered treatment by a crisis resolution and home treatment team if you need more urgent care. the team will try to treat you at home or in a crisis house ( an alternative to hospital that helps people keep their independence during a crisis ) or day hospital, but some people with psychosis and schizophrenia may need to be admitted to hospital ( see if you need to stay in hospital ). in addition to antipsychotic medication, cbt and family intervention you may also be offered an arts therapy, particularly if you are withdrawn and have lost interest in things psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 5 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 5, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "that you used to enjoy. see antipsychotic medication and psychological therapy for more information. you should continue therapy after you have left hospital or another service until you have completed the course. treatments that have not been prescribed if you wish to use treatments that have not been prescribed by your healthcare professional, including complementary therapies, you should discuss this with your healthcare professional. they should advise you whether such treatments are safe, helpful and whether they are likely to affect your prescribed medication and psychological therapy. if you need to stay in hospital if you need to stay in hospital for treatment, the hospital should be suitable for someone of your age and gender, and your family or carer should be supported, especially if the unit is a long way from where they live. the crisis resolution and home treatment team can help you go home earlier. for more information on what should happen if you need to stay in hospital and what should happen if you are treated under the mental health act, see nice ' s guideline on service user experience in adult mental health. if there is a risk to yourself or others if you are very unwell and could be a risk to yourself or others you may be given medication to help calm or ' sedate ' you.", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 6, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• you should only be sedated like this in hospital. • you should be closely monitored afterwards.", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 6, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "as soon as possible afterwards, healthcare professionals should talk to you about what has happened and explain why you were sedated. they should make detailed notes and encourage you to write your own account to go in your medical notes. psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 6 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 6, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "if you have harmed yourself or your behaviour is threatening or violent, you should receive treatment and support. ( see the section on other nice guidance for details of our guidance on self - harm and managing disturbed or violent behaviour. ) antipsychotic medication antipsychotic medications ( also called antipsychotics ) are used to treat symptoms of psychosis such as hearing voices and seeing things that are not real. before you start before starting medication, your healthcare professional will do a health check and discuss possible medications with you. your healthcare professional should check your :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• weight and waist measurements • pulse and blood pressure • general health ( including some blood tests and asking whether you eat healthily and", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "take regular exercise ). they may also check your heart using a test called an electrocardiogram ( sometimes called an ecg ). antipsychotic medication can often have side effects. your healthcare professional should :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• give you the details of different antipsychotic medications, how they can help, and", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "their benefits and side effects", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• ask which side effects you are most willing to accept • involve you ( and your family or carer if appropriate ) in deciding which medication to", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "take. you should not usually be prescribed antipsychotic medication by a gp ( unless they have had advice from a psychiatrist ). psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 7 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 7, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "starting antipsychotic medication when you first take antipsychotic medication, your healthcare professional should :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 8, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• see you regularly while you are taking it, especially at first • ask if it is helping, if you are having any side effects and if you are having problems", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 8, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "taking the medication", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 8, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• monitor your general health ( including weekly weight checks for the first 6 weeks and", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 8, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "weight, pulse, blood pressure and blood tests at 3 months ). see also looking after your general health. the medication may take some time to work, but if you have distressing side effects or it is not helping after 4 to 6 weeks, your healthcare team may offer you a different antipsychotic medication. you should not be offered more than one antipsychotic at the same time, except temporarily if your medication is changed. healthcare professionals should tell you that drinking alcohol, smoking or taking other drugs while taking antipsychotic medication could stop the treatment working properly and make your symptoms worse. psychological therapy psychological therapy involves meeting with a therapist ( a healthcare professional competent in giving psychological therapy to people with psychosis or schizophrenia ) to talk about your feelings and thoughts and how these affect your behaviour and wellbeing. cognitive behavioural therapy cognitive behavioural therapy ( cbt ) involves at least 16 meetings on your own with a healthcare professional. it can be used to help encourage you to find different ways of coping with your symptoms by helping you understand how your thoughts, feelings and behaviour are linked to your psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 8 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 8, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "symptoms of psychosis or schizophrenia. family intervention family intervention should last between 3 months and a year and include at least 10 meetings ; these meetings can take place with or without other families depending on your and your family ' s preference. family intervention can help support your family to work together to help you cope and to reduce stress for your family members. the healthcare professional should make sure that everyone involved is happy with how the therapy is going. arts therapies arts therapies can help you to express yourself and work through your problems using art, music, dance or drama. they usually take place in groups of people with similar mental health problems. other psychological therapies you should not usually be offered other types of therapy ( such as counselling and therapies called supportive psychotherapy and social skills training ) because they have not been found to be as helpful for people with psychosis or schizophrenia. however, your personal choice should be taken into account, especially if cbt, family intervention and arts therapies are not available. you should not be offered a treatment called adherence therapy because there is not enough good evidence that it can help people with psychosis or schizophrenia. support after an episode after an episode of psychosis or schizophrenia, you should take your medication for 1 to 2 years to help prevent your symptoms returning. psychosis and schizophrenia in adults : prevention and management © nice 2025.", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 9, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "psychosis or schizophrenia. support after an episode after an episode of psychosis or schizophrenia, you should take your medication for 1 to 2 years to help prevent your symptoms returning. psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 9 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 9, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "when you no longer need medication :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 10, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• you should stop taking it gradually with help from your healthcare professional • you should see your healthcare professional regularly while stopping medication and", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 10, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "for at least 2 years after you have stopped taking it. your healthcare team should encourage you to write about each episode for your medical notes. many people find this helps them spot the early signs of an episode and understand their illness and treatment. looking after your general health you should be offered help to prevent weight gain, diabetes and other health problems that can happen because of your medication and changes in your lifestyle. healthy eating and physical activity you should be offered :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 10, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• advice on healthy eating • help to increase your physical activity.", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 10, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "if you start to gain weight and are concerned about it, or you are at risk of diabetes, you should be offered further help. ( see the section on other nice guidance for details of our guidance on obesity and diabetes. ) smoking if you smoke, you should be offered help to stop smoking. you may be offered one of the following :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 10, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• nicotine patches and an inhalator, gum, lozenges or spray, or • medication called bupropion, but only if you have a diagnosis of schizophrenia, or • medication called varenicline.", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 10, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 10 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 10, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "possible side effects of bupropion and varenicline if you are offered bupropion or varenicline your healthcare professional should discuss with you that there may be an increased risk of anxiety, depression or thoughts of suicide. if you take either of these drugs you should be monitored regularly, particularly during the first 2 - 3 weeks. there is more information about medicines on the nhs website. if you are in hospital and do not want to stop smoking you should be offered help ( such as nicotine patches and an inhalator, gum, lozenges or spray ) to reduce the amount you smoke or stop temporarily. general health checks you should have a health check with your gp at least once a year. your gp should :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 11, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• check for weight gain, diabetes, and heart, lung and breathing problems ( this should", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 11, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "include measuring your weight and waist, taking your pulse and blood pressure, and giving you blood tests )", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 11, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• ask if you are eating well and taking regular exercise • keep your care coordinator and psychiatrist informed about the results.", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 11, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "if you have a heart problem or diabetes, or there is a risk you could develop them, your gp should offer you further help and treatment. ( see the section on other nice guidance for details of our guidance on heart problems and diabetes. ) peer support and self - management you may be offered ' peer support ' which is support from someone who has recovered from psychosis or schizophrenia and has trained to be a peer support worker. psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 11 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 11, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "you may also be offered support from a health or social care professional to help you manage your condition and other parts of your life yourself ( called a self - management programme ). both types of support should include :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 12, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• information and advice about psychosis and schizophrenia • how to take medication • how to recognise and cope with symptoms • how to get help from mental health and other support services • what to do in a crisis • meeting other people who can support you • help to recover and stay well.", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 12, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "helping you to stay well in the future professionals and services that can help you stay well once you have recovered from an episode of psychosis or schizophrenia, you can continue to receive care and treatment from the early intervention service or from another local team of professionals called a ' community - based team '. this team should offer you treatment, and support you to stay well in the future. if you need help and support from more than one service, a ' care coordinator ' should organise all the care you receive. you should have an annual appointment to check that your medication is still working and any side effects are manageable. if you feel well enough, your care can be transferred to your gp, if you prefer. when this happens your gp should do a health check, which should include your mental and physical health ( see looking after your general health ). psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 12 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 12, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "if you are moving and need support and treatment from another mental health or social care service, this should be discussed with you first ( and with your family or carer if you agree ). while your care is being transferred to the other service, your healthcare team should make sure you still receive the support you need, especially during a crisis. support with work and education if possible, you should be supported by mental health services to stay in work or education, or find new work or education opportunities. you may also be offered a place on an employment scheme or other training or activities, including help to continue with your education at home or at a special college until you get better. treatments to help you stay well taking medication and continuing psychological therapy can help you to recover and stay well in the future. your healthcare professional should help you decide on the best medication for you and the best way for you to take it in the long term. this could be by taking an antipsychotic medication that has long - lasting effects ( called ' depot antipsychotics ' ). these are usually given every 2 to 4 weeks ( depending on the type ) by injection into muscle. you should be asked whether you want to receive your medication in this way and where ( for example, at your gp ' s surgery, a day hospital or at home ). if you decide to try a depot antipsychotic", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 13, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "injection into muscle. you should be asked whether you want to receive your medication in this way and where ( for example, at your gp ' s surgery, a day hospital or at home ). if you decide to try a depot antipsychotic, your healthcare professional should give you a test dose to check that it suits you. once you are taking it you should have your treatment reviewed regularly. it is usually better to take medication regularly. but if you would prefer not to take medication all the time or you have had unpleasant side effects, you may be given the option of taking medication only when you to start to feel ill again. if you start to feel ill again your gp should check your care plan and may refer you to your care coordinator or psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 13 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 13, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "psychiatrist if :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 14, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• you start to have symptoms again • your treatment is not working • you have unpleasant side effects from your medication • you are using alcohol or drugs • there is a risk to yourself or others.", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 14, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "if you need further treatment, the healthcare professionals should take account of your wishes and discuss side effects and other treatments you would like to try. if treatment does not help if treatment does not help, your healthcare professional should try and find out why and may offer you alternative treatments. your healthcare professional should check :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 14, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• that you have been taking your medication as discussed • for other reasons why you are not getting better ( such as illness, drinking too much", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 14, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "alcohol or taking other prescribed or non - prescribed drugs ). your healthcare professional should also check how your psychological therapy is going. if you have tried at least two different antipsychotics and these have not helped, you should be offered an antipsychotic called clozapine. if this does not help, you may be offered a second antipsychotic to take at the same time as clozapine. if you are receiving care from an early intervention service and your symptoms have not improved, you may continue to attend this service beyond the usual 3 years. psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 14 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 14, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "families and carers involving your family or carer it can be helpful for a family member or carer to know about what you are going through and any risks that you may face, and to understand things from your point of view. they can also be involved in helping to make decisions about your care, if you agree. the health and social care team should discuss regularly with you and your family member or carer, if they are involved in your care, how your personal information will be shared. information and support for families and carers the health and social care team should :", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 15, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• give your family or carer information ( both written and spoken ) about psychosis or", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 15, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "schizophrenia, including diagnosis, treatment, the services and teams involved, and recovery, and offer them support if they have any questions", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 15, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• tell them about the types of support available for carers and how to get help in a crisis • offer them an assessment of their own needs and develop a care plan with them if", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 15, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "needed, which is reviewed every year", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 15, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• discuss with them their role in your care • tell them about their right to a carer ' s assessment by social care services, and explain", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 15, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "how to arrange this", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 15, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• offer them education and support ( which may be part of a family intervention ).", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 15, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "questions to ask about psychosis and schizophrenia these questions may help you discuss your condition or the treatments you have been offered with your healthcare team. psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 15 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 15, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "finding out what ' s wrong", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 16, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• why am i being offered an assessment? • what could have caused my symptoms? • who can i contact if i have a crisis or if my symptoms get worse? • are there any support organisations in my local area? • can you provide any information for my family or carers?", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 16, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "first episode of psychosis", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 16, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• where can i have treatment? • can i choose to stay in hospital for treatment? • what happens if i decide not to have antipsychotic medication? • can i write down something about what treatment i would like?", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 16, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "treatments", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 16, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• how will the treatment help me? what effect will it have on my symptoms and", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 16, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "everyday life? what sort of improvements might i expect?", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 16, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• how long will it take to have an effect? • are there any risks associated with this treatment? • what are my options for treatments other than the recommended treatment? • are there any leaflets about the treatment ( s ) that i can have? • how long will psychological treatments last? • how long will i have to take medication? • might i have problems when i stop taking the medication? • are there any serious side effects associated with this medication that are likely to", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 16, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 16 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 16, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "affect me?", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 17, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• what should i do if i get any side effects? ( for example, should i call my gp, or go to", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 17, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "the accident and emergency department at a hospital? )", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 17, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• are there any long - term effects of taking this medication?", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 17, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "questions for family members and carers to ask", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 17, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• can you give me some information about psychosis or schizophrenia, and the", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 17, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "treatments for it?", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 17, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• is there anything in particular that i can do to support my family member? • can you give me any information about specialist support for families and carers, such", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 17, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "as helplines?", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 17, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• who can i contact for help during a crisis? • what help and support is available to me? • can i have a carer ' s assessment? what does it involve?", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 17, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "sources of advice and support", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 17, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• mental health foundation • mind, 0300 123 3393 • rethink mental illness, 0808 801 0525 • sane ( saneline ), 0300 307 7000", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 17, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "you can also go to the nhs website for more information. nice is not responsible for the quality or accuracy of any information or advice provided by these organisations. psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 17 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 17, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "other nice guidance", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 18, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• overweight and obesity management ( 2025 ) nice guideline ng246 • cardiovascular disease : risk assessment and reduction, including lipid modification", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 18, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "( 2023 ) nice guideline ng238", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 18, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• self - harm ( 2022 ) nice guideline ng225 • depression in adults ( 2022 ) nice guideline ng222 • tobacco ( 2021 ) nice guideline ng209 • post - traumatic stress disorder ( 2018 ) nice guideline cg116 • type 2 diabetes ( 2015 ) nice guideline ng28 • violence and aggression ( 2015 ) nice guideline ng10 • bipolar disorder ( 2014 ) nice guideline cg185 • service user experience in adult mental health ( 2011 ) nice guideline cg136 • coexisting severe mental illness ( psychosis ) and substance misuse ( 2011 ) nice", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 18, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "guideline cg120", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 18, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "• alcohol - use disorders ( 2011 ) nice guideline cg115 • generalised anxiety disorder and panic disorder in adults ( 2011 ) nice guideline cg113", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 18, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "isbn : 978 - 1 - 4731 - 0429 - 7 psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 18 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 18, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "accreditation psychosis and schizophrenia in adults : prevention and management © nice 2025. all rights reserved. subject to notice of rights ( https : / / www. nice. org. uk / terms - and - conditions # notice - of - rights ). page 19 of 19", "metadata": {"doc_name": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781", "page": 19, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "psychosis-and-schizophrenia-in-adults-prevention-and-management-pdf-248578083781"}}
{"text": "module : psychoses 179 psy overview learning objectives", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• promote respect and dignity for people with psychoses. • name common presentations of psychoses. • name assessment principles of psychoses. • name management principles of psychoses. • perform an assessment for psychoses. • use effective communication skills when interacting with a person psychoses. • assess and manage physical health concerns in psychoses. • assess and manage emergency presentations of psychoses. • provide psychosocial interventions to persons with psychoses and their carers. • deliver pharmacological interventions as needed and appropriate in psychoses", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "considering special populations.", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• plan and performs follow - up sessions for people with psychoses. • refer to specialist and links with outside agencies for psychoses as appropriate and", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "available. module : psychoses key messages", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• psychoses includes psychosis and bipolar disorder. • common presentations of psychosis include :", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "– marked behavioural changes, neglecting usual responsibilities. – agitation, aggression or decreased activity. – delusions – a fixed false beliefs. – hallucinations – hearing voices or seeing things that are not there.", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• bipolar disorder is often characterized by significant disturbance in mood and", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "activity levels with manic episodes ( in which the person ’ s mood is elevated and their activity levels increase ) and depressive episodes ( in which the person ’ s mood is", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "lowered ( depressive ) and their energy levels decrease ).", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• psychoses can be managed in non - specialized health settings. • when assessing for psychoses make sure you assess for and rule out other medical", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "conditions ( i. e. delirium ).", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• provide both psychosocial and pharmacological interventions as first - line treatments", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "for people with psychoses.", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• most people with psychoses can make a full recovery. • seek specialist support when needed. • the best way to reduce the stigma and discrimination against people with psychoses", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "is to treat them with respect and dignity and integrate them into the community.", "metadata": {"doc_name": "psy_module", "page": 1, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "180 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "session learning objectives duration training activities", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "1. introduction to", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "psychoses name common presentations of psychoses promote respect and dignity for people with psychoses understand that psychoses can be treated in non - specialized health settings 30 minutes 20 minutes activity 1 : person ’ s story followed by group discussion", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• use the person ’ s story to introduce", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "psychoses", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• encourage participants to reflect on local", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "understandings of psychoses presentation to supplement the story use the story as a basis for discussions on :", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• common presentations of psychosis and", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "bipolar disorder", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• how psychoses impact on a person ’ s life • human rights and psychoses • why it is a public health priority and how", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "can it be managed in non - specialized health settings activity 2 : case scenarios : hallucinations and delusions", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "2. assessment of", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "psychoses perform an assessment for psychoses use effective communication skills when interacting with people with psychoses assess and manage emergency presentations of psychoses assess and manage physical health in psychoses 40 minutes 30 minutes activity 3 : video demonstration : assessment use video / demonstration role play to show an assessment and allow participants to note the principles of assessment ( all aspects covered ) activity 4 : role play : assessment feedback and reflection", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "3. management", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "of psychoses provide psychosocial interventions to persons with psychoses and their carer deliver pharmacological interventions as needed and appropriate in psychoses considering, special populations refer to specialists and links with outside agencies as appropriate and available 30 minutes 20 minutes 25 minutes 35 minutes activity 5 : video demonstration : management use video / demonstration role play to evaluate a management session discussing use of pharmacological interventions and psychosocial interventions", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "activity 6 : delivering psychoeducation enable participants to practise delivering key psychoeducation messages activity 7 : promoting functioning in daily activities give participants practical experience in understanding how important daily routines and functioning are to recovery discussion on psychosocial and pharmacological interventions", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• use the mhgap - ig to introduce participants", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "to psychosocial and pharmacological interventions and how to deliver them", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• use case scenarios as examples", "metadata": {"doc_name": "psy_module", "page": 2, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 181 psy", "metadata": {"doc_name": "psy_module", "page": 3, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "session learning objectives duration training activities", "metadata": {"doc_name": "psy_module", "page": 3, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "4. follow - up plan and perform follow - up", "metadata": {"doc_name": "psy_module", "page": 3, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "sessions for people with psychoses 5 minutes 30 minutes discussion on the principles of follow - up use the mhgap - ig to discuss follow - up for people with psychoses activity 8 : role play : follow - up", "metadata": {"doc_name": "psy_module", "page": 3, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "5. review 15 minutes quiz", "metadata": {"doc_name": "psy_module", "page": 3, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "total duration ( without breaks ) = 4 hours 40 minutes", "metadata": {"doc_name": "psy_module", "page": 3, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "182 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy session 1. introduction to psychoses 50 minutes begin the session by briefly listing the topics that will be covered. session outline", "metadata": {"doc_name": "psy_module", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• introduction to psychoses. • assessment of psychoses. • management of psychoses. • follow - up. • review.", "metadata": {"doc_name": "psy_module", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "2 step - by - step facilitator ’ s guide activity 1 : person ’ s story followed by group discussion activity 1 : person ’ s story", "metadata": {"doc_name": "psy_module", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• present the person ’ s story of what", "metadata": {"doc_name": "psy_module", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "it feels like to live with psychoses.", "metadata": {"doc_name": "psy_module", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• first thoughts.", "metadata": {"doc_name": "psy_module", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "3 how to use the person ’ s story", "metadata": {"doc_name": "psy_module", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• introduce the activity and ensure", "metadata": {"doc_name": "psy_module", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "participants have access to pens and paper.", "metadata": {"doc_name": "psy_module", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• tell the story – be creative in how you tell", "metadata": {"doc_name": "psy_module", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "the account to ensure the participants are engaged.", "metadata": {"doc_name": "psy_module", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• first thoughts – give participants time to", "metadata": {"doc_name": "psy_module", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "give their immediate reflections on the story. give participants time to reflect on how living with psychoses can impact on a person ’ s life.", "metadata": {"doc_name": "psy_module", "page": 4, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 183 psy what do local people believe?", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• what are the local names for people with", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "psychoses?", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• how are individuals with psychoses treated", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "in the local community? how are their family treated?", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• where can the individual and their family", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "seek help? 4 presentation on psychoses ask the participants these questions and give them time to discuss ( 5 – 10 minutes ). emphasize that :", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• local names and terms may imply the", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "person with psychoses is mad, possessed, stupid, cursed, dangerous etc.", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• explain why you want to avoid using", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "those terms ( emphasize how damaging those names can be for people who live with them ).", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• discuss with the participants the impact", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "that negative names can have on the individual and their family.", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• with the participants seek a sensitive and", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "non - judgemental term that can be applied when talking about psychoses. note : in some countries there may not be an equivalent term for psychoses and participants will only know the term schizophrenia. in this case, you will need to communicate that psychoses is a syndrome that occurs in people with schizophrenia but also in other mental disorders. direct participants to page 33 mhgap - ig version 2. 0 and read through the common symptoms of someone with psychosis and bipolar disorder. refer back to the story used at the beginning of the session to compare the common presentations with the descriptions in the story. ask participants to give examples of any other presentations that they have seen in people with psychosis and people with bipolar disorder in their non - specialized health setting. symptoms 5", "metadata": {"doc_name": "psy_module", "page": 5, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "184 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy symptoms of psychosis now take a look at the symptoms of psychosis in more detail. explain that psychosis is characterized by disturbed perceptions ( give examples of hallucinations ) and disturbed thinking ( give examples of delusions ). disturbed behaviour and emotions : explain that people with psychosis may show very little emotion on their faces or in the body language and instead appear to be detached and disconnected from their surroundings. quite often they do not interact with family and friends and become socially withdrawn preferring to spend time alone. their speech may be slow, and their interactions short. their thoughts and ideas about what is happening to them as well as their behaviour may be disorganized, erratic and confusing to follow. symptoms of bipolar disorder describe the symptoms on the slide and explain that people with bipolar disorder may experience hallucinations and delusions during a manic episode. but they can also have features of depressive episodes. although bipolar disorder is normally characterized by the changes in mood ( mania to depression ), people who experience only manic episodes are also classified as having bipolar disorder. explain that the first symptoms of psychosis usually start between the ages of 15 – 29 years old. sometimes this first experience can be", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "changes in mood ( mania to depression ), people who experience only manic episodes are also classified as having bipolar disorder. explain that the first symptoms of psychosis usually start between the ages of 15 – 29 years old. sometimes this first experience can be called a psychotic episode. how long the episode lasts depends on the causes of the psychosis but they can last for a few weeks, months or even years. symptoms of psychosis disturbed perceptions : hallucinations", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• altered perception, i. e. hearing", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "voices, seeing or feeling things that are not there. disturbed thinking : delusions :", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• false belief that the person is", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "sure is true, i. e. person believes", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "family are poisoning her. or", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "person believes he is royalty. or person may believe his family", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "are aliens in disguise.", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "disturbed behaviours and emotions :", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• disturbances of behaviour :", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "social withdrawal, agitation,", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "disorganized behaviour, inactivity or hyperactivity, self - neglect, loss of interest and motivation.", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• disturbances of emotions :", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "marked apathy, poor speech, one word answers, slowed speech, thoughts may be disorganized and hard to follow, disconnect between reported emotion and facial expressions or body language.", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "6 symptoms of bipolar disorder disturbed mood :", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• person has episodes where", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "they are manic and other", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "episodes where they are depressed", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• characteristically recovery", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "between the episodes is complete. manic episode : increased activity levels, elevation", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "of mood ( potentially very happy and very agitated ). they may talk very rapidly, have lots of different ideas and increased levels of self - worth and self -", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "importance.", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "they may have hallucinations and delusions, i. e. hear voices and / or", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "believe that they are powerful, that", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "their ideas can change the world.", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "engage in risk taking behaviours", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "( gambling, spending money,", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "promiscuity etc. ). 7 natural history of psychosis", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• first onset typically between age 15 and", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "29 years.", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• there are three possible clinical courses :", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "o the person recovers completely or partially with some symptoms. o the person recovers but has a future episode ( relapse ). o symptoms continue for a longer period. 8", "metadata": {"doc_name": "psy_module", "page": 6, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 185 psy explain that after the first episode the person can either recovery completely or partially ( and never have another episode ) or recover but have future episodes. alternatively, symptoms continue for a longer period. explain that usually people will experience their first symptoms of bipolar disorder between the ages of 15 – 29 years old. the changes in mood and symptoms of associated with those changes in mood can vary widely between people.", "metadata": {"doc_name": "psy_module", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "explain that sometimes people have a couple of bipolar episodes in their lifetime while others have many episodes. some people will have just one manic episode in their life and others will experience one manic episode but many more depressed episodes. ask the participants how they think psychoses impacts on a person ’ s life? allow a brief discussion before revealing the slide. psychoses impacts dramatically on all areas of a person ’ s life. natural history of bipolar disorder", "metadata": {"doc_name": "psy_module", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• first onset typically between the ages of", "metadata": {"doc_name": "psy_module", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "15 – 29 years.", "metadata": {"doc_name": "psy_module", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• the pattern of mood swings can vary", "metadata": {"doc_name": "psy_module", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "widely between people : o some will have a couple of bipolar episodes in their life time and stay stable in between. o others will have many episodes. o some will only experience manic episodes. o some will experience more depressed episodes than manic episodes. 9 impact of psychoses impact on the individual :", "metadata": {"doc_name": "psy_module", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• break up of relationships • negative and at times scary experience of symptoms. • loss of employment, studies, opportunities. • financial consequences. • stigma and rejection by community.", "metadata": {"doc_name": "psy_module", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "impact on the family :", "metadata": {"doc_name": "psy_module", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• medical costs. • time and energy looking after the person ( carer burden ). • emotional distress.", "metadata": {"doc_name": "psy_module", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "10", "metadata": {"doc_name": "psy_module", "page": 7, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "186 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy explain the points in the slide. add that although people with psychoses can work they are usually marginalized from the workforce because of the stigma and discrimination attached to the disorder. because of fear about the disorder, people with psychoses are often admitted to hospital and often abandoned by their families. this is costly and quite often human rights are abused in the hospital. talk through the human rights abuses. ask the participants to read this example and decide which human rights have been violated? answers : adsila is detained in prison and then a psychiatric hospital although she has not committed any offence. therefore her right to liberty and security ( article 14 ) in the convention on the rights of persons with disabilities, to equal protection before the law ( articles 5 and 12 ) and her right not to be arbitrarily arrested or detained ( article 15 ) have been violated. the fact that she cannot challenge her detention violates her right to a fair hearing ( article 13 ). the fact she is bullied and attacked violates her right to not be subjected to torture or to cruel, in human or degrading treatment or punishment ( article 15 ). note : convention on the rights of person with disabilities : articles related", "metadata": {"doc_name": "psy_module", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": ". the fact she is bullied and attacked violates her right to not be subjected to torture or to cruel, in human or degrading treatment or punishment ( article 15 ). note : convention on the rights of person with disabilities : articles related to the treatment of person with psychosis. the right not to be locked up or detained in mental health facilities against your will ( article 14 ). the right to be free from violence and abuse, the right not to be restrained or put in seclusion ( articles 15 and 16 ). the right to make decisions and choices rather than having others make decisions for you ( article 12 ). impact of psychoses impact on society :", "metadata": {"doc_name": "psy_module", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• loss of workforce. • costly medical interventions and ( unnecessarily )", "metadata": {"doc_name": "psy_module", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "lengthy hospitalizations. human rights violations :", "metadata": {"doc_name": "psy_module", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• people with psychoses maybe chained and", "metadata": {"doc_name": "psy_module", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "confined.", "metadata": {"doc_name": "psy_module", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• they may be beaten as punishment or treatment. • they may receive treatments that are ineffective", "metadata": {"doc_name": "psy_module", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "and dangerous due to misunderstanding the causes of psychoses. 11 human rights violations asdila is a young woman who hears voices. as she was wandering on the street and talking out loud, the police arrested her. she had not committed any offence but while in custody she was told that she would be transferred to a psychiatric hospital. in the hospital she was forced to take high doses of psychotropic drugs which made her extremely unwell. she was bullied and attacked by staff and other male patients. she has no way to challenge her detention. 12 discussion", "metadata": {"doc_name": "psy_module", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• what stigma and discrimination do", "metadata": {"doc_name": "psy_module", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "people with psychoses face in your community?", "metadata": {"doc_name": "psy_module", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• what can you do to reduce the stigma?", "metadata": {"doc_name": "psy_module", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "13", "metadata": {"doc_name": "psy_module", "page": 8, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 187 psy the right to give informed consent to treatment and the right to refuse treatment ( article 25 ). brief discussion ( 20 minutes ) ask participants to think about ways that the human rights of people with psychoses are violated in their community? ask participants to think what they can do to stop these human rights violations? emphasize that the participants have a unique role, because they can treat psychoses. showing that psychoses can be treated is an important method to reduce stigma. talk through the points on the slide. emphasize that the person with mental disabilities and their carers must be involved in the decision - making process about their treatment. explain that to decrease stigma, discrimination and human rights abuses participants can :", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• provide families, individuals and", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "communities with accurate information about psychoses.", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• ensure people understand what they", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "can expect from treatment and recovery ; support them and give them hope.", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• explain clearly that people", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "can recover from psychotic episodes and that with treatment and support they can lead fulfilling and productive lives.", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• dispel any myths about psychoses and", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "correct any misinformation.", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• raise awareness about human rights", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "abuses and advocate for rights of people with psychoses.", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• involve people with psychoses and their", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "carers in any awareness raising activities. empower them to speak for themselves. what you can do to decrease stigma, discrimination and human rights violations", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• treat people with respect and dignity. • avoid making assumptions, e. g. the person is dangerous or the", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "person lacks capacity.", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• do not assume that the person is unable to make choices or", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "decisions concerning treatment. involve the person in the development of their treatment plan. • avoid involuntary admission and treatment, seclusions and", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "restraints and other coercive practices.", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• treat psychoses at the non - specialist level which is less", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "stigmatizing, more acceptable and accessible for people.", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "14 what you can do to decrease stigma, discrimination and human rights violations", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• provide accurate and supportive information to the person", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "concerned and their family : o about psychoses as well as treatment and recovery options. o dispel myths about psychoses. o raise awareness on the rights of people with mental disorders including psychoses. • raise awareness among other health professionals and colleagues, family members and the wider community in order to dispel the stigma, myths and misconceptions about", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "psychoses.", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• involve people with mental disabilities and their carers in any", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "awareness raising activities. empower them to speak for themselves. 15", "metadata": {"doc_name": "psy_module", "page": 9, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "188 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy talk through the points on the slide. acknowledge that psychoses does not affect as many people worldwide as other priority mns conditions. but the impacts that it has on the individual ( including human rights violations ) and the burden it places on the family make it a critical public health concern. talk through the points of the slides and add the information below to expand on the points. emphasize that available treatment is effective and can be carried out in non - specialized health settings. non - specialized treatment is more accessible and less stigmatizing than institutional care. explain that there is clear evidence that old - style mental hospitals are not the best way to treat people with psychoses and often violate basic human rights. therefore, caring for people through non - specialized health settings and in the community is essential. global impact of psychoses", "metadata": {"doc_name": "psy_module", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• affects 21 million people globally ( more", "metadata": {"doc_name": "psy_module", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "common among men – 12 million than women – 9 million ).", "metadata": {"doc_name": "psy_module", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• has an early onset in many ( 15 – 29 years old ). • people with psychoses are two and a half", "metadata": {"doc_name": "psy_module", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "times more likely to die early than the general population, due to physical illness such as cardiovascular, metabolic and infectious diseases. 16 why it is important to treat in non - specialized health settings", "metadata": {"doc_name": "psy_module", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• psychoses is treatable. • medicines and psychosocial interventions are", "metadata": {"doc_name": "psy_module", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "effective at treating psychoses.", "metadata": {"doc_name": "psy_module", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• people with psychoses can be cared for outside", "metadata": {"doc_name": "psy_module", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "of hospitals – in non - specialized health settings and the community.", "metadata": {"doc_name": "psy_module", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• engaging the family and community in the care", "metadata": {"doc_name": "psy_module", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "of people with psychoses is important. 17", "metadata": {"doc_name": "psy_module", "page": 10, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 189 psy activity 2 : case scenarios : hallucinations and delusions duration : 20 minutes. purpose : an interactive discussion using case scenarios that enables participants to explore the experiences of hallucinations and delusions. instructions :", "metadata": {"doc_name": "psy_module", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• divide participants into three small groups. • give each group a different case scenario ( see psy supporting material ) to discuss and", "metadata": {"doc_name": "psy_module", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "analyse.", "metadata": {"doc_name": "psy_module", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• have participants analyse the case scenarios using the instructions on the card which", "metadata": {"doc_name": "psy_module", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "include : – identify whether the person is experiencing a hallucination or delusion. why did the group come to that decision? – identify how that hallucination or delusion is impacting on the person ’ s life. give as many details as possible.", "metadata": {"doc_name": "psy_module", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• instruct each group to briefly present their case scenario and findings to the rest of the", "metadata": {"doc_name": "psy_module", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "group.", "metadata": {"doc_name": "psy_module", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• facilitate a discussion.", "metadata": {"doc_name": "psy_module", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "activity 2 : exploring the symptoms of psychoses", "metadata": {"doc_name": "psy_module", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "1. identify whether the person is experiencing a", "metadata": {"doc_name": "psy_module", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "hallucination or delusions? explain your decisions.", "metadata": {"doc_name": "psy_module", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "2. identify how the hallucination or delusion", "metadata": {"doc_name": "psy_module", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "impact on the person ’ s life? explain your decisions. 18", "metadata": {"doc_name": "psy_module", "page": 11, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "2. 0 ( page 34 ). talk through the principles of assessment :", "metadata": {"doc_name": "psy_module", "page": 12, "section": "2.0", "domain": "other", "doc_id": "psy_module"}}
{"text": "• explore other explanations for symptoms :", "metadata": {"doc_name": "psy_module", "page": 12, "section": "2.0", "domain": "other", "doc_id": "psy_module"}}
{"text": "– evaluate for medical conditions. – evaluate for other relevant mns conditions.", "metadata": {"doc_name": "psy_module", "page": 12, "section": "2.0", "domain": "other", "doc_id": "psy_module"}}
{"text": "• assess for acute manic episode. • evaluate if the person has psychosis.", "metadata": {"doc_name": "psy_module", "page": 12, "section": "2.0", "domain": "other", "doc_id": "psy_module"}}
{"text": "ask participants to give their immediate thoughts about why these particular assessment principles are important? explain that they are going to watch a video of an assessment for psychoses. explain that many clinicians are unnecessarily uncomfortable in communicating with people with psychoses. and as we learned from the “ hearing voices, seeing things ” person story ( activity 1 ), we know that it can be difficult for the clinician and for the person. talk through the points on the slide that highlight why these factors influence communication. the person may be distracted by their symptoms and may find it hard to concentrate on what is being asked of them. 20 factors influencing communication", "metadata": {"doc_name": "psy_module", "page": 12, "section": "2.0", "domain": "other", "doc_id": "psy_module"}}
{"text": "• the person ’ s thoughts might be disorganized and unclear. • the person might be sharing unusual beliefs. • the person might refuse to speak. • the person might avoid any eye contact. • the person may not feel that they need medical care. • often the family will report the issue, not the person.", "metadata": {"doc_name": "psy_module", "page": 12, "section": "2.0", "domain": "other", "doc_id": "psy_module"}}
{"text": "now we will discuss how these issues affect your interaction with the person.", "metadata": {"doc_name": "psy_module", "page": 12, "section": "2.0", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 191 psy describe the points on the slide and highlight that these are ways to help improve communication with a person with psychoses. be patient, treat the person with respect and dignity, use active listening skills to really understand what the person is trying to tell you and establish trust and a rapport with the person.", "metadata": {"doc_name": "psy_module", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• explain that building trust is an extremely", "metadata": {"doc_name": "psy_module", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "important step for helping a person with possible psychoses.", "metadata": {"doc_name": "psy_module", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• one goal of the first session is to make the", "metadata": {"doc_name": "psy_module", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "person comfortable enough to return for follow - up.", "metadata": {"doc_name": "psy_module", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• give the following example of how", "metadata": {"doc_name": "psy_module", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "to pose questions without making the person uncomfortable. “ i would like to ask you a question that might sound strange but is a routine question : do you hear voices that no one else can hear even when you ’ re with other people? ” explain to participants that they are going to watch a video of amir being assessed for possible psychoses. https : / / www. youtube. com / watch? v = tpy5nbfmijy & index = 4 & list = p lu4ieskoli8gicaendwesq6 - yagxhes5v. during the video, ask participants to scan the psychoses assessment algorithm in the mhgap - ig to follow the assessment and then discuss it. after the participants have watched the video ask the group : what symptoms does amir have? use the mhgap - ig algorithm to decide : are there any other explanations for amir ’ s symptoms? seek group consensus. how did the health - care provider assess if there were other explanations? 21 establish communication and build trust", "metadata": {"doc_name": "psy_module", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• treat the person with respect and dignity. • try to understand the person ’ s perspective. • introduce your questions in a respectful way. • do not rush ; it may take several sessions to build trust. • do not challenge false beliefs or mock the person. • ask how the person ’ s life has been affected. • advocate on the person ' s behalf.", "metadata": {"doc_name": "psy_module", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "activity 3 : video demonstration : assessment show the mhgap - ig psychoses", "metadata": {"doc_name": "psy_module", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "assessment video.", "metadata": {"doc_name": "psy_module", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "22 23", "metadata": {"doc_name": "psy_module", "page": 13, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "192 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy delirium can present in a similar way to psychoses. therefore, it is crucial to make sure that there are no acute physical conditions resulting in delirium, i. e. infection, cerebral malaria, dehydration, metabolic abnormalities or medication side -", "metadata": {"doc_name": "psy_module", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "effects.", "metadata": {"doc_name": "psy_module", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "explain the key features of delirium that differentiate it from psychoses i. e. diurnal variation, acute onset, medical history, clouding of consciousness, disorientation. talk through the points on the slide. emphasize that if you do suspect delirium then assess and manage the acute physical condition and refer to emergency services and specialists as needed. continue to reassess the person after initial management in order to monitor the state of the person. did the health - care provider assess amir for dementia, depression, substance use ( alcohol / drug intoxication or withdrawal )? if you suspect any other mns conditions, then consider consultation with a mental health specialist and / or assess and manage the concurrent conditions by using the relevant modules in the mhgap - ig. 24 delirium an organic brain syndrome characterized by acute onset of :", "metadata": {"doc_name": "psy_module", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• confusion ( person appears confused, struggles to", "metadata": {"doc_name": "psy_module", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "understand surroundings ).", "metadata": {"doc_name": "psy_module", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• difficulty in focusing, shifting or maintaining attention. • changes in feeling ( sensations and perceptions ). • changes in level of consciousness or awareness. • disturbance in orientation to time, place and", "metadata": {"doc_name": "psy_module", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "sometimes person.", "metadata": {"doc_name": "psy_module", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• disorganized thinking – speech does not make sense. • changes in mood – anger, agitation, anxiety,", "metadata": {"doc_name": "psy_module", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "irritability, anxiety to apathy and depression. management of delirium", "metadata": {"doc_name": "psy_module", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "if you think that a person has delirium : • try to identify and manage underlying cause. • assess for dehydration and give fluid. • ensure that the person is safe and comfortable. • continue to reassess and monitor the person after initiating", "metadata": {"doc_name": "psy_module", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "management.", "metadata": {"doc_name": "psy_module", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• refer th e p erso n to a sp eci a l i st ( e. g. neurologist, psychiatrist, or", "metadata": {"doc_name": "psy_module", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "internal medicine specialist ).", "metadata": {"doc_name": "psy_module", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "25 26", "metadata": {"doc_name": "psy_module", "page": 14, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 193 psy for the management of depression see the module : depression in the mhgap - ig. for the management of substance use disorders see the module : disorders due to substance use in the mhgap - ig. to manage psychoses in dementia, see the module : dementia.", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "when considering the needs of special populations like pregnant women or women who have just given birth always refer to a specialist where available. explain that people with psychoses can present “ in crisis ” and as emergency cases in a number of ways.", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• with thoughts, plans, attempts of self -", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "harm / suicide.", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• acute agitation and / or anger.", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "explain that assessing for self - harm suicide will be covered in the module : self - harm / suicide. remind participants of the principles of managing acute agitation and / or aggression ( discussed in the module : essential care and practice ). managing concurrent mns conditions and psychoses psychoses can occur with :", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• depressive episodes – people can experience hallucinations and", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "delusions when depressed.", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• post - partum psychosis – in the days and weeks after giving birth", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "women can experience changes in mood ( including mania and", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "depression ). they can experience hallucinations and delusions and", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "significant confusion in their thinking and behaviour.", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• substance use disorders – intoxication due to substance use can", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "produce significant disturbances in mood and changes in levels of", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "consciousness, confusions and erratic behaviour. withdrawal from", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "substances can also cause confusion, erratic behaviour, changes in consciousness and perception.", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• dementia – people living with dementia can report experiencing", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "changes in perceptions ( hallucinations and delusions ).", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "27 28 29", "metadata": {"doc_name": "psy_module", "page": 15, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "194 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy talk through the case scenario. using the guidelines in the mhgap - ig page 45. facilitate a brief discussion about how participants could manage this scenario? would they consider medication? ( five minutes. ) make a note of their answers on a piece of flip chart paper. explain that the first step is safety first! therefore, participants should make sure that the girl, her father, mother and themselves are all safe. as the focus of the young woman ’ s agitation is the father, the safest thing to do is ask the father to leave. or ask the father to see another colleague so they can check his injuries. remain calm and encourage the young woman to talk by removing the father see if the young woman calms down. it is important that you remain calm. ask the woman to tell you why she is feeling so agitated. use a calm voice and try and address any of her immediate concerns. listen attentively – devote time to this young lady as she is clearly very upset. do not laugh at her, do not be aggressive and do not argue with her beliefs about her father. involve the mother ( if the young woman allows it ) ask the mother why she thinks this", "metadata": {"doc_name": "psy_module", "page": 16, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "to this young lady as she is clearly very upset. do not laugh at her, do not be aggressive and do not argue with her beliefs about her father. involve the mother ( if the young woman allows it ) ask the mother why she thinks this is happening? if the young woman calms down enough then try and assess her for psychosis. case scenario", "metadata": {"doc_name": "psy_module", "page": 16, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• a 22 - year - old woman is brought to the clinic", "metadata": {"doc_name": "psy_module", "page": 16, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "by her parents. they are concerned about her bizarre behaviour and strange speech. they explain the young woman keeps getting very agitated and angry and states that she wishes to “ escape from a terrible monster taking the shape of her father ”. today she violently attacked her father. 30 case scenario continued", "metadata": {"doc_name": "psy_module", "page": 16, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• her father has multiple cuts and bruises on his", "metadata": {"doc_name": "psy_module", "page": 16, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "face and body from where he was attacked.", "metadata": {"doc_name": "psy_module", "page": 16, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• the young woman is obviously still agitated and", "metadata": {"doc_name": "psy_module", "page": 16, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "restless. she cannot stay still and keeps trying to get away from her father. she is shouting at him to “ go away ” “ get out ” “ leave me ”.", "metadata": {"doc_name": "psy_module", "page": 16, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• what can you do to manage the situation?", "metadata": {"doc_name": "psy_module", "page": 16, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "31", "metadata": {"doc_name": "psy_module", "page": 16, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 195 psy bring the participants attention back to the video of amir. seek group consensus as to whether amir is having an acute manic episode? in this case, amir is not having an acute manic episode. therefore, continue to step 3. does amir have psychosis? the answer should be yes as he has hallucinations ( hearing voices ), signs of self - neglect or appearing unkempt, mumbling speech and reports ( from his parents ) about laughing to himself. read out the examples on the slide and ask participants to comment. discuss for five minutes and establish culturally appropriate questions you could use to ask whether people are experiencing hallucinations and delusions? note : write those questions and leave them in clear view so that participants can use them when they are doing role plays. 32 33 34 how to ask about hallucinations and delusions? symptoms person family hallucinations e. g. do you hear voices", "metadata": {"doc_name": "psy_module", "page": 17, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "or see things that no", "metadata": {"doc_name": "psy_module", "page": 17, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "one else can? e. g. do you see the", "metadata": {"doc_name": "psy_module", "page": 17, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "person talking to", "metadata": {"doc_name": "psy_module", "page": 17, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "someone else when", "metadata": {"doc_name": "psy_module", "page": 17, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "alone? as if the person is talking to someone?", "metadata": {"doc_name": "psy_module", "page": 17, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "delusions e. g. do you believe that", "metadata": {"doc_name": "psy_module", "page": 17, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "someone is planning to hurt you?", "metadata": {"doc_name": "psy_module", "page": 17, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "do you feel that you are", "metadata": {"doc_name": "psy_module", "page": 17, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "under surveillance?", "metadata": {"doc_name": "psy_module", "page": 17, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "e. g. did the person", "metadata": {"doc_name": "psy_module", "page": 17, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "share any ideas that you found strange and unlikely to be true?", "metadata": {"doc_name": "psy_module", "page": 17, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "196 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy activity 4 : role play : assessment duration : 30 minutes. purpose : this role play gives participants an opportunity to practise using the mhgap - ig to assess for psychoses. situation :", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• you are a health - care worker in a clinic • a man who is well known to you, is homeless and lives under the tree opposite your", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "practice, he has been seen talking to himself and laughing to himself, is unkempt and", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "un - groomed.", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• assess him according to the psychoses assessment algorithm on page 35 mhgap - ig", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "version 2. 0. instructions :", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• divide the participants into groups of three. • instruct one person to play the role of the health - care provider, one the person seeking", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "help and one the observer.", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• distribute the role play instructions to each person depending on their role. • ensure that the participants keep to the allotted time.", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "activity 4 : role play : assessment", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "- a man who is well known to you is", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "homeless and lives under the tree opposite your practice. he has been seen talking to himself and laughing to himself, is unkempt and ungroomed.", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "- assess him according to the psychoses", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "assessment algorithm on page 35 mhgap -", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "ig. 35 see psy supporting material role play 1.", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "print the three different instruction sheets for the participants playing the different roles.", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "ensure the person playing the role of the observer also has a competency assessment form ( see tohp training forms ) in order to assess the participants.", "metadata": {"doc_name": "psy_module", "page": 18, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 197 psy session 3. management of psychoses 1 hours 50 minutes hold up your hand and ask participants to tell you which management interventions should be used when treating people with psychoses. briefly talk through the different interventions that could be used in a treatment plan. 36 psychoeducation reducing stress and", "metadata": {"doc_name": "psy_module", "page": 19, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "strengthening social", "metadata": {"doc_name": "psy_module", "page": 19, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "support", "metadata": {"doc_name": "psy_module", "page": 19, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "promoting daily activities", "metadata": {"doc_name": "psy_module", "page": 19, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "pharmacology", "metadata": {"doc_name": "psy_module", "page": 19, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "ensuring safety in the", "metadata": {"doc_name": "psy_module", "page": 19, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "community and mobility", "metadata": {"doc_name": "psy_module", "page": 19, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "community support", "metadata": {"doc_name": "psy_module", "page": 19, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "37", "metadata": {"doc_name": "psy_module", "page": 19, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "198 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy direct participants to the management protocols on page 38 of the mhgap - ig version 2. 0. choose volunteers to read them out loud. ask participants how confident they would feel using these management interventions. 38 activity 5 : video demonstration : management duration : 30 minutes. purpose : to enable participants to watch how a health - care provider could offer basic management to an individual with psychoses. https : / / www. youtube. com / watch? v = ybn401r2gl4 & list = plu4ieskoli8gicaend wesq6 - yagxhes5v & index = 5. while watching ask participants to think about these questions :", "metadata": {"doc_name": "psy_module", "page": 20, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• how the health - care provider explains the", "metadata": {"doc_name": "psy_module", "page": 20, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "treatment options?", "metadata": {"doc_name": "psy_module", "page": 20, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• were the risks and benefits of medication", "metadata": {"doc_name": "psy_module", "page": 20, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "explained?", "metadata": {"doc_name": "psy_module", "page": 20, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• were the benefits of psychosocial", "metadata": {"doc_name": "psy_module", "page": 20, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "interventions explained? give the participants time to read through the psychosocial interventions on page 40 mhgap - ig. emphasize to participants the importance of delivering psychosocial interventions to people with psychoses and their carers. explain that focusing on a person ’ s recovery and taking time to ensure that they start to take part in activities of daily living and reconnect with their family and communities is an essential and crucial part of treatment. activity 5 video demonstration : managing psychoses", "metadata": {"doc_name": "psy_module", "page": 20, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• how did the health - care provider", "metadata": {"doc_name": "psy_module", "page": 20, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "explain the treatment options?", "metadata": {"doc_name": "psy_module", "page": 20, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• were the risks and benefits of", "metadata": {"doc_name": "psy_module", "page": 20, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "medication explained?", "metadata": {"doc_name": "psy_module", "page": 20, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• were the benefits of psychosocial", "metadata": {"doc_name": "psy_module", "page": 20, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "interventions explained? 39 40", "metadata": {"doc_name": "psy_module", "page": 20, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 199 psy activity 6 : delivering psychoeducation duration : 20 minutes. purpose : to enable participants to familiarize themselves with key psychoeducation messages and practise delivering those messages to the rest of the group. instructions :", "metadata": {"doc_name": "psy_module", "page": 21, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• divide the participants quickly into two groups. • give each group paper, pens, flip chart paper, sticky notes etc. • give one group the topic : psychoeducation for psychosis. • give the other group the topic : psychoeducation for bipolar disorder. • give each group 10 minutes to use the mhgap - ig and come up with a creative way to", "metadata": {"doc_name": "psy_module", "page": 21, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "deliver the key psychoeducation messages to the other group.", "metadata": {"doc_name": "psy_module", "page": 21, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• after 10 minutes of planning. give each group five minutes to present the key", "metadata": {"doc_name": "psy_module", "page": 21, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "psychoeducation messages. correct any misinformation. emphasize the importance of delivering clear psychoeducation to carers, including advising carers :", "metadata": {"doc_name": "psy_module", "page": 21, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• not to try and convince the person that their beliefs or experiences are false and not real.", "metadata": {"doc_name": "psy_module", "page": 21, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "explain that instead carers should be open to listening to the person talk about their experience but should not have a judgement or opinion about the experiences. instead stay neutral.", "metadata": {"doc_name": "psy_module", "page": 21, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• remind carers to stay calm and patient and not to get angry with the person.", "metadata": {"doc_name": "psy_module", "page": 21, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "explain that participants are now going to focus on how to promote functioning in daily living activities for people with psychoses. activity 6 : psychoeducation", "metadata": {"doc_name": "psy_module", "page": 21, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• group 1 : key messages in", "metadata": {"doc_name": "psy_module", "page": 21, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "psychoeducation for psychosis.", "metadata": {"doc_name": "psy_module", "page": 21, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• group 2 : key messages in", "metadata": {"doc_name": "psy_module", "page": 21, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "psychoeducation for bipolar disorder. 41", "metadata": {"doc_name": "psy_module", "page": 21, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "200 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy activity 7 : promoting functioning in daily living activities duration : 25 minutes. purpose : to introduce participants to the importance of promoting functioning in daily living activities for people with psychoses as a way of helping their recovery. instructions :", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• explain to participants that promoting functioning in daily living activities for people", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "with psychoses is a crucial step in their journey to recovery.", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• it is crucial because it will :", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "– help the person cope with and manage their symptoms. – reconnect the person with their community. – empower the person to take back some control of their life. – give the person the opportunity to learn and / or earn an income so they can live independently in the future. – give the person hope that they will recover and have a better future.", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• ask participants to :", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "– think about a time when you had to recover from something – it can be now or in the past ( two minutes ). for example, losing someone you loved, battling a difficult illness, being the survivor of abuse, losing an important opportunity or job? it can be anything you can think of, not necessarily related to mental health.", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• ask participants to :", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "– think what was difficult about recovering from that situation?", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• after a brief discussion, ask participants the following questions :", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "– think what helped you get better / overcome this situation?", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• give participants two minutes to think about or write down their personal recovery", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "experiences and journeys. ask for one or more volunteers to share their experience. the goal is to let the group think about what is involved in recovery in general. highlight how important continued functioning and participation in everyday activities were for their own recovery.", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• then ask participants to :", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "– think what might make recovery more difficult for people with psychoses?", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• ask the group to brainstorm ideas and write them on the flip chart. some possible", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "answers are : – major losses of social support – being isolated from friends and family / being physically restrained and isolated. – distress from being abused and mistreated. activity 7 : promoting functioning in daily living activities promoting functioning in daily living activities is a crucial step in their journey to recovery. it will :", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• help a person cope with and manage their symptoms. • reconnect the person with their community. • empower the person to take back some control of their", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "life.", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• give the person the opportunity to learn and / or earn an", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "income so they can live independently in the future.", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• give the person hope that they will recover and have a", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "better future. 42", "metadata": {"doc_name": "psy_module", "page": 22, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 201 psy – negative effects of medication. – loss of trust in the mental health system. – loss of trust in the community and family. – not being allowed to make decisions for yourself anymore. – feeling that your opinion is not respected. – negative attitudes from health - care providers. – devaluing and disempowering practices attitudes and environments. – stigma and discrimination from the family and the community. – lack of education, income generating, social and other opportunities. – lack of sense of identity, self - respect and hope. – lack of access to treatment and support. – lack of access to other people who have gone through similar things. – lack of information about your condition and situation. – demeaning remarks and maltreatment from others. – being told you will never recover. – being overprotected by family.", "metadata": {"doc_name": "psy_module", "page": 23, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• now that the group has thought about their own personal recovery, identified how", "metadata": {"doc_name": "psy_module", "page": 23, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "important everyday functioning was and identified what might make it difficult for people with psychoses to recover, ask the group to : – create a treatment plan of steps they could take to promote functioning in daily living activities for people with psychoses in their own communities.", "metadata": {"doc_name": "psy_module", "page": 23, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• give the participants five minutes to write an individual plan and then ask for volunteers", "metadata": {"doc_name": "psy_module", "page": 23, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "to share their ideas with the rest of the group.", "metadata": {"doc_name": "psy_module", "page": 23, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• discuss any barriers and obstacles that participants identify and try and brainstorm", "metadata": {"doc_name": "psy_module", "page": 23, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "solutions as a group. pharmacological interventions ask the group the question on the slide and give them time to answer before revealing the answer. the answer is early. early identification and early intervention is linked to better treatment outcomes. ask the group the question on the slide and give them time to answer before revealing the answer. the answer is a low dose. explain that severe side - effects from antipsychotic medication can reduce adherence, therefore to minimize those side - effects we want the lowest therapeutic dose. 43 initiating antipsychotic medication are antipsychotics better started early or late? early! for prompt control of psychotic symptoms,", "metadata": {"doc_name": "psy_module", "page": 23, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "health - care providers should begin antipsychotic medication immediately after assessment. the", "metadata": {"doc_name": "psy_module", "page": 23, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "sooner the better. 44 initiating antipsychotic medication is it better to start with a low dose or a high dose? low! start with a low dose within the therapeutic range and increase slowly to the lowest effective dose in order to reduce the risk of side - effects. start low, go slow.", "metadata": {"doc_name": "psy_module", "page": 23, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "202 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy ask the group the question on the slide and give them time to answer before revealing the answer. the answer is oral. oral medication can be more dignified than using intramuscular treatment. it is also empowering as it means the person has to take responsibility in their own recovery by taking medication every day. only use intramuscular treatment if oral routes are not possible. ask the group the question on the slide and give them time to answer before revealing the answer. the answer is one. try one medication and give it time to work before considering it ineffective. explain that antipsychotic medication should be offered routinely to a person with psychosis. highlight the importance of regular monitoring and follow - up of anyone started on antipsychotic medication. especially important is monitoring for health considerations : weight gain, blood pressure, fasting sugar, cholesterol changes, ecg changes, and extrapyramidal side - effects such as : akathisia, acute dystonic reactions, tremor, muscular rigidity etc. 45 initiating antipsychotic medication", "metadata": {"doc_name": "psy_module", "page": 24, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "which route is preferable?", "metadata": {"doc_name": "psy_module", "page": 24, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• oral • intramuscular.", "metadata": {"doc_name": "psy_module", "page": 24, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "oral!", "metadata": {"doc_name": "psy_module", "page": 24, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "consider intramuscular treatment only if oral treatment is not feasible. do not prescribe long - term injections ( depot ) for control of acute psychotic", "metadata": {"doc_name": "psy_module", "page": 24, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "symptoms. 46 initiating antipsychotic medication", "metadata": {"doc_name": "psy_module", "page": 24, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "how many antipsychotic medications should", "metadata": {"doc_name": "psy_module", "page": 24, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "we prescribe at a time?", "metadata": {"doc_name": "psy_module", "page": 24, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• one • more than one.", "metadata": {"doc_name": "psy_module", "page": 24, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "one! try the first medication at an optimum dose for at least four to six weeks before considering it ineffective. 47", "metadata": {"doc_name": "psy_module", "page": 24, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 203 psy direct participants ’ attention to the instructions in the mhgap - ig for managing manic episodes with pharmacological interventions. ask participants : why a person with mania would be on antidepressants? remind them that people with bipolar disorders can experience episodes of mania and depression. in fact, remind them that often people with bipolar may experience more episodes of depression, therefore they may have already been prescribed an antidepressant. if they have then point out that if they have had a manic episode, their antidepressants should be stopped. treatment with lithium, valproate and carbamazepine, haloperidol and risperidone should be considered. introduce participants to the story of yosef and explain that after carrying out a thorough assessment you decided to start him on antipsychotic medication as well as delivering psychoeducation and psychosocial interventions. instruct participants to look at tables 1 – 4 pages 42 – 44 mhgap - ig version 2. 0. find the answers to the following questions on the slide. 48 case scenario", "metadata": {"doc_name": "psy_module", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "yosef is 21 years old has been brought to you by his mother.", "metadata": {"doc_name": "psy_module", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "his mother says that recently yosef \" is not the same. \" he is no", "metadata": {"doc_name": "psy_module", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "longer studying and prefers to stay home doing nothing. you notice that yosef is wearing summer clothes although it is cold and raining. he looks like he has not washed for weeks. when yo u ta l k to h i m, yosef avoids eye contact. he gazes at the ceiling as if looking at someone. he mumbles and gestures as if", "metadata": {"doc_name": "psy_module", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "he is talking to someone.", "metadata": {"doc_name": "psy_module", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "he does not want to see his friends, he seems disconnected from his family and has no energy.", "metadata": {"doc_name": "psy_module", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "he is refusing to eat food in the home as he believes his mother is", "metadata": {"doc_name": "psy_module", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "trying to poison him. you assess yosef and decide to start him on antispyshchotic medication to see if that improves his symptoms.", "metadata": {"doc_name": "psy_module", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "49 antipsychotic medications", "metadata": {"doc_name": "psy_module", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• what are the starting doses for", "metadata": {"doc_name": "psy_module", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "haloperidol, chlorpromazine and riseperdione?", "metadata": {"doc_name": "psy_module", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• what are the effective doses? • what are the side - effects for each drug?", "metadata": {"doc_name": "psy_module", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "50", "metadata": {"doc_name": "psy_module", "page": 25, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "204 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy introduce participants to the story of maria. after a thorough assessment, you decide that she is having a manic episode and decide to start her on a mood stabilizer. instruct the participants to use the mhgap - ig to answer these questions. discuss these answers using table 4 ( page 44 mhgap version 2. 0 ). case scenario", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "maria is a 35 - year - old woman. she is married and has two children ( 10 and 8 years old ). for the last five years she has held a management level position in a local bank and has been enjoying her career. in the last two months she has been experiencing changes in her mood. she has been arguing with people at work and her family at home. she is getting frustrated as she does not", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "feel people are listening to her or understanding her. her speech", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "is very fast and confusing as she is having so many ideas at the same time. she is spending a lot of money and that is causing arguments with her husband. she is active all the time and is not", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "sleeping well.", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "after a thorough assessment you decide she is experiencing a", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "manic episode. 51 mood stabilizers", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• what are the starting doses for lithium,", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "sodium valproate and carbamazepine?", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• when should you not use lithium? • what are the effective doses? • what are the side - effects of each drug?", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "52 review and adherence", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• what should you do if yos efcomplains of muscle", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "rigidity and stiffness, and you notice that he has involuntary repetitive lip smacking?", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• what could you do if a person who has started", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "to take risperidone complains that they feel it is not doing anything to help them?", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• how would you help someone who stopped", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "taking sodium valproate because they were gaining too much weight and felt uncomfortable? 53", "metadata": {"doc_name": "psy_module", "page": 26, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 205 psy introduce participants to the case study and ask them to use the mhgap - ig to decide what management options are available to them. ask them to refer to page 39 of the mhgap - ig. special populations", "metadata": {"doc_name": "psy_module", "page": 27, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• ask participants to read through the", "metadata": {"doc_name": "psy_module", "page": 27, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "differences in special populations.", "metadata": {"doc_name": "psy_module", "page": 27, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• then ask for a volunteer to give a", "metadata": {"doc_name": "psy_module", "page": 27, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "brief summary of the differences in management of : – women who are pregnant or breastfeeding – adolescents – older adults. case scenario a 28 - year - old woman called fatima gave birth to her second child two weeks ago. her husband explains that she is not sleeping at all and she is struggling to feed the baby. she believes that her baby is in danger but she does not know how to protect it. sometimes she thinks it would be better if she and the baby were both dead.", "metadata": {"doc_name": "psy_module", "page": 27, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "on one occasion the husband has stopped her", "metadata": {"doc_name": "psy_module", "page": 27, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "from being violent towards the baby. 54 55", "metadata": {"doc_name": "psy_module", "page": 27, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "206 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy session 4.", "metadata": {"doc_name": "psy_module", "page": 28, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "follow - up", "metadata": {"doc_name": "psy_module", "page": 28, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "35 minutes ask for a volunteer from the participants to read out loud step 1 of the follow - up algorithm and possible outcomes to that step. ask participants to reflect on how they will know if the person is improving or not and the reasons why the person may not be taking their medication. reflect on how they might support a person to take their medication. ask another volunteer to read out loud steps 2 and 3 of the follow - up algorithm. ask participants to reflect on how could they routinely monitor treatment? what could they do? who could they ask? clarify any concerns or questions they may have about step 3 and the discontinuation of medication. 56 57", "metadata": {"doc_name": "psy_module", "page": 28, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 207 psy ask a volunteer to read out loud step 1 and possible outcomes in the follow - up of bipolar disorder. ask participants to reflect on how will they know if the person is improving? how will they know if the person is taking medication? ask another volunteer to read through steps 2 and 3 of the algorithm and possible outcomes. clarify any queries or concerns the participants may have with these steps and outcomes. ask participants to reflect on how they will know if the person is in full remission? ask participants to consider how they would learn about the number of manic or depressive episodes the person has had? explain that people with bipolar disorder may have more depressive episodes than manic episodes. therefore it is important to explore their mental state. 58 59", "metadata": {"doc_name": "psy_module", "page": 29, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "208 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy duration : 30 minutes. purpose : gives participants the opportunity to practise conducting a follow - up appointment with a person who is being managed for psychosis. situation : follow up with a person with psychosis. focus on re - assessment of the symptoms. assessment of side - effects of medication. assessment of psychosocial interventions specifically strengthening social support, reducing stress and life skills. instructions", "metadata": {"doc_name": "psy_module", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• divide the participants into groups of three. • instruct one person to play the role of the health - care provider, one the person seeking", "metadata": {"doc_name": "psy_module", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "help and one the observer.", "metadata": {"doc_name": "psy_module", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• distribute the role play instructions to each person depending on their role. • ensure that the participants keep to the allotted time.", "metadata": {"doc_name": "psy_module", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "activity 8 : role play : follow - up see psy supporting material role play 2.", "metadata": {"doc_name": "psy_module", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "print the three different instruction sheets for the participants playing the different roles.", "metadata": {"doc_name": "psy_module", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "ensure the person playing the role of the observer also has a competency assessment form ( see tohp training forms ) in order to assess the participants. activity 8 : role play : follow - up", "metadata": {"doc_name": "psy_module", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• follow - up with a person with psychosis. • focus on reassessment of the symptoms. • assessment of side - effects of medication. • assessment of psychosocial interventions", "metadata": {"doc_name": "psy_module", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "specifically strengthening social support, reducing stress and life skills. 60", "metadata": {"doc_name": "psy_module", "page": 30, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "module : psychoses 209 psy session 5.", "metadata": {"doc_name": "psy_module", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "review", "metadata": {"doc_name": "psy_module", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "15 minutes duration : minimum 15 minutes ( depends on participants ’ questions ). purpose : to review the knowledge and skills gained during this training session by delivering mcqs and facilitating a discussion. instructions :", "metadata": {"doc_name": "psy_module", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• administer the psychoses mcqs ( see psy supporting material ) to participants. • discuss the answers as a group. • facilitate a brief discussion answering any queries or concerns the participants may have.", "metadata": {"doc_name": "psy_module", "page": 31, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "210 mhgap training manual for the mhgap intervention guide for mental, neurological and substance use disorders in non - specialized health settings – version 2. 0 ( for field testing ) psy psy supporting material", "metadata": {"doc_name": "psy_module", "page": 32, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "• person stories • case scenarios • role plays • multiple choice questions • video links activity 3 : mhgap psy module – assessment https : / / www. youtube. com / watch? v = tpy5nbfmijy & index = 4 & list = plu4ieskoli8gicaend", "metadata": {"doc_name": "psy_module", "page": 32, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "wesq6 - yagxhes5v activity 5 : mhgap psy module – management https : / / www. youtube. com / watch? v = ybn401r2gl4 & list = plu4ieskoli8gicaendwesq6 - yagxhes5v & index = 5 supporting material available online at : www. who. int / mental _ health / mhgap / psy _ supporting _ material. pdf epi [ divider goes here ] psy powerpoint slide presentation powerpoint slide presentation available online at : http : / / www. who. int / mental _ health / mhgap / psy _ slides. pdf", "metadata": {"doc_name": "psy_module", "page": 32, "section": "NO_SECTION", "domain": "other", "doc_id": "psy_module"}}
{"text": "sign 145 • assessment, diagnosis and interventions for", "metadata": {"doc_name": "sign145", "page": 1, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autism spectrum disorders", "metadata": {"doc_name": "sign145", "page": 1, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "a national clinical guideline june 2016 evidence", "metadata": {"doc_name": "sign145", "page": 1, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "key to evidence statements and recommendations levels of evidence 1 + + high - quality meta - analyses, systematic reviews of rcts, or rcts with a very low risk of bias 1 + well - conducted meta - analyses, systematic reviews, or rcts with a low risk of bias 1 - meta - analyses, systematic reviews, or rcts with a high risk of bias 2 + + high - quality systematic reviews of case - control or cohort studies", "metadata": {"doc_name": "sign145", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "high - quality case - control or cohort studies with a very low risk of confounding or bias and a high probability that the", "metadata": {"doc_name": "sign145", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "relationship is causal 2 + well - conducted case - control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal 2", "metadata": {"doc_name": "sign145", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "- case - control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal", "metadata": {"doc_name": "sign145", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "3 non - analytic studies, eg case reports, case series 4 expert opinion recommendations some recommendations can be made with more certainty than others. the wording used in the recommendations in this guideline denotes the certainty with which the recommendation is made ( the ‘ strength ’ of the recommendation ). the ‘ strength ’ of a recommendation takes into account the quality ( level ) of the evidence. although higher - quality evidence is more likely to be associated with strong recommendations than lower - quality evidence, a particular level of quality does not automatically lead to a particular strength of recommendation. other factors that are taken into account when forming recommendations include : relevance to the nhs in scotland ; applicability of published evidence to the target population ; consistency of the body of evidence, and the balance of benefits and harms of the options. r", "metadata": {"doc_name": "sign145", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "for ‘ strong ’ recommendations on interventions that ‘ should ’ be used, the guideline development group is confident that, for", "metadata": {"doc_name": "sign145", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the vast majority of people, the intervention ( or interventions ) will do more good than harm. for ‘ strong ’ recommendations on interventions that ‘ should not ’ be used, the guideline development group is confident that, for the vast majority of people, the intervention ( or interventions ) will do more harm than good. r for ‘ conditional ’ recommendations on interventions that should be ‘ considered ’, the guideline development group is confident that the intervention will do more good than harm for most patients. the choice of intervention is therefore more likely to vary depending on a person ’ s values and preferences, and so the healthcare professional should spend more time discussing the options with the patient. good - practice points", "metadata": {"doc_name": "sign145", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "recommended best practice based on the clinical experience of the guideline development group.", "metadata": {"doc_name": "sign145", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "nice has accredited the process used by scottish intercollegiate guidelines network to produce clinical guidelines. the accreditation term is valid until 31 march 2020 and is applicable to guidance produced using the processes described in sign 50 : a guideline developer ’ s handbook, 2015 edition ( www. sign. ac. uk / guidelines / fulltext / 50 / index. html ). more information on accreditation can be viewed at www. nice. org. uk / accreditation healthcare improvement scotland ( his ) is committed to equality and diversity and assesses all its publications for likely impact on the six equality groups defined by age, disability, gender, race, religion / belief and sexual orientation. sign guidelines are produced using a standard methodology that has been equality impact assessed to ensure that these equality aims are addressed in every guideline. this methodology is set out in the current version of sign 50, our guideline manual, which can be found at www. sign. ac. uk / guidelines / fulltext / 50 / index. html. the eqia assessment of the manual can be seen at www. sign. ac. uk / pdf / sign50eqia. pdf. the full report in paper form and / or alternative format is available on request from the healthcare improvement scotland equality and diversity officer. every care is taken to ensure that this publication is correct in every detail at the time of publication. however, in the event of", "metadata": {"doc_name": "sign145", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "full report in paper form and / or alternative format is available on request from the healthcare improvement scotland equality and diversity officer. every care is taken to ensure that this publication is correct in every detail at the time of publication. however, in the event of errors or omissions corrections will be published in the web version of this document, which is the definitive version at all times. this version can be found on our web site www. sign. ac. uk.", "metadata": {"doc_name": "sign145", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "this document is produced from elemental chlorine - free material and is sourced from sustainable forests.", "metadata": {"doc_name": "sign145", "page": 2, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "scottish intercollegiate guidelines network", "metadata": {"doc_name": "sign145", "page": 3, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for", "metadata": {"doc_name": "sign145", "page": 3, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autism spectrum disorders a national clinical guideline june 2016", "metadata": {"doc_name": "sign145", "page": 3, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders scottish intercollegiate guidelines network gyle square, 1 south gyle crescent edinburgh eh12 9eb www. sign. ac. uk first published june 2016 isbn 978 1 909103 46 7 citation text", "metadata": {"doc_name": "sign145", "page": 4, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "scottish intercollegiate guidelines network ( sign ).", "metadata": {"doc_name": "sign145", "page": 4, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders. edinburgh : sign ; 2016. ( sign publication no. 145 ). [ june 2016 ]. available from url : http : / / www. sign. ac. uk", "metadata": {"doc_name": "sign145", "page": 4, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "sign consents to the photocopying of this guideline for the purpose", "metadata": {"doc_name": "sign145", "page": 4, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of implementation in nhsscotland.", "metadata": {"doc_name": "sign145", "page": 4, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 1 the need for a guideline...................................................................................................................................................................... 1", "metadata": {"doc_name": "sign145", "page": 5, "section": "1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 2 remit of the guideline.......................................................................................................................................................................... 3", "metadata": {"doc_name": "sign145", "page": 5, "section": "1.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 3 statement of intent................................................................................................................................................................................ 3 2 key recommendations..............................................................................................", "metadata": {"doc_name": "sign145", "page": 5, "section": "1.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "........................................................................................................ 6", "metadata": {"doc_name": "sign145", "page": 5, "section": "1.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2. 1 diagnostic criteria................................................................................................................................................................................... 6", "metadata": {"doc_name": "sign145", "page": 5, "section": "2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2. 2 recognition, assessment and diagnosis......................................................................................................................................... 6", "metadata": {"doc_name": "sign145", "page": 5, "section": "2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2. 3 non - pharmacological interventions for children....................................................................................................................... 6", "metadata": {"doc_name": "sign145", "page": 5, "section": "2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2. 4 non - pharmacological interventions for adults............................................................................................................................ 6 3 definitions and concepts...........................................................................................................................................", "metadata": {"doc_name": "sign145", "page": 5, "section": "2.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "...................................................... 7", "metadata": {"doc_name": "sign145", "page": 5, "section": "2.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "3. 1 definitions................................................................................................................................................................................................. 7", "metadata": {"doc_name": "sign145", "page": 5, "section": "3.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "3. 2 diagnostic criteria................................................................................................................................................................................... 7 4 recognition, assessment and diagnosis.........................................................................................", "metadata": {"doc_name": "sign145", "page": 5, "section": "3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": ".............................................................................. 8", "metadata": {"doc_name": "sign145", "page": 5, "section": "3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1 recognition in primary care................................................................................................................................................................ 8", "metadata": {"doc_name": "sign145", "page": 5, "section": "4.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 2 methods of assessment........................................................................................................................................................................ 12", "metadata": {"doc_name": "sign145", "page": 5, "section": "4.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 3 individual profiling................................................................................................................................................................................. 15", "metadata": {"doc_name": "sign145", "page": 5, "section": "4.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 4 conditions associated with asd....................................................................................................................................................... 16", "metadata": {"doc_name": "sign145", "page": 5, "section": "4.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 5 biomedical investigations.................................................................................................................................................................... 17", "metadata": {"doc_name": "sign145", "page": 5, "section": "4.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 6 prognostic indicators in childhood.................................................................................................................................................. 19 5 principles of intervention........................................................................................................................", "metadata": {"doc_name": "sign145", "page": 5, "section": "4.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "......................................................................... 20 6 non - pharmacological interventions for children and young people.................................................................... 21", "metadata": {"doc_name": "sign145", "page": 5, "section": "4.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 1 parent - mediated interventions.......................................................................................................................................................... 21", "metadata": {"doc_name": "sign145", "page": 5, "section": "6.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 2 communication interventions........................................................................................................................................................... 21", "metadata": {"doc_name": "sign145", "page": 5, "section": "6.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3 behavioural / psychological interventions...................................................................................................................................... 23", "metadata": {"doc_name": "sign145", "page": 5, "section": "6.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 4 nutritional interventions...................................................................................................................................................................... 28", "metadata": {"doc_name": "sign145", "page": 5, "section": "6.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 5 other interventions................................................................................................................................................................................ 28 7 non - pharmacological interventions for adults........................................................................................", "metadata": {"doc_name": "sign145", "page": 5, "section": "6.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "................................................................... 29", "metadata": {"doc_name": "sign145", "page": 5, "section": "6.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "7. 1 communication interventions........................................................................................................................................................... 29", "metadata": {"doc_name": "sign145", "page": 5, "section": "7.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "7. 2 facilitated communication.................................................................................................................................................................. 29", "metadata": {"doc_name": "sign145", "page": 5, "section": "7.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "7. 3 social skills interventions..................................................................................................................................................................... 29", "metadata": {"doc_name": "sign145", "page": 5, "section": "7.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "7. 4 behavioural interventions................................................................................................................................................................... 30", "metadata": {"doc_name": "sign145", "page": 5, "section": "7.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "7. 5 cognitive behavioural therapies....................................................................................................................................................... 30 8 pharmacological interventions for children and young people............................................................................. 32", "metadata": {"doc_name": "sign145", "page": 5, "section": "7.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 1 general principles................................................................................................................................................................................... 32", "metadata": {"doc_name": "sign145", "page": 5, "section": "8.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 2 second - generation antipsychotics.................................................................................................................................................. 32", "metadata": {"doc_name": "sign145", "page": 5, "section": "8.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 3 methylphenidate.................................................................................................................................................................................... 34", "metadata": {"doc_name": "sign145", "page": 5, "section": "8.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 4 noradrenergic reuptake inhibitors................................................................................................................................................... 34", "metadata": {"doc_name": "sign145", "page": 5, "section": "8.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 5 antidepressants....................................................................................................................................................................................... 34", "metadata": {"doc_name": "sign145", "page": 5, "section": "8.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 6 naltrexone................................................................................................................................................................................................. 35", "metadata": {"doc_name": "sign145", "page": 5, "section": "8.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 7 hormonal interventions....................................................................................................................................................................... 35", "metadata": {"doc_name": "sign145", "page": 5, "section": "8.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 8 melatonin................................................................................................................................................................................................... 35", "metadata": {"doc_name": "sign145", "page": 5, "section": "8.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 1 general principles................................................................................................................................................................................... 37", "metadata": {"doc_name": "sign145", "page": 6, "section": "9.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 2 antipsychotics.......................................................................................................................................................................................... 37", "metadata": {"doc_name": "sign145", "page": 6, "section": "9.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 3 pharmacotherapy to improve cognition........................................................................................................................................ 37", "metadata": {"doc_name": "sign145", "page": 6, "section": "9.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 4 methylphenidate.................................................................................................................................................................................... 38", "metadata": {"doc_name": "sign145", "page": 6, "section": "9.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 5 noradrenergic reuptake inhibitors................................................................................................................................................... 38", "metadata": {"doc_name": "sign145", "page": 6, "section": "9.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 6 antidepressants....................................................................................................................................................................................... 38", "metadata": {"doc_name": "sign145", "page": 6, "section": "9.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 7 anxiolytics................................................................................................................................................................................................. 38", "metadata": {"doc_name": "sign145", "page": 6, "section": "9.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 8 anticonvulsants....................................................................................................................................................................................... 38", "metadata": {"doc_name": "sign145", "page": 6, "section": "9.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 9 naltrexone................................................................................................................................................................................................. 38", "metadata": {"doc_name": "sign145", "page": 6, "section": "9.9", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 10 hormonal interventions....................................................................................................................................................................... 38", "metadata": {"doc_name": "sign145", "page": 6, "section": "9.10", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 11 melatonin................................................................................................................................................................................................... 39 10 service provision...........................................................................", "metadata": {"doc_name": "sign145", "page": 6, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "..................................................................................................................................... 40", "metadata": {"doc_name": "sign145", "page": 6, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "10. 1 training....................................................................................................................................................................................................... 40", "metadata": {"doc_name": "sign145", "page": 6, "section": "10.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "10. 2 interventions and meeting support needs................................................................................................................................... 40", "metadata": {"doc_name": "sign145", "page": 6, "section": "10.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "10. 3 information provision and support for parents / carers............................................................................................................. 41", "metadata": {"doc_name": "sign145", "page": 6, "section": "10.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "10. 4 support during transition.................................................................................................................................................................... 41 11 provision of information.........................................................................................................", "metadata": {"doc_name": "sign145", "page": 6, "section": "10.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": ".......................................................................................... 42", "metadata": {"doc_name": "sign145", "page": 6, "section": "10.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "11. 1 providing information and support................................................................................................................................................. 42", "metadata": {"doc_name": "sign145", "page": 6, "section": "11.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "11. 2 checklist for provision of information............................................................................................................................................. 44", "metadata": {"doc_name": "sign145", "page": 6, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "11. 3 sources of further information.......................................................................................................................................................... 46 12 implementing the guideline.................................................................................................................", "metadata": {"doc_name": "sign145", "page": 6, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "........................................................................... 48", "metadata": {"doc_name": "sign145", "page": 6, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "12. 1 implementation strategy..................................................................................................................................................................... 48", "metadata": {"doc_name": "sign145", "page": 6, "section": "12.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "12. 2 resource implications of key recommendations........................................................................................................................ 48", "metadata": {"doc_name": "sign145", "page": 6, "section": "12.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "12. 3 auditing current practice..................................................................................................................................................................... 48", "metadata": {"doc_name": "sign145", "page": 6, "section": "12.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "12. 4 health technology assessment advice for nhsscotland.......................................................................................................... 49 13 the evidence base........................................................................................................................................................... 50", "metadata": {"doc_name": "sign145", "page": 6, "section": "12.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "13. 1 systematic literature review................................................................................................................................................................ 50", "metadata": {"doc_name": "sign145", "page": 6, "section": "13.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "13. 2 recommendations for research......................................................................................................................................................... 51", "metadata": {"doc_name": "sign145", "page": 6, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "13. 3 review and updating............................................................................................................................................................................ 52 14 development of the guideline..............................................................................................", "metadata": {"doc_name": "sign145", "page": 6, "section": "13.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": ".......................................................................................... 53", "metadata": {"doc_name": "sign145", "page": 6, "section": "13.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14. 1 introduction.............................................................................................................................................................................................. 53", "metadata": {"doc_name": "sign145", "page": 6, "section": "14.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14. 2 the guideline development group.................................................................................................................................................. 53", "metadata": {"doc_name": "sign145", "page": 6, "section": "14.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14. 3 consultation and peer review............................................................................................................................................................ 54 abbreviations..................................................................................................................", "metadata": {"doc_name": "sign145", "page": 6, "section": "14.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "................................................................................................................ 56 annexes.....................................................................................................................................................................", "metadata": {"doc_name": "sign145", "page": 6, "section": "14.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "....................................................................... 58 references...................................................................................................................................................................................... 69", "metadata": {"doc_name": "sign145", "page": 6, "section": "14.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 1 the need for a guideline since sign 98 : assessment, diagnosis and clinical interventions for children and young people with autism spectrum disorders was published in july 2007, there have been significant developments in interagency working attributable to the getting it right for every child ( girfec ) approach now enshrined in the children and young people ( scotland ) act 2014.", "metadata": {"doc_name": "sign145", "page": 7, "section": "1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1, 2 the scottish strategy for autism ( 2011 ) has provided a ten - year framework to progress implementation, planning and outcomes for adult and children and young people ’ s", "metadata": {"doc_name": "sign145", "page": 7, "section": "1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "services with a view to developing effective joint pathways for service delivery.", "metadata": {"doc_name": "sign145", "page": 7, "section": "1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "3", "metadata": {"doc_name": "sign145", "page": 7, "section": "1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "this guideline updates sign 98 to reflect new evidence for managing children and young people and to incorporate evidence which applies to adults and older people. the inclusion of adults is in response to the increasing understanding that autism spectrum disorder ( asd ) is a lifelong condition in which the core features of asd persist whilst manifesting differently according to different age stages. depending on the severity of autistic difficulties, asd may not be evident as a presentation throughout preschool, primary, or secondary school years or in adulthood. it may not be recognised because of associated coexisting conditions. variable environmental factors, for example relatively smaller class size in primary school years, or family ‘ scaffolding ’ of social impairment in childhood or adolescence or, in adults, unmasking of symptoms and signs of asd due to loss of informal carers, will also influence this dynamic. 4 alternatively the signs and symptoms of asd may not always have been recognised by parents, carers, the individual themselves or other professionals, 5 so may not present until adulthood, or perhaps even older adulthood. there is therefore a need for a guideline which reflects the whole age range. this is a highly prevalent condition. a community survey in england in 2007 estimated around 1 % of adults have asd. 6 prevalence in children is also around 1 %. 7, 8 a study in greater glasgow of children 0 – 6 years", "metadata": {"doc_name": "sign145", "page": 7, "section": "1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "range. this is a highly prevalent condition. a community survey in england in 2007 estimated around 1 % of adults have asd. 6 prevalence in children is also around 1 %. 7, 8 a study in greater glasgow of children 0 – 6 years old reported a prevalence of autism of 11. 1 per year per 10, 000 children ( 0. 1 % ) in 2007. 9 asd is recognised more commonly in boys than girls, at a ratio of approximately 4 : 1, although this varies across the spectrum. 10 prompt diagnosis and appropriate intervention, specialised educational programmes, and structured support may help a person with asd maximise his or her potential. since the publication of sign 98, services across scotland have adhered to the majority of the recommendations on assessment and diagnosis. 11, 12 it is hoped that this update will contribute further to a reduction in variation in practice and improve services for people of all ages with asd.", "metadata": {"doc_name": "sign145", "page": 7, "section": "1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 1. 1 updating the evidence this guideline updates sign 98 to reflect evidence published between 2006 and 2014. for sections not included in the update, and sections where no new evidence was found, text and recommendations are reproduced verbatim from sign 98. the original supporting evidence was not reappraised by the current guideline development group. the evidence review underpinning the sections on adults used the key questions and evidence identified to develop the national institute for health and care excellence ( nice ) guideline 142, autism : recognition, referral, diagnosis and management of adults on the autism spectrum. 13 further searches were conducted to identify studies published after publication of nice 142. see section 13 for further details of the literature search and annex 1 for details of the key questions addressed in this update. 1 • introduction", "metadata": {"doc_name": "sign145", "page": 7, "section": "1.1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 1. 2 summary of updates to the guideline, by section the following list details the sections which have been revised with new evidence, to reflect new legislation, or to incorporate advice on adults with asd. the remaining sections were not included in the selective update and are reproduced verbatim from sign 98. 2 key recommendations new 3 definitions and concepts updated 4 recognition, assessment and diagnosis", "metadata": {"doc_name": "sign145", "page": 8, "section": "1.1.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 1 introduction updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "4.1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 3 surveillance updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "4.1.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 4 secondary screening minor revision", "metadata": {"doc_name": "sign145", "page": 8, "section": "4.1.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 6 identifying adults for assessment new", "metadata": {"doc_name": "sign145", "page": 8, "section": "4.1.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 7 instruments to aid identification of adults with asd new", "metadata": {"doc_name": "sign145", "page": 8, "section": "4.1.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 8 gender differences across the age ranges new", "metadata": {"doc_name": "sign145", "page": 8, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 2. 2 specialist assessment updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 2. 3 components of specialist assessment updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 3 individual profiling updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "4.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 4 conditions associated with asd updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "4.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 5 biomedical investigations updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "4.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 6 prognostic indicators in childhood updated 5 principles of intervention minor revision 6 non - pharmacological interventions for children and young people", "metadata": {"doc_name": "sign145", "page": 8, "section": "4.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 1 parent - mediated interventions updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "6.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 2. 1 support for early communication skills updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "6.2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 2. 2 interventions for social communication and interaction updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "6.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 1 intensive behavioural and developmental programmes completely revised", "metadata": {"doc_name": "sign145", "page": 8, "section": "6.3.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 2 specific interventions for asd new", "metadata": {"doc_name": "sign145", "page": 8, "section": "6.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 3 cognitive behavioural therapies new", "metadata": {"doc_name": "sign145", "page": 8, "section": "6.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 4 auditory integration training updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "6.3.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 5 occupational therapy and sensory integration therapy completely revised", "metadata": {"doc_name": "sign145", "page": 8, "section": "6.3.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 6 music therapy updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "6.3.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 7 sleep management updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "6.3.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 8 facilitated communication no new evidence identified", "metadata": {"doc_name": "sign145", "page": 8, "section": "6.3.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 9 additional interventions to address behavioural challenges updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "6.3.9", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 4 nutritional interventions updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "6.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 5 other interventions new 7 non - pharmacological interventions for adults new 8 pharmacological interventions for children and young people", "metadata": {"doc_name": "sign145", "page": 8, "section": "6.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 2 second - generation antipsychotics completely revised", "metadata": {"doc_name": "sign145", "page": 8, "section": "8.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 3 methylphenidate updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "8.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 4 noradrenergic reuptake inhibitors new", "metadata": {"doc_name": "sign145", "page": 8, "section": "8.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 5 antidepressants new", "metadata": {"doc_name": "sign145", "page": 8, "section": "8.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 6 naltrexone no new evidence identified", "metadata": {"doc_name": "sign145", "page": 8, "section": "8.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 7. 1 secretin updated", "metadata": {"doc_name": "sign145", "page": 8, "section": "8.7.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 7. 2 oxytocin new", "metadata": {"doc_name": "sign145", "page": 8, "section": "8.7.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 8 melatonin completely revised", "metadata": {"doc_name": "sign145", "page": 8, "section": "8.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "10. 4 support during transition updated 11 provision of information", "metadata": {"doc_name": "sign145", "page": 9, "section": "10.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "11. 2 checklist for provision of information minor revision", "metadata": {"doc_name": "sign145", "page": 9, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "11. 3 sources of further information updated 12 implementing the guideline completely revised 13 the evidence base new", "metadata": {"doc_name": "sign145", "page": 9, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 2 remit of the guideline", "metadata": {"doc_name": "sign145", "page": 9, "section": "1.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 2. 1 overall objectives this guideline provides recommendations based on current evidence for best practice in the assessment, diagnosis and interventions for children, young people, adults and older adults with asd. it includes screening and surveillance, diagnosis and assessment, clinical interventions and service provision, as well as recommendations for research and audit.", "metadata": {"doc_name": "sign145", "page": 9, "section": "1.2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 2. 2 target users of the guideline this guideline will be of interest to healthcare professionals and other multiagency colleagues who work with children and adults with asd, as well as people with asd, their parents, carers, relatives, partners and others with whom they interact.", "metadata": {"doc_name": "sign145", "page": 9, "section": "1.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 2. 3 aim and ethos of the guideline the aim of this guideline is to provide the evidence base and recommendations to inform clinical service provision, in particular, assessment and clinical intervention. it is the hope of the guideline development", "metadata": {"doc_name": "sign145", "page": 9, "section": "1.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "group that the concept of ' asd - friendly ' services is a constant throughout this guideline. the involvement of", "metadata": {"doc_name": "sign145", "page": 9, "section": "1.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "parents, family, carers and the individual with asd is important to the success of any intervention. healthcare professionals should be given adequate time for discussion with patients and carers, and there should be continuity of care across services.", "metadata": {"doc_name": "sign145", "page": 9, "section": "1.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 2. 4 patient version patient versions of this guideline are available from the sign website, www. sign. ac. uk", "metadata": {"doc_name": "sign145", "page": 9, "section": "1.2.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 3 statement of intent this guideline is not intended to be construed or to serve as a standard of care. standards of care are determined on the basis of all clinical data available for an individual case and are subject to change as scientific knowledge and technology advance and patterns of care evolve. adherence to guideline recommendations will not ensure a successful outcome in every case, nor should they be construed as including all proper methods of care or excluding other acceptable methods of care aimed at the same results. the ultimate judgement must be made by the appropriate healthcare professional ( s ) responsible for clinical decisions regarding a particular clinical procedure or treatment plan. this judgement should only be arrived at following discussion of the options with the patient, covering the diagnostic and treatment choices available. it is advised, however, that significant departures from the national guideline or any local guidelines derived from it should be fully documented in the patient ’ s case notes at the time the relevant decision is taken. 1 • introduction", "metadata": {"doc_name": "sign145", "page": 9, "section": "1.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 3. 1 influence of financial and other interests it has been recognised that financial interests in, or close working relationships with, pharmaceutical companies may have an influence on the interpretation of evidence from clinical studies. it is not possible to completely eliminate any possible bias from this source, nor even to quantify the degree of bias with any certainty. sign requires that all those involved in the work of guideline development should declare all financial interests, whether direct or indirect, annually for as long as they are actively working with the organisation. by being explicit about the influences to which contributors are subjected, sign acknowledges the risk of bias and makes it possible for guideline users or reviewers to assess for themselves how likely it is that the conclusions and guideline recommendations are based on a biased interpretation of the evidence. details of those involved in developing this guideline can be found in section 14.", "metadata": {"doc_name": "sign145", "page": 10, "section": "1.3.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 3. 2 prescribing of licensed medicines outwith their marketing authorisation recommendations within this guideline are based on the best clinical evidence. some recommendations may be for medicines prescribed outwith the marketing authorisation ( ma ) also known as product licence. this is known as ‘ off label ’ use. medicines may be prescribed ‘ off label ’ in the following circumstances : y for an indication not specified within the marketing authorisation y for administration via a different route y for administration of a different dose y for a different patient population. an unlicensed medicine is a medicine which does not have ma for medicinal use in humans. generally ‘ off label ’ prescribing of medicines becomes necessary if the clinical need cannot be met by licensed medicines within the marketing authorisation. such use should be supported by appropriate evidence and experience. 14 “ prescribing medicines outside the conditions of their marketing authorisation alters ( and probably increases ) the prescribers ’ professional responsibility and potential liability. ”", "metadata": {"doc_name": "sign145", "page": 10, "section": "1.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14", "metadata": {"doc_name": "sign145", "page": 10, "section": "1.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the general medical council ( gmc ) recommends that when prescribing a medicine ‘ off label ’, doctors should :", "metadata": {"doc_name": "sign145", "page": 10, "section": "1.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y be satisfied that such use would better serve the patient ’ s needs than an authorised alternative ( if one", "metadata": {"doc_name": "sign145", "page": 10, "section": "1.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "exists )", "metadata": {"doc_name": "sign145", "page": 10, "section": "1.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y be satisfied that there is sufficient evidence / experience of using the medicines to show its safety and", "metadata": {"doc_name": "sign145", "page": 10, "section": "1.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "efficacy, seeking the necessary information from appropriate sources", "metadata": {"doc_name": "sign145", "page": 10, "section": "1.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y record in the patient ’ s clinical notes the medicine prescribed and, when not following common practice,", "metadata": {"doc_name": "sign145", "page": 10, "section": "1.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the reasons for the choice", "metadata": {"doc_name": "sign145", "page": 10, "section": "1.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y take responsibility for prescribing the medicine and for overseeing the patient ’ s care, including monitoring", "metadata": {"doc_name": "sign145", "page": 10, "section": "1.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the effects of the medicine. non - medical prescribers should ensure that they are familiar with the legislative framework and their own professional prescribing standards. prior to any prescribing, the licensing status of a medication should be checked in the summary of product characteristics ( spc ) or the british national formulary for children. 14, 15 the prescriber must be competent, operate within the professional code of ethics of their statutory bodies and the prescribing practices of their employers. 16", "metadata": {"doc_name": "sign145", "page": 10, "section": "1.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 3. 3 additional advice to nhsscotland from healthcare improvement scotland and the scottish medicines consortium healthcare improvement scotland processes multiple technology appraisals ( mtas ) for nhsscotland that have been produced by nice in england and wales. the scottish medicines consortium ( smc ) provides advice to nhs boards and their area drug and therapeutics committees about the status of all newly licensed medicines and any major new indications for established products. smc advice relevant to this guideline is summarised in section 12. 4. 1 • introduction", "metadata": {"doc_name": "sign145", "page": 11, "section": "1.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2. 1 diagnostic criteria", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r all professionals involved in diagnosing asd in children, young people or adults should consider", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "using the current version of either icd or dsm. the classification system used for diagnosis should be recorded in the patient ’ s notes.", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2. 2 recognition, assessment and diagnosis", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r as part of the core programme of child health surveillance, healthcare professionals can aid early", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "identification of children requiring further assessment for asd and other developmental disorders. clinical assessment should incorporate a high level of vigilance for features suggestive of asd, in the domains of social interaction and play, speech, language and communication difficulties and behaviour.", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the assessment of children and young people with developmental delay, emotional and behavioural", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "problems, psychiatric disorders, impaired mental health or genetic syndromes should include surveillance for asd as part of routine practice.", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r healthcare professionals should consider that females with asd may present with a different", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "symptom profile and level of impairment than males with asd.", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r a diagnostic assessment, alongside a profile of the individual ’ s strengths and weaknesses, carried", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "out by a multidisciplinary team which has the skills and experience to undertake the assessments, should be considered as the optimum approach for individuals suspected of having asd.", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "specialist assessment should involve a history - taking element, a clinical observation / assessment", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "element, and the obtaining of wider contextual and functional information.", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2. 3 non - pharmacological interventions for children", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "parent - mediated intervention programmes should be considered for children and young people of all", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "ages who are affected by asd, as they may help families interact with their child, promote development and increase parental satisfaction, empowerment and mental health.", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "behavioural interventions may be considered to address a wide range of specific behaviours, including", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "those that challenge, in children and young people with asd, both to reduce symptom frequency and severity and to increase the development of adaptive skills.", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2. 4 non - pharmacological interventions for adults", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "psychosocial interventions should be considered for adults with asd if indicated for managing", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "coexisting conditions.", "metadata": {"doc_name": "sign145", "page": 12, "section": "2.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "3. 1 definitions autism spectrum disorder is a complex developmental condition, behaviourally defined, that includes a range of possible developmental impairments in reciprocal social interaction and communication, and also a stereotyped, repetitive or limited behavioural repertoire. sensory differences may also be a presenting feature. 4 asd may occur in association with any level of general intellectual / learning ability, and manifestations range from subtle problems of understanding and impaired social function to severe disabilities. 17 impairments in each of the areas relevant to asd diagnoses occur along a continuum from minimal to severe and categorical diagnoses inevitably involve defining a cut off. diagnostic classification in itself should not be the basis for decisions about provision within education, or need for social care and support. 18 some affected individuals advocate that it is inappropriate to describe them as having a disorder and consider that autism spectrum condition ( asc ) is a more appropriate term.", "metadata": {"doc_name": "sign145", "page": 13, "section": "3.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "3. 2 diagnostic criteria there are two major diagnostic classification systems in current use, the international classification of diseases, version 10 ( icd - 10 ) and the diagnostic and statistical manual of mental disorders 5th edition ( dsm - 5 ). 4, 19 because dsm - 5 is the most recent classification system, published in 2013 ( whilst icd - 10 was published in 1993 ) this guideline has referred only to dsm - 5 in terms of the current approach to diagnostic classification. given that icd - 11 is not due for publication until 2017, it is uncertain to what extent the two systems will correspond. the most important difference between icd - 10 and dsm - 5 is that icd - 10 uses the concept of pervasive developmental disorders ( pdd ). whilst the conditions of childhood autism and asperger ’ s syndrome are included in pdd, the concept of an autism spectrum is not. a further important difference is that the two conditions of childhood autism and asperger ’ s syndrome in icd - 10 are determined by the concept of a “ triad of impairments ”, which dsm has now reduced to a dyad of impairments. thus, the new dsm - 5 dimension of \" persistent deficits in social communication and social interaction across multiple contexts \" reflects the view that problems with reciprocal social interaction and communication overlap and cannot be reliably", "metadata": {"doc_name": "sign145", "page": 13, "section": "3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "to a dyad of impairments. thus, the new dsm - 5 dimension of \" persistent deficits in social communication and social interaction across multiple contexts \" reflects the view that problems with reciprocal social interaction and communication overlap and cannot be reliably distinguished. the second diagnostic dimension of the dsm - 5 dyad of restricted, repetitive patterns of behaviour, interests, or activities is unchanged from the triad, but has been operationalised. another significant difference between dsm - 5 and icd - 10 is that, because the disorder spectrum concept has now", "metadata": {"doc_name": "sign145", "page": 13, "section": "3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "been fully integrated into autism classification, the condition of asperger ’ s syndrome ( or asperger ’ s disorder", "metadata": {"doc_name": "sign145", "page": 13, "section": "3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "from dsm - iv ) 20 is no longer used. in addition, domain b of dsm - 5 classification adds in new clinical signs of stereotypical speech and also hyper - or hyporeactivity to sensory input or interest in sensory aspects of the environment. 4 studies included in the guideline were conducted before the introduction of dsm - 5 and discussion of the evidence base reflects the use of dsm - iv. three studies all found that the use of dsm - iv and icd - 10 criteria for autism improve the reliability of the diagnostic process. 21 - 23 the studies consistently found that :", "metadata": {"doc_name": "sign145", "page": 13, "section": "3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y using either dsm - iv or icd - 10 increases the reliability of the diagnostic process. the effect is even greater", "metadata": {"doc_name": "sign145", "page": 13, "section": "3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "when inexperienced practitioners are making the diagnosis y the current criteria for asperger ’ s syndrome and autism have poor discriminant validity.", "metadata": {"doc_name": "sign145", "page": 13, "section": "3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r all professionals involved in diagnosing asd in children, young people or adults should consider", "metadata": {"doc_name": "sign145", "page": 13, "section": "3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "using the current version of either icd or dsm. the classification system used for diagnosis should be recorded in the patient ’ s notes. 2 + 3 • definitions and concepts", "metadata": {"doc_name": "sign145", "page": 13, "section": "3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1 recognition in primary care", "metadata": {"doc_name": "sign145", "page": 14, "section": "4.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 1 introduction autism spectrum disorder can be recognised for the first time at any age, despite the fact that it is a lifelong disorder that starts in early life. some people will not present to a health professional until later in life. it is important to be aware of the possibility of an asd diagnosis not only in primary care but also in education, social work and employment settings. people may present at any time but particularly at times of change or stress, for example moving to university, after the death of a spouse or at times of work or life stress. in keeping with the principles of girfec and the children and young people ( scotland ) act 2014, children in scotland are offered a programme of immunisation, screening, surveillance, health promotion and parenting", "metadata": {"doc_name": "sign145", "page": 14, "section": "4.1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "support through the mechanism of the universal child health review. 1, 2, 24, 25 in 2014, nhsscotland reintroduced", "metadata": {"doc_name": "sign145", "page": 14, "section": "4.1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "a 27 – 30 month universal child health review within this programme. this child health review remains broadly aligned to health for all children ( hall 4 ), which states that every child and parent should have access to a universal or core programme of preventative preschool care, but that formal screening should be confined to the evidence - based programmes agreed by the uk national screening committee.", "metadata": {"doc_name": "sign145", "page": 14, "section": "4.1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "26 hall 4 does not recommend formal universal screening for speech and language", "metadata": {"doc_name": "sign145", "page": 14, "section": "4.1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "delay, global developmental delay or asd, but states that staff should elicit and respond to parental concerns as part of child health surveillance. the report emphasises the need for an efficient preliminary assessment, or triage process, to determine which children may need referral for fuller assessment and / or intervention. identifying adults for assessment is discussed in section 4. 1. 6.", "metadata": {"doc_name": "sign145", "page": 14, "section": "4.1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 2 screening screening has been defined by the uk national screening committee as “ a public health service in which members of a defined population, who do not necessarily perceive they are at risk of, or are already affected by a disease or its complications, are asked a question or offered a test, to identify those individuals who are more likely to be helped than harmed by further tests or treatment to reduce the risk of a disease or its complications ”. 27 any screening test must have a known specificity ( analogous to the risk of false positives ) and sensitivity ( analogous to the risk of false negatives ) within the population to which it is being applied. a systematic", "metadata": {"doc_name": "sign145", "page": 14, "section": "4.1.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "review has not identified any research into screening instruments for asd that meet the rigorous criteria", "metadata": {"doc_name": "sign145", "page": 14, "section": "4.1.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "for a robust population screening test. 28 population screening for asd is not recommended. 29 false positive or false negative results from inappropriate use of screening tests may delay correct diagnosis. the decision about the need for referral and further assessment should be made on clinical grounds. r population screening for asd is not recommended. identifying adults for assessment is discussed in section 4. 1. 6.", "metadata": {"doc_name": "sign145", "page": 14, "section": "4.1.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 3 surveillance outwith the scheduled opportunities for surveillance of children within the universal child health review, primary care is well placed to offer opportunistic surveillance for older children and adults. child health surveillance takes a broad clinical approach involving partnership between parents, children and health professionals. child health surveillance can contribute to the early recognition and diagnosis of asd. 30 surveillance for asd should follow general developmental surveillance and should be considered by all professionals working with children and young people. 2 +", "metadata": {"doc_name": "sign145", "page": 14, "section": "4.1.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 4 secondary screening secondary screening of children and young people thought to be at high risk may be appropriate, for example for children referred to services because of developmental delay, emotional and behavioural problems or", "metadata": {"doc_name": "sign145", "page": 15, "section": "4.1.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "certain genetic syndromes ( see section 4. 1. 3 and annexes 2 and 3 ). siblings of individuals with asd also have", "metadata": {"doc_name": "sign145", "page": 15, "section": "4.1.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "an increased risk ( rr 13. 40, ci 6. 93 to 25. 92 ). 5 secondary screening is dependent on an awareness that a child is at higher risk of asd and the application of sound clinical knowledge and skills. several structured instruments for use in secondary screening have been examined in a number of studies using relatively small cohorts. 36 - 42 with all these instruments, the findings of the studies have not been replicated outwith the study settings. see annex 4 for a list of instruments. 3 2 + + 2 + 2 + 4 2 + + 2 + + 2 + 4 • recognition, assessment and diagnosis", "metadata": {"doc_name": "sign145", "page": 15, "section": "4.1.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 5 timing of diagnosis assessment is part of a continuum which occurs from the point of recognition to the time of diagnosis and can occur at any age. in children under two years old typical asd behaviours may not be evident. 30 the evidence regarding the minimum age at which asd can be reliably diagnosed is not clear.", "metadata": {"doc_name": "sign145", "page": 16, "section": "4.1.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y the diagnosis of autism is always more reliable and stable than the diagnosis of other autism spectrum", "metadata": {"doc_name": "sign145", "page": 16, "section": "4.1.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "disorders, regardless of age, and can be reliably diagnosed between the ages of 2 – 3 years by experienced healthcare professionals. 43, 44", "metadata": {"doc_name": "sign145", "page": 16, "section": "4.1.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y in children later identified as having asd, features reported when they were under two years of age may", "metadata": {"doc_name": "sign145", "page": 16, "section": "4.1.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "have been non - specific. 45", "metadata": {"doc_name": "sign145", "page": 16, "section": "4.1.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r asd should be part of the differential diagnosis for preschool children displaying absence of age -", "metadata": {"doc_name": "sign145", "page": 16, "section": "4.1.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "appropriate developmental features, as typical asd behaviours may not be obvious in this age group.", "metadata": {"doc_name": "sign145", "page": 16, "section": "4.1.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "regardless of the findings of any earlier assessments, referral for further assessment for asd should", "metadata": {"doc_name": "sign145", "page": 16, "section": "4.1.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "be considered at any age. features which alert to the possibility of asd in older children are given in annex 2.", "metadata": {"doc_name": "sign145", "page": 16, "section": "4.1.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 6 identifying adults for assessment no relevant studies were identified on specific signs and symptoms suggestive of asd in adults. using expert opinion, nice suggested that the presence of at least one of the following signs or symptoms should prompt asd assessment : 13 y persistent difficulty in social interaction y persistent difficulty in social communication", "metadata": {"doc_name": "sign145", "page": 16, "section": "4.1.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y stereotypic ( rigid and repetitive ) behaviours, resistance to change ( in, for example, diet, routine or", "metadata": {"doc_name": "sign145", "page": 16, "section": "4.1.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "environment ) or restricted interests. nice suggested there are a number of factors associated with the presence of asd : 13 y problems with staying in education or finding and sustaining employment y difficulty in initiating or sustaining social relationships", "metadata": {"doc_name": "sign145", "page": 16, "section": "4.1.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y history of a neurodevelopmental condition ( including intellectual disability and attention deficit", "metadata": {"doc_name": "sign145", "page": 16, "section": "4.1.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "hyperactivity disorders ( adhd ) ) or a mental disorder. 4 4 3", "metadata": {"doc_name": "sign145", "page": 16, "section": "4.1.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 7 instruments to aid identification of adults with asd a systematic review by nice identified studies using the autism spectrum quotient - 10 ( aq - 10 ), the autism screening questionnaire / social communication questionnaire ( asq / scq ), the autism behaviour checklist ( abc ) and the pervasive developmental disorder in mental retardation scale ( pdd - mrs ) for case identification in adults. most were appraised to be at high risk of bias. 13 no high - quality studies published after the nice guideline have been identified. studies into the use of aq - 10 to identify adults with autism reported good sensitivity and specificity. 13 it is freely available and only takes a few minutes to complete. 13 the aq instrument requires self completion so may not be suitable for people with an intellectual disability. therefore, it is recommended for use in people with an intelligence quotient ( iq ) greater than 70. 13 no other studies of instruments for this group were of sufficient quality to inform a recommendation. it is preferable to use the indicators listed in annex 2 to identify who should be referred for assessment.", "metadata": {"doc_name": "sign145", "page": 17, "section": "4.1.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r the use of the autism spectrum quotient - 10 instrument may be considered to help identify", "metadata": {"doc_name": "sign145", "page": 17, "section": "4.1.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "adults with possible asd capable of self completing the instrument, who should be referred for assessment. 3 3 3 2 + + 4 4 • recognition, assessment and diagnosis", "metadata": {"doc_name": "sign145", "page": 17, "section": "4.1.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 8 gender differences across the age ranges the number of females presenting with asd is consistently under - reported due to misdiagnosis. 50 - 53 a possible explanation for this is that the instruments used are not sufficiently sensitive or specific enough to identify asd characteristics in females. how presentations of asd vary between males and females remains to be completely determined. research regarding the possible different symptom profile of females is in its infancy and is susceptible to sampling issues due either to gender stereotyping at diagnosis or better adaptation by females potentially leading to under - representation of females in clinical samples. 50, 53 studies have highlighted the potential differences in the way females with asd may present compared to males :", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y both males and females with asd experience pervasive difficulties in developing and maintaining friendships, but females may show more of a desire to have friends and fit in with their peer group than", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "males. 51", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y both males and females with asd show impairments in play behaviour, however this skill may be less impaired in females with asd. females with asd may mask social play deficits by imitating their typically", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "developing peers. 51 female interests may be in more socially accepted domains than males ( for example, horses, dolls or pop stars ) therefore seeming less unusual or impairing. 51, 53", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y females with asd may have better coping skills than males with asd which may lead to fewer females", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "being diagnosed, even when they have equivalently high levels of autistic traits to males who do receive a diagnosis. 50 this may lead to females being older when asd is considered as a potential diagnosis. 53", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y females with asd may show less severe signs of repetitive and restricted behaviours and interests than males with asd. this may be evident from six years onwards but not before age six. 53", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y there may be a higher incidence of disordered eating in females with asd than males with asd. 51 y females with asd may show less impairment in theory of mind tasks than males with asd. 51", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y there may be differences in the communication profile and executive functioning skills between males", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "and females with asd although there is conflicting evidence about what the specific differences are. 51", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y research indicates that in the absence of intellectual disability or behavioural issues, females are less likely than males to meet diagnostic criteria for asd. this is hypothesised to be due to females presenting", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "with a different phenotype ; displaying less restricted interests and stereotyped behaviours. 53 if asd is", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "accompanied with an intellectual disability, however, the female to male ratio is 1 : 2. as restricted interests", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "and stereotyped behaviours are common in people with intellectual disability, this ratio may reflect an", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "over - representation of asd in females with low iq. alternatively, this may support the hypothesis that", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "females with a higher iq have better adaptation and compensation abilities which prevent asd symptoms reaching a diagnostic threshold. 50", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r healthcare professionals should consider that females with asd may present with a different", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "symptom profile and level of impairment than males with asd.", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 2 methods of assessment", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 2. 1 initial assessment the initial presentation can be to a wide range of professionals in primary care, education or social services. important information can be gathered at this stage that may suggest the need for specialist assessment. those involved in carrying out the initial assessment should be aware of the core features of asd as well as of the wide range of different possible presentations, depending on the individual ’ s level of communication and intellect, personality, gender differences, family and educational supports. 2 + + 2 + 4", "metadata": {"doc_name": "sign145", "page": 18, "section": "4.2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 2. 2 specialist assessment specialist assessment is conducted by professionals who have sufficient expertise and training to establish a diagnosis of asd and to conduct the individual profiling. professionals need to give regard to the balance between their competencies and the complexity of the clinical presentation. 5, 54 the aim of specialist assessment is to gather and record information that enables diagnosis and to formulate a multiagency management plan, leading to the development of an appropriate programme of supportive intervention. such an assessment is necessarily comprehensive and may take place over a period of time. 18 a diagnosis of asd may be seen as a lifelong ‘ label ’. for this reason, it is of equal importance that clinicians diagnose, and not diagnose, accurately. specialist healthcare professionals must ensure that they are sufficiently informed and experienced to confidently diagnose in the majority of cases and that they collaborate, where possible, with relevant multiagency colleagues, so as to achieve diagnostic consensus. healthcare professionals should also have a low threshold of referral to more specialised colleagues in cases of diagnostic disagreement or subtle presentation. the process of assessment and diagnosis aims to review functioning in relevant domains, make diagnoses as appropriate and facilitate seamless, multiagency intervention. it should acknowledge that other conditions ( for example specific language impairment in a three year old, first onset depression in a 13 year old, or acute psychosis in", "metadata": {"doc_name": "sign145", "page": 19, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "domains, make diagnoses as appropriate and facilitate seamless, multiagency intervention. it should acknowledge that other conditions ( for example specific language impairment in a three year old, first onset depression in a 13 year old, or acute psychosis in a young adult ) may present in a superficially similar way to asd and also that there is significant potential for an individual to present with more than one condition. research evidence on multidisciplinary compared to single assessment is limited. nice identified one low - quality study which compared clinical diagnosis by a single practitioner with that of a panel. it reported agreement between the individual healthcare professional and the multidisciplinary team. expert opinion, however, advocates the use of multidisciplinary assessment by experienced professionals to ensure diagnostic accuracy and profiling of the skills, difficulties and subsequent needs of the individual. this should aid tailored care planning and interventions for the individual and their carers. 5, 13", "metadata": {"doc_name": "sign145", "page": 19, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the use of different professional groups in the assessment process is recommended as it may identify", "metadata": {"doc_name": "sign145", "page": 19, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "different aspects of asd and aid accurate diagnosis.", "metadata": {"doc_name": "sign145", "page": 19, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r a diagnostic assessment, alongside a profile of the individual ’ s strengths and weaknesses, carried", "metadata": {"doc_name": "sign145", "page": 19, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "out by a multidisciplinary team which has the skills and experience to undertake the assessments, should be considered as the optimum approach for individuals suspected of having asd.", "metadata": {"doc_name": "sign145", "page": 19, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "specialist assessment should involve a history - taking element, a clinical observation / assessment", "metadata": {"doc_name": "sign145", "page": 19, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "element, and obtaining wider contextual and functional information.", "metadata": {"doc_name": "sign145", "page": 19, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "specialist assessment should be available for any individuals who need it. specialist teams should assess", "metadata": {"doc_name": "sign145", "page": 19, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "if their service is being used equitably. apparent inequalities should be investigated and addressed.", "metadata": {"doc_name": "sign145", "page": 19, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "an assessment of mental health needs, well being and risk should be considered for all individuals", "metadata": {"doc_name": "sign145", "page": 19, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "with asd presenting to any agency. 4 4 • recognition, assessment and diagnosis", "metadata": {"doc_name": "sign145", "page": 19, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 2. 3 components of specialist assessment history taking ( parent / carer / informant interview ) history taking is an important component of any asd assessment, including those of adults or older people. without it, evidence of asd - like behaviour cannot be put into context. use of asd - specific history - taking instruments can be useful in this process, although healthcare professionals should be mindful of the need for a global perspective on the circumstances of an individual, taking into consideration the possibility of coexisting conditions and possible differential diagnoses. a clinical history should include :", "metadata": {"doc_name": "sign145", "page": 20, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y a history of the individual ’ s prenatal, perinatal and developmental history ( including social and emotional", "metadata": {"doc_name": "sign145", "page": 20, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "factors ) up to the patient ’ s age at assessment. this should include a detailed enquiry into evidence of any problems in social relationships at home, in education or work settings", "metadata": {"doc_name": "sign145", "page": 20, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y a description of the current problems experienced by the individual and other informants ( eg relative,", "metadata": {"doc_name": "sign145", "page": 20, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "nursery staff, teachers, educational psychologists, employers ). the focus should be on eliciting features consistent with the diagnosis of asd", "metadata": {"doc_name": "sign145", "page": 20, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y a family history including evidence of any asd, speech and language difficulties, psychiatric disorders,", "metadata": {"doc_name": "sign145", "page": 20, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "intellectual disability, epilepsy, developmental neurological problems or addictions", "metadata": {"doc_name": "sign145", "page": 20, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y a description of who is in the family ( eg use of a genogram ) and any history of family problems ( eg", "metadata": {"doc_name": "sign145", "page": 20, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "parental separation / divorce ) or significant life events ( eg loss ) which might be affecting the individual ’ s behaviour. a framework for an asd - specific developmental history is important and a version is available in the national autism plan for children and for adults from the royal college of psychiatrists. 18, 55 asd - specific diagnostic instruments may be used to supplement the process of clinical history taking, for example the autism diagnostic interview - revised ( adi - r ), 56, 57 the diagnostic interview for social and", "metadata": {"doc_name": "sign145", "page": 20, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "communication disorders ( disco ) 58 and the developmental, dimensional and diagnostic interview ( 3di ). 59", "metadata": {"doc_name": "sign145", "page": 20, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the adi - r has been shown to be a reliable diagnostic instrument. 56, 57, 60 it should be used with caution in children with a developmental level below the age of two years. it can be used as an information gathering instrument to complement and guide clinical judgement. 61 the 3di and disco allow structured data collection in relation to asd and other conditions. the published data on the 3di suggests that it is a reliable and valid asd diagnostic interview schedule when compared to the adi - r. 59 these instruments were developed and tested on child populations but can be valuable in supporting diagnosis in adults and older people. 13 clinical observation / assessment ( individual assessment / interview ) the experience of interacting with an individual, in order to elicit clinical evidence of asd that is compatible with icd - 10 or dsm - 5, is a significant professional task, which cannot be undertaken without a substantial amount of clinical experience. such skills are not exclusive to disciplines. the crucial elements are training and experience. assessments of individuals for asd cannot be rushed. it may not be possible to obtain sufficient evidence in one session and the individual may require observation in different settings, for example at school ( especially", "metadata": {"doc_name": "sign145", "page": 20, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "in unstructured activity such as break time ) as well as the clinic.", "metadata": {"doc_name": "sign145", "page": 20, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "18 asd - specific diagnostic instruments may be used to supplement the process of clinical observation, as part of the diagnostic assessment. the childhood autism rating scale ( cars ) is an older instrument which encompasses history and observation of spontaneous behaviours relevant to autism. 62, 63 it has recently been updated to cars - 2. 2 + 2 + 4", "metadata": {"doc_name": "sign145", "page": 20, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 3 individual profiling people with asd vary considerably in their individual strengths and difficulties. more detailed assessment of communication, neuropsychological functioning, motor and sensory skills, and adaptive functioning may be helpful.", "metadata": {"doc_name": "sign145", "page": 21, "section": "4.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 3. 1 communication skills by definition, all individuals with asd have an impairment in communication which ranges from profound comprehension problems and lack of speech to subtle pragmatic or functional use of language difficulties, such as failure to understand sarcasm or use of metaphor. receptive and expressive language skills are generally equally impaired. 67 a wide range of speech and language and communication assessments are available but there is limited evidence to support the use of one assessment instrument over another. 68 - 70 2 + 2 + 4 3 4 • recognition, assessment and diagnosis", "metadata": {"doc_name": "sign145", "page": 21, "section": "4.3.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 3. 2 cognitive, neuropsychological and adaptive functioning assessment consideration of the wider developmental level is an essential part of the assessment process. a cognitive or neuropsychological assessment will not confirm asd but it may be helpful to use these tools to establish a profile of relative strengths and difficulties. this may be useful in identifying intellectual disability ( as a differential or coexisting diagnosis ) and to benchmark which developmental and social skills should be expected in the context of a person ’ s level of ability.", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "71 this information may also be useful when considering", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "what interventions are most appropriate and effective. 71 individuals with asd will have a range of impairments in intellectual, neuropsychological and adaptive skills. assessments are useful for individual profiling but are not diagnostic instruments. 72 - 77 an assessment", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of adaptive functioning allows for information regarding the child ’ s typical functioning at home or at school.", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "this may be different from their cognitive abilities and highlights functional impairments and areas where", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "support may be required. some impairments, such as theory of mind", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "73, 75, 77 and executive function74 are not specific to asd, although they may be more severe in this group. the degree of impairment is also influenced by levels of speech and language, communication and verbal mental age. this applies equally to adults. 13 insights from these assessments may promote understanding by caregivers, therapists, education and social work staff in optimally supporting the individual with asd to reach their potential.", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r individuals with asd should be considered for assessment of intellectual, neuropsychological and", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "adaptive functioning.", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 3. 3 motor and sensory skills there was insufficient evidence to make recommendations about occupational therapy or physiotherapy", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessments. however, dsm - 5 includes hyper - or hyporeactivity to sensory input within its diagnostic criteria.", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4 sensory behaviours should be taken into account when profiling the needs of individuals with asd. occupational therapy and physiotherapy assessments should be considered where relevant.", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 4 conditions associated with asd individuals with asd can experience the full range of developmental, medical and mental health problems that are experienced by those who do not have asd. clinicians should not assume that any problems are", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "inevitable aspects of asd. clinical features of asd may overlap and coexist with symptoms of other disorders.", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "it is essential that any differential or comorbid diagnoses are identified during the assessment period to ensure that appropriate interventions and support are put in place to address all aspects of the clinical presentation. 71 parent - reported sleep problems are more frequent in children and young people with asd. 78 - 81 4 3 4 2 +", "metadata": {"doc_name": "sign145", "page": 22, "section": "4.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 5 biomedical investigations", "metadata": {"doc_name": "sign145", "page": 23, "section": "4.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "asd can be associated with a wide range of underlying conditions including genetic abnormalities. medical", "metadata": {"doc_name": "sign145", "page": 23, "section": "4.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "investigations however should not be routinely performed but may be considered on an individual basis that takes into account findings on physical examination, such as dysmorphism and neurocutaneous stigmata, congenital anomalies and intellectual disability or suspicion of epilepsy. 5 the autism spectrum is highly variable and can be investigated with an ever increasing range of genetic techniques such as microarray", "metadata": {"doc_name": "sign145", "page": 23, "section": "4.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "comparative genomic hybridisation ( cgh ), whole exome and whole genome sequencing. however, the", "metadata": {"doc_name": "sign145", "page": 23, "section": "4.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "clinical judgement to understand how to incorporate these techniques into an individual ’ s assessment requires a systematic approach. 99 the genetic alterations giving rise to asd phenotypes arise from chromosomal syndromes, such as turner and down ’ s syndrome, large segmental cytogenetic alterations, single gene disorders and copy number variants. 99 2 + + 2 + 4 2 + 2 + 2 - 2 + 4 • recognition, assessment and diagnosis", "metadata": {"doc_name": "sign145", "page": 23, "section": "4.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "18 |", "metadata": {"doc_name": "sign145", "page": 24, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders chromosomal microarray has largely replaced microscopy - based karyotyping and in various clinical situations microarray - cgh yields a typical pathogenic copy number variant detection rate of 10 % for autism and asd ( higher detection rates with concomitant intellectual disability ). 100 a wide range of these techniques were assessed by nice and all studies were deemed to be of low quality. 5 routinely performed genetic tests led to a clinical diagnosis in 9 % of individuals with autism and 14 % with autism spectrum disorder ( 95 % ci 7 to 22 ).", "metadata": {"doc_name": "sign145", "page": 24, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "5 recent reviews on the role of genetic investigations in asd state", "metadata": {"doc_name": "sign145", "page": 24, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "that rare neurometabolic conditions in asd are mostly single gene disorders and in patients with suspected asd a first and second tier approach for investigations as regards asd is advocated ( see table 1 ). 99, 101, 102 table 1 : first and second tier genetic investigations for possible asd 101 first tier three - generation family history with pedigree analysis initial evaluation to identify known syndromes or associated conditions y examination with special attention to dysmorphic features y if specific syndromic diagnosis is suspected, proceed with targeted investigations", "metadata": {"doc_name": "sign145", "page": 24, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y if appropriate clinical indicators are present, perform metabolic and / or mitochondrial testing", "metadata": {"doc_name": "sign145", "page": 24, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "( alternatively, consider referral to a metabolic specialist ) chromosomal microarray : oligonucleotide array - comparative genomic hybridisation or single - nucleotide polymorphism array dna testing for fragile x ( to be performed routinely for male patients only ) * second tier mecp2 sequencing to be performed for all females with asd mecp2 duplication testing in males, if phenotype is suggestive pten testing only if the head circumference is > 2. 5 sd above the mean brain magnetic resonance imaging only in the presence of specific indicators ( eg microcephaly, regression, seizures, and history of stupor / coma ) mecp2, methyl - cpg - binding protein 2 ; pten, phosphatase and tensin homolog ; sd standard deviation. * dna testing for fragile x in females if indicators present ( eg family history and phenotype ). reprinted by permission from macmillan publishers ltd : schaefer gb, mendelsohn nj. clinical genetics evaluation in identifying the etiology of autism spectrum disorders : 2013 guideline revisions. genet med 2013 ; 15 ( 5 ) : 399 - 407, copyright 2013.", "metadata": {"doc_name": "sign145", "page": 24, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "investigations are not only carried out to aid diagnosis through establishing aetiology, but also to exclude", "metadata": {"doc_name": "sign145", "page": 24, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "treatable conditions, to identify coexisting conditions and to establish baseline information prior to starting treatment. the evidence does not support the use of routine magnetic resonance imaging ( mri ) of the brain. 103 - 105 whilst epilepsy is common in individuals with asd, 13, 106 there is no indication for an electroencephalogram ( eeg ) in the absence of other clinical criteria. 13, 107 a fifth to a third of preschool children with asd have a history of regression in acquired language skills during their second year of life. a total loss of acquired language skills is associated with a high probability of asd when this occurs in children under the age of three.", "metadata": {"doc_name": "sign145", "page": 24, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "108 when children undergo language regression over", "metadata": {"doc_name": "sign145", "page": 24, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the age of three, they are more likely to experience seizures and the differential diagnosis should include consideration of an acquired epileptic dysphasia / landau kleffner dysphasia. 108 other conditions such as rett syndrome may appear superficially similar to asd, 109 and other neurodegenerative conditions such as mitochondriopathies may need to be considered and investigated. 110 3", "metadata": {"doc_name": "sign145", "page": 24, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 6 prognostic indicators in childhood in one small study, early joint attention and imitation skills were found to be predictive of preschool language levels. 111 high iq and language skills at an early age were also found to predict better eventual outcome in communication and social competence domains, 112 - 116 although social impairments and repetitive behaviours may persist. 115 improvements in adaptive behaviour and decline in atypical features have been reported for adolescents with asd and a high iq, with poorer outcomes evident in social impairment and social skills for young people with intellectual disability.", "metadata": {"doc_name": "sign145", "page": 25, "section": "4.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "117, 118 nine percent of individuals with a measured verbal iq over 70 at the age of", "metadata": {"doc_name": "sign145", "page": 25, "section": "4.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2 years no longer met diagnostic criteria for asd when followed up at 19 years of age. 119 a well - conducted systematic review of the diagnostic stability of asd considered distinct from autistic disorder prior to dsm - 5 diagnostic criteria found that autistic disorder is a reasonably stable diagnosis but other autism spectrum disorders have very variable stability between studies and clinicians, when using this", "metadata": {"doc_name": "sign145", "page": 25, "section": "4.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "diagnosis, need to inform parents of its instability. to what extent this remains relevant under the diagnostic", "metadata": {"doc_name": "sign145", "page": 25, "section": "4.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "criteria in dsm - 5 requires long term, large population cohort studies. 120", "metadata": {"doc_name": "sign145", "page": 25, "section": "4.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "early language regression before three years of age, in children referred for paediatric neurology assessment, or referred for asd assessment, has a high probability of being associated with an asd diagnosis.", "metadata": {"doc_name": "sign145", "page": 25, "section": "4.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "108, 121 the majority of children with asd who are reported to regress subsequently regain the lost skills. 122 regression does not appear to be associated with a worse prognosis during preschool years. 45, 121 there have been no good - quality studies of later childhood or adolescent onset regression and it is not clear whether the phenomena are clinically the same. evidence for prognostic indicators in adulthood has not been reviewed. 2 + 3 2 + + 2 + 4 4 • recognition, assessment and diagnosis", "metadata": {"doc_name": "sign145", "page": 25, "section": "4.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "20 |", "metadata": {"doc_name": "sign145", "page": 26, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders 5 principles of intervention following a diagnosis of asd, individuals, parents, relatives, carers, and professionals want effective interventions to be available and need information to help make decisions about what form these could take. there are many different interventions for people with asd in everyday use, some of which are not evidence based. 123 following a baseline assessment, the potential balance of risks and benefits from any intervention needs to be considered for each individual, and discussed as appropriate with them and their parents, relatives or carers, so that they can make an informed decision. individuals with asd, their parents, relatives, carers, and healthcare professionals should, as far as possible, plan how they intend to evaluate the benefits from any intervention. this will help them to make a decision about whether or not to continue after any trial period. everyone is entitled to benefit from their education and have positive wider life experiences. asd symptoms can constitute a significant barrier and psychoeducational interventions for asd are employed in this context. parents, educationalists, health professionals, social workers and the voluntary sector may employ pragmatic, eclectic, individualised interventions to optimise a person ’ s functioning, by promoting development of skills, or adapting the environment to compensate when skills are not present. 124 many of these approaches are based on theoretical principles germane to", "metadata": {"doc_name": "sign145", "page": 26, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "pragmatic, eclectic, individualised interventions to optimise a person ’ s functioning, by promoting development of skills, or adapting the environment to compensate when skills are not present. 124 many of these approaches are based on theoretical principles germane to asd. some are derived from generic considerations such as visual support to communication, or behavioural approaches to reduce behaviour that challenges. others are derived from more autism - specific considerations such as the difficulty in ‘ mentalising ’ experienced in asd, whereby the individual experiences difficulties understanding the motivations and perspectives of others. where appropriate, the guideline comments on these interventions as good practice points, recognising that many are in use in everyday practice in the uk and have widespread practitioner support. given the highly individualised nature of behavioural interventions, single - case research is a widespread and increasingly rigorous way of testing and developing the field. it is encouraging that scientifically and statistically rigorous methods are being developed for collating and analysing this data, but it is still a developing area which needs replication, further peer review and consensus. where evidence - based interventions are available, they should be delivered by personnel with the appropriate skills and training, according to the protocols used in the original research.", "metadata": {"doc_name": "sign145", "page": 26, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 1 parent - mediated interventions parent - mediated intervention programmes are used to both advance the development and communication of an affected child and to offer practical advice and support to parents. 125, 126, 127, 128 a well - conducted cochrane review of parent - mediated early intervention for young children ( aged 1 – 6 years ) with asd identified 17 studies, all of which had a risk of bias and used a variety of interventions, intensity and treatment duration. 129 results were inconsistent and inconclusive. there was a statistically significant benefit from parent - child interaction for joint attention. small improvements were also seen in language comprehension and expression and reduction in parental stress, although these results need to be substantiated by further, larger randomised controlled trials ( rcts ).", "metadata": {"doc_name": "sign145", "page": 27, "section": "6.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "parent - mediated intervention programmes should be considered for children and young people of all", "metadata": {"doc_name": "sign145", "page": 27, "section": "6.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "ages who are affected by asd, as they may help families interact with their child, promote development and increase parental satisfaction, empowerment and mental health.", "metadata": {"doc_name": "sign145", "page": 27, "section": "6.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 2 communication interventions", "metadata": {"doc_name": "sign145", "page": 27, "section": "6.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 2. 1 support for early communciation skills many children and young people with asd have little or no speech. those who do have speech have difficulties in using language effectively ( pragmatic language impairment or social communication difficulty ). parent - and clinician - led interventions the manner in which the communication impairment is manifest is influenced by the child ’ s acquisition of joint attention and early interaction skills, which are a precursor to communication through language. many of the strategies implemented to support communication are designed and managed by speech and language therapists, working in combination with a wide range of professionals and in partnership with parents. parent - led interventions incorporate features such as working on joint attention and communicative intent ( see section 6. 1 ). clinician - mediated interventions target early purposeful communication skills such as joint attention, motivation to communicate, understanding and using language communication. meta - analysis of rcts of parent - mediated communication - focused treatment ( pact ) reported no reduction in autism symptoms, compared to treatment as usual, but there was benefit for parent - child social communication. 130 visual supports", "metadata": {"doc_name": "sign145", "page": 27, "section": "6.2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "alternative / augmentative communication, also referred to as visual supports, are employed in day - to - day", "metadata": {"doc_name": "sign145", "page": 27, "section": "6.2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "educational support and at home to enhance both understanding of expectations and routines and to support the child in expressive communication. visual supports may be objects of reference, photographs, picture symbols, signs and gestures and may be displayed in a variety of ways, including using electronic technology. 131 picture exchange communication system the picture exchange communication system ( pecs ) is a programme devised to develop social and communication skills in children with asd using picture symbols. staff trained in using the system teach the use of symbols to communicate in a progressive programme of up to six phases which draws on specific", "metadata": {"doc_name": "sign145", "page": 27, "section": "6.2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "applied behavioural analysis techniques. individuals learning pecs do not need to master prerequisite", "metadata": {"doc_name": "sign145", "page": 27, "section": "6.2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "skills such as eye contact or gestures", "metadata": {"doc_name": "sign145", "page": 27, "section": "6.2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "132 and pecs can be used with children with or without intellectual", "metadata": {"doc_name": "sign145", "page": 27, "section": "6.2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1 + + 1 + + 3 6 • non - pharmacological interventions for children and young people", "metadata": {"doc_name": "sign145", "page": 27, "section": "6.2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 2. 2 interventions for social communication and interaction a cochrane review of five rcts of 196 young people of average or above average intelligence with asd ( aged 6 – 21 years ) showed that social skills groups improve overall social competence ( weighted mean difference between treatment and control groups 0. 47, 95 % ci 0. 16 to 0. 78, p = 0. 003 ). 145 all the studies had some risk of bias, and the review concluded that further studies are needed to substantiate these results. eleven studies were identified in another systematic review which showed short - term benefit in parent - reported social skills, although the quality of the studies was low and inconsistency in outcome measures across the studies makes it difficult to generalise skills beyond the intervention setting. 146 three systematic reviews of studies into the use of computer - based interventions ( cbi ) concluded that, although the studies identified were small and of low quality, cbi showed promising results for social skills - related outcomes. 147 - 149 results were seen across an age range of three to 29 years and iq between 55 and 99. although it is difficult to synthesise the evidence due to heterogeneity, the interventions are linked to theories about underlying core deficits in asd. they fall into a number of areas, for example offering additional support to verbal - social initiations, such as tact", "metadata": {"doc_name": "sign145", "page": 28, "section": "6.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "##e the evidence due to heterogeneity, the interventions are linked to theories about underlying core deficits in asd. they fall into a number of areas, for example offering additional support to verbal - social initiations, such as tactile prompting, or visual reinforcement, to help children with asd acquire an alternative to a theory of mind. studies also looked at peer training, to support the social interaction and communication of the child with asd and buddy programmes that aim to elicit more appropriate social skills in students with asd, in comparison to a passive proximity approach. the evidence does not clarify which of these approaches is the most effective but many of them are currently in everyday educational use for children with asd.", "metadata": {"doc_name": "sign145", "page": 28, "section": "6.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r interventions to support social communication should be considered for children and young", "metadata": {"doc_name": "sign145", "page": 28, "section": "6.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "people with asd, with the most appropriate intervention being assessed on an individual basis.", "metadata": {"doc_name": "sign145", "page": 28, "section": "6.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "adapting the communicative, social and physical environments of children and young people with", "metadata": {"doc_name": "sign145", "page": 28, "section": "6.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "asd may be of benefit ( options include providing visual prompts, reducing requirements for complex social interactions, using routine, timetabling and prompting and minimising sensory irritations ). 3 1 - 3 1 + + 2 - 2 +", "metadata": {"doc_name": "sign145", "page": 28, "section": "6.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3 behavioural / psychological interventions behavioural and other psychological interventions for people with asd may be divided into three main groups :", "metadata": {"doc_name": "sign145", "page": 29, "section": "6.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y intensive behavioural and developmental programmes aimed at improving overall functioning and", "metadata": {"doc_name": "sign145", "page": 29, "section": "6.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "altering outcome", "metadata": {"doc_name": "sign145", "page": 29, "section": "6.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y interventions which aim to address specific behavioural difficulties associated with asd, such as sleep", "metadata": {"doc_name": "sign145", "page": 29, "section": "6.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "disturbance, or to increase positive behaviours such as initiating social contact with peers", "metadata": {"doc_name": "sign145", "page": 29, "section": "6.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y a range of other behavioural / psychological interventions which do not fall readily into the other two groups.", "metadata": {"doc_name": "sign145", "page": 29, "section": "6.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 1 intensive behavioural and developmental programmes early intensive behavioural intervention ( eibi ) programmes aim to engage the child with asd in a structured learning programme that is highly individualised, taking into account the idiosyncratic motivations and specific metacognitive and learning needs of each child. although programmes vary widely in the emphasis given to different skills ( verbal behaviours, pivotal responses, play, joint attention, etc ) they tend to start with very basic skills ( sitting, looking, listening ) and over time work towards more complex metacognitive skills such as self monitoring or theory of mind. eibi programmes involve varying levels of parental involvement. generalisation of skills from prompted to spontaneous use is a key element. eibi programmes attempt to address a comprehensive range of behaviours associated with asd, rather than focusing on one specific aspect such as communication, social skills or interaction. given that asd is a pervasive condition, these comprehensive programmes are necessarily intensive. they vary considerably in terms of technologies and emphasis but are all based on applied behaviour analysis ( aba ). 146 programmes have evolved considerably since early models such as the university of california, los angeles ( ucla ) project, 150 and reviews of comprehensive, aba - based and intensive programmes increasingly include developmental programmes such as the learning experiences and alternative program for preschoolers and their parents ( leap ) and", "metadata": {"doc_name": "sign145", "page": 29, "section": "6.3.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "early models such as the university of california, los angeles ( ucla ) project, 150 and reviews of comprehensive, aba - based and intensive programmes increasingly include developmental programmes such as the learning experiences and alternative program for preschoolers and their parents ( leap ) and the early start denver model ( esdm ). 146, 151, 152 eibi programmes are manualised, intensive and target a comprehensive range of skills for training, practice and generalisation. it is important to distinguish aba, which has a wide range of applications at varying intensities, from eibi,", "metadata": {"doc_name": "sign145", "page": 29, "section": "6.3.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "which is one application of aba. eibi programmes should not be referred to as ‘ aba for autism ’, as this is not an", "metadata": {"doc_name": "sign145", "page": 29, "section": "6.3.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "accurate label. 151 modern eibi programmes are best described as behavioural and developmental programmes. programmes usually start when the child with asd is three or four, with some reviewed studies starting at 18 months. they aim to build the prerequisite learning skills required to be ready for starting primary school. eibi therefore describes comprehensive teaching programmes, rather than interventions that aim to reduce symptoms. while such aba principles have been applied widely in community, hospital and educational settings for many years to address deficits and delays in learning resulting from a wide range of neurological conditions, they are not typically comprehensive or high intensity. early models of eibi for children with asd typically required up to 30 or more hours per week, but more recent reviews include programmes ranging from 13 – 28 hours per week. 146 a number of more specific aba - based interventions are also available ( for example pecs ) which do not require the same level of intensity ( see section 6. 2. 1 ). ten well - conducted systematic reviews assessed the quality of trials on eibi as low to moderate due to the complexities of conducting long - term studies in this area. 146, 151 - 159 early intervention based on high - intensity behaviour analysis over extended timeframes, whether delivered by parents or clinicians, was associated with improvement in cognitive functioning, language skills, adaptive behavior, including social competence and daily living", "metadata": {"doc_name": "sign145", "page": 29, "section": "6.3.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "area. 146, 151 - 159 early intervention based on high - intensity behaviour analysis over extended timeframes, whether delivered by parents or clinicians, was associated with improvement in cognitive functioning, language skills, adaptive behavior, including social competence and daily living skills relative to community controls in some groups of young children. not all improvements were maintained at long - term follow up. 146 only one systematic review concluded there was no impact. 156 this may be due to the inclusion of a study which compared high - intensity clinic - based aba with high intensity parent - delivered aba. both programmes produced positive impact but the difference was not significant, diluting the gains found in the other included studies, and invalidating the author ’ s conclusions. 159 the reviews show a steady improvement in study quality over time, although there are problems with small sample sizes, non - randomisation and partial blinding. 146, 151 - 158 while these are relevant to any research in this area, they constitute biases that make it possible that the conclusions may change in the light of further evidence. 1 + + 2 + + 2 + 6 • non - pharmacological interventions for children and young people", "metadata": {"doc_name": "sign145", "page": 29, "section": "6.3.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 2 specific interventions for asd the treatment and education of autistic and related communication handicapped children ( teacch ) approach involves the development of a programme around the individual ’ s skills, interests and needs. a meta - analysis reported that teacch had small effects on perceptual, motor, verbal and cognitive skills. improvements in social and maladaptive behaviours were moderate to large.", "metadata": {"doc_name": "sign145", "page": 30, "section": "6.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "160 effects on communication, activities of daily living and motor functioning were non - significant or small. the studies included in the study", "metadata": {"doc_name": "sign145", "page": 30, "section": "6.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "were small or of poor quality and outcomes were heterogeneous. further research is needed to determine efficacy and the duration, intensity and setting required to implement teacch. social stories tm are short individualised stories which describe a social situation or skill to help individuals with asd. they are commonly used to enable individuals to understand socially - expected behaviours. ten criteria guide story development tailored to each individual. these criteria ensure that the story structure and content is descriptive, meaningful and safe for its audience. the use of social stories™ has been studied mostly through single - subject research design, which is appropriate to highlight the individualised nature of the intervention. 161 - 163 while the studies showed considerable variation, most reported only a small clinical effect on behaviour. social stories™ may be easy to implement and require few resources, but those using them should be aware that the potential for improvement may be limited. 1 + + 2 + + 2 + 1 + + 2 + + 2 + 3", "metadata": {"doc_name": "sign145", "page": 30, "section": "6.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 3 cognitive behavioural therapies", "metadata": {"doc_name": "sign145", "page": 31, "section": "6.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "mental health difficulties are more prevalent among individuals with asd than the typically developing population ( see section 4. 4 ), and there has been a number of reviews of cognitive behavioural therapy ( cbt ) for co - occurring mental health conditions in asd. 146, 151, 164, 165 cbt for children and adolescents with asd has consistently shown positive effects for reduction in anxiety ( clinician - rated anxiety cohen ’ s d effect size ( d ) = 1. 19, parent - rated anxiety d = 1. 21, child - reported anxiety d = 0. 68 ). 146, 151, 164, 165 outcomes were better when rated by clinicians or parents compared to ratings by children themselves. despite some evidence of beneficial outcomes, important theoretical questions remain about whether anxiety in asd is a true comorbidity or a manifestation of core asd symptoms. 164 the studies were in children with iq > 70. no evidence was identified on whether cbt is beneficial for children presenting with a combination of asd and intellectual disability. adaptations that take account of an individual ’ s asd presentation were employed in every study reviewed. these adaptations are not condition specific but reflect individual needs. noteworthy adaptations include involving carers / parents, considering the impact of limited emotional insight, using concrete and visual material to support communication and structure sessions, considering the sensory environment and incorporating the person ’ s interests.", "metadata": {"doc_name": "sign145", "page": 31, "section": "6.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "are not condition specific but reflect individual needs. noteworthy adaptations include involving carers / parents, considering the impact of limited emotional insight, using concrete and visual material to support communication and structure sessions, considering the sensory environment and incorporating the person ’ s interests. a systematic review of cognitive skills training in children and adolescents with asd reported improvements in theory of mind ( d = 0. 75 ), imitation ( d = 0. 2 ), play ( joint engagement with mother d = 0. 67 ), emotion recognition ( d = 0. 75 ) and initiations of joint attention ( d = 0. 23 ). 166 generalisation of skills learned being applied to different situations was demonstrated to be a problem for individuals with asd across the studies, with few showing any change in non - taught measures. matching interventions to patients is likely to require expertise in needs assessment and patient / family engagement, to identify where emotional disorder is the result of environmental factors, skills deficits or cognitive distortions, so as to advise on suitability of behavioural, skills training or cbt interventions. a cost - utility analysis, assessing the relative cost effectiveness of group cbt and individual cbt ( relative to individuals remaining on a waiting list ) for the management of anxiety in children and young people with autism found that, over the 38 weeks of the analysis, group cbt was the most cost - effective intervention of the", "metadata": {"doc_name": "sign145", "page": 31, "section": "6.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "##t and individual cbt ( relative to individuals remaining on a waiting list ) for the management of anxiety in children and young people with autism found that, over the 38 weeks of the analysis, group cbt was the most cost - effective intervention of the options within this economic model ( cost - effective relative to waiting list at £13, 910 per quality adjusted", "metadata": {"doc_name": "sign145", "page": 31, "section": "6.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "life years ( qaly ) for group cbt versus £97, 367 per qaly for individual cbt ). 151 r cognitive behavioural therapy may be considered, using a group format where available and", "metadata": {"doc_name": "sign145", "page": 31, "section": "6.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "appropriate, to treat anxiety in children and young people with asd and who have average verbal and cognitive ability. the delivery of cognitive behavioural therapy should be adapted for people with asd.", "metadata": {"doc_name": "sign145", "page": 31, "section": "6.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "cognitive behavioural therapy can be considered as a means of treating a coexisting condition if", "metadata": {"doc_name": "sign145", "page": 31, "section": "6.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "recommended in guidelines for that condition.", "metadata": {"doc_name": "sign145", "page": 31, "section": "6.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 4 auditory integration training auditory integration training ( ait ) is offered to children with asd on the premise that they experience discomfort when listening to certain sound frequencies. in ait the participant listens to modulated music", "metadata": {"doc_name": "sign145", "page": 31, "section": "6.3.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "tapes through headphones for specified time periods. a well - conducted cochrane review identified seven", "metadata": {"doc_name": "sign145", "page": 31, "section": "6.3.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "small rcts analysing ait with a variety of outcome measures. results for or against the use of ait were inconclusive. three of the trials reported no long - term benefits of ait, while three small studies reported improvement in the aberrant behaviour checklist total score. 167 2 + + 2 + 1 + + 1 + + 6 • non - pharmacological interventions for children and young people", "metadata": {"doc_name": "sign145", "page": 31, "section": "6.3.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 5 occupational therapy and sensory integration therapy occupational therapists ( ot ) work with individuals and their carers to assess skills in the areas of self care, leisure and accessing an educational curriculum. they may draw on an understanding of sensory processing and motor skill development to generate solutions and strategies. the aim is to enable the individual to maximise his or her potential with activities of daily living. this could include reducing the impact of sensory sensitivities, if necessary. sensory integration therapy ( sit ) is a theory and approach developed by ots that targets difficulties with sensory processing and motor skills. it is a manualised clinic - based intervention that is child directed and aims to elicit adaptive responses to sensory experience. three systematic reviews reported insufficient high - quality evidence to support the use of sit. 168 - 170 two small, low - quality rcts reported positive effects using goal attainment scaling as an outcome measure. 168 sensory - based interventions ( sbi ) are usually classroom based, devised, but often not directly administered, by ots. these use sensory strategies such as deep touch pressure or movement breaks ( and possibly equipment such as weighted vests or therapy balls ) to influence a child ’ s state of arousal and adaptive behaviour. studies of sbis identified in a systematic review were of low quality and showed limited consistent improvement. 168", "metadata": {"doc_name": "sign145", "page": 32, "section": "6.3.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "children and young people affected by asd may benefit from occupational therapy, advice and", "metadata": {"doc_name": "sign145", "page": 32, "section": "6.3.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "support in adapting environments, activities and routines in daily life.", "metadata": {"doc_name": "sign145", "page": 32, "section": "6.3.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 6 music therapy music therapy may help children with asd to improve their skills in social interaction, verbal communication, initiating behaviour, and social - emotional reciprocity, compared to placebo or standard care, in the short - to medium - term. the ten studies included in a cochrane review were small ( with a total of 165 participants ) and of moderate quality and the authors concluded that, while results are positive, larger trials are needed to confirm the results. 171 music therapy is delivered by practitioners with specialised academic and clinical training. 171", "metadata": {"doc_name": "sign145", "page": 32, "section": "6.3.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 7 sleep management", "metadata": {"doc_name": "sign145", "page": 32, "section": "6.3.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "by the age of one year most children are able to sleep through the night. if after this time a child is regularly unable to sleep, or has a period of good sleep which is disrupted, then this constitutes a sleep problem. sleep disturbance is reported to be a common problem for children and young people with asd. one moderate - quality rct compared cognitive behavioural therapy, melatonin, combined melatonin and cbt to a placebo pill in children aged 4 – 10 years with asd and sleep problems ( 40 in each arm of the trial ). participants in the cbt arm received four weeks of family therapy. all three active arms showed improvements in sleep onset latency ( sol ), total sleep time, waking after sleep onset and sleep efficiency compared to placebo at 12 weeks, based on actigraph data. 172 the best results were reported for the combination of cbt and melatonin with a 22 % increase in total sleep time from baseline ( 0. 07 % placebo ), increase in naptime 67. 85 % ( 3. 3 % placebo ) and sleep efficiency 20 % ( 1. 12 % placebo ) and a reduction in sol of 60. 75 % ( - 0. 02 % placebo ). cognitive behavioural therapy alone saw improvements in : total sleep time 9. 31 % ; sol 60. 75 % ; naptime 37", "metadata": {"doc_name": "sign145", "page": 32, "section": "6.3.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "% placebo ) and a reduction in sol of 60. 75 % ( - 0. 02 % placebo ). cognitive behavioural therapy alone saw improvements in : total sleep time 9. 31 % ; sol 60. 75 % ; naptime 37. 14 % and sleep efficiency 11. 26 %. due to paucity of evidence nice used expert opinion to recommend the development of a sleep plan to address sleep problems and establish a regular night - time sleep pattern. behavioural interventions should be tried before a pharmacological intervention. 151 1 + 1 + 1 + + 1 + + 1 + 4", "metadata": {"doc_name": "sign145", "page": 32, "section": "6.3.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 8 facilitated communication facilitated communication is defined by the american psychological society as “ a process by which a facilitator supports the hand or arm of a communicatively impaired individual while using a keyboard or typing device ”. two systematic reviews of facilitated communication conclude that there is no evidence to validate claims that the person with autism is being helped to communicate, although there is extensive evidence of communications that are generated by the facilitator. 174, 175 given the ethical implications of these findings in relation to the integrity and dignity of children and young people with asd, the american psychological association has passed a resolution against the use of facilitated communication for people with asd on ethical grounds. 176", "metadata": {"doc_name": "sign145", "page": 33, "section": "6.3.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r facilitated communication should not be used as a means to communicate with children and", "metadata": {"doc_name": "sign145", "page": 33, "section": "6.3.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "young people with asd.", "metadata": {"doc_name": "sign145", "page": 33, "section": "6.3.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 9 additional interventions to address behavioural challenges a range of behavioural challenges may present in individuals with asd ( for example self injury, aggression, passivity and lack of engagement ). nice concluded that existing programmes to target core features of autism that can result in behaviours that challenge are variable in availability and quality. confounding factors in studies may include specific skills deficits or sensory problems which may contribute to a particular behaviour pattern, along with the social and physical environment. 151 a systematic review identified a range of behavioural and educational interventions addressing behaviours that challenge. they varied in scope, target and intensity so it was not possible to determine which components linked to clinically meaningful changes in functioning. 152 although common behavioural interventions result in positive behavioural outcomes across a wide range of target areas, 151, 152 further rcts are required with sufficient duration to ascertain which components of interventions are effective and have a sustainable effect on outcomes.", "metadata": {"doc_name": "sign145", "page": 33, "section": "6.3.9", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "behavioural interventions may be considered to address a wide range of specific behaviours, including", "metadata": {"doc_name": "sign145", "page": 33, "section": "6.3.9", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "those that challenge, in children and young people with asd, both to reduce symptom frequency and severity and to increase the development of adaptive skills.", "metadata": {"doc_name": "sign145", "page": 33, "section": "6.3.9", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "healthcare professionals should be aware that some behaviours that challenge may be due to an", "metadata": {"doc_name": "sign145", "page": 33, "section": "6.3.9", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "underlying lack of skills development in the child / young person and may also represent an individual ’ s strategy for coping with their difficulties and circumstances.", "metadata": {"doc_name": "sign145", "page": 33, "section": "6.3.9", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "healthcare professionals should be aware that factors in the social and physical environment may", "metadata": {"doc_name": "sign145", "page": 33, "section": "6.3.9", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "contribute to positive behaviours or those that challenge. 1 - 1 + + 2 + + 2 + + 6 • non - pharmacological interventions for children and young people", "metadata": {"doc_name": "sign145", "page": 33, "section": "6.3.9", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 4 nutritional interventions a systematic review of gluten - free and / or casein - free diets identified three rcts which reported no improvement in measures of language, attention, activity level, sleep, or bowel habits. two further studies reported some improvements in behavior but the results may have been compromised by placebo effect and high attrition rates. all the studies had small sample sizes, so further research is needed to confirm results. 177 a cochrane review of omega - 3 fatty acids supplementation for people with asd identified two rcts which were not sufficiently robust to draw any conclusions. 178 a further rct published since the cochrane review is also underpowered. 151, 179 one low - quality trial of omega - 3 for sleep problems identified by nice reported a statistically significant negative treatment effect for omega - 3 compared to a healthy diet control group ( standardised mean difference ( smd ) 1. 11, 95 % ci 0. 21 to 2. 00 ). 151 a cochrane review of combined vitamin b6 and magnesium intervention for children and young people with asd found insufficiently robust studies to meet the criteria set for the review and therefore no recommendation can be made. 180 as with all children and young people, nutritional interventions may be required for children and young people with asd who also have significant food selectivity and dysfunctional feeding behavior.", "metadata": {"doc_name": "sign145", "page": 34, "section": "6.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "gastrointestinal symptoms in children and young people with asd should be managed in the same", "metadata": {"doc_name": "sign145", "page": 34, "section": "6.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "way as in children and young people without asd.", "metadata": {"doc_name": "sign145", "page": 34, "section": "6.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "advice on diet and food intake should be sought from a dietician for children and young people", "metadata": {"doc_name": "sign145", "page": 34, "section": "6.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "with asd who display significant food selectivity and dysfunctional feeding behaviour, or who are on restricted diets that may be adversely impacting on growth, or producing physical symptoms of recognised nutritional deficiencies or intolerances.", "metadata": {"doc_name": "sign145", "page": 34, "section": "6.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 5 other interventions systematic reviews of complementary therapies, acupuncture and animal - assisted interventions reported that evidence for the use of complementary and alternative therapies for individuals with asd is sparse and no strong conclusions could be drawn. 181 - 183 meta - analysis of small trials of various physical activities concluded that exercise for individuals with asd may be beneficial for improving motor skills and social interaction. further, larger, more rigorous trials are needed to support the findings. 184 1 + 1 + + 1 - 1 + + 2 - 2 + 2 +", "metadata": {"doc_name": "sign145", "page": 34, "section": "6.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "7. 1 communication interventions", "metadata": {"doc_name": "sign145", "page": 35, "section": "7.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "two uncontrolled studies looking at communication skills training in adults, both with asd and severe to profound intellectual disability were identified by nice. 13 samples were small and no conclusions could be drawn. no further, more recent evidence was identified.", "metadata": {"doc_name": "sign145", "page": 35, "section": "7.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "7. 2 facilitated communication a single uncontrolled study on facilitated communication with adults found no significant improvement in target behaviours. 13 given that potential harms have been associated with this intervention, it is not recommended that services provide facilitated communication. 13 see section 6. 3. 8 for further advice on facilitated communication.", "metadata": {"doc_name": "sign145", "page": 35, "section": "7.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r facilitated communication should not be used as a means to communicate with adults with asd.", "metadata": {"doc_name": "sign145", "page": 35, "section": "7.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "7. 3 social skills interventions difficulties with relationships and social participation are widespread among adults with asd. the skills required to initiate and maintain relationships are beneficial in other areas, for example employment, wider participation in society and help seeking. 13 one rct and two observational studies on social skills interventions were identified in the nice review. 13 also included were studies looking at adolescents ( mean age > 15 years ; one rct and three observational studies ) and one rct in adults with intellectual disability. 13 no further, more recent studies were identified. 2 + + 2 + + 2 + + 7 • non - pharmacological interventions for adults", "metadata": {"doc_name": "sign145", "page": 35, "section": "7.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "7. 4 behavioural interventions one rct and three uncontrolled studies looking at adaptive functioning, one of which looked at childcare skills, were identified. the studies included adolescents ( > 15 years ) and adults with intellectual disability. there were no studies addressing behavioural therapies for behaviour that challenges, and the evidence for adaptive skills was limited and low quality. nice used expert opinion to recommend that behavioural", "metadata": {"doc_name": "sign145", "page": 36, "section": "7.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "interventions should be considered for adaptive functioning and behaviour that challenges.", "metadata": {"doc_name": "sign145", "page": 36, "section": "7.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "13 one further meta - analysis which addressed behavioural interventions for academic skills, adaptive skills, behaviour that challenges, social skills, phobic avoidance and vocational skills 187 reviewed 48 studies,", "metadata": {"doc_name": "sign145", "page": 36, "section": "7.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "reporting on interventions for 110 participants, with quality varying from low ( n = 32 ) to high ( n = 7 ). the review included adolescents, and single - case studies. interventions for problem behaviour, academic skills", "metadata": {"doc_name": "sign145", "page": 36, "section": "7.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "and phobic avoidance were reported by fewer than five studies each, limiting the reviewers ’ ability to draw conclusions from these articles. studies looking at adaptive behaviour and social skills were the most frequent, and some evidence of benefit was reported in these domains. conclusions must be made with caution given that it is a meta - analysis of single - case studies, and because the quality of many of the studies included in the review was low. it is not possible to make definitive recommendations on the basis of the evidence considered. however, it is recognised that behavioural interventions are an important option to consider when addressing behaviour that challenges and adaptive functioning in adults with asd. further advice is available in nice 11, challenging behaviour and learning disabilities : prevention and interventions for people with learning disabilities whose behaviour challenges. 188", "metadata": {"doc_name": "sign145", "page": 36, "section": "7.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "7. 5 cognitive behavioural therapies cognitive behavioural therapy has sometimes been seen as inaccessible for people with asd because of the abstract and emotional nature of the approach. a number of adaptations have been developed and can improve accessibility for people with asd and / or intellectual disability. 13 one rct of cbt for adults with asd, comparing interventions for obsessive - compulsive disorder ( ocd ) with treatment as usual found no treatment effect. 13 the study did not report adapting their intervention and that the lack of treatment effect may suggest that modification is necessary. 2 + + 4 2 + + 4 3 2 + +", "metadata": {"doc_name": "sign145", "page": 36, "section": "7.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "| 31", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders the nice guideline development group used expert opinion to recommend that cbt should be offered to individuals presenting with both asd and intellectual disability who are at risk of victimisation, or those with or without intellectual disability who experience problems associated with anger or aggression. where individuals with asd experience problems such as anxiety or depression which are typically treated with cbt clinicians should consider using the following adaptations : 13", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y a more concrete and structured approach with a greater use of written and visual information, which", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "may include worksheets, thought bubbles, images and ‘ tool boxes ’", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y placing greater emphasis on changing behaviour, rather than cognitions, and using the behaviour as", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the starting point for intervention y making rules explicit and explaining their context y using plain english and avoiding excessive use of metaphor, ambiguity and hypothetical situations", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y involving a family member, partner, carer or professional ( if the person with asd agrees ) to support the", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "implementation of an intervention", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y maintaining the person ’ s attention by offering regular breaks and incorporating their special interests", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "into therapy if possible, such as using computers to present information. a further five small studies addressing cbt for adults with asd were identified. two were rcts 189, 190 and the others were quasi - experimental or preliminary trials. 191 - 193 comparison across studies was not possible because the target of the intervention in each study was different, covering ocd ; depression and stress ; anxiety, depression and rumination ; quality of life and self esteem ; or cognitive and social impairments. one rct found twice as many responders in their cbt group, but overall improvement was similar to their anxiety management control group. 189 these overall improvements were similar to those reported in non - asd trials of cbt for ocd ( aggregated effect sizes of 1. 12 to 1. 45 ). 189 noting that it is unusual to find anxiety management being as effective as cbt in non - asd trials, the authors speculated that perhaps education about emotions and anxiety management has a more powerful impact on people with asd, given their relative deficits in emotion recognition and self reflection. in the other rct, non - blinded outcome measures", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "indicated significant improvements in depression, anxiety, rumination and positive affect for the mindfulness", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "group, whilst their waiting list control group showed no change at all on these measures. 190 a preliminary rct reported that both the cbt group and a recreational activity control group showed significant improvement on a measure of quality of life which was maintained at follow up, but found no difference in any of their measures of psychiatric symptoms. 191 no harms were reported in the studies and one reported that more participants requested cbt than anxiety management, suggesting that these approaches seem to be acceptable to adults with asd. 189 no individuals with intellectual disability were included. one study recommends involving carers and supportive individuals in the intervention. 189 there is insufficient evidence to recommend any specific model of psychosocial intervention. however, a diagnosis of asd should not prevent anyone from receiving these interventions. therefore, if an individual with asd experiences a symptom or condition that would usually be treated with cbt or related psychosocial intervention ( for example anxiety ), then they should receive the intervention recommended by guidelines for", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "that symptom or condition. it is important not to assume that complex intervention is required ; interventions", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "to improve emotional literacy, distress tolerance, relaxation skills or general adjustment could be considered as first line.", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "psychosocial interventions should be considered for adults with asd if indicated for managing", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "coexisting conditions. 4 1 + 1 - 2 - 1 + 1 - 1 + 7 • non - pharmacological interventions for adults", "metadata": {"doc_name": "sign145", "page": 37, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 1 general principles any pharmacological intervention considered for children and young people with asd should not be viewed in isolation but seen as a possible component of a multistranded package of care. there are no controlled long - term studies demonstrating that pharmacological interventions affect the core difficulties or outcomes in children and young people with asd. there is little evidence directly comparing pharmacological and non - pharmacological approaches. pharmacological interventions may be considered when appropriate, for management of coexisting psychiatric or neurodevelopmental conditions in individuals with asd. pharmacological approaches may also be considered as a short - to medium - term intervention for specific severe symptoms occurring in children and young people with asd. interventions for other coexisting medical conditions, for example epilepsy, which may be required for children and young people with asd, are not discussed in this guideline. only medications available in the uk are discussed. no pharmacological interventions have asd as a licensing indication, and there are few drugs specifically licensed for use in children and adolescents. 194 prescribing medicines in this situation therefore brings extra responsibilities ( see section 1. 3. 2 for further advice on prescribing of licensed medicines outwith their marketing authorisation ). an assessment of the need for pharmacological intervention", "metadata": {"doc_name": "sign145", "page": 38, "section": "8.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "prescribing medicines in this situation therefore brings extra responsibilities ( see section 1. 3. 2 for further advice on prescribing of licensed medicines outwith their marketing authorisation ). an assessment of the need for pharmacological intervention should include an appraisal of the child ’ s environment ( school and home ) and daily routines ( for example sleep, daily activities, meals etc ). changes in these areas may be worth attempting before using medication and are likely to complement the effects of any appropriate medication prescribed. it is possible that management of coexisting conditions with medication may enhance the ability of children and young people to benefit from other approaches.", "metadata": {"doc_name": "sign145", "page": 38, "section": "8.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 1. 1 framework for use of medication the balance of potential risks and benefits arising from any pharmacological intervention needs to be carefully considered for each individual child and discussed as appropriate with them and their parents / carers so that they can make an informed decision. if a trial of pharmacological intervention is agreed, there should be careful pretreatment assessment of the child ’ s overall symptoms and functioning, and definition of the ‘ target symptoms ’, that is those symptoms potentially responsive to the drug. there should be agreement about how symptoms and any emergent side effects of treatment will be measured, as well as the monitoring arrangements and expected duration of any trial of medication. children and young people, their parents / carers and healthcare professionals, should, as far as possible, plan how they intend to make a decision about whether or not to continue with medication, after any trial period.", "metadata": {"doc_name": "sign145", "page": 38, "section": "8.1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "pharmacological intervention for children and young people with asd should only be undertaken by", "metadata": {"doc_name": "sign145", "page": 38, "section": "8.1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "doctors with appropriate training and access to pharmacy or other support as required.", "metadata": {"doc_name": "sign145", "page": 38, "section": "8.1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 2 second - generation antipsychotics in children with asd aripiprazole ( 2. 5 – 15 mg per day ) can be effective in reducing irritability ( mean improvement 6. 17 points on abc irritability subscale ), and hyperactivity ( mean improvement 7. 93 point on abc hyperactivity subscale ) compared to placebo over eight weeks. 195 this effect did not continue when used as maintenance therapy, with no significant difference in time to relapse between aripiprazole and placebo. 196 use of apriprazole was associated with greater risk of developing adverse effects, with the likelihood of sedation 4. 28 times higher, drooling 9. 64 times higher and tremor 10. 26 times higher than the control group. 195 other studies found weight gain, somnolence, vomiting, and extrapyramidal effects to be common. 152, 196 1 + + 2 +", "metadata": {"doc_name": "sign145", "page": 38, "section": "8.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 2. 1 risperidone adjunctive therapies", "metadata": {"doc_name": "sign145", "page": 39, "section": "8.2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "used as adjunctive therapies to risperidone, galantamine and celecoxib may reduce irritability, lethargy and social withdrawal in children with asd. 202, 203 memantine showed a reduction in stereotypical behaviour and irritability and riluzole reduced irritability, stereotypical behaviour and hyperactivity. 204, 205 in all four studies the diagnosis of asd may be unreliable as there was a lack of clarity over the baseline characteristics in terms of treatment history. the high rates of administration of risperidone used in these iranian trials are unfeasible in scotland. 1 + 1 + + 2 + 1 + 2 + 4 1 + + 4 1 + 8 • pharmacological interventions for children and young people", "metadata": {"doc_name": "sign145", "page": 39, "section": "8.2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 3 methylphenidate there is evidence that methylphenidate reduces hyperactivity in children up to 14 years with asd and coexisting adhd ( with a mean iq in the intellectual disability range ). 206 after eight weeks ' follow up 49 % of the 72 participants responded to methylphenidate, with a 30 % reduction in hyperactivity in parent or teacher rating scales, and ‘ much improved ’ or ‘ very much improved ’ reporting on the clinical global impression ( cgi )", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "scale. adverse effects ( appetite decrease, difficulty falling asleep, irritability and emotional outbursts ) were more common in children receiving methylphenidate compared to those on placebo.", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "206 in one study from a specialist paediatric clinic, response to methylphenidate and level of side effects were not significantly different in children with adhd and asd compared with children with adhd alone. 207 the use of a test dose is worthwhile to assess whether methylphenidate will be tolerated. 206, 208 no further rcts of a larger sample size have been published. smaller rcts and uncontrolled studies support the efficacy of methylphenidate for the reduction of adhd - like symptoms. 209 there is no evidence about the use of other stimulant medication for adhd symptoms in children and young people with asd. 209 if methylphenidate is not tolerated use of other medication could be considered with reference to sign guideline 112 on attention deficit and hyperkinetic disorders in children and young people. 210", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r methylphenidate may be considered for management of attention difficulties / hyperactivity in", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "children or young people with asd.", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "use of a test dose to assess if methylphenidate is tolerated could be considered in children prior to", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "any longer trial.", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "side effects should be carefully monitored ( see sign guideline 112 on attention deficit and hyperkinetic", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "disorders in children and young people ). 210", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 4 noradrenergic reuptake inhibitors one rct studying the use of atomoxetine demonstrated reduced adhd symptoms in children with asd compared to placebo. further studies are required to establish the efficacy and safety profile of this intervention. 211", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 5 antidepressants", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 5. 1 selective serotonin reuptake inhibitors trials of fluoxetine, fluvoxamine, fenfluramine and citalopram showed no significant difference in cgi or obsessive - compulsive disorders for children with asd compared to placebo. 212 citalopram was associated with higher rates of seizures and fenfluramine increased withdrawal, sadness, stereotypical movements, appetite reduction and weight loss. no adverse effects were found with use of fluoxetine or fluvoxamine. 212 no evidence for the use of selective serotonin reuptake inhibitors ( ssris ) to improve the core features of asd has been identified. 151 insufficient evidence was identified to determine the efficacy of ssris to reduce repetitive behaviours in children with asd. 152 ssris may be considered for children with common coexisting conditions such as depression for which there is established evidence for their use. 213, 214, 152", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.5.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r selective serotonin reuptake inhibitors should not be used to manage core features of asd ( eg", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.5.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "repetitive behaviours ) in children and young people.", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.5.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r selective serotonin reuptake inhibitors should be considered for children and young people with", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.5.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "symptoms of coexisting conditions on a case - by - case basis. 1 + 1 + 1 + +", "metadata": {"doc_name": "sign145", "page": 40, "section": "8.5.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 5. 2 tricyclic antidepressants a well - conducted cochrane review identified three small studies on the use of tricyclic antidepressants ( tcas ) for symptoms of asd, two of which were in children and one in children and young adults. 215 findings were inconsistent. for tianeptine, parents and teachers reported improvements but this was not supported by clinician ratings. two studies on clomipramine showed improved outcomes for core features of asd but mixed results for hyperactivity. all three studies reported adverse effects such as drowsiness and fatigue. further evidence is needed before a recommendation on the use of tcas for core symptoms of asd can be made. this should not preclude the use of tcas for coexisting conditions in people with asd, and appropriate guidance should be followed.", "metadata": {"doc_name": "sign145", "page": 41, "section": "8.5.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 6 naltrexone all studies identified related to children less than eight years of age and naltrexone did not improve symptoms of autism. 216 - 219", "metadata": {"doc_name": "sign145", "page": 41, "section": "8.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 7 hormonal interventions", "metadata": {"doc_name": "sign145", "page": 41, "section": "8.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 7. 1 secretin secretin ( human or porcine ) as a single dose, or in multiple doses, for up to six months does not improve asd symptoms, and no subgroup of children who benefit has been identified. 152, 220", "metadata": {"doc_name": "sign145", "page": 41, "section": "8.7.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r secretin is not recommended for the management of symptoms of asd in children and young", "metadata": {"doc_name": "sign145", "page": 41, "section": "8.7.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "people.", "metadata": {"doc_name": "sign145", "page": 41, "section": "8.7.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 7. 2 oxytocin small pilot studies of oxytocin demonstrated positive findings on eye gaze and emotion recognition but effects on repetitive behaviours were inconsistent and no effect was seen in cgi. further, larger studies are needed to determine efficacy. 221", "metadata": {"doc_name": "sign145", "page": 41, "section": "8.7.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8. 8 melatonin melatonin ( 3 mg controlled release ) is effective in reducing sleep problems in children with asd. in a four - way trial melatonin increased total sleep time by 17. 31 %, reduced sol by 44. 33 % and increased naptime by 51. 51 % over baseline at 12 weeks. 151, 172 in the same study melatonin in combination with cbt was most effective, with 84. 62 % of the children meeting a standard sleep criterion of sol of 30 minutes or less or a reduction of sol by 50 % after 12 weeks, compared to 39. 92 % for the melatonin group, 10. 34 % for cbt and no reduction for the placebo group172 ( see section 6. 3. 7 for results from the other arms of the trial ). a further rct of immediate - release melatonin ( 0. 5 mg increased incrementally to 12 mg over four weeks ) in children with asd showed melatonin was effective for sol measured by a sleep diary, but effects on total sleep time were non - significant. 151 neither study reported any statistically significant adverse effects from the use of melatonin. 35, 172 the melatonin prolonged - release tablet, slenyto, is licensed for use in children with autism who experience insomnia, however it is not recommended", "metadata": {"doc_name": "sign145", "page": 41, "section": "8.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "any statistically significant adverse effects from the use of melatonin. 35, 172 the melatonin prolonged - release tablet, slenyto, is licensed for use in children with autism who experience insomnia, however it is not recommended for use in nhsscotland by the scottish medicines consortium ( see section 12. 4 ). prescribing of circadin for children is considered as off - label use and prescribing of any other melatonin products would be unlicensed use ( see section 1. 3. 2 ). 194", "metadata": {"doc_name": "sign145", "page": 41, "section": "8.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r in children with asd who have sleep difficulties which have not resolved following behavioural", "metadata": {"doc_name": "sign145", "page": 41, "section": "8.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "interventions, a trial of melatonin to improve sleep onset should be considered. 1 + + 1 + 1 + + 1 + + 1 + 1 + 1 + 8 • pharmacological interventions for children and young people", "metadata": {"doc_name": "sign145", "page": 41, "section": "8.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "36 |", "metadata": {"doc_name": "sign145", "page": 42, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders", "metadata": {"doc_name": "sign145", "page": 42, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9 use of melatonin should follow consultation with a paediatrician or psychiatrist with expertise in", "metadata": {"doc_name": "sign145", "page": 42, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the management of sleep medicine in children and / or asd, and be in conjunction with behavioural interventions.", "metadata": {"doc_name": "sign145", "page": 42, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9 melatonin prescription should be reviewed regularly in the context of any emerging possible side", "metadata": {"doc_name": "sign145", "page": 42, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "effects and / or reduced therapeutic effect.", "metadata": {"doc_name": "sign145", "page": 42, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9 children with asd who present with signs of possible obstructive sleep apnoea, or sleep - disordered", "metadata": {"doc_name": "sign145", "page": 42, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "breathing ( loud snoring, choking or periodic stopping of breathing during sleep ) should be referred to sleep medicine services for assessment. 9 obtain an adequate baseline sleep diary before any trial of melatonin.", "metadata": {"doc_name": "sign145", "page": 42, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "continue sleep hygiene measures ( bedtime and wake - up routine, avoidance of day - time sleep ) and a sleep diary, during any medication trial.", "metadata": {"doc_name": "sign145", "page": 42, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "prescribing of circadin for children is considered as off - label use and prescribing of any other melatonin products would be unlicensed use ( see section 1. 3. 2 ). 194", "metadata": {"doc_name": "sign145", "page": 42, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 1 general principles the evidence considered in this section addresses pharmacological interventions for the core symptoms of asd. many adults with asd have coexisting conditions, such as anxiety, depression or adhd. while some of the therapies may not have evidence to support their use for managing symptoms of asd, this should not preclude their use in adults with asd for the management of a coexisting condition. in these cases, advice should be sought from guidance relevant to the particular condition.", "metadata": {"doc_name": "sign145", "page": 43, "section": "9.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "adults with asd who are prescribed any pharmacological therapies should be reviewed regularly to", "metadata": {"doc_name": "sign145", "page": 43, "section": "9.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "ensure the intervention is of benefit, being used appropriately, and for any signs of adverse events or interactions with other medications. 13", "metadata": {"doc_name": "sign145", "page": 43, "section": "9.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 2 antipsychotics meta - analysis of two small open label rcts on the use of risperidone in adults with asd showed benefit in reducing behaviour that challenges. 13 one of the trials also reported improvement in repetitive behaviours and symptom severity. a small rct ( n = 36 ) comparing haloperidol to placebo found no significant treatment effect for autistic behaviours. this study had a 21 % drop out rate compared to 3 % in the placebo arm due to fatigue, dystonia and depression. 13 a more recent systematic review on psychopharmacological interventions for behaviour that challenges in adults with asd and intellectual disability did not find any further studies. 222 due to the lack of trials in adults with asd, nice identified studies of adults with intellectual disabilities and extrapolated the findings for adults with asd. some patients within the trials had coexisting psychiatric conditions. the results were inconsistent, but suggest risperidone may improve symptom severity and behaviour that challenges. three studies of zuclopenthixol in adults with learning disability had conflicting results. cis - clopenthixol may be superior to haloperidol for behaviour management. one observational study of olanzapine showed an improvement in challenging behavior amongst adolescents with intellectual disability, but reported weight gain as a side effect. 13", "metadata": {"doc_name": "sign145", "page": 43, "section": "9.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": ". cis - clopenthixol may be superior to haloperidol for behaviour management. one observational study of olanzapine showed an improvement in challenging behavior amongst adolescents with intellectual disability, but reported weight gain as a side effect. 13 side effects were considered to be tolerable. statistically significant weight gain was reported in two of the risperidone studies. studies were short term, between three to 12 weeks ’ intervention and up to 24 weeks ’ follow up, so long - term data on the effects of antipsychotics in adults with asd are unavailable. it is recommended that effects of the medication are reviewed after three to four weeks and treatment", "metadata": {"doc_name": "sign145", "page": 43, "section": "9.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "discontinued if there is no clinically important response at six weeks.", "metadata": {"doc_name": "sign145", "page": 43, "section": "9.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "13", "metadata": {"doc_name": "sign145", "page": 43, "section": "9.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r antipsychotic medication should be considered for addressing behaviour that challenges in adults", "metadata": {"doc_name": "sign145", "page": 43, "section": "9.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "with asd when psychosocial or other interventions could not be delivered due to the severity of behaviour that challenges.", "metadata": {"doc_name": "sign145", "page": 43, "section": "9.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r antipsychotics should be prescribed by a specialist and quality of life outcomes monitored carefully.", "metadata": {"doc_name": "sign145", "page": 43, "section": "9.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "review the effects of medication after three to four weeks and discontinue if there is no indication of clinically important response at six weeks.", "metadata": {"doc_name": "sign145", "page": 43, "section": "9.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 3 pharmacotherapy to improve cognition", "metadata": {"doc_name": "sign145", "page": 43, "section": "9.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "no trials were identified on pharmacotherapy to improve cognition in adults with asd. two small", "metadata": {"doc_name": "sign145", "page": 43, "section": "9.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "observational studies in children reported inconsistent results. 13 evidence on memantine and galantamine as risperidone adjunctive therapies in studies in children is detailed in section 8. 2. 1. 1 + + 1 + + 2 + + 2 + + 4 2 + + 9 • pharmacological interventions for adults", "metadata": {"doc_name": "sign145", "page": 43, "section": "9.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 4 methylphenidate no evidence was identified on the use of methylphenidate for the core symptoms of asd in adults. it has been found to have benefit in reducing hyperactivity in children with asd and adhd ( see section 8. 3 ).", "metadata": {"doc_name": "sign145", "page": 44, "section": "9.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 5 noradrenergic reuptake inhibitors no evidence was identified on the use of noradrenergic reuptake inhibitors for the core symptoms of asd in adults. evidence from studies in children is also limited ( see section 8. 4 ).", "metadata": {"doc_name": "sign145", "page": 44, "section": "9.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 6 antidepressants studies on the efficacy of ssris in managing symptoms of asd in adults are small, heterogeneous and of short duration ( 12 weeks ).", "metadata": {"doc_name": "sign145", "page": 44, "section": "9.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "212 improvements were found in cgi, obsessive - compulsive behaviours and aggression with fluvoxamine, and in cgi and anxiety with fluoxetine. 212 one study of fluvoxamine compared to placebo", "metadata": {"doc_name": "sign145", "page": 44, "section": "9.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "also reported a statistically significant reduction on repetitive behaviours and autistic behaviours. 13, 222 a further study on the effects of fluoxetine in adolescents with asd reported improvements in cgi ratings for overall clinical severity and compulsive behaviours, but 26 % of participants had side effects that impacted on functioning. a study of sertraline reported a reduction in repetitive behaviours, autistic behaviours, maladaptive behaviours and overall symptom severity. 13 one study comparing clomipramine to placebo reported no effect on core symptoms of asd and had a 34 % dropout rate due to side effects. 13 there is a lack of recent good - quality evidence to support a recommendation on the use of antidepressants for the core symptoms of asd. this should not preclude their use for other conditions in adults with asd.", "metadata": {"doc_name": "sign145", "page": 44, "section": "9.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "adults with asd who have coexisting mental ill health that may respond to antidepressants should", "metadata": {"doc_name": "sign145", "page": 44, "section": "9.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "be offered treatment, with close monitoring for response and adverse effects.", "metadata": {"doc_name": "sign145", "page": 44, "section": "9.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 7 anxiolytics no evidence was identified on the use of anxiolytics for the core symptoms of asd in adults. their use in adults with asd and anxiety should follow appropriate guidance on the management of anxiety.", "metadata": {"doc_name": "sign145", "page": 44, "section": "9.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 8 anticonvulsants no evidence was identified on the use of anticonvulsants for the core symptoms of asd in adults. studies in children were of low quality and had mixed results. 13 there is insufficient evidence on which to base a recommendation.", "metadata": {"doc_name": "sign145", "page": 44, "section": "9.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 9 naltrexone no evidence was identified on the use of naltrexone for the core symptoms of asd in adults. limited evidence suggests that it is not effective in children ( see section 8. 6 ).", "metadata": {"doc_name": "sign145", "page": 44, "section": "9.9", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 10 hormonal interventions", "metadata": {"doc_name": "sign145", "page": 44, "section": "9.10", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 10. 1 secretin no studies on the use of secretin for managing symptoms of asd in adults were identified. studies in children did not find it to be of benefit ( see section 8. 7. 1 ). r secretin should not be considered for the management of symptoms of asd in adults. 1 + + 1 + +", "metadata": {"doc_name": "sign145", "page": 44, "section": "9.10.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 10. 2 oxytocin no good - quality evidence was identified on the use of oxytocin for the core symptoms of asd in adults. four placebo - controlled trials were identified but each had fewer than ten participants per arm and results were inconsistent. 13", "metadata": {"doc_name": "sign145", "page": 45, "section": "9.10.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9. 11 melatonin no evidence was identified on the use of melatonin in adults with asd to improve sleep problems. rcts in children have shown improvements in sleep time and sleep - onset latency, particularly when used with cbt ( see sections 8. 8 and 6. 3. 7 ).", "metadata": {"doc_name": "sign145", "page": 45, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r in adults with asd who have sleep difficulties which have not resolved following behavioural", "metadata": {"doc_name": "sign145", "page": 45, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "interventions, a trial of melatonin to improve sleep onset may be considered.", "metadata": {"doc_name": "sign145", "page": 45, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "use of melatonin should follow consultation with a psychiatrist with expertise in the management", "metadata": {"doc_name": "sign145", "page": 45, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of sleep medicine and / or asd, and be in conjunction with behavioural interventions. obtain an adequate baseline sleep diary before any trial of melatonin.", "metadata": {"doc_name": "sign145", "page": 45, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "continue sleep hygiene measures ( bedtime and wake - up routine, avoidance of day - time sleep ) and", "metadata": {"doc_name": "sign145", "page": 45, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "a sleep diary, during any medication trial.", "metadata": {"doc_name": "sign145", "page": 45, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "melatonin prescription should be regularly reviewed in the context of any emerging possible side", "metadata": {"doc_name": "sign145", "page": 45, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "effects and / or reduced therapeutic effect.", "metadata": {"doc_name": "sign145", "page": 45, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "adults with asd who present with signs of possible obstructive sleep apnoea, or sleep disordered", "metadata": {"doc_name": "sign145", "page": 45, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "breathing ( loud snoring, choking or periodic stopping of breathing during sleep ) should be referred to sleep medicine services for assessment. melatonin products are not licensed for use in the uk, with the exception of circadin which is licensed as monotherapy for the short - term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over ( see section 1. 3. 2 for advice on prescribing of licensed medicines outwith their marketing authorisation ).", "metadata": {"doc_name": "sign145", "page": 45, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14 circadin has not been accepted for use in nhsscotland by the smc ( see section", "metadata": {"doc_name": "sign145", "page": 45, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "12. 4 ). 2 + + 9 • pharmacological interventions for adults", "metadata": {"doc_name": "sign145", "page": 45, "section": "9.11", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "10. 1 training despite the increasing awareness of, and interest in, the nature of asd, there remain some gaps in training for professionals working with people with asd. this can cause service delivery to be less effective. the small body of evidence on training points to improvement in attitudes of mainstream teachers towards the inclusion of children with asd in their classes,", "metadata": {"doc_name": "sign145", "page": 46, "section": "10.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "223, 224 increased levels of parental confidence in relation", "metadata": {"doc_name": "sign145", "page": 46, "section": "10.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "to service provision, 17 and in benefits in knowledge for medical staff from evidence - based educational interventions. 225 the autism training framework outlines the skills and knowledge required at different levels within the health - and social - care workforce to achieve key outcomes for people with asd. it describes the knowledge and skills required by generic health - and social - care workers who will occasionally encounter a person with asd, through to those who provide highly specialist interventions in asd services. 54", "metadata": {"doc_name": "sign145", "page": 46, "section": "10.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r all professions and service providers working in the asd field should review their training", "metadata": {"doc_name": "sign145", "page": 46, "section": "10.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "arrangements to ensure that staff have up - to - date knowledge and adequate skill levels.", "metadata": {"doc_name": "sign145", "page": 46, "section": "10.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "10. 2 interventions and meeting support needs", "metadata": {"doc_name": "sign145", "page": 46, "section": "10.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "education services are a key resource in the provision of support and intervention to reduce the impact of asd on children, young people and their families. the co - ordination of services and collaboration between services as outlined in girfec and related legislation is paramount for the provision of effective interventions and support. most local authorities have asd strategies in place to provide a range of educational input and support. 226 4", "metadata": {"doc_name": "sign145", "page": 46, "section": "10.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "10. 3 information provision and support for parents / carers", "metadata": {"doc_name": "sign145", "page": 47, "section": "10.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "see section 11 for advice on provision of information and support.", "metadata": {"doc_name": "sign145", "page": 47, "section": "10.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "10. 4 support during transition", "metadata": {"doc_name": "sign145", "page": 47, "section": "10.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "transitions, at all stages from preschool through adulthood and into older adulthood, are challenging for people with asd. however, evidence regarding best practice around transition is very limited. a single study was identified in which telephone interviews with parents were used to capture their perceptions of transition and the support needed. 233 parents reported that increased social work contact with families during periods of transition was valued. professionals should be aware that difficulties during transition may arise because the high level of support being provided prior to such transition was unrecognised. reassessing support needs and planning ahead prior to a transition may allow appropriate new support to be put in place. although individual support needs will vary, some basic aspects may be generally applicable. for example, a survey of supervisors of adults with asd employed within a supported work environment, indicated that the support strategies used were based on principles largely applicable to all young people, including clear guidance, mentoring and regular reviews. 234 principles of good transitions are outlined by the scottish transitions forum ( see section 11. 3. 2 ) families and services should plan ahead to reduce the impact of transitions. social work contact with families should be instituted or extended during periods of transition.", "metadata": {"doc_name": "sign145", "page": 47, "section": "10.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "families should be advised of relevant legislation under the adults with incapacity ( scotland ) act", "metadata": {"doc_name": "sign145", "page": 47, "section": "10.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2000, 235 the adult support and protection ( scotland ) act 2007, 236 and the children and young people act ( scotland ) 2014. 2 4 1 + 4 10 • service provision", "metadata": {"doc_name": "sign145", "page": 47, "section": "10.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "11. 1 providing information and support provision of information should always be viewed as a two - way process. the concerns and questions which children, young people, adults with asd, and their parents / carers wish to raise should be identified during assessment, and be responded to as far as possible. a limited amount of evidence was identified where either outcomes were not described in terms of parent satisfaction, 237 there was no information on the diagnostic instrument used to classify the children studied, 238 or the number of subjects was unclear. 239 the principles which emerged were that parents felt more satisfied if at the time of diagnosis sharing they were given good - quality written information, with an opportunity to ask questions", "metadata": {"doc_name": "sign145", "page": 48, "section": "11.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "238 and that parents value a multidisciplinary diagnostic assessment. 239", "metadata": {"doc_name": "sign145", "page": 48, "section": "11.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "information on the diagnostic process and the implications for children, young people, adults and parents should be explained along with information on the roles of the various professions involved. parents and carers need to have their early concerns acknowledged and to receive support in the management of their child or the adult in their care. 238, 240 - 242 it is essential that parents or carers of individuals diagnosed with asd, and the individual themselves, receive clear, accurate and appropriate written and verbal information about the condition including short - and long - term consequences. the information should be appropriate to the patient ’ s age, ability level and cultural background and should be provided at a pace that suits the circumstances. where feasible and appropriate childcare should be made available for a short time during sharing of the diagnosis. this will allow parents or carers to focus fully on the information being given and allow for questions. consideration should be given as to how the diagnosis should be shared. this may require seeing children, young people and adults, their parents and carers separately, sequentially or simultaneously. for young people and adults their own engagement and understanding of the diagnosis will be important in negotiating appropriate supports. assessment is a particularly stressful period for the individual, their parents and carers and links forged with local professionals at this time can be helpful following diagnosis. surveys of parents report the importance placed on the quality of the communication skills of the", "metadata": {"doc_name": "sign145", "page": 48, "section": "11.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "appropriate supports. assessment is a particularly stressful period for the individual, their parents and carers and links forged with local professionals at this time can be helpful following diagnosis. surveys of parents report the importance placed on the quality of the communication skills of the professionals disclosing the diagnosis. 238, 240 - 242 a negative experience could affect parental or carer satisfaction and cause added stress. healthcare professionals should be aware that the absence of clearly - defined terminology and uncertainty of diagnosis is difficult for parents or carers. this can be challenging when the individual has a mixture of difficulties. where a diagnosis can be clearly made the use of straightforward terminology in communication to parents and carers is important. when the diagnosis is uncertain ( borderline according to current diagnostic criteria ) then healthcare professionals should explain this situation to parents and carers. in all circumstances healthcare professionals should work with the family to identify how services can meet the needs of the child or adult. children, young people and adults, their parents or carers should have the opportunity to ask questions following the diagnosis. follow - up arrangements should be offered once there has been time to reflect on the implications of the diagnosis. 17 professionals should recognise that children, young people and adults, their parents or carers may have a significant adjustment reaction to the diagnosis and for some this adjustment period may be prolonged and difficult. asd affects all aspects of the child ’ s", "metadata": {"doc_name": "sign145", "page": 48, "section": "11.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "diagnosis. 17 professionals should recognise that children, young people and adults, their parents or carers may have a significant adjustment reaction to the diagnosis and for some this adjustment period may be prolonged and difficult. asd affects all aspects of the child ’ s or adult ’ s and the family ’ s life and the importance of social support and family networks were noted. 228, 231, 232, 241, 243 families are required to take on multiple roles when their child is diagnosed including at times, the roles of cotherapist, and advocate. supporting family involvement in these roles is crucial and will impact on the success of any intervention. 4", "metadata": {"doc_name": "sign145", "page": 48, "section": "11.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "| 43", "metadata": {"doc_name": "sign145", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders a number of studies comment on the issue of encouraging families to participate in any decisions related to their child and the importance of feeling that their opinions are valued. 238, 240 - 242 the sample checklist in section 11. 2 suggests the type of information individuals with asd or their families / carers may require.", "metadata": {"doc_name": "sign145", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r professionals should offer individuals, parents and carers good - quality written information and", "metadata": {"doc_name": "sign145", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "an opportunity to ask questions when sharing information about the individual with asd.", "metadata": {"doc_name": "sign145", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r information should be provided in an accessible and understandable form. for adults with asd appropriate consent must be obtained before information is shared with", "metadata": {"doc_name": "sign145", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "carers. the information shared should relate to the individual ’ s particular asd presentation.", "metadata": {"doc_name": "sign145", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "people with asd and their families / carers require support and high - quality verbal and written", "metadata": {"doc_name": "sign145", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "information at time of diagnosis. this should include a written report of the outcome of the various assessments and the final diagnosis. copies of the letters sent to the various professionals who have been asked to assess their child or the adult may also be included.", "metadata": {"doc_name": "sign145", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "professionals involved in sharing of an asd diagnosis and information provision should receive", "metadata": {"doc_name": "sign145", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "ongoing education and training.", "metadata": {"doc_name": "sign145", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "individuals with asd and their parents, relatives or carers should be encouraged to continue to learn", "metadata": {"doc_name": "sign145", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "about asd and about any useful interventions and support. 11 • provision of information", "metadata": {"doc_name": "sign145", "page": 49, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "11. 2 checklist for provision of information this section gives examples of the information patients / carers may find helpful at the key stages of the patient journey. the checklist was designed by members of the guideline development group based on their experience and their understanding of the evidence base. the points are provided for use by health professionals when discussing asd with patients and carers and in guiding the production of locally - produced information materials. the checklist is neither exhaustive nor exclusive. before assessment initial professional concerned ( eg health visitor, teacher, gp ) should :", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y explain to child / young person / adult and parent / carer that a person ’ s behaviour", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "shows various ‘ clinical clues ’ that may suggest the possibility of asd or a social interaction or social communication difficulty ( see annex 2 )", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y discuss the advantages and disadvantages of further assessment with the", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "individual ( as appropriate ) and / or parent / carer, as they see it, and check there is agreement to organise this person ( s ) making referral for further assessment should :", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y include all relevant information regarding any concerns, the individual ’ s current", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "situation and details of any professionals involved y explain the patient / parent / carer ’ s understanding of the reason for referral y consider providing the patient / parent / carer with a copy of the referral letter", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y initiate general management / behaviour strategies and family support in the", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "interim, if necessary by involving multiagency colleagues the specialist team receiving the referral should :", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y ensure that the patient and parents / carers receive information about the process", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "which will follow referral, including likely timescale of any preassessment and assessment phases, and who will be involved", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y if corresponding with professional colleagues to arrange assessments, consider", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "copying correspondence to families", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y consider developing protocols to gather as much relevant information", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "preassessment as possible, in order to reduce assessment duration", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y inform the parent / carer that they are welcome to bring a supporter to the", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment if they wish", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y explain that, if any part of the assessment is to be video recorded, the team will", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "obtain written consent of the patient and / or carer ( as appropriate ) to retain the recording at the assessment appointment ( s ) the specialist team should :", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y check the current understanding of the patient and parents / carers, as appropriate", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "about the reasons for referral and their level of agreement with the concerns of the referring professional", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y explain the proposed assessments and agree with patient and parent / carer how", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "these will be organised and which colleagues will be involved y repeat explanations and revise arrangements as needed", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y if a diagnosis of asd or any differential diagnosis is not confirmed, provide an", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "explanation and respond constructively to any requests for a second opinion y ensure that any identified unmet needs are signposted to the appropriate services", "metadata": {"doc_name": "sign145", "page": 50, "section": "11.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "| 45", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders at any feedback appointment ( s ) the specialist team should : :", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y allow sufficient time for explanation and discussion of the assessment findings", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "and be sensitive to the potential distress that may arise in the patient and parent / carer and their possible needs to be seen separately", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y find out what the patient and family understand about diagnosis and add", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "information as appropriate ( eg if a diagnosis of asd has been made, a member of the team should explain how the referred patient ’ s presentation fits into icd - 10 or dsm - 5 criteria )", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y include the diagnostic criteria used ( icd - 10 or dsm - 5 ) in the written feedback", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "report", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y offer basic information based on current knowledge about causation, intervention", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "and prognosis, any investigations indicated, and the probable steps to provide appropriate multiagency supportive intervention", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y provide information about what written feedback will be made available, and", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "check with the patient and parent / relative / carer ( as appropriate ) how it should be shared with relevant multiagency colleagues", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y if any part of the assessment has been video recorded, obtain written consent", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "from the patient and parent / relative / carer ( as appropriate ) to retain the recording", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y if the patient is considered unable to have the outcome of the assessment", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "explained to them at feedback, discuss with the parent / carer how this might be undertaken at a later date and the best timescale", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y in cases of diagnostic uncertainty, discuss with the patient and parent / relative /", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "carer ( as appropriate ) how and when to best review / repeat the assessment, or options for further specialist assessment supportive intervention following diagnosis of asd multiagency multiprofessionals ( integrated and collaborative and in partnership with the family ) should :", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y involve relevant multiagency colleagues ( education, social work, voluntary sector,", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "careers advisors, employers, as appropriate )", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y tailor intervention to the requirements of the individual and family, working in", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "partnership", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y provide further information as needed, eg about impairments or coexisting", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "conditions", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y discuss potential educational approaches with the parent / carer and patient ( as", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "appropriate ), including additional support for learning", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y have in place arrangements for liaising / sharing required information with", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "education services", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y discuss wider family / sibling support, provision of respite, and the role of social", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "work assistance y provide information about :", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "- entitlement to social security benefits - potential voluntary / community supports - available parent training opportunities - recommended sources of further information y organise for the family to have a named contact for ongoing assistance ( consider", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "implementing the national autism plan for children ’ s recommendation for a key worker ). 18", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "11 • provision of information", "metadata": {"doc_name": "sign145", "page": 51, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "11. 3 sources of further information autism initiatives 11 granton square, edinburgh eh5 1hx tel : 0131 551 7260 www. autisminitiatives. org • e - mail : hos @ aiscotland. org. uk autism initiatives is a parent - led charity offering support to people with autism and their families.", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autism network scotland", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "level 6, curran building, the university of strathclyde, 101 st james road, glasgow g4 0ns tel : 0141 444 8146", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "www. autismnetworkscotland. org. uk • email : autism. network @ strath. ac. uk", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autism network scotland connects and communicates with those interested in the field of asd. it signposts asd professionals and practitioners, people with asd, their families and carers toward examples of good practice, resources and information. healthtalk. org www. healthtalk. org healthtalk. org provides free, reliable information about health issues, by sharing real - life experiences. national autistic society scotland nas scotland, central chambers, 1st floor, 109 hope street, glasgow g2 6ll tel : 0141 221 8090 www. autism. org. uk • email : scotland @ nas. org. uk the national autistic society scotland works throughout scotland to provide a wide range of quality, personalised support services for people with asd and their families and carers.", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "nhs inform caledonia house, fifty pitches road, cardonald park, glasgow g51 4eb", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "tel : 0800 22 44 88", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "www. nhsinform. co. uk • email : nhs. inform @ nhs24. scot. nhs. uk", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "nhs inform is the national health information service for scotland. research autism 25 nutford place, london w1h 5yq tel : 020 3490 3091", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "www. researchautism. net • email : info @ researchautism. net", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "research autism provides information on high - quality, independent research into new and existing health, education, social and other interventions.", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "scottish autism ( autism advice line )", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "hilton house, alloa business park, whins road, alloa fk10 3sa tel : 01259 222 022", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "www. scottishautism. org • email : autism @ scottishautism. org", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "scottish autism provides a team of autism advisors trained and experienced in working with people on the autism spectrum and who can offer personalised help and support. swan - scottish women ’ s autism network www. autismnetworkscotland. org. uk / swan • email : swan. scotland @ gmail. com swan works in partnership with autism network scotland and offers peer support and networking opportunities to women with autism.", "metadata": {"doc_name": "sign145", "page": 52, "section": "11.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "11. 3. 1 local support groups and telephone helplines www. nhsinform. co. uk / support - services tel : 0800 22 44 88 the support service directory on the nhs inform website provides details of local support groups.", "metadata": {"doc_name": "sign145", "page": 53, "section": "11.3.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "11. 3. 2 professional resources nhs education for scotland learning resource on autism spectrum disorders for gps and primary care practitioners www. asd. nes. scot. nhs. uk a learning resource designed for any professional who is working in the healthcare system at the primary - care level ( eg general practitioners ; allied health professionals, dentists, optometrists, public health nurses, district nurses, practice nurses, and dental nurses. nhs education for scotland e - learning module ‘ practical strategies for the primary care practitioner ’ www. knowledge. scot. nhs. uk / home / learning - and - cpd / learning - spaces / autism - spectrum - disorder. aspx this is a learning module that provides practitioners with advice about adapting routine consultations in primary care to accommodate the needs of people with asd their families and carers. scottish strategy for autism menu of interventions www. gov. scot / resource / 0043 / 00438221. pdf this is a non - evidence - based, multi - agency guide to interventions and supports for people with asd, in line with the scottish autism strategy recommendations for good autism provision. scottish transitions forum www. scottishtransitions. org. uk the scottish transitions forum aims to improve the experience of people with additional support needs, as they go through life transitions, particularly the transition of young people from school or college", "metadata": {"doc_name": "sign145", "page": 53, "section": "11.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autism provision. scottish transitions forum www. scottishtransitions. org. uk the scottish transitions forum aims to improve the experience of people with additional support needs, as they go through life transitions, particularly the transition of young people from school or college to adult life. 11 • provision of information", "metadata": {"doc_name": "sign145", "page": 53, "section": "11.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "12. 1 implementation strategy implementation of national clinical guidelines is the responsibility of each nhs board and is an essential part of clinical governance. mechanisms should be in place to review care provided against the guideline recommendations. the reasons for any differences should be assessed and addressed where appropriate. local arrangements should then be made to implement the national guideline in individual hospitals, units and practices. implementation of this guideline will be encouraged and supported by sign. the implementation strategy for this guideline encompasses the following tools and activities.", "metadata": {"doc_name": "sign145", "page": 54, "section": "12.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "12. 2 resource implications of key recommendations no recommendations are considered likely to reach the £5 million threshold which warrants full cost impact analysis.", "metadata": {"doc_name": "sign145", "page": 54, "section": "12.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "12. 3 auditing current practice a first step in implementing a clinical practice guideline is to gain an understanding of current clinical practice. audit tools designed around guideline recommendations can assist in this process. audit tools should be comprehensive but not time consuming to use. successful implementation and audit of guideline recommendations requires good communication between staff and multidisciplinary team working. the guideline development group has identified the following as key points to audit to assist with the implementation of this guideline : y are children undergoing universal child health surveillance activities being assessed for asd?", "metadata": {"doc_name": "sign145", "page": 54, "section": "12.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y are children presenting with developmental delay, emotional and behavioural problems, or genetic", "metadata": {"doc_name": "sign145", "page": 54, "section": "12.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "syndromes, receiving surveillance for asd as part of their routine practice? y are individuals being diagnosed with asd using icd - 10 or dsm - 5?", "metadata": {"doc_name": "sign145", "page": 54, "section": "12.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y what is the number of females being diagnosed with asd and the age of females at diagnosis compared", "metadata": {"doc_name": "sign145", "page": 54, "section": "12.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "to males? y what is the number of patients with asd who have a coexisting condition? y is there adequate linking from diagnosis of asd in individuals into intervention and support services? y are individuals, parents and carers offered written information at the time of diagnosis? y are individuals with asd and sleep difficulties being offered therapy? y are parent - mediated intervention programmes being offered and appraised? y are there interventions in place to support communication? y do children have access to support from staff trained in aba - based interventions? y is there access to group cbt / tailored cbt for children and young people with asd and anxiety? y are patients with asd treated with second - generation antipsychotics reviewed after three weeks?", "metadata": {"doc_name": "sign145", "page": 54, "section": "12.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y what is the number of staff who have received asd training in line with the autism training framework?", "metadata": {"doc_name": "sign145", "page": 54, "section": "12.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "54 an audit tool designed to measure adherence to assessment recommendations in sign 98 is available. 11", "metadata": {"doc_name": "sign145", "page": 54, "section": "12.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "12. 4 health technology assessment advice for nhsscotland in june 2007 the scottish medicines consortium ( smc ) advised that methylphenidate prolonged - release capsule ( medikinet xl® ) is accepted for restricted use within nhsscotland as part of a comprehensive treatment programme for attention deficit hyperactivity disorder ( adhd ) in children over six years of age when remedial measures alone prove insufficient. melatonin prolonged - release tablets ( circadin ) are not recommended for use within nhsscotland as monotherapy for the short - term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over due to a lack of submission from the holder of the marketing authorisation ( august 2008 ). melatonin prolonged - release tablets ( slenyto ) are not recommended for use within nhsscotland for the treatment of insomnia in children and adolescents aged 2 – 18 with autism spectrum disorder ( asd ) and / or smith - magenis syndrome, where sleep hygiene measures have been insufficient. the submitting company ’ s justification of the treatment ’ s cost in relation to its health benefits was not sufficient and the company did not present a sufficiently robust clinical and economic analysis to gain acceptance by smc ( september 2019 ). 12 • implementing the guideline", "metadata": {"doc_name": "sign145", "page": 55, "section": "12.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "13. 1 systematic literature review the evidence base for this guideline was synthesised in accordance with sign methodology. a systematic review of the literature was carried out using an explicit search strategy devised by an evidence and information scientist. databases searched include medline, embase, cinahl, psycinfo and the cochrane library. the year range covered was 2006 – 2014. internet searches were carried out on various websites including the us national guidelines clearinghouse. the main searches were supplemented by material identified by individual members of the development group. each of the selected papers was evaluated by two members of the group using standard sign methodological checklists before conclusions were considered as evidence.", "metadata": {"doc_name": "sign145", "page": 56, "section": "13.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "13. 1. 1 literature search for patient issues at the start of the guideline development process, an evidence and information scientist conducted a literature search for qualitative and quantitative studies that addressed patient issues of relevance to diagnosis and interventions for patients with asd. databases searched include medline, embase, cinahl and psycinfo, and the results were summarised by the sign patient involvement officer and presented to the guideline development group.", "metadata": {"doc_name": "sign145", "page": 56, "section": "13.1.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "13. 1. 2 literature search for cost effectiveness the guideline development group identified key questions with potential cost - effectiveness implications where it was judged particularly important to gain an understanding of the additional costs and benefits of different intervention strategies, based on the following criteria : y treatments which may have a significant resource impact y opportunities for significant disinvestment or resource release y the potential need for significant service redesign y cost - effectiveness evidence could aid implementation of a recommendation. a systematic literature search for economic evidence for these questions was conducted using medline, embase, nhs economic evaluation database ( nhs eed ) and health economics evaluation database ( heed ), covering the years 2010 – 2014. papers were selected and evaluated by a health economist, and considered for clinical relevance by guideline group members. interventions are considered to be cost effective if they fall below the commonly - accepted uk threshold of £20, 000 per quality - adjusted life year ( qaly ). the key questions are listed in annex 1.", "metadata": {"doc_name": "sign145", "page": 56, "section": "13.1.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "13. 2 recommendations for research the guideline development group was not able to identify sufficient evidence to answer all of the key questions asked in this guideline ( see annex 1 ). the following areas for further research have been identified :", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y studies into case identification instruments using populations that have not previously encountered the", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "diagnostic journey or already been diagnosed with asd. these populations may not have the insight to complete the questionnaire in the same way. a supporting question would be, do individuals with undiagnosed asd complete questionnaires in the same way as individuals with diagnosed asd?", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y studies into the adaptation and / or development of identification and screening tools for children and", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "adults with asd who have an intellectual disability.", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y research into the impact of the professional make - up of the diagnostic team and the assessment processes", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "used on the speed and quality of diagnosis.", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y a study to ascertain whether the identification of asd in adults with an eating disorder provides patient", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "benefit through improved management options. y a study to determine the diagnostic utility of the combined use of adi - r and ados in children.", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y studies on the accuracy of neuropsychological assessment tools in the diagnostic process for identifying", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "asd.", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y further research into the benefits of social - skills groups with consistent definitions of interventions,", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "target populations and outcome measures, particularly those related to improvements in quality of life.", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y research into pecs, including measures of treatment fidelity, maintenance and generalisation, and speech", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "and communication outcomes compared to other interventions for people with asd. the potential influence of pretreatment variables ( eg joint attention ) should be taken into account.", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y studies on the efficacy of computer - based interventions to improve social skills and identify individual", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "characteristics which may predict the effectiveness of cbi. the research should consider the preferences and abilities of the individual with asd, and whether the software can be customised to their needs. y further research into eibi with improved methodological rigour and long - term follow up. y studies on the cost effectiveness of eibi. y a study of the impact of high - intensity interventions on families and siblings.", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y a study into the factors associated with decline in benefit of eibi ( between the ages 3 and 4 and age 5", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "and 6 ), including what the associated factors may be ( for example starting school, or condition - related factors ), whether a decline is found in neurotypical and other conditions, and whether the decline resolves over time.", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y studies of the short - and long - term efficacy of psychological therapies compared to placebo, attention", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "control or pharmacological interventions. better measures of outcomes, particularly self - reported outcomes ( for example quality of life, symptoms and emotional distress ) are needed to support research into these interventions. studies should consider cost effectiveness and efficacy of modifications to therapies to adapt to asd ( for example inclusion of parents, longer sessions, more frequent sessions ). y studies of social stories™ to include data on generalisation and maintenance of skills. y studies into who benefits from skills - based interventions – younger children, older children or adults.", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y an rct of auditory integration therapy, with explicit methodology and validated outcome measures. the", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "trial should demonstrate how ait has modulated the music delivered, what type of filtering has been involved to attenuate sounds at selected frequencies, and how they have been modulated.", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y controlled trials with large sample sizes to evaluate the efficacy of sensory integration and sensory - based", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "interventions.", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y rcts on behavioural interventions to reduce behaviour that challenges with outcomes measured over", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "long follow - up periods.", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y a study into the neurophysiological mechanisms by which sensory regulation influences psychological", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "state and behaviour in asd.", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y an adequately powered, blinded rct on the efficacy of gluten - free and casein - free diets. monitoring of", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "adverse dietary impacts should be included. 13 • the evidence base", "metadata": {"doc_name": "sign145", "page": 57, "section": "13.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "13. 3 review and updating this guideline was issued in 2016 and will be considered for review in three years. the review history, and any updates to the guideline in the interim period, will be noted in the review report, which is available in the supporting material section for this guideline on the sign website : www. sign. ac. uk comments on new evidence that would update this guideline are welcome and should be sent to the sign executive, gyle square, 1 south gyle crescent, edinburgh, eh12 9eb ( email : sign @ sign. ac. uk ).", "metadata": {"doc_name": "sign145", "page": 58, "section": "13.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14. 1 introduction sign is a collaborative network of clinicians, other healthcare professionals and patient organisations and is part of healthcare improvement scotland. sign guidelines are developed by multidisciplinary groups of practising healthcare professionals using a standard methodology based on a systematic review of the evidence. further details about sign and the guideline development methodology are contained in ‘ sign 50 : a guideline developer ’ s handbook ’, available at www. sign. ac. uk this guideline was developed according to the 2015 edition of sign 50.", "metadata": {"doc_name": "sign145", "page": 59, "section": "14.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14. 2 the guideline development group", "metadata": {"doc_name": "sign145", "page": 59, "section": "14.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "dr iain mcclure consultant child and adolescent psychiatrist, royal hospital for sick ( chair ) children, edinburgh mrs corinne booth senior health economist, healthcare improvement scotland ms carolyn brown area depute principal psychologist, fife council psychological service, cupar ms juliet brown evidence and information scientist, healthcare improvement scotland dr laura cameron consultant psychiatrist in learning disabilities, adult learning disability service, nhs lanarkshire mr ed clifton senior health economist, healthcare improvement scotland dr magnus cormack consultant clinical psychologist, adult autism team, nhs greater glasgow and clyde dr elaine dale associate specialist, community child health, musselburgh primary care centre mrs yvonne fraser lay representative, kirriemuir, angus mrs anne marie gallagher speech and language therapist, adult autism team, nhs greater glasgow and clyde", "metadata": {"doc_name": "sign145", "page": 59, "section": "14.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "professor jean maclellan obe professor, national autism institute, university of strathclyde professor karen mckenzie clinical psychologist, northumbria university, newcastle upon tyne", "metadata": {"doc_name": "sign145", "page": 59, "section": "14.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "dr craig melville clinical senior lecturer in learning disabilities psychiatry, gartnavel royal hospital, glasgow dr claire moir gp principal, mill practice, dundee professor anne o ’ hare consultant paediatrician and director, salvesen / mindroom centre, university of edinburgh ms melanie ross specialist occupational therapist, keycomm, edinburgh ms marion rutherford speech and language therapist, royal hospital for sick children, edinburgh dr halina rzepecka clinical psychologist, centre for child health, nhs tayside dr jennifer shields clinical psychologist, child and adolescent mental health service, ayrshire central hospital ms ailsa stein programme manager, sign dr lorna thompson health services researcher, healthcare improvement scotland ms margaret young clinical nurse specialist, child and adolescent mental health service, argyll and bute hospital", "metadata": {"doc_name": "sign145", "page": 59, "section": "14.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14 • development of the guideline", "metadata": {"doc_name": "sign145", "page": 59, "section": "14.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14. 2. 1 acknowledgements sign would like to acknowledge the guideline development group responsible for the development of sign 98 : assessment, diagnosis and clinical interventions for children and young people with autism spectrum disorder, on which this guideline is based. sign is grateful to the following former members of the guideline development group :", "metadata": {"doc_name": "sign145", "page": 60, "section": "14.2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "ms jane ansell chief executive, sleep scotland, edinburgh dr jill ogston clinical psychologist, child and adolescent mental health service, ayrshire central hospital dr andrew watson consultant psychiatrist, nhs lothian", "metadata": {"doc_name": "sign145", "page": 60, "section": "14.2.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14. 3 consultation and peer review a report of the consultation and peer review comments and responses is available in the supporting material section for this guideline on the sign website. all expert referees and other contributors made declarations of interests and further details of these are available on request from the sign executive.", "metadata": {"doc_name": "sign145", "page": 60, "section": "14.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14. 3. 1 specialist review this guideline was reviewed in draft form by the following independent expert referees, who were asked to comment primarily on the comprehensiveness and accuracy of interpretation of the evidence base supporting the recommendations in the guideline. the guideline group addresses every comment made by an external reviewer, and must justify any disagreement with the reviewers ’ comments. sign is very grateful to all of these experts for their contribution to the guideline.", "metadata": {"doc_name": "sign145", "page": 60, "section": "14.3.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "professor gillian baird consultant paediatrician ( neurodisability ), guy ’ s and st thomas trust, london professor simon baron - cohen professor of developmental psychopathology, director, autism research centre, cambridge university professor tony charman chair in clinical child psychology, king ’ s college london dr mecca chiesa president elect, uk society for behaviour analysis, university of kent dr carolyn cormie community paediatrician, whitehills health and community care centre, forfar mr andy fleming asd nurse practitioner, adult learning disability service, nhs lanarkshire mr james fletcher director, association for real change scotland, dalkeith", "metadata": {"doc_name": "sign145", "page": 60, "section": "14.3.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14. 3. 2 public consultation the draft guideline was also available on the sign website for a month to allow all interested parties to comment.", "metadata": {"doc_name": "sign145", "page": 61, "section": "14.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14. 3. 3 sign editorial group as a final quality control check, the guideline is reviewed by an editorial group comprising the relevant specialty representatives on sign council to ensure that the specialist reviewers ’ comments have been addressed adequately and that any risk of bias in the guideline development process as a whole has been minimised. the editorial group for this guideline was as follows. all members of sign council make yearly declarations of interest. a register of interests is available on the sign council membership page of the sign website www. sign. ac. uk", "metadata": {"doc_name": "sign145", "page": 61, "section": "14.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "dr iris clarke allied health professions dr roberta james sign programme lead ; co - editor professor john kinsella chair of sign ; co - editor", "metadata": {"doc_name": "sign145", "page": 61, "section": "14.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "professor ronan o ’ carroll british psychological society", "metadata": {"doc_name": "sign145", "page": 61, "section": "14.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "dr werner pretorius royal college of psychiatrists in scotland dr karen ritchie healthcare improvement scotland mr alan timmins royal pharmaceutical society", "metadata": {"doc_name": "sign145", "page": 61, "section": "14.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14 • development of the guideline", "metadata": {"doc_name": "sign145", "page": 61, "section": "14.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "56 |", "metadata": {"doc_name": "sign145", "page": 62, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders abbreviations 3di developmental, dimensional and diagnostic interview aba applied behaviour analysis abc autism behaviour checklist adhd attention deficit hyperactivity disorder adi - r autism diagnostic interview - revised ados - g autism diagnostic observation schedule - generic ait auditory integration training aq autism spectrum quotient asc autism spectrum condition asd autistic spectrum disorder asq / scq autism screening questionnaire / social communication questionnaire assq autism spectrum screening questionnaire auc area under the curve cars childhood autism rating scale cast childhood asperger syndrome test cbi computer - based interventions cbt cognitive behavioural therapy cgh comparative genomic hybridisation cgi clinical global impression chat checklist for autism in toddlers d cohen ’ s d effect size ; small ( d = 0. 2 ), medium ( d = 0. 5 ), and large ( d ≥ 0. 8 ) disco diagnostic interview for social and communication disorders dsm diagnostic and statistical manual of mental disorders eeg electroencephalogram eibi early intensive behavioural interventions esdm early start denver model girfec getting it right for every child gmc general medical council hall 4 health for all children, 4th edition heed health economics evaluation database icd international classification of diseases icer incremental cost effectiveness ratio iq intelligence quotient leap learning experiences and alternative program ma marketing authorisation", "metadata": {"doc_name": "sign145", "page": 62, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "| 57", "metadata": {"doc_name": "sign145", "page": 63, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders", "metadata": {"doc_name": "sign145", "page": 63, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "m - chat modified checklist for autism in toddlers", "metadata": {"doc_name": "sign145", "page": 63, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "mecp2 methyl - cpg - binding protein 2 mri magnetic resonance imaging mta multiple technology appraisal nhs eed nhs economic evaluation database nice national institute for health and care excellence npv negative predictive value ocd obsessive - compulsive disorder or odds ratio ot occupational therapist pact parent - mediated communication - focused treatment pdd pervasive developmental disorder pdd - mrs pervasive developmental disorder in mental retardation scale pecs picture exchange communication system peds parents evaluation of developmental status ppv positive predictive value pten phosphatase and tensin homolog qaly quality - adjusted life years rct randomised controlled trial rr relative risk sbi sensory - based intervention sd standard deviation sign scottish intercollegiate guidelines network sit sensory integration therapy smc scottish medicines consortium smd standardised mean difference sol sleep onset latency spc summary of product characteristics ssri selective serotonin reuptake inhibitors stat screening tool for autism in two - year olds tca tricyclic antidepressant", "metadata": {"doc_name": "sign145", "page": 63, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "teacch treatment and education of autistic and related communication handicapped children", "metadata": {"doc_name": "sign145", "page": 63, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "ucla university of california, los angeles abbreviations", "metadata": {"doc_name": "sign145", "page": 63, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 6 1a is there evidence that specific findings at the time of asd diagnosis can reliably predict prognosis?", "metadata": {"doc_name": "sign145", "page": 64, "section": "4.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 3 2 is the use of a structured assessment tool more effective than an unstructured review for early identification of children with potential autism / asd at the 27 – 30 month health check? if so, which structured tool is the most robust for early identification? does efficacy differ depending on the gender of the child? tools : asq, modified checklist for autism in toddlers ( m - chat ), parents evaluation of developmental status ( peds ), surestart language scale, strengths and difficulties questionnaire outcomes : to prompt referral. sensitivity, specificity, positive predictive value ( ppv ), negative predictive value ( npv )", "metadata": {"doc_name": "sign145", "page": 64, "section": "4.1.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 2. 2 3 does multidisciplinary or single practitioner assessment of children and adolescents with suspected autism / asd provide more accurate diagnosis, a more comprehensive profile, and most efficiency in terms of the length of time taken for the assessment and speed of assessment to feedback on diagnosis? if multidisciplinary assessment is better, which healthcare professionals should be involved? consider : cost / health economics consider : rural versus urban", "metadata": {"doc_name": "sign145", "page": 64, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 2. 3 4 in children or adolescents with suspected autism / asd is diagnosis more reliable if both ados and adi - r are used, compared to a single tool or neither? which interview tool is most effective? which observational tool is most effective? does efficacy differ depending on the gender of the child / adolescent? consider : the level training for professionals using the tool", "metadata": {"doc_name": "sign145", "page": 64, "section": "4.2.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 6 5 are there differences in the way girls with autism / asd present and respond to interventions compared to boys? consider : triad / dyad of symptoms", "metadata": {"doc_name": "sign145", "page": 65, "section": "4.1.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 3. 2 6 are there neuropsychological assessment tools for children and adolescents that can accurately detect autism / asd? executive function tests : y nepsy - theory of mind, memory for faces, affect recognition y deliskaplan, executive function system ( dkefs ) y behavioural assessment of dysexecutive syndrome ( bads ) y others : weschler intelligence scale for children ( wisc ) y weschler adult intelligence scale ( wais ) y weschler memory scales ( wms / cms ) y brief neuropsychological cognitive examination y happe stories outcomes : sensitivity, specificity, ppv, npv", "metadata": {"doc_name": "sign145", "page": 65, "section": "4.3.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 5 7 in children and adolescents with suspected asd, does genetic testing aid accurate diagnosis, speed of diagnosis, and inform appropriate follow up? 6. 2, 6. 3. 2, 6. 3. 9,", "metadata": {"doc_name": "sign145", "page": 65, "section": "4.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 5 8 in children and adolescents with autism / asd, are any of the following interventions effective in improving outcome? y social stories tm y computer - based interventions y social skills groups y picture exchange communication system ( pecs )", "metadata": {"doc_name": "sign145", "page": 65, "section": "6.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y treatment and education of autistic and related communication handicapped", "metadata": {"doc_name": "sign145", "page": 65, "section": "6.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "children ( teacch ) y interventions for behaviour that challenges y see additional search terms on page 62 outcomes : improved communication and social interaction, quality of life, behavioural improvement, repetitive interests / activities ; reduction in overall autistic behaviours", "metadata": {"doc_name": "sign145", "page": 65, "section": "6.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 1 9 in children and adolescents with autism / asd, are early intensive behaviour interventions effective in improving outcome? outcomes : improved communication and social interaction, repetitive interests / activities, reduction in overall autistic behaviours, behavioural improvements, adaptive functioning, quality of life", "metadata": {"doc_name": "sign145", "page": 65, "section": "6.3.1", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 3 10 in children and adolescents with autism / asd do psychological therapies improve outcome? y cognitive behavioural therapy y cognitive remediation therapy comparison : other interventions, no therapy", "metadata": {"doc_name": "sign145", "page": 65, "section": "6.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "outcomes : improvement in mental health and social functioning, improved", "metadata": {"doc_name": "sign145", "page": 65, "section": "6.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "communication and social interaction, repetitive interests / activities ; reduction in overall autistic behaviours, behavioural improvement, quality of life consider : cost effectiveness annexes", "metadata": {"doc_name": "sign145", "page": 65, "section": "6.3.3", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 3. 5 11 in children and adolescents with autism / asd, does sensory integration therapy improve outcomes? comparison : other interventions, no therapy", "metadata": {"doc_name": "sign145", "page": 66, "section": "6.3.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "outcomes : improvement in repetitive interests / activities ; reduction in overall autistic", "metadata": {"doc_name": "sign145", "page": 66, "section": "6.3.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "behaviours, behavioural improvement, sensory profiles / sensory modulation, quality of life 6. 3. 7, 6. 4, 8. 8 12 in children and adolescents with autism / asd and sleep problems, do any of the following interventions improve outcomes : y cognitive / behavioural interventions y sleep programme y referral to a sleep counsellor y omega - 3 fatty acids supplementation y melatonin outcomes : improvements in sleep patterns, sleep hygiene and sleep problems, daytime learning and daytime behaviour, quality of life", "metadata": {"doc_name": "sign145", "page": 66, "section": "6.3.5", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6. 4 13 in children and adolescents with autism / asd, do the following nutritional interventions improve outcome, compared to children without asd : y omega - 3 fatty acids supplementation y gluten - free and casein - free diets", "metadata": {"doc_name": "sign145", "page": 66, "section": "6.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "outcomes : improvement in repetitive interests / activities ; reduction in overall autistic", "metadata": {"doc_name": "sign145", "page": 66, "section": "6.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "behaviours, behavioural improvement, gastrointestinal symptoms and growth quality of life 8 14 in children and adolescents with autism / asd, does use of, or discontinuing the use of, any of the following pharmacological therapies improve outcomes? y risperidone y aripiprazole y antidepressants and anxiolytics y ssris, fluoxetine, sertraline y tricyclic antidepressants y anticonvulsants y hormonal interventions y snris y antihistamines and antioxidants y secretin y stimulants", "metadata": {"doc_name": "sign145", "page": 66, "section": "6.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "outcomes : improvement in repetitive interests / activities ; reduction in overall autistic", "metadata": {"doc_name": "sign145", "page": 66, "section": "6.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "behaviours, behavioural improvement, improvements in mental health, side effects, iq, improvement in communication and social interaction, quality of life consider : cost effectiveness", "metadata": {"doc_name": "sign145", "page": 66, "section": "6.4", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 6 16 what is the effectiveness of screening for asd in adults who have mental ill health, eg recurrent severe depression, a family history of asd, or other developmental disorders? outcomes : speed of diagnosis, quality of life", "metadata": {"doc_name": "sign145", "page": 67, "section": "4.1.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 6 17 what signs or symptoms should prompt any professional who comes into contact with an adult with possible autism / asd to consider assessment? outcomes : to prompt referral, sensitivity, specificity, ppv, npv, area under the curve ( auc )", "metadata": {"doc_name": "sign145", "page": 67, "section": "4.1.6", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 1. 8 18 what are the most effective methods / tools for case identification in autism / asd in adults? comparison : dsm or icd", "metadata": {"doc_name": "sign145", "page": 67, "section": "4.1.8", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4. 2. 2 19 in adults with possible autism / asd, what are the key components of, and the most effective structure for, a diagnostic assessment? to answer this question, consideration should be given to :", "metadata": {"doc_name": "sign145", "page": 67, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y the nature and content of the clinical interview and observation ( including an early", "metadata": {"doc_name": "sign145", "page": 67, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "developmental history where possible ) y formal diagnostic methods / psychological instruments ( including risk assessment ) y biological measures y the setting ( s ) in which the assessment takes place y who the informant needs to be ( to provide a developmental history ) y comorbidities outcomes : sensitivity and specificity, ppv, npv, reliability, validity, auc", "metadata": {"doc_name": "sign145", "page": 67, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "7 20 for adults with autism / asd, what are the benefits and / or potential harms associated with", "metadata": {"doc_name": "sign145", "page": 67, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "different psychosocial interventions ( for example, applied behavioural analysis, cognitive behavioural therapy, mentoring, social groups, and befriending schemes )? comparison : treatment as usual, waitlist control, other interventions outcomes : improved social interaction, communication, repetitive interests / activities, reduction in overall autistic behaviours, improved management of behaviour that challenges, outcomes involving treatment of coexisting conditions 9 21 for adults with autism / asd, what is the effectiveness of biomedical interventions : y pharmacotherapy ( eg antipsychotics, antidepressants, anticonvulsants )", "metadata": {"doc_name": "sign145", "page": 67, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y vitamins and dietary supplements ( eg omega - 3 fatty acid supplements, vitamin b", "metadata": {"doc_name": "sign145", "page": 67, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "12, vitamin a ) y hormones ( eg oxytocin, secretin, melatonin )", "metadata": {"doc_name": "sign145", "page": 67, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "comparison : placebo, other interventions", "metadata": {"doc_name": "sign145", "page": 67, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "outcomes : improved social interaction, communication, repetitive interests / activities ; reduction in overall autistic behaviours, improved management of behaviour that challenges, outcomes involving treatment of coexisting conditions, side effects annexes", "metadata": {"doc_name": "sign145", "page": 67, "section": "4.2.2", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "62 |", "metadata": {"doc_name": "sign145", "page": 68, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders additional search terms for kq 8 : animal / pet therapy precision teaching art therapy psychotherapy ; autogenic training auditory integration therapy psychodynamic psychotherapy british sign language scerts® child ’ s talk self awareness training communication / language training ; augmentive communication sensory integration therapy ddat ( dyslexia, dyspraxia, attention deficit treatment centre ) developmental skills sexual health dolphins social communication training earlybird sonrise options facilitated communication spell gentle teaching ; growing minds ; intensive interaction spirals hanen parent programme talking mats heavy metal chelation teaching methods ; brain gym help theory of mind training holding therapy tomatis method hyperacusis prevention total communication light and sound therapy verbal behaviour makaton visual language movement programmes ; physical exercise visual therapies ; colorimetric therapy ; irlen lenses / glasses ; orthoptics parent programmes white noise portage ward infant language screening test assessment acceleration remediation ( wilstaar )", "metadata": {"doc_name": "sign145", "page": 68, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "| 63", "metadata": {"doc_name": "sign145", "page": 69, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders annex 2 indicators of possible asd preschool children244 y delay or absence of spoken language y looks through people ; not aware of others y not responsive to other people ’ s facial expression / feelings y lack of pretend play ; little or no imagination y does not show typical interest in or play near peers purposefully y lack of turn - taking y unable to share pleasure y qualitative impairment in non - verbal communication y does not point at an object to direct another person to look at it y lack of gaze monitoring y lack of initiation of activity or social play y unusual or repetitive hand and finger mannerisms y unusual reactions, or lack of reaction, to sensory stimuli. school - age children18 communication impairments : y abnormalities in language development including muteness y odd or inappropriate prosody y persistent echolalia y reference to self as ‘ you ’, ‘ she ’ or ‘ he ’ beyond three years y unusual vocabulary for child ’ s age / social group y limited use of language for communication and / or tendency to talk freely only about specific topics y qualitative impairment in non - verbal communication. * social impairments :", "metadata": {"doc_name": "sign145", "page": 69, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y inability to join in play of other children or inappropriate attempts at joint play ( may manifest as aggressive or", "metadata": {"doc_name": "sign145", "page": 69, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "disruptive behaviour )", "metadata": {"doc_name": "sign145", "page": 69, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y lack of awareness of classroom ‘ norms ’ ( criticising teachers, overt unwillingness to co - operate in classroom activities,", "metadata": {"doc_name": "sign145", "page": 69, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "inability to appreciate or follow current trends ) y easily overwhelmed by social and other stimulation y failure to relate normally to adults ( too intense / no relationship ) y showing extreme reactions to invasion of personal space and resistance to being hurried. impairments of interests, activities and / or behaviours : y lack of flexible co - operative imaginative play / creativity y difficulty in organising self in relation to unstructured space ( eg hugging the perimeter of playgrounds, halls )", "metadata": {"doc_name": "sign145", "page": 69, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y inability to cope with change or unstructured situations, even ones that other children enjoy ( school trips, teachers", "metadata": {"doc_name": "sign145", "page": 69, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "being away etc ). other factors : y unusual profile of skills / deficits y any other evidence of odd behaviours including unusual responses to sensory stimuli. * based on the expert opinion of the guideline development group annexes", "metadata": {"doc_name": "sign145", "page": 69, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "64 |", "metadata": {"doc_name": "sign145", "page": 70, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders adolescents * these indicators are in addition to those in younger children. difficulties are likely to be more subtle in older individuals or those without intellectual disability. general picture :", "metadata": {"doc_name": "sign145", "page": 70, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y long standing difficulties in social behaviours, communication and coping with change, which are more obvious", "metadata": {"doc_name": "sign145", "page": 70, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "at times of transition ( eg change of school, leaving school )", "metadata": {"doc_name": "sign145", "page": 70, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y significant discrepancy between academic ability and ‘ social ’ intelligence, most difficulties in unstructured social", "metadata": {"doc_name": "sign145", "page": 70, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "situations, eg in school or work breaks y socially ‘ naive ’, lack common sense, not as independent as peers. language, non - verbal skills and social communication :", "metadata": {"doc_name": "sign145", "page": 70, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y problems with communication, even if wide vocabulary and normal use of grammar. may be unduly quiet, may", "metadata": {"doc_name": "sign145", "page": 70, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "talk at others rather than hold a to and fro conversation, or may provide excessive information on topics of own interest", "metadata": {"doc_name": "sign145", "page": 70, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y unable to adapt style of communication to social situations eg may sound like ‘ a little professor ’ ( overly formal ),", "metadata": {"doc_name": "sign145", "page": 70, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "or be inappropriately familiar y may have speech peculiarities including ‘ flat ’, unmodulated speech, repetitiveness, use of stereotyped phrases y may take things literally and fail to understand sarcasm or metaphor y unusual use and timing of non - verbal interaction ( eg eye contact, gesture and facial expression ). social problems : y difficulty making and maintaining peer friendships, though may find it easier with adults or younger children", "metadata": {"doc_name": "sign145", "page": 70, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "y can appear unaware or uninterested in peer group ‘ norms ’, may alienate by behaviours which transgress ‘ unwritten", "metadata": {"doc_name": "sign145", "page": 70, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "rules ’ y may lack awareness of personal space, or be intolerant of intrusions on own space. rigidity in thinking and behaviour : y preference for highly specific, narrow interests or hobbies, or may enjoy collecting, numbering or listing y strong preferences for familiar routines, may have repetitive behaviours or intrusive rituals y problems using imagination eg in writing, future planning y may have unusual reactions to sensory stimuli eg sounds, tastes, smell, touch, hot or cold. * based on the expert opinion of the guideline development group adults 13 y persistent difficulty in social interaction y persistent difficulty in social communication y stereotypic ( rigid / repetitive ) behaviours, resistance to change y restricted interests y problems with obtaining / sustaining employment / education y difficulty in initiating or sustaining social relationships y history of neurodevelopmental condition ( including intellectual disability and adhd ) or mental disorder y gender dysphoria y diagnosis of an eating disorder.", "metadata": {"doc_name": "sign145", "page": 70, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "| 65", "metadata": {"doc_name": "sign145", "page": 71, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders adults who have a moderate or severe intellectual disability13 if necessary use information from a family member, partner or carer. presence of two or more of the following : y difficulties in reciprocal social interaction including :", "metadata": {"doc_name": "sign145", "page": 71, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "- limited interaction with others ( eg being aloof, indifferent or unusual ) - interaction to fulfil needs only - interaction that is naive or one sided y lack of responsiveness to others y little or no change in behaviour in response to different social situations y limited social demonstration of empathy y rigid routines and resistance to change y marked repetitive activities ( eg rocking and hand or finger flapping ), especially when under stress or expressing", "metadata": {"doc_name": "sign145", "page": 71, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "emotion. individuals with severe intellectual disability without asd may present with rigid routines, repetitive activities and limited empathy. those with this level of intellectual disability and asd will present with a more significant level of such difficulties with a qualitative autistic difference. annexes", "metadata": {"doc_name": "sign145", "page": 71, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "66 |", "metadata": {"doc_name": "sign145", "page": 72, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders annex 3 risk factors for autism and asd adjusted relative risk or odds ratios for factors for autism5 factors studies quality number of participants adjusted or / rr ( 95 % ci ) asd non - asd familiar or parental factors maternal age over 40 years 1 low 12, 159 4, 935, 776 adj or 1. 51 ( 1. 35 to 1. 70 ) mother ' s race ( black ) 2 low 4, 957 3, 498, 470 adj or 1. 66 ( 1. 48 to 1. 85 ) paternal age over 40 years 1 low 12, 159 4, 935, 776 adj or 1. 36 ( 1. 26 to 1. 47 ) perinatal or neonatal factors birthweight under 2500 g 2 low 655 90, 358 adj or 2. 15 ( 1. 47 to 3. 15 ) prematurity ( under 37 weeks ) 1 low 182 85, 628 adj or 2. 3 ( 1. 5 to 3. 7 ) admission to neonatal intensive care unit 1 low 461 461 adj or 1. 8 ( 1. 3 to 2. 7 ) male gender 3 low 5, 439 3, 584, 098 adj or 4. 28 ( 4. 02 to 4. 57 ) serum bilirubin", "metadata": {"doc_name": "sign145", "page": 72, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "adj or 1. 8 ( 1. 3 to 2. 7 ) male gender 3 low 5, 439 3, 584, 098 adj or 4. 28 ( 4. 02 to 4. 57 ) serum bilirubin test undertaken 1 low 461 461 adj or 3. 7 ( 1. 3 to 10. 5 ) hypertonic / hyper - reflexive / jittery 1 low 461 461 adj or 6. 7 ( 1. 5 to 29. 7 ) pregnancy - related factors no studies found for this analysis environmental factors no studies found for this analysis reproduced with permission from national institute for health and clinical excellence ( 2011 ) cg 128 : autism : recognition, referral and diagnosis of children and young people on the autism spectrum. london : nice. available from www. nice. org. uk / cg128", "metadata": {"doc_name": "sign145", "page": 72, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1. 7 ( 1. 31 to 52. 20 ) male gender 1 low 1, 251 253, 347 adj or 4. 2 ( 3. 7 to 4. 9 ) pregnancy - related factors", "metadata": {"doc_name": "sign145", "page": 73, "section": "1.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "threatened abortion", "metadata": {"doc_name": "sign145", "page": 73, "section": "1.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "at before 20 weeks 1 low 465 1, 313 adj or 2. 09 ( 1. 32 to 3. 32 )", "metadata": {"doc_name": "sign145", "page": 73, "section": "1.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "elective caesarean 1 low 465 1, 313 adj or 1. 83 ( 1. 32 to 2. 54 )", "metadata": {"doc_name": "sign145", "page": 73, "section": "1.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "residing in capital city 1 low 818 942, 836 adj rr 2. 05 ( 1. 67 to 2. 51 ) residing in capital city suburb 1 low 818 942, 836 adj rr 1. 67 ( 1. 35 to 2. 06 ) a. reference group 15 – 29 years b. reference group 25 years or younger reproduced with permission from national institute for health and clinical excellence ( 2011 ) cg 128 : autism : recognition, referral", "metadata": {"doc_name": "sign145", "page": 73, "section": "1.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "and diagnosis of children and young people on the autism spectrum. london : nice. available from www. nice. org. uk / cg128", "metadata": {"doc_name": "sign145", "page": 73, "section": "1.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "annexes", "metadata": {"doc_name": "sign145", "page": 73, "section": "1.7", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "68 |", "metadata": {"doc_name": "sign145", "page": 74, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders annex 4 structured instruments for use in screening high risk groups instrument format description target age range pervasive developmental disorders rating scale 229 completed by a professional adequate reliability 1 – 18 years old modified - checklist for autism in toddlers ( m - chat ) 30 parent questionnaire developed from the chat, accurately discriminates autism from other developmental disorders 18 – 30 months old the childhood autism rating scale ( cars and cars - 2 ) 53 completed by professionals after taking a clinical history and observing the child over 2 years old the screening tool for autism in two year olds ( stat ) 34 completed by a professional after interacting with the child in a structured play context high sensitivity, specificity and acceptable reliability 24 – 35 months old checklist for autism in toddlers ( chat ) 37 completed by a professional after a brief interview with parents and a semi - structured observation period with the child accurately discriminates autism from other developmental disorders 2 – 3 years old the social communication disorders checklist 230 parent self report good reliability and validity 3 – 18 years old social communication questionnaire 36 parent or primary care giver report based on adi - r, able to discriminate between children with a diagnosis of an asd and children who do not have an asd over 4 years old social responsiveness scale 231 parent or teacher report measures the severity of social impairment. correlates with", "metadata": {"doc_name": "sign145", "page": 74, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "- r, able to discriminate between children with a diagnosis of an asd and children who do not have an asd over 4 years old social responsiveness scale 231 parent or teacher report measures the severity of social impairment. correlates with adi - r scores 4 – 18 years old childhood asperger syndrome test ( cast ) 33, 232 parent questionnaire good sensitivity and specificity 5 – 11 years old autism spectrum screening questionnaire ( assq ) 245 27 point questionnaire to be completed by parent, carer or teacher children and adolescents", "metadata": {"doc_name": "sign145", "page": 74, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "| 69", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders references", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "1 getting it right for every child ( girfec ). [ cited 37 may 2015 ].", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "available from url : http : / / www. gov. scot / topics / people / young - people / gettingitright", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2 children and young people ( scotland ) act 2014 ; 3 the scottish government. the scottish strategy for autism.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "edinburgh : the scottish government ; 2011.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "4 american psychiatric association. diagnostic and statistical manual", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of mental disorders. 5th edition. arlington, va : american psychiatric association ; 2013.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "5 national institute for health and care excellence ( nice ). autism :", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "recognition, referral and diagnosis of children and young people on the autism spectrum ( nice clinical guideline 128 ). london : national collaborating centre for women ’ s and childrens health ;", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2011. [ cited 1 / 12 / 2013 ]. available from url : http : / / www. nice. org.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "uk / guidance / cg128", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "6 brugha ts, mcmanus s, bankart j, scott f, purdon s, smith j, et", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "al. epidemiology of autism spectrum disorders in adults in the community in england. arch gen psychiatry 2011 ; 68 ( 5 ) : 459 - 65.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "7 baron - cohen s, scott fj, allison c, williams j, bolton p, matthews fe,", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "et al. prevalence of autism - spectrum conditions : uk school - based population study. br j psychiatry 2009 ; 194 ( 6 ) : 500 - 9.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "8 suren p, bakken ij, aase h, chin r, gunnes n, lie kk, et al.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autism spectrum disorder, adhd, epilepsy, and cerebral palsy in norwegian children. pediatrics 2012 ; 130 ( 1 ) : e152 - 8.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "9 campbell m, reynolds l, cunningham j, minnis h, gillberg c.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autism in glasgow : cumulative incidence and the effects of referral age, deprivation and geographical location. child care health dev 2013 ; 39 ( 5 ) : 688 - 94", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "10 fombonne e. epidemiology of pervasive developmental disorders.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "pediatr res 2009 ; 65 ( 6 ) : 591 - 8.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "11 mckenzie k, forsyth k, o ’ hare a, mcclure i, rutherford m, murray", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "a, et al. the relationship between waiting times and ‘ adherence ’ to the scottish intercollegiate guidelines network 98 guideline in autism spectrum disorder diagnostic services in scotland. autism 2016 ; 20 ( 4 ) : 395 - 401.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "12 hathorn c, alateeqi n, graham c, o ’ hare a. impact of adherence to", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "best practice guidelines on the diagnostic and assessment services for autism spectrum disorder. j autism dev disord 2014 ; 44 ( 8 ) : 1859 - 66.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "13 national institute for health and care excellence ( nice ). autism", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "in adults : diagnosis and management ( nice guideline cg142 ). london : national collaborating centre for women ’ s and childrens health. ; 2012. ( nice guideline cg142 ). [ cited 23 / 05 / 2016 ]. available from url : http : / / www. nice. org. uk / guidance / cg142 / resources / guidance - autism - recognition - referral - diagnosis - and - management - of - adults - on - the - autism - spectrum - pdf", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "14 joint formulary committee. guidance on prescribing. in :", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "british national formulary ( online ) london : bmj group and pharmaceutical press. [ cited 22 jan 2016 ]. available from url : https : / / www. medicinescomplete. com / mc / bnf / current / php97234 - guidance - on - prescribing. htm", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "15 electronic medicines compendium ( emc ). [ cited 1 / 12 / 2013 ].", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "available from url : www. medicines. org. uk", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "16 medicines and healthcare products regulatory agency. off - label", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "or unlicensed use of medicines : prescribers ’ responsibilities. 2009. [ cited 25 apr 2013 ]. available from url : http : / / www. mhra. gov. uk / safetyinformation / drugsafetyupdate / con087990", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "17 public health institute of scotland ( phis ). autistic spectrum", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "disorders : needs assessment report. glasgow : phis ; 2001. [ cited 10 june 2015 ]. available from url : http : / / www. gov. scot / resource / doc / 1095 / 0076895. pdf", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "18 le couteur a. national autism plan for children. london : national", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autistic society for niasa. ; 2003. ( national initiative for autism : screening and assessment )", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "19 world health organization ( who ). the icd - 10 classification", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of mental and behavioural disorders : a diagnostic criteria for research. geneva : who ; 1993.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "20 american psychiatric association ( apa ). diagnostic and statistical", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "manual of mental disorders ( dsm - iv. arlington ( va ) : apa ; 1994.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "21 volkmar fr, klin a, siegel b, szatmari p, lord c, campbell m,", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "et al. field trial for autistic disorder in dsm - iv. am j psychiatry 1994 ; 151 ( 9 ) : 1361 - 7.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "22 klin a, lang j, cicchetti dv, volkmar fr. brief report : interrater", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "reliability of clinical diagnosis and dsm - iv criteria for autistic disorder : results of the dsm - iv autism field trial. j autism dev disord 2000 ; 30 ( 2 ) : 163 - 7.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "23 volkmar fr, cicchetti dv, bregman j, cohen dj. three diagnostic", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "systems for autism : dsm - iii, dsm - iii - r, and icd - 10. j autism dev disord 1992 ; 22 ( 4 ) : 483 - 92.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "24 wood r, stirling a, nolan c, chalmers j, blair m. trends in the", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "coverage of ‘ universal ’ child health reviews : observational study using routinely available data. bmj open 2012 ; 2 ( 2 ).", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "25 wood r, wilson p. general practitioner provision of preventive", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "child health care : analysis of routine consultation data. bmc family practice 2012 ; ( 13 ) : 73.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "26 hall d, elliman d ( eds ). health for all children. 4th ed. oxford", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "university press ; 2003.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "27 uk national screeing committee. what is screening? [ cited 11", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "march 2015 ]. available from url : http : / / www. screening. nhs. uk / screening", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "28 mawle e, griffiths p. screening for autism in pre - school children", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "in primary care : systematic review of english language tools. int j nurs stud 2006 ; 43 ( 5 ) : 623 - 36.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "29 uk national screening committee. the uk nsc recommendation", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "on autism screening in children. 2012. [ cited 12 / 05 / 2016 ]. available from url : http : / / legacy. screening. nhs. uk / autism", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "30 tebruegge m, nandini v, ritchie j. does routine child health", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "surveillance contribute to the early detection of children with pervasive developmental disorders? an epidemiological study in kent, u. k. bmc pediatr 2004 ; 4 : 4.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "31 de giacomo a, fombonne e. parental recognition of developmental", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "abnormalities in autism. eur child adolesc psychiatry 1998 ; 7 ( 3 ) : 131 - 6.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "32 dissanayake c, crossley sa. autistic children ’ s responses to", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "separation and reunion with their mothers. j autism dev disord 1997 ; 27 ( 3 ) : 295 - 312.", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "33 malhi p, singhi p. recognition of autism in young children. stud", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "psychol ( bratisl ) 2003 ; 45 ( 1 ) : 75 - 80. references", "metadata": {"doc_name": "sign145", "page": 75, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "70 |", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "34 rogers sj, hepburn s, wehner e. parent reports of sensory", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "symptoms in toddlers with autism and those with other developmental disorders. j autism dev disord 2003 ; 33 ( 6 ) : 631 - 42.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "35 national institute for health and care excellence ( nice ). autism", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "diagnosis in children and young people evidence update. london : national institute for health and care excellence ; 2013. [ cited 23 / 05 / 2016 ]. available from url : https : / / www. nice. org. uk / guidance / cg128 / evidence / evidence - update - 183224557", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "36 robins dl, fein d, barton ml, green ja. the modified checklist for", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autism in toddlers : an initial study investigating the early detection of autism and pervasive developmental disorders. j autism dev disord 2001 ; 31 ( 2 ) : 131 - 44.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "37 berument sk, rutter m, lord c, pickles a, bailey a. autism screening", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "questionnaire : diagnostic validity. br j psychiatry 1999 ; 175 : 444 - 51.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "38 brereton av, tonge bj, mackinnon aj, einfeld sl. screening young", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "people for autism with the development behavior checklist. j am acad child adolesc psychiatry 2002 ; 41 ( 11 ) : 1369 - 75.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "39 scambler d, rogers sj, wehner ea. can the checklist for autism", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "in toddlers differentiate young children with autism from those with developmental delays? j am acad child adolesc psychiatry 2001 ; 40 ( 12 ) : 1457 - 63.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "40 scott fj, baron - cohen s, bolton p, brayne c. the cast ( childhood", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "asperger syndrome test ) : preliminary development of a uk screen for mainstream primary - school - age children. autism 2002 ; 6 ( 1 ) : 9 - 31.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "41 stone wl, coonrod ee, turner lm, pozdol sl. psychometric", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "properties of the stat for early autism screening. j autism dev disord 2004 ; 34 ( 6 ) : 691 - 701.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "42 seigel b. pddst - ii pervasive developmental disorders screening", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "test - ii : early childhood screener for autistic spectrum disorders. san antonio ( tx ) : harcourt assessment ; 2004.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "43 cox a, klein k, charman t, baird g, baron - cohen s, swettenham", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "j, et al. autism spectrum disorders at 20 and 42 months of age : stability of clinical and adi - r diagnosis. j child psychol psychiatry 1999 ; 40 ( 5 ) : 719 - 32.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "44 stone wl, lee eb, ashford l, brissie j, hepburn sl, coonrod ee, et", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "al. can autism be diagnosed accurately in children under 3 years? j child psychol psychiatry 1999 ; 40 ( 2 ) : 219 - 26.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "45 werner e, dawson g, munson j, osterling j. variation in early", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "developmental course in autism and its relation with behavioral outcome at 3 - 4 years of age. j autism dev disord 2005 ; 35 ( 3 ) : 337 - 50.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "46 fraser r, cotton s, gentle e, angus b, allott k, thompson a. non -", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "expert clinicians ’ detection of autistic traits among attenders of a youth mental health service. early interv psychiatry 2012 ; 6 ( 1 ) : 83 - 6.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "47 hallerback mu, lugnegard t, gillberg c. is autism spectrum disorder", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "common in schizophrenia? psychiatry res 2012 ; 198 ( 1 ) : 12 - 7.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "48 huke v, turk j, saeidi s, kent a, morgan jf. autism spectrum", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "disorders in eating disorder populations : a systematic review. eur eat disord rev 2013 ; 21 ( 5 ) : 345 - 51.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "49 pasterski v, gilligan l, curtis r. traits of autism spectrum disorders", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "in adults with gender dysphoria. arch sex behav 2014 ; 43 ( 2 ) : 387 - 93.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "50 dworzynski k, ronald a, bolton p, happe f. how different are", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "girls and boys above and below the diagnostic threshold for autism spectrum disorders? j am acad child adolesc psychiatry 2012 ; 51 ( 8 ) : 788 - 97.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "51 kirkovski m, enticott pg, fitzgerald pb. a review of the role of", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "female gender in autism spectrum disorders. j autism dev disord 2013 ; 43 ( 11 ) : 2584 - 603.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "52 lai mc, lombardo mv, auyeung b, chakrabarti b, baron - cohen s.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "sex / gender differences and autism : setting the scene for future research. j am acad child adolesc psychiatry 2015 ; 54 ( 1 ) : 11 - 24.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "53 van wijngaarden - cremers pj, van eeten e, groen wb, van deurzen", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "pa, oosterling ij, van der gaag rj. gender and age differences in the core triad of impairments in autism spectrum disorders : a systematic review and meta - analysis. j autism dev disord 2014 ; 44 ( 3 ) : 627 - 35.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "54 nhs education for scotland. optimising outcomes : the nhs", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "education for scotland autism training framework nhs education for scotland and the scottish government ; 2014. [ cited 23 / 05 / 2016 ]. available from url : http : / / elearning. scot. nhs. uk : 8080 / intralibrary / open _ virtual _ file _ path / i1923n4027869t / nesd0350asdtrainingframework - web. pdf", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "55 royal college of psychiatrists. good practice in the management", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of autism ( including asperger syndrome ) in adults. london : royal college of psychiatrists ; 2014. [ cited 16 / 05 / 2016 ]. available from url : http : / / www. rcpsych. ac. uk / files / pdfversion / cr191. pdf", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "56 noterdaeme m, mildenberger k, sitter s, amorosa h. parent", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "information and direct observation in the diagnosis of pervasive and specific developmental disorders. autism 2002 ; 6 ( 2 ) : 159 - 68.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "57 noterdaeme m, sitter s, mildenberger k, amorosa h. diagnostic", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment of communicative and interactive behaviours in children with autism and receptive language disorder. eur child adolesc psychiatry 2000 ; 9 ( 4 ) : 295 - 300.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "58 leekam sr, libby sj, wing l, gould j, taylor c. the diagnostic", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "interview for social and communication disorders : algorithms for icd - 10 childhood autism and wing and gould autistic spectrum disorders. j child psychol psychiatry 2002 ; 43 ( 3 ) : 327 - 42.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "59 skuse d, warrington r, bishop d, chowdhury u, lau j, mandy w, et", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "al. the developmental, dimensional and diagnostic interview ( 3di ) : a novel computerized assessment for autism spectrum disorders. j am acad child adolesc psychiatry 2004 ; 43 ( 5 ) : 548 - 58.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "60 lord c, rutter m, le couteur a. autism diagnostic interview - -", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "revised : a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. j autism dev disord 1994 ; 24 ( 5 ) : 659 - 85.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "61 falkmer t, anderson k, falkmer m, horlin c. diagnostic procedures", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "in autism spectrum disorders : a systematic literature review. eur child adolesc psychiatry 2013 ; 22 ( 6 ) : 329 - 40.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "62 rellini e, tortolani d, trillo s, carbone s, montecchi f. childhood", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autism rating scale ( cars ) and autism behavior checklist ( abc ) correspondence and conflicts with dsm - iv criteria in diagnosis of autism. j autism dev disord 2004 ; 34 ( 6 ) : 703 - 8.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "63 schopler e, reichler rj, devellis rf, daly k. toward objective", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "classification of childhood autism : childhood autism rating scale ( cars ). j autism dev disord 1980 ; 10 ( 1 ) : 91 - 103.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "64 lord c, risi s, lambrecht l, cook eh, jr., leventhal bl, dilavore", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "pc, et al. the autism diagnostic observation schedule - generic : a standard measure of social and communication deficits associated with the spectrum of autism. j autism dev disord 2000 ; 30 ( 3 ) : 205 - 23.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "65 molloy ca, murray ds, akers r, mitchell t, manning - courtney p.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "use of the autism diagnostic schedule ( ados ) in a clinical setting. autism 2011 ; 15 ( 2 ) : 143 - 62.", "metadata": {"doc_name": "sign145", "page": 76, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "| 71", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "66 lord catherine, rutter michael, dilavore pamela c, risi susan,", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "gotham katherine, bishop somer l, et al. autism diagnostic observation schedule, second edition : ados - 2,. 2014.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "67 kwok eyl, brown hm, smyth re, oram cardy j. meta - analysis", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of receptive and expressive language skills in autism spectrum disorder. res autism spectr disord 2015 ; 9 : 202 - 22.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "68 botting n, conti - ramsden g. autism, primary pragmatic difficulties,", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "and specific language impairment : can we distinguish them using psycholinguistic markers? dev med child neurol 2003 ; 45 ( 8 ) : 515 - 24.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "69 charman t, drew a, baird c, baird g. measuring early language", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "development in preschool children with autism spectrum disorder using the macarthur communicative development inventory ( infant form ). j child lang 2003 ; 30 ( 1 ) : 213 - 36.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "70 cohen il, schmidt - lackner s, romanczyk r, sudhalter v. the", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "pdd behavior inventory : a rating scale for assessing response to intervention in children with pervasive developmental disorder. j autism dev disord 2003 ; 33 ( 1 ) : 31 - 45.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "71 the psychological society of ireland autism spectrum disorders", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "special interest group. best practice guidelines for the assessment and diagnosis of autistic spectrum disorders for children and adolescents ( birth to 18 years ). the psychological society of ireland ;", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2010. [ cited 23 / 05 / 2016 ]. available from url : http : / / www. psihq. ie /", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "page / file _ dwn / 102 / autism % 20spectrum % 20disorders % 20 - % 20 best % 20practice % 20guidelines. pdf", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "72 carter as, volkmar fr, sparrow ss, wang jj, lord c, dawson g, et al.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the vineland adaptive behavior scales : supplementary norms for individuals with autism. j autism dev disord 1998 ; 28 ( 4 ) : 287 - 302.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "73 dahlgren s, sandberg ad, hjelmquist e. the non - specificity of", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "theory of mind deficits : evidence from children with communicative disabilities. eur j cognit psychol 2003 ; 15 ( 1 ) : 129 - 55.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "74 gilotty l, kenworthy l, sirian l, black do, wagner ae. adaptive", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "skills and executive function in autism spectrum disorders. child neuropsychol 2002 ; 8 ( 4 ) : 241 - 8.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "75 kaland n, moller - nielsen a, smith l, mortensen el, callesen k,", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "gottlieb d. the strange stories test - - a replication study of children and adolescents with asperger syndrome. eur child adolesc psychiatry 2005 ; 14 ( 2 ) : 73 - 82.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "76 norbury cf, nash m, baird g, bishop dvm. using a parental checklist", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "to identify diagnostic groups in children with communication impairment : a validation of the children ’ s communication checklist - - 2. int j lang commun disord 2004 ; 39 ( 3 ) : 345 - 64.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "77 rajendran g, mitchell p, rickards h. how do individuals with", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "asperger syndrome respond to nonliteral language and inappropriate requests in computer - mediated communication? j autism dev disord 2005 ; 35 ( 4 ) : 429 - 43.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "78 allik h, larsson j - o, smedje h. sleep patterns of school - age", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "children with asperger syndrome or high - functioning autism. j autism dev disord 2006 ; 36 ( 5 ) : 585 - 95.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "79 cotton s, richdale a. brief report : parental descriptions of sleep", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "problems in children with autism, down syndrome, and prader - willi syndrome. res dev disabil 2006 ; 27 ( 2 ) : 151 - 61.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "80 couturier jl, speechley kn, steele m, norman r, stringer b,", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "nicolson r. parental perception of sleep problems in children of normal intelligence with pervasive developmental disorders : prevalence, severity, and pattern. j am acad child adolesc psychiatry 2005 ; 44 ( 8 ) : 815 - 22.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "81 honomichl rd, goodlin - jones bl, burnham m, gaylor e, anders tf.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "sleep patterns of children with pervasive developmental disorders. j autism dev disord 2002 ; 32 ( 6 ) : 553 - 61.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "82 bradley ea, summers ja, wood hl, bryson se. comparing rates", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of psychiatric and behavior disorders in adolescents and young", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "adults with severe intellectual disability with and without autism.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autism dev disord 2004 ; 34 ( 2 ) : 151 - 61.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "83 evans dw, canavera k, kleinpeter fl, maccubbin e, taga k.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the fears, phobias and anxieties of children with autism spectrum disorders and down syndrome : comparisons with developmentally and chronologically age matched children. child psychiatry hum dev 2005 ; 36 ( 1 ) : 3 - 26.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "84 gillott a, furniss f, walter a. anxiety in high - functioning children", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "with autism. autism 2001 ; 5 ( 3 ) : 277 - 86.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "85 kim ja, szatmari p, bryson se, streiner dl, wilson fj. the prevalence", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of anxiety and mood problems among children with autism and asperger syndrome. autism 2000 ; 4 ( 2 ) : 117 - 32.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "86 muris p, steerneman p, merckelbach h, holdrinet i, meesters", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "c. comorbid anxiety symptoms in children with pervasive developmental disorders. j anxiety disord 1998 ; 12 ( 4 ) : 387 - 93.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "87 weisbrot dm, gadow kd, devincent cj, pomeroy j. the", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "presentation of anxiety in children with pervasive developmental disorders. j child adolesc psychopharmacol 2005 ; 15 ( 3 ) : 477 - 96.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "88 frazier ja, biederman j, bellordre ca, garfield sb, geller da, coffey", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "bj, et al. should the diagnosis of attention - deficit / hyperactivity disorder be considered in children with pervasive developmental disorder? j atten disord 2001 ; 4 ( 4 ) : 203 - 11.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "89 sturm h, fernell e, gillberg c. autism spectrum disorders in", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "children with normal intellectual levels : associated impairments and subgroups. dev med child neurol 2004 ; 46 ( 7 ) : 444 - 7.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "90 woolfenden s, sarkozy v, ridley g, coory m, williams k. a systematic", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "review of two outcomes in autism spectrum disorder - epilepsy and mortality. dev med child neurol 2012 ; 54 ( 4 ) : 306 - 12.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "91 kielinen m, rantala h, timonen e, linna sl, moilanen i. associated", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "medical disorders and disabilities in children with autistic disorder : a population - based study. autism 2004 ; 8 ( 1 ) : 49 - 60.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "92 rosenhall u, nordin v, sandstrom m, ahlsen g, gillberg c. autism", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "and hearing loss. j autism dev disord 1999 ; 29 ( 5 ) : 349 - 57.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "93 noterdaeme m, mildenberger k, minow f, amorosa h. evaluation", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of neuromotor deficits in children with autism and children with a specific speech and language disorder. eur child adolesc psychiatry 2002 ; 11 ( 5 ) : 219 - 25.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "94 baron - cohen s, o ’ riordan m, stone v, jones r, plaisted k.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "recognition of faux pas by normally developing children and children with asperger syndrome or high - functioning autism. j autism dev disord 1999 ; 29 ( 5 ) : 407 - 18.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "95 rutgers ah, bakermans - kranenburg mj, van ijzendoorn mh, van", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "berckelaer - onnes ia. autism and attachment : a meta - analytic review. j child psychol psychiatry 2004 ; 45 ( 6 ) : 1123 - 34.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "96 clarke df, roberts w, daraksan m, dupuis a, mccabe j, wood h, et al.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the prevalence of autistic spectrum disorder in children surveyed in a tertiary care epilepsy clinic. epilepsia 2005 ; 46 ( 12 ) : 1970 - 7.", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "97 black c, kaye ja, jick h. relation of childhood gastrointestinal", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "disorders to autism : nested case - control study using data from the uk general practice research database. bmj 2002 ; 325 ( 7361 ) : 419 - 21. references", "metadata": {"doc_name": "sign145", "page": 77, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "72 |", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "98 valicenti - mcdermott m, mcvicar k, rapin i, wershil bk, cohen", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "h, shinnar s. frequency of gastrointestinal symptoms in children with autistic spectrum disorders and association with family history of autoimmune disease. j dev behav pediatr 2006 ; 27 ( suppl2 ) : s128 - s37.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "99 rosti ro, sadek aa, vaux kk, gleeson jg. the genetic landscape of", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autism spectrum disorders. dev med child neurol 2014 ; 56 ( 1 ) : 12 - 8.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "100 kharbanda m, tolmie j, joss s. how to use … microarray", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "comparative genomic hybridisation to investigate developmental disorders. arch dis child educ pract ed 2015 ; 100 ( 1 ) : 24 - 9.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "101 schaefer gb, mendelsohn nj. clinical genetics evaluation in", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "identifying the etiology of autism spectrum disorders : 2013 guideline revisions. genet med 2013 ; 15 ( 5 ) : 399 - 407.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "102 jeste s, geschwind d. disentangling the heterogeneity of autism", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "spectrum disorder through genetic findings. nat rev neurol 2014 ; 10 ( 2 ) : 74 - 81.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "103 brambilla p, hardan a, ucelli di nemi s, perez j, soares jc, barale f.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "brain anatomy and development in autism : review of structural mri studies. brain res bull 2003 ; 61 ( 6 ) : 557 - 69.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "104 goldberg j, szatmari p, nahmias c. imaging of autism : lessons", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "from the past to guide studies in the future. can j psychiatry 1999 ; 44 ( 8 ) : 793 - 801.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "105 lahuis b, kemner c, van engeland h. magnetic resonance imaging", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "studies on autism and childhood - onset schizophrenia in children and adolescents - a review. acta neuropsychiatr 2003 ; 15 ( 3 ) : 140 - 7.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "106 billstedt e, gillberg c. autism after adolescence : population - based", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "13 - to 22 - year follow - up study of 120 individuals with autism diagnosed in childhood. j autism dev disord 2005 ; 35 ( 3 ) : 351 - 60.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "107 kagan - kushnir t, roberts sw, snead oc, 3rd. screening", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "electroencephalograms in autism spectrum disorders : evidence - based guideline. j child neurol 2005 ; 20 ( 3 ) : 197 - 206.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "108 shinnar s, rapin i, arnold s, tuchman rf, shulman l, ballaban -", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "gil k, et al. language regression in childhood. pediatr neurol 2001 ; 24 ( 3 ) : 185 - 91.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "109 kerr a. annotation : rett syndrome : recent progress and", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "implications for research and clinical practice. j child psychol psychiatry 2002 ; 43 ( 3 ) : 277 - 87.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "110 oliveira g, matoso e, vicente a, ribeiro p, marques c, ataide a, et", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "al. partial tetrasomy of chromosome 3q and mosaicism in a child with autism. j autism dev disord 2003 ; 33 ( 2 ) : 177 - 85.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "111 charman t, baron - cohen s, swettenham j, baird g, drew a,", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "cox a. predicting language outcome in infants with autism and pervasive developmental disorder. int j lang commun disord 2003 ; 38 ( 3 ) : 265 - 85.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "112 charman t, taylor e, drew a, cockerill h, brown ja, baird g.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "outcome at 7 years of children diagnosed with autism at age 2 : predictive validity of assessments conducted at 2 and 3 years of age and pattern of symptom change over time. j child psychol psychiatry 2005 ; 46 ( 5 ) : 500 - 13.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "113 fisch gs, simensen rj, schroer rj. longitudinal changes in", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "cognitive and adaptive behavior scores in children and adolescents with the fragile x mutation or autism. j autism dev disord 2002 ; 32 ( 2 ) : 107 - 14.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "114 sigman m, mcgovern cw. improvement in cognitive and language", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "skills from preschool to adolescence in autism. j autism dev disord 2005 ; 35 ( 1 ) : 15 - 23.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "115 starr e, szatmari p, bryson s, zwaigenbaum l. stability and change", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "among high - functioning children with pervasive developmental disorders : a 2 - year outcome study. j autism dev disord 2003 ; 33 ( 1 ) : 15 - 22.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "116 szatmari p, bryson se, boyle mh, streiner dl, duku e. predictors", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of outcome among high functioning children with autism and asperger syndrome. j child psychol psychiatry 2003 ; 44 ( 4 ) : 520 - 8.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "117 mcgovern cw, sigman m. continuity and change from early", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "childhood to adolescence in autism. j child psychol psychiatry 2005 ; 46 ( 4 ) : 401 - 8.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "118 coplan j, jawad af. modeling clinical outcome of children with", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autistic spectrum disorders. pediatrics 2005 ; 116 ( 1 ) : 117 - 22.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "119 anderson dk, liang jw, lord c. predicting young adult outcome", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "among more and less cognitively able individuals with autism spectrum disorders. j child psychol psychiatry 2014 ; 55 ( 5 ) : 485 - 94.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "120 woolfenden s, sarkozy v, ridley g, williams k. a systematic review", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of the diagnostic stability of autism spectrum disorder. res autism spectr disord 2012 ; 6 ( 1 ) : 345 - 54.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "121 lord c, shulman c, dilavore p. regression and word loss in autistic", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "spectrum disorders. j child psychol psychiatry 2004 ; 45 ( 5 ) : 936 - 55.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "122 goldberg wa, osann k, filipek pa, laulhere t, jarvis k, modahl c,", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "et al. language and other regression : assessment and timing. j autism dev disord 2003 ; 33 ( 6 ) : 607 - 16.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "123 francis k. autism interventions : a critical update. dev med child", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "neurol 2005 ; 47 ( 7 ) : 493 - 9.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "124 jordan r, jones g, murray d. educational interventions for children", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "with autism : a literature review of recent and current research. london : department for education and employment ; 1998. ( research report 77 ).", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "125 shields j. the nas earlybird programme : partnership with parents", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "in early intervention. the national autistic society. autism 2001 ; 5 ( 1 ) : 49 - 56.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "126 sofronoff k, leslie a, brown w. parent management training and", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "asperger syndrome : a randomized controlled trial to evaluate a parent based intervention. autism 2004 ; 8 ( 3 ) : 301 - 17.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "127 sussman f. more than words : helping parents promote", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "communication skills in children with autism spectrum disorder. toronto : the hanen centre ; 1999.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "128 tonge b, brereton a, kiomall m, mackinnon a, king n, rinehart", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "n. effects on parental mental health of an education and skills training program for parents of young children with autism : a randomized controlled trial. j am acad child adolesc psychiatry 2006 ; 45 ( 5 ) : 561 - 9.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "129 oono ip, honey ej, h m. parent - mediated early intervention for", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "young children with autism spectrum disorders ( asd ). cochrane database of systematic reviews 2013, issue 4.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "130 green j, charman t, mcconachie h, aldred c, slonims v, howlin", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "p, et al. parent - mediated communication - focused treatment in children with autism ( pact ) : a randomised controlled trial. lancet 2010 ; 375 ( 9732 ) : 2152 - 60.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "131 beukelman david r, mirenda pat. augmentative and alternative", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "communication : supporting children and adults with complex communication needs baltimore : brookes publishing company ; 2013.", "metadata": {"doc_name": "sign145", "page": 78, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "| 73", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "132 flippin m, reszka s, watson lr. effectiveness of the picture", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "exchange communication system ( pecs ) on communication and speech for children with autism spectrum disorders : a meta - analysis. am j speech lang pathol 2010 ; 19 ( 2 ) : 178 - 95.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "133 ganz jb, davis jl, lund em, goodwyn fd, simpson rl. meta - analysis", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of pecs with individuals with asd : investigation of targeted versus non - targeted outcomes, participant characteristics, and implementation phase. res dev disabil 2012 ; 33 ( 2 ) : 406 - 18.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "134 bolte s, rudolf l, poustka f. the cognitive structure of higher", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "functioning autism and schizophrenia : a comparative study compr psychiatry 2002 ; 43 ( 4 ) : 325 - 30.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "135 laushey km, heflin lj. enhancing social skills of kindergarten", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "children with autism through the training of multiple peers as tutors. j autism dev disord 2000 ; 30 ( 3 ) : 183 - 93.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "136 roeyers h. the influence of nonhandicapped peers on the social", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "interactions of children with a pervasive development disorder. j autism dev disord 1996 ; 26 ( 3 ) : 303 - 20.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "137 shabani db, katz rc, wilder da, beauchamp k, taylorcr, fischer", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "kj. increasing social initiations in children with autism : effects of a tactile prompt. j appl behav anal 2002 ; 35 ( 1 ) : 79 - 83.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "138 solomon m, goodlin - jones bl, tf a. a social adjustment", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "enhancement intervention for high functioning autism, asperger ’ s syndrome, and pervasive developmental disorder nos. j autism dev disord 2004 ; 34 ( 6 ) : 649 - 68.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "139 thiemann ks, goldstein h. social stories, written text cues, and", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "video feedback : effects on social communication of children with autism. j appl behav anal 2001 ; 34 ( 4 ) : 425 - 46.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "140 thiemann ks, goldstein h. effects of peer training and written", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "text cueing on social communication of school - age children with pervasive developmental disorder. j speech lang hear res 2004 ; 47 ( 1 ) : 126 - 44.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "141 wellman hm, baron - cohen s, caswell r, gomez jc, swettenham j,", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "toye e, et al. thought - bubbles help children with autism acquire an alternative to a theory of mind. autism 2002 ; 6 ( 4 ) : 343 - 63.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "142 koegel rl, camarata s, koegel lk, ben - tall a, smith ae. increasing", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "speech intelligibility in children with autism. j autism dev disord 1998 ; 28 ( 3 ) : 241 - 51.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "143 bebko jm, perry a, bryson s. multiple method validation study of", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "facilitated communication : ii. individual differences and subgroup results. j autism dev disord 1996 ; 26 ( 1 ) : 19 - 42.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "144 eikeseth s, jahr e. the ucla reading and writing program : an", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "evaluation of the beginning stages. res dev disabil 2001 ; 22 ( 4 ) : 289 - 307.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "145 reichow b, steiner am, volkmar f. social skills groups for people", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "aged 6 to 21 with autism spectrum disorders ( asd ). cochrane database of systematic reviews 2012, issue 7.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "146 ahrq. therapies for children with autism spectrum disorder :", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "behavioural interventions update ( comparative effectiveness review number 137 ). rockvill md : agency for healthcare research and quality ; 2014. [ cited 24 / 05 / 2016 ]. available from url : https : / / effectivehealthcare. ahrq. gov / ehc / products / 544 / 1946 / autism - update - executive - 140806. pdf", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "147 grynszpan o, weiss pl, perez - diaz f, gal e. innovative technology -", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "based interventions for autism spectrum disorders : a meta - analysis. autism 2014 ; 18 ( 4 ) : 346 - 61.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "148 ramdoss s, lang r, mulloy a, franco j, o ’ reilly m, didden r, et al.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "use of computer - based interventions to teach communication skills to children with autism spectrum disorders : a systematic review. j behav educ 2011 ; 20 ( 1 ) : 55 - 76.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "149 ramdoss s, machalicek w, rispoli m, mulloy a, lang r, o ’ reilly m.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "computer - based interventions to improve social and emotional skills in individuals with autism spectrum disorders : a systematic review. dev neurorehabil 2012 ; 15 ( 2 ) : 119 - 35.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "150 lovaas oi. behavioral treatment and normal educational and", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "intellectual functioning in young autistic children. j consult clin psychol 1987 ; 55 ( 1 ) : 3 - 9.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "151 national institute for health and care excellence ( nice ). autism :", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the management and support of children and young people on the autism spectrum ( nice guideline cg170 ). london : national collaborating centre for women ’ s and children ’ s health ; 2013. ( cg170 ). [ cited 24 / 05 / 2016 ]. available from url : http : / / www. nice. org. uk / guidance / cg170", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "152 warren z, veenstra - vanderweele j, stone w, bruzek jl, nahmias as,", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "foss - feig jh, et al. therapies for children with autism spectrum disorders. ahrq ; 2011. [ cited 24 / 05 / 2016 ]. available from url : https : / / effectivehealthcare. ahrq. gov / ehc / products / 544 / 1945 / autism - update - report - 140929. pdf", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "153 eldevik s, hastings rp, hughes jc, jahr e, eikeseth s, cross s. meta -", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "analysis of early intensive behavioral intervention for children with autism. journal of clinical child and adolescent psychology : the official journal for the society of clinical child and adolescent psychology, american psychological association, division 53 2009 ; 38 ( 3 ) : 439 - 50.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "154 makrygianni mk rp. a meta - analytic review of the effectiveness of", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "behavioural early intervention programs for children with autistic spectrum disorders. res autism spectr disord 2010 ; 4 ( 4 ) : 577 - 93.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "155 peters - scheffer n, didden r, korzilius h, sturmey p. a meta -", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "analytic study on the effectiveness of comprehensive aba - based early intervention programs for children with autism spectrum disorders. res autism spectr disord 2011 ; 5 ( 1 ) : 60 - 9.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "156 spreckley m, boyd r. efficacy of applied behavioral intervention in", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "preschool children with autism for improving cognitive, language, and adaptive behavior : a systematic review and meta - analysis. j pediatr 2009 ; 154 ( 3 ) : 338 - 44.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "157 virues - ortega j. applied behavior analytic intervention for autism", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "in early childhood : meta - analysis, meta - regression and dose - response meta - analysis of multiple outcomes. clinical psychology review 2010 ; 30 ( 4 ) : 387 - 99.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "158 reichow b, wolery m. comprehensive synthesis of early intensive", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "behavioral interventions for young children with autism based on the ucla young autism project model. j autism dev disord 2009 ; 39 ( 1 ) : 23 - 41.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "159 reichow b, barton ee, boyd ba, hume k. early intensive behavioral", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "intervention ( eibi ) for young children with autism spectrum disorders ( asd ). cochrane database of systematic reviews 2012, issue 10.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "160 virues - ortega j, julio fm, pastor - barriuso r. the teacch program", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "for children and adults with autism : a meta - analysis of intervention studies. clinical psychology review 2013 ; 33 ( 8 ) : 940 - 53.", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "161 kokina a, kern l. social story interventions for students with", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autism spectrum disorders : a meta - analysis. j autism dev disord 2010 ; 40 ( 7 ) : 812 - 26. references", "metadata": {"doc_name": "sign145", "page": 79, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "74 |", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "162 reynhout g, carter m. evaluation of the efficacy of social stories", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "using three single subject metrics. res autism spectr disord 2011 ; 5 ( 2 ) : 885 - 900.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "163 test dw, richter s, knight v, spooner f. a comprehensive review", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "and meta - analysis of the social stories literature. focus autism other dev disabil 2011 ; 26 ( 1 ) : 49 - 62.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "164 sukhodolsky dg, bloch mh, panza ke, reichow b. cognitive -", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "behavioral therapy for anxiety in children with high - functioning autism : a meta - analysis. pediatrics 2013 ; 132 ( 5 ) : e1341 - 50.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "165 ung d, selles r fau - small bj, small bj fau - storch ea, storch ea.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "a systematic review and meta - analysis of cognitive - behavioral therapy for anxiety in youth with high - functioning autism spectrum disorders. child psychiatry hum dev 2014 ( 1573 - 3327 ( electronic ) ).", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "166 fletcher - watson s, mcconnell f, manola e, mcconachie h.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "interventions based on the theory of mind cognitive model for autism spectrum disorder ( asd ). cochrane database of systematic reviews 2014, issue 3.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "167 sinha y, silove n, hayen a, williams k. auditory integration training", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "and other sound therapies for autism spectrum disorders ( asd ). cochrane database of systematic reviews 2011, issue 12.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "168 case - smith j, weaver ll, fristad ma. a systematic review of sensory", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "processing interventions for children with autism spectrum disorders. autism 2015 ; 19 ( 2 ) : 133 - 48.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "169 lang r, o ’ reilly m, healy o, rispoli m, lydon h, streusand w, et", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "al. sensory integration therapy for autism spectrum disorders : a systematic review. res autism spectr disord 2012 ; 6 ( 3 ) : 1004 - 18.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "170 watling r, hauer s. effectiveness of ayres sensory integration ( r )", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "and sensory - based interventions for people with autism spectrum disorder : a systematic review. the american journal of occupational therapy : official publication of the american occupational therapy association 2015 ; 69 ( 5 ) : 6905180030p1 - 12.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "171 geretsegger m, elefant c, mossler karin a, gold c. music therapy", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "for people with autism spectrum disorder. cochrane database of systematic reviews 2014, issue 6.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "172 cortesi f, giannotti f, sebastiani t, panunzi s, valente d. controlled -", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "release melatonin, singly and combined with cognitive behavioural therapy, for persistent insomnia in children with autism spectrum disorders : a randomized placebo - controlled trial. j sleep res 2012 ; 21 ( 6 ) : 700 - 9.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "173 gringras p, green d, wright b, rush c, masako s, pratt k, et al.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "weighted blankets and sleep in autistic children — a randomized controlled trial. pediatrics 2014 ; 134 ( 2 ) : 298 - 306.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "174 mostert mp. facilitated communication since 1995 : a review of", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "published studies j autism dev disord 2001 ; 31 ( 3 ) : 287 - 313.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "175 simpson rl, myles bs. effectiveness of facilitated communication", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "with children and youth with autism. j spec educ 1995 ; 28 ( 4 ) : 424 - 39.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "176 jacobson jw, mulick ja, schwartz aa. a history of facilitated", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "communication : science, pseudoscience, and antiscience science working group on facilitated communication. am psychol 1995 ; 50 ( 9 ) : 750 - 65.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "177 hurwitz s. the gluten - free, casein - free diet and autism : limited", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "return on family investment. j early interv 2013 ; 35 ( 1 ) : 3 - 19.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "178 james s, montgomery p, williams k. omega - 3 fatty acids", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "supplementation for autism spectrum disorders ( asd ). cochrane database of systematic reviews 2011, issue 11.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "179 bent s, hendren rl, zandi t, law k, choi je, widjaja f, et al.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "internet - based, randomized, controlled trial of omega - 3 fatty acids for hyperactivity in autism. j am acad child adolesc psychiatry 2014 ; 53 ( 6 ) : 658 - 66.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "180 nye c, brice a. combined vitamin b6 - magnesium treatment in", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autism spectrum disorder. cochrane database of systematic reviews 2004, issue 4.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "181 brondino n, fusar - poli l, rocchetti m, provenzani u, barale f,", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "politi p. complementary and alternative therapies for autism spectrum disorder. evid based complement alternat med 2015 ; 2015 ( 258589 ).", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "182 ming x, chen x, wang xt, zhang z, kang v, zimmerman - bier b.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "acupuncture for treatment of autism spectrum disorders. evid based complement alternat med 2012 ; 2012 ( 679845 ).", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "183 o ’ haire me. animal - assisted intervention for autism spectrum", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "disorder : a systematic literature review. j autism dev disord 2013 ; 43 ( 7 ) : 1606 - 22.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "184 sowa m, meulenbroek r. effects of physical exercise on autism", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "spectrum disorders : a meta - analysis. res autism spectr disord 2012 ; 6 ( 1 ) : 46 - 57.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "185 howlin p, moss p. adults with autism spectrum disorders. can j", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "psychiatry 2012 ; 57 ( 5 ) : 275 - 83.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "186 cadman t, eklund h, howley d, hayward h, clarke h, findon j, et", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "al. caregiver burden as people with autism spectrum disorder and attention - deficit / hyperactivity disorder transition into adolescence and adulthood in the united kingdom. j am acad child adolesc psychiatry 2012 ; 51 ( 9 ) : 879 - 88.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "187 roth m, gillis j, digennaro reed f. a meta - analysis of behavioral", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "interventions for adolescents and adults with autism spectrum disorders. j behav educ 2014 ; 23 : 258 - 86.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "188 british psychological society and the royal college of psychiatrists.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "challenging behaviour and learning disabilities : prevention and interventions for people with learning disabilities whose behaviour challenges. national institute for health and care excellence ( nice ) ;", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2015.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "189 russell aj, jassi a, fullana ma, mack h, johnston k, heyman i, et", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "al. cognitive behavior therapy for comorbid obsessive - compulsive disorder in high - functioning autism spectrum disorders : a randomized controlled trial. depress anxiety 2013 ; 30 ( 8 ) : 697 - 708.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "190 spek aa, van ham nc, nyklicek i. mindfulness - based therapy in", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "adults with an autism spectrum disorder : a randomized controlled trial. res dev disabil 2013 ; 34 ( 1 ) : 246 - 53.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "191 eack sm, greenwald dp, hogarty ss, bahorik al, litschge my,", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "mazefsky ca, et al. cognitive enhancement therapy for adults with autism spectrum disorder : results of an 18 - month feasibility study. j autism dev disord 2013 ; 43 ( 12 ) : 2866 - 77.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "192 hesselmark e, plenty s, bejerot s. group cognitive behavioural", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "therapy and group recreational activity for adults with autism spectrum disorders : a preliminary randomized controlled trial. autism 2014 ; 18 ( 6 ) : 672 - 83.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "193 mcgillivray j, evert h. group cognitive behavioural therapy", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "program shows potential in reducing symptoms of depression and stress among young people with asd. j autism dev disord 2014 ; 44 ( 8 ) : 2041 - 51.", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "194 british national formulary for children. [ cited 10 may 2016 ].", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "available from url : https : / / www. medicinescomplete. com / mc / bnfc / current /", "metadata": {"doc_name": "sign145", "page": 80, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "| 75", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "195 ching h, pringsheim t. aripiprazole for autism spectrum disorders", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "( asd ). cochrane database of systematic reviews 2012, issue 5.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "196 findling rl, mankoski r, timko k, lears k, mccartney t, mcquade", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "rd, et al. a randomized controlled trial investigating the safety and efficacy of aripiprazole in the long - term maintenance treatment of pediatric patients with irritability associated with autistic disorder. j clin psychiatry 2014 ; 75 ( 1 ) : 22 - 30.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "197 kent jm, hough d, singh j, karcher k, pandina g. an open - label", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "extension study of the safety and efficacy of risperidone in children and adolescents with autistic disorder. j child adolesc psychopharmacol 2013 ; 23 ( 10 ) : 676 - 86.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "198 roke y, buitelaar jk, boot am, tenback d, van harten pn. risk of", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "hyperprolactinemia and sexual side effects in males 10 - 20 years old diagnosed with autism spectrum disorders or disruptive behavior disorder and treated with risperidone. j child adolesc psychopharmacol 2012 ; 22 ( 6 ) : 432 - 9.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "199 roke y, van harten pn, buitelaar jk, tenback de, quekel lgba,", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "de rijke yb, et al. bone mineral density in male adolescents with autism spectrum disorders and disruptive behavior disorder with or without antipsychotic treatment. eur j endocrinol 2012 ; 167 ( 6 ) : 855 - 63.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "200 cohen d, raffin m, canitano r, bodeau n, bonnot o, perisse d, et", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "al. risperidone or aripiprazole in children and adolescents with autism and / or intellectual disability : a bayesian meta - analysis of efficacy and secondary effects. res autism spectr disord 2013 ; 7 ( 1 ) : 167 - 75.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "201 wink lk, early m, schaefer t, pottenger a, horn p, mcdougle cj,", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "et al. body mass index change in autism spectrum disorders : comparison of treatment with risperidone and aripiprazole. j child adolesc psychopharmacol 2014 ; 24 ( 2 ) : 78 - 82.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "202 asadabadi m, mohammadi mr, ghanizadeh a, modabbernia a,", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "ashrafi m, hassanzadeh e, et al. celecoxib as adjunctive treatment to risperidone in children with autistic disorder : a randomized, double - blind, placebo - controlled trial. psychopharmacology 2013 ; 225 ( 1 ) : 51 - 9.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "203 ghaleiha a, ghyasvand m, mohammadi mr, farokhnia m, yadegari", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "n, tabrizi m, et al. galantamine efficacy and tolerability as an augmentative therapy in autistic children : a randomized, double - blind, placebo - controlled trial. j psychopharmacol 2014 ( 7 ) : 677 - 85.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "204 ghaleiha a, asadabadi m, mohammadi mr, shahei m, tabrizi", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "m, hajiaghaee r, et al. memantine as adjunctive treatment to risperidone in children with autistic disorder : a randomized, double - blind, placebo - controlled trial. int journal neuropsychopharmacol 2013 ; 16 ( 4 ) : 783 - 9.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "205 ghaleiha a, mohammadi e, mohammadi mr, farokhnia m,", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "modabbernia a, yekehtaz h, et al. riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder : a double - blind, placebo - controlled, randomized trial. pediatric drugs 2013 ; 15 ( 6 ) : 505 - 14.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "206 research units on pediatric psychopharmacology autism network.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. arch gen psychiatry 2005 ; 62 ( 11 ) : 1266 - 74.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "207 santosh pj, baird g, pityaratstian n, tavare e, gringras p. impact", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder : a retrospective and prospective effectiveness study. child care health dev 2006 ; 32 ( 5 ) : 575 - 83.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "208 di martino a, melis g, cianchetti c, zuddas a. methylphenidate for", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "pervasive developmental disorders : safety and efficacy of acute single dose test and ongoing therapy : an open - pilot study. j child adolesc psychopharmacol 2004 ; 14 ( 2 ) : 207 - 18.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "209 cortese s, castelnau p, morcillo c, roux s, bonnet - brilhault f.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "psychostimulants for adhd - like symptoms in individuals with autism spectrum disorders. expert rev neurother 2012 ; 12 ( 4 ) : 461 - 73.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "210 scottish intercollegiate guidelines network ( sign ). management of", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "attention deficit and hyperkinetic disorders in children and young people. edinburgh : sign ; 2009. [ cited 12 march 2015 ]. available from url : http : / / www. sign. ac. uk / pdf / sign112. pdf", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "211 harfterkamp m, van de loo - neus g, minderaa rb, van der gaag", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "r - j, escobar r, schacht a, et al. a randomized double - blind study of atomoxetine versus placebo for attention - deficit / hyperactivity disorder symptoms in children with autism spectrum disorder. j am acad child adolesc psychiatry 2012 ; 51 ( 7 ) : 733 - 41.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "212 williams k, brignell a, randall m, silove n, hazell p. selective", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "serotonin reuptake inhibitors ( ssris ) for autism spectrum disorders ( asd ). cochrane database of systematic reviews 2013, issue 8.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "213 national collaborating centre for mental health. depression in", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "children and young people : identification and management in primary, community and secondary care. national institute for health and care excellence ( nice ) ; 2005. [ cited 12 may 2015 ]. available from url : http : / / www. nice. org. uk / guidance / cg28 / evidence / cg28 - depression - in - children - and - young - people - full - guideline - 2", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "214 national collaborating centre for mental health. the treatment and", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "management of depression in adults ( updated edition ). national institute for health and clinical excellence ; 2010. [ cited 12 may 2010 ]. available from url : http : / / www. nice. org. uk / guidance / cg90 / evidence / cg90 - depression - in - adults - full - guidance2", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "215 hurwitz r, blackmore r, hazell p, williams k, woolfenden s. tricyclic", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "antidepressants for autism spectrum disorders ( asd ) in children and adolescents. cochrane database of systematic reviews 2012, issue 3.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "216 feldman hm, kolmen bk, gonzaga am. naltrexone and", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "communication skills in young children with autism. j am acad child adolesc psychiatry 1999 ; 38 ( 5 ) : 587 - 93.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "217 kolmen bk, feldman hm, handen bl, janosky je. naltrexone in", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "young autistic children : replication study and learning measures. j am acad child adolesc psychiatry 1997 ; 36 ( 11 ) : 1570 - 8.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "218 willemsen - swinkels sh, buitelaar jk, van berckelaer - onnes ia, van", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "engeland h. brief report : six months continuation treatment in naltrexone - responsive children with autism : an open - label case - control design. j autism dev disord 1999 ; 29 ( 2 ) : 167 - 9.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "219 williams pg, allard a, sears l, dalrymple n, bloom as. brief report :", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "case reports on naltrexone use in children with autism : controlled observations regarding benefits and practical issues of medication management. j autism dev disord 2001 ; 31 ( 1 ) : 103 - 8.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "220 williams k, wray john a, wheeler danielle m. intravenous secretin", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "for autism spectrum disorders ( asd ). cochrane database of systematic reviews 2012, issue 4.", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "221 preti a, melis m, siddi s, vellante m, doneddu g, fadda r. oxytocin", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "and autism : a systematic review of randomized controlled trials. j child adolesc psychopharmacol 2014 ; 24 ( 2 ) : 54 - 68. references", "metadata": {"doc_name": "sign145", "page": 81, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "76 |", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "assessment, diagnosis and interventions for autism spectrum disorders", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "2 2 2 sawyer a, lake jk, lunsky y, liu s - k, desarkar p.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "psychopharmacological treatment of challenging behaviours in adults with autism and intellectual disabilities : a systematic review. res autism spectr disord 2014 ; 8 ( 7 ) : 803 - 13.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "223 barnard j, broach s, potter d, prior a. autism in scotland ’ s schools :", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "crisis or challenge? london : the national autistic society ; 2002.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "224 mcgregor e, campbell e. the attitudes of teachers in scotland to", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the integration of children with autism into mainstream schools. autism 2001 ; 5 ( 2 ) : 189 - 207.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "225 kennedy t, regehr g, rosenfield j, roberts sw, lingard l. exploring", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "the gap between knowledge and behavior : a qualitative study of clinician action following an educational intervention. acad med 2004 ; 79 ( 5 ) : 386 - 93.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "226 brown c, paterson s. the contribution of educational psychologists", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "to the identification, assessment and diagnosis of autism : a scottish perspective. gap 2013 ; 14 ( supplement 1 ) : 87 - 93.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "227 eisenhower as, baker bl, blacher j. preschool children with", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "intellectual disability : syndrome specificity, behaviour problems, and maternal well - being. j intellect disabil res 2005 ; 49 ( 9 ) : 657 - 71.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "228 rivers jw, stoneman z. sibling relationships when a child has", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "autism : marital stress and support coping. j autism dev disord 2003 ; 33 ( 4 ) : 383 - 94.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "229 sharpley cf, bitsika v, efremidis b. influence of gender, parental", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "health, and perceived expertise of assistance upon stress, anxiety, and depression among parents of children with autism. j intellect dev disabil 1997 ; 22 ( 1 ) : 19 - 28.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "230 weiss mj. hardiness and social support as predictors of stress in", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "mothers of typical children, children with autism, and children with mental retardation. autism 2002 ; 6 ( 1 ) : 115 - 30.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "231 hastings rp, johnson e. stress in uk families conducting intensive", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "home - based behavioral intervention for their young child with autism. j autism dev disord 2001 ; 31 ( 3 ) : 327 - 36.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "232 pakenham ki, sofronoff k, c s. finding meaning in parenting a child", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "with asperger syndrome : correlates of sense making and benefit finding. res dev disabil 2004 ; 25 ( 3 ) : 245 - 64.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "233 newsome ws. parental perceptions during periods of transition :", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "implications for social workers serving families coping with autism. j fam soc work 2000 ; 5 ( 2 ) : 17 - 31.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "234 hagner d, cooney bf. “ i do that for everybody ” : supervising", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "employees with autism.. focus autism other dev disabl 2005 ; 20 ( 2 ) : 91 - 7.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "235 adults with incapacity ( scotland ) act 2000 ; 236 adult support and protection ( scotland ) act. 2007 ; 237 bartolo pa. communicating a diagnosis of developmental disability", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "to parents : multiprofessional negotiation frameworks. child care health dev 2002 ; 28 ( 1 ) : 65 - 71.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "238 brogan ca, knussen c. the disclosure of a diagnosis of an autistic", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "spectrum disorder : determinants of satisfaction in a sample of scottish parents. autism 2003 ; 7 ( 1 ) : 31 - 46.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "239 moore v, titcomb j, johnson c, cronk e, baker s, thysson l, et al.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "developing an autism assessment service ii : analysis of the first 81 cases seen. child psychol psychiatr rev 1998 ; 3 ( 3 ) : 121 - 7.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "240 howlin p, moore a. diagnosis in autism : a survey of over 1200", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "patients in the uk. autism. 1997 ; 1 ( 2 ) : 135 - 62.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "241 mansell w, morris k. a survey of parents ’ reactions to the diagnosis", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "of an autistic spectrum disorder by a local service : access to information and use of services. autism 2004 ; 8 ( 4 ) : 387 - 407.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "242 reed p, osborne la. parents and caregivers ’ perceptions of", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "communication with professionals during the diagnosis of autism : report by the south east region special educational needs partnership. [ cited 25 may 2016 ]. available from url : can be accessed from : http : / / www. neurodiversity. com / diagnostic _ process. html", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "243 symon jb. parent education for autism : issues in providing services", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "at a distance. [ references ]. j posit behav interv 2001 ; 3 ( 3 ) : 160 - 74.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "244 clinical practice guideline : autism / pervasive developmental", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "disorders : assessment and intervention for young children ( age 0 - 3 years ) : report of recommendations. [ cited 1 june 2015 ]. available from url : http : / / www. health. ny. gov / community / infants _ children / early _ intervention / disorders / autism / early. htm", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "245 ehlers s, gillberg c, wing l. a screening questionnaire for asperger", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "syndrome and other high - functioning autism spectrum disorders in school age children. j autism dev disord 1999 ; 29 ( 2 ) : 129 - 41.", "metadata": {"doc_name": "sign145", "page": 82, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "isbn 978 1 909103 46 7 www. sign. ac. uk www. healthcareimprovementscotland. org", "metadata": {"doc_name": "sign145", "page": 83, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "edinburgh office | gyle square | 1 south gyle crescent | edinburgh | eh12 9eb", "metadata": {"doc_name": "sign145", "page": 83, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "telephone 0131 623 4300 fax 0131 623 4299", "metadata": {"doc_name": "sign145", "page": 83, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "glasgow office | delta house | 50 west nile street | glasgow | g1 2np", "metadata": {"doc_name": "sign145", "page": 83, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
{"text": "telephone 0141 225 6999 fax 0141 248 3776 the healthcare environment inspectorate, the scottish health council, the scottish health technologies group, the scottish intercollegiate guidelines network ( sign ) and the scottish medicines consortium are key components of our organisation.", "metadata": {"doc_name": "sign145", "page": 83, "section": "NO_SECTION", "domain": "psychosis", "doc_id": "sign145"}}
